CA2581017A1 - Compositions monovalent for cd40l binding and methods of use - Google Patents
Compositions monovalent for cd40l binding and methods of use Download PDFInfo
- Publication number
- CA2581017A1 CA2581017A1 CA002581017A CA2581017A CA2581017A1 CA 2581017 A1 CA2581017 A1 CA 2581017A1 CA 002581017 A CA002581017 A CA 002581017A CA 2581017 A CA2581017 A CA 2581017A CA 2581017 A1 CA2581017 A1 CA 2581017A1
- Authority
- CA
- Canada
- Prior art keywords
- polypeptide
- antibody
- cd40l
- sequence
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000027455 binding Effects 0.000 title claims abstract description 290
- 238000000034 method Methods 0.000 title claims abstract description 117
- 239000000203 mixture Substances 0.000 title claims description 75
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 551
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 541
- 229920001184 polypeptide Polymers 0.000 claims abstract description 540
- 102100032937 CD40 ligand Human genes 0.000 claims abstract description 262
- 108010029697 CD40 Ligand Proteins 0.000 claims abstract description 248
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract description 165
- 102000018358 immunoglobulin Human genes 0.000 claims abstract description 165
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims abstract description 84
- 101150013553 CD40 gene Proteins 0.000 claims abstract description 83
- 230000000694 effects Effects 0.000 claims abstract description 62
- 230000003993 interaction Effects 0.000 claims abstract description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 16
- 201000010099 disease Diseases 0.000 claims abstract description 13
- 230000003042 antagnostic effect Effects 0.000 claims abstract description 5
- 239000000427 antigen Substances 0.000 claims description 199
- 108091007433 antigens Proteins 0.000 claims description 199
- 102000036639 antigens Human genes 0.000 claims description 199
- 239000003446 ligand Substances 0.000 claims description 190
- 108090000623 proteins and genes Proteins 0.000 claims description 165
- 229920001223 polyethylene glycol Polymers 0.000 claims description 145
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 136
- 235000001014 amino acid Nutrition 0.000 claims description 75
- 230000001965 increasing effect Effects 0.000 claims description 62
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims description 58
- -1 IFN-.gamma. Proteins 0.000 claims description 56
- 210000004602 germ cell Anatomy 0.000 claims description 54
- 230000009977 dual effect Effects 0.000 claims description 51
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 43
- 150000001413 amino acids Chemical class 0.000 claims description 43
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims description 34
- 238000003556 assay Methods 0.000 claims description 29
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 29
- 235000018417 cysteine Nutrition 0.000 claims description 28
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 28
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 27
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims description 26
- 239000005557 antagonist Substances 0.000 claims description 23
- 238000001727 in vivo Methods 0.000 claims description 23
- 230000002776 aggregation Effects 0.000 claims description 22
- 238000004220 aggregation Methods 0.000 claims description 22
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 22
- 230000001939 inductive effect Effects 0.000 claims description 21
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 20
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 19
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 19
- 230000000139 costimulatory effect Effects 0.000 claims description 15
- 208000024891 symptom Diseases 0.000 claims description 15
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 claims description 14
- 101710160107 Outer membrane protein A Proteins 0.000 claims description 12
- 230000028327 secretion Effects 0.000 claims description 12
- 101000759376 Escherichia phage Mu Tail sheath protein Proteins 0.000 claims description 11
- 108090001007 Interleukin-8 Proteins 0.000 claims description 11
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 11
- 208000023275 Autoimmune disease Diseases 0.000 claims description 10
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 10
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 10
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 10
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 10
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 9
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 9
- 239000013642 negative control Substances 0.000 claims description 9
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 9
- 102100027207 CD27 antigen Human genes 0.000 claims description 8
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 8
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 8
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims description 8
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 8
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims description 8
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 8
- 108010002350 Interleukin-2 Proteins 0.000 claims description 8
- 108090000978 Interleukin-4 Proteins 0.000 claims description 8
- 108090001005 Interleukin-6 Proteins 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 8
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 8
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 7
- 102000013462 Interleukin-12 Human genes 0.000 claims description 7
- 108010065805 Interleukin-12 Proteins 0.000 claims description 7
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 7
- 230000026731 phosphorylation Effects 0.000 claims description 7
- 238000006366 phosphorylation reaction Methods 0.000 claims description 7
- 230000019491 signal transduction Effects 0.000 claims description 7
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 6
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 6
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 claims description 6
- 102000000589 Interleukin-1 Human genes 0.000 claims description 6
- 108010002352 Interleukin-1 Proteins 0.000 claims description 6
- 108090000171 Interleukin-18 Proteins 0.000 claims description 6
- 102000003810 Interleukin-18 Human genes 0.000 claims description 6
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 claims description 6
- 238000013265 extended release Methods 0.000 claims description 6
- 230000011664 signaling Effects 0.000 claims description 6
- 102100025221 CD70 antigen Human genes 0.000 claims description 5
- 241000251152 Ginglymostoma cirratum Species 0.000 claims description 5
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims description 5
- 102000043131 MHC class II family Human genes 0.000 claims description 5
- 108091054438 MHC class II family Proteins 0.000 claims description 5
- 108010042215 OX40 Ligand Proteins 0.000 claims description 5
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 5
- 210000002540 macrophage Anatomy 0.000 claims description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims description 5
- 101150089247 B7 gene Proteins 0.000 claims description 4
- 101100341510 Mus musculus Itgal gene Proteins 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 208000024908 graft versus host disease Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 18
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 18
- 241001098636 Trichogramma alpha Species 0.000 claims 12
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 2
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims 2
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims 2
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 125000002228 disulfide group Chemical group 0.000 claims 1
- 208000035475 disorder Diseases 0.000 abstract description 3
- 102000004169 proteins and genes Human genes 0.000 description 82
- 235000018102 proteins Nutrition 0.000 description 77
- 239000013598 vector Substances 0.000 description 75
- 229920000642 polymer Polymers 0.000 description 61
- 210000004027 cell Anatomy 0.000 description 58
- 229940024606 amino acid Drugs 0.000 description 43
- 150000007523 nucleic acids Chemical class 0.000 description 39
- 230000014509 gene expression Effects 0.000 description 38
- 102000039446 nucleic acids Human genes 0.000 description 31
- 108020004707 nucleic acids Proteins 0.000 description 31
- 239000012634 fragment Substances 0.000 description 28
- 108020004705 Codon Proteins 0.000 description 27
- 125000005647 linker group Chemical group 0.000 description 26
- 229960002433 cysteine Drugs 0.000 description 25
- 239000000178 monomer Substances 0.000 description 25
- 108091006905 Human Serum Albumin Proteins 0.000 description 21
- 102000008100 Human Serum Albumin Human genes 0.000 description 21
- 230000006870 function Effects 0.000 description 21
- 238000010367 cloning Methods 0.000 description 20
- 238000004458 analytical method Methods 0.000 description 19
- 239000013604 expression vector Substances 0.000 description 19
- 238000006467 substitution reaction Methods 0.000 description 19
- 230000010076 replication Effects 0.000 description 18
- 108091026890 Coding region Proteins 0.000 description 17
- 230000004913 activation Effects 0.000 description 17
- 230000000295 complement effect Effects 0.000 description 17
- 239000002773 nucleotide Substances 0.000 description 17
- 239000002904 solvent Substances 0.000 description 17
- 108020004414 DNA Proteins 0.000 description 16
- 125000003729 nucleotide group Chemical group 0.000 description 16
- 241000588724 Escherichia coli Species 0.000 description 14
- 238000013459 approach Methods 0.000 description 14
- 238000010494 dissociation reaction Methods 0.000 description 14
- 230000005593 dissociations Effects 0.000 description 14
- 230000035772 mutation Effects 0.000 description 14
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 14
- 241001529936 Murinae Species 0.000 description 13
- 102000007562 Serum Albumin Human genes 0.000 description 13
- 108010071390 Serum Albumin Proteins 0.000 description 13
- 125000000539 amino acid group Chemical group 0.000 description 13
- 230000004927 fusion Effects 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 13
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 12
- 239000000539 dimer Substances 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 11
- 229940027941 immunoglobulin g Drugs 0.000 description 11
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 10
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 238000002703 mutagenesis Methods 0.000 description 10
- 231100000350 mutagenesis Toxicity 0.000 description 10
- 238000002823 phage display Methods 0.000 description 10
- 238000012216 screening Methods 0.000 description 10
- 102000004127 Cytokines Human genes 0.000 description 9
- 108090000695 Cytokines Proteins 0.000 description 9
- 101100059511 Homo sapiens CD40LG gene Proteins 0.000 description 9
- 102000004890 Interleukin-8 Human genes 0.000 description 9
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 9
- 102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 9
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 9
- 101150117115 V gene Proteins 0.000 description 9
- 238000009396 hybridization Methods 0.000 description 9
- 229940096397 interleukin-8 Drugs 0.000 description 9
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 9
- 239000011159 matrix material Substances 0.000 description 9
- 230000001404 mediated effect Effects 0.000 description 9
- 210000004379 membrane Anatomy 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 8
- 239000004472 Lysine Substances 0.000 description 8
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 102000018594 Tumour necrosis factor Human genes 0.000 description 8
- 108050007852 Tumour necrosis factor Proteins 0.000 description 8
- 230000015556 catabolic process Effects 0.000 description 8
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 8
- 238000006731 degradation reaction Methods 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 108020001507 fusion proteins Proteins 0.000 description 8
- 102000037865 fusion proteins Human genes 0.000 description 8
- 230000006698 induction Effects 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 230000037361 pathway Effects 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 7
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 7
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 7
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 238000009295 crossflow filtration Methods 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 230000010118 platelet activation Effects 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 7
- 238000000108 ultra-filtration Methods 0.000 description 7
- 241001515965 unidentified phage Species 0.000 description 7
- AASBXERNXVFUEJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) propanoate Chemical compound CCC(=O)ON1C(=O)CCC1=O AASBXERNXVFUEJ-UHFFFAOYSA-N 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 102000004864 Fibroblast growth factor 10 Human genes 0.000 description 6
- 108090001047 Fibroblast growth factor 10 Proteins 0.000 description 6
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 6
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 6
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 6
- 102000000588 Interleukin-2 Human genes 0.000 description 6
- 102000004388 Interleukin-4 Human genes 0.000 description 6
- 102000004889 Interleukin-6 Human genes 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 206010003246 arthritis Diseases 0.000 description 6
- 238000002869 basic local alignment search tool Methods 0.000 description 6
- 238000004422 calculation algorithm Methods 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 210000004443 dendritic cell Anatomy 0.000 description 6
- 238000011026 diafiltration Methods 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 210000001322 periplasm Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 125000003396 thiol group Chemical group [H]S* 0.000 description 6
- 150000003573 thiols Chemical class 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 5
- 102000003814 Interleukin-10 Human genes 0.000 description 5
- 108090000174 Interleukin-10 Proteins 0.000 description 5
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical group OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 5
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 5
- 239000004473 Threonine Substances 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000004132 cross linking Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 229940076144 interleukin-10 Drugs 0.000 description 5
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 5
- 238000010369 molecular cloning Methods 0.000 description 5
- 210000001616 monocyte Anatomy 0.000 description 5
- 230000006320 pegylation Effects 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 238000001525 receptor binding assay Methods 0.000 description 5
- 230000006798 recombination Effects 0.000 description 5
- 238000005215 recombination Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 229960002898 threonine Drugs 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 229960004441 tyrosine Drugs 0.000 description 5
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 5
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 4
- 101100136076 Aspergillus oryzae (strain ATCC 42149 / RIB 40) pel1 gene Proteins 0.000 description 4
- 108010081589 Becaplermin Proteins 0.000 description 4
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 102100031107 Disintegrin and metalloproteinase domain-containing protein 11 Human genes 0.000 description 4
- 101710121366 Disintegrin and metalloproteinase domain-containing protein 11 Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 4
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical group C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Chemical group C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 4
- 108091008605 VEGF receptors Proteins 0.000 description 4
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 229960003767 alanine Drugs 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 238000006471 dimerization reaction Methods 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 229960002449 glycine Drugs 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 229940099472 immunoglobulin a Drugs 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000000893 inhibin Substances 0.000 description 4
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 238000004091 panning Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 101150040383 pel2 gene Proteins 0.000 description 4
- 101150050446 pelB gene Proteins 0.000 description 4
- 230000037452 priming Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 230000000392 somatic effect Effects 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- 108010032595 Antibody Binding Sites Proteins 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Chemical group OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241000282836 Camelus dromedarius Species 0.000 description 3
- 108010078239 Chemokine CX3CL1 Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102100037362 Fibronectin Human genes 0.000 description 3
- 108010067306 Fibronectins Proteins 0.000 description 3
- 241000724791 Filamentous phage Species 0.000 description 3
- 102000013818 Fractalkine Human genes 0.000 description 3
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 3
- 102000000646 Interleukin-3 Human genes 0.000 description 3
- 108010002386 Interleukin-3 Proteins 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical group OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical group C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 3
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 241000219061 Rheum Species 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- 101710120037 Toxin CcdB Proteins 0.000 description 3
- 108010033576 Transferrin Receptors Proteins 0.000 description 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 3
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000008484 agonism Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229960001230 asparagine Drugs 0.000 description 3
- 235000009582 asparagine Nutrition 0.000 description 3
- 229940009098 aspartate Drugs 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229940076264 interleukin-3 Drugs 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 206010025135 lupus erythematosus Diseases 0.000 description 3
- 229920001427 mPEG Polymers 0.000 description 3
- 230000003278 mimic effect Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 239000013638 trimer Substances 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- ASUGWWOMVNVWAW-UHFFFAOYSA-N 1-(2-methoxyethyl)pyrrole-2,5-dione Chemical compound COCCN1C(=O)C=CC1=O ASUGWWOMVNVWAW-UHFFFAOYSA-N 0.000 description 2
- 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 description 2
- 101100295756 Acinetobacter baumannii (strain ATCC 19606 / DSM 30007 / JCM 6841 / CCUG 19606 / CIP 70.34 / NBRC 109757 / NCIMB 12457 / NCTC 12156 / 81) omp38 gene Proteins 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108010005853 Anti-Mullerian Hormone Proteins 0.000 description 2
- 101000716807 Arabidopsis thaliana Protein SCO1 homolog 1, mitochondrial Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
- 102100023702 C-C motif chemokine 13 Human genes 0.000 description 2
- 101710112613 C-C motif chemokine 13 Proteins 0.000 description 2
- 102100023698 C-C motif chemokine 17 Human genes 0.000 description 2
- 102100023701 C-C motif chemokine 18 Human genes 0.000 description 2
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 2
- 102100036848 C-C motif chemokine 20 Human genes 0.000 description 2
- 102100036846 C-C motif chemokine 21 Human genes 0.000 description 2
- 102100036849 C-C motif chemokine 24 Human genes 0.000 description 2
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 2
- 102100032366 C-C motif chemokine 7 Human genes 0.000 description 2
- 101710155834 C-C motif chemokine 7 Proteins 0.000 description 2
- 102100034871 C-C motif chemokine 8 Human genes 0.000 description 2
- 101710155833 C-C motif chemokine 8 Proteins 0.000 description 2
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 2
- 102100036153 C-X-C motif chemokine 6 Human genes 0.000 description 2
- 101710085504 C-X-C motif chemokine 6 Proteins 0.000 description 2
- 102100032528 C-type lectin domain family 11 member A Human genes 0.000 description 2
- 108010084313 CD58 Antigens Proteins 0.000 description 2
- 101150093802 CXCL1 gene Proteins 0.000 description 2
- 101100123850 Caenorhabditis elegans her-1 gene Proteins 0.000 description 2
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 108010058432 Chaperonin 60 Proteins 0.000 description 2
- 108010082155 Chemokine CCL18 Proteins 0.000 description 2
- 108010083647 Chemokine CCL24 Proteins 0.000 description 2
- 108010055166 Chemokine CCL5 Proteins 0.000 description 2
- 201000003874 Common Variable Immunodeficiency Diseases 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102000000541 Defensins Human genes 0.000 description 2
- 108010002069 Defensins Proteins 0.000 description 2
- 102100023471 E-selectin Human genes 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- 102100023688 Eotaxin Human genes 0.000 description 2
- 101710139422 Eotaxin Proteins 0.000 description 2
- 241000701959 Escherichia virus Lambda Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 description 2
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 101710115997 Gamma-tubulin complex component 2 Proteins 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 2
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 102100036683 Growth arrest-specific protein 1 Human genes 0.000 description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
- 101000978362 Homo sapiens C-C motif chemokine 17 Proteins 0.000 description 2
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 description 2
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 description 2
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 description 2
- 101000942297 Homo sapiens C-type lectin domain family 11 member A Proteins 0.000 description 2
- 101001072723 Homo sapiens Growth arrest-specific protein 1 Proteins 0.000 description 2
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 2
- 101000960954 Homo sapiens Interleukin-18 Proteins 0.000 description 2
- 101000973997 Homo sapiens Nucleosome assembly protein 1-like 4 Proteins 0.000 description 2
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 2
- 101000947178 Homo sapiens Platelet basic protein Proteins 0.000 description 2
- 101001076715 Homo sapiens RNA-binding protein 39 Proteins 0.000 description 2
- 101000851030 Homo sapiens Vascular endothelial growth factor receptor 3 Proteins 0.000 description 2
- 208000003352 Hyper-IgM Immunodeficiency Syndrome Diseases 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 2
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 2
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 2
- 102100025390 Integrin beta-2 Human genes 0.000 description 2
- 102000003815 Interleukin-11 Human genes 0.000 description 2
- 108090000177 Interleukin-11 Proteins 0.000 description 2
- 102000003816 Interleukin-13 Human genes 0.000 description 2
- 108090000176 Interleukin-13 Proteins 0.000 description 2
- 102000003812 Interleukin-15 Human genes 0.000 description 2
- 108090000172 Interleukin-15 Proteins 0.000 description 2
- 102000049772 Interleukin-16 Human genes 0.000 description 2
- 101800003050 Interleukin-16 Proteins 0.000 description 2
- 102000013691 Interleukin-17 Human genes 0.000 description 2
- 108050003558 Interleukin-17 Proteins 0.000 description 2
- 102100039898 Interleukin-18 Human genes 0.000 description 2
- 102000000743 Interleukin-5 Human genes 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 102000000704 Interleukin-7 Human genes 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- 102000000585 Interleukin-9 Human genes 0.000 description 2
- 108010002335 Interleukin-9 Proteins 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical group CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 2
- 102100035304 Lymphotactin Human genes 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 2
- 108010006519 Molecular Chaperones Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 108090000742 Neurotrophin 3 Proteins 0.000 description 2
- 108090000099 Neurotrophin-4 Proteins 0.000 description 2
- 108010015406 Neurturin Proteins 0.000 description 2
- 102100021584 Neurturin Human genes 0.000 description 2
- 108091005461 Nucleic proteins Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 102000004140 Oncostatin M Human genes 0.000 description 2
- 108090000630 Oncostatin M Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 102100035194 Placenta growth factor Human genes 0.000 description 2
- 102000013566 Plasminogen Human genes 0.000 description 2
- 108010051456 Plasminogen Proteins 0.000 description 2
- 102100036154 Platelet basic protein Human genes 0.000 description 2
- 108090000778 Platelet factor 4 Proteins 0.000 description 2
- 101100084022 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) lapA gene Proteins 0.000 description 2
- 108010025832 RANK Ligand Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 102100023361 SAP domain-containing ribonucleoprotein Human genes 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 108700012920 TNF Proteins 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 102100027188 Thyroid peroxidase Human genes 0.000 description 2
- 101710113649 Thyroid peroxidase Proteins 0.000 description 2
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 102100024568 Tumor necrosis factor ligand superfamily member 11 Human genes 0.000 description 2
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 2
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000001270 agonistic effect Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000000868 anti-mullerian hormone Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 108010026054 apolipoprotein SAA Proteins 0.000 description 2
- 101150042295 arfA gene Proteins 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 239000005667 attractant Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000031902 chemoattractant activity Effects 0.000 description 2
- BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 108010030175 colony inhibiting factor Proteins 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000011035 continuous diafiltration Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 102000003675 cytokine receptors Human genes 0.000 description 2
- 108010057085 cytokine receptors Proteins 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000013583 drug formulation Substances 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 108700014844 flt3 ligand Proteins 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 102000054766 genetic haplotypes Human genes 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 238000003365 immunocytochemistry Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 108010019677 lymphotactin Proteins 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 101150087557 omcB gene Proteins 0.000 description 2
- 101150115693 ompA gene Proteins 0.000 description 2
- 230000002188 osteogenic effect Effects 0.000 description 2
- 101150098295 pel1 gene Proteins 0.000 description 2
- 108700010839 phage proteins Proteins 0.000 description 2
- 101150009573 phoA gene Proteins 0.000 description 2
- 229940012957 plasmin Drugs 0.000 description 2
- 108010017843 platelet-derived growth factor A Proteins 0.000 description 2
- 108010000685 platelet-derived growth factor AB Proteins 0.000 description 2
- 229920001281 polyalkylene Polymers 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000002731 protein assay Methods 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 230000009919 sequestration Effects 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 239000002753 trypsin inhibitor Substances 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- ZJIFDEVVTPEXDL-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) hydrogen carbonate Chemical compound OC(=O)ON1C(=O)CCC1=O ZJIFDEVVTPEXDL-UHFFFAOYSA-N 0.000 description 1
- BGPJLYIFDLICMR-UHFFFAOYSA-N 1,4,2,3-dioxadithiolan-5-one Chemical class O=C1OSSO1 BGPJLYIFDLICMR-UHFFFAOYSA-N 0.000 description 1
- MFGALGYVFGDXIX-UHFFFAOYSA-N 2,3-Dimethylmaleic anhydride Chemical compound CC1=C(C)C(=O)OC1=O MFGALGYVFGDXIX-UHFFFAOYSA-N 0.000 description 1
- 101710191093 A' protein Proteins 0.000 description 1
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 1
- 208000008190 Agammaglobulinemia Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 102100022987 Angiogenin Human genes 0.000 description 1
- 244000303258 Annona diversifolia Species 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 101710081722 Antitrypsin Proteins 0.000 description 1
- 108010025628 Apolipoproteins E Proteins 0.000 description 1
- 102000013918 Apolipoproteins E Human genes 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 108010045634 B7 Antigens Proteins 0.000 description 1
- 102000005738 B7 Antigens Human genes 0.000 description 1
- 238000000035 BCA protein assay Methods 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102100037437 Beta-defensin 1 Human genes 0.000 description 1
- 101710125314 Beta-defensin 1 Proteins 0.000 description 1
- 101710125089 Bindin Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 1
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 1
- 102100036842 C-C motif chemokine 19 Human genes 0.000 description 1
- 102100036850 C-C motif chemokine 23 Human genes 0.000 description 1
- 102100036150 C-X-C motif chemokine 5 Human genes 0.000 description 1
- 101100228196 Caenorhabditis elegans gly-4 gene Proteins 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 102100028892 Cardiotrophin-1 Human genes 0.000 description 1
- 102000004225 Cathepsin B Human genes 0.000 description 1
- 108090000712 Cathepsin B Proteins 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 101710178035 Chorismate synthase 2 Proteins 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000012192 Cystatin C Human genes 0.000 description 1
- 108010061642 Cystatin C Proteins 0.000 description 1
- 101710152694 Cysteine synthase 2 Proteins 0.000 description 1
- 101150097493 D gene Proteins 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 108010024212 E-Selectin Proteins 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 108091006020 Fc-tagged proteins Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 102100039165 Heat shock protein beta-1 Human genes 0.000 description 1
- 101710100504 Heat shock protein beta-1 Proteins 0.000 description 1
- 101000780591 Homo sapiens AFG3-like protein 2 Proteins 0.000 description 1
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 description 1
- 101000713081 Homo sapiens C-C motif chemokine 23 Proteins 0.000 description 1
- 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 description 1
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
- 101001057612 Homo sapiens Dual specificity protein phosphatase 5 Proteins 0.000 description 1
- 101000622123 Homo sapiens E-selectin Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 101000972485 Homo sapiens Lupus La protein Proteins 0.000 description 1
- 101000622137 Homo sapiens P-selectin Proteins 0.000 description 1
- 101000629361 Homo sapiens Paraplegin Proteins 0.000 description 1
- 101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 1
- 101150088952 IGF1 gene Proteins 0.000 description 1
- 101150002416 Igf2 gene Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 102100037872 Intercellular adhesion molecule 2 Human genes 0.000 description 1
- 101710148794 Intercellular adhesion molecule 2 Proteins 0.000 description 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 1
- 101150008942 J gene Proteins 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical group OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical group CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical group CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 241000282852 Lama guanicoe Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical group CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000001851 Low Density Lipoprotein Receptor-Related Protein-1 Human genes 0.000 description 1
- 108010015340 Low Density Lipoprotein Receptor-Related Protein-1 Proteins 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- 102100022742 Lupus La protein Human genes 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 102000004378 Melanocortin Receptors Human genes 0.000 description 1
- 108090000950 Melanocortin Receptors Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102100030335 Midkine Human genes 0.000 description 1
- 108010092801 Midkine Proteins 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 102000007990 Organic Anion Transporters Human genes 0.000 description 1
- 108010089503 Organic Anion Transporters Proteins 0.000 description 1
- 102100023472 P-selectin Human genes 0.000 description 1
- 101710126321 Pancreatic trypsin inhibitor Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 102000011195 Profilin Human genes 0.000 description 1
- 108050001408 Profilin Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Chemical group OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102400001107 Secretory component Human genes 0.000 description 1
- 206010058556 Serositis Diseases 0.000 description 1
- 108700028909 Serum Amyloid A Proteins 0.000 description 1
- 102000054727 Serum Amyloid A Human genes 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 108010003165 Small Nuclear Ribonucleoproteins Proteins 0.000 description 1
- 102000004598 Small Nuclear Ribonucleoproteins Human genes 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 108010004408 TRPP Cation Channels Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102100031372 Thymidine phosphorylase Human genes 0.000 description 1
- 108700023160 Thymidine phosphorylases Proteins 0.000 description 1
- 102000001999 Transcription Factor Pit-1 Human genes 0.000 description 1
- 108010040742 Transcription Factor Pit-1 Proteins 0.000 description 1
- 102000007238 Transferrin Receptors Human genes 0.000 description 1
- 102100029290 Transthyretin Human genes 0.000 description 1
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 1
- 208000006391 Type 1 Hyper-IgM Immunodeficiency Syndrome Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical group CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 241001416177 Vicugna pacos Species 0.000 description 1
- 208000023940 X-Linked Combined Immunodeficiency disease Diseases 0.000 description 1
- 201000001696 X-linked hyper IgM syndrome Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 108010072788 angiogenin Proteins 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001475 anti-trypsic effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000009831 antigen interaction Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 238000003236 bicinchoninic acid assay Methods 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000004781 brain capillary Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 108010041776 cardiotrophin 1 Proteins 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000012504 chromatography matrix Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 230000008519 endogenous mechanism Effects 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 210000000285 follicular dendritic cell Anatomy 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 101150054895 ftsH gene Proteins 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Chemical group OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 108010021083 hen egg lysozyme Proteins 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 102000054037 human AFG3L2 Human genes 0.000 description 1
- 102000043381 human DUSP5 Human genes 0.000 description 1
- 102000055335 human SPG7 Human genes 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 208000026095 hyper-IgM syndrome type 1 Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- 210000003297 immature b lymphocyte Anatomy 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 108040006870 interleukin-10 receptor activity proteins Proteins 0.000 description 1
- 108040002014 interleukin-18 receptor activity proteins Proteins 0.000 description 1
- 102000008625 interleukin-18 receptor activity proteins Human genes 0.000 description 1
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Chemical group CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 238000000670 ligand binding assay Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229930182817 methionine Chemical group 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 210000003458 notochord Anatomy 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- QIIPQYDSKRYMFG-UHFFFAOYSA-M phenyl carbonate Chemical compound [O-]C(=O)OC1=CC=CC=C1 QIIPQYDSKRYMFG-UHFFFAOYSA-M 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Chemical group OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000003615 platelet activation assay Methods 0.000 description 1
- 229920002859 polyalkenylene Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 210000004896 polypeptide structure Anatomy 0.000 description 1
- 210000002729 polyribosome Anatomy 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 230000029983 protein stabilization Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000001350 reed-sternberg cell Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 108091000053 retinol binding Proteins 0.000 description 1
- 102000029752 retinol binding Human genes 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 230000009131 signaling function Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 108010033419 somatotropin-binding protein Proteins 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 108010036927 trypsin-like serine protease Proteins 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000002476 tumorcidal effect Effects 0.000 description 1
- 239000004474 valine Chemical group 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
The invention relates to antibody polypeptides that monovalently bind CD40L.
Antibody polypeptides that are monovalent for binding of CD40L can inhibit CD40L activity while avoiding potential undesirable effects that can occur with antibodies capable of divalent or multivalent binding of CD40L. In one aspect, a monovalent anti-CD40L antibody polypeptide consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD40L, preferably without substantially agonizing CD40 and/or CD40L activity. In another aspect, the monovalent anti-CD40L
antibody polypeptide is a human antibody polypeptide. The invention further encompasses methods of antagonizing CD40/CD40L interactions in an individual and methods of treating diseases or disorders involving CD40/CD40L
interactions, the methods involving administering a monovalent anti-CD40L
antibody polypeptide to the individual.
Antibody polypeptides that are monovalent for binding of CD40L can inhibit CD40L activity while avoiding potential undesirable effects that can occur with antibodies capable of divalent or multivalent binding of CD40L. In one aspect, a monovalent anti-CD40L antibody polypeptide consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD40L, preferably without substantially agonizing CD40 and/or CD40L activity. In another aspect, the monovalent anti-CD40L
antibody polypeptide is a human antibody polypeptide. The invention further encompasses methods of antagonizing CD40/CD40L interactions in an individual and methods of treating diseases or disorders involving CD40/CD40L
interactions, the methods involving administering a monovalent anti-CD40L
antibody polypeptide to the individual.
Description
DEMANDE OU BREVET VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND
PLUS D'UN TOME.
NOTE : Pour les tomes additionels, veuillez contacter le Bureau canadien des brevets JUMBO APPLICATIONS/PATENTS
THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE
VOLUME
NOTE: For additional volumes, please contact the Canadian Patent Office NOM DU FICHIER / FILE NAME:
NOTE POUR LE TOME / VOLUME NOTE:
COlVITGSITIONS MONOVALENT FOR CI340L BINDING AND METHODS
OF USE
BACKGROUND OF THE INVENTION
CD40 is a 50 kD cell surface glycoprotein molecule expressed on the surface of mature and immature B cells, macrophages, follicular dendritic cells, thymic epithelium, normal basal epithelium, and some tumor-derived cell lines. The molecule is a member of the TNF receptor family, and has important signaling functions leading to a variety of downstream effects in various cell types.
Early studies showed that cross-linking of CD40 on the B cell surface with an antibody resulted in B cell proliferation and activation. Antibody cross linking of CD40 in the presence of IL-4 induces proliferation and class switching in vitro, B cell aggregation via LFA-1 (Gordon et al., 1988, J. Immunol. 140: 1425), and serine/threonine and tyrosine phosphorylation of a number of intracellular substrates (Gordon et al., 1988, supra; Uckun et al., 1991, J. Biol. Chem. 266:17478). Anti-CD40 monoclonal antibodies also prime B cells to proliferate in response to agents such as PMA
(Gordon et al., 1987, Eur. J. Immunol. 17: 1535) and anti-CD20 antibody (Clark &
Ledbetter, 1986, Proc. Natl. Acad. Sci. U.S.A. 83: 4494).
The receptor homology of CD40 and the antibody cross-linking studies showing a central role for CD40 in B cell activation prompted the search for a natural ligand. A mutant of the Jurkat T cell line was found to constitutively activate human B cells to secrete immunoglobulin (Yellin et al., 1991, J. Immunol. 147: 3389-3395).
A monoclonal antibody, termed 5c8, was raised which specifically reacted with the mutant line, but not with the parental Jurkat cell line. The 5c8 antibody immunoprecipitated a 30 kD (more accurately, 29.3 kD, 261 amino acids) cell surface polypeptide and was found to specifically inhibit the B cell helper function of the mutant cell line. (Lederman et al., 1992, J. Exp. Med., 175: 1091-1101;
Lederman et al., 1992, J. Immunol. 149: 3817-3826; Lederman et al., 1993, Curr. Opin.
Immunol.
5: 439-444;). The 30 kD polypeptide ligand of the 5c8 antibody was ternied T-BAM, for T-B-cell Activating Molecule. A second line of studies used molecular cloning SUBSTITUTE SHEET (RULE 26) techniques to identify polypeptides that specifically bind the CD40 molecule.
cDNA
clones for a specific ligand of CD40 were identified in a CD40 binding assay and alternately termed CD40 Ligand (CD40L), gp39, CD154, or TRAP (Graf et al., 1992, Eur. J. Immunol. 22: 3191-3194; Arinitage et al., 1992, Nature 357: 80-82; and Aruffo et al., 1993, Cell 72: 291-300). Subsequently, the CD40L clone was found to have the same structure as T-BAM (Covey et al., 1994, Mol. Immunol. 31: 471-484).
Human CD40L protein shows 82.8% and 77.4% identity at the nucleic acid and amino acid levels, respectively, to a similar protein isolated from murine EL4 thymoma cells. Both of these proteins are ligands for CD40 cell surface antigen expressed on resting B cells. CD40L has also been described as IMD3, a protein involved in hyper-IgM immunodeficiency syndrome.
The human gene encoding CD40L maps to chromosome Xq26.3-q27. The gene contains five exons. Deletions, point mutations and frameshift mutations clustering within a limited region of the CD40L extracellular domain have been found to be the basis of a rare X-linked immunodeficiency syndrome (Hyper-IgM
immunodeficiency syndrome, HIGM1) characterized by recurrent bacterial infections, very low or absent IgG, IgA and IgE, and normal to increased IgM and IgD serum levels. Causally-related. mutations have been found to consist of clustered deletions arising by splice-donor mutations with exon skipping, splice-acceptor mutations with utilization of a cryptic splice site, and deletion/insertion events with the creation of a new splice site.
CD40L is expressed on activated, but not resting CD4+ T cells, and was found to play a particularly important role in the humoral immune response, being linked to B cell proliferation, antibody and cytolcine production, and cell viability.
Ifa vivo, deletion or mutation of CD40L leads to severe immunodeficiency, both in mice and in humans, characterized by hypogammaglobulinemia and T cell deficits in cell-mediated immunity (Chess, C., 2001, in Therapeutic Immunology, 2d edition, Austen, K.F., Burakoff, S., Rosen, F. and Strom, T., eds., Blacl.-well Sciences, pp.
441-456). Human CD4+ T cells infected by HIV1, which causes severe dysfunction of cellular immunity, but paradoxically results in intense polyclonal activation of B
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND
PLUS D'UN TOME.
NOTE : Pour les tomes additionels, veuillez contacter le Bureau canadien des brevets JUMBO APPLICATIONS/PATENTS
THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE
VOLUME
NOTE: For additional volumes, please contact the Canadian Patent Office NOM DU FICHIER / FILE NAME:
NOTE POUR LE TOME / VOLUME NOTE:
COlVITGSITIONS MONOVALENT FOR CI340L BINDING AND METHODS
OF USE
BACKGROUND OF THE INVENTION
CD40 is a 50 kD cell surface glycoprotein molecule expressed on the surface of mature and immature B cells, macrophages, follicular dendritic cells, thymic epithelium, normal basal epithelium, and some tumor-derived cell lines. The molecule is a member of the TNF receptor family, and has important signaling functions leading to a variety of downstream effects in various cell types.
Early studies showed that cross-linking of CD40 on the B cell surface with an antibody resulted in B cell proliferation and activation. Antibody cross linking of CD40 in the presence of IL-4 induces proliferation and class switching in vitro, B cell aggregation via LFA-1 (Gordon et al., 1988, J. Immunol. 140: 1425), and serine/threonine and tyrosine phosphorylation of a number of intracellular substrates (Gordon et al., 1988, supra; Uckun et al., 1991, J. Biol. Chem. 266:17478). Anti-CD40 monoclonal antibodies also prime B cells to proliferate in response to agents such as PMA
(Gordon et al., 1987, Eur. J. Immunol. 17: 1535) and anti-CD20 antibody (Clark &
Ledbetter, 1986, Proc. Natl. Acad. Sci. U.S.A. 83: 4494).
The receptor homology of CD40 and the antibody cross-linking studies showing a central role for CD40 in B cell activation prompted the search for a natural ligand. A mutant of the Jurkat T cell line was found to constitutively activate human B cells to secrete immunoglobulin (Yellin et al., 1991, J. Immunol. 147: 3389-3395).
A monoclonal antibody, termed 5c8, was raised which specifically reacted with the mutant line, but not with the parental Jurkat cell line. The 5c8 antibody immunoprecipitated a 30 kD (more accurately, 29.3 kD, 261 amino acids) cell surface polypeptide and was found to specifically inhibit the B cell helper function of the mutant cell line. (Lederman et al., 1992, J. Exp. Med., 175: 1091-1101;
Lederman et al., 1992, J. Immunol. 149: 3817-3826; Lederman et al., 1993, Curr. Opin.
Immunol.
5: 439-444;). The 30 kD polypeptide ligand of the 5c8 antibody was ternied T-BAM, for T-B-cell Activating Molecule. A second line of studies used molecular cloning SUBSTITUTE SHEET (RULE 26) techniques to identify polypeptides that specifically bind the CD40 molecule.
cDNA
clones for a specific ligand of CD40 were identified in a CD40 binding assay and alternately termed CD40 Ligand (CD40L), gp39, CD154, or TRAP (Graf et al., 1992, Eur. J. Immunol. 22: 3191-3194; Arinitage et al., 1992, Nature 357: 80-82; and Aruffo et al., 1993, Cell 72: 291-300). Subsequently, the CD40L clone was found to have the same structure as T-BAM (Covey et al., 1994, Mol. Immunol. 31: 471-484).
Human CD40L protein shows 82.8% and 77.4% identity at the nucleic acid and amino acid levels, respectively, to a similar protein isolated from murine EL4 thymoma cells. Both of these proteins are ligands for CD40 cell surface antigen expressed on resting B cells. CD40L has also been described as IMD3, a protein involved in hyper-IgM immunodeficiency syndrome.
The human gene encoding CD40L maps to chromosome Xq26.3-q27. The gene contains five exons. Deletions, point mutations and frameshift mutations clustering within a limited region of the CD40L extracellular domain have been found to be the basis of a rare X-linked immunodeficiency syndrome (Hyper-IgM
immunodeficiency syndrome, HIGM1) characterized by recurrent bacterial infections, very low or absent IgG, IgA and IgE, and normal to increased IgM and IgD serum levels. Causally-related. mutations have been found to consist of clustered deletions arising by splice-donor mutations with exon skipping, splice-acceptor mutations with utilization of a cryptic splice site, and deletion/insertion events with the creation of a new splice site.
CD40L is expressed on activated, but not resting CD4+ T cells, and was found to play a particularly important role in the humoral immune response, being linked to B cell proliferation, antibody and cytolcine production, and cell viability.
Ifa vivo, deletion or mutation of CD40L leads to severe immunodeficiency, both in mice and in humans, characterized by hypogammaglobulinemia and T cell deficits in cell-mediated immunity (Chess, C., 2001, in Therapeutic Immunology, 2d edition, Austen, K.F., Burakoff, S., Rosen, F. and Strom, T., eds., Blacl.-well Sciences, pp.
441-456). Human CD4+ T cells infected by HIV1, which causes severe dysfunction of cellular immunity, but paradoxically results in intense polyclonal activation of B
cells, do not express CD40L. Gene and cell surface expression of the CD40L by activated T cells has been shown to be depressed in a subgroup of patients with common variable immunodeficiency (CVI). Thus, inefficient signaling via CD40 may be responsible, at least in part, for the failure of B cell differentiation in these patients.
The functional consequences of CD40L binding to CD40 include, for example, a) rescuing B cells from apoptosis induced by Fas or cross-linking of IgM, b) induction of the co-stimulator molecules CD80 (B7-1) and CD86 (B7-2) which interact with CD28 and CD152 (CTLA-4) on the surface of activated T cells; c) increased expression of other cell surface activation molecules including CD23, CD54, CD95 and lymphotoxin-a; and d) inducing immunoglobulin class switching (see Chess, supra, and references 25, 44, and 47-60 cited therein). CD40L
binding to CD40 also augments the antigen-presenting functions of dendritic cells, inducing maintenance of high levels of MHC class II antigens and upregulation of accessory molecules including CD58 (LFA-3). CD40L induces cytokine production and tumoricidal activity in peripheral blood monocytes. CD40L also co-stimulates the proliferation of activated T cells, and the co-stimulation is accompanied by the production of IFN-y, TNF-a and IL2. The expression of CD40L on murine T-helper cells and CD4+ T cells is inhibited by IFN-y, and is inhibited on T-helper-type 2 cells by TGF-(3.
CD40L upregulates the expression of CD54 by cultured Hodgkin and Reed-Sternberg cells. The increased CD54 surface expression is accompanied by increased shedding of surface-bound CD54.
CD40L has also been suggested to be important in the induction of tolerance -CD80 and CD86, which are upregulated by CD40L, interact with CD28 to provide essential co-stimulation of T cells, in concert with T cell receptor activation, that results in full activation of T cells. In the absence of CD80 and CD86-triggered activation of CD28, anergy or tolerance occurs as a consequence of antigen triggering (Linsley & Ledbetter, 1993, Ann. Rev. Immunol. 11- 191-212; Jenkins et al., 1993, Curr Opin. Immunol. 5: 361-367; and Boussiotis et al., 1996, Immunol. Rev.
153: 5-26).
The CD40L/CD40 pathway has been implicated in the in vivo priming of CD8+ cytotoxic T lymphocytes (CTSs) by CD4+ T cells. As noted, CD40L
expressed on the surface of activated CD4+ T cells interacts with CD40 expressed on dendritic cells, inducing the dendritic cells to express more MHC, and signaling through CD40 can replace the requirement for CD4+ T-helper cells in priming CDB+
CTL responses. Blockade of CD40L inhibits CTL priming, emphasizing the vital role of CD40L/CD40 interactions in CTL priming by helper T cells (Ridge et al., 1998, Nature 393: 474-478; Schoenberger.et al., 1998, Nature 393: 480-483; Bennett et al., 1998, Nature 393: 478-480).
CD40L can also mediate functional interactions of CD4+ T cells with other cells that express CD40, such as fibroblasts, synovial cells and endothelial cells (Yellin et al., 1995, J. Leuko. Biol. 58: 209-216; Yellin et al., 1995, J.
Exp. Med. 182:
1857-1864). CD40L induces the expression of CD54 (ICAM-1) and CD106 (VCAM-1) by fibroblasts, as well as increasing fibroblast IL-6, collagenase and collagen production and inducing fibroblast proliferation. Thus, CD40L/CD40 interactions may be involved in the induction of fibrosis associated with autoiinmunity and immune responses.
CD40L interaction with CD40 induces endothelial cells to express CD62E (E-selectin), ICAM-1 and VCAM-1. The upregulation of these adhesion molecules may be involved in the binding of inflammatory cells to vascular endothelium and the subsequent migration of the inflammatory cells to sites of inflammation. CD40L
blockade retards the migration of leukocytes through endothelial cell barriers. In animal models of autoimmunity, antibodies to CD40L interfere with the accumulation of inflammatory cells at the site of inflammation.
CD40/CD40L interactions have been implicated in diseases having an immune or autoimmune connection. Animal models of immune-related disease in which the CD40L/CD40 pathway has been demonstrated to play a role in the pathology include, for example, murine nlodels of systemic lupus erythematosis (Lupus or SLE; see, e.g., Kalled et al., 1998, J. Immunol. 160: 2158-2165), arthritis (collagen-induced arthritis, see, e.g., Durie et al., 1993, Science 261: 1328-1330), multiple sclerosis (experimental autoimmune encephalomyelitis, EAE; see, e.g., Howard et al., 1999, J. Clin . Invest. 103: 281-290), autoimmune thyroiditis (experimental autoimmune thyroiditis, EAT; see, e.g., Caryanniotis et al., 1997, Immunology 90: 421-426), colitis (hapten-induced colitis; see, e.g., Stuber et al., 1996, J. Exp. Med. 183: 693-698), atherosclerosis and coronary artery disease (see, e.g., Mach et al., 1998, Nature 394: 200-203), and allograft rejection (see, e.g., Parker et al., 1995, Proc. Natl. Acad. Sci. U.S.A. 92: 9560-9564; Kirk et al., 1997, Proc.
Natl. Acad. Sci. U.S.A. 94: 8789-8794; Larsen et al., 1996, Nature 381: 434-438 and Blazar et al., 1997, J. Immunol. 158: 29-39).
CD40L antibody trials for treatment of human immune-related diseases include studies in patients with Lupus (see, e.g., Huang et al., 2002, Arthritis Rheum.
46: 1554-1562). A phase I trial demonstrated that anti-CD40L humanized monoclonal antibody (IDEC-131) is safe and well tolerated by patients with Lupus (Davis et al., 2001, J. Rheumatol. 28: 95-101). A phase II study with the IDEC-antibody showed improvement in clinical symptoms, but efficacy of the drug over placebo controls was not demonstrated (Kalunian et al., 2002, Arthritis Rheum.
46:
3251-3258). In a phase II study with BG9588 anti-CD40L antibody, clinical efficacy was demonstrated, but the study was terminated due to the occurrence of thromboembolic events (Boumpas et al., 2003, Arthritis Rheum. 48: 719-727).
U.S. Patent Nos. 5,474,771 (Lederman et al.) and 5,876,950 (Siadak et al.) disclose murine monoclonal antibodies specific for different epitopes of human gp39.
W095/06666 (Noelle & Foy) discloses murine anti-gp39 antibodies.
U.S. Patent No. 6,328,964 (Noelle & Claassen) discloses methods for the treatment of multiple sclerosis using gp39-specific antibodies.
U.S. Patent No. 5,747,037 (Noelle et al.), and EP0721469B 1 (Ledbetter et al.) and its U.S. counterpart U.S. 5,869,049 disclose anti-human monoclonal (mouse) .5 antibodies specific for gp39. U.S. Patent No. 5,876,718 (Noelle et al.) discloses methods of inducing T cell non-responsiveness to transplanted tissues and of treating graft-versus-host disease with anti-gp39 monoclonal (mouse) antibodies.
EP0742721B 1(Noelle et al.) discloses methods of inhibiting a humoral immune response to a thymus-dependent antigen that use anti-gp39 monoclonal (mouse) antibodies. U.S. Patent No. 6,375,950 describes metliods for inducing T cell unresponsiveness to donor tissue or organs in a transplant recipient through use of anti-gp39 monoclonal (murine) antibodies.
EP1005372B1 (De Boer et al.) describes methods for the selective killing of autoreactive CD40L+ T cells using anti-CD40L monoclonal (mouse) antibody-toxin fusion proteins.
U.S. Patent No. 6,340,459 (Yellin et al.) describes the use of murine anti gp39 monoclonal antibody 5c8 for the treatmeilt or prevention of reperfusion injury.
EP0831906B 1(Claassen et al.) describes methods for the treatment of T cell-mediated tissue destruction in autoimmune diseases such as multiple sclerosis using anti-gp39 monoclonal (mouse) antibodies. Antibodies used in therapeutic approaches in the prior art have been divalent antibodies of murine origin.
A number of smaller antigen binding fragments of naturally occurring antibodies have been identified following protease digestion. These include, for example, the "Fab fragment" (VL-CL-CHI-VH), "Fab' fragment" (a Fab with the heavy chain hinge region) and "F(ab')2 fragment" (a dimer of Fab' fragments joined by the heavy chain hinge region). Recombinant methods have been used to generate even smaller antigen-binding fragments, referred to as "single chain Fv"
(variable fragment) or "scFv," consisting of VL and VH joined by a synthetic peptide linker.
While the antigen binding unit of a naturally-occurring antibody (e.g., in humans and most other mammals) is generally known to be comprised of a pair of V
regions (VL/VH), camelid species express a large proportion of fully functional, highly specific antibodies that are devoid of liglit chain sequences. The camelid heavy chain antibodies are found as homodimers of a single heavy chain, dimerized via their constant regions. The variable domains of these camelid heavy chain antibodies are referred to as VHH domains and retain the ability, when isolated as fragments of the VH chain, to bind antigen with high specificity ((Hamers-Casterman et al., 1993, Nature 363: 446-448; Gahroudi et al., 1997, FEBS Lett. 414: 521-526). Antigen binding single VH domains have also been identified from, for example, a library of murine VH genes anlplified from genomic DNA from the spleens of immunized mice and expressed in E. coli (Ward et al., 1989, Nature 341: 544-546). Ward et al.
named the isolated single VH domains "dAbs," for "domain antibodies." The term "dAb"
will refer herein to an antibody single variable domain (VH or VL) polypeptide that specifically binds antigen. A "dAb" binds antigen independently of other V
domains;
however, as the term is used herein, a "dAb" can be present in a homo- or heteromultimer with other VH or VL domains where the other domains are not required for antigen binding by the dAb, i.e., where the dAb binds antigen independently of the additional VH or VL domains.
Antibody single variable domains, for example, VHH, are the smallest antigen-binding antibody unit known. For use in therapy, human antibodies are preferred, primarily because they are not as likely to provoke an immune response when administered to a patient. As noted above, isolated non-camelid VH domains tend to be relatively insoluble and are often poorly expressed. Comparisons of camelid VHH
with the VH domains of human antibodies reveals several key differences in the framework regions of the camelid VHH domain corresponding to the VH/VL
interface of the human VH domains. Mutation of these residues of human VH3 to more closely resemble the VHH sequence (specifically Gly 44-Glu, Leu 45--+Arg and Trp 47-->Gly) has been performed to produce "cainelized" human VH domains that retain antigen binding activity (Davies & Riechmann, 1994, FEBS Lett. 339: 285-290) yet have improved expression and solubility. (Variable domain amino acid numbering used herein is consistent with the Kabat numbering convention (Kabat et al., 1991, Sequences of Immunological Interest, 5t ed. U.S. Dept. Health & Human Services, Washington, D.C.)) WO 03/035694 (Muyldermans) reports that the Trp 103-Arg mutation improves the solubility of non-cainelid VH domains. Davies &
Riechmann (1995, Biotechnology N:Y. 13: 475-479) also report production of a phage-displayed repertoire of camelized human VH domains and selection of clones that bind hapten with affinities in the range of 100-400 nM, but clones selected for binding to protein antigen had weaker affinities.
While many antibodies and their derivatives are useful for diagnosis and therapy, the ideal pharmacokinetics of antibodies. are often not achieved for a particular application. In order to provide improvement in the pharmacokinetics of antibody molecules, the present invention provides single domain variable region polypeptides that are linked to polymers which provide increased stability and half-life. The attachment of polymer molecules (e.g., polyethylene glycol; PEG) to proteins is well established and has been shown to modulate the pharmacokinetic properties of the modified proteins. For example, PEG modification of proteins has been shovvn to alter the in vivo circulating half-life, antigenicity, solubility, and resistance to proteolysis of the protein (Abuchowski et al., J. Biol. Chem.
1977, 252:3578; Nucci et al., Adv. D ug Delive7), Reviews 1991, 6:133; Francis et al., Pharmaceutical Biotechnology Vol. 3 (Borchardt, R. T. ed.); and Stability of Protein Pharmaceuticals: i vivo Pathways of Degradation and Strategies for Protein Stabilization 1991 pp235-263, Plenum, NY).
Both site-specific and random PEGylation of protein molecules is known in the art (See, for example, Zalipsky and Lee, Polv(ethylene glvcol Chemistry:
Biotechnical and Biomedical Applications 1992, pp 347-370, Plenum, NY; Goodson and Katre, 1990, Bio/Tech.nology, 8:343; Hershfield et al., 1991, PNAS
88:7185).
More specifically, random PEGylation of antibody molecules has been described at lysine residues and thiolated derivatives (Ling and Mattiasson, 1983, Ifsam.unol.
Methods 59: 327; Willcinson et al., 1987, Inanaunol. Letters, 15: 17; Kitamura et al., 1991, Cancer Res. 51:4310; Delgado et al., 1996 Br. J. Cancer, 73: 175; Pedley et al., 1994, Br. J. Cancer, 70:1126).
SUMMARY OF THE INVENTION
The invention relates to antibody polypeptides that monovalently bind CD40L. Because of the clear importance of CD40L in the production of antibodies, the CD40ICD40L interaction and pathways present important targets for the development of therapeutic approaches for the treatment of diseases and disorders that involve inappropriate or excessive antibody responses, such as autoimmune diseases. Antibody polypeptides that are monovalent for binding of CD40L can inhibit CD40L activity, including binding and activation of CD40 on the B cell surface and downstream effects, while avoiding potential undesirable effects that can occur with antibodies capable of divalent or multivalent binding of CD40L.
Monovalent anti-CD40L antibody polypeptides can also be applied to any of a number of uses for which standard divalent antibodies are also used, e.g., in vivo imaging and diagnosis.
In one aspect, the antibody polypeptide consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD40L, preferably without substantially agonizing CD40 and/or CD40L
activity.
In another aspect, because human antibodies will avoid the generation of an immune response to the antibodies when administered to human subjects for the treatment or prevention of disease, the antibody polypeptide is a human antibody polypeptide that monovalently binds CD40L, preferably without substantially agonizing CD40 and/or CD40L activity.
In summary then, in one embodiment, the invention provides an - antibody polypeptide, preferably a human antibody polypeptide, that is monovalent for binding to CD40L (gp39).
In one embodiment, the human antibody polypeptide dissociates from human CD40L with a Kd in the range of 50 nM to 20 pM, inclusive, as measured by surface plasmon resonance. For example, the Kd for human CD40L can be 25 nM to 20 pM, 10 nM to 20 pM, 5 nm to 20 pM, 1 nM to 20 pM, 0.5 nM to 20 pM, 0.1 nM to 20 pM, 0.1 nM to 50 nM, 75 pM to 20 pM or even 50 pM to 20 pM.
Unless otherwise stated, all ranges described herein are inclusive of the specific endpoints.
In another embodiment, the antibody polypeptide inhibits the binding of CD40L to CD40.
In another embodiment, the binding of the antibody polypeptide to CD40L
does not substantially agonize CD40 and/or CD40L activity.
In anotller embodiment, the human antibody polypeptide inhibits the binding of CD40 to CD40L, and does not substantially agonize signaling by CD40.
In anotller embodiment, the binding of the antibody polypeptide to CD40L
does not substantially induce JNK phosphorylation in Jurkat T-cells.
In another embodiment, the binding of the antibody polypeptide to CD40L
does not substantially induce IFN-y secretion by Jurkat T-cells co-stimulated with anti-CD3 antibody.
In another embodiment, the presence of the antibody polypeptide in a standard platelet aggregation assay does not result in aggregation of more than 25%
over the aggregation observed in a negative control assay performed without the addition of antibody.
In another embodiment, the human antibody polypeptide comprises a single immunoglobulin variable domain that binds CD40L. In a preferred embodiment, the single immunoglobulin variable domain is a VH or a VL domain.
In another embodiment, the antibody polypeptide is selected from the group consisting of a dAb, a FAb, an scFv, an Fv, or a disulfide-bonded Fv.
In another embodiment, the human antibody polypeptide is PEG-linked. In one embodiment, the PEG is covalently linked to the human antibody polypeptide. In one preferred embodiment, the PEG-linked human antibody polypeptide has a hydrodynamic size of at least 24 kD. In another preferred embodiment, the PEG
is linked to the antibody polypeptide at a cysteine or lysine residue. In another preferred embodiment, the total PEG size is from 20 to 60 1cD, inclusive. In another preferred embodiment, the PEG-linl:ed human antibody polypeptide has a hydrodynamic size of at least 200 kD.
In one embodiment, the antibody polypeptide has an increased in vivo half-life relative to the same antibody polypeptide composition lacking polyethylene glycol.
In another embodiinent, the ta-half life of the antibody polypeptide composition is increased by 10% or more. In another embodiment, the ta-half life of the antibody polypeptide composition is increased by 50% or more. In another embodiment, the ta-half life of the antibody polypeptide composition is increased by 2X or more. In another embodiment, the ta-half life of the antibody polypeptide composition is increased by 5X or more, e.g., IOX, 15X, 20X, 25X, 30X, 40X, or more. In another embodiment, the ta-half life of the antibody polypeptide composition is increased by 50X or more.
In another embodiment, the PEG-linked antibody polypeptide has a ta half-life of 0.25 to 6 hours, inclusive. In another embodiment, the ta half-life is in the range of 30 minutes to 12 hours, inclusive. In another embodiment, the ta-half life of the antibody polypeptide composition is in the range of 1 to 6 hours.
In another embodiment, the t(3-half life of the antibody polypeptide composition is increased by 10% or more. In another embodiment, the t(3-half life of the antibody polypeptide composition is increased by 50% or more. In another embodiment, the t(3-half life of the antibody polypeptide composition is increased by 2X or more. In another embodiment, the tp-half life of the antibody polypeptide composition is increased by 5X or more, e.g., lOX, 15X, 20X, 25X, 30X, 40X, or more. In another embodiment, the t(3-half life of the antibody polypeptide composition is increased by 50X or more.
In another embodiment, the antibody polypeptide composition has a t(3 half-life of 1 to 170 hours, inclusive. In another embodiment, the t(3-half life is in the range of 12 to 48 hours, inclusive. In another embodiment, the t(3-half life is in the range of 12 to 26 hours, inclusive.
In addition, or alternatively to the above criteria, the present invention provides a dAb containing composition comprising a ligand according to the invention having an AUC value (area under the curve) in the range of 1 mg.min/ml or more. In one embodiment, the lower end of the range is 5, 10, 15, 20, 30, 100, 200 or 300 mg.min/ml. In addition, or alternatively, a ligand or composition according to the invention has an AUC in the range of up to 600 mg.min/ml. In one embodiment, the upper end of the range is 500, 400, 300, 200, 150, 100, 75 or 50 mg.min/ml.
Advantageously a ligand according to the invention will have an AUC in the range selected from the group consisting of the following: 15 to 150 mg.min/ml, 15 to 100 mg.min/ml, 15 to 75 mg.min/ml, and 15 to 50 mg.min/ml.
In another embodiment, the antibody polypeptides described herein can be linked to human serum albumin (HSA), which also has the effect of increasing the ifl vivo half life of the molecule. The human serum albumin coding sequences can be obtained by PCR using primers derived from the cDNA sequence available at GenBank Accession No. NM000477. Such coding sequences can be fused to the coding sequence for a monovalent anti-CD40L antibody polypeptide as described herein, and the fusion can be expressed by one of skill in the art.
In another embodiment, the ta-half life of the HSA-linlced human antibody polypeptide composition is increased by 10% or more.
In another embodiment, the ta-half life of the HSA-linked human antibody polypeptide composition is in the range of 0.25 hours to 6 hours.
In another embodiment, the t(3-half life of the HSA-linked human antibody polypeptide composition is increased by 10% or more.
In another embodiment, the t(3-half life of the HSA-linked human antibody polypeptide composition is in the range of 12 to 48 hours.
In another embodiment, the human antibody polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs 7-82 and 246-360.
In another embodiment, the human antibody polypeptide inhibits binding of CD40L to CD40 with an IC50 in the range of 20 pM to 1.5 M, inclusive; IC50 for inhibition of CD40L binding to CD40 in any embodiment described herein is preferably measured as described herein in Example 6. The IC;o can preferably be in the range of 20 pM to 1 M, 20 pM to 900 nM, 20 pM to 800 nM, 20 pM to 700 nM, 20 pM to 600 nM, 20 pM to 500 nM, 20 pM to 400 nM, 20 pM to 300 nM, 20 pM to 200 nM, 20 pM to 100 nM, or 20 pM to 50 nM. Further acceptable or preferred ranges include, for example, 50 pM to 1 M, 100 pM to 500 nM, 125 pM to 250 n2v1, 150 pM to 200 nM, 150 pM to 100 nM and 200 pM to 50 nM.
In another embodiment, the antibody polypeptide is fused to a second antibody polypeptide which binds a ligand other than CD40L. In a preferred embodiment, the antibody polypeptide which binds a ligand other than CD40L
binds a ligand selected from the group consisting of HSA, TNFa, IL-1, IL-2, IL-4, IL-6, IL-8, IL-12, IL-18, IFN-y, CD2, CD4, CDB, CTLA4, LFA1, LFA3, VLA4, CD80 (B7-1), CD28, CD86 (B7-2), and CTLA-4.
In another embodiment, the human antibody polypeptide is free of an Fc domain. The limits of an Fc domain are set out in Kabat et al. (1991, Sequences of Immunological Interest, 5'l' ed. U.S. Dept. Health & Human Services, Washington, D.C.; incorporated herein by reference). In the alternative, an Fc domain consists of the CH2-CH3 regions, optionally including a hinge region linked to the CH2. In a preferred embodiment, the human antibody polypeptide does not mediate platelet aggregation in a standard platelet aggregation assay.
The invention furtller encompasses a human antibody polypeptide which has an amino acid sequence at least 85% identical to a sequence selected from the group consisting of SEQ ID NOs 7-82 and 246-360, which antibody polypeptide specifically and monovalently binds CD40L.
The invention further encompasses an antigen-binding polypeptide, the polypeptide comprising a single immunoglobulin variable domain which specifically and monovalently binds CD40L. Recited differently, the invention further encoinpasses a polypeptide comprising a moiety ~ihich specifically binds CD40L, which moiety consists of a single immunoglobulin variable domain.
In one embodiment, the polypeptide consists of a human single immunoglobulin variable domain.
In another embodiment, the polypeptide has a Kd for human CD40L in the range of 50 nM to 20 pM, inclusive, as determined by surface plasmon resonance.
For example, the Kd for human CD40L can be 25 nM to 20 pM, 10 nM to 20 pM, 5 nm to 20 pM, 1 nM to 20 pM, 0.5 nM to 20 pM,Ø1 nM to 20 pM, 75 pM to 20 pM
or even 50 pM to 20 pM.
In another embodiment, the polypeptide inhibits the binding of CD40L to CD40.
In another embodiment, the polypeptide inhibits the binding of CD40 to CD40L and has an IC5o in the range of 20 pM to 1.5 M, inclusive. For example, the IC50 can be in the range of 20 pM to 1 M, 20 pM to 900 nM, 20 pM to 800 nM, pM to 700 nM, 20 pM to 600 nM, 20 pM to 500 nM, 20 pM to 400 nM, 20 pM to 300 nM, 20 pM to 200 nM, 20 pM to 100 nM, or 20 pM to 50 nM. Further acceptable or preferred ranges include, for example, 50 pM to 1 M, 100 pM to 500 nM, 125 pM
to 250 nM, 150 pM to 200 nM, 150 pM to 100 nM and 200 pM to 50 nM.
In another embodiment, the binding of the polypeptide to CD40L does not substantially agonize CD40 and/or CD40L activity.
In another embodiment, the binding of the polypeptide to CD40L does not substantially induce JNK phosphorylation in Jurkat T-cells.
In another embodiment, the binding of the polypeptide to CD40L does not substantially induce IFN-y secretion by Jurl:at T-cells co-stimulated with anti-CD3 antibody.
In another embodiment, the presence of the antibody polypeptide in a standard platelet aggregation assay does not result in aggregation more than 25% over the aggregation observed in a negative control assay lacking antibody polypeptide.
In another embodiment, the single immunoglobulin variable domain is a human single immunoglobulin variable domain.
In another embodiment, the single immunoglobulin variable domain is a VH or a VL domain.
In one embodiment, the polypeptide is PEG-linked. In one embodiment, the PEG is covalently linked. In one preferred embodiment, the PEG-linked antigen-binding polypeptide has a hydrodynamic size of at least 24 kD. In another preferred embodiment, the PEG is linked to the antigen-binding polypeptide at a cysteine or lysine residue. In another preferred embodiment, the total PEG size is from 20 to 60 kD, inclusive. In another preferred embodiment, the PEG-linked antigen-binding polypeptide has a hydrodynamic size of at least 200 kD.
In another embodiment, the PEG-linked polypeptide has an increased in vivo half-life relative to the same polypeptide composition lacking linked polyethylene glycol. In another embodiment, the ta-half life of the polypeptide composition is increased by 10% or more. In another embodiment, the ta-half life of the polypeptide composition is increased by 50% or more. In another embodiment, the ta-half life of the polypeptide composition is increased by 2X or more. In another embodiment, the ta-half life of the polypeptide composition is increased by 5X or more, e.g., IOX, 15X, 20X, 25X, 30X, 40X, or more. In another embodiment, the ta-half life of the polypeptide composition is increased by 50X or more.
In another embodiment, the PEG-linked antibody polypeptide has a ta half-life of 0.25 to 6 hours, inclusive. In another embodiment, the ta half-life is in the range of 30 minutes to 12 hours, inclusive. In another embodiment, the ta-half life of the polypeptide composition is in the range of 1 to 6 hours.
In another embodiment, the tp-half life of the polypeptide composition is increased by 10% or more. In another embodiment, the tp-half life of the polypeptide composition is increased by 50% or more. In another embodiment, the tp-half life of the polypeptide composition is increased by 2X or more. In another embodiment, the tp-half life of the polypeptide composition is increased by 5X or more, e.g., IOX, 15X, 20X, 25X, 30X, 40X, or more. In another embodiment, the tp-half life of the polypeptide composition is increased by 50X or more.
In another embodiment, the antibody polypeptide composition has a t(3 half-life of 1 to 170 hours, inclusive. In another embodiment, the tp-half life is in the range of 12 to 48 hours, inclusive. In another embodiment, the tp-half life is in the range of 12 to 26 hours, inclusive.
In another embodiment, the composition has an AUC value (area under the curve) in the range of 1 tng.min/ml or more. In one embodiment, the lower end of the range is 5, 10, 15, 20, 30, 100, 200 or 300 mg.min/ml. In addition, or alternatively, a ligand or composition according to the invention has an AUC in the range of up to 600 mg.min/ml. In one embodiment, the upper end of the range is 500, 400, 300, 200, 150, 100, 75 or 50 mg.min/ml. Advantageously a ligand according to the invention will have an AUC in the range selected from the group consisting of the following: 15 to 150 mg.min/ml, 15 to 100 mg.min/ml, 15 to 75 mg.min/ml, and to 50 mg.min/ml.
In anotller embodiment, the antibody polypeptide is linked to human serum albumin (HSA). In another embodimeilt, the antibody polypeptide has an increased in vivo half-life relative to the same polypeptide coinposition lacking linked HSA. In another embodiment, the antibody polypeptide has a ta-half life that is increased by 10% or more relative to a molecule lacking linked HSA. In another einbodiment, the ta-half life of the polypeptide composition is in the range of 0.25 minutes to 6 hours.
In another embodiment, the tp-half life of the polypeptide composition is increased by 10% or more. In another embodiment, the tJ3-half life is in the range of 12 to hours.
In another embodiment, the antigen-binding polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs 7-82 and 246-360.
In another embodiment, the antigen-binding polypeptide is free of an Fc domain.
In another aspect, the invention encompasses an immunoglobulin variable domain polypeptide which has an amino acid sequence at least 85% identical to a sequence selected from the group consisting of SEQ ID NOs 7-82 and 246-360, which polypeptide specifically and monovalently binds CD40L.
In one embodiment, the immunoglobulin variable domain polypeptide antagonizes the binding of CD40L to CD40.
In another embodiment, the immunoglobulin variable domain polypeptide inhibits the binding of CD40 to CD40L and has an ICSo in the range of 20 pM to 1.5 M, inclusive. For example, the IC50 can be in the range of 20 pM to 1 M, 20 pM to 900 nM, 20 pM to 800 nM, 20 pM to 700 nM, 20 pM to 600 nM, 20 pM to 500 nM, pM to 400 nM, 20 pM to 300 nM, 20 pM to 200 nM, 20 pM to 100 nM, or 20 pM
20 to 50 nM. Further acceptable or preferred ranges include, for example, 50 pM to 1 M, 100 pM to 500 nM, 125 pM to 250 nM, 150 pM to 200 nM, 150 pM to 100 nM
and 200 pM to 50 nM.
In another embodiment, the immunoglobulin variable domain polypeptide inhibits the interaction of CD40 with CD40L, but does not substantially agonize intracellular signaling by CD40. In a preferred embodiment, the binding of the polypeptide to CD40L does not substantially induce JNK phosphorylation in Jurkat T-cells. In another preferred embodiment, the binding of the polypeptide to does not substantially induce IFN-y secretion by Jurkat T-cells co-stimulated with anti-CD3 antibody. In another preferred embodiment, the binding of the antibody polypeptide to CD40L does not substantially induce platelet aggregation in a platelet aggregation assay.
In another embodiment, the antigen-binding polypeptide further comprises a second antibody polypeptide which binds a ligand other than CD40L. In a preferred embodiment, the second antibody polypeptide binds a ligand selected from the group consisting of HSA, TNFa, IL-l, IL-2, IL-4, IL-6, IL-8, IL-12, IL-18, IFN-y, CD2, CD4, CDS, CTLA4, LFA1, LFA3 and VLA4.
In one embodiment, the invention relates to an antibody polypeptide comprising an immunoglobulin variable domain which specifically and monovalently binds CD40L (e.g., an anti-CD40L dAb, FAb, an scFv, an Fv, or a disulfide-bonded Fv), and which comprises one or more framework regions comprising an amino acid sequence that is the same as the amino acid sequence of a corresponding framework region encoded by a human germline antibody gene segment, or the amino acid sequence of one or more of said framework regions collectively comprises up to amino acid differences relative to the amino acid sequence of said corresponding framework region encoded by a human germline antibody gene segment.
In one embodiment, the amino acid sequences of FW1, FW2, FW3 and FW4 of the anti-CD40L variable domain or dAb are the same as the amino acid sequences of corresponding frainework regions encoded by a human germline antibody gene segment, or the amino acid sequences of FWI, FW2, FW3 and FW4 collectively contain up to 10 amino acid differences relative to the amino acid sequences of corresponding frameworlc regions encoded by said human germline antibody gene segment. In a further embodiment, the amino acid sequences of FW1, FW2 and FW3 of the anti-CD40L variable domain or dAb are the same as the amino acid sequences of corresponding framework regions encoded by human germline antibody gene segments.
In a further embodiment of the foregoing, the human germline antibody gene segment can be selected from the group consisting of DP47, DP45, DP48 and DPK9.
The invention further encompasses a method of antagonizing the binding of CD40 to CD40L in an individual, the method comprising administering a monovalent anti-CD40L antibody polypeptide as described .lierein to the individual, wherein the polypeptide antagonizes the binding of CD40 to CD40L in the individual.
The invention further encompasses a method of antagonizing an activity of CD40 or CD40L in an individual, the method comprising administering a monovalent anti-CD40L antibody polypeptide as described herein to the individual, wherein the polypeptide antagonizes an activity of CD40 or CD40L or both.
The invention further encompasses a composition comprising an extended release formulation comprising a monovalent anti-CD40L antibody polypeptide, preferably, but not limited to, a polypeptide comprising a single immunoglobulin variable domain that binds CD40L. In one embodiment, the single immunoglobulin variable domain is a non-human mammalian single immunoglobulin variable domain.
In another embodiment, the single immunoglobulin variable domain is a human single immunoglobulin variable domain.
A.
The invention further encompasses a method of treating or preventing a disease or disorder mediated by CD40L in an individual in need of such treatment, the method comprising administering to the individual a therapeutically effective amount of a composition comprising a monovalent anti-CD40L antibody polypeptide, preferably a composition comprising a single human immunoglobulin variable domain that binds CD40L. In one embodiment, the disease or disorder is an autoimmune disease or disorder.
The invention further encompasses a method of treating or preventing a symptom of systemic lupus erythematosus (SLE) in an individual, the method comprising administering a monovalent aiiti-CD40L antibody polypeptide to said individual in an amount effective to treat or prevent a symptom of SLE. The invention fui-ther encompasses a method of reducing or alleviating a symptom of a disease such as systemic lupus erythematosis, multiple sclerosis, rheumatoid arthritis, allograft rejection, xenograft rejection, and Diabetes, including insulin-dependent Type I Diabetes.
The invention further encompasses an antibody polypeptide that is monovalent for binding to CD40L, wherein the antibody polypeptide comprises a universal framework.
In one embodiment, the universal frameworlc comprises a VH framework selected from the group consisting of DP47, DP45 and DP38, and/or the VL
framework is DPK9.
In another embodiment, the antibody polypeptide comprises a generic ligand binding site. In another embodiment, the generic ligand binding site binds a generic ligand selected from the group consisting of protein A, protein L and protein G.
In another embodiment, the antibody polypeptide comprises a variable domain having one or more framework regions comprising an amino acid sequence that is the same as the amino acid sequence of a corresponding framework region encoded by a human germline antibody gene segment, or the amino acid sequences of one or more of the frameworlc regions collectively comprises up to 5 amino acid differences relative to the amino acid sequence of the corresponding framework region encoded by a human germline antibody gene segment.
In another embodiment, the antibody polypeptide comprises a variable domain, wherein the amino acid sequences of FWl, FW2, FW3 and FW4 are the same as the amino acid sequences of corresponding framework regions encoded by a human germline antibody gene segment, or the antibody sequences of FWl, FW2, FW3 aind FW4 collectively contain up to 10 amino acid differences relative to the amino acid sequences of corresponding framework regions encoded by the human germline antibody gene segment.
In anotller embodiment, the antibody polypeptide comprises an antibody variable domain comprising FWl, FW2 and FW3 regions, and the amino acid sequence of said FW1, FW2 and FW3 are the same as the amino acid sequences of corresponding framework regions encoded 'by human germline antibody gene segments. In another embodiment, the human germline antibody gene segment is selected from the group consisting of DP47, DP45, DP48 and DPK9.
The invention includes an antibody single variable domain polypeptide that binds to CD40L, wherein the polypeptide has an amino acid sequence that is identical to the amino acid sequence of DOM8-24, or differs from the amino acid sequence of DOM8-24 at no more than 25 amino acid positions and has a sequence that is at least 80% homologous to the sequence of DOM8-24. In one embodiment, the antibody single variable domain polypeptide differs form the amino acid sequence of 24 at 25 or fewer amino acid positions, 20 or fewer amino acid positions, 15 or fewer amino acid positions, 10 or fewer amino acid positions, 5 or fewer amino acid positions, 2 or fewer amino acid positions, or as few as one amino acid position. In a further embodiment, the antibody single variable domain polypeptide is at least 80%
homologous to the sequence of DOMB-24, for example, at least 85% homologous, at least 90% homologous, at least 95% homologous, and up to and including 96%, 97%, 98%, or 99% homologous.
The invention includes an antibody single variable domain polypeptide that binds to CD40L, wherein the polypeptide has an amino acid sequence that is identical to the amino acid sequence of DOM8-24, or differs from the amino acid sequence of DOMB-24 at no more than 25 amino acid positions and has a CDRI sequence that is at least 50% homologous to the CDRl sequence of DOMB-24, or has a CDR2 sequence that is at least 50% homologous to the CDR2 sequence of DOM8-24, or has a CDR3 sequence that is at least 50% homologous to the CDR3 sequence of DOM8-24.
The invention also includes an antibody single variable domain polypeptide that binds CD40L, wherein the dAb has an amino acid sequence that is identical to the amino acid sequence of DOM8-24, or differs from the amino acid sequence of DOMB-24 at no more than 25 amino acid positions and has a CDRI sequence that is at least 50% homologous to the CDRl sequence of DOM8-24 and has a CDR2 sequence that is at least 50% homologous to the CDR2 sequence of DOM8-24.
The invention also includes an antibody single variable domain polypeptide that binds CD40L, wherein the dAb has an amino acid sequence that is identical to the amino acid sequence of DOMB-24, or differs from the amino acid sequence of DOM8-24 at no more than 25 amino acid positions and has a CDR2 sequence that is at least 50% homologous to the CDR2 sequence of DOM8-24 and has a CDR3 sequence that is at least 50% homologous to the CDR3 sequence of DOM8-24.
The invention also includes an antibody single variable domain polypeptide that binds CD40L, wherein the dAb has an amino acid sequence that is identical to the amino acid sequence of DOM8-24, or differs from the amino acid sequence of DOM8-24 at no more than 25 amino acid positions and has a CDRl sequence that is at least 50% homologous to the CDRl sequence of DOM8-24 and has a CDR3 sequence that is at least 50% homologous to the CDR3 sequence of DOM8-24 .
The invention also includes an antibody single variable domain polypeptide that binds CD40L, wherein the dAb has an amino acid sequence that is identical to the amino acid sequence of DOM8-24, or differs from the amino acid sequence of DOM8-24 at no more than 25 amino acid positions and has a CDR1 sequence that is at least 50% homologous to the CDR1 sequence of DOMB-24 and has a CDR2 sequence that is at least 50% homologous to the CDR2 sequence of DOM8-24 and has a CDR3 sequence that is at least 50% homologous to the CDR3 sequence of DOM8-24.
In one embodiment, the antibody single variable domain polypeptide that binds to CD40L, if not identical in sequence to that of DOM8-24, differs form the amino acid sequence of DOM8-24 at 25 or fewer amino acid positions, 20 or fewer amino acid positions, 15 or fewer amino acid positions, 10 or fewer amino acid positions, 5 or fewer amino acid positions, 2 or fewer amino acid positions, or as few as one amino acid position.
The invention also includes a CD40L antagonist having a CDRI sequence that is at least 50% homologous to the CDRl sequence of DOMB-24.
The invention also includes a CD40L antagonist having a CDR2 sequence that is at least 50% homologous to the CDR2 sequence of DOMB-24.
The invention also includes a CD40L antagonist having a CDR3 sequence that is at least 50% homologous to the CDR3 sequence of DOMB-24.
The invention also includes a CD40L antagonist having a CDRI sequence that is at least 50% homologous to the CDR1 sequence of DOM8-24 and a CDR2 sequence that is at least 50% homologous to the CDR2 sequence of DOMB-24.
The invention also includes a CD40L antagonist having a CDR2 sequence that is at least 50% homologous to the CDR2 sequence of DOMB-24 and a CDR3 sequence that is at least 50% homologous to the CDR3 sequence of DOM8-24.
The invention also includes a CD40L antagonist having a CDR1 sequence that is at least 50% homologous to the CDR1 sequence of DOMB-24 and a CDR3 sequence that is at least 50% homologous to the CDR3 sequence of DOM8-24.
The invention also includes a CD40L antagonist having a CDRl sequence that is at least 50% homologous to the CDR1 sequence of DOM8-24 and a CDR2 sequence that is at least 50% homologous to the CDR2 sequence of DOM8-24 and a CDR3 sequence that is at least 50% homologous to the CDR3 sequence of DOM8-24.
In one embodiment the CD40L antagonist inhibits the binding of CD40 to CD40L, and/or inhibits an activity of CD40 and/or CD40L, and/or results in no more than 25% platelet aggregation in a platelet aggregation assay. In one embodiment, the antagonist results in platelet aggregation of 25% or less, 20% or less, 15% or less, 10% or less, 5% or less, and as little as zero platelet aggregation.
The invention- also includes a dual specific ligand comprising a first immunoglobulin single variable domain having a binding specificity to a first antigen and a second single variable domain having a binding activity to a second antigen, wherein the first antigen is CD40L and binding of the second single variable domain to the second antigen acts to increase the half-life of the ligand in vivo. In one embodiment, the dual specific ligand is a four chain IgG immunoglobulin.
In one embodiment, the four chain IgG comprises two dual specific ligands, said dual specific ligands being different in their variable domains.
The invention also includes a dual specific ligand comprising ai1 anti-human CD40L dAb and an anti-SA dAb.
In one embodiment, the dAbs are Camelid VHH domains.
In one embodiment of the dual specific ligand, either (i) the first and second immunoglobulin variable domains are heavy chain variable domains; or (ii) the first and the second immunoglobulin variable domains are light chain variable domains.
In one embodiment, the ligand is provided as an IgG immunoglobulin comprising four heavy chain single variable domains or four light chain single variable domains. The heavy chain can comprise Camelid VHH domains.
In a further embodiment of the dual specific ligand, the first and second domains bind independently, such that the dual specific ligand may simultaneously bind both the first and second antigens.
In one embodiment of the dual specific ligand, the first single variable domain has a dissociation constant (Kd) of lxl0"s M or less for human CD40L, and a Koff rate constant of lxl0-3 s1 or less, as determined by surface plasmon resonance.
In one embodiment of the.dual specific ligand, the second single variable domain is specific for serum albumin (SA) and has a dissociation constant (Kd) of InM to 500 m for SA, as determined by surface plasmon resonance.
In a further embodiment, the second domain binds SA in a standard ligand binding assay with an IC50 of 1nM to 500 M. The second single variable domain may be specific for SA, and comprise the amino acid sequence of MSA-16 or a sequence that is at least 80% homologous tllereto. Alternatively, the second single variable domain may be specific for SA, and comprise the amino acid sequence of MSA-26 or a sequence that is at last 80% homologous thereto.
In one embodiment of the dual specific ligand, the anti-CD40L variable domain or dAb comprises a universal framework. The anti-CD40L variable domain or dAb may also comprise a VH framework selected from the group consisting of DP47, DP45 and DP38; or a VL framework which is DPK9. In a further embodiment, the dual specific ligand or dAb can comprise a binding site for a generic ligand.
In one embodiment, the generic ligand binding site is selected from the group consisting of protein A, protein L and protein G binding site.
In one embodiment of the dual specific ligand, the anti-CD40L variable domain or dAb comprises one or more framework regions comprising an amino acid sequence that is the same as the amino acid sequence of a corresponding framework region encoded by a human germline antibody gene segment, or the amino acid sequence of one or more of said framework regions collectively comprises up to amino acid differences relative to the amino acid sequence of said corresponding frameworlc region encoded by a human germline antibody gene segment.
In one embodiment, the amino acid sequences of FWI, FW2, FW3 and FW4 of the anti-CD40L variable domain or dAb are the same as the amino acid sequences of corresponding framework regions encoded by a human germline antibody gene segment, or the amino acid sequences of FW1, FW2, FW3 and FW4 collectively contain up to 10 amino acid differences relative to the amino acid sequences of corresponding framework regions encoded by said human germline antibody gene segment.
In one embodiment, the ainino acid sequences of said FWI, FW2 and FW3 of the anti-CD40L variable domain or 'dAb are the same as the ainino acid sequences of corresponding framework regions encoded by human germline antibody gene segments. The human germline antibody gene segments are preferably selected from the group consisting of DP47, DP45, DP48 and DPK9.
The invention also includes a metl7od for producing a dual specific ligand as described herein, comprising a first immunoglobulin single variable domain having a binding specificity for CD40L and a second single immunoglobulin single variable domain having a binding specificity for a protein which increases the half-life of the ligand in vivo, the method comprising the steps of:selecting a first variable domain by its ability to bind CD40L; selecting a second variable domain by its ability to bind to said protein; combining the variable domains; and selecting the ligand by its ability to bind to CD40L and said protein.
In one embodiment, the first variable domain is selected for binding to CD40L
in absence of a complementary variable domain.
The invention also includes nucleic acid encoding a dual specific ligand described herein. The nucleic acid may comprise the nucleic acid sequence of MSA-16 or a sequence that is at least 80% homologous thereto, or alternatively may comprise, the nucleic acid sequence of MSA-26 or a sequence that is at least 70%
homologous thereto. The nucleic acid may be incorporated into a vector, which may be incorporated into a host cell.
The invention also includes a pharmaceutical composition comprising a dual specific ligand as described herein and a pharmaceutically acceptable excipient, carrier or diluent.
The invention also includes a dAb monomer specific for CD40L, which monomer has a dissociation constant (Kd) of Ix10"8 M or less for human CD40L, and a Kpff rate constant of 1X10"3 s"1 or less, as determined by surface plasmon resonance.
In one embodiment, the dAb monomer specific for CD40L has a dissociation constant (Kd) of 1x10-7 M or less, as determined by surface plasmon resonance.
In one embodiment, the dAb monomer has binding specificity to CD40L with a dissociation constant (Kd) of 1x10"8 M or less, as determined by surface plasmon resonance.
In one embodiment, the dAb monomer has binding specificity to CD40L with a dissociation constant (Kd) of 50nM to 20pM, as determined by surface plasmon resonance.
In one embodiment, the monomer inhibits binding of CD40 to CD40L with an IC50 of 50nM or less.
In a further embodiment, the dAb monomer has binding specificity to CD40L
with a Koff rate constant of 1x10"3 s"1 or less, 1x10-4 s"1 or less, lxl0-5 s I or less, or lxl0"6 s 1 or less,as determined by surface plasmon resonance.
In one embodiment, the dAb monomer neutralizes CD40L in a standard assay with an ND50 of 50nM or less.
In invention also includes a dual specific ligand comprising first and second heavy chain single variable domains, or first and second light chain single variable domains, wherein the first variable domain is an anti-CD40L dAb monomer.
In one embodiment, the second variable domain has binding specificity for an antigen other than CD40L.
In a further embodiment, the second variable domain has binding specificity for an antigen selected from the group consisting of EPO receptor, ApoE, Apo-SAA, BDNF, Cardiotrophin-l, EGF, EGF receptor, ENa-78, Eotaxin, Eotaxin-2, Exodus-2, EpoR, FGF-acidic, FGF-basic, fibroblast growth factor-10, FLT3 ligand, Fractalkine (CX3C), GDNF, G-CSF, GM-CSF, GF-bl, insulin, IFN-g, IGF-I, IGF-II, IL-la, II-lb, IL-2, I1-3, IL-4, IL-5, IL-6, IL-7, IL-8 (72 a.a.), IL-8 (77 a.a.), IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, IL-16, IL-17, IL-18 (IGIF), Inhibin a, Inhibin b, IP-10, keratinocyte growth factor-2 (KGF-2), KGF, Leptin, LIF, Lymphotactin, Mullerian inhibitory substance, monocyte colony inhibitory factor, monocyte attractant protein, M-CSF, MDC (67 a.a.), h/IDC (69 a.a.), MCP-1 (MCAF), MCP-2, MCP-3, MCP-4, MDC (67 a.a.), MIG, MIP-la, MIP-ib, MIP-3a, MIP-3b, MIP-4, myeloid progenitor inhibitor factor-1 (MPIF-1), NAP-2, Neurturin, Nerve growtli factor, b-NGF, NT-3, NT-4, Oncostatin M, PDGF-AA, PDGF-AB, PDGF-BB, PF-4, RANTES, SDFla, DFGlb SCF, SCGF, stem cell factor, (SCF), TARC, TGF-a, TGF-b, TGF-b2; TGF-b3, tumour necrosis factor (TNF), TNF-a, TNF-b, TNF receptor I, TNF receptor II, TNIL-1, TPO, VEGF, VEGF receptor 1, VEGF receptor 2, VEGF receptor-3, GCP-2, GRO/MGSA, GRO-b, GRO-g, HCC1, 1-309, HER 1, HER 2, HER 3, HER 4, TACE
recognition site, TNF BP-1, TNF BP-II, and an antigen disclosed in Annex 2 or 3.
The invention also includes an antibody polypeptide that antagonizes or inhibits the binding of DOMS-24 to CD40L, or an antibody polypeptide that binds to the same epitope of CD40L bound by DOM8-24.
The invention also includes a dual specific ligand comprising a. first immunoglobulin single variable domain having a binding specificity to a first antigen and a second single variable domain having a binding activity to a second antigen, wherein the first antigen is CD40L and the second single variable domain is an Antigen Presenting Cell surface antigen or a T cell surface antigen. The Antigen Presenting Cell surface antigen can be selected from one of the group consisting of dendritic cell surface antigens, activated macrophage surface antigens, activated B
cell surface antigens, co-stimulatory signal pathway surface antigens, and MHC.
In one embodiment, the MHC is class II, and the class II can be alpha or beta.
The Antigen Presenting Cell surface antigen may be selected from the group consisting of CD28, Inducible costimulatory molecule (ICOS), CD27, CD30, OX40, CD45, CD69, CD3, CD70, Inducible costimulatory molecule ligand (ICOSL), OX40L, CD80, CD86, HVEM (Herpes Virus Entry Mediator), and LIGHT, but is preferably one of CD28, Inducible costimulatory molecule (ICOS), CD27, CD30, OX40, CD45, CD69, or CD3.
The surface antigen is preferably a B7 gene surface antigen such as B7-2 or B7-1.
Definitions:
As used herein, the term "human" when applied to an antibody polypeptide or to an immunoglobulin variable domain means that the polypeptide has a sequence derived from a human immunoglobulin. A sequence is "derived from" a human immunoglobulin coding sequence when the sequence is either: a) isolated from a human individual or from cells or a cell line from a human individual; b) isolated from a library of cloned human antibody gene sequences (or a library of human antibody V domain sequences); or c) when a cloned human antibody gene sequence (or a cloned human V region sequence (including, e.g., a germline V gene segment)) was used to generate one or more diversified sequences that were then selected for binding to a desired target antigen. The term "human" as applied herein to an antibody polypeptide or to an immunoglobulin variable domain does not encompass an immunoglobulin from another species, e.g., mouse, camel, etc., that has been "humanized" through grafting of human constant region sequences onto an antibody polypeptide (i.e., replacing non-human constant regions with human constant regions) or through grafting of human V region framework sequences onto an immunoglobulin variable domain from a non-human mammal (i.e., replacing non-human framework regions of a V domain with human framework regions).
At a minimum, a human variable domain has at least 85% amino acid similarity (including, for example, 87%, 90%, 93%, 95%, 97%, 99% or higher similarity) to a naturally-occurring human immunoglobulin variable domain sequence.
As used herein, the term "domain" refers to a folded protein structure which retains its tertiary structure independently of the rest of the protein.
Generally, domains are responsible for discrete functional properties of proteins, and in many cases may be added, removed or transferred to other proteins without loss of function of the remainder of the protein and/or of the domain.
By "single immunoglobulin variable domain" is meant a folded polypeptide domain which comprises a sequence characteristic of immunoglobulin variable domains and which specifically binds an antigen (e.g., dissociation constant of 500 nM or less). A "single immunoglobulin variable domain" therefore includes complete antibody variable domains as well as modified variable domains, for example in which one or more loops have been replaced by sequences which are not characteristic of antibody variable domains, or antibody variable domains which have been truncated or comprise N- or C-terminal extensions, as well as folded fragments of variable domains which retain a dissociation constant of 500 nM or less (e.g., 450 nM or less, 400 nM or less, 350 nM or less, 300 nM or less, 250 nM or less, 200 nM
or less, 150 nM or less, 100 nM or less) and the target antigen specificity of the full-length domain. Where necessary or in case of any doubt, the numbering convention and boundaries set forth by Kabat et al. (1991, supW) are applicable to immunoglobulin variable and constant domains referred to herein.
An antibody single variable domain polypeptide, as used herein refers to a mammalian single immunoglobulin variable domain polypeptide, preferably human, but also includes rodent (for example, as disclosed in W000/29004, the contents of wllich are incorporated herein in their entirety) or camelid VHH dAbs. Camelid dAbs are antibody single variable domain polypeptides which are derived from species including camel, llama, alpaca, dromedary, and guanaco, and comprise heavy chain antibodies naturally devoid of light chain: VHH. VHI3 molecules are about I Ox smaller than IgG molecules, and as single polypeptides, they are very stable, resisting extreme pH and temperature conditions. Moreover, camelid antibody single variable domain polypeptides are resistant to the action of proteases. Camelid antibodies are described in, for example, U.S. Pat. Nos. 5,759,808; 5,800,988; 5,840,526; 5,874,541;
The functional consequences of CD40L binding to CD40 include, for example, a) rescuing B cells from apoptosis induced by Fas or cross-linking of IgM, b) induction of the co-stimulator molecules CD80 (B7-1) and CD86 (B7-2) which interact with CD28 and CD152 (CTLA-4) on the surface of activated T cells; c) increased expression of other cell surface activation molecules including CD23, CD54, CD95 and lymphotoxin-a; and d) inducing immunoglobulin class switching (see Chess, supra, and references 25, 44, and 47-60 cited therein). CD40L
binding to CD40 also augments the antigen-presenting functions of dendritic cells, inducing maintenance of high levels of MHC class II antigens and upregulation of accessory molecules including CD58 (LFA-3). CD40L induces cytokine production and tumoricidal activity in peripheral blood monocytes. CD40L also co-stimulates the proliferation of activated T cells, and the co-stimulation is accompanied by the production of IFN-y, TNF-a and IL2. The expression of CD40L on murine T-helper cells and CD4+ T cells is inhibited by IFN-y, and is inhibited on T-helper-type 2 cells by TGF-(3.
CD40L upregulates the expression of CD54 by cultured Hodgkin and Reed-Sternberg cells. The increased CD54 surface expression is accompanied by increased shedding of surface-bound CD54.
CD40L has also been suggested to be important in the induction of tolerance -CD80 and CD86, which are upregulated by CD40L, interact with CD28 to provide essential co-stimulation of T cells, in concert with T cell receptor activation, that results in full activation of T cells. In the absence of CD80 and CD86-triggered activation of CD28, anergy or tolerance occurs as a consequence of antigen triggering (Linsley & Ledbetter, 1993, Ann. Rev. Immunol. 11- 191-212; Jenkins et al., 1993, Curr Opin. Immunol. 5: 361-367; and Boussiotis et al., 1996, Immunol. Rev.
153: 5-26).
The CD40L/CD40 pathway has been implicated in the in vivo priming of CD8+ cytotoxic T lymphocytes (CTSs) by CD4+ T cells. As noted, CD40L
expressed on the surface of activated CD4+ T cells interacts with CD40 expressed on dendritic cells, inducing the dendritic cells to express more MHC, and signaling through CD40 can replace the requirement for CD4+ T-helper cells in priming CDB+
CTL responses. Blockade of CD40L inhibits CTL priming, emphasizing the vital role of CD40L/CD40 interactions in CTL priming by helper T cells (Ridge et al., 1998, Nature 393: 474-478; Schoenberger.et al., 1998, Nature 393: 480-483; Bennett et al., 1998, Nature 393: 478-480).
CD40L can also mediate functional interactions of CD4+ T cells with other cells that express CD40, such as fibroblasts, synovial cells and endothelial cells (Yellin et al., 1995, J. Leuko. Biol. 58: 209-216; Yellin et al., 1995, J.
Exp. Med. 182:
1857-1864). CD40L induces the expression of CD54 (ICAM-1) and CD106 (VCAM-1) by fibroblasts, as well as increasing fibroblast IL-6, collagenase and collagen production and inducing fibroblast proliferation. Thus, CD40L/CD40 interactions may be involved in the induction of fibrosis associated with autoiinmunity and immune responses.
CD40L interaction with CD40 induces endothelial cells to express CD62E (E-selectin), ICAM-1 and VCAM-1. The upregulation of these adhesion molecules may be involved in the binding of inflammatory cells to vascular endothelium and the subsequent migration of the inflammatory cells to sites of inflammation. CD40L
blockade retards the migration of leukocytes through endothelial cell barriers. In animal models of autoimmunity, antibodies to CD40L interfere with the accumulation of inflammatory cells at the site of inflammation.
CD40/CD40L interactions have been implicated in diseases having an immune or autoimmune connection. Animal models of immune-related disease in which the CD40L/CD40 pathway has been demonstrated to play a role in the pathology include, for example, murine nlodels of systemic lupus erythematosis (Lupus or SLE; see, e.g., Kalled et al., 1998, J. Immunol. 160: 2158-2165), arthritis (collagen-induced arthritis, see, e.g., Durie et al., 1993, Science 261: 1328-1330), multiple sclerosis (experimental autoimmune encephalomyelitis, EAE; see, e.g., Howard et al., 1999, J. Clin . Invest. 103: 281-290), autoimmune thyroiditis (experimental autoimmune thyroiditis, EAT; see, e.g., Caryanniotis et al., 1997, Immunology 90: 421-426), colitis (hapten-induced colitis; see, e.g., Stuber et al., 1996, J. Exp. Med. 183: 693-698), atherosclerosis and coronary artery disease (see, e.g., Mach et al., 1998, Nature 394: 200-203), and allograft rejection (see, e.g., Parker et al., 1995, Proc. Natl. Acad. Sci. U.S.A. 92: 9560-9564; Kirk et al., 1997, Proc.
Natl. Acad. Sci. U.S.A. 94: 8789-8794; Larsen et al., 1996, Nature 381: 434-438 and Blazar et al., 1997, J. Immunol. 158: 29-39).
CD40L antibody trials for treatment of human immune-related diseases include studies in patients with Lupus (see, e.g., Huang et al., 2002, Arthritis Rheum.
46: 1554-1562). A phase I trial demonstrated that anti-CD40L humanized monoclonal antibody (IDEC-131) is safe and well tolerated by patients with Lupus (Davis et al., 2001, J. Rheumatol. 28: 95-101). A phase II study with the IDEC-antibody showed improvement in clinical symptoms, but efficacy of the drug over placebo controls was not demonstrated (Kalunian et al., 2002, Arthritis Rheum.
46:
3251-3258). In a phase II study with BG9588 anti-CD40L antibody, clinical efficacy was demonstrated, but the study was terminated due to the occurrence of thromboembolic events (Boumpas et al., 2003, Arthritis Rheum. 48: 719-727).
U.S. Patent Nos. 5,474,771 (Lederman et al.) and 5,876,950 (Siadak et al.) disclose murine monoclonal antibodies specific for different epitopes of human gp39.
W095/06666 (Noelle & Foy) discloses murine anti-gp39 antibodies.
U.S. Patent No. 6,328,964 (Noelle & Claassen) discloses methods for the treatment of multiple sclerosis using gp39-specific antibodies.
U.S. Patent No. 5,747,037 (Noelle et al.), and EP0721469B 1 (Ledbetter et al.) and its U.S. counterpart U.S. 5,869,049 disclose anti-human monoclonal (mouse) .5 antibodies specific for gp39. U.S. Patent No. 5,876,718 (Noelle et al.) discloses methods of inducing T cell non-responsiveness to transplanted tissues and of treating graft-versus-host disease with anti-gp39 monoclonal (mouse) antibodies.
EP0742721B 1(Noelle et al.) discloses methods of inhibiting a humoral immune response to a thymus-dependent antigen that use anti-gp39 monoclonal (mouse) antibodies. U.S. Patent No. 6,375,950 describes metliods for inducing T cell unresponsiveness to donor tissue or organs in a transplant recipient through use of anti-gp39 monoclonal (murine) antibodies.
EP1005372B1 (De Boer et al.) describes methods for the selective killing of autoreactive CD40L+ T cells using anti-CD40L monoclonal (mouse) antibody-toxin fusion proteins.
U.S. Patent No. 6,340,459 (Yellin et al.) describes the use of murine anti gp39 monoclonal antibody 5c8 for the treatmeilt or prevention of reperfusion injury.
EP0831906B 1(Claassen et al.) describes methods for the treatment of T cell-mediated tissue destruction in autoimmune diseases such as multiple sclerosis using anti-gp39 monoclonal (mouse) antibodies. Antibodies used in therapeutic approaches in the prior art have been divalent antibodies of murine origin.
A number of smaller antigen binding fragments of naturally occurring antibodies have been identified following protease digestion. These include, for example, the "Fab fragment" (VL-CL-CHI-VH), "Fab' fragment" (a Fab with the heavy chain hinge region) and "F(ab')2 fragment" (a dimer of Fab' fragments joined by the heavy chain hinge region). Recombinant methods have been used to generate even smaller antigen-binding fragments, referred to as "single chain Fv"
(variable fragment) or "scFv," consisting of VL and VH joined by a synthetic peptide linker.
While the antigen binding unit of a naturally-occurring antibody (e.g., in humans and most other mammals) is generally known to be comprised of a pair of V
regions (VL/VH), camelid species express a large proportion of fully functional, highly specific antibodies that are devoid of liglit chain sequences. The camelid heavy chain antibodies are found as homodimers of a single heavy chain, dimerized via their constant regions. The variable domains of these camelid heavy chain antibodies are referred to as VHH domains and retain the ability, when isolated as fragments of the VH chain, to bind antigen with high specificity ((Hamers-Casterman et al., 1993, Nature 363: 446-448; Gahroudi et al., 1997, FEBS Lett. 414: 521-526). Antigen binding single VH domains have also been identified from, for example, a library of murine VH genes anlplified from genomic DNA from the spleens of immunized mice and expressed in E. coli (Ward et al., 1989, Nature 341: 544-546). Ward et al.
named the isolated single VH domains "dAbs," for "domain antibodies." The term "dAb"
will refer herein to an antibody single variable domain (VH or VL) polypeptide that specifically binds antigen. A "dAb" binds antigen independently of other V
domains;
however, as the term is used herein, a "dAb" can be present in a homo- or heteromultimer with other VH or VL domains where the other domains are not required for antigen binding by the dAb, i.e., where the dAb binds antigen independently of the additional VH or VL domains.
Antibody single variable domains, for example, VHH, are the smallest antigen-binding antibody unit known. For use in therapy, human antibodies are preferred, primarily because they are not as likely to provoke an immune response when administered to a patient. As noted above, isolated non-camelid VH domains tend to be relatively insoluble and are often poorly expressed. Comparisons of camelid VHH
with the VH domains of human antibodies reveals several key differences in the framework regions of the camelid VHH domain corresponding to the VH/VL
interface of the human VH domains. Mutation of these residues of human VH3 to more closely resemble the VHH sequence (specifically Gly 44-Glu, Leu 45--+Arg and Trp 47-->Gly) has been performed to produce "cainelized" human VH domains that retain antigen binding activity (Davies & Riechmann, 1994, FEBS Lett. 339: 285-290) yet have improved expression and solubility. (Variable domain amino acid numbering used herein is consistent with the Kabat numbering convention (Kabat et al., 1991, Sequences of Immunological Interest, 5t ed. U.S. Dept. Health & Human Services, Washington, D.C.)) WO 03/035694 (Muyldermans) reports that the Trp 103-Arg mutation improves the solubility of non-cainelid VH domains. Davies &
Riechmann (1995, Biotechnology N:Y. 13: 475-479) also report production of a phage-displayed repertoire of camelized human VH domains and selection of clones that bind hapten with affinities in the range of 100-400 nM, but clones selected for binding to protein antigen had weaker affinities.
While many antibodies and their derivatives are useful for diagnosis and therapy, the ideal pharmacokinetics of antibodies. are often not achieved for a particular application. In order to provide improvement in the pharmacokinetics of antibody molecules, the present invention provides single domain variable region polypeptides that are linked to polymers which provide increased stability and half-life. The attachment of polymer molecules (e.g., polyethylene glycol; PEG) to proteins is well established and has been shown to modulate the pharmacokinetic properties of the modified proteins. For example, PEG modification of proteins has been shovvn to alter the in vivo circulating half-life, antigenicity, solubility, and resistance to proteolysis of the protein (Abuchowski et al., J. Biol. Chem.
1977, 252:3578; Nucci et al., Adv. D ug Delive7), Reviews 1991, 6:133; Francis et al., Pharmaceutical Biotechnology Vol. 3 (Borchardt, R. T. ed.); and Stability of Protein Pharmaceuticals: i vivo Pathways of Degradation and Strategies for Protein Stabilization 1991 pp235-263, Plenum, NY).
Both site-specific and random PEGylation of protein molecules is known in the art (See, for example, Zalipsky and Lee, Polv(ethylene glvcol Chemistry:
Biotechnical and Biomedical Applications 1992, pp 347-370, Plenum, NY; Goodson and Katre, 1990, Bio/Tech.nology, 8:343; Hershfield et al., 1991, PNAS
88:7185).
More specifically, random PEGylation of antibody molecules has been described at lysine residues and thiolated derivatives (Ling and Mattiasson, 1983, Ifsam.unol.
Methods 59: 327; Willcinson et al., 1987, Inanaunol. Letters, 15: 17; Kitamura et al., 1991, Cancer Res. 51:4310; Delgado et al., 1996 Br. J. Cancer, 73: 175; Pedley et al., 1994, Br. J. Cancer, 70:1126).
SUMMARY OF THE INVENTION
The invention relates to antibody polypeptides that monovalently bind CD40L. Because of the clear importance of CD40L in the production of antibodies, the CD40ICD40L interaction and pathways present important targets for the development of therapeutic approaches for the treatment of diseases and disorders that involve inappropriate or excessive antibody responses, such as autoimmune diseases. Antibody polypeptides that are monovalent for binding of CD40L can inhibit CD40L activity, including binding and activation of CD40 on the B cell surface and downstream effects, while avoiding potential undesirable effects that can occur with antibodies capable of divalent or multivalent binding of CD40L.
Monovalent anti-CD40L antibody polypeptides can also be applied to any of a number of uses for which standard divalent antibodies are also used, e.g., in vivo imaging and diagnosis.
In one aspect, the antibody polypeptide consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD40L, preferably without substantially agonizing CD40 and/or CD40L
activity.
In another aspect, because human antibodies will avoid the generation of an immune response to the antibodies when administered to human subjects for the treatment or prevention of disease, the antibody polypeptide is a human antibody polypeptide that monovalently binds CD40L, preferably without substantially agonizing CD40 and/or CD40L activity.
In summary then, in one embodiment, the invention provides an - antibody polypeptide, preferably a human antibody polypeptide, that is monovalent for binding to CD40L (gp39).
In one embodiment, the human antibody polypeptide dissociates from human CD40L with a Kd in the range of 50 nM to 20 pM, inclusive, as measured by surface plasmon resonance. For example, the Kd for human CD40L can be 25 nM to 20 pM, 10 nM to 20 pM, 5 nm to 20 pM, 1 nM to 20 pM, 0.5 nM to 20 pM, 0.1 nM to 20 pM, 0.1 nM to 50 nM, 75 pM to 20 pM or even 50 pM to 20 pM.
Unless otherwise stated, all ranges described herein are inclusive of the specific endpoints.
In another embodiment, the antibody polypeptide inhibits the binding of CD40L to CD40.
In another embodiment, the binding of the antibody polypeptide to CD40L
does not substantially agonize CD40 and/or CD40L activity.
In anotller embodiment, the human antibody polypeptide inhibits the binding of CD40 to CD40L, and does not substantially agonize signaling by CD40.
In anotller embodiment, the binding of the antibody polypeptide to CD40L
does not substantially induce JNK phosphorylation in Jurkat T-cells.
In another embodiment, the binding of the antibody polypeptide to CD40L
does not substantially induce IFN-y secretion by Jurkat T-cells co-stimulated with anti-CD3 antibody.
In another embodiment, the presence of the antibody polypeptide in a standard platelet aggregation assay does not result in aggregation of more than 25%
over the aggregation observed in a negative control assay performed without the addition of antibody.
In another embodiment, the human antibody polypeptide comprises a single immunoglobulin variable domain that binds CD40L. In a preferred embodiment, the single immunoglobulin variable domain is a VH or a VL domain.
In another embodiment, the antibody polypeptide is selected from the group consisting of a dAb, a FAb, an scFv, an Fv, or a disulfide-bonded Fv.
In another embodiment, the human antibody polypeptide is PEG-linked. In one embodiment, the PEG is covalently linked to the human antibody polypeptide. In one preferred embodiment, the PEG-linked human antibody polypeptide has a hydrodynamic size of at least 24 kD. In another preferred embodiment, the PEG
is linked to the antibody polypeptide at a cysteine or lysine residue. In another preferred embodiment, the total PEG size is from 20 to 60 1cD, inclusive. In another preferred embodiment, the PEG-linl:ed human antibody polypeptide has a hydrodynamic size of at least 200 kD.
In one embodiment, the antibody polypeptide has an increased in vivo half-life relative to the same antibody polypeptide composition lacking polyethylene glycol.
In another embodiinent, the ta-half life of the antibody polypeptide composition is increased by 10% or more. In another embodiment, the ta-half life of the antibody polypeptide composition is increased by 50% or more. In another embodiment, the ta-half life of the antibody polypeptide composition is increased by 2X or more. In another embodiment, the ta-half life of the antibody polypeptide composition is increased by 5X or more, e.g., IOX, 15X, 20X, 25X, 30X, 40X, or more. In another embodiment, the ta-half life of the antibody polypeptide composition is increased by 50X or more.
In another embodiment, the PEG-linked antibody polypeptide has a ta half-life of 0.25 to 6 hours, inclusive. In another embodiment, the ta half-life is in the range of 30 minutes to 12 hours, inclusive. In another embodiment, the ta-half life of the antibody polypeptide composition is in the range of 1 to 6 hours.
In another embodiment, the t(3-half life of the antibody polypeptide composition is increased by 10% or more. In another embodiment, the t(3-half life of the antibody polypeptide composition is increased by 50% or more. In another embodiment, the t(3-half life of the antibody polypeptide composition is increased by 2X or more. In another embodiment, the tp-half life of the antibody polypeptide composition is increased by 5X or more, e.g., lOX, 15X, 20X, 25X, 30X, 40X, or more. In another embodiment, the t(3-half life of the antibody polypeptide composition is increased by 50X or more.
In another embodiment, the antibody polypeptide composition has a t(3 half-life of 1 to 170 hours, inclusive. In another embodiment, the t(3-half life is in the range of 12 to 48 hours, inclusive. In another embodiment, the t(3-half life is in the range of 12 to 26 hours, inclusive.
In addition, or alternatively to the above criteria, the present invention provides a dAb containing composition comprising a ligand according to the invention having an AUC value (area under the curve) in the range of 1 mg.min/ml or more. In one embodiment, the lower end of the range is 5, 10, 15, 20, 30, 100, 200 or 300 mg.min/ml. In addition, or alternatively, a ligand or composition according to the invention has an AUC in the range of up to 600 mg.min/ml. In one embodiment, the upper end of the range is 500, 400, 300, 200, 150, 100, 75 or 50 mg.min/ml.
Advantageously a ligand according to the invention will have an AUC in the range selected from the group consisting of the following: 15 to 150 mg.min/ml, 15 to 100 mg.min/ml, 15 to 75 mg.min/ml, and 15 to 50 mg.min/ml.
In another embodiment, the antibody polypeptides described herein can be linked to human serum albumin (HSA), which also has the effect of increasing the ifl vivo half life of the molecule. The human serum albumin coding sequences can be obtained by PCR using primers derived from the cDNA sequence available at GenBank Accession No. NM000477. Such coding sequences can be fused to the coding sequence for a monovalent anti-CD40L antibody polypeptide as described herein, and the fusion can be expressed by one of skill in the art.
In another embodiment, the ta-half life of the HSA-linlced human antibody polypeptide composition is increased by 10% or more.
In another embodiment, the ta-half life of the HSA-linked human antibody polypeptide composition is in the range of 0.25 hours to 6 hours.
In another embodiment, the t(3-half life of the HSA-linked human antibody polypeptide composition is increased by 10% or more.
In another embodiment, the t(3-half life of the HSA-linked human antibody polypeptide composition is in the range of 12 to 48 hours.
In another embodiment, the human antibody polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs 7-82 and 246-360.
In another embodiment, the human antibody polypeptide inhibits binding of CD40L to CD40 with an IC50 in the range of 20 pM to 1.5 M, inclusive; IC50 for inhibition of CD40L binding to CD40 in any embodiment described herein is preferably measured as described herein in Example 6. The IC;o can preferably be in the range of 20 pM to 1 M, 20 pM to 900 nM, 20 pM to 800 nM, 20 pM to 700 nM, 20 pM to 600 nM, 20 pM to 500 nM, 20 pM to 400 nM, 20 pM to 300 nM, 20 pM to 200 nM, 20 pM to 100 nM, or 20 pM to 50 nM. Further acceptable or preferred ranges include, for example, 50 pM to 1 M, 100 pM to 500 nM, 125 pM to 250 n2v1, 150 pM to 200 nM, 150 pM to 100 nM and 200 pM to 50 nM.
In another embodiment, the antibody polypeptide is fused to a second antibody polypeptide which binds a ligand other than CD40L. In a preferred embodiment, the antibody polypeptide which binds a ligand other than CD40L
binds a ligand selected from the group consisting of HSA, TNFa, IL-1, IL-2, IL-4, IL-6, IL-8, IL-12, IL-18, IFN-y, CD2, CD4, CDB, CTLA4, LFA1, LFA3, VLA4, CD80 (B7-1), CD28, CD86 (B7-2), and CTLA-4.
In another embodiment, the human antibody polypeptide is free of an Fc domain. The limits of an Fc domain are set out in Kabat et al. (1991, Sequences of Immunological Interest, 5'l' ed. U.S. Dept. Health & Human Services, Washington, D.C.; incorporated herein by reference). In the alternative, an Fc domain consists of the CH2-CH3 regions, optionally including a hinge region linked to the CH2. In a preferred embodiment, the human antibody polypeptide does not mediate platelet aggregation in a standard platelet aggregation assay.
The invention furtller encompasses a human antibody polypeptide which has an amino acid sequence at least 85% identical to a sequence selected from the group consisting of SEQ ID NOs 7-82 and 246-360, which antibody polypeptide specifically and monovalently binds CD40L.
The invention further encompasses an antigen-binding polypeptide, the polypeptide comprising a single immunoglobulin variable domain which specifically and monovalently binds CD40L. Recited differently, the invention further encoinpasses a polypeptide comprising a moiety ~ihich specifically binds CD40L, which moiety consists of a single immunoglobulin variable domain.
In one embodiment, the polypeptide consists of a human single immunoglobulin variable domain.
In another embodiment, the polypeptide has a Kd for human CD40L in the range of 50 nM to 20 pM, inclusive, as determined by surface plasmon resonance.
For example, the Kd for human CD40L can be 25 nM to 20 pM, 10 nM to 20 pM, 5 nm to 20 pM, 1 nM to 20 pM, 0.5 nM to 20 pM,Ø1 nM to 20 pM, 75 pM to 20 pM
or even 50 pM to 20 pM.
In another embodiment, the polypeptide inhibits the binding of CD40L to CD40.
In another embodiment, the polypeptide inhibits the binding of CD40 to CD40L and has an IC5o in the range of 20 pM to 1.5 M, inclusive. For example, the IC50 can be in the range of 20 pM to 1 M, 20 pM to 900 nM, 20 pM to 800 nM, pM to 700 nM, 20 pM to 600 nM, 20 pM to 500 nM, 20 pM to 400 nM, 20 pM to 300 nM, 20 pM to 200 nM, 20 pM to 100 nM, or 20 pM to 50 nM. Further acceptable or preferred ranges include, for example, 50 pM to 1 M, 100 pM to 500 nM, 125 pM
to 250 nM, 150 pM to 200 nM, 150 pM to 100 nM and 200 pM to 50 nM.
In another embodiment, the binding of the polypeptide to CD40L does not substantially agonize CD40 and/or CD40L activity.
In another embodiment, the binding of the polypeptide to CD40L does not substantially induce JNK phosphorylation in Jurkat T-cells.
In another embodiment, the binding of the polypeptide to CD40L does not substantially induce IFN-y secretion by Jurl:at T-cells co-stimulated with anti-CD3 antibody.
In another embodiment, the presence of the antibody polypeptide in a standard platelet aggregation assay does not result in aggregation more than 25% over the aggregation observed in a negative control assay lacking antibody polypeptide.
In another embodiment, the single immunoglobulin variable domain is a human single immunoglobulin variable domain.
In another embodiment, the single immunoglobulin variable domain is a VH or a VL domain.
In one embodiment, the polypeptide is PEG-linked. In one embodiment, the PEG is covalently linked. In one preferred embodiment, the PEG-linked antigen-binding polypeptide has a hydrodynamic size of at least 24 kD. In another preferred embodiment, the PEG is linked to the antigen-binding polypeptide at a cysteine or lysine residue. In another preferred embodiment, the total PEG size is from 20 to 60 kD, inclusive. In another preferred embodiment, the PEG-linked antigen-binding polypeptide has a hydrodynamic size of at least 200 kD.
In another embodiment, the PEG-linked polypeptide has an increased in vivo half-life relative to the same polypeptide composition lacking linked polyethylene glycol. In another embodiment, the ta-half life of the polypeptide composition is increased by 10% or more. In another embodiment, the ta-half life of the polypeptide composition is increased by 50% or more. In another embodiment, the ta-half life of the polypeptide composition is increased by 2X or more. In another embodiment, the ta-half life of the polypeptide composition is increased by 5X or more, e.g., IOX, 15X, 20X, 25X, 30X, 40X, or more. In another embodiment, the ta-half life of the polypeptide composition is increased by 50X or more.
In another embodiment, the PEG-linked antibody polypeptide has a ta half-life of 0.25 to 6 hours, inclusive. In another embodiment, the ta half-life is in the range of 30 minutes to 12 hours, inclusive. In another embodiment, the ta-half life of the polypeptide composition is in the range of 1 to 6 hours.
In another embodiment, the tp-half life of the polypeptide composition is increased by 10% or more. In another embodiment, the tp-half life of the polypeptide composition is increased by 50% or more. In another embodiment, the tp-half life of the polypeptide composition is increased by 2X or more. In another embodiment, the tp-half life of the polypeptide composition is increased by 5X or more, e.g., IOX, 15X, 20X, 25X, 30X, 40X, or more. In another embodiment, the tp-half life of the polypeptide composition is increased by 50X or more.
In another embodiment, the antibody polypeptide composition has a t(3 half-life of 1 to 170 hours, inclusive. In another embodiment, the tp-half life is in the range of 12 to 48 hours, inclusive. In another embodiment, the tp-half life is in the range of 12 to 26 hours, inclusive.
In another embodiment, the composition has an AUC value (area under the curve) in the range of 1 tng.min/ml or more. In one embodiment, the lower end of the range is 5, 10, 15, 20, 30, 100, 200 or 300 mg.min/ml. In addition, or alternatively, a ligand or composition according to the invention has an AUC in the range of up to 600 mg.min/ml. In one embodiment, the upper end of the range is 500, 400, 300, 200, 150, 100, 75 or 50 mg.min/ml. Advantageously a ligand according to the invention will have an AUC in the range selected from the group consisting of the following: 15 to 150 mg.min/ml, 15 to 100 mg.min/ml, 15 to 75 mg.min/ml, and to 50 mg.min/ml.
In anotller embodiment, the antibody polypeptide is linked to human serum albumin (HSA). In another embodimeilt, the antibody polypeptide has an increased in vivo half-life relative to the same polypeptide coinposition lacking linked HSA. In another embodiment, the antibody polypeptide has a ta-half life that is increased by 10% or more relative to a molecule lacking linked HSA. In another einbodiment, the ta-half life of the polypeptide composition is in the range of 0.25 minutes to 6 hours.
In another embodiment, the tp-half life of the polypeptide composition is increased by 10% or more. In another embodiment, the tJ3-half life is in the range of 12 to hours.
In another embodiment, the antigen-binding polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs 7-82 and 246-360.
In another embodiment, the antigen-binding polypeptide is free of an Fc domain.
In another aspect, the invention encompasses an immunoglobulin variable domain polypeptide which has an amino acid sequence at least 85% identical to a sequence selected from the group consisting of SEQ ID NOs 7-82 and 246-360, which polypeptide specifically and monovalently binds CD40L.
In one embodiment, the immunoglobulin variable domain polypeptide antagonizes the binding of CD40L to CD40.
In another embodiment, the immunoglobulin variable domain polypeptide inhibits the binding of CD40 to CD40L and has an ICSo in the range of 20 pM to 1.5 M, inclusive. For example, the IC50 can be in the range of 20 pM to 1 M, 20 pM to 900 nM, 20 pM to 800 nM, 20 pM to 700 nM, 20 pM to 600 nM, 20 pM to 500 nM, pM to 400 nM, 20 pM to 300 nM, 20 pM to 200 nM, 20 pM to 100 nM, or 20 pM
20 to 50 nM. Further acceptable or preferred ranges include, for example, 50 pM to 1 M, 100 pM to 500 nM, 125 pM to 250 nM, 150 pM to 200 nM, 150 pM to 100 nM
and 200 pM to 50 nM.
In another embodiment, the immunoglobulin variable domain polypeptide inhibits the interaction of CD40 with CD40L, but does not substantially agonize intracellular signaling by CD40. In a preferred embodiment, the binding of the polypeptide to CD40L does not substantially induce JNK phosphorylation in Jurkat T-cells. In another preferred embodiment, the binding of the polypeptide to does not substantially induce IFN-y secretion by Jurkat T-cells co-stimulated with anti-CD3 antibody. In another preferred embodiment, the binding of the antibody polypeptide to CD40L does not substantially induce platelet aggregation in a platelet aggregation assay.
In another embodiment, the antigen-binding polypeptide further comprises a second antibody polypeptide which binds a ligand other than CD40L. In a preferred embodiment, the second antibody polypeptide binds a ligand selected from the group consisting of HSA, TNFa, IL-l, IL-2, IL-4, IL-6, IL-8, IL-12, IL-18, IFN-y, CD2, CD4, CDS, CTLA4, LFA1, LFA3 and VLA4.
In one embodiment, the invention relates to an antibody polypeptide comprising an immunoglobulin variable domain which specifically and monovalently binds CD40L (e.g., an anti-CD40L dAb, FAb, an scFv, an Fv, or a disulfide-bonded Fv), and which comprises one or more framework regions comprising an amino acid sequence that is the same as the amino acid sequence of a corresponding framework region encoded by a human germline antibody gene segment, or the amino acid sequence of one or more of said framework regions collectively comprises up to amino acid differences relative to the amino acid sequence of said corresponding framework region encoded by a human germline antibody gene segment.
In one embodiment, the amino acid sequences of FW1, FW2, FW3 and FW4 of the anti-CD40L variable domain or dAb are the same as the amino acid sequences of corresponding frainework regions encoded by a human germline antibody gene segment, or the amino acid sequences of FWI, FW2, FW3 and FW4 collectively contain up to 10 amino acid differences relative to the amino acid sequences of corresponding frameworlc regions encoded by said human germline antibody gene segment. In a further embodiment, the amino acid sequences of FW1, FW2 and FW3 of the anti-CD40L variable domain or dAb are the same as the amino acid sequences of corresponding framework regions encoded by human germline antibody gene segments.
In a further embodiment of the foregoing, the human germline antibody gene segment can be selected from the group consisting of DP47, DP45, DP48 and DPK9.
The invention further encompasses a method of antagonizing the binding of CD40 to CD40L in an individual, the method comprising administering a monovalent anti-CD40L antibody polypeptide as described .lierein to the individual, wherein the polypeptide antagonizes the binding of CD40 to CD40L in the individual.
The invention further encompasses a method of antagonizing an activity of CD40 or CD40L in an individual, the method comprising administering a monovalent anti-CD40L antibody polypeptide as described herein to the individual, wherein the polypeptide antagonizes an activity of CD40 or CD40L or both.
The invention further encompasses a composition comprising an extended release formulation comprising a monovalent anti-CD40L antibody polypeptide, preferably, but not limited to, a polypeptide comprising a single immunoglobulin variable domain that binds CD40L. In one embodiment, the single immunoglobulin variable domain is a non-human mammalian single immunoglobulin variable domain.
In another embodiment, the single immunoglobulin variable domain is a human single immunoglobulin variable domain.
A.
The invention further encompasses a method of treating or preventing a disease or disorder mediated by CD40L in an individual in need of such treatment, the method comprising administering to the individual a therapeutically effective amount of a composition comprising a monovalent anti-CD40L antibody polypeptide, preferably a composition comprising a single human immunoglobulin variable domain that binds CD40L. In one embodiment, the disease or disorder is an autoimmune disease or disorder.
The invention further encompasses a method of treating or preventing a symptom of systemic lupus erythematosus (SLE) in an individual, the method comprising administering a monovalent aiiti-CD40L antibody polypeptide to said individual in an amount effective to treat or prevent a symptom of SLE. The invention fui-ther encompasses a method of reducing or alleviating a symptom of a disease such as systemic lupus erythematosis, multiple sclerosis, rheumatoid arthritis, allograft rejection, xenograft rejection, and Diabetes, including insulin-dependent Type I Diabetes.
The invention further encompasses an antibody polypeptide that is monovalent for binding to CD40L, wherein the antibody polypeptide comprises a universal framework.
In one embodiment, the universal frameworlc comprises a VH framework selected from the group consisting of DP47, DP45 and DP38, and/or the VL
framework is DPK9.
In another embodiment, the antibody polypeptide comprises a generic ligand binding site. In another embodiment, the generic ligand binding site binds a generic ligand selected from the group consisting of protein A, protein L and protein G.
In another embodiment, the antibody polypeptide comprises a variable domain having one or more framework regions comprising an amino acid sequence that is the same as the amino acid sequence of a corresponding framework region encoded by a human germline antibody gene segment, or the amino acid sequences of one or more of the frameworlc regions collectively comprises up to 5 amino acid differences relative to the amino acid sequence of the corresponding framework region encoded by a human germline antibody gene segment.
In another embodiment, the antibody polypeptide comprises a variable domain, wherein the amino acid sequences of FWl, FW2, FW3 and FW4 are the same as the amino acid sequences of corresponding framework regions encoded by a human germline antibody gene segment, or the antibody sequences of FWl, FW2, FW3 aind FW4 collectively contain up to 10 amino acid differences relative to the amino acid sequences of corresponding framework regions encoded by the human germline antibody gene segment.
In anotller embodiment, the antibody polypeptide comprises an antibody variable domain comprising FWl, FW2 and FW3 regions, and the amino acid sequence of said FW1, FW2 and FW3 are the same as the amino acid sequences of corresponding framework regions encoded 'by human germline antibody gene segments. In another embodiment, the human germline antibody gene segment is selected from the group consisting of DP47, DP45, DP48 and DPK9.
The invention includes an antibody single variable domain polypeptide that binds to CD40L, wherein the polypeptide has an amino acid sequence that is identical to the amino acid sequence of DOM8-24, or differs from the amino acid sequence of DOM8-24 at no more than 25 amino acid positions and has a sequence that is at least 80% homologous to the sequence of DOM8-24. In one embodiment, the antibody single variable domain polypeptide differs form the amino acid sequence of 24 at 25 or fewer amino acid positions, 20 or fewer amino acid positions, 15 or fewer amino acid positions, 10 or fewer amino acid positions, 5 or fewer amino acid positions, 2 or fewer amino acid positions, or as few as one amino acid position. In a further embodiment, the antibody single variable domain polypeptide is at least 80%
homologous to the sequence of DOMB-24, for example, at least 85% homologous, at least 90% homologous, at least 95% homologous, and up to and including 96%, 97%, 98%, or 99% homologous.
The invention includes an antibody single variable domain polypeptide that binds to CD40L, wherein the polypeptide has an amino acid sequence that is identical to the amino acid sequence of DOM8-24, or differs from the amino acid sequence of DOMB-24 at no more than 25 amino acid positions and has a CDRI sequence that is at least 50% homologous to the CDRl sequence of DOMB-24, or has a CDR2 sequence that is at least 50% homologous to the CDR2 sequence of DOM8-24, or has a CDR3 sequence that is at least 50% homologous to the CDR3 sequence of DOM8-24.
The invention also includes an antibody single variable domain polypeptide that binds CD40L, wherein the dAb has an amino acid sequence that is identical to the amino acid sequence of DOM8-24, or differs from the amino acid sequence of DOMB-24 at no more than 25 amino acid positions and has a CDRI sequence that is at least 50% homologous to the CDRl sequence of DOM8-24 and has a CDR2 sequence that is at least 50% homologous to the CDR2 sequence of DOM8-24.
The invention also includes an antibody single variable domain polypeptide that binds CD40L, wherein the dAb has an amino acid sequence that is identical to the amino acid sequence of DOMB-24, or differs from the amino acid sequence of DOM8-24 at no more than 25 amino acid positions and has a CDR2 sequence that is at least 50% homologous to the CDR2 sequence of DOM8-24 and has a CDR3 sequence that is at least 50% homologous to the CDR3 sequence of DOM8-24.
The invention also includes an antibody single variable domain polypeptide that binds CD40L, wherein the dAb has an amino acid sequence that is identical to the amino acid sequence of DOM8-24, or differs from the amino acid sequence of DOM8-24 at no more than 25 amino acid positions and has a CDRl sequence that is at least 50% homologous to the CDRl sequence of DOM8-24 and has a CDR3 sequence that is at least 50% homologous to the CDR3 sequence of DOM8-24 .
The invention also includes an antibody single variable domain polypeptide that binds CD40L, wherein the dAb has an amino acid sequence that is identical to the amino acid sequence of DOM8-24, or differs from the amino acid sequence of DOM8-24 at no more than 25 amino acid positions and has a CDR1 sequence that is at least 50% homologous to the CDR1 sequence of DOMB-24 and has a CDR2 sequence that is at least 50% homologous to the CDR2 sequence of DOM8-24 and has a CDR3 sequence that is at least 50% homologous to the CDR3 sequence of DOM8-24.
In one embodiment, the antibody single variable domain polypeptide that binds to CD40L, if not identical in sequence to that of DOM8-24, differs form the amino acid sequence of DOM8-24 at 25 or fewer amino acid positions, 20 or fewer amino acid positions, 15 or fewer amino acid positions, 10 or fewer amino acid positions, 5 or fewer amino acid positions, 2 or fewer amino acid positions, or as few as one amino acid position.
The invention also includes a CD40L antagonist having a CDRI sequence that is at least 50% homologous to the CDRl sequence of DOMB-24.
The invention also includes a CD40L antagonist having a CDR2 sequence that is at least 50% homologous to the CDR2 sequence of DOMB-24.
The invention also includes a CD40L antagonist having a CDR3 sequence that is at least 50% homologous to the CDR3 sequence of DOMB-24.
The invention also includes a CD40L antagonist having a CDRI sequence that is at least 50% homologous to the CDR1 sequence of DOM8-24 and a CDR2 sequence that is at least 50% homologous to the CDR2 sequence of DOMB-24.
The invention also includes a CD40L antagonist having a CDR2 sequence that is at least 50% homologous to the CDR2 sequence of DOMB-24 and a CDR3 sequence that is at least 50% homologous to the CDR3 sequence of DOM8-24.
The invention also includes a CD40L antagonist having a CDR1 sequence that is at least 50% homologous to the CDR1 sequence of DOMB-24 and a CDR3 sequence that is at least 50% homologous to the CDR3 sequence of DOM8-24.
The invention also includes a CD40L antagonist having a CDRl sequence that is at least 50% homologous to the CDR1 sequence of DOM8-24 and a CDR2 sequence that is at least 50% homologous to the CDR2 sequence of DOM8-24 and a CDR3 sequence that is at least 50% homologous to the CDR3 sequence of DOM8-24.
In one embodiment the CD40L antagonist inhibits the binding of CD40 to CD40L, and/or inhibits an activity of CD40 and/or CD40L, and/or results in no more than 25% platelet aggregation in a platelet aggregation assay. In one embodiment, the antagonist results in platelet aggregation of 25% or less, 20% or less, 15% or less, 10% or less, 5% or less, and as little as zero platelet aggregation.
The invention- also includes a dual specific ligand comprising a first immunoglobulin single variable domain having a binding specificity to a first antigen and a second single variable domain having a binding activity to a second antigen, wherein the first antigen is CD40L and binding of the second single variable domain to the second antigen acts to increase the half-life of the ligand in vivo. In one embodiment, the dual specific ligand is a four chain IgG immunoglobulin.
In one embodiment, the four chain IgG comprises two dual specific ligands, said dual specific ligands being different in their variable domains.
The invention also includes a dual specific ligand comprising ai1 anti-human CD40L dAb and an anti-SA dAb.
In one embodiment, the dAbs are Camelid VHH domains.
In one embodiment of the dual specific ligand, either (i) the first and second immunoglobulin variable domains are heavy chain variable domains; or (ii) the first and the second immunoglobulin variable domains are light chain variable domains.
In one embodiment, the ligand is provided as an IgG immunoglobulin comprising four heavy chain single variable domains or four light chain single variable domains. The heavy chain can comprise Camelid VHH domains.
In a further embodiment of the dual specific ligand, the first and second domains bind independently, such that the dual specific ligand may simultaneously bind both the first and second antigens.
In one embodiment of the dual specific ligand, the first single variable domain has a dissociation constant (Kd) of lxl0"s M or less for human CD40L, and a Koff rate constant of lxl0-3 s1 or less, as determined by surface plasmon resonance.
In one embodiment of the.dual specific ligand, the second single variable domain is specific for serum albumin (SA) and has a dissociation constant (Kd) of InM to 500 m for SA, as determined by surface plasmon resonance.
In a further embodiment, the second domain binds SA in a standard ligand binding assay with an IC50 of 1nM to 500 M. The second single variable domain may be specific for SA, and comprise the amino acid sequence of MSA-16 or a sequence that is at least 80% homologous tllereto. Alternatively, the second single variable domain may be specific for SA, and comprise the amino acid sequence of MSA-26 or a sequence that is at last 80% homologous thereto.
In one embodiment of the dual specific ligand, the anti-CD40L variable domain or dAb comprises a universal framework. The anti-CD40L variable domain or dAb may also comprise a VH framework selected from the group consisting of DP47, DP45 and DP38; or a VL framework which is DPK9. In a further embodiment, the dual specific ligand or dAb can comprise a binding site for a generic ligand.
In one embodiment, the generic ligand binding site is selected from the group consisting of protein A, protein L and protein G binding site.
In one embodiment of the dual specific ligand, the anti-CD40L variable domain or dAb comprises one or more framework regions comprising an amino acid sequence that is the same as the amino acid sequence of a corresponding framework region encoded by a human germline antibody gene segment, or the amino acid sequence of one or more of said framework regions collectively comprises up to amino acid differences relative to the amino acid sequence of said corresponding frameworlc region encoded by a human germline antibody gene segment.
In one embodiment, the amino acid sequences of FWI, FW2, FW3 and FW4 of the anti-CD40L variable domain or dAb are the same as the amino acid sequences of corresponding framework regions encoded by a human germline antibody gene segment, or the amino acid sequences of FW1, FW2, FW3 and FW4 collectively contain up to 10 amino acid differences relative to the amino acid sequences of corresponding framework regions encoded by said human germline antibody gene segment.
In one embodiment, the ainino acid sequences of said FWI, FW2 and FW3 of the anti-CD40L variable domain or 'dAb are the same as the ainino acid sequences of corresponding framework regions encoded by human germline antibody gene segments. The human germline antibody gene segments are preferably selected from the group consisting of DP47, DP45, DP48 and DPK9.
The invention also includes a metl7od for producing a dual specific ligand as described herein, comprising a first immunoglobulin single variable domain having a binding specificity for CD40L and a second single immunoglobulin single variable domain having a binding specificity for a protein which increases the half-life of the ligand in vivo, the method comprising the steps of:selecting a first variable domain by its ability to bind CD40L; selecting a second variable domain by its ability to bind to said protein; combining the variable domains; and selecting the ligand by its ability to bind to CD40L and said protein.
In one embodiment, the first variable domain is selected for binding to CD40L
in absence of a complementary variable domain.
The invention also includes nucleic acid encoding a dual specific ligand described herein. The nucleic acid may comprise the nucleic acid sequence of MSA-16 or a sequence that is at least 80% homologous thereto, or alternatively may comprise, the nucleic acid sequence of MSA-26 or a sequence that is at least 70%
homologous thereto. The nucleic acid may be incorporated into a vector, which may be incorporated into a host cell.
The invention also includes a pharmaceutical composition comprising a dual specific ligand as described herein and a pharmaceutically acceptable excipient, carrier or diluent.
The invention also includes a dAb monomer specific for CD40L, which monomer has a dissociation constant (Kd) of Ix10"8 M or less for human CD40L, and a Kpff rate constant of 1X10"3 s"1 or less, as determined by surface plasmon resonance.
In one embodiment, the dAb monomer specific for CD40L has a dissociation constant (Kd) of 1x10-7 M or less, as determined by surface plasmon resonance.
In one embodiment, the dAb monomer has binding specificity to CD40L with a dissociation constant (Kd) of 1x10"8 M or less, as determined by surface plasmon resonance.
In one embodiment, the dAb monomer has binding specificity to CD40L with a dissociation constant (Kd) of 50nM to 20pM, as determined by surface plasmon resonance.
In one embodiment, the monomer inhibits binding of CD40 to CD40L with an IC50 of 50nM or less.
In a further embodiment, the dAb monomer has binding specificity to CD40L
with a Koff rate constant of 1x10"3 s"1 or less, 1x10-4 s"1 or less, lxl0-5 s I or less, or lxl0"6 s 1 or less,as determined by surface plasmon resonance.
In one embodiment, the dAb monomer neutralizes CD40L in a standard assay with an ND50 of 50nM or less.
In invention also includes a dual specific ligand comprising first and second heavy chain single variable domains, or first and second light chain single variable domains, wherein the first variable domain is an anti-CD40L dAb monomer.
In one embodiment, the second variable domain has binding specificity for an antigen other than CD40L.
In a further embodiment, the second variable domain has binding specificity for an antigen selected from the group consisting of EPO receptor, ApoE, Apo-SAA, BDNF, Cardiotrophin-l, EGF, EGF receptor, ENa-78, Eotaxin, Eotaxin-2, Exodus-2, EpoR, FGF-acidic, FGF-basic, fibroblast growth factor-10, FLT3 ligand, Fractalkine (CX3C), GDNF, G-CSF, GM-CSF, GF-bl, insulin, IFN-g, IGF-I, IGF-II, IL-la, II-lb, IL-2, I1-3, IL-4, IL-5, IL-6, IL-7, IL-8 (72 a.a.), IL-8 (77 a.a.), IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, IL-16, IL-17, IL-18 (IGIF), Inhibin a, Inhibin b, IP-10, keratinocyte growth factor-2 (KGF-2), KGF, Leptin, LIF, Lymphotactin, Mullerian inhibitory substance, monocyte colony inhibitory factor, monocyte attractant protein, M-CSF, MDC (67 a.a.), h/IDC (69 a.a.), MCP-1 (MCAF), MCP-2, MCP-3, MCP-4, MDC (67 a.a.), MIG, MIP-la, MIP-ib, MIP-3a, MIP-3b, MIP-4, myeloid progenitor inhibitor factor-1 (MPIF-1), NAP-2, Neurturin, Nerve growtli factor, b-NGF, NT-3, NT-4, Oncostatin M, PDGF-AA, PDGF-AB, PDGF-BB, PF-4, RANTES, SDFla, DFGlb SCF, SCGF, stem cell factor, (SCF), TARC, TGF-a, TGF-b, TGF-b2; TGF-b3, tumour necrosis factor (TNF), TNF-a, TNF-b, TNF receptor I, TNF receptor II, TNIL-1, TPO, VEGF, VEGF receptor 1, VEGF receptor 2, VEGF receptor-3, GCP-2, GRO/MGSA, GRO-b, GRO-g, HCC1, 1-309, HER 1, HER 2, HER 3, HER 4, TACE
recognition site, TNF BP-1, TNF BP-II, and an antigen disclosed in Annex 2 or 3.
The invention also includes an antibody polypeptide that antagonizes or inhibits the binding of DOMS-24 to CD40L, or an antibody polypeptide that binds to the same epitope of CD40L bound by DOM8-24.
The invention also includes a dual specific ligand comprising a. first immunoglobulin single variable domain having a binding specificity to a first antigen and a second single variable domain having a binding activity to a second antigen, wherein the first antigen is CD40L and the second single variable domain is an Antigen Presenting Cell surface antigen or a T cell surface antigen. The Antigen Presenting Cell surface antigen can be selected from one of the group consisting of dendritic cell surface antigens, activated macrophage surface antigens, activated B
cell surface antigens, co-stimulatory signal pathway surface antigens, and MHC.
In one embodiment, the MHC is class II, and the class II can be alpha or beta.
The Antigen Presenting Cell surface antigen may be selected from the group consisting of CD28, Inducible costimulatory molecule (ICOS), CD27, CD30, OX40, CD45, CD69, CD3, CD70, Inducible costimulatory molecule ligand (ICOSL), OX40L, CD80, CD86, HVEM (Herpes Virus Entry Mediator), and LIGHT, but is preferably one of CD28, Inducible costimulatory molecule (ICOS), CD27, CD30, OX40, CD45, CD69, or CD3.
The surface antigen is preferably a B7 gene surface antigen such as B7-2 or B7-1.
Definitions:
As used herein, the term "human" when applied to an antibody polypeptide or to an immunoglobulin variable domain means that the polypeptide has a sequence derived from a human immunoglobulin. A sequence is "derived from" a human immunoglobulin coding sequence when the sequence is either: a) isolated from a human individual or from cells or a cell line from a human individual; b) isolated from a library of cloned human antibody gene sequences (or a library of human antibody V domain sequences); or c) when a cloned human antibody gene sequence (or a cloned human V region sequence (including, e.g., a germline V gene segment)) was used to generate one or more diversified sequences that were then selected for binding to a desired target antigen. The term "human" as applied herein to an antibody polypeptide or to an immunoglobulin variable domain does not encompass an immunoglobulin from another species, e.g., mouse, camel, etc., that has been "humanized" through grafting of human constant region sequences onto an antibody polypeptide (i.e., replacing non-human constant regions with human constant regions) or through grafting of human V region framework sequences onto an immunoglobulin variable domain from a non-human mammal (i.e., replacing non-human framework regions of a V domain with human framework regions).
At a minimum, a human variable domain has at least 85% amino acid similarity (including, for example, 87%, 90%, 93%, 95%, 97%, 99% or higher similarity) to a naturally-occurring human immunoglobulin variable domain sequence.
As used herein, the term "domain" refers to a folded protein structure which retains its tertiary structure independently of the rest of the protein.
Generally, domains are responsible for discrete functional properties of proteins, and in many cases may be added, removed or transferred to other proteins without loss of function of the remainder of the protein and/or of the domain.
By "single immunoglobulin variable domain" is meant a folded polypeptide domain which comprises a sequence characteristic of immunoglobulin variable domains and which specifically binds an antigen (e.g., dissociation constant of 500 nM or less). A "single immunoglobulin variable domain" therefore includes complete antibody variable domains as well as modified variable domains, for example in which one or more loops have been replaced by sequences which are not characteristic of antibody variable domains, or antibody variable domains which have been truncated or comprise N- or C-terminal extensions, as well as folded fragments of variable domains which retain a dissociation constant of 500 nM or less (e.g., 450 nM or less, 400 nM or less, 350 nM or less, 300 nM or less, 250 nM or less, 200 nM
or less, 150 nM or less, 100 nM or less) and the target antigen specificity of the full-length domain. Where necessary or in case of any doubt, the numbering convention and boundaries set forth by Kabat et al. (1991, supW) are applicable to immunoglobulin variable and constant domains referred to herein.
An antibody single variable domain polypeptide, as used herein refers to a mammalian single immunoglobulin variable domain polypeptide, preferably human, but also includes rodent (for example, as disclosed in W000/29004, the contents of wllich are incorporated herein in their entirety) or camelid VHH dAbs. Camelid dAbs are antibody single variable domain polypeptides which are derived from species including camel, llama, alpaca, dromedary, and guanaco, and comprise heavy chain antibodies naturally devoid of light chain: VHH. VHI3 molecules are about I Ox smaller than IgG molecules, and as single polypeptides, they are very stable, resisting extreme pH and temperature conditions. Moreover, camelid antibody single variable domain polypeptides are resistant to the action of proteases. Camelid antibodies are described in, for example, U.S. Pat. Nos. 5,759,808; 5,800,988; 5,840,526; 5,874,541;
6,005,079; and 6,015,695, the contents of each of which are incorporated herein in their entirety. Camelid VHH antibody single variable domain polypeptides useful according to the invention include a class of camelid antibody single variable domain polypeptides having human-like sequences, wherein the class is characterized in that the Vj-nl domains carry an amino acid from the group consisting of glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, tyrosine, tryptophan, methionine, serine, threonine, asparagine, or glutamine at position 45, such as for eaample L45, and further comprise a tryptophan at position 103 according to the Kabat numbering.
Humanized camelid VHH polypeptides are taught, for example in W004/041862, the teachings of which are incorporated herein in their entirety. It will be understood by one of skill in the art that naturally occurring camelid antibody single variable domain polypeptides may be modified according to the teachings of W004/041862 (e.g., amino acid substitutions at positions 45 and 103) to generate humanized camelid VHH
polypeptides. Also included in the present invention are antibody single variable domain polypeptides which are nurse shark VHH. Nurse shark dAbs are antibody single variable domain polypeptides derived from the nurse shark, that comprise heavy chain antibodies naturally devoid of light chain: V~. Nurse Shark V~
dAbs are described, for example, in Greenberg et al. (Nature 374 pp168-173 1995) and U.S.
20050043519.
The phrase "single immunoglobulin variable domain polypeptide"
encompasses not only an isolated single immunoglobulin variable domain polypeptide, but also larger polypeptides that comprise a monomer of a single immunoglobulin variable domain polypeptide sequence. A "domain antibody" or "dAb" is equivalent to a"single immunoglobuliil variable domain polypeptide"
as the term is used herein. With regard to a single immunoglobulin variable domain polypeptide, the binding to antigen, e.g., CD40L, is mediated by the single immunoglobulin V domain without a requirement for a complementary V domain.
According to the iilvention, the terms "antibody single variable domain polypeptide", "antibody single variable domain", "single antibody variable domain", and "single immunoglobulin variable domain" are understood to be equivalent.
As used herein, the phrase "sequence characteristic of immunoglobulin variable domains" refers to an amino acid sequence that is homologous, over 20 or more, 25 or more, 30 or more, 35 or more, 40 or more, 45 or more, or even 50 or more contiguous amino acids, to a sequence comprised by an immunoglobulin variable domain sequence.
Sequences similar or homologous (e.g., at least about 70% sequence identity) to the sequences disclosed herein are also part of the invention. In some embodiments, the sequence identity at the amino acid level can be about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher. At the nucleic acid level, the sequence identity can be about 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher. Alternatively, substantial identity exists when the nucleic acid segments will hybridize under selective hybridization conditions (e.g., very high stringency hybridization conditions), to the complement of the strand. The nucleic acids may be present in whole cells, in a cell lysate, or in a partially purified or substantially pure form.
As used herein, the terms "homology" or "similarity" refer to the degree with which two nucleotide or amino acid sequences structurally resemble each other.
As used herein, sequence "similarity" is a measure of the degree to which amino acid sequences share similar amino acid residues at corresponding positions in an alignment of the sequences. Amino acids are similar to each otlier where their side chains are similar. Specifically, "similarity" encompasses amino acids that are conservative substitutes for each other. A "conservative" substitution is any substitution that has a positive score in the blosum62 substitution matrix (Hentikoff and Hentikoff, 1992, Proc. Natl. Acad. Sci. USA 89: 10915-10919). By the statement "sequence A is n% similar to sequence B" is meant that n% of the positions of an optimal global alignment between sequences A and B consists of identical amino acids or conservative substitutions. Optimal global alignments can be performed using the following parameters in the Needleman-Wunsch alignment algoritlun:
For polypeptides:
Substitution matrix: blosum62.
Gap scoring function: -A -B*LG, where A=11 (the gap penalty), B=1 (the gap lengtll penalty) and LG is the length of the gap.
For nucleotide sequences:
Substitution matrix: 10 for matches, 0 for mismatches.
Gap scoring function: -A -B*LG where A=50 (the gap penalty), B=3 (tlie gap length penalty) and LG is the length of the gap.
Typical conservative substitutions are among Met, Val, Leu and Ile; among Ser and Thr; among the residues Asp, Glu and Asn; among the residues Gln, Lys and Arg; or aromatic residues Phe and Tyr.
As used herein, two sequences are "homologous" or "similar" to each other where they have at least 70%, 80%, or 85% sequence similarity to each other, including, e.g., 90%, 95%, 97%, 99% or even 100% sequence similarity, when aligned using either the Needleman-Wunsch algorithm or the "BLAST 2 sequences"
algorithm described by Tatusova & Madden, 1999, FEMS Microbiol Lett. 174:247-250. Where amino acid sequences are aligned using the "BLAST 2 sequences algorithm," the Blosum 62 matrix is the default matrix.
As used herein, the tenns "inhibit," "inhibits" and "inhibited" refer to a decrease in a given measurable activity (e.g., binding activity) by at least 10% relative to a reference. Where inhibition is desired, such inhibition is preferably at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more, up to and including 100%, i.e., complete inliibition or absence of the given activity. One way that inhibition of CD40L binding to CD40 is measured is as described in Example 6 herein. As used herein, the term "substantially inhibits" refers to a decrease in a given measurable activity (e.g., the binding of CD40L to CD40) by at least 50% relative to a reference.
For example, "substantially inhibits" refers to a decrease in a given measurable activity of at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% and up to and including 100% relative to a reference. As used herein, "inhibits the binding", with reference to the binding of an antibody polypeptide binding to CD40L, or binding to CD40L, refers to a decrease in binding by at least 10% relative to a reference. "Inhibits the binding" preferably refers to a decrease in binding of at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more, up to and including 100%.
As used herein, the terms "activate," "activates" and "activated" refer to an increase in a given measurable activity by at least 5% relative to a reference, for example, at least 10%, 25%, 50%, 75% or even 100%.
As used herein, the term "antagonist" refers to an agent that inhibits at least one activity mediated by CD40L, inhibits the binding of CD40 to CD40L, and/or results in no more than 25% platelet activation and/or aggregation in a platelet aggregation assay or platelet activation assay as described herein, and preferably results in 25% or less platelet activation and/or aggregation, 20% or less, 15% or less, 10% or less, 5% or less, and as little as zero platelet activation and/or aggregation.
An activity is "antagonized" if the activity (i.e., CD40L mediated activity, binding of CD40 or CD40L, or platelet activation and/or aggregation) is reduced by at least 10%, and preferably at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 97% or even 100% (i.e., no activity) in the presence, relative to the absence of an antagonist.
An antagonist as the term is used herein preferably comprises a single immunoglobulin variable domain that binds monovalently to CD40L.
As used herein, the term "agonist" refers to an agent that activates at least one activity mediated by CD40L, either alone or when combined with another co-stimulus, relative to a reference. An activity is "agonized" if the activity is increased by at least 10%, e.g., 50%, in the presence, relative to the absence of an agonist.
As used herein, the term "epitope" refers to a unit of structure conventionally bound by an immunoglobulin VH/VL pair. Epitopes define the minimum binding site for an antibody, and thus represent the target of specificity of an antibody.
In the case of a single immunoglobulin variable domain, an epitope represents the unit of structure bound by a single variable domain in isolation. That is, the binding site is provided by one, single immunoglobulin variable domain.
As used herein, the tenn "extended release" or the equivalent terms "controlled release" or "slow release" refer to drug formulations that release active drug, such as a polypeptide drug, over a period of time following administration to an individual. Extended release of polypeptide drugs, which can occur over a range of desired times, e.g., minutes, hours, days, weeks or longer, depending upon the drug formulation, is in contrast to standard formulations in which substantially the entire dosage unit is available for immediate absorption or immediate distribution via the bloodstream. Preferred extended release formulations result in a level of circulating drug from a single administration that is sustained, for example, for 8 hours or more, 12 hours or more, 24 hours or more, 36 hours or more, 48 liours or more, 60 hours or more, 72 hours or more 84 hours or more, 96 hours or more, or even, for example, for 1 week or 2 weeks or more, for example, I month or more.
As used herein, a"CD40L activity" is an activity involving or resulting from the binding of CD40L to CD40, and includes, but is not limited to binding to (assayed, for example, according to the method described in Example 6), activation of Jun-N-terminal Kinase (JNK), the induction of T cells to produce and secrete cytokines including, for example, IL-10, IFN-y and TNF-a, and the mediation of platelet activation and/or aggregation. Assays for these activities are provided herein below.
As used herein, the term "does not substantially agonize" means that a given agent, e.g., an anti-CD40L antibody polypeptide, does not activate one or more of the CD40L activities including Jun-N-terminal kinase activation (phosphorylation) in Jurkat T cells and induction of IFN-y production or secretion in anti-CD3-stimulated Jurkat T cells, as the term "activate" is defined herein. As used herein, "does not substantially agonize" means that the agent does not activate more than 20% of the activity which is activated by CD40 binding to CD40L, preferably, the agent does not activate more 'than 10%, 8%, 5%, 3%, or more than 2% or less, iiicluding zero activation, of the activity which is activated by CD40 binding to CD40L.
As used herein, the term "antibody polypeptide" refers to a polypeptide which either is an antibody or is a part of an antibody, modified or unmodified, which retains the ability to specifically bind antigen. Thus, the teim antibody polypeptide includes an antigen-binding heavy chain, light chain, heavy chain-light chain dimer, Fab fragment, F(ab')2 fragment, dAb, or an Fv fragment, including a single chain Fv (scFv). The phrase "antibody polypeptide" is intended to encompass recombinant fusion polypeptides that comprise an antibody polypeptide sequence that retains the ability to specifically bind antigen in the context of the fusion.
As used herein, the term "monovalent" means that a given antibody polypeptide or single immunoglobulin variable domain polypeptide can bind only a single molecule of its target. Naturally-occurring antibodies are generally divalent, in that they have two functional antigen-binding arms, each comprising a VH and a VL
domain. Where steric hindrance is not an issue, a divalent antibody can bind two separate molecules of the same antigen. In contrast, a "monovalent" antibody has the capacity to binci only one such antigen molecule. As the term is used herein, a "monovalent" antibody can also comprise more than one antigen binding site, e.g., two antigen binding sites, but the binding sites must be for different antigens, such that the antibody can only bind one molecule of CD40L at a time. The antigen-binding domain of a monovalent antibody can comprise a VH and a VL domain, but preferably comprises only a single immunoglobulin variable domain, i.e., a VH
or a VL domain, that has the capacity to bind CD40L without the need for a corresponding VL or VH domain, respectively. A monovalent antibody lacks the capacity to cross link molecules of a single antigen.
As used herein, the term "standard platelet aggregation assay" means the assay described in the section herein below, entitled "Platelet Aggregation Assay."
As used herein, the terms "VH domain" and "VL domain" refer to immunoglobulin variable regions as defined by Kabat et al.(supra), which is incorporated herein by reference.
As used herein, "linked" refers to the attachment of a polymer moiety, such as PEG to an amino acid residue of an antibody polypeptide. Attachment of a PEG
polymer to an arnino acid residue of an antibody polypeptide, e.g., an anti-dAb, is referred to as "PEGylation" and may be achieved using several PEG
attachment moieties including, but not limited to N-hydroxylsuccinimide (NIIS) active ester, succinimidyl propionate (SPA), maleimide (MAL), vinyl sulfone (VS), or thiol. A PEG polymer, or other polymer, can be linked to an antibody polypeptide at eitlier a predetermined position, or may be randomly linked to the an antibody polypeptide molecule. It is preferred, however, that the PEG polymer be linked to an antibody polypeptide at a predetermined position. A PEG polymer may be linked to any residue in the an antibody polypeptide, however, it is preferable that the polymer is linked to either a lysine or cysteine, rhich is either naturally occurring in the antibody polypeptide, or which has been engineered into the antibody polypeptide, for example, by mutagenesis of a naturally occurring residue in the antibody polypeptide to either a cysteine or lysine. PEG-linkage can also be mediated through a peptide linker attached to an antibody polypeptide. That is, the PEG moiety can be attached to a peptide linker fused to an antibody polypeptide, where the linker provides the site, e.g., a free cysteine or lysine, for PEG attachment. As used herein, "linked" can also refer to the association of two or more antibody polypeptides, e.g., dAb monomers, to form a dimer, trimer, tetramer, or other multimer. Antibody polypeptide monomers can be liiiked to form a multimer by several methods known in the art, including, but not limited to, expression of the antibody polypeptide monomers as a fusion protein, linkage of two or more monomers via a peptide linker between monomers, or by chemically joining monomers after translation, either to each other directly, or through a linker by disulfide bonds, or by linkage to a di-, tri-or multivalent linking moiety (e.g., a multi-arm PEG). While dAb multimers are specifically contemplated herein, e.g., in the context of dual- or multi-specifc antibody polypeptide constructs, it is emphasized that for any given antibody polypeptide construct, the construct should only be able to bind one molecule of CD40L, i.e., the constructs can have only one CD40L-binding element, and cannot cross liiik CD40L.
As used herein, "polymer" refers to a macromolecule made up of repeating monomeric units, and can refer to a syiithetic or naturally occurring polymer such as an optionally substituted straight or branched chain polyalkylene, polyalkenylene, or polyoxyalkylene polynier or a branched or unbranched polysaccharide. A
"polymer"
as used herein, specifically refers to an optionally substituted or branched chain poly(etllylene glycol), poly(propylene glycol), or poly(vinyl alcohol) and derivatives thereof.
As used herein, "PEG" or "PEG polymer" refers to polyethylene glycol, and more specifically can refer to a derivitized form of PEG, including, but not limited to N-hydroaylsuccinimide (NHS) active esters of PEG such as succinimidyl propionate, benzotriazole active esters, PEG derivatized with maleimide, vinyl sulfones, or thiol groups. Particular PEG formulations can include PEG-O-CH?CH--,CH,-CO-,-NHS;
PEG-O-CH,-NHS; PEG-O-CH2CH,-CO,-NHS; PEG-S-CH,CH2-CO-NHS; PEG-O,CNH-CH(R.)-CO?-NHS; PEG-NHCO-CH,CH2-CO-NHS; and PEG-O-CH2-CO7-NHS; where R is (CH-'1)4)NHCO,(mPEG). PEG polymers useful in the invention may be linear molecules, or may be branched wllerein multiple PEG moieties are present in a single polymer. Some particularly preferred PEG conformations that are useful in the invention include, but are not limited to the following:
QnPGC~---C;-~.-N-1 C' CH 'C~
o l r~ePE~x~--O- C---NK/ "'C- NH-,K;CHa-NH--C--CH3Ct~,; a,~y mPEG-N
C
mPEG-MAL mPEG2-MAL
CH OH {{~~
CH2CONH(CH2CHz0)2-CHzCHZN P~~ Pit& OtG
mPEG-CONHCH O ; flO-"I.- ''0~0 V\ Ã' ~0\!~-OG{
CH 2CONH(CH 2CH20)2-CH2CH7N ' multi-arm PEG
mPEG-(MAL)2 0 ll CHzCONH(CHzCHzO)z-CHZCHzN ~
O/
mPEG-O- C-NH
mPEG-0- li NH
0 CHzCONH(CHZCHZ0)2-CH2CHzN I
mPEG2-(MAL)2 ~
nwrIny-O-O-NH
1 (_~~ Iz~ 0 ~ W
mPECr-0-CH:CHz-L--'0-N ntPEO-O-c-NH/ \C-O-hl inPEG2-NHS
mPEG-SPA
As used herein, a "sulfhydryl-selective reagent" is a reagent which is useful for the attachment of a PEG polymer to a thiol-containing amino acid. Thiol groups on the amino acid residue cysteine are particularly useful for interaction with a sulfhydryl-selective reagent. Sulfliydryl-selective reagents which are useful for such attachment include, but are not limited to maleimide, vinyl sulfone, and thiol. The use of sulfl7ydryl-selective reagents for coupling to cysteine residues is known in the art and may be adapted as needed according to the present invention (See Eg., Zalipsky, 1995, Bioconjug. Chein. 6:150; Greenwald et al., 2000, Crit. Rev.
Ther.
Drug Carrier Syst. 17:101; Herman et al., 1994, Macromol. Chem. Phys.
195:203).
The attachment of PEG or another agent, e.g., HSA, to an antibody polypeptide or to a single immunoglobulin variable domain polypeptide as described herein will preferably not impair the ability of the polypeptide to specifically bind CD40L. That is, the PEG-linked antibody polypeptide or single immunoglobulin variable domain polypeptide will retain its binding activity relative to a non-PEG-linked counterpart. As used herein, "retains activity" refers to a level of activity of a PEG-linlced antibody polypeptide which is at least 10% of the level of activity of a non-PEG-linked antibody polypeptide, preferably at least 20%, 30%, 40%, 50%, 60%, 70%, 80% and up to 90%, preferably up to 95%, 98%, and up to 100% of the activity of a non-PEG-linked antibody polypeptide comprising the same antigen-binding domain or domains. More specifically, the activity of a PEG-linked antibody polypeptide compared to a non-PEG linked antibody variable domain should be determined on an antibody polypeptide molar basis; that is equivalent numbers of moles of each of the PEG-linked and non-PEG-linked antibody polypeptides should be used in each trial. In determining whether a particular PEG-linked antibody polypeptide "retains activity", it is preferred that the activity of a PEG-liiilced antibody polypeptide be compared with the activity of the same antibody polypeptide in the absence of PEG.
As used herein, the term "in vivo half-life" refers to the time taken for the serum concentration of a ligand (e.g., a single immunoglobulin variable domain) to reduce by 50%, in vivo, for exainple due to degradation of the ligand and/or clearance or sequestration of the ligand by natural mechanisms. The anti CD40L antibody polypeptides or single immunoglobulin variable domain polypeptides described herein can be stabilized in vivo and their half-life increased by binding to molecules, such as PEG, Nvhich resist degradation and/or clearance or sequestration. The half-life of an antibody polypeptide is increased if its functional activity persists, in VNo, for a longer period than a similar antibody polypeptide which is not linlced to a PEG
polymer. Typically, the half life of a PEGylated antibody polypeptide is increased by 10%, 20%, 30%, 40%, 50% or more relative to a non-PEGylated antibody polypeptide. Increases in the range of 2x, 3x, 4x, 5x, l Ox, 20x, 30x, 40x, 50x or more of the half life are possible. Alternatively, or in addition, increases in the range of up to 30x, 40x, 50x, 60x, 70x, 80x, 90x, 100x, 150x of the half life are possible.
According to the invention, a PEG-linlced antibody single variable domain has a half-life of between 0.25 and 170 hours, preferably between 1 and 100 hours, more preferably between 30 and 100 hours, and still more preferably between 50 and hours, and up to 170, 180, 190, and 200 hours or more.
As used herein, "resistant to degradation" or "resists degradation" with respect to a PEG or other polymer-linl:ed antibody polypeptide monomer or multimer means that the PEG- or other polymer-linlced antibody polypeptide mozlomer or multimer is degraded by no more than 10% when exposed to pepsin at pH 2.0 for 30 minutes and preferably not degraded at all.
As used herein, "hydrodynamic size" refers to the apparent size of a molecule (e.g., a protein molecule) based on the diffusion of the molecule through an aqueous solution. The diffusion, or motion of a protein through solution can be processed to derive an apparent size of the protein, where the size is given by the "Stokes radius"
- or "hydrodynamic radius" of the protein particle. The "hydrodynamic size" of a protein depends on both mass and shape (conformation), such that two proteins having the same molecular mass may have differing hydrodynamic sizes based on the overall conformation of the protein. Hydrodynamic size is measured, for example, by size exclusion chromatography. The hydrodynamic size of a PEG-linked antibody polypeptide, e.g., a single immunoglobulin variable domain (including antibody variable domain multimers as described herein), can be in the range of 24 kDa to 500 kDa; 30 to 500 kDa; 40 to 500 kDa; 50 to 500 kDa; 100 to 500 kDa; 150 to 500 kDa;
200 to 500 kDa; 250 to 500 kDa; 300 to 500 10a; 350 to 500 kDa; 400 to 500 kDa and 450 to 500 l:Da. Preferably the hydrodynamic size of a PEGylated antibody polypeptide of the invention is 30 to 40 kDa; 70 to 80 lcDa or 200 to 300 1cDa. Where a single immunoglobulin variable domain polypeptide is desired for use in imaging applications, the polypeptide should have a hydrodynamic size of between 50 and 100 kDa. Alternatively, where a single immunoglobulin variable domain polypeptide is desired for therapeutic applications, the polypeptide preparation should have a hydrodynamic size of greater than 200 kDa.
As used herein, the term "IC50" refers to the concentration of an inhibitor necessary to inhibit a given activity by 50%. IC50 is determined by assaying a given activity, e.g., binding of CD40L to CD40, in the presence of varying amounts of the inhibitor (e.g., monovalent anti-CD40L antibody polypeptide), and plotting the inhibitor concentration versus the activity being targeted. Binding of CD40L
to CD40 is measured herein by the metllod described in Example 6. Alternatively, SPR
can be used.
As used herein, the term "fused to an antibody polypeptide" means that a polypeptide is fused to a given antibody through use of recombinant DNA
techniques.
Thus, an antibody "fused to" another polypeptide, e.g., to another antibody of different binding specificity, does not exist in nature and is generated through recombinant means. The term "fused to an antibody polypeptide" also encompasses the linkage of a polypeptide to a given antibody polypeptide through, for, example, disulfide or other chemical linkages, where the fused polypeptide is not naturally found fused to the antibody polypeptide. Recombinant and chemical methods of fusing a polypeptide to another polypeptide, e.g., to an antibody, are well known in the art.
As used herein, the term "Fc domain" refers to the constant region antibody sequences coinprising CH2 and CH3 constant domains as delimited according to Kabat et al., supra. The Fc portion of the heavy chain polypeptide has the ability to self-associate, a function which facilitates the formation of divalent antibodies. The ternl "lacks an Fc domain" means that a given antibody polypeptide lacks at least the portion of an immunoglobulin Fc domain (as such domains are defined according to Kabat et al., supM) sufficient to mediate the dimerization of Fc-containing antibody polypeptides. Dimerization of Fc-containing antibody polypeptides is measured, for example, by chromatographic methods or by surface plasmon resonance. An antibody polypeptide lacking an Fe domain avoids Fe-platelet interactions and tllerefore avoids induction of platelet aggregation.
As used herein "treat", "reduce", "prevent", or "alleviate" as it relates to a symptom of disease refer to a decrease of the a symptom by at least 10% based on a a clinically measurable paraineter, or by at least one point on a clinically-accepted scale of disease or symptom severity. As used herein, the term "symptom of systemic lupus erythematosus" refers to any of the clinically relevant symptoms of SLE
known to those of skill in the art. Non-limiting examples include the accumulation of IgG
autoantibodies (e.g., against nuclear antigtzl ens such as chromatin, snRNPs (especially U1, Sm, Ro/SSA and La/SSB), phospholipids and cell surface molecules), hemolytic anemia, thrombocytopenia, leukopenia, glomerulonephritis, vasculitis, arthritis, and serositis). A reduction in such a symptom is a reduction by at least 10% in a clinically measurable parameter, or by at least one point on a clinically-accepted scale of disease severity.
As used herein, the phrase "specifically binds" refers to the binding of an antigen by an immunoglobulin variable domain with a dissociation constant (Kd) of 1 M or lower as measured by surface plasmon resonance analysis using, for example, a BlAcoreTM surface plasmon resonance system and BlAcoreTM kinetic evaluation software (e.g., version 2.1). The affinity or Kd for a specific binding interaction is preferably about 500 nM or lower, more preferably about 300 nM or lower.
As used herein, a "generic ligand" is a ligand that binds a substantial proportion of functional members in a given repertoire, e.g., in a phage display library. Thus, the same generic ligand can bind many members of the repertoire regardless of their target ligand specificities. In general, the presence of a functional generic ligand binding site indicates that the repertoire member is expressed and folded correctly. Thus, binding of the generic ligand to its binding site provides a method for preselecting functional polypeptides from a repertoire of polypeptides.
Generic ligands include, for example, Protein A, Protein G and Protein L.
As used herein, the term "universal framework" refers to a single antibody framework sequence corresponding to the regions of an antibody conserved in sequence as defined by Kabat (supra) or corresponding to the human germline immunoglobulin repertoire or structure as defined by Chothia and Lesk, (1987) J.
Mol. Biol. 196:910-917. The invention provides for the use of a single framework, or a set of such frameworks, which has been found to permit the derivation of virtually any binding specificity though variation in the hypervariable regions alone.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1 shows gel analysis of the quality of biotin-labeled CD40L used in the screening procedures described herein. (a) 1 g of non-biotinylated-CD40L
(Lane 1) and 0.3 ~g of biotin-CD40L (Lane 2) were analysed on SDS-PAGE and detected by Simply Blue Safe-Stain. (b) 0.1 g of biotin-CD40L (Lane 1) and 0.02 g of biotin-CD40L (Lane 2) were detected by Western-blot probing with 1:5000 Streptavidin-I IRP.
Figure 2 shows a graphical representation of a dose response receptor binding assay (RBA) readout, analysing the inhibition of CD40L binding to CD40-Fc by dAbs DOM-l0, -20, -27, -30, -31, -62, -77, titrated from 1 M down to 10 pM.
dAbs DOM-20, -30, and -31 are the most potent with IC50 values of approximately 8 nM.
Figure 3 shows a graphical representation of a dose response receptor binding assay readout, analysing the inhibition of CD40L binding to CD40-Fc by dAbs DOM-4 and DOM-5, titrated from 1 M down to 500 pM. The IC50 values for dAbs DOM-and DOM-4 are approximately 3 nM and 100 nM respectively.
Figure 4 shows a graphical representation of a dose response receptor binding assay readout, analysing the inhibition of CD40L binding to CD40-Fc by dAb DOM-5 24, titrated from 100 nM down to 0.5 pM. The data were curve-fitted using GraphPad Prism software.
Figure 5 shows the sequence of the VH frameworlc based on germline sequence DP47 - JH4b (SEQ ID NO: 1, amino acid sequence; SEQ ID NO: '2, nucleotide sequence - both sense and antisense strands are shown - SEQ ID NO:
2 is the top strand (sense) and SEQ ID NO: 476 is the lower strand (anti-sense)).
HCDRs 1-3 are indicated by underlining.
Figure 6 shows the sequence of the Vh framework based on germline sequence DPK9 - JK1 (SEQ ID NO: 3, amino acid sequence; SEQ ID NO: 4, nucleotide sequence - both sense and antisense strands are shown - SEQ ID NO:
4 is the top strand (sense) and SEQ ID NO: 477 is the lower strand (anti-sense)).
LCDRs 1-3 are indicated by underlining.
Figure 7 shows a schematic representation of the CD40L binding assay used herein, e.g., in Example 6.
Figure 8 shows various GAS1 secretion signal peptide coding sequences.
GAS wt: The natural occurring sequence in yeast. GAS E.Coli: The , nucleotide sequence according to optimal E. Coli codon usage (Wada et al. 1992 NAR 20 p 2111). GAS leader AT: AT rich nucleotide sequence. All nucleotide sequences encode the same amino acid sequence. Yellow (light grey in greyscale) indicates nucleotides that are similar for all sequences. Blue (dark grey in greyscale) indicates nucleotides that are similar to the wt sequence. White (white in greyscale) indicates nucleotides that are different from the wt sequence.
Figure 9 shows the results of a receptor binding assay which demonstrates the affinity of PEGylated DOM8-24cys with either 30K PEG MAL or 40K PEG2-IvIAL.
Figure 10 shows the results of an assay to assess the simultaneous binding of a dual specific dimer to HSA and CD40L (shaded bars). Binding to control BSA
antigen is also shown (solid bars).
Figure 11 shows the results of an assay to assess the simultaneous binding of a dual specific Fab to HSA and CD40L (shaded bars). Binding to control skimmed mild powder antigen is also shown (solid bars).
45a Figure 12 shows the results of FACS analysis of the inhibitory effect of monomeric DOM-24 (grey dotted line). Control stimulated cells ae shown as the solid black line and a control dAb is shown as the grey solid line.
Figure 13 shows the results of FACS analysis of the inhibitory effect of the Vk dAb DOM-116 (dotted line). Control stimulated cells are shown as the solid black line and a control dAb is shown as the grey solid line.
DETAILED DESCRIPTION
The invention provides antibody polypeptides that are monovalent for binding to CD40L. Monovalency for CD40L binding removes the possibility for cross-linking that occurs with prior art antibodies, and which plays a role in undesirable side effects observed with anti-CD40L monoclonal antibodies. Further, while not wishing to be limited to any specific mechanism or theory, because antibody polypeptides monovalent for CD40L cannot cross link CD40L, the possibility is eliminated that cross-linked CD40L may in turn cross-link cell surface CD40 and result in agonism of CD40 signaling activity. Thus, in a preferred aspect, the anti-CD40L antibodies disclosed herein not only inhibit or antagonize the binding of CD40L to CD40, they do not substantially agonize CD40 and/or CD40L activity.
In one aspect, the antibodies monovalent for CD40L binding are human antibody polypeptides. Human antibody polypeptides can be administered to human patients while largely avoiding the anti-antibody immune response often provoked by the administration of antibodies from other species, e.g., mouse. While murine antibodies can be "humanized" by grafting human constant domains onto the murine antigen-binding domains, human antibodies as disclosed herein are produced without the need for laborious and time-consuming genetic manipulation of a murine antibody sequence.
Monovalent antibody polypeptides:
The heavy and light polypeptide chains of antibodies comprise variable (V) regions that directly participate in antigen interactions, and constant (C) regions that provide structural support and function in non-antigen-specific interactions with immune effectors. The antigen binding domain of a conventional antibody is comprised of two separate domains: a heavy chain variable domain (VH) and a light chain variable domain (VL: which can be either VK or V)J. The antigen binding site itself is formed by six polypeptide loops: three from the VH domain (Hl, H2 and H3) and three from the VL domain (Ll, L2 and L3). I71 >>ivo, a diverse primary repertoire of V genes that encode the VH and VL domains is produced by the combinatorial rearrangement of gene segments. C regions include the light chain C regions (referred to as CL regions) and the heavy chain C regions (referred to as CHl, CH2 and CH3 regions). A naturally-occurring antibody generally comprises two antigen binding domains and is therefore divalent.
A number of smaller antigen binding fragments of naturally occurring antibodies have been identified following protease digestion. These include, for example, the "Fab fragment" (VL-CL-CHl-VH), "Fab' fragment" (a Fab with the heavy chain hinge region), and "F(ab')2 fragment" (a dimer of Fab' fragments joined by the heavy chain hinge region). Recombinant methods have been used to generate such fragments and to generate even smaller antigen-binding fragments, e.g., those referred to as "single chain Fv" (variable fragment) or "scFv," consisting of VL and VH joined by a synthetic peptide linker (VL-linker-VH). Fab fragments, Fab' fragments and scFv fragments are monovalent for antigen binding, as they each comprise only one antigen binding domain comprising one VH/VL dimer. Even smaller monovalent antibody fragments are the "domain antibodies," or "dAbs,"
which comprise only a single immunoglobulin variable domain, e.g., VH or VL, that alone specifically binds antigen, i.e., without the need for a complementary VL or VH
domain, respectively.
The term "dAb" will refer herein to a single immunoglobulin variable domain (VH or VL) polypeptide that specifically binds antigen. A. "dAb" binds antigen independently of other V domains; however, a "dAb" can be present in a homo-or heteromultimer with other VH or VL domains where the other domains are not required for antigen binding by the dAb, i.e., where the dAb binds antigen independently of the additional VH or VL domains. The preparation of single immunoglobulin variable domains is described and exemplified herein below.
Monovalent antibody polypeptides can be generated in several different ways.
For example, the nucleic acid sequence encoding heavy and light chains of an antibody known to bind CD40L can be manipulated to generate a number of different antibody polypeptides that are monovalent for CD40L binding. Thus, given the sequences encoding the heavy and light chain polypeptides that constitute an antibody and standard molecular cloning methodologies, one can generate monovalent antigen-binding polypeptide constructs such as Fab fragments, scFv, dAbs, or even bispecific antibodies (i.e., antibodies that comprise two different antigen-binding moieties and can therefore bind two separate antigens, preferably simultaneously) that are monovalent for CD40L.
Thus, one means of generating monovalent antibody polypeptides specific for CD40L is to amplify and express the VH and VL regions of the heavy chain and light chain gene sequences isolated, for example, from a hybridoma (e.g., a mouse hybridoma) that expresses anti-CD40L monoclonal antibody. The boundaries of VH
and VL domains are set out by Kabat et al. (1991, supra). The information regarding the boundaries of the VH and VL domains of heavy and light chain genes is used to design PCR primers that amplify the V domain from a heavy or light chain coding sequence encoding an antibody lcnown to bind CD40L. The amplified V domains are inserted into a suitable expression vector, e.g., pHEN-1 (Hoogenboom et al., 1991, Nucleic Acids Res. 19: 4133-4137) and expressed, e.g., as a fusion of the VH
and VL
in an scFv or other suitable monovalent format. The resulting polypeptide is then screened- for high affinity monovalent binding to CD40L. For all aspects of the present invention, screening for binding is performed as Icnown in the art or as described herein below.
Alternatively, library screening methods can be used to identify monovalent CD40L-specific binding proteins. Phage display technology (see, e.g., Smith, 1985, Science 228: 1315; Scott & Smith, 1990, Science 249: 386; McCafferty et al., 1990, Nature 348: 552) provides an approach for the selection of antibody polypeptides which bind a desired target from among large, diverse repertoires of antibody polypeptides. These phage-antibody libraries can be grouped into two categories:
natural libraries which use rearranged V genes harvested from human B cells (Marks et al., 1991, J. Mol. Biol., 222: 581; Vaughan et al., 1996, Nature Biotech., 14: 309) or synthetic libraries whereby germline V gene segments or other antibody polypeptide coding sequences are 'rearranged' in vitro (Hoogenboom & Winter, 1992, J. Mol. Biol., 227: 381; Nissim et al., 1994, EMBO J., 13: 692; Griffiths et al., 1994, EMBO J., 13: 3245; De Kruif et al., 1995, J. Mol. Biol., 248: 97) or where synthetic CDRs are incorporated into a single rearranged V gene (Barbas et al., 1992.
Proc.
Natl. Acad. Sci. USA, 89: 4457). Methods involving genetic display packages (e.g., phage display, polysome display) are well-suited for the selection of monovalent CD40L-specific antibody constructs because they generally express only monovalent fragments, rather than whole, divalent antibodies, on the display packages.
Methods for the preparation of phage display libraries displaying various antibody fragments are described in the preceding references. Such methods are also described, for example, in U.S. Patent No. 6,696,245, which is incorporated herein by reference.
The methods described in the '245 patent generally involve the randomization of selected regions of immunoglobulin gene coding regions, in particular VH and VL
coding regions, while leaving other regions non-randomized (see below). The '245 patent also describes the generation of scFv constructs comprising individually randomized VH and VL domains.
The VH gene is produced by the recombination of three gene segments, VH, D
and JH. In humans, there are approximately 51 functional VH segments (Cook and Tomlinson (1995) Immunol Today 16: 237), 25 functional D segments (Corbett et al.
(1997) J. Mol. Biol. 268: 69) and 6 functional JH segments (Ravetch et al.
(1981) Cell 27: 583), depending on the haplotype. The VH segment encodes the region of the polypeptide chain which forms the first and second antigen binding loops of the VH
domain (H1 and H2), while the VH, D and JH segments combine to form the third antigen binding loop of the Vn domain (H3).
The VL gene is produced by the recombination of only two gene segments, VL
and JL. In humans, there are approximately 40 functional VK segments (Schable and Zachau (1993) Biol. Chem. Hoppe-Seyler 374: 1001), 31 functional Vk segments (Williams et al. (1996) J. Mol. Biol. 264: 220; Kawasaki et al. (1997) Genome Res. 7:
250), 5 functional JK segments (Hieter et al. (1982) J. Biol. Chem. 257: 1516) and 4 functional J~, segments (Vasicek and Leder (1990) J. Exp. Med. 172: 609), depending on the haplotype. The VL segment encodes the region of the polypeptide chain which forms the first and second antigen binding loops of the VL domain (Ll and L2), while the VL and JL segments combine to form the third antigen binding loop of the VL
domain (L3). Antibodies selected from this primary repertoire are believed to be sufficiently diverse to bind almost all antigens with at least moderate affinity. High affinity antibodies are produced in vivo by "affinity maturation" of the rearranged genes, in which point mutations are generated and selected by the immune system on the basis of improved binding.
Analysis of the structures and sequences of antibodies has shown that five of the six antigen binding loops (H1, H2, LI, L2, L3) possess a limited number of main-chain conformations or canonical structures (Chothia and Lesk (1987) J. Mol.
Biol.
196: 901; Chothia et al. (1989) Nature 342: 877). The main-chain conformations are determined by (i) the length of the antigen binding loop, and (ii) particular residues, or types of residue, at certain key positions in the antigen biiiding loop and the antibody framework. Analysis of the loop lengths and key residues has enabled the prediction of the main-chain conformations of Hl, H2, L1, L2 and L3 encoded by the majority of human antibody sequences (Chothia et al. (1992) J. Mol. Biol. 227:
799;
Tomlinson et al. (1995) EMBO J. 14: 4628; Williams et al. (1996) J. Mol. Biol.
264:
220). Although the H3 region is much more diverse in terms of sequence, length and structure. (due to the use of D segments), it also forms a limited number of main-chain conformations for short loop lengths which depend on the length and the presence of particular residues, or types of residue, at key positions in the loop and the antibody framework (Martin et al. (1996) J. Mol. Biol. 263: 800; Shirai et al. (1996) FEBS
Letters 399: 1.
While, in one approach, diversity can be added to synthetic repertoires at any site in the CDRs of the various antigen-binding loops, this 'approach results in a g2=eater proportion of V domains that do not properly fold and therefore contribute to a lower proportion of molecules with the potential to bind antigen. An understanding of the residues contributing to the main chain conformation of the antigen-binding loops permits the identification of specific residues to diversify in a synthetic repertoire of VH or VL domains. That is, diversity is best introduced in residues that are not essential to maintaining the main chain conformation. As an example, for the diversification of loop L2, the conventional approach would be to diversify all the residues in the corresponding CDR (CDR2) as defined by Kabat et al. (1991, supra), some seven residues. However, for L2, it is known that positions 50 and 53 are diverse in naturally occurring antibodies and are observed to malce contact with the antigen. The preferred approach would be to diversify only those two residues in this loop. This represents a significant improvement in terms of the functional diversity required to create a range of antigen binding specificities.
Immunoglobulin polypeptide libraries can advantageously be designed to be based on predetermined variable domain main chain conformation. Such libraries may be constructed as described in International Patent Application WO
99/20749, the contents of which are incorporated herein by reference. Thus, in one aspect, an antibody polypeptide comprises the amino acid sequence of a given human germline V region gene segment, e.g., VH germline gene segment DP-47, or VK germline gene segment DPK9. Such variable region polypeptides can be used for the production of scFvs or Fabs, e.g., an scFv or Fab comprising (i) an antibody heavy chain variable domain (VH), or antigen binding fragment thereof, which comprises the amino acid sequence of germline VH segment DP-47 and (ii) an antibody light chain variable domain (VL), or antigen binding fragment thereof, which comprises the amino acid sequence oT germline V,, segment DPK9. Diversification of sequences within the context of the selected heavy and light chain germline gene segments,. e.g., DP-47, DPK 9, DP45, DP38, etc. can generate a repertoire of diverse immunoglobulin coding sequences. One approach to diversification is described below in the context of generating a library of diversified dAb or scFv sequences. These variable region polypeptides can also be expressed as dAbs and screened for high affinity binding to CD40L. The repertoire can be cloned into or generated in a vector suitable for phage display, e.g., a lambda or filamentous bacteriophage display vector and is then screened for binding to a given target antiaen, e.g., CD40L.
Preparation of Human Single Immunoglobulin Variable Domain Polypeptides:
A single immunoglobulin variable domain is a folded polypeptide domain which coinprises sequences characteristic of immunoglobulin variable domains and which specifically binds an antigen (e.g., dissociation constant of 500 nM or less), and which binds antigen as a single variable domain; that is, there is one binding site provided by a single immunoglobulin variable domain without any complementary variable domain. A single immunoglobulin variable domain therefore includes complete antibody variable domains as well as modified variable domains, for example in which one or more loops have been replaced by sequences which are not characteristic of antibody variable domains or antibody variable domains which have been truncated or comprise N- or C-terminal extensions, as well as folded fragments of variable domains which retain a dissociation constant of 500 nM or less (e.g., 450 nM or less, 400 nM or less, 350 nM or less, 300 nM or less, 250 nM or less, 200 nM
or less, 150 nM or less, 100 nM or less) and the target antigen specificity of the full-length domain. Preferably an antibody single variable domain useful in the invention is selected from the group of VH and VL, including Vkappa and Vla,,,baa. The single immunoglobulin variable domains of use herein are preferably "human" as that term is defined herein.
Preparation of Single Immunoglobulin Variable Domains:
Single immunoglobulin variable domains are prepared in a number of ways.
For each of these approaches, well-known methods of preparing (e.g., amplifying, mutating, etc.) and manipulating nucleic acid sequences are applicable.
One means of preparing single immunoglobulin variable domains is to amplify and express the VH or VL region of a heavy chain or light chain gene for a cloned antibody known to bind the desired antigen. That is, the VH or VL
domain of a known anti-CD40L antibody coding region can be amplified and expressed as a single domain (or as a fusion of a single domain) and evaluated for binding to CD40L.
The boundaries of VH and VL domains are set out by Kabat et al. (1991, supra). The information regarding the boundaries of the VH and VL domains of heavy and light chain genes is used to design PCR primers that amplify the V domain from a cloned heavy or light chain coding sequence encoding an antibody known to bind CD40L.
The amplified V domain is inserted into a suitable expression vector, e.g., pHEN-1 (Hoogenboom et al., 1991, Nucleic Acids Res. 19: 4133-4137) and expressed, either alone or as a fusion with another polypeptide sequence.
In a preferred approach, a repertoire of VH or VL domains, preferably human VH or VL domains, is screened by, for example, phage display, panning against the desired antigen. Methods for the construction of bacteriophage display libraries and lambda phage expression libraries are well known in the art, and taught, for example, by: McCafferty et al., 1990, Nature 348: 552; Kang et al., 1991, Proc. Natl.
Acad.
Sci. U.S.A., 88: 4363; Clackson et al., 1991, Nature 352: 624; Lowman et al., 1991, Biochemistry 30: 10832; Burton et al., 1991, Proc. Natl. Acad. Sci U.S.A. 88:
10134;
Hoogenboom et al., 1991, Nucleic Acids Res. 19: 4133; Chang et al.,1991, J.
Immunol. 147: 3610; Breitling et al., 1991, Gene 104: 147; Marks et al., 1991, J. Mol.
Biol. 222: 581; Barbas et al., 1992, Proc. Natl. Acad. Sci. U.S.A. 89: 445.7;
Hawkins and Winter (1992) J. Immunol., 22: 867; Marks et al. (1992) J. Biol. Chem., 267:
16007; and Lerner et al. (1992) Science, 258: 1313. Fab phage display libraries are taught, for example, by U.S. 5,922,545. scFv phage libraries are taught, for example, by Huston et al., 1988, Proc. Natl. Acad. Sci U.S.A. 85: 5879-5883; Chaudhary et al., 1990, Proc. Natl. Acad. Sci U.S.A. 87: 1066-1070; McCafferty et al., 1990, supra;
Clackson et al., 1991, supra; Marks et al., 1991, supra=, Chiswell et al., 1992, Trends Biotech. 10: 80.; and Marks et al., 1992, supra. Various embodiments of scFv librar,ies displayed on bacteriophage coat proteins have been described.
Refinements of phage- display approaches are also known, for example as described in W096/06213 and W092/01047 (Medical Research Council et al.) and W097/08320 (Morphosys, supra).
The repertoire of VH or VL domains can be a naturally-occurring repertoire of immunoglobulin sequences or a synthetic repertoire. A naturally-occurring repertoire is one prepared, for exainple, from immunoglobulin-expressing cells harvested from one or more individuals. Sucll repertoires can be "naive," i.e., prepared, for example, from human fetal or newborn immuhoglobulin-expressing cells, or rearranged, i.e., prepared from, for exatnple, adult human B cells. Natural repertoires are described, for example, by Marks et a1., 1991, J. Mol. Biol. 222: 581 and Vaughan et a1., 1996, Nature Biotech. 14: 309. If desired, clones identified from a natural repertoire, or any repertoire, for that matter, that bind the target antigen are then subjected to mutagenesis and further screening in order to produce and select variants with improved binding characteristics.
Synthetic repertoires of s'rngle immunoglobulin variable domains are prepared by artificially introducing diversity into a cloned V domain. Synthetic repertoires are described, for example, by Hoogenboom & Winter, 1992, J. Mol. Biol. 227: 381;
Barbas et al., 1992, Proc. Natl. Acad. Sci. U.S.A. 89: 4457; Nissim et al., 1994, EMBO J. 13: 692; Griffiths et al., 1994, EMBO J. 13: 3245; DeKriuf et al., 1995, J.
Mol. Biol. 248: 97; and WO 99/20749.
In one aspect, synthetic variable domain repertoires are prepared in VH or VK
backgrounds, based on artificially diversified germline VH or VK sequences.
For example, the VH domain repertoire can be based on cloned germline VH gene segments V3-23/DP47 (Tomlinson et al., 1992, J. Mol. Biol. 227: 7768) and JH4b.
The V, domain repertoire can be based, for example, on germline Vh gene segments 02/O12/DPK9 (Cox et al., 1994, Eur. J. Immunol. 24: 827) and J,;1. Diversity is introduced into these or other gene segments by, for example, PCR mutagenesis.
Diversity can be randomly introduced, for example, by error prone PCR
(Hawkins, et al., 1992, J.Mol. Biol. 226: 889) or chemical mutagenesis. As discussed above, however it is preferred that the introduction of diversity is targeted to particular residues. It is further preferred that the desired residues are targeted by introduction of the codon NNK using mutagenic primers (using the IUPAC nomenclature; where N = G, A, T or C, and K= G or T), which encodes all amino acids and the TAG
stop codon. Other codons which achieve similar ends are also of use, including the NNN
codon (which leads to the production of the additional stop codons TGA and TAA), DVT codon ((A/G/T) (A/G/C)T), DVC codon ((A/G/T)(A/G/C)C), and DVY codon ((A/G/T)(A/G/C)(C/T). The DVT codon encodes 22% serine and 11% tyrosine, asgpargine, glycine, alanine, aspartate, threonine and 'cysteine, which most closely mimics the distribution of amino acid residues for the antigen binding sites of natural human antibodies. Repertoires are made using PCR primers having the selected degenerate codon or codons at each site to be diversified. PCR mutagenesis is well l:nown in the art.
In one aspect, diversity is introduced into the sequence of human germline VH
gene segments V3-23/DP47 (Tomlinson et al., 1992, J. Mol. Biol. 227: 7768) and JH4b using the NNK codon at sites H30, H31, H33, H35, H50, H52, H52a, H53, H55, H56, H58, H95, H97 and H98, corresponding to diversity in CDRs 1, 2 and 3, with the numbering as used in U.S. 6,696,245.
In another aspect, diversity is also introduced into the sequence of human germline VH gene segments V3-23/DP47 and JH4b, for example, using the NNK
codon at sites H30, H31, H33, H35, H50, H52, H52a, H53, H55, H56, H58, H95, H97, H98, H99, H100, H100a and H100b, corresponding to diversity in CDRs 1, 2 and 3,with the numbering as used in U.S. 6,696,245.
In another aspect, diversity is introduced into the sequence of human germline V,; gene segments 02/O12/DPK9 and J,;l, for example, using the NNK codon at sites L30, L31, L32, L34, L50, L53, L91, L92, L93, L94 and L96, corresponding to diversity in CDRs 1, 2 and 3,with the numbering as used in U.S. 6,696,245.
Diversified repertoires are cloned into phage display vectors as known in the art and as described, for example, in WO 99/20749. In general, the nucleic acid molecules and vector constructs required for the performance of the present inventiori are available in the art and are constructed and manipulated as set forth in standard laboratory manuals, such as Sambrook et al. (1989). Molecular Cloning: A
Laboratory Manual, Cold Spring Harbor, USA.
The manipulation of nucleic acids in the present invention is typically carried out in recombinant vectors. As used herein, "vector" refers to a discrete element that is used to introduce heterologous DNA into cells for the expression and/or replication thereof. Methods by which to select or construct and, subsequently, use such vectors are well known to one of slcill in the art. Numerous vectors are publicly available, including bacterial plasmids, bacteriophage, artificial chromosomes and episomal vectors. Such vectors may be used for simple cloning and mutagenesis;
alternatively, as is typical of vectors in which repertoire (or pre-repertoire) members of the invention are carried, a gene expression vector is employed. A vector of use according to the invention is selected to accommodate a polypeptide coding sequence of a desired size, typically from 0.25 kilobase (kb) to 40 kb in length. A
suitable host cell is transformed with the vector after in vitro cloning manipulations. Each vector contains various functional components, which generally include a cloning (or "polylinker") site, an origin of replication and at least one selectable marker gene. If a given vector is an expression vector, it additionally possesses one or more of the following: enhancer element, promoter, transcription, termination and signal sequences, each positioned in the vicinity of the cloning site, such that they are operatively linked to the gene encoding a polypeptide repertoire member according to the invention.
Both cloning and expression vectors generally contain nucleic acid sequences that enable the vector to replicate in one or more selected host cells.
Typically in cloning vectors, this sequence is one that enables the vector to replicate independently of the host chromosomal DNA and includes origins of replication or autonomously replicating sequences. Such sequences are well known for a variety of bacteria, yeast and viruses. The origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, the 2 micron plasmid origin is suitable for yeast, and various viral origins (e.g. SV 40, adenovirus) are useful for cloning vectors in mammalian cells. Generally, the origin of replication,is not needed for mammalian expression vectors unless these are used in mammalian cells able to replicate high levels of DNA, such as COS cells.
Advantageously, a cloning or expression vector also contains a selection gene also referred to as selectable marker. This gene encodes a protein necessary for the I.n survival or growth of transformed host cells grown in a selective culture medium.
Host cells not transformed with the vector containing the selection gene will therefore not survive in the culture medium. Typical selection genes encode proteins that confer resistance to antibiotics and other toxins, e.g. ampicillin, neomycin, methotrexate or tetracycline, complement auxotrophic deficiencies, or supply critical nutrients not available in the growth media.
Because the replication of vectors according to the present invention is most conveniently performed in E. coli, an E. coli-selectable marker, for example, the (3-lactamase gene that confers resistance to the antibiotic ampicillin, is of use. These can be obtained from E. coli plasmids, such as pBR322 or a pUC plasmid such as pUC 18 or pUC 19.
Expression vectors usually contain a promoter that is recognized by the host organism and is operably linked to the coding sequence of interest. Such a promoter may be inducible or constitutive. The term "operably linked" refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner. A control sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences.
Promoters suitable for use with prokaryotic hosts include, for example, the (3-lactamase and lactose promoter systems, alkaline phosphatase, the tryptophan (trp) promoter system and hybrid promoters such as the tac promoter. Promoters for use in bacterial systems will also generally contain a Shine-Dalgarno -sequence operably linked to the coding sequence.
In libraries or repertoires as described herein, the preferred vectors are expression vectors that enable the expression of a nucleotide sequence corresponding to a polypeptide library member. Thus, selection is performed by separate propagation and expression of a single clone expressing the polypeptide library member or by use of any selection display system. As described above, a preferred selection display system uses bacteriophage display. Thus, phage or phageinid vectors can be used. Preferred vectors are phagemid vectors, which have an E.
coli origin of replication (for double stranded replication) and also a phage origin of replication (for production of single-stranded DNA). The manipulation and expression of such vectors is well known in the art (Hoogenboom and Winter (1992) supra; Nissim et al. (1994) supra). Briefly, the vector contains a,3-lactamase or other selectable marker gene to confer selectivity on the phagemid, and a lac promoter upstream of a expression cassette that consists (N to C terminal) of a pelB
leader sequence (which directs 'the expressed polypeptide to the periplasmic space), a multiple cloning site (for cloning the nucleotide version of the library member), optionally, one or more peptide tags (for detection), optionally, one or more TAG stop codons and the phage protein pIII. In one embodiment, the vector encodes, rather than the pelB leader sequence, a eukaryotic GAS1 leader sequence which serves to direct the secretion of the fusion polypeptide to the periplasmic space in E.
coli or to the medium in eukaryotic cell systems. Using various suppressor and non-suppressor strains of E. coli and with the addition of glucose, iso-propyl thio-(3-D-galactoside (IPTG) or a helper phage, such as VCS M13, the vector is able to replicate as a plasmid wltli no expression, produce large quantities of the polypeptide library member only, or produce phage, some of which contain at least one copy of the polypeptide-pIIl fusion on their surface.
An example of a preferred vector is the pHENI phagemid vector (Hoogenboom et al., 1991, Nucl. Acids Res. 19: 4133-4137; sequence is available, e.g., as SEQ ID NO: 7 in WO 0' V031611), in which the production of plll fusion protein is under the control of the LacZ promoter, which is inhibited in the presence of glucose and induced with IPTG. V02en grown in -suppressor strains of E.
coli, e.g., TG1, the gene III fusion protein is produced and packaged into phage, vvhile growth in non-suppressor strains, e.g., HB2151, permits the secretion of soluble fusion protein into the bacterial periplasm and into the culture medium. Because the expression of gene III prevents later infection with helper phage, the bacteria harboring the phagemid vectors are propagated in the presence of glucose before infection with VCSM13 helper phage for phage rescue.
Construction of vectors according to the invention employs conventional ligation techniques. Isolated vectors or DNA fragments are cleaved, tailored, and re-ligated in the form desired to generate the required vector. If desired, sequence analysis to confirm that the correct sequences are present in the constructed vector is performed using standard methods. Suitable methods for constructing expression vectors, preparing in vitro transcripts, introducing DNA into host cells, and performing analyses for assessing expression and function are known to those skilled in the art. The presence of a gene sequence in a sample is detected, or its amplification and/or expression quantified by conventional methods, such as Southern or Northern analysis, Western blotting, dot blotting of DNA, RNA or protein, in situ hybridization, immunocytochemistry or sequence analysis of nucleic acid or protein molecules. Those skilled in the art will readily envisage how these methods may be modified, if desired.
Screening Single Immunoglobulin Variable Domains for Anti2en Bindin Following expression of a repertoire of single immunoglobulin variable domains on the surface of phage, selection is performed by contacting the phage repertoire with immobilized target antigen (e.g., CD40L and/or an epitope bound by DOM8-24), washing to remove unbound phage, and propagation of the bound phage, the whole process frequently referred to as "panning." This process is applicable to the screening of single immunoglobulin variable domains as well as other antibody fragments that can be expressed on a display library, e.g., scFv, Fab, etc.
Alternatively, phage are pre-selected for the expression of properly folded member variants by panning against an immobilized generic ligand (e.g., protein A or protein L) that is only bound by folded members. This has the advantage of reducing the proportion of non-functional members, thereby increasing the proportion of members likely to bind a target antigen. Pre-selection with generic ligands is taught in WO
99/20749. The screening of phage antibody libraries is generally described, for example, by Harrison et al., 1996, Meth. Enzymol. 267: 83-109.
Screening is commonly performed using purified antigen immobilized on a solid support, for example, plastic tubes or wells, or on a chromatography matrix, for example SepharoseTM (Pharmacia). Screening or selection can also be performed on complex antigens, such as the surface of cells (Marks et al., 1993, BioTechnology 1 l:
1145; de Kruif et al., 1995, Proc. Natl. Acad. Sci. U.S.A. 92: 3938). Another alternative involves selection by binding biotinylated antigen in solution, followed by capture on streptavidin-coated beads.
In a preferred aspect, panning is performed by immobilizing antigen (generic or specific) on tubes or wells in a plate, e.g., Nunc MAxISORPTM immunotube 8 well strips. Wells are coated with 150 l of antigen (100 g/m1 in PBS) and incubated overnight. The wells are then washed 3 times with PBS and blocked with 400 l PBS-2% skim milk (2%MPBS) at 37 C for 2 hr. The wells are rinsed 3 times with PBS and phage are added in 2%MPBS. The mixture is incubated at room temperature for 90 minutes and the liquid, containing unbound phage, is removed.
Wells are rinsed 10 times with PB S-0.1 % tween 20, and then 10 times with PB
S to remove detergent. Bound phage are eluted by adding 200 l of freshly prepared mM triethylamine, mixing well and incubating for 10 min at room temperature.
Eluted phage are transferred to a tube containing 100 1 of IM Tris-HCI, pH
Humanized camelid VHH polypeptides are taught, for example in W004/041862, the teachings of which are incorporated herein in their entirety. It will be understood by one of skill in the art that naturally occurring camelid antibody single variable domain polypeptides may be modified according to the teachings of W004/041862 (e.g., amino acid substitutions at positions 45 and 103) to generate humanized camelid VHH
polypeptides. Also included in the present invention are antibody single variable domain polypeptides which are nurse shark VHH. Nurse shark dAbs are antibody single variable domain polypeptides derived from the nurse shark, that comprise heavy chain antibodies naturally devoid of light chain: V~. Nurse Shark V~
dAbs are described, for example, in Greenberg et al. (Nature 374 pp168-173 1995) and U.S.
20050043519.
The phrase "single immunoglobulin variable domain polypeptide"
encompasses not only an isolated single immunoglobulin variable domain polypeptide, but also larger polypeptides that comprise a monomer of a single immunoglobulin variable domain polypeptide sequence. A "domain antibody" or "dAb" is equivalent to a"single immunoglobuliil variable domain polypeptide"
as the term is used herein. With regard to a single immunoglobulin variable domain polypeptide, the binding to antigen, e.g., CD40L, is mediated by the single immunoglobulin V domain without a requirement for a complementary V domain.
According to the iilvention, the terms "antibody single variable domain polypeptide", "antibody single variable domain", "single antibody variable domain", and "single immunoglobulin variable domain" are understood to be equivalent.
As used herein, the phrase "sequence characteristic of immunoglobulin variable domains" refers to an amino acid sequence that is homologous, over 20 or more, 25 or more, 30 or more, 35 or more, 40 or more, 45 or more, or even 50 or more contiguous amino acids, to a sequence comprised by an immunoglobulin variable domain sequence.
Sequences similar or homologous (e.g., at least about 70% sequence identity) to the sequences disclosed herein are also part of the invention. In some embodiments, the sequence identity at the amino acid level can be about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher. At the nucleic acid level, the sequence identity can be about 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher. Alternatively, substantial identity exists when the nucleic acid segments will hybridize under selective hybridization conditions (e.g., very high stringency hybridization conditions), to the complement of the strand. The nucleic acids may be present in whole cells, in a cell lysate, or in a partially purified or substantially pure form.
As used herein, the terms "homology" or "similarity" refer to the degree with which two nucleotide or amino acid sequences structurally resemble each other.
As used herein, sequence "similarity" is a measure of the degree to which amino acid sequences share similar amino acid residues at corresponding positions in an alignment of the sequences. Amino acids are similar to each otlier where their side chains are similar. Specifically, "similarity" encompasses amino acids that are conservative substitutes for each other. A "conservative" substitution is any substitution that has a positive score in the blosum62 substitution matrix (Hentikoff and Hentikoff, 1992, Proc. Natl. Acad. Sci. USA 89: 10915-10919). By the statement "sequence A is n% similar to sequence B" is meant that n% of the positions of an optimal global alignment between sequences A and B consists of identical amino acids or conservative substitutions. Optimal global alignments can be performed using the following parameters in the Needleman-Wunsch alignment algoritlun:
For polypeptides:
Substitution matrix: blosum62.
Gap scoring function: -A -B*LG, where A=11 (the gap penalty), B=1 (the gap lengtll penalty) and LG is the length of the gap.
For nucleotide sequences:
Substitution matrix: 10 for matches, 0 for mismatches.
Gap scoring function: -A -B*LG where A=50 (the gap penalty), B=3 (tlie gap length penalty) and LG is the length of the gap.
Typical conservative substitutions are among Met, Val, Leu and Ile; among Ser and Thr; among the residues Asp, Glu and Asn; among the residues Gln, Lys and Arg; or aromatic residues Phe and Tyr.
As used herein, two sequences are "homologous" or "similar" to each other where they have at least 70%, 80%, or 85% sequence similarity to each other, including, e.g., 90%, 95%, 97%, 99% or even 100% sequence similarity, when aligned using either the Needleman-Wunsch algorithm or the "BLAST 2 sequences"
algorithm described by Tatusova & Madden, 1999, FEMS Microbiol Lett. 174:247-250. Where amino acid sequences are aligned using the "BLAST 2 sequences algorithm," the Blosum 62 matrix is the default matrix.
As used herein, the tenns "inhibit," "inhibits" and "inhibited" refer to a decrease in a given measurable activity (e.g., binding activity) by at least 10% relative to a reference. Where inhibition is desired, such inhibition is preferably at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more, up to and including 100%, i.e., complete inliibition or absence of the given activity. One way that inhibition of CD40L binding to CD40 is measured is as described in Example 6 herein. As used herein, the term "substantially inhibits" refers to a decrease in a given measurable activity (e.g., the binding of CD40L to CD40) by at least 50% relative to a reference.
For example, "substantially inhibits" refers to a decrease in a given measurable activity of at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% and up to and including 100% relative to a reference. As used herein, "inhibits the binding", with reference to the binding of an antibody polypeptide binding to CD40L, or binding to CD40L, refers to a decrease in binding by at least 10% relative to a reference. "Inhibits the binding" preferably refers to a decrease in binding of at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more, up to and including 100%.
As used herein, the terms "activate," "activates" and "activated" refer to an increase in a given measurable activity by at least 5% relative to a reference, for example, at least 10%, 25%, 50%, 75% or even 100%.
As used herein, the term "antagonist" refers to an agent that inhibits at least one activity mediated by CD40L, inhibits the binding of CD40 to CD40L, and/or results in no more than 25% platelet activation and/or aggregation in a platelet aggregation assay or platelet activation assay as described herein, and preferably results in 25% or less platelet activation and/or aggregation, 20% or less, 15% or less, 10% or less, 5% or less, and as little as zero platelet activation and/or aggregation.
An activity is "antagonized" if the activity (i.e., CD40L mediated activity, binding of CD40 or CD40L, or platelet activation and/or aggregation) is reduced by at least 10%, and preferably at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 97% or even 100% (i.e., no activity) in the presence, relative to the absence of an antagonist.
An antagonist as the term is used herein preferably comprises a single immunoglobulin variable domain that binds monovalently to CD40L.
As used herein, the term "agonist" refers to an agent that activates at least one activity mediated by CD40L, either alone or when combined with another co-stimulus, relative to a reference. An activity is "agonized" if the activity is increased by at least 10%, e.g., 50%, in the presence, relative to the absence of an agonist.
As used herein, the term "epitope" refers to a unit of structure conventionally bound by an immunoglobulin VH/VL pair. Epitopes define the minimum binding site for an antibody, and thus represent the target of specificity of an antibody.
In the case of a single immunoglobulin variable domain, an epitope represents the unit of structure bound by a single variable domain in isolation. That is, the binding site is provided by one, single immunoglobulin variable domain.
As used herein, the tenn "extended release" or the equivalent terms "controlled release" or "slow release" refer to drug formulations that release active drug, such as a polypeptide drug, over a period of time following administration to an individual. Extended release of polypeptide drugs, which can occur over a range of desired times, e.g., minutes, hours, days, weeks or longer, depending upon the drug formulation, is in contrast to standard formulations in which substantially the entire dosage unit is available for immediate absorption or immediate distribution via the bloodstream. Preferred extended release formulations result in a level of circulating drug from a single administration that is sustained, for example, for 8 hours or more, 12 hours or more, 24 hours or more, 36 hours or more, 48 liours or more, 60 hours or more, 72 hours or more 84 hours or more, 96 hours or more, or even, for example, for 1 week or 2 weeks or more, for example, I month or more.
As used herein, a"CD40L activity" is an activity involving or resulting from the binding of CD40L to CD40, and includes, but is not limited to binding to (assayed, for example, according to the method described in Example 6), activation of Jun-N-terminal Kinase (JNK), the induction of T cells to produce and secrete cytokines including, for example, IL-10, IFN-y and TNF-a, and the mediation of platelet activation and/or aggregation. Assays for these activities are provided herein below.
As used herein, the term "does not substantially agonize" means that a given agent, e.g., an anti-CD40L antibody polypeptide, does not activate one or more of the CD40L activities including Jun-N-terminal kinase activation (phosphorylation) in Jurkat T cells and induction of IFN-y production or secretion in anti-CD3-stimulated Jurkat T cells, as the term "activate" is defined herein. As used herein, "does not substantially agonize" means that the agent does not activate more than 20% of the activity which is activated by CD40 binding to CD40L, preferably, the agent does not activate more 'than 10%, 8%, 5%, 3%, or more than 2% or less, iiicluding zero activation, of the activity which is activated by CD40 binding to CD40L.
As used herein, the term "antibody polypeptide" refers to a polypeptide which either is an antibody or is a part of an antibody, modified or unmodified, which retains the ability to specifically bind antigen. Thus, the teim antibody polypeptide includes an antigen-binding heavy chain, light chain, heavy chain-light chain dimer, Fab fragment, F(ab')2 fragment, dAb, or an Fv fragment, including a single chain Fv (scFv). The phrase "antibody polypeptide" is intended to encompass recombinant fusion polypeptides that comprise an antibody polypeptide sequence that retains the ability to specifically bind antigen in the context of the fusion.
As used herein, the term "monovalent" means that a given antibody polypeptide or single immunoglobulin variable domain polypeptide can bind only a single molecule of its target. Naturally-occurring antibodies are generally divalent, in that they have two functional antigen-binding arms, each comprising a VH and a VL
domain. Where steric hindrance is not an issue, a divalent antibody can bind two separate molecules of the same antigen. In contrast, a "monovalent" antibody has the capacity to binci only one such antigen molecule. As the term is used herein, a "monovalent" antibody can also comprise more than one antigen binding site, e.g., two antigen binding sites, but the binding sites must be for different antigens, such that the antibody can only bind one molecule of CD40L at a time. The antigen-binding domain of a monovalent antibody can comprise a VH and a VL domain, but preferably comprises only a single immunoglobulin variable domain, i.e., a VH
or a VL domain, that has the capacity to bind CD40L without the need for a corresponding VL or VH domain, respectively. A monovalent antibody lacks the capacity to cross link molecules of a single antigen.
As used herein, the term "standard platelet aggregation assay" means the assay described in the section herein below, entitled "Platelet Aggregation Assay."
As used herein, the terms "VH domain" and "VL domain" refer to immunoglobulin variable regions as defined by Kabat et al.(supra), which is incorporated herein by reference.
As used herein, "linked" refers to the attachment of a polymer moiety, such as PEG to an amino acid residue of an antibody polypeptide. Attachment of a PEG
polymer to an arnino acid residue of an antibody polypeptide, e.g., an anti-dAb, is referred to as "PEGylation" and may be achieved using several PEG
attachment moieties including, but not limited to N-hydroxylsuccinimide (NIIS) active ester, succinimidyl propionate (SPA), maleimide (MAL), vinyl sulfone (VS), or thiol. A PEG polymer, or other polymer, can be linked to an antibody polypeptide at eitlier a predetermined position, or may be randomly linked to the an antibody polypeptide molecule. It is preferred, however, that the PEG polymer be linked to an antibody polypeptide at a predetermined position. A PEG polymer may be linked to any residue in the an antibody polypeptide, however, it is preferable that the polymer is linked to either a lysine or cysteine, rhich is either naturally occurring in the antibody polypeptide, or which has been engineered into the antibody polypeptide, for example, by mutagenesis of a naturally occurring residue in the antibody polypeptide to either a cysteine or lysine. PEG-linkage can also be mediated through a peptide linker attached to an antibody polypeptide. That is, the PEG moiety can be attached to a peptide linker fused to an antibody polypeptide, where the linker provides the site, e.g., a free cysteine or lysine, for PEG attachment. As used herein, "linked" can also refer to the association of two or more antibody polypeptides, e.g., dAb monomers, to form a dimer, trimer, tetramer, or other multimer. Antibody polypeptide monomers can be liiiked to form a multimer by several methods known in the art, including, but not limited to, expression of the antibody polypeptide monomers as a fusion protein, linkage of two or more monomers via a peptide linker between monomers, or by chemically joining monomers after translation, either to each other directly, or through a linker by disulfide bonds, or by linkage to a di-, tri-or multivalent linking moiety (e.g., a multi-arm PEG). While dAb multimers are specifically contemplated herein, e.g., in the context of dual- or multi-specifc antibody polypeptide constructs, it is emphasized that for any given antibody polypeptide construct, the construct should only be able to bind one molecule of CD40L, i.e., the constructs can have only one CD40L-binding element, and cannot cross liiik CD40L.
As used herein, "polymer" refers to a macromolecule made up of repeating monomeric units, and can refer to a syiithetic or naturally occurring polymer such as an optionally substituted straight or branched chain polyalkylene, polyalkenylene, or polyoxyalkylene polynier or a branched or unbranched polysaccharide. A
"polymer"
as used herein, specifically refers to an optionally substituted or branched chain poly(etllylene glycol), poly(propylene glycol), or poly(vinyl alcohol) and derivatives thereof.
As used herein, "PEG" or "PEG polymer" refers to polyethylene glycol, and more specifically can refer to a derivitized form of PEG, including, but not limited to N-hydroaylsuccinimide (NHS) active esters of PEG such as succinimidyl propionate, benzotriazole active esters, PEG derivatized with maleimide, vinyl sulfones, or thiol groups. Particular PEG formulations can include PEG-O-CH?CH--,CH,-CO-,-NHS;
PEG-O-CH,-NHS; PEG-O-CH2CH,-CO,-NHS; PEG-S-CH,CH2-CO-NHS; PEG-O,CNH-CH(R.)-CO?-NHS; PEG-NHCO-CH,CH2-CO-NHS; and PEG-O-CH2-CO7-NHS; where R is (CH-'1)4)NHCO,(mPEG). PEG polymers useful in the invention may be linear molecules, or may be branched wllerein multiple PEG moieties are present in a single polymer. Some particularly preferred PEG conformations that are useful in the invention include, but are not limited to the following:
QnPGC~---C;-~.-N-1 C' CH 'C~
o l r~ePE~x~--O- C---NK/ "'C- NH-,K;CHa-NH--C--CH3Ct~,; a,~y mPEG-N
C
mPEG-MAL mPEG2-MAL
CH OH {{~~
CH2CONH(CH2CHz0)2-CHzCHZN P~~ Pit& OtG
mPEG-CONHCH O ; flO-"I.- ''0~0 V\ Ã' ~0\!~-OG{
CH 2CONH(CH 2CH20)2-CH2CH7N ' multi-arm PEG
mPEG-(MAL)2 0 ll CHzCONH(CHzCHzO)z-CHZCHzN ~
O/
mPEG-O- C-NH
mPEG-0- li NH
0 CHzCONH(CHZCHZ0)2-CH2CHzN I
mPEG2-(MAL)2 ~
nwrIny-O-O-NH
1 (_~~ Iz~ 0 ~ W
mPECr-0-CH:CHz-L--'0-N ntPEO-O-c-NH/ \C-O-hl inPEG2-NHS
mPEG-SPA
As used herein, a "sulfhydryl-selective reagent" is a reagent which is useful for the attachment of a PEG polymer to a thiol-containing amino acid. Thiol groups on the amino acid residue cysteine are particularly useful for interaction with a sulfhydryl-selective reagent. Sulfliydryl-selective reagents which are useful for such attachment include, but are not limited to maleimide, vinyl sulfone, and thiol. The use of sulfl7ydryl-selective reagents for coupling to cysteine residues is known in the art and may be adapted as needed according to the present invention (See Eg., Zalipsky, 1995, Bioconjug. Chein. 6:150; Greenwald et al., 2000, Crit. Rev.
Ther.
Drug Carrier Syst. 17:101; Herman et al., 1994, Macromol. Chem. Phys.
195:203).
The attachment of PEG or another agent, e.g., HSA, to an antibody polypeptide or to a single immunoglobulin variable domain polypeptide as described herein will preferably not impair the ability of the polypeptide to specifically bind CD40L. That is, the PEG-linked antibody polypeptide or single immunoglobulin variable domain polypeptide will retain its binding activity relative to a non-PEG-linked counterpart. As used herein, "retains activity" refers to a level of activity of a PEG-linlced antibody polypeptide which is at least 10% of the level of activity of a non-PEG-linked antibody polypeptide, preferably at least 20%, 30%, 40%, 50%, 60%, 70%, 80% and up to 90%, preferably up to 95%, 98%, and up to 100% of the activity of a non-PEG-linked antibody polypeptide comprising the same antigen-binding domain or domains. More specifically, the activity of a PEG-linked antibody polypeptide compared to a non-PEG linked antibody variable domain should be determined on an antibody polypeptide molar basis; that is equivalent numbers of moles of each of the PEG-linked and non-PEG-linked antibody polypeptides should be used in each trial. In determining whether a particular PEG-linked antibody polypeptide "retains activity", it is preferred that the activity of a PEG-liiilced antibody polypeptide be compared with the activity of the same antibody polypeptide in the absence of PEG.
As used herein, the term "in vivo half-life" refers to the time taken for the serum concentration of a ligand (e.g., a single immunoglobulin variable domain) to reduce by 50%, in vivo, for exainple due to degradation of the ligand and/or clearance or sequestration of the ligand by natural mechanisms. The anti CD40L antibody polypeptides or single immunoglobulin variable domain polypeptides described herein can be stabilized in vivo and their half-life increased by binding to molecules, such as PEG, Nvhich resist degradation and/or clearance or sequestration. The half-life of an antibody polypeptide is increased if its functional activity persists, in VNo, for a longer period than a similar antibody polypeptide which is not linlced to a PEG
polymer. Typically, the half life of a PEGylated antibody polypeptide is increased by 10%, 20%, 30%, 40%, 50% or more relative to a non-PEGylated antibody polypeptide. Increases in the range of 2x, 3x, 4x, 5x, l Ox, 20x, 30x, 40x, 50x or more of the half life are possible. Alternatively, or in addition, increases in the range of up to 30x, 40x, 50x, 60x, 70x, 80x, 90x, 100x, 150x of the half life are possible.
According to the invention, a PEG-linlced antibody single variable domain has a half-life of between 0.25 and 170 hours, preferably between 1 and 100 hours, more preferably between 30 and 100 hours, and still more preferably between 50 and hours, and up to 170, 180, 190, and 200 hours or more.
As used herein, "resistant to degradation" or "resists degradation" with respect to a PEG or other polymer-linl:ed antibody polypeptide monomer or multimer means that the PEG- or other polymer-linlced antibody polypeptide mozlomer or multimer is degraded by no more than 10% when exposed to pepsin at pH 2.0 for 30 minutes and preferably not degraded at all.
As used herein, "hydrodynamic size" refers to the apparent size of a molecule (e.g., a protein molecule) based on the diffusion of the molecule through an aqueous solution. The diffusion, or motion of a protein through solution can be processed to derive an apparent size of the protein, where the size is given by the "Stokes radius"
- or "hydrodynamic radius" of the protein particle. The "hydrodynamic size" of a protein depends on both mass and shape (conformation), such that two proteins having the same molecular mass may have differing hydrodynamic sizes based on the overall conformation of the protein. Hydrodynamic size is measured, for example, by size exclusion chromatography. The hydrodynamic size of a PEG-linked antibody polypeptide, e.g., a single immunoglobulin variable domain (including antibody variable domain multimers as described herein), can be in the range of 24 kDa to 500 kDa; 30 to 500 kDa; 40 to 500 kDa; 50 to 500 kDa; 100 to 500 kDa; 150 to 500 kDa;
200 to 500 kDa; 250 to 500 kDa; 300 to 500 10a; 350 to 500 kDa; 400 to 500 kDa and 450 to 500 l:Da. Preferably the hydrodynamic size of a PEGylated antibody polypeptide of the invention is 30 to 40 kDa; 70 to 80 lcDa or 200 to 300 1cDa. Where a single immunoglobulin variable domain polypeptide is desired for use in imaging applications, the polypeptide should have a hydrodynamic size of between 50 and 100 kDa. Alternatively, where a single immunoglobulin variable domain polypeptide is desired for therapeutic applications, the polypeptide preparation should have a hydrodynamic size of greater than 200 kDa.
As used herein, the term "IC50" refers to the concentration of an inhibitor necessary to inhibit a given activity by 50%. IC50 is determined by assaying a given activity, e.g., binding of CD40L to CD40, in the presence of varying amounts of the inhibitor (e.g., monovalent anti-CD40L antibody polypeptide), and plotting the inhibitor concentration versus the activity being targeted. Binding of CD40L
to CD40 is measured herein by the metllod described in Example 6. Alternatively, SPR
can be used.
As used herein, the term "fused to an antibody polypeptide" means that a polypeptide is fused to a given antibody through use of recombinant DNA
techniques.
Thus, an antibody "fused to" another polypeptide, e.g., to another antibody of different binding specificity, does not exist in nature and is generated through recombinant means. The term "fused to an antibody polypeptide" also encompasses the linkage of a polypeptide to a given antibody polypeptide through, for, example, disulfide or other chemical linkages, where the fused polypeptide is not naturally found fused to the antibody polypeptide. Recombinant and chemical methods of fusing a polypeptide to another polypeptide, e.g., to an antibody, are well known in the art.
As used herein, the term "Fc domain" refers to the constant region antibody sequences coinprising CH2 and CH3 constant domains as delimited according to Kabat et al., supra. The Fc portion of the heavy chain polypeptide has the ability to self-associate, a function which facilitates the formation of divalent antibodies. The ternl "lacks an Fc domain" means that a given antibody polypeptide lacks at least the portion of an immunoglobulin Fc domain (as such domains are defined according to Kabat et al., supM) sufficient to mediate the dimerization of Fc-containing antibody polypeptides. Dimerization of Fc-containing antibody polypeptides is measured, for example, by chromatographic methods or by surface plasmon resonance. An antibody polypeptide lacking an Fe domain avoids Fe-platelet interactions and tllerefore avoids induction of platelet aggregation.
As used herein "treat", "reduce", "prevent", or "alleviate" as it relates to a symptom of disease refer to a decrease of the a symptom by at least 10% based on a a clinically measurable paraineter, or by at least one point on a clinically-accepted scale of disease or symptom severity. As used herein, the term "symptom of systemic lupus erythematosus" refers to any of the clinically relevant symptoms of SLE
known to those of skill in the art. Non-limiting examples include the accumulation of IgG
autoantibodies (e.g., against nuclear antigtzl ens such as chromatin, snRNPs (especially U1, Sm, Ro/SSA and La/SSB), phospholipids and cell surface molecules), hemolytic anemia, thrombocytopenia, leukopenia, glomerulonephritis, vasculitis, arthritis, and serositis). A reduction in such a symptom is a reduction by at least 10% in a clinically measurable parameter, or by at least one point on a clinically-accepted scale of disease severity.
As used herein, the phrase "specifically binds" refers to the binding of an antigen by an immunoglobulin variable domain with a dissociation constant (Kd) of 1 M or lower as measured by surface plasmon resonance analysis using, for example, a BlAcoreTM surface plasmon resonance system and BlAcoreTM kinetic evaluation software (e.g., version 2.1). The affinity or Kd for a specific binding interaction is preferably about 500 nM or lower, more preferably about 300 nM or lower.
As used herein, a "generic ligand" is a ligand that binds a substantial proportion of functional members in a given repertoire, e.g., in a phage display library. Thus, the same generic ligand can bind many members of the repertoire regardless of their target ligand specificities. In general, the presence of a functional generic ligand binding site indicates that the repertoire member is expressed and folded correctly. Thus, binding of the generic ligand to its binding site provides a method for preselecting functional polypeptides from a repertoire of polypeptides.
Generic ligands include, for example, Protein A, Protein G and Protein L.
As used herein, the term "universal framework" refers to a single antibody framework sequence corresponding to the regions of an antibody conserved in sequence as defined by Kabat (supra) or corresponding to the human germline immunoglobulin repertoire or structure as defined by Chothia and Lesk, (1987) J.
Mol. Biol. 196:910-917. The invention provides for the use of a single framework, or a set of such frameworks, which has been found to permit the derivation of virtually any binding specificity though variation in the hypervariable regions alone.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1 shows gel analysis of the quality of biotin-labeled CD40L used in the screening procedures described herein. (a) 1 g of non-biotinylated-CD40L
(Lane 1) and 0.3 ~g of biotin-CD40L (Lane 2) were analysed on SDS-PAGE and detected by Simply Blue Safe-Stain. (b) 0.1 g of biotin-CD40L (Lane 1) and 0.02 g of biotin-CD40L (Lane 2) were detected by Western-blot probing with 1:5000 Streptavidin-I IRP.
Figure 2 shows a graphical representation of a dose response receptor binding assay (RBA) readout, analysing the inhibition of CD40L binding to CD40-Fc by dAbs DOM-l0, -20, -27, -30, -31, -62, -77, titrated from 1 M down to 10 pM.
dAbs DOM-20, -30, and -31 are the most potent with IC50 values of approximately 8 nM.
Figure 3 shows a graphical representation of a dose response receptor binding assay readout, analysing the inhibition of CD40L binding to CD40-Fc by dAbs DOM-4 and DOM-5, titrated from 1 M down to 500 pM. The IC50 values for dAbs DOM-and DOM-4 are approximately 3 nM and 100 nM respectively.
Figure 4 shows a graphical representation of a dose response receptor binding assay readout, analysing the inhibition of CD40L binding to CD40-Fc by dAb DOM-5 24, titrated from 100 nM down to 0.5 pM. The data were curve-fitted using GraphPad Prism software.
Figure 5 shows the sequence of the VH frameworlc based on germline sequence DP47 - JH4b (SEQ ID NO: 1, amino acid sequence; SEQ ID NO: '2, nucleotide sequence - both sense and antisense strands are shown - SEQ ID NO:
2 is the top strand (sense) and SEQ ID NO: 476 is the lower strand (anti-sense)).
HCDRs 1-3 are indicated by underlining.
Figure 6 shows the sequence of the Vh framework based on germline sequence DPK9 - JK1 (SEQ ID NO: 3, amino acid sequence; SEQ ID NO: 4, nucleotide sequence - both sense and antisense strands are shown - SEQ ID NO:
4 is the top strand (sense) and SEQ ID NO: 477 is the lower strand (anti-sense)).
LCDRs 1-3 are indicated by underlining.
Figure 7 shows a schematic representation of the CD40L binding assay used herein, e.g., in Example 6.
Figure 8 shows various GAS1 secretion signal peptide coding sequences.
GAS wt: The natural occurring sequence in yeast. GAS E.Coli: The , nucleotide sequence according to optimal E. Coli codon usage (Wada et al. 1992 NAR 20 p 2111). GAS leader AT: AT rich nucleotide sequence. All nucleotide sequences encode the same amino acid sequence. Yellow (light grey in greyscale) indicates nucleotides that are similar for all sequences. Blue (dark grey in greyscale) indicates nucleotides that are similar to the wt sequence. White (white in greyscale) indicates nucleotides that are different from the wt sequence.
Figure 9 shows the results of a receptor binding assay which demonstrates the affinity of PEGylated DOM8-24cys with either 30K PEG MAL or 40K PEG2-IvIAL.
Figure 10 shows the results of an assay to assess the simultaneous binding of a dual specific dimer to HSA and CD40L (shaded bars). Binding to control BSA
antigen is also shown (solid bars).
Figure 11 shows the results of an assay to assess the simultaneous binding of a dual specific Fab to HSA and CD40L (shaded bars). Binding to control skimmed mild powder antigen is also shown (solid bars).
45a Figure 12 shows the results of FACS analysis of the inhibitory effect of monomeric DOM-24 (grey dotted line). Control stimulated cells ae shown as the solid black line and a control dAb is shown as the grey solid line.
Figure 13 shows the results of FACS analysis of the inhibitory effect of the Vk dAb DOM-116 (dotted line). Control stimulated cells are shown as the solid black line and a control dAb is shown as the grey solid line.
DETAILED DESCRIPTION
The invention provides antibody polypeptides that are monovalent for binding to CD40L. Monovalency for CD40L binding removes the possibility for cross-linking that occurs with prior art antibodies, and which plays a role in undesirable side effects observed with anti-CD40L monoclonal antibodies. Further, while not wishing to be limited to any specific mechanism or theory, because antibody polypeptides monovalent for CD40L cannot cross link CD40L, the possibility is eliminated that cross-linked CD40L may in turn cross-link cell surface CD40 and result in agonism of CD40 signaling activity. Thus, in a preferred aspect, the anti-CD40L antibodies disclosed herein not only inhibit or antagonize the binding of CD40L to CD40, they do not substantially agonize CD40 and/or CD40L activity.
In one aspect, the antibodies monovalent for CD40L binding are human antibody polypeptides. Human antibody polypeptides can be administered to human patients while largely avoiding the anti-antibody immune response often provoked by the administration of antibodies from other species, e.g., mouse. While murine antibodies can be "humanized" by grafting human constant domains onto the murine antigen-binding domains, human antibodies as disclosed herein are produced without the need for laborious and time-consuming genetic manipulation of a murine antibody sequence.
Monovalent antibody polypeptides:
The heavy and light polypeptide chains of antibodies comprise variable (V) regions that directly participate in antigen interactions, and constant (C) regions that provide structural support and function in non-antigen-specific interactions with immune effectors. The antigen binding domain of a conventional antibody is comprised of two separate domains: a heavy chain variable domain (VH) and a light chain variable domain (VL: which can be either VK or V)J. The antigen binding site itself is formed by six polypeptide loops: three from the VH domain (Hl, H2 and H3) and three from the VL domain (Ll, L2 and L3). I71 >>ivo, a diverse primary repertoire of V genes that encode the VH and VL domains is produced by the combinatorial rearrangement of gene segments. C regions include the light chain C regions (referred to as CL regions) and the heavy chain C regions (referred to as CHl, CH2 and CH3 regions). A naturally-occurring antibody generally comprises two antigen binding domains and is therefore divalent.
A number of smaller antigen binding fragments of naturally occurring antibodies have been identified following protease digestion. These include, for example, the "Fab fragment" (VL-CL-CHl-VH), "Fab' fragment" (a Fab with the heavy chain hinge region), and "F(ab')2 fragment" (a dimer of Fab' fragments joined by the heavy chain hinge region). Recombinant methods have been used to generate such fragments and to generate even smaller antigen-binding fragments, e.g., those referred to as "single chain Fv" (variable fragment) or "scFv," consisting of VL and VH joined by a synthetic peptide linker (VL-linker-VH). Fab fragments, Fab' fragments and scFv fragments are monovalent for antigen binding, as they each comprise only one antigen binding domain comprising one VH/VL dimer. Even smaller monovalent antibody fragments are the "domain antibodies," or "dAbs,"
which comprise only a single immunoglobulin variable domain, e.g., VH or VL, that alone specifically binds antigen, i.e., without the need for a complementary VL or VH
domain, respectively.
The term "dAb" will refer herein to a single immunoglobulin variable domain (VH or VL) polypeptide that specifically binds antigen. A. "dAb" binds antigen independently of other V domains; however, a "dAb" can be present in a homo-or heteromultimer with other VH or VL domains where the other domains are not required for antigen binding by the dAb, i.e., where the dAb binds antigen independently of the additional VH or VL domains. The preparation of single immunoglobulin variable domains is described and exemplified herein below.
Monovalent antibody polypeptides can be generated in several different ways.
For example, the nucleic acid sequence encoding heavy and light chains of an antibody known to bind CD40L can be manipulated to generate a number of different antibody polypeptides that are monovalent for CD40L binding. Thus, given the sequences encoding the heavy and light chain polypeptides that constitute an antibody and standard molecular cloning methodologies, one can generate monovalent antigen-binding polypeptide constructs such as Fab fragments, scFv, dAbs, or even bispecific antibodies (i.e., antibodies that comprise two different antigen-binding moieties and can therefore bind two separate antigens, preferably simultaneously) that are monovalent for CD40L.
Thus, one means of generating monovalent antibody polypeptides specific for CD40L is to amplify and express the VH and VL regions of the heavy chain and light chain gene sequences isolated, for example, from a hybridoma (e.g., a mouse hybridoma) that expresses anti-CD40L monoclonal antibody. The boundaries of VH
and VL domains are set out by Kabat et al. (1991, supra). The information regarding the boundaries of the VH and VL domains of heavy and light chain genes is used to design PCR primers that amplify the V domain from a heavy or light chain coding sequence encoding an antibody lcnown to bind CD40L. The amplified V domains are inserted into a suitable expression vector, e.g., pHEN-1 (Hoogenboom et al., 1991, Nucleic Acids Res. 19: 4133-4137) and expressed, e.g., as a fusion of the VH
and VL
in an scFv or other suitable monovalent format. The resulting polypeptide is then screened- for high affinity monovalent binding to CD40L. For all aspects of the present invention, screening for binding is performed as Icnown in the art or as described herein below.
Alternatively, library screening methods can be used to identify monovalent CD40L-specific binding proteins. Phage display technology (see, e.g., Smith, 1985, Science 228: 1315; Scott & Smith, 1990, Science 249: 386; McCafferty et al., 1990, Nature 348: 552) provides an approach for the selection of antibody polypeptides which bind a desired target from among large, diverse repertoires of antibody polypeptides. These phage-antibody libraries can be grouped into two categories:
natural libraries which use rearranged V genes harvested from human B cells (Marks et al., 1991, J. Mol. Biol., 222: 581; Vaughan et al., 1996, Nature Biotech., 14: 309) or synthetic libraries whereby germline V gene segments or other antibody polypeptide coding sequences are 'rearranged' in vitro (Hoogenboom & Winter, 1992, J. Mol. Biol., 227: 381; Nissim et al., 1994, EMBO J., 13: 692; Griffiths et al., 1994, EMBO J., 13: 3245; De Kruif et al., 1995, J. Mol. Biol., 248: 97) or where synthetic CDRs are incorporated into a single rearranged V gene (Barbas et al., 1992.
Proc.
Natl. Acad. Sci. USA, 89: 4457). Methods involving genetic display packages (e.g., phage display, polysome display) are well-suited for the selection of monovalent CD40L-specific antibody constructs because they generally express only monovalent fragments, rather than whole, divalent antibodies, on the display packages.
Methods for the preparation of phage display libraries displaying various antibody fragments are described in the preceding references. Such methods are also described, for example, in U.S. Patent No. 6,696,245, which is incorporated herein by reference.
The methods described in the '245 patent generally involve the randomization of selected regions of immunoglobulin gene coding regions, in particular VH and VL
coding regions, while leaving other regions non-randomized (see below). The '245 patent also describes the generation of scFv constructs comprising individually randomized VH and VL domains.
The VH gene is produced by the recombination of three gene segments, VH, D
and JH. In humans, there are approximately 51 functional VH segments (Cook and Tomlinson (1995) Immunol Today 16: 237), 25 functional D segments (Corbett et al.
(1997) J. Mol. Biol. 268: 69) and 6 functional JH segments (Ravetch et al.
(1981) Cell 27: 583), depending on the haplotype. The VH segment encodes the region of the polypeptide chain which forms the first and second antigen binding loops of the VH
domain (H1 and H2), while the VH, D and JH segments combine to form the third antigen binding loop of the Vn domain (H3).
The VL gene is produced by the recombination of only two gene segments, VL
and JL. In humans, there are approximately 40 functional VK segments (Schable and Zachau (1993) Biol. Chem. Hoppe-Seyler 374: 1001), 31 functional Vk segments (Williams et al. (1996) J. Mol. Biol. 264: 220; Kawasaki et al. (1997) Genome Res. 7:
250), 5 functional JK segments (Hieter et al. (1982) J. Biol. Chem. 257: 1516) and 4 functional J~, segments (Vasicek and Leder (1990) J. Exp. Med. 172: 609), depending on the haplotype. The VL segment encodes the region of the polypeptide chain which forms the first and second antigen binding loops of the VL domain (Ll and L2), while the VL and JL segments combine to form the third antigen binding loop of the VL
domain (L3). Antibodies selected from this primary repertoire are believed to be sufficiently diverse to bind almost all antigens with at least moderate affinity. High affinity antibodies are produced in vivo by "affinity maturation" of the rearranged genes, in which point mutations are generated and selected by the immune system on the basis of improved binding.
Analysis of the structures and sequences of antibodies has shown that five of the six antigen binding loops (H1, H2, LI, L2, L3) possess a limited number of main-chain conformations or canonical structures (Chothia and Lesk (1987) J. Mol.
Biol.
196: 901; Chothia et al. (1989) Nature 342: 877). The main-chain conformations are determined by (i) the length of the antigen binding loop, and (ii) particular residues, or types of residue, at certain key positions in the antigen biiiding loop and the antibody framework. Analysis of the loop lengths and key residues has enabled the prediction of the main-chain conformations of Hl, H2, L1, L2 and L3 encoded by the majority of human antibody sequences (Chothia et al. (1992) J. Mol. Biol. 227:
799;
Tomlinson et al. (1995) EMBO J. 14: 4628; Williams et al. (1996) J. Mol. Biol.
264:
220). Although the H3 region is much more diverse in terms of sequence, length and structure. (due to the use of D segments), it also forms a limited number of main-chain conformations for short loop lengths which depend on the length and the presence of particular residues, or types of residue, at key positions in the loop and the antibody framework (Martin et al. (1996) J. Mol. Biol. 263: 800; Shirai et al. (1996) FEBS
Letters 399: 1.
While, in one approach, diversity can be added to synthetic repertoires at any site in the CDRs of the various antigen-binding loops, this 'approach results in a g2=eater proportion of V domains that do not properly fold and therefore contribute to a lower proportion of molecules with the potential to bind antigen. An understanding of the residues contributing to the main chain conformation of the antigen-binding loops permits the identification of specific residues to diversify in a synthetic repertoire of VH or VL domains. That is, diversity is best introduced in residues that are not essential to maintaining the main chain conformation. As an example, for the diversification of loop L2, the conventional approach would be to diversify all the residues in the corresponding CDR (CDR2) as defined by Kabat et al. (1991, supra), some seven residues. However, for L2, it is known that positions 50 and 53 are diverse in naturally occurring antibodies and are observed to malce contact with the antigen. The preferred approach would be to diversify only those two residues in this loop. This represents a significant improvement in terms of the functional diversity required to create a range of antigen binding specificities.
Immunoglobulin polypeptide libraries can advantageously be designed to be based on predetermined variable domain main chain conformation. Such libraries may be constructed as described in International Patent Application WO
99/20749, the contents of which are incorporated herein by reference. Thus, in one aspect, an antibody polypeptide comprises the amino acid sequence of a given human germline V region gene segment, e.g., VH germline gene segment DP-47, or VK germline gene segment DPK9. Such variable region polypeptides can be used for the production of scFvs or Fabs, e.g., an scFv or Fab comprising (i) an antibody heavy chain variable domain (VH), or antigen binding fragment thereof, which comprises the amino acid sequence of germline VH segment DP-47 and (ii) an antibody light chain variable domain (VL), or antigen binding fragment thereof, which comprises the amino acid sequence oT germline V,, segment DPK9. Diversification of sequences within the context of the selected heavy and light chain germline gene segments,. e.g., DP-47, DPK 9, DP45, DP38, etc. can generate a repertoire of diverse immunoglobulin coding sequences. One approach to diversification is described below in the context of generating a library of diversified dAb or scFv sequences. These variable region polypeptides can also be expressed as dAbs and screened for high affinity binding to CD40L. The repertoire can be cloned into or generated in a vector suitable for phage display, e.g., a lambda or filamentous bacteriophage display vector and is then screened for binding to a given target antiaen, e.g., CD40L.
Preparation of Human Single Immunoglobulin Variable Domain Polypeptides:
A single immunoglobulin variable domain is a folded polypeptide domain which coinprises sequences characteristic of immunoglobulin variable domains and which specifically binds an antigen (e.g., dissociation constant of 500 nM or less), and which binds antigen as a single variable domain; that is, there is one binding site provided by a single immunoglobulin variable domain without any complementary variable domain. A single immunoglobulin variable domain therefore includes complete antibody variable domains as well as modified variable domains, for example in which one or more loops have been replaced by sequences which are not characteristic of antibody variable domains or antibody variable domains which have been truncated or comprise N- or C-terminal extensions, as well as folded fragments of variable domains which retain a dissociation constant of 500 nM or less (e.g., 450 nM or less, 400 nM or less, 350 nM or less, 300 nM or less, 250 nM or less, 200 nM
or less, 150 nM or less, 100 nM or less) and the target antigen specificity of the full-length domain. Preferably an antibody single variable domain useful in the invention is selected from the group of VH and VL, including Vkappa and Vla,,,baa. The single immunoglobulin variable domains of use herein are preferably "human" as that term is defined herein.
Preparation of Single Immunoglobulin Variable Domains:
Single immunoglobulin variable domains are prepared in a number of ways.
For each of these approaches, well-known methods of preparing (e.g., amplifying, mutating, etc.) and manipulating nucleic acid sequences are applicable.
One means of preparing single immunoglobulin variable domains is to amplify and express the VH or VL region of a heavy chain or light chain gene for a cloned antibody known to bind the desired antigen. That is, the VH or VL
domain of a known anti-CD40L antibody coding region can be amplified and expressed as a single domain (or as a fusion of a single domain) and evaluated for binding to CD40L.
The boundaries of VH and VL domains are set out by Kabat et al. (1991, supra). The information regarding the boundaries of the VH and VL domains of heavy and light chain genes is used to design PCR primers that amplify the V domain from a cloned heavy or light chain coding sequence encoding an antibody known to bind CD40L.
The amplified V domain is inserted into a suitable expression vector, e.g., pHEN-1 (Hoogenboom et al., 1991, Nucleic Acids Res. 19: 4133-4137) and expressed, either alone or as a fusion with another polypeptide sequence.
In a preferred approach, a repertoire of VH or VL domains, preferably human VH or VL domains, is screened by, for example, phage display, panning against the desired antigen. Methods for the construction of bacteriophage display libraries and lambda phage expression libraries are well known in the art, and taught, for example, by: McCafferty et al., 1990, Nature 348: 552; Kang et al., 1991, Proc. Natl.
Acad.
Sci. U.S.A., 88: 4363; Clackson et al., 1991, Nature 352: 624; Lowman et al., 1991, Biochemistry 30: 10832; Burton et al., 1991, Proc. Natl. Acad. Sci U.S.A. 88:
10134;
Hoogenboom et al., 1991, Nucleic Acids Res. 19: 4133; Chang et al.,1991, J.
Immunol. 147: 3610; Breitling et al., 1991, Gene 104: 147; Marks et al., 1991, J. Mol.
Biol. 222: 581; Barbas et al., 1992, Proc. Natl. Acad. Sci. U.S.A. 89: 445.7;
Hawkins and Winter (1992) J. Immunol., 22: 867; Marks et al. (1992) J. Biol. Chem., 267:
16007; and Lerner et al. (1992) Science, 258: 1313. Fab phage display libraries are taught, for example, by U.S. 5,922,545. scFv phage libraries are taught, for example, by Huston et al., 1988, Proc. Natl. Acad. Sci U.S.A. 85: 5879-5883; Chaudhary et al., 1990, Proc. Natl. Acad. Sci U.S.A. 87: 1066-1070; McCafferty et al., 1990, supra;
Clackson et al., 1991, supra; Marks et al., 1991, supra=, Chiswell et al., 1992, Trends Biotech. 10: 80.; and Marks et al., 1992, supra. Various embodiments of scFv librar,ies displayed on bacteriophage coat proteins have been described.
Refinements of phage- display approaches are also known, for example as described in W096/06213 and W092/01047 (Medical Research Council et al.) and W097/08320 (Morphosys, supra).
The repertoire of VH or VL domains can be a naturally-occurring repertoire of immunoglobulin sequences or a synthetic repertoire. A naturally-occurring repertoire is one prepared, for exainple, from immunoglobulin-expressing cells harvested from one or more individuals. Sucll repertoires can be "naive," i.e., prepared, for example, from human fetal or newborn immuhoglobulin-expressing cells, or rearranged, i.e., prepared from, for exatnple, adult human B cells. Natural repertoires are described, for example, by Marks et a1., 1991, J. Mol. Biol. 222: 581 and Vaughan et a1., 1996, Nature Biotech. 14: 309. If desired, clones identified from a natural repertoire, or any repertoire, for that matter, that bind the target antigen are then subjected to mutagenesis and further screening in order to produce and select variants with improved binding characteristics.
Synthetic repertoires of s'rngle immunoglobulin variable domains are prepared by artificially introducing diversity into a cloned V domain. Synthetic repertoires are described, for example, by Hoogenboom & Winter, 1992, J. Mol. Biol. 227: 381;
Barbas et al., 1992, Proc. Natl. Acad. Sci. U.S.A. 89: 4457; Nissim et al., 1994, EMBO J. 13: 692; Griffiths et al., 1994, EMBO J. 13: 3245; DeKriuf et al., 1995, J.
Mol. Biol. 248: 97; and WO 99/20749.
In one aspect, synthetic variable domain repertoires are prepared in VH or VK
backgrounds, based on artificially diversified germline VH or VK sequences.
For example, the VH domain repertoire can be based on cloned germline VH gene segments V3-23/DP47 (Tomlinson et al., 1992, J. Mol. Biol. 227: 7768) and JH4b.
The V, domain repertoire can be based, for example, on germline Vh gene segments 02/O12/DPK9 (Cox et al., 1994, Eur. J. Immunol. 24: 827) and J,;1. Diversity is introduced into these or other gene segments by, for example, PCR mutagenesis.
Diversity can be randomly introduced, for example, by error prone PCR
(Hawkins, et al., 1992, J.Mol. Biol. 226: 889) or chemical mutagenesis. As discussed above, however it is preferred that the introduction of diversity is targeted to particular residues. It is further preferred that the desired residues are targeted by introduction of the codon NNK using mutagenic primers (using the IUPAC nomenclature; where N = G, A, T or C, and K= G or T), which encodes all amino acids and the TAG
stop codon. Other codons which achieve similar ends are also of use, including the NNN
codon (which leads to the production of the additional stop codons TGA and TAA), DVT codon ((A/G/T) (A/G/C)T), DVC codon ((A/G/T)(A/G/C)C), and DVY codon ((A/G/T)(A/G/C)(C/T). The DVT codon encodes 22% serine and 11% tyrosine, asgpargine, glycine, alanine, aspartate, threonine and 'cysteine, which most closely mimics the distribution of amino acid residues for the antigen binding sites of natural human antibodies. Repertoires are made using PCR primers having the selected degenerate codon or codons at each site to be diversified. PCR mutagenesis is well l:nown in the art.
In one aspect, diversity is introduced into the sequence of human germline VH
gene segments V3-23/DP47 (Tomlinson et al., 1992, J. Mol. Biol. 227: 7768) and JH4b using the NNK codon at sites H30, H31, H33, H35, H50, H52, H52a, H53, H55, H56, H58, H95, H97 and H98, corresponding to diversity in CDRs 1, 2 and 3, with the numbering as used in U.S. 6,696,245.
In another aspect, diversity is also introduced into the sequence of human germline VH gene segments V3-23/DP47 and JH4b, for example, using the NNK
codon at sites H30, H31, H33, H35, H50, H52, H52a, H53, H55, H56, H58, H95, H97, H98, H99, H100, H100a and H100b, corresponding to diversity in CDRs 1, 2 and 3,with the numbering as used in U.S. 6,696,245.
In another aspect, diversity is introduced into the sequence of human germline V,; gene segments 02/O12/DPK9 and J,;l, for example, using the NNK codon at sites L30, L31, L32, L34, L50, L53, L91, L92, L93, L94 and L96, corresponding to diversity in CDRs 1, 2 and 3,with the numbering as used in U.S. 6,696,245.
Diversified repertoires are cloned into phage display vectors as known in the art and as described, for example, in WO 99/20749. In general, the nucleic acid molecules and vector constructs required for the performance of the present inventiori are available in the art and are constructed and manipulated as set forth in standard laboratory manuals, such as Sambrook et al. (1989). Molecular Cloning: A
Laboratory Manual, Cold Spring Harbor, USA.
The manipulation of nucleic acids in the present invention is typically carried out in recombinant vectors. As used herein, "vector" refers to a discrete element that is used to introduce heterologous DNA into cells for the expression and/or replication thereof. Methods by which to select or construct and, subsequently, use such vectors are well known to one of slcill in the art. Numerous vectors are publicly available, including bacterial plasmids, bacteriophage, artificial chromosomes and episomal vectors. Such vectors may be used for simple cloning and mutagenesis;
alternatively, as is typical of vectors in which repertoire (or pre-repertoire) members of the invention are carried, a gene expression vector is employed. A vector of use according to the invention is selected to accommodate a polypeptide coding sequence of a desired size, typically from 0.25 kilobase (kb) to 40 kb in length. A
suitable host cell is transformed with the vector after in vitro cloning manipulations. Each vector contains various functional components, which generally include a cloning (or "polylinker") site, an origin of replication and at least one selectable marker gene. If a given vector is an expression vector, it additionally possesses one or more of the following: enhancer element, promoter, transcription, termination and signal sequences, each positioned in the vicinity of the cloning site, such that they are operatively linked to the gene encoding a polypeptide repertoire member according to the invention.
Both cloning and expression vectors generally contain nucleic acid sequences that enable the vector to replicate in one or more selected host cells.
Typically in cloning vectors, this sequence is one that enables the vector to replicate independently of the host chromosomal DNA and includes origins of replication or autonomously replicating sequences. Such sequences are well known for a variety of bacteria, yeast and viruses. The origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, the 2 micron plasmid origin is suitable for yeast, and various viral origins (e.g. SV 40, adenovirus) are useful for cloning vectors in mammalian cells. Generally, the origin of replication,is not needed for mammalian expression vectors unless these are used in mammalian cells able to replicate high levels of DNA, such as COS cells.
Advantageously, a cloning or expression vector also contains a selection gene also referred to as selectable marker. This gene encodes a protein necessary for the I.n survival or growth of transformed host cells grown in a selective culture medium.
Host cells not transformed with the vector containing the selection gene will therefore not survive in the culture medium. Typical selection genes encode proteins that confer resistance to antibiotics and other toxins, e.g. ampicillin, neomycin, methotrexate or tetracycline, complement auxotrophic deficiencies, or supply critical nutrients not available in the growth media.
Because the replication of vectors according to the present invention is most conveniently performed in E. coli, an E. coli-selectable marker, for example, the (3-lactamase gene that confers resistance to the antibiotic ampicillin, is of use. These can be obtained from E. coli plasmids, such as pBR322 or a pUC plasmid such as pUC 18 or pUC 19.
Expression vectors usually contain a promoter that is recognized by the host organism and is operably linked to the coding sequence of interest. Such a promoter may be inducible or constitutive. The term "operably linked" refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner. A control sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences.
Promoters suitable for use with prokaryotic hosts include, for example, the (3-lactamase and lactose promoter systems, alkaline phosphatase, the tryptophan (trp) promoter system and hybrid promoters such as the tac promoter. Promoters for use in bacterial systems will also generally contain a Shine-Dalgarno -sequence operably linked to the coding sequence.
In libraries or repertoires as described herein, the preferred vectors are expression vectors that enable the expression of a nucleotide sequence corresponding to a polypeptide library member. Thus, selection is performed by separate propagation and expression of a single clone expressing the polypeptide library member or by use of any selection display system. As described above, a preferred selection display system uses bacteriophage display. Thus, phage or phageinid vectors can be used. Preferred vectors are phagemid vectors, which have an E.
coli origin of replication (for double stranded replication) and also a phage origin of replication (for production of single-stranded DNA). The manipulation and expression of such vectors is well known in the art (Hoogenboom and Winter (1992) supra; Nissim et al. (1994) supra). Briefly, the vector contains a,3-lactamase or other selectable marker gene to confer selectivity on the phagemid, and a lac promoter upstream of a expression cassette that consists (N to C terminal) of a pelB
leader sequence (which directs 'the expressed polypeptide to the periplasmic space), a multiple cloning site (for cloning the nucleotide version of the library member), optionally, one or more peptide tags (for detection), optionally, one or more TAG stop codons and the phage protein pIII. In one embodiment, the vector encodes, rather than the pelB leader sequence, a eukaryotic GAS1 leader sequence which serves to direct the secretion of the fusion polypeptide to the periplasmic space in E.
coli or to the medium in eukaryotic cell systems. Using various suppressor and non-suppressor strains of E. coli and with the addition of glucose, iso-propyl thio-(3-D-galactoside (IPTG) or a helper phage, such as VCS M13, the vector is able to replicate as a plasmid wltli no expression, produce large quantities of the polypeptide library member only, or produce phage, some of which contain at least one copy of the polypeptide-pIIl fusion on their surface.
An example of a preferred vector is the pHENI phagemid vector (Hoogenboom et al., 1991, Nucl. Acids Res. 19: 4133-4137; sequence is available, e.g., as SEQ ID NO: 7 in WO 0' V031611), in which the production of plll fusion protein is under the control of the LacZ promoter, which is inhibited in the presence of glucose and induced with IPTG. V02en grown in -suppressor strains of E.
coli, e.g., TG1, the gene III fusion protein is produced and packaged into phage, vvhile growth in non-suppressor strains, e.g., HB2151, permits the secretion of soluble fusion protein into the bacterial periplasm and into the culture medium. Because the expression of gene III prevents later infection with helper phage, the bacteria harboring the phagemid vectors are propagated in the presence of glucose before infection with VCSM13 helper phage for phage rescue.
Construction of vectors according to the invention employs conventional ligation techniques. Isolated vectors or DNA fragments are cleaved, tailored, and re-ligated in the form desired to generate the required vector. If desired, sequence analysis to confirm that the correct sequences are present in the constructed vector is performed using standard methods. Suitable methods for constructing expression vectors, preparing in vitro transcripts, introducing DNA into host cells, and performing analyses for assessing expression and function are known to those skilled in the art. The presence of a gene sequence in a sample is detected, or its amplification and/or expression quantified by conventional methods, such as Southern or Northern analysis, Western blotting, dot blotting of DNA, RNA or protein, in situ hybridization, immunocytochemistry or sequence analysis of nucleic acid or protein molecules. Those skilled in the art will readily envisage how these methods may be modified, if desired.
Screening Single Immunoglobulin Variable Domains for Anti2en Bindin Following expression of a repertoire of single immunoglobulin variable domains on the surface of phage, selection is performed by contacting the phage repertoire with immobilized target antigen (e.g., CD40L and/or an epitope bound by DOM8-24), washing to remove unbound phage, and propagation of the bound phage, the whole process frequently referred to as "panning." This process is applicable to the screening of single immunoglobulin variable domains as well as other antibody fragments that can be expressed on a display library, e.g., scFv, Fab, etc.
Alternatively, phage are pre-selected for the expression of properly folded member variants by panning against an immobilized generic ligand (e.g., protein A or protein L) that is only bound by folded members. This has the advantage of reducing the proportion of non-functional members, thereby increasing the proportion of members likely to bind a target antigen. Pre-selection with generic ligands is taught in WO
99/20749. The screening of phage antibody libraries is generally described, for example, by Harrison et al., 1996, Meth. Enzymol. 267: 83-109.
Screening is commonly performed using purified antigen immobilized on a solid support, for example, plastic tubes or wells, or on a chromatography matrix, for example SepharoseTM (Pharmacia). Screening or selection can also be performed on complex antigens, such as the surface of cells (Marks et al., 1993, BioTechnology 1 l:
1145; de Kruif et al., 1995, Proc. Natl. Acad. Sci. U.S.A. 92: 3938). Another alternative involves selection by binding biotinylated antigen in solution, followed by capture on streptavidin-coated beads.
In a preferred aspect, panning is performed by immobilizing antigen (generic or specific) on tubes or wells in a plate, e.g., Nunc MAxISORPTM immunotube 8 well strips. Wells are coated with 150 l of antigen (100 g/m1 in PBS) and incubated overnight. The wells are then washed 3 times with PBS and blocked with 400 l PBS-2% skim milk (2%MPBS) at 37 C for 2 hr. The wells are rinsed 3 times with PBS and phage are added in 2%MPBS. The mixture is incubated at room temperature for 90 minutes and the liquid, containing unbound phage, is removed.
Wells are rinsed 10 times with PB S-0.1 % tween 20, and then 10 times with PB
S to remove detergent. Bound phage are eluted by adding 200 l of freshly prepared mM triethylamine, mixing well and incubating for 10 min at room temperature.
Eluted phage are transferred to a tube containing 100 1 of IM Tris-HCI, pH
7.4 and vortexed to neutralize the triethylamine. Exponentially-growing E. coli host cells (e.g., TG1) are infected with, for example, 150 ml of the eluted phage by incubating for 30 min at 37 C. Infected cells are spun down, resuspended in fresh medium and plated in top agarose. Phage plaques are eluted or picked into fresh cultures of host cells to propagate for analysis or for further rounds of selection. One or more rounds of plaque purification are performed' if necessary to ensure pure populations of selected phage. Other screening approaches are described by Harrison et al., 1996, supra.
Following identification of phage expressing a single immunoglobulin variable domain that binds a desired target, if a phagemid vector such as pHENI has been used, the variable domain fusion proteins are easily produced in soluble form by infecting non-suppressor strains of bacteria, e.g., HB2151 that permit the secretion of soluble gene III fusion protein. If a GAS I secretion signal peptide is encoded by the vector, the fusion polypeptide can be secreted by eukaryotic (e.g., yeast or mammalian) or prokaryotic (e.g., E. coli) cells. Alternatively, the V domain sequence can be sub-cloned into an appropriate expression vector to produce soluble protein according to methods Icnown in the art.
Purification and Concentration of Sinale Immunoglobulin Variable Domains:
Single immunoglobulin variable domain polypeptides or other monovalent antibody polypeptides secreted into the periplasmic space or into the medium of bacteria are harvested and purified according to known methods (Harrison et al., 1996, supra). Skerra & Pluckthun (1988, Science 240: 1038) and Breitling et al.
(1991, Gene 104: 147) describe the harvest of antibody polypeptides from the periplasm,, and Better et al. (1988, Science 240: 1041) describes harvest from the culture supernatant. For some antibody polypeptides, purification can also be achieved by binding to generic ligands, such as protein A or Protein L.
Alternatively, the variable domains can be expressed with a peptide tag, e.g., the Myc, HA or His tags, which facilitates purification by affinity chromatography.
If necessary, monovalent anti-CD40L antibody polypeptides are concentrated by any of several methods well known in the art, including, for example, ultrafiltration, diafiltration and tangential flow filtration. The process of ultrafiltration uses semi-permeable membranes and pressure to separate molecular species on the basis of size and shape. The pressure is provided by gas pressure or by centrifugation. Commercial' ultrafiltration products are widely available, e.g., from Millipore (Bedford, MA; examples include the CentriconTM and MicroconTM
concentrators) and Vivascience (Haiulover, Germany; examples include the VivaspinTM concentrators). By selection of a molecular weight cutoff smaller than the target polypeptide (usually 1/3 to 1/6 the molecular weight of the target polypeptide, although differences of as little as 10 kD can be used successfully), the polypeptide is retained when solvent and smaller solutes pass through the membrane.
Thus, a molecular weight cutoff of about 5 kD is useful for concentration of anti-CD40L single immunoglobulin variable domain polypeptides described herein.
1 Diafiltration, which uses ultrafiltration membranes with a "washing"
process, is used where it is desired to remove or exchange the salt or buffer in a polypeptide preparation. The polypeptide is concentrated by the passage of solvent and small solutes through the membrane, and remaining salts or buffer are removed by dilution of the retained polypeptide with a new buffer or salt solution or water, as desired, accompanied by continued ultrafiltration. In continuous diafiltration, new buffer is added at the same rate that filtrate passes through the membrane. A
diafiltration volume is the volume of polypeptide solution prior to the start of diafiltration - using continuous diafiltration, greater than 99.5% of a fully permeable solute can be removed by washing through six diafiltration volumes with the new buffer.
Alternatively, the process can be performed in a discontinuous manner, wherein the sample is.repeatedly diluted and then filtered back to its original volume to remove or exchange salt or buffer and ultimately concentrate the polypeptide. Equipment for diafiltration and detailed methodologies for its use are available, for example, from Pall Life Sciences (Ann Arbor, MI) and Sartorius AG/Vivascience (Hannover, Germany).
Tangential flow filtration (TFF), also known as "cross-flow filtration," also uses ultrafiltration membrane. Fluid containing the target polypeptide is pumped tangentially along the surface of the membrane. The pressure causes a portion of the fluid to pass through the membrane while the target polypeptide is retained above the filter. In contrast to standard ultrafiltration, however, the retained molecules do not accumulate on the surface of the membrane, but are carried along by the tangential flow. The solution that does not pass through the filter (containing the target polypeptide) can be repeatedly circulated across the membrane to achieve the desired degree of concentration. Equipment for TFF and detailed methodologies for its use 3 0 are available, for example, from Millipore (e.g., the ProFlux M12TM
Benchtop TFF
system and the PelliconTM systems), Pall Life Sciences (e.g., the MiniinTM
Tangential Flow Filtration system).
Protein concentration is measured in a number of ways that are well known in the art. These include, for example, amino acid analysis, absorbance at 280 nm, the "Bradford" and "Lowry" methods, and SDS-PAGE. The most accurate method is total hydrolysis followed by amino acid analysis by HPLC, concentration is then determined then comparison with the lcnown sequence of the single immunoglobulin variable domain polypeptide. While this method is the most accurate, it is expensive and time-consuming. Protein determination by measurement of W absorbance at 280 nm faster and much less expensive, yet relatively accurate and is preferred as a compromise over amino acid analysis. Absorbance at 280 nm was used to determine protein concentrations reported in the Examples described herein.
"Bradford" and "Lowry" protein assays (Bradford, 1976, Anal. Biochem. 72:
248-254; Lowry et al.,1951, J. Biol. Chem. 193: 265-275) compare sample protein concentration to a standard curve most often based on bovine serum albumin (BSA).
These methods are less accurate, tending to undersetimate the concentration of single immunoglobulin variable domains. Their accuracy could be improved, however, by using a VH or V,; single domain polypeptide as a standard.
An additional protein assay method is the bicinchoninic acid assay described in U.S. Patent No. 4,839,295 (incorporated herein by reference) and marketed by Pierce= Biotechnology (Rockford, IL) as the "BCA Protein Assay" (e.g., Pierce Catalog No. 23227).
The SDS-PAGE method uses gel electrophoresis and Coomassie Blue staining .in comparison to known concentration standards, e.g., known amounts of a single immunoglobulin variable domain polypeptide. Quantitation can be done by eye or by densitometry.
Single human immunoglobulin variable domain antigen-binding polypeptides described herein retain solubility at high concentration (e.g., at least 4.8 mg (-400 M) in aqueous solution (e.g., PBS), and preferably at least 5 mg/ml (-417 M), mg/ml (-833 gM), 20 mg/ml (- 1.7 mM), 25 mg/ml (-2.1 mM), 30 mg/ml (-2.5 mM), 35 mg/ml (-2.9 mM), 40 mg/ml (-3.3 mM), 45 mg/ml (-3.75 mM), 50 mg/ml (-4.2 mM), 55 mg/m1 (-4.6 mM), 60 mg/ml (-5.0 mM), 65 mg/ml (-5.4 mM), 70 mg/ml (-5.8 mM), 75 mg/ml (-6.3 mM), 100 mg/ml (-8.33 mM), 150 mg/mI (-12.5 mM), 200 mg/ml (-16.7 mM), 240 mg/ml (-20 mM) or higher). One structural feature that promotes high solubility is the relatively small size of the single immunoglobulin variable domain polypeptides. A full length conventional four chain antibody, e.g., IgG is about 150 kD in size. In contrast, single immunoglobulin variable domains, which all have a general structure comprising 4 framework (FW) regions and 3 CDRs, have a size of approximately 12 kD, or less than 1/10 the size of a conventional antibody. Similarly, single immunoglobulin variable domains are approximately % the size of an scFv molecule (-26 kD), and approximately 1/5 the size of a Fab molecule (-60 kD). It is preferred that the size of a single immunoglobulin variable domain-containing structure disclosed herein is 100 kD
or less, including structures of, for example, about 90 kD or less, 80 kD or less, 70 kD or less, 60 kD or less, 50 kD or less, 40 kD or less, 30 kD or less, 20 kD or less, down to and including about 12 kD, or a single immunoglobulin variable domain in isolation.
The solubility of a polypeptide is primarily determined by the interactions of the amino acid side chains with the surrounding solvent. Hydrophobic side chains tend to be localized internally as a polypeptide folds, away from the solvent-interacting surfaces of the polypeptide. Conversely, hydrophilic residues tend to be localized at the solvent-interacting surfaces of a polypeptide. Generally, polypeptides having a primary sequence ,that permits the molecule to fold to expose more hydrophilic residues to the aqueous environment are more soluble than one that folds to expose fewer hydrophilic residues to the surface. Thus, the arrangement and number of hydrophobic and hydrophilic residues is an important determinant of solubility. Other parameters that determine polypeptide solubility include solvent pH, temperature, and ionic strength. In a common practice, the solubility of polypeptides can be maintained or enhanced by the addition of glycerol (e.g., -10% v/v) to the solution.
As discussed above, specific amino acid residues have been identified in conserved residues of human VH domains that vary in the VH domains of camelid species, which are generally more soluble than human VH domains. These include, for example, Gly 44 (Glu in camelids), Leu 45 (Arg in camelids) and Trp 47 (Gly in camelids). Amino acid residue 103 of VH is also implicated in solubility, with mutation from Trp to Arg tending to confer increased VH solubility.
ln preferred aspects of the invention, single immunoglobulin variable domain polypeptides are based on the DP47 germline VH gene segment or the DPK9 germline VK gene segment. Thus, these germline gene segments are capable, particularly when diversified at selected structural locations described herein, of producing specific binding single immunoglobulin variable domain polypeptides that are highly soluble.
In particular, the four framework regions, which are preferably not diversified, can contribute to the high solubility of the resulting proteins.
It is expected that a single human immunoglobulin variable domain that is highly homologous to one having a known high solubility will also tend to be highly soluble. Thus, as one means of prediction or recognition that a given single immunoglobulin variable domain would have the high solubility recited herein, one can compare the sequence of a single immunoglobulin variable domain polypeptide to one or more single immunoglobulin variable domain polypeptides having known solubility. Thus, when a single immunoglobulin variable domain polypeptide is identified that 'has high binding affinity but unlcnown solubility, comparison of its amino acid sequence with that of one or more (preferably more) human single immunoglobulin variable domain polypeptides known to have high solubility (e.g., a dAb sequence disclosed herein) can permit prediction of its solubility. While it is not an absolute predictor, where there is a high degree of similarity to a known highly soluble sequence, e.g., 90-95% or greater similarity, and particularly where there is a hig11 degree of similarity with respect to hydrophilic amino acid residues, or residues likely to be exposed,at the solvent interface, it is more likely that a newly identified binding polypeptide will have solubility similar to that of the known highly soluble sequence.
Molecular modeling software can also be used to predict the solubility of a polypeptide sequence relative to that of a polypeptide of known solubility.
For example, the substitution or addition of a hydrophobic residue at the solvent-exposed surface, relative to a molecule of lcnown solubility that has a less hydrophobic or even hydrophilic residue exposed in that position is expected to decrease the relative solubility of the polypeptide. Similarly, the substitution or addition of a more hydrophilic residue at such a location is expected to increase the relative solubility.
That is, a change in the net number of hydrophilic or hydrophobic residues located at the surface of the molecule (or the overall hydrophobic or hydrophilic nature of the surface-exposed residues) relative to a single immunoglobulin variable domain polypeptide structure with known solubility can predict the relative solubility of a single immunoglobulin variable domain polypeptide.
Alternatively, or in conjunction with such prediction, one can determine limits of a single immunoglobulin variable domain polypeptide's solubility by simply concentrating the polypeptide.
Affinity Determination:
Isolated single immunoglobulin variable domain- and antibody polypeptide-containing polypeptides as described herein preferably have affinities (dissociation constant, Kd, = Koff/Koõ) of at least 500 nM or less, and preferably at least 400 nM-50 pM, 300 nM-50 pM, 200 nM - 50 pM, and more preferably at least 100 nM - 50 pM, 75nM-50pM,50nM-50pM,25nM-50pM, 10 nM - 50 pM, 5 nM - 50 pM, 1 nM - 50 pM, 950 pM - 50 pM, 900 pM - 50 pM, 850 pM - 50 pM, 800 pM - 50 pM, 750pM-50pM, 700 pM - 50 pM, 650 pM - 50 pM, 600pM-50pM, 550pM-50 pM, 500 pM - 50 pM, 450 pM - 50 pM, 400 pM - 50 pM., 350 pM - 50 pM, 300 pM
-50pM,250pM-50pM,200pM-50pM, l50pM-50pM, 100pM-50pM,90 pM - 50 pM, 80 pM - 50 pM, 70 pM - 50 pM, 60 pM - 50 pM, or even as Iow as 50 pM.
The antigen-binding affinity of an antibody. polypeptide, e.g., a single immunoglobulin variable domain polypeptide or other monovalent antibody polypeptide, can be conveniently measured by SPR using the BlAcore system (Pharmacia Biosensor, Piscataway, N.J.). In this method, antigen is coupled to the BlAcore chip at known concentrations, and variable domain polypeptides are introduced. Specific binding between the variable domain polypeptide and the immobilized antigen results in increased protein concentration on the chip matrix and a change in the SPR signal. Changes in SPR signal are recorded as resonance units (RU) and displayed with respect to time along the Y axis of a sensorgram.
Baseline signal is taken with solvent alone (e.g., PBS) passing over the chip. The net difference between baseline signal and signal after completion of antibody polypeptide injection represents the binding value of a given sample. To determine the off rate (Koff), on rate (Koõ) and dissociation rate (Kd) constants, BlAcore kinetic evaluation software (e.g., version 2.1) is used.
Thus, SPR can be used to monitor antagonism of CD40L binding to CD40 by a monovalent anti-CD40L antibody preparation by measuring the displacement or inhibition of binding of CD40L to CD40 caused the monovalent antibody preparation.
SPR can also be used to monitor the dimerization, or preferably, the lack of dimerization, occurring via Fc region in antibody preparations as described herein.
High affinity is dependent upon the complementarity between a surface of the antigen and the CDRs of the antibody or antibody fragment. Complementarity is determined by the type and strength of the molecular interactions possible between portions of the target and the CDR, for example, the potential ionic interactions, van der Waals attractions, hydrogen bonding or other interactions that can occur.
tends to contribute more to antigen binding interactions than CDRs 1 and 2, probably due to its generally larger size, which provides more opportunity for favorable surface interactions. (See, e.g., Padlan et al., 1994, Mol. Immunol. 31: 169-217;
Chothia &
Lesk, 1987, J. Mol. Biol. 196: 904-917; and Chotllia et al., 1985, J. Mol.
Biol. 186:
651-663.) High affinity indicates antibody polypeptide/antigen pairings that have a high degree of complementarity, which is directly related to the structures of the variable domain and the target.
In one aspect, a monovalent anti-CD40L antibody polypeptide, e.g., a single immunoglobulin variable domain polypeptide, is linked to another antibody polypeptide to form a heterodimer in which each individual antibody polypeptide is capable of binding a different cognate antigen. Fusing antibody polypeptides, such as single immunoglobulin variable domains, as heterodimers, wherein each monomer binds a different target antigen, can produce a dual-specific ligand capable, for example, of bridging the respective target antigens. Such dual specific ligands may be used to target cytokines and other molecules which cooperate synergistically in therapeutic situations in the body of an organism. Thus, there is provided a method for synergising the activity of two or more cytokines, comprising administering a dual specific antibody heterodimer capable of binding to the two or more cytokines.
Non-limiting examples of second targets for anti-CD40L dual specific antibody polypeptides include the following: TNF-a; IL-l; IL-2; IL-4; IL-6; IL-8; IL-12; IL-18; IFN-y; CD2; CD4; CD8; CTLA4; LFAl; LFA3, VLA4, CD80, B7-1, CD28, CD86, B7-2, and CTLA-4. In particular, second targets useful according to the invention include CD80, B7-1, CD28, CD86, B7-2, and CTLA-4. These targets are thought to be involved in a co-stimulatory pathway critical for T-cell activation (termed, co-stimulatory signal pathway antigens). This pathway includes activation of the molecule CD28 on the surface of T cells. This molecule can receive a costimulatory signal delivered by a ligand on B cells or other APCs. Ligands for CD28 include members of the B7 family of B lymphocyte activation antigens, such as B7-1 and/or B7-2 (Freedman, A. S. et al. (1987) J. Immunol. 137, 3260-3267;
Freeman, G. J. et al. (1989) J. Immunol. 143, 2714-2722; Freeman, G. J. et al.
(1991) J. Exp. Med. 174, 625-631; Freeman, G. J. et al. (1993) Science 262, 909-911;
Azuma, M. et al. (1993) Nature 366, 76-79; Freeman, G. J. et al. (1993) J.
Exp. Med.
178, 2185-2192). B7-1 and B7-2 are also ligands for anotller molecule, CTLA4, present on the surface of activated T cells. Accordingly, the present invention contemplates that members of the CD28 signalling pathway may be useful second targets for the dual-specific format anti-CD40L antibody polypeptides.
Homolo og us sequences;
The invention encompasses anti-CD40L antibody polypeptides, e.g., CD40L-binding single immunoglobulin variable domain clones, and clones with substantial sequence similarity or homology to them that also bind target antigen with high affinity. As used herein, "substantial" sequence similarity or homology is at least 85% similarity or homology.
Calculations of "homology" or "sequence identity" between two sequences (the terms are equivalent and used interchangeably herein) are performed as follows.
The sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, the length of a reference sequence aligned for comparison purposes is at least 30%, preferably at least 40%, more preferably at least 50%, even more preferably at least 60%, and even more preferably at least 70%, 80%, 90%, 100% of the length of the reference sequence. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid or nucleic acid "homology" is equivalent to amino acid or nucleic acid "identity").
The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.
As used herein, sequence "similarity" is a measure of the degree to which amino acid sequences share similar ainino acid residues at corresponding positions in an alignment of the sequences. Amino acids are similar to each other where their side chains are similar. Specifically, "similarity" encompasses amino acids that are conservative substitutes for each other. A "conservative" substitution is any substitution that has a positive score in the blosum62 substitution matrix (Hentikoff and Hentikoff, 1992, Proc. Natl. Acad. Sci. USA 89: 10915-10919). By the statement "sequence A is n% similar to sequence B" is meant that n% of the positions of an optimal global alignment between sequences A and B consists of identical amino acids or conservative substitutions. Optimal global alignments can be performed using the following parameters in the Needleman-Wunsch alignment algorithm:
For polypeptides:
Substitution matrix: biosum62.
Gap scoring function: -A -B*LG, where A=11 (the gap penalty), B=1 (the gap length penalty) and LG is the length of the gap.
For nucleotide sequences:
Substitution matrix: 10 for matches, 0 for mismatches.
Gap scoring function: -A -B*LG where A=50 (the gap penalty), B=3 (the gap length penalty) and LG is the length of the gap.
Typical conservative substitutions are among Met, Val, Leu and lle; among Ser and Thr; among the residues Asp, Glu and Asn; among the residues Gln, Lys and Arg; or aromatic residues Phe and Tyr. In calculating the degree (most often as a percentage) of similarity between two polypeptide sequences, one considers the number of positions at which identity or similarity is observed between corresponding amino acid residues in the two polypeptide sequences in relation to the entire lengths of the two molecules being compared.
Alternatively, the BLAST (Basic Local Alignment Search Tool) algoritlun is employed for sequence alignment, with parameters set to default values. The BLAST
algorithm "BLAST 2 Sequences" is available at the world wide web site ("www") of the National Center for Biotechnology Information (".nebi"), of the National Library of Medicine (".nlm") of the National Institutes of Health ("nih") of the U.S.
government (".gov"), in the "/blast/" directory, sub-directories "bl2seq/b12.htm1."
This algorithm aligns two sequences for comparison and is described by Tatusova &
Madden, 1999, FEMS Microbiol Lett. 174:247-250.
An additional measure of homology or similarity is the ability to hybridize under highly stringent hybridization conditions. Thus, a first sequence encoding a single immunoglobulin variable domain polypeptide is substantially similar to a second coding sequence if the first sequence hybridizes to the second sequence (or its complement) under highly stringent hybridization conditions (such as those described by Sambrook et al., Molecular Cloning, Laboratory Manuel, Cold Spring, Harbor Laboratory press, New York). "Highly stringent hybridization conditions" refer to hybridization in 6X SSC at about 45 C, followed by one or more washes in 0.2X
SSC, 0.1% SDS at 65 C. "Very highly stringent hybridization conditions" refer to hybridization in 0.5M sodium phosphate, 7% SDS at 65 C, followed by one or more washes at 0.2X SSC, 1% SDS at 65 C.
Assays for CD40L Activities:
It is preferred that a monovalent anti-CD40L antibody polypeptides as described herein bind to CD40L yet do not substantially agonize CD40 signaling.
Activation of the CD40L/CD40 pathway manifests a number of different outcomes that can be measured in order to assess the effect of a given monovalent anti-antibody polypeptide on the activity of the pathway. However, for the assessment of the antagonist or agonist function of monovalent anti-CD40L antibody polypeptides described herein, at least one of the following CD40L assays can be used:
1) Activation of Jun-N-Terminal Kinase (JNK):
Stimulation of T-lymphocytes via CD40L induces strong activation of JNIL.
The ability of a monovalent anti-CD40L antibody polypeptide to activate this signaling pathway is measured as follows. Human leukemic Jurlcat cells are stimulated with a positive control agonistic anti-CD40L antibody (2 g/ml monoclonal anti-human or anti-mouse gp39/CD40L antibody (Pharmingen, San Diego, CA, USA) or isotype matched hamster or mouse immunoglobulins (Dianova, Hanlburg, Germany)), monovalent anti-CD40L antibody polypeptide, or a negative control irrelevant antibody as described by Brenner et al., 1997, FEBS Lett.
417: 301-306, which is incorporated herein by reference. The cells are lysed and the extract assayed for phosphorylated JNK via colorimetric assay (e.g., TiterzymeTM
colorimetric (EIA) phospho-JNK1/2 immunoassay lcit, by Assay Designs Inc., Catalog # 900-106). An increase in phospho-JNK (e.g., by 5% or more) for anti-CD40L-stimulated cells over non-stimulated cells indicates agonism of CD40L
activity by the antibody polypeptide.
2. Induction of Cytokine Secretion:
Co-stimulation of T cells with anti-CD3 Ab and CD40L has been shown to upregulate the production of IL-10, IFN-y and TNF-a by those cells. The ability of a monovalent anti-CD40L antibody polypeptide to activate this signaling pathway is measured as follows. Human leukemic Jurkat T cells (or freshly isolated CD4+ T
cells) are plated into 96 well plates containing immobilized anti-CD3 antibody. The cells are then cultured for 72 hours in the presence of a positive control agonistic anti-CD40L antibody, CD40L, monovalent anti-CD40L antibody polypeptide, or a negative control irrelevant antibody, as described by Blair et al., 2000, J.
Exp. Med.
191: 651-660. IFN-y (or IL-10 of TNF-a) is then quantitated in the supernatant by sandwich ELISA using an IFN-g standard to generate a standard curve from which all other unknowns can be calculated. An increase in IFN-g (e.g., by 5% or more) for anti-CD40L-stimulated cells over non-stimulated cells indicates agonism by the antibody polypeptide.
3. Platelet Aggregation Assay:
Divalent anti-CD40L antibodies tend to cause platelet aggregation, which is likely associated with the thromboembolic events observed in clinical trials of divalent anti-CD40L antibodies in the prior art. Monovalent anti-CD40L
antibody polypeptides as described herein preferably do not substantially mediate or agonize CD40L-mediated platelet aggregation. With regard tothis aspect, the "standard platelet aggregation assay" is as follows:
Platelets are prepared at 2.5x105/ml and left stirring in a 500-Ca lumi-aggregometer (or its equivalent, e.g., a Platelet Aggregation Profiler (BioData, Horsham, PA)). Platelets are partially activated by the addition of a dilution series of 0.1-10 M ADP (the 10 M ADP induces aggregation, and is used as a positive control - lower concentrations activate platelets but do not induce aggregation).
CD40L mediated platelet aggregation is stimulated by addition of either anti-monoclonal antibodies (i.e., divalent monoclonal antibodies, available from, e.g., Pharmingen, San Diego, CA, USA) or soluble CD40/Fc fusion protein (available from R&D Systems). The reaction is allowed to proceed for between 3 and 5 minutes. Stimulation of platelet aggregation above the mininimal aggregation/activation achieved with ADP alone is plotted against stimulating anti-CD40L or CD40/Fc concentration. The percentage of platelet aggregation is measured by the change in light transmittance following addition of antibody polypeptide being tested or positive control peptide. A value greater than that observed for negative control lacking antibody and amounting to 25% or more of the positive control value (divalent anti-CD40L or CD40/Fc fusion) is considered to be indicative of induction of platelet aggregation.
Other methods to assess platelet aggregation and/or activation, including events which precede aggregation, or which are downstream from platelet aggregation, include assays which deterinine various indicators of platelet activation, and are known in the art. For example, platelet activation (and, thus, activity) can be determined by assaying for CD62P expression in platelets (e.g., using anti-CD26P antibodies and flow cytometry), assaying for monocyte-platelet-conjugate formation, assaying for platelet closure time under high shear conditions (e.g., using a PFA-100, Dade Behring, Newark, DE), and assaying for platelet dense granule release. Methods for performing such assays are known in the art and can be found, for example, in Langer et al., 2005 Thromb. Haemost. 93: 1137-46.
PEGylation of monovalent anti-CD40L antibody polypeptides The present invention provides PEGylated monovalent anti-CD40L antibody polypeptides which have increased half-life and preferably also resistance to degradation witliout a loss in activity (e.g., binding affinity) relative to non-PEGylated antibody polypeptides.
Monovalent anti-CD40L antibody polypeptides according to this aspect can be coupled, using methods known in the art to polymer molecules (preferably PEG) useful for achieving the increased half-life and degradation resistance properties encompassed by the present invention. Polymer moieties which can be utilized in the invention can be synthetic or naturally occurring and include, but are not limited to straight or branched chain polyalkylene, polyallcenylene or polyoxyalkylene polymers, or a branched or unbranched polysaccharide such as a homo- or heteropolysaccharide. Preferred examples of synthetic polymers which may be used in the invention include straight or branched chain poly(ethylene glycol) (PEG), poly(propylene glycol), or poly(vinyl alcohol) and derivatives or substituted forms thereof. Particularly preferred substituted polymers useful in the invention include substituted PEG, including methoxy(polyethylene glycol). Naturally occurring polymer moieties which may be used according to the invention in addition to or in place of PEG include lactose, amylose, dextran, or glycogen, as well as derivatives thereof which would be recognized by one of skill in the art. Derivatized forms of polymer molecules of the invention include, for example, derivatives which have additional moieties or reactive groups present therein to permit interaction with amino acid residues of the dAb polypeptides described herein. Such derivatives include N-hydroxylsuccinimide (NHS) active esters, succinimidyl propionate polymers, and sulfhydryl-selective reactive agents such as maleimide, vinyl sulfone, and thiol.
Particularly preferred derivatized polymers include, but are not limited to PEG
polymers having the formulae: PEG-O-CH~CH2CH2-C02-NHS; PEG-O-CHZ-NHS;
PEG-O-CH2CH2-C0,-NHS; PEG-S-CH,CH2-CO-NHS; PEG-O2CNH-CH(R)-COZ-NHS; PEG-NHCO-CH,,CH?-CO-NHS; and PEG-O-CH.,-C02-NHS; where R is (CH2)4)NHC02(mPEG). PEG polymers useful in the invention may be linear molecules, or may be branched wherein multiple PEG moieties are present in a single polymer. Some particularly preferred PEG derivatives which are useful in the invention include, but are not limited to the following:
O
rnPfC-o-Cr- NI H
O ICtiAA
CH
,-hslH--CHCi t,-NH
mPEta-N ~ 1t+~~""~y"'CC~11[/ \j O
mPEG-MAL mPEG2-MAL
CH2CONH(CHZCHzO)Z CH2CH2N
C l '~H OH (H
~ ~
//
mPEG-CONHCH O Ho-pm/ 0i'v(gp ,yPEO-om I f.-04 CHaCONH(CH 2CH20)2-CHzCHZN I
mPEG-(MAL)2 multi-arin PEG
It ~~-3-t~- C~t~H
O 0 [C~2?4 0 mf-EG--O-CHzC}~~=,..=C-Q-N
11 ~~'~-~ ~t.
mPEG-SPA mPEG2-NHS
mPEG2-(MAL)2 II CH2CONH(CH2CH2O)2-CH2CH2N I
mPEG-O- C-Ni oi mPEG-O-Ii NH
0 CH2CONH(CH2CH2O)2- CH2CH2N
; and The reactive group (e.g., MAL, NHS, SPA, VS, or Thiol) may be attached directly to the PEG polymer or may be attached to PEG via a linker molecule.
The size of polymers useful in the invention can be in the range of between 500 Da to 60 kDa, for example, between 1000 Da and 60 kDa, 10 kDa and 60 kDa, kDa and 60 kDa, 30 kDa and 60 kDa, 40 kDa and 60 kDa, and up to between 50 kDa and 60 kDa. The polymers used in the invention, particularly PEG, can be straight chain polymers or can possess a branched conformation. Depending on the combination of molecular weight and conformation, the polymer molecules useful in the invention, when attached to a monovalent anti-CD40L antibody polypeptide, will yield a molecule having an average hydrodynamic size of between 24 and 500 kDa.
The hydrodynamic size of a polymer molecule used herein refers to the apparent size of a molecule (e.g., a protein molecule) based on the diffusion of the molecule through an aqueous solution. The diffusion, or motion of a protein through solution can be processed to derive an apparent size of the protein, where the size is given by the Stokes radius or hydrodynamic radius of the protein particle. The "hydrodynamic size" of a protein depends on both mass and shape (conformation), such that two proteins having the same molecular mass may have differing hydrodynamic sizes based on the overall conformation of the protein. The hydrodynamic size of a PEG-linked monovalent anti-CD40L antibody polypeptide, e.g., an anti-CD40L single immunoglobulin variable domain as described herein, can be in the range of 24 kDa to 500 kDa; 30 to 500 kDa; 40 to 500 kDa; 50 to 500 kDa; 100 to 500 kDa; 150 to 500 kDa; 200 to 500 kDa; 250 to 500 kDa; 300 to 500 kDa; 350 to 500 l:Da; 400 to 500 lcba and 450 to 500 kDa. Preferably the hydrodynamic size of a PEGylated antibody polypeptide as described herein is 30 to 40 kDa; 70 to 80 l:Da or 200 to 300 lcDa. The size of a polymer molecule attached to a monovalent anti-CD40L
antibody polypeptide may thus be varied depending upon the desired application. For example, where the PEGylated antibody polypeptide is intended to leave the circulation and enter into peripheral tissues, it is desirable to keep the size of the attached polymer low to facilitate extravazation from the blood stream. Alternatively, where it is desired to have the PEGylated antibody polypeptide remain in the circulation for a longer period of time, a higher molecular weight polymer can be used (e.g., a 30 to 60 kDa polymer).
The polymer (PEG) molecules useful in the invention can be attached to antibody polypeptides using methods that are well known in the art. The first step in the attachment of PEG or other polymer moieties to an antibody polypeptide is the substitution of the hydroxyl end-groups of the PEG polymer by electrophile-containing functional groups. Particularly, PEG polymers are attached to either cysteine or lysine residues present in the antibody polypeptide. The cysteine and lysine residues can be naturally occurring, or can be engineered into the antibody polypeptide molecule. For example, cysteine residues can be recombinantly engineered at the C-terminus of antibody polypeptides, or residues at specific solvent accessible locations in the antibody polypeptide can be substituted with cysteine or lysine. In a preferred embodiment, a PEG moiety is attached to a cysteine residue which is present in the hinge region at the C-terminus of an antibody polypeptide.
In a further preferred embodiment a PEG moiety or other polymer is attached to a cysteine or lysine residue which is either naturally occurring at or engineered into the N-terminus of antibody single variable domain polypeptide of the invention. In a still further embodimeilt, a PEG moiety or other polymer is attached to an antibody single variable domain according to the invention at a cysteine or lysiiie residue (either naturally occurring or engineered) which is at least 2 residues away from (e.g., internal to) the C- and/or N-terminus of the antibody single variable domain polypeptide.
In one embodiment, the PEG polymer(s) is attached to one or more cysteine or lysine residues present in a framework region (FWs) and one or more heterologous CDRs of a single immunoglobulin variable domain. CDRs and framework regions (e.g., CDR1-CDR3 and FWI-FW4) are those regions of an immunoglobulin variable domain as defined in the Kabat database of Sequences of Proteins of Immunological Interest (Kabat et al., 1991, supra). In a preferred embodiment, a PEG polymer is linked to a cystine or lysine residue in the VH framework segment DP47, or the Vk, framework segment DPK9. Cysteine and/or lysine residues of DP47 which may be linked to PEG according to the invention include the cysteine at positions 22, or 96 and the lysine at positions 43, 65, 76, or 98 of SEQ ID NO: 1(Figure 5).
Cysteine and/or lysine residues of DPK9 which may be linked to PEG according to the invention include the cysteine residues at positions 23, or 88 and the lysine residues at positions 39, 42, 45, 103, or 107 of SEQ ID NO: 3 (Figure 6). In addition, specific cysteine or lysine residues may be linked to PEG in the VH canonical framework region DP38, or DP45.
In addition, specific solvent accessible sites in the antibody molecule which are not naturally occurring cysteine or lysine residues may be mutated to a cysteine or lysine for attachment of a PEG polymer. Solvent accessible residues in any given antibody, e.g., a dAb, can be determined using metllods known in the art such as analysis of the crystal structure of the antibody polypeptide. For example, using the solved crystal structure of the VH dAb HEL4 (SEQ ID NO: 3; a dAb that binds hen egg lysozyme), the residues Gln-13, Pro-14, Gly-15, Pro-41, Gly-42, Lys-43, Asp-62, Lys-65, Arg-87, Ala-88, Glu-89, Gln-112, Leu-115, Thr-117, Ser-119, and Ser-have been identified as being solvent accessible, and according to the present invention would be attractive candidates for mutation to cysteine or lysine residues for the attachment of a PEG polymer. In addition, using the solved crystal structure of the Vk dummy dAb (SEQ ID NO: 4), the residues Val-15, Pro-40, Gly-41, Ser-56, Gly-57, Ser-60, Pro-80, Glu-81, Gin-100, Lys-107, and Arg-108 have been identified as being solvent accessible, and according to the present invention would be attractive candidates for mutation to cysteine or lysine residues for the attachment of a PEG
polymer. In one embodiment of the invention, a PEG polymer is linked to multiple solvent accessible cysteine or lysine residues, or to solvent accessible residues which have been mutated to a cysteine or lysine residue. Alternatively, only one solvent accessible residue is linked to PEG, either where the particular antibody polypeptide only possesses one solvent accessible cysteine or lysine (or residue modified to a cysteine or lysine) or where a particular solvent accessible residue is selected from among several such residues for PEGylation.
Primary amino acid sequence of HEL4 (SEQ ID NO: 5).
PGKGLEWVSS
TAVYYCASAL
Primary amino acid sequence of Vk- dummy (SEQ ID NO: 6).
GKAPKLLIYA
SYSTPNTFGQ
Several PEG attachment schemes which are useful in the invention are provided by the company Nektar (SanCarlos, CA). For example, where attachment of PEG or other polymer to a lysine residue is desired, active esters of PEG
polymers which have been derivatized with N-hydroxylsuccinimide, such as succinimidyl propionate may be used. Where attachment to a cysteine residue is intended, PEG
polymers which have been derivatized with sulfhydryl-selective reagents such as maleimide, vinyl sulfone, or thiols may be used. Other examples of specific embodiments of PEG derivatives which may be used according to the invention to generate PEGylated antibodies can be found in the Nektar Catalog (available on the world wide web at nektar.com). In addition, several derivitized forms of PEG
may be used according to the invention to facilitate attachment of the PEG polymer to an antibody polypeptide. PEG derivatives useful in the invention include, but are not limited to PEG-succinimidyl succinate, urethane liill;ed PEG, PEG
phenylcarbonate, PEG succinimidyl carbonate, PEG-carboxymethyl azide, dimethylmaleic anhydride PEG, PEG dithiocarbonate derivatives, PEG-tresylates (2,2,2-trifluoroethanesolfonates), mPEG imidoesters, and other as described in Zalipsky and Lee, (1992) ("Use of functionalized poly(ethylene glycol)s for modification of peptides" in Poly(Ethylene Glycol) Chemistry: Biotechnical and Biomedical Applications, J. Milton Harris, Ed., Plenum Press, NY).
In one embodiment, the invention provides an anti-CD40L antibody single variable domain composition comprising an antibody single variable domain and PEG
polymer wherein the ratio of PEG polymer to antibody single variable domain is a molar ratio of at least 0.25:1. In a further einbodiment, the molar ratio of PEG
polymer to antibody single variable domain is 0.33:1 or greater. In a still further embodiment the molar ratio of PEG polymer to antibody single variable domain is 0.5:1 or greater.
Dual-specific Ligands The invention also provides dual-specific ligands comprising immunoglobulin single variable domains which each have different specificities; that is, the first and the second epitopes bound by the dual-specific ligand are preferably different. As used herein a "dual-specific ligand" refers to a ligand comprising a first immunoglobulin single variable domain and a second immunoglobulin single variable domain as herein defined, wherein the variable regions are capable of binding to two different antigens or two epitopes on the same antigen which are not normally bound by a monospecific immunoglobulin. For example, the two epitopes may be on the same hapten, but are not the same epitope or sufficiently adjacent to be bound by a monospecific ligand. The dual specific ligands according to the invention are composed of variable domains which have different specificities, and do not contain mutually complementary variable domain pairs which have the same specificity.
Dual-specific ligands may be, or be part of, polypeptides, proteins or nucleic acids, which may be naturally occurring or synthetic. In this respect, the ligand of the invention may bind an epiotpe or antigen and act as an antagonist or agonist (eg, EPO
receptor agonist). The epitope binding domains of the ligand in one embodiment have the same epitope specificity, and may for example simultaneously bind their epitope when multiple copies of the epitope are present on the same antigen. In another embodiment, these epitopes are provided on different antigens such that the ligand can bind the epitopes and bridge the antigens. One skilled in the art will appreciate that the choice of epitopes and antigens is large and varied. They may be for instance human or animal proteins, cytokines, cytokine receptors, enzymes co-factors for enzymes or DNA binding proteins. Suitable cytokines and growth factors include but are not limited to: ApoE, Apo-SAA, BDNF, Cardiotrophin-1, EGF, EGF
receptor, ENA-78, Eotaxin, Eotaxin-2, Exodus-2, EpoR, FGF-acidic, FGF-basic, fibroblast growth factor-10, FLT3 ligand, Fractalkine (CX3C), GDNF, G-CSF, GM-CSF, GF-j31, insulin, IFN-y, IGF-I, IGF-II, IL-la, IL-1(3, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8(72 a.a.), IL-8 (77 a.a.), IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, IL-16, IL-17, IL-1$
(IGIF), Inhibin a, Inhibin (3, IP-10, keratinocyte growth factor-2 (KGF-2), KGF, Leptin, LIF, Lymphotactin, Mullerian inhibitory substance, monocyte colony inhibitory factor, monocyte attractant protein, M-CSF, MDC (67 a.a.), NIDC (69 a.a.), MCP-1 (MCAF), MCP-2, MCP-3, MCP-4, MDC (67 a.a.), MDC (69 a.a.), MIG, MIP-la, MIP-1f3, MIP-3a, MIP-3(3, MIP-4, myeloid progenitor inhibitor factor-I
(MPIF-1), NAP-2, Neurturin, Nerve growth factor, (3-NGF, NT-3, NT-4, Oncostatin M, PDGF-AA, PDGF-AB, PDGF-BB, PF-4, RANTES, SDFla, SDFl(3, SCF, SCGF, stem cell factor (SCF), TARC, TGF-a, TGF-(3, TGF-(32, TGF-(33, tumour necrosis factor (TNF), TNF-a, TNF-(3, TNF receptor I, TNF receptor II, TNIL-1, TPO, VEGF, VEGF receptor 1, VEGF receptor 2, VEGF receptor 3, GCP-2, GRO/MGSA, GRO-(3, GRO-y, HCC1, 1-309, HER 1, HER 2, HER 3, HER 4, TACE recognition site, TNF
BP-I and TNF BP-II, as well as any target disclosed in Annex 2 or Annex 3 hereto, whether in combination as set forth in the Annexes, in a different combination or individually. Cytokine receptors include receptors for the foregoing cytokines, e.g.
IL-1 RI; IL-6R; IL-10R; IL-18R, as well as receptors for cytokines set forth in Annex 2 or Annex 3 and also receptors disclosed in Annex 2 and 3. It will be appreciated that this list is by no means exhaustive. Where the multispecific ligand binds to two epitopes (on the same or different antigens), the antigen(s) may be selected from this list.
In one embodiment of the second configuration of the invention, the variable domains are derived from an antibody directed against the first and/or second antigen or epitope. In a preferred embodiment the variable domains are derived from a repertoire of single variable antibody domains. In one example, the repertoire is a repertoire that is not created in an animal or a synthetic repertoire. In another example, the single variable domains are not isolated (at least in part) by animal immunisation. Thus, the single domains can be isolated from a naive library.
In another aspect, the invention provides a multi-specific ligand comprising a first epitope binding domain having a first epitope binding specificity and a non-complementary second epitope binding domain having a second epitope binding specificity. The first and second binding specificities may be the same or different.
In a furtlier aspect, the present invention provides a closed conformation multi-specific ligand comprising a first epitope binding domain having a first epitope binding specificity and a non-complementary second epitope binding domain having a second epitope binding specificity wllerein the first and second binding specificities are capable of competing for epitope binding such that the closed conformation multi-specific ligand caimot bind both epitopes simultaneously.
In a still further aspect, the invention provides open conformation ligands comprising non-complementary binding domains, wherein the domains are specific for a different epitope on the same target. Such ligands bind to targets with increased avidity. Similarly, the invention provides multivalent ligands comprising non-complementary binding domains specific for the same epitope and directed to targets which comprise multiple copies of said epitope.
In a similar aspect, ligands according to the invention can be configured to bind individual epitopes with low affinity, such that binding to individual epitopes is not therapeutically significant; but the increased avidity resulting from binding to two epitopes provides a therapeutic benefit. In a particular example, epitopes may be targeted which are present individually on normal cell types, but present together only on abnormal or diseased cells, such as tumour cells. In such a situation, only the abnormal or diseased cells are effectively targeted by the bispecific ligands according to the invention.
Ligand specific for multiple copies of the same epitope, or adjacent epitopes, on the same target (known as chelating dAbs) may also be trimeric or polymeric (tertrameric or more) ligands coinprising three, four or more non-complementary binding domains. For example, ligands may be constructed comprising three or four VH domains or VL domains.
Moreover, ligands are provided which bind to multisubunit targets, wherein each binding domain is specific for a subunit of said target. The ligand may be dimeric, trimeric or polymeric.
The invention also includes a dual specific ligand comprising a first immunoglobulin single variable domain having a binding specificity to a first antigen and a second single variable domain having a binding activity to a second antigen, wherein the first antigen is CD40L and the second single variable domain is an Antigen Presenting Cell surface antigen or a T cell surface antigen. The Antigen Presenting Cell (APC) surface antigen can be selected from one of the group consisting of dendritic cell surface antigens, activated macrophage surface antigens, activated B cell surface antigens, co-stimulatory signal pathway surface antigens, and MHC, such as MHC II alpha or beta.
The (APC) surface antigen may be selected from the group consisting of CD28, Inducible costimulatory molecule (ICOS), CD27, CD30, OX40, CD45, CD69, CD3, CD70, Inducible costimulatory molecule ligand (ICOSL), OX40L, CD80, CD86, HVEM (Herpes Virus Entry Mediator), and LIGHT, but is preferably one of CD28, Inducible costimulatory molecule (ICOS), CD27, CD'O, OX40, CD45, CD69, or CD3.
The surface antigen is preferably a B7 gene surface antigen such as B7-2 or B7-1.
Dendritic cell surface antigens are known in the art and can include but are not limited to ICAM-1, ICAM-2, LFA-1, LFA-3, DEC205, MHC class I, MHC class II, B7-1, and B7-2. Activated macrophage surface antigens include, but are not limited to, TNF receptor, CD40, MHC class I and II, and B7 molecules. Activated B-cell surface antigens are lcnown in the art (e.g., including but not limited to CD20 and CD86)and further described above (see, for example, Janeway et al., 1999, Immunobiolow, Garland Publishing NY, NY).
Preferably, the multi-specific ligands according to the above aspects of the invention are obtainable by the method comprising the steps of:
a) selecting a first epitope binding domain by its ability to bind to a first epitope, b) selecting a second epitope binding domain by its ability to bind to a second epitope, c) combining the epitope binding domains; and d) selecting the closed conformation multispecific ligand. by its ability to bind to said first second epitope and said second epitope..
Advantageously the first epitope binding domain and the second epitope binding domains are non-complementary immunoglobulin variable domains, as herein defined. That is either ~7H vH or VL-VL variable domains.
Chelating dAbs in particular may be prepared according to a preferred aspect of the invention, namely the use of anchor dAbs, in which a library of dimeric, trimeric or multimeric dAbs is constructed using a vector which comprises a constant dAb upstream or downstream of a linker sequence, with a repertoire of second, third and further dAbs being inserted on the other side of the linker. In alternative methodologies, the use of linlcers may be avoided, for example by the use of non-covalent bonding or natural affinity between binding domains such as VH and V.
The invention accordingly provides a method for preparing a multimeric ligand comprising the steps of:
(a) providing a vector comprising a nucleic acid sequence encoding a single binding domain specific for a first epitope on a target;
(b) providing a vector encoding a repertoire comprising second binding domains specific for a second epitope on said target, which epitope can be the same or different to the first epitope, said second epitope being adjacent to said first epitope;
and (c) expressing said first and second binding domains; and (d) isolating those combinations of first and second binding domains which combine together to produce a target-binding dimer.
The first and second epitopes are adjacent such that a multimeric ligand is capable of binding to both epitopes simultaneously. This provides the ligand with the advantages of increased avidity if binding. Where the epitopes are the same, the increased avidity is obtained by the presence of multiple copies of the epitope on the target, allowing at least two copies to be simultaneously bound in order to obtain the increased avidity effect.
In an alternative embodiment of the above aspect of the second configuration of the invention, at least one epitope binding domain comprises a non-immunoglobulin 'protein scaffold' or 'protein skeleton' as herein defined.
Suitable non-immunoglobulin protein scaffolds include but are not limited to any of those selected from the group consisting of: SpA, fibronectin, GroEL and other chaperones, lipocallin, CCTLA4 and affibodies, as set forth above.
According to the above aspect of the second configuration of the invention, advantageously, the epitope binding domains are attached to a'protein skeleton'.
Advantageously, a protein skeleton according to the invention is an immunoglobulin skeleton.
According to the present invention, the term 'immunoglobulin skeleton' refers to a protein which comprises at least one immunoglobulin fold and which acts as a nucleus for one or more epitope binding domains, as defined herein.
Preferred immunoglobulin skeletons as herein defined includes any one or more of those selected from the following: an immunoglobulin molecule comprising at least (i) the CL (kappa or lambda subclass) domain of an antibody; or (ii) the CH1 domain of an antibody heavy chain; an immunoglobulin molecule comprising the CHI and CH2 domains of an antibody heavy chain; an immunoglobulin molecule comprising the CH1, CH2 and CH3 domains of an antibody heavy chain; or any of the subset (ii) in conjunction with the CL (kappa or lambda subclass) domain of an antibody. A hinge region domain may also be included. Such combinations of domains may, for example, mimic natural antibodies, such as IgG or IgM, or fragments thereof, such as Fv, scFv, Fab or F(ab')2 molecules. Those skilled in the art will be aware that this list is not intended to be exhaustive.
Linking of the skeleton to the epitope binding domains, as herein defined may be achieved at the polypeptide level, that is after expression of the nucleic acid encoding the skeleton and/or the epitope binding domains. Altematively, the linlcing step may be performed at the nucleic acid level. Methods of linking a protein skeleton according to the present invention, to the one or more epitope binding domains include the use of protein chemistry and/or molecular biology techniques which will be familiar to those skilled in the art and are described herein.
Advantageously, the dual- or multispecific ligand may comprise a first domain capable of binding a target molecule, and a second domain capable of binding a molecule or group which extends the half-life of the ligand. For example, the molecule or group may be a bulky agent, such as HSA or a cell matrix protein.
As used herein, the phrase "molecule or group which extends the half-life of a ligand"
refers to a molecule or chemical group which, when bound by a dual-specific ligand as described herein increases the .in vivo half-life of such dual specific ligand when administered to an animal, relative to a ligand that does not bind that molecule or group. Examples of molecules or groups that extend the half-life of a ligand are described hereinbelow. Iti a preferred embodiment, the closed conformation multispecific ligand may be capable of binding the target molecule only on displacement of the half-life enhancing molecule or group. Thus, for example, a closed conformation multispecific Iigand is maintained in circulation in the bloodstream of a subject by a bulky molecule such as HSA. When a target molecule is encountered, competition between the binding domains of the closed conformation multispecifc ligand results in displacement of the HSA and binding of the target.
Molecules which increase half-life are discussed in further detail above.
Ligands according to any aspect of the present invention, as well as dAb monomers useful in constructing such ligands, may advantageously dissociate from their cognate target(s) with a Kd of 300nM to 5pM (ie, 3 x 10-7 to 5 x 10-12 M), preferably 50nM to20pM, or 5nM to 200pM or InM to I00pM, 1 x 10'7 M or less, I
x 10-8 M or less, 1 x 10"9 M or less, I x 10"10 M or less, 1 x 10"31 M or less;
and/or a Koff rate constant of 5 x 10'1 to 1 x 10-7 S-', preferably 1 x 10'2 to 1 x 10-6 S"1, or 5 x 10"' to 1 x 10"5 S-I, or 5 x 10-1 S-1 or less, or I x 10"2 S"1 or less, or 1 x 10-3 S-1 or less, or 1 x 10-4 S-1 or less, or I x 10'5 S-1 or less, or 1 x I0"6 S-1 or less as determined by surface plasmon resonance. The Kd rate constand is defined as Koff/Kor,.
Furthermore, the invention provides a dAb monomer(or dual specific ligand comprising such a dAb) that binds to serum albumin (SA) with a Kd of 1nM to 500gM (ie, x 10"9 to 5 x 10-4), preferably lOOnM to lO M. Preferably, for a dual specific ligand comprising a first anti-SA dAb and a second dAb to another target, the affinity (eg Kd and/or Koff as measured by surface plasmon resonance, eg using BiaCore) of the second dAb for its target is from 1 to 100000 times (preferably 100 to 100000, more preferably 1000 to 100000, or 10000 to 100000 times) the affinity of the first dAb for SA. For example, the first dAb binds SA with an affinity of approximately 10 M, while the second dAb binds its target with an affinity of 100pM. Preferably, the serum albumin is human serum albumin (HSA).
In one embodiment, the first dAb (or a dAb monomer) binds SA (eg, HSA) with a Kd of approximately 50, preferably 70, and more preferably 100, 150 or nM.
The invention moreover provides dimers, trimers and polymers of the aforementioned dAb monomers, in accordance with the foregoing aspect of the present invention.
Ligands according to the invention, including dAb monomers, dimers and trimers, can be linked to an antibody Fc region, comprising one or both of CH2 and CH3 domains, and optionally a hinge region. For example, vectors encoding ligands linked as a single nucleotide sequence to an Fc region may be used to prepare such polypeptides. Alternatively, ligands according to the invention may be free of an Fc domain.
In a further aspect, the present invention provides one or more nucleic acid molecules encoding at least a dual- or multispecific ligand as herein defined.
In one embodiment, the ligand is a closed conformation ligand. In another embodiment, it is an open conformation ligand. The multispecific ligand may be encoded on a single nucleic acid molecule; alternatively, each epitope binding domain may be encoded by a separate nucleic acid molecule. Where the ligand is encoded by a single nucleic acid molecule, the domains may be expressed as a fusion polypeptide, or may be separately expressed and subsequently linked together, for example using chemical linking agents. Ligands expressed from separate nucleic acids will be linked together by appropriate means.
The nucleic acid may further encode a signal sequence for export of the polypeptides from a host cell upon expression and may be fused with a surface component of a filamentous bacteriophage particle (or other component of a selection display system) upon expression. Leader sequences, which may be used in bacterial expression and/or phage or phagemid display, include pelB, stII, ompA, phoA, bla and pelA.
In a further aspect of the second configuration of the invention the present invention provides a vector comprising nucleic acid according to the present invention.
In a yet further aspect, the present invention provides a host cell transfected with a vector according to the present invention.
Expression from such a vector may be configured to produce, for example on the surface of a bacteriophage particle, epitope binding domains for selection. This allows selection of displayed domains and thus selection of 'multispecific ligands' using the method of the present invention.
Combining single variable domains Domains useful in the invention, once selected using methods exemplified above, may be combined by a variety of methods known in the art, including covalent and non-covalent methods.
Preferred methods include the use of polypeptide linkers, as described, for example, in connection with scFv molecules (Bird et al., (1988) Science 242:423-426). Discussion of suitable linkers is provided in Bird et al. Science 242, 423-426;
Hudson et al, Journal Immunol Methods 231 (1999) 177-189; Hudson et al, Proc Nat Acad Sci USA 85, 5879-5883. Linkers are preferably flexible, allowing the two single domains to interact. One linker example is a(Gly4 Ser)õ linker, where n=1 to 8, eg, 2, 3, 4, 5 or 7. The linkers used in diabodies, which are less flexible, may also be employed (Holliger et al., (1993) PNAS (USA) 90:6444-6448).
In one embodiment, the linker employed is not an immunoglobulin hinge region.
Variable domains may be combined using methods other than linkers. For example, the use of disulphide bridges, provided through naturally-occurring or engineered cysteine residues, may be exploited to stabilise VH-VH,VL-VL or VIi-VL
dimers (Reiter et al., (1994) Protein Eng. 7:697-704) or by remodelling the interface between the variable domains to improve the "fit" and thus the stability of interaction (Ridgeway et al., (1996) Protein Eng. 7:617-621; Zhu et al., (1997) Protein Science 6:781-788).
Other techniques for joining or stabilizing variable domains of immunoglobulins, and in particular antibody VH domains, may be employed as appropriate.
In accordance with the present invention, dual specific ligands can be in "closed" conformations in solution. A "closed" configuration is that in which the two domains (for example VH and VL) are present in associated form, such as that of an associated VH-VL pair which forins an antibody binding site. For example, scFv may be in a closed conformation, depending on the arrangement of the linker used to link the VH and VL domains. If this is sufficiently flexible to allow the domains to associate, or rigidly holds them in the associated position, it is likely that the domains will adopt a closed conformation.
Similarly, VH domain pairs and VL domain pairs may exist in a closed conformation. Generally, this will be a function of close association of the domains, such as by a rigid linlcer, in the ligand molecule. Ligands in a closed conformation will be unable to bind both the molecule which increases the half-life of the ligand and a second target molecule. Thus, the ligand will typically only bind the second target molecule on dissociation from the molecule which increases the half-life of the ligand.
Moreover, the construction of VH/VH, VLIVL or VH/VL dimers without linkers provides for competition between the domains.
Ligands according to the invention may moreover be in an open conformation.
In such a conformation, the ligands will be able to simultaneously bind both the molecule which increases the half-life of the ligand and the second target molecule.
Typically, variable domains in an open configuration are (in the case of VH-VL
pairs) held far enough apart for the domains not to interact and form an antibody binding site and not to compete for binding to their respective epitopes. In the case of VH/VH
or VL/VL dimers, the domains are not forced together by rigid linkers.
Naturally, such domain pairings will not compete for antigen binding or form an antibody binding site.
Fab fragments and whole antibodies will exist primarily in the closed conformation, although it will be appreciated that open and closed dual specific ligands are likely to exist in a variety of equilibria under different circumstances.
Binding of the ligand to a target is likely to shift the balance of the equilibrium towards the open configuration. Thus, certain ligands according to the invention can exist in two conformations in solution, one of which (the open form) can bind two antigens or epitopes independently, whilst the alternative conformation (the closed form) can only bind one antigen or epitope; antigens or epitopes thus compete for binding to the ligand in this conformation.
Although the open form of the dual specific ligand may thus exist in equilibrium with the closed form in solution, it is envisaged that the equilibrium will favor the closed form; moreover, the open form can be sequestered by target binding into a closed conformation. Preferably, therefore, certain dual specific ligands of the invention are present in an equilibrium between two (open and closed) conformations.
Dual specific ligands according to the invention may be modified in order to favor an open or closed conformation. For example, stabilisation of VH-VL
interactions with disulphide bonds stabilises -the closed conformation.
Moreover, linkers used to join the domains, including VH domain and VL domain pairs, may be constructed such that the open from is favoured; for example, the linkers may sterically hinder the association of the domains, such as by incorporation of large amino acid residues in opportune locations, or the designing of a suitable rigid structure which will keep the domains physically spaced apart.
Characterisation of the dual-specific IiQand.
The binding of the dual-specific ligand to its specific antigens or epitopes (e.g., CD40L and/or an epitope bound by DOM8-24) can be tested by methods which will be familiar to those skilled in the art and include ELISA. In a preferred embodiment of the invention binding is tested using monoclonal phage ELISA.
Phage ELISA may be performed according to any suitable procedure: an exemplary protocol is set forth below.
Populations of phage produced at each round of selection can be screened for binding by ELISA to the selected antigen or epitope, to identify "polyclonal"
phage antibodies. Phage from single infected bacterial colonies from these populations can then be screened by ELISA to identify "monoclonal" phage antibodies. It is also desirable to screen soluble antibody fragments for binding to antigen or epitope, and this can also be undertaken by ELISA using reagents, for example, against a C-or N-terminal tag (see for example Winter et al. (1994) Ann. Rev. Immunology 12, and references cited therein.
The diversity of the selected phage monoclonal antibodies may also be assessed by gel electrophoresis of PCR products (Marks et al. 1991, supra;
Nissim et al. 1994 supra), probing (Tomlinson et al., 1992) J. Mol. Biol. 227, 776) or by sequencing of the vector DNA.
Structure of 'Dual-specific ligands'.
As described above, an antibody is herein defined as an antibody (for exaznple IgG, IgM, IgA, IgA, IgE) or fragment (Fab, Fv, disulphide linked Fv, scFv, diabody) which comprises at least one heavy and a light chain variable domain, at least two heavy chain variable domains or at least two light chain variable domains. It may be at least partly derived from any species naturally producing an antibody, or createdby recombinant DNA technology; whether isolated from serum, B-cells, hybridomas, transfectomas, yeast or bacteria).
in a preferred embodiment of the invention the dual-specific ligand comprises at least one single heavy chain variable domain of an antibody and one single light chain variable domain of an antibody, or two single heavy or light chain variable domains. For example, the ligand may comprise a VH/VL pair, a pair of VH
domains or a pair of VL domains.
The first and the second variable domains of such a ligand may be on the same polypeptide chain. Alternatively they may be on separate polypeptide chains.
In the case that they are on the same polypeptide chain they may be linked by a linker, which is preferentially a peptide sequence, as described above.
The first and second variable domains may be covalently or non-covalently associated. In the case that they are covalently associated, the covalent bonds may be disulphide bonds.
In the case that the variable domains are selected from V-gene repertoires selected for instance using phage display technology as herein described, then these variable domains comprise a universal framework region, such that is they may be recognised by a specific generic ligand as herein defined. The use of universal frameworks, generic ligands and the like is described in W099/20749.
Where V-gene repertoires are used variation in polypeptide sequence is preferably located within the structural loops of the variable domains. The polypeptide sequences of either variable domain may be altered by DNA
shuffling or by mutation in order to enhance the interaction of each variable domain with its complementary pair. DNA shuffling is known in the art and taught, for example, by Stemmer, 1994, Nature 370: 389-391 and U.S. Patent No. 6,297,053, both of which are incorporated herein by reference. Other methods of mutagenesis are well known to those of skill in the art.
In one embodiment of the invention the 'dual-specific ligand' is a single chain Fv fragment. In an alternative embodiment of the invention, the 'dual-specific ligand' consists of a Fab format.
In a further aspect, the present invention provides nucleic acid encoding at least a'dual-specific ligatld' as herein defined.
One skilled in the art will appreciate that, depending on the aspect of the invention, both antigens or epitopes may bind simultaneously to the same antibody molecule. Alternatively, they may compete for binding to the same antibody molecule. For example, where both epitopes are bound simultaneously, both variable domains of a dual specific ligand are able to independently bind their target epitopes.
Where the domains compete, the one variable domain is capable of binding its target, but not at the same time as the other variable domain binds its cognate target; or the first variable domain is capable of binding its target, but not at the same time as the second variable domain binds its cognate target.
The variable regions may be derived from antibodies directed against target antigens or epitopes. Alternatively they may be derived from a repertoire of single antibody domains such as those expressed on the surface of filamentous bacteriophage. Selection may be performed as described below.
In general, the nucleic acid molecules and vector constructs required for the performance of the present invention may be constructed and manipulated as set forth in standard laboratory manuals, such as Sambrook et al. (1989) Molecular Cloning: A
Laboratwy Manual, Cold Spring Harbor, USA.
The manipulation of nucleic acids useful in the present invention is typically carried out in recombinant vectors.
Thus in a further aspect, the present invention provides a vector comprising nucleic acid encoding at least a'dual-specific ligand' as herein defined.
As used herein, vector refers to a discrete element that is used to introduce heterologous DNA into cells for the expression and/or replication thereof.
Methods by which to select or construct and, subsequently, use such vectors are well known to one of ordinary skill in the art. Numerous vectors are publicly available, including bacterial plasmids, bacteriophage, artificial clu-omosomes and episomal vectors. Such vectors may be used for simple cloning aiid mutagenesis; alternatively gene expression vector is employed. A vector of use according to the invention may be selected to accommodate a polypeptide coding sequence of a desired size, typically from 0.25 kilobase (kb) to 40 kb or more in length A suitable host cell is transformed with the vector after in vitro cloning manipulations. Each vector contains various functional components, which generally include a cloning (or "polylinker") site, an origin of replication and at least one selectable marker gene. If given vector is an expression vector, it additionally possesses one or more of the following:
enhancer element, promoter, transcription termination and signal sequences, each positioned in the vicinity of the cloning site, such that they are operatively linked to the gene encoding a ligand according to the invention.
Both cloning and expression vectors generally contain nucleic acid sequences that enable the vector to replicate in one or more selected host cells.
Typically in cloning vectors, this sequence is one that enables the vector to replicate independently of the host chromosomal DNA and includes origins of replication or autonomously replicating sequences. Such sequences are well known for a variety of bacteria, yeast and viruses. The origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, the 2 micron plasmid origin is suitable for yeast, and various viral origins (e.g. SV 40, adenovirus) are useful for cloning vectors in mammalian cells. Generally, the origin of replication is not needed for mammalian expression vectors unless these are used in mammalian cells able to replicate high levels of DNA, such as COS cells.
Advantage.ously, a cloning or expression vector may contain a selection gene also referred to as selectable marker. This gene encodes a protein necessary for the survival or growth of transformed host cells grown in a selective culture medium.
Host cells not transformed with the vector containing the selection gene will therefore not survive in the culture medium. Typical selection genes encode proteins that confer resistance to antibiotics and other toxins, e.g. ampicillin, neomycin, methotrexate or tetracycline, complement auxotrophic deficiencies, or supply critical nutrients not available in the growth media.
Since the replication of vectors encoding a ligand according to the present invention is most conveniently performed in E. coli, an E. coli-selectable marker, for example, the j3-lactamase gene that confers resistance to the antibiotic ampicillin, is of use. These can be obtained from E. coli plasmids, such as pBR' )22 or a pUC
plasmid such as pUC 18 or pUC 19.
Expression vectors usually contain a promoter that is recognised by the host organism and is operably linked to the coding sequence of interest. Such a promoter may be inducible or constitutive. The term "operably linked" refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner. A coiltrol sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences.
Promoters suitable for use with prokaryotic hosts include, for example, the (3-lactamase and lactose promoter systems, alkaline phosphatase, the tryptophan (trp) promoter system and hybrid promoters such as the tac promoter. Promoters for use in bacterial systems will also generally contain a Shine-Delgamo sequence operably linked to the coding sequence.
The preferred vectors are expression vectors that enables the expression of a nucleotide sequence corresponding to a polypeptide library member. Thus, selection with the first andlor second antigen or epitope can be performed by separate propagation and expression of a single clone expressing the polypeptide library member or by use of any selection display system. As described above, the preferred selection display system is bacteriophage display. Thus, phage or phagemid vectors may be used, eg pITI or pIT2. Leader sequences useful in the invention include pelB, stll, ompA, phoA, bla and pelA. One example are phagemid vectors which have an E. coli. origin of replication (for double stranded replication) and also a phage origin of replication (for production of single-stranded DNA). The manipulation and expression of such vectors is well known in the art (Hoogenboom and Winter (1992) supra; Nissim et al. (1994) supra). Briefly, the vector contains a(3-lactarnase gene to confer selectivity on the phagemid and a lac promoter upstream of a expression cassette that consists (N to C terminal) of a pe1B leader sequence (which directs the expressed polypeptide to the periplasmic space), a multiple cloning site (for cloning the nucleotide version of the library member), optionally, one or more peptide tag (for detection), optionally, one or more TAG stop codon and the phage protein pIIl.
Thus, using various suppressor and non-suppressor strains of E. coli and with the addition of glucose, iso-propyl thio-(3-D-galactoside (IPTG) or a helper phage, such as VCS M13, the vector is able to replicate as a plasmid with no expression, produce large quantities of the polypeptide library member only or produce phage, some of which contain at least one copy of the polypeptide-plII fusion on their surface.
Construction of vectors encoding ligands according to the invention employs conventional ligation techniques. Isolated vectors or DNA fragments are cleaved, tailored, and religated in the form desired to generate the required vector.
If desired, analysis to confirm that the correct sequences are present in the constructed vector can be performed in a known fashion. Suitable methods for constructing expression vectors, preparing in >>itro transcripts, introducing DNA into host cells, and performing analyses for assessing expression and function are known to those skilled in the art. The presence of a gene sequence in a sample is detected, or its amplification and/or expression quantified by conventional methods, such as Southern or Northern analysis, Western blotting, dot blotting of DNA, RNA or protein, in situ hybridisation, immunocytochemistry or sequence analysis of nucleic acid or protein molecules. Those skilled in the art will readily envisage how these methods may be modified, if desired.
Structure of ligands According to one aspect of the invention, two or more non-complementary epitope binding domains are linked so that they are in a closed conformation as herein defined. Advantageously, they may be further attached to a skeleton which may, as a alternative, or on addition to a linker described herein, facilitate the formation and/or maintenance of the closed conformation of the epitope binding sites with respect to one another. Alternatively, the monomeric anti-CD40L antibody single variable domain polypeptides of the invention may be constructed using scaffold or skeleton frameworks as discussed herein.
(1) Skeletons Skeletons may be based on immunoglobulin molecules or may be non-immunoglobulin in origin as set forth above. Preferred immunoglobulin skeletons as herein defined includes any one or more of those selected from the following:
an immunoglobulin molecule comprising at least (i) the CL (kappa or lambda subclass) domain of an antibody; or (ii) the CH1 domain of an antibody heavy chain; an immunoglobulin molecule comprising the CH1 and CH2 domains of an antibody heavy chain; an immunoglobulin molecule comprising the CHI, CH2 and CH3 domains of an antibody heavy chain; or any of the subset (ii) in conjunction with the CL (kappa or lambda subclass) domain of an antibody. A hinge region domain may also be included.. Such combinations of domains may, for example, mimic natural antibodies, such as IgG or lgM, or fragments thereof, such as Fv, scFv, Fab or F(ab')2 molecules. Those skilled in the art will be aware that this list is not intended to be exhaustive.
(II) Protein scaffolds Each epitope binding domain comprises a protein scaffold and one or more CDRs which are involved in the specific interaction of the domain with one or more epitopes. Advantageously, an epitope binding domain according to the present invention comprises three CDRs. Suitable protein scaffolds, in addition to those based on immunoglobulin domains, may also. be based on protein scaffolds or skeletons other than iminunoglobulin domains. For exainple natural bacterial receptors such as SpA have been used as scaffolds for the grafting of CDRs to generate ligands which bind specifically to one or more epitopes. Details of this procedure are described in US 5,831,012. Other suitable scaffolds include those based on fibronectin and affibodies (Affibody, Bromma, Sweeden). Details of suitable procedures are described in WO 98/58965. Other suitable. scaffolds include lipocallin and CTLA4, as described in van den Beuken etal., J. Mol. Biol. (2001) 310, 591-601, and scaffolds such as those described in W00069907 (Medical Research Coi.uncil), which are based for example on the ring structure of bacterial GroEL or other chaperone polypeptides. Other non-immunoglobulin based scaffolds which may be used according to the invention include those based on the LDL receptor class A, EGF domain monomers and mutimers, and scaffolds available from Biorexis (King of Prussia, PA) or Avidia (Mountaiii View, CA). Other non-immunoglobulin scaffolds which may be used are described, for example, in W005/040229, W004/044011, and Scaffolds for use in Constructing Ligands i. Selection of the main-chain conformation The members of the immunoglobulin superfamily all share a similar fold for their polypeptide chain. For example, although antibodies are highly diverse in terms of their primary sequence, comparison of sequences and crystallographic structures has revealed that, contrary to expectation, five of the six antigen binding loops of antibodies (H1, H2, LI, L2, L3) adopt a limited number of main-chain conformations, or canonical structures (Chothia and Lesk (1987) J. Mol. Biol., 196: 901;
Chothia et al. (1989) Nature, 342: 877). Analysis of loop lengths and key residues has therefore enabled prediction of the main-chain conformations of H1, H2, L1, L2 and L3 found in the majority of human antibodies (Chothia et al. (1992) J. Mol. Biol., 227:
799;
Tomlinson et al. (1995) EMBO J., 14: 4628; Williams et al. (1996) J. Mol.
Biol., 264:
220). Although the H3 region is much more diverse in terms of sequence, length and structure (due to the use of D segments), it also for'ms a limited number of main-chain conformations for short loop lengths which depend on the length and the presence of particular residues, or types of residue, at key positions in the loop and the antibody framework (Martin et al. (1996) J. Mol. Biol., 263: 800; Shirai et al. (1996) FEBS
Letters, 399: 1).
The ligands of the present invention are advantageously selected and/or assembled from libraries of domains, suc11 as libraries 'of VH domains and/or libraries of VL domains. Moreover, the ligands of the invention may themselves be provided in the form of libraries. In one aspect of the present invention, libraries of ligands and/or domains are designed in which certain loop lengths and key residues have been chosen to ensure that the main-chain conformation of the members is l:nown.
Advantageously, these are real conformations of immunoglobulin superfamily molecules found in nature, to minimise the chances that they are non-functional, as discussed above. Germline V gene segments serve as one suitable basic framework for constructing antibody or T-cell receptor libraries; other sequences are also of use.
Variations may occur at a low frequency, such that a small number of functional members may possess an altered main-chain conformation, which does not affect its function.
Canonical structure theory is also of use to assess the number of different main-chain conformations encoded by ligands, to predict the main-chain conformation based on ligand sequences and to chose residues for diversification which do not affect the canonical structure.-It is known that, in the human V,; domain, the Ll loop can adopt one of four canonical structures, the L2 loop has a single canonical structure and that 90% of human V,; domains adopt one of four or five canonical structures for the L3 loop (Tomlinson et al. (1995) supra); thus, in the V,;
domain alone, different canonical structures can combine to create a range of different main-chain conformations. Given that the Va, domain encodes a different range of canonical structures for the L1, L2 and L3 loops and that V,; and V?, domains can pair with any VH domain which can encode. several canonical structures for the HI
and H2 loops, the number of canonical structure combinations observed for these five loops is very large. This implies that the generation of diversity in the main-chain conformation may be essential for the production of a wide range of binding specificities. However, by constructing an antibody library based on a single known main-chain conformation it has been found, contrary to expectation, that diversity in the main-chain conformation is not required to generate sufficient diversity to target substantially all antigens. Even more surprisingly, the single main-chain conformation need not be a consensus structure - a single naturally occurring conformation can be used as the basis for an entire library. Tllus, in a preferred aspect, the ligands of the invention possess a single lmown main-chain conformation.
The single main-chain confonnation that is chosen is preferably commonplace among molecules of the immunoglobulin superfamily type in 'question. A
conformation is commonplace when a significant number of naturally occurring molecules are observed to adopt it. Accordingly, in a preferred aspect of the invention, the natural occurrence of the different main-chain conformations for each binding loop of an immunoglobulin domain are considered separately and then a naturally occurring variable domain is chosen which possesses the desired combination of main-chain conformations for the different loops. If none is available, the nearest.equivalent may be chosen. It is preferable that the desired combination of main-chain conformations for the different loops is created by selecting germline gene segments which encode the desired main-chain conformations. It is more preferable, that the selected germline gene segments are frequently expressed in nature, and most preferable that they are the most frequently expressed of all natural germline gene segments.
In designing ligands or libraries thereof the incidence of the different main-chain conformations for each of the antigen binding loops may be considered separately. For H1, H2, L1, L2 and L3, a given conformation that is adopted by between 20% and 100% of the antigen binding loops of naturally occurring molecules is chosen. Typically, its observed incidence is above 35% (i.e. between 35%
and 100%) and, ideally, above 50% or even above 65%. Since the vast majority of H3 loops do not have canonical structures, it is preferable to select a main-chain conformation which is commonplace among those loops which do display canonical structures. For each of the loops, the conformation which is observed most often in the natural repertoire is therefore selected. In human antibodies, the most popular canonical structures (CS) for each loop are as follows: H1 - CS 1 (79% of the expressed repertoire), H2 - CS 3 (46%), L1 - CS 2 of V,; (39%), L2 - CS 1 (100%), L3 - CS 1 of V,; (36%) (calculation assumes a 1c:~ ratio of 70:30, Hood et al.
(1967) Cold Spring Harbo7- Sy77p. Quant. Biol., 48: 133). For H3 loops that have canonical structures, a CDR3 length (Kabat et al. (1991) Sequences of proteins of innmunological interest, U.S. Department of Health and Human Services) of seven residues with a salt-bridge from residue 94 to residue 101 appears to be the most common. There are at least 16 human antibody sequences in the EMBL data library with the required H3 length and key residues to form this conformation and at least two crystallographic structures in the protein data bank which can be used as a basis for antibody modelling (2cgr and ltet). The most frequently expressed germline gene segments that this combination of canonical structures are the VH segment 3-23 (DP-47), the JH segment JH4b, the V,; segment 02/012 (DPK9) and the J,; segment Jl.
VH segments DP45 and DP38 are also suitable. These segments can therefore be used in combination as a basis to construct a library with the desired single main-chain conformation.
Alternatively, instead of choosing the single main-chain conformation based on the natural occurrence of the different main-chain conformations for each of the binding loops in isolation, the natural occurrence of combinations of main-chain conformations is used as the basis for choosing the single main-chain conformation.
In the case of antibodies, for example, -the natural occurrence of canonical structure combinations for any two, three, four, five or for all six of the antigen binding loops can be determined. Here, it is preferable that the chosen conformation, is commonplace in naturally occurring antibodies and most preferable that it observed most frequently in the natural repertoire. Thus, in human antibodies, for example, when natural combinations of the five antigen binding loops, H1, H2, Ll, L2 and L3, are considered, -the most frequent combination of canonical structures is determined and then combined with the most popular conformation for the H3 loop, as a basis for choosing the single main-chain conformation.
ii. Diversification of the canonical sequence Having selected several known main-chain conformations or, preferably a single known main-chain conformation, ligands according to the invention or libraries for use in the invention can be constructed by varying the binding site of the molecule in order to generate a repertoire with structural and/or functional diversity.
This means that variants are generated such that they possess sufficient diversity in their structure and/or in their function so that they are capable of providing a range of activities.
The desired diversity is typically generated by varying the selected molecule at one or more positions. The positions to be changed can be chosen at random or are preferably selected. The variation can then be achieved either by randomisation, during which the resident amino acid is replaced by any amino acid or analogue thereof, natural or synthetic, producing a very large number of variants or by replacing the resident amino acid with one or more of a defined subset of amino acids, producing a more limited number of variants.
Various methods have been reported for introducing such diversity. Error-prone PCR (Hawkins et al. (1992) J. Mol. Biol., 226: 889), chemical mutagenesis (Deng et al. (1994) J. Biol. Chem., 269: 9533) or bacterial mutator strains (Low et al.
(1996) J. Mol. Biol., 260: 359) can be used to introduce random mutations into the genes that encode the molecule. Methods for mutating selected positions are also well known in the art and include the use of mismatched oligonucleotides or degenerate oligonucleotides, with or without the use of PCR. For example, several synthetic antibody libraries have been created by targeting mutations to the antigen binding loops. The H3 region of a human tetanus toxoid-binding Fab has been randomised to create a range of new binding specificities (Barbas et al. (1992) Proc. Natl.
Acad. Sci.
USA, 89: 4457). Random or semi-random H3 and L3 regions have been appended to germline V gene segments to produce large libraries with unmutated framework regions (Hoogenboom & Winter (1992) J. Mol. Biol., 227: 381; Barbas et al.
(1992) Proc. Natl. Acad. Sci. USA, 89: 4457; Nissim et al. (1994) EMBO J., 13: 692;
Griffiths et al. (1994) EMBO J., 13: 3245; De Kruif et al. (1995) J. Mol.
Biol., 248:
97). Such diversification has been extended to include some or all of the other antigen binding loops (Crameri et al. (1996) Nature Med., 2: 100; Riechmann et al.
(1995) Bio/Technology, 13: 475; Morphosys, W097/08320, supra).
Since loop randomisation has the potential to create approximately more tlian 101' structures for 113 alone and a similarly large number of variants for the other five loops, it is not feasible using current transformation technology or even by using cell free systems to produce a library representing all possible combinations. For example, in one of the largest libraries constructed to date, 6 x 1010 different antibodies, which is only a fraction of the potential diversity for a library of this design, were generated (Griffiths et al. (1994) supra).
In a preferred embodiment, only those residues which are directly involved in creating or modifying the desired function of the molecule are diversified.
For many molecules, the function will be to bind a target and therefore diversity should be concentrated in the target binding site, while avoiding changing residues which are crucial to the overall packing of the molecule or to maintaining the chosen main-chain conformation.
Diversification of the canonical sequence as it applies to antibodv domains In the case of the ligands of the invention, the binding site for the target is most often the antigen binding site. Thus, in a highly preferred aspect, the invention provides libraries of or for the assembly of antibody ligands in which only those residues in the antigen binding site are varied. These residues are extremely diverse in the human antibody repertoire and are known to make contacts in high-resolution antibody/antigen complexes. For example, in L2 it is known that positions 50 and 53 are diverse in naturally occurring antibodies and are observed to make contact with the antigen. In contrast, the conventional approach would have been to diversify all the residues in the corresponding Complementarity Determining Region (CDRl) as defined by Kabat et al. (1991, supra), some seven residues compared to the two diversified in the library for use according to the invention. This represents a significant improvement in terms of the functional diversity required to create a range of antigen binding specificities.
In nature, antibody diversity is the result of two processes: somatic recombination of germline V, D and J gene segments to create a naive primary repertoire (so called germline and junctional diversity) and somatic hypennutation of the resulting rearranged V genes. Analysis of human antibody sequences has shown that diversity in the primary repertoire is focused at the centre of the antigen binding site whereas somatic hypermutation spreads diversity to regions at the periphery of the antigen binding site that are highly conserved in the primary repertoire (see Tomlinson et al. (1996) J. Mol. Biol., 256: 813). This complementarity has probably evolved as an efficient strategy for searching sequence space and, although apparently unique to antibodies, it can easily be applied to other polypeptide repertoires. The residues which are varied are a subset of those that form the binding site for the target. Different (including overlapping) subsets of residues in the target binding site are diversified at different stages during selection, if desired.
In the case of an antibody repertoire, an initial 'naive' repertoire is created where some, but not all, of the residues in the antigen binding site are diversified. As used herein in this context, the term "naive" refers to antibody molecules that have no pre-determined target. These molecules resemble those which are encoded by the immunoglobulin genes of an individual who has not undergone immune diversification, as is the case with fetal and newborn individuals, whose immune systems have not yet been challenged by a wide variety of antigenic stimuli.
This repertoire is then selected against a range of antigens or epitopes. If required, further diversity can then be introduced outside the region diversified in the initial repertoire.
This matured repertoire can be selected for modified function, specificity or affinity.
The invention provides two different naive repertoires of binding domains for the construction of ligands, or a naive library of ligands, in which some or all of the residues in the antigen binding site are varied. The "primary" library mimics the natural primary repertoire, with diversity restricted to residues at the centre of the antigen binding site that are diverse in the germline V gene segments (germline diversity) or diversified during the recombination process (junctional diversity).
Those residues which are diversified include, but are not limited to, H50, H52, H52a, H53, H55, H56, H58, H95, H96, H97, H98, L50, L53, L91, L92, L93, L94 and L96.
In the "somatic" library, diversity is restricted to residues that are diversified during the recombination process (junctional diversity) or are highly somatically mutated).
Those residues which are diversified include, but are not limited to: H31, 1133, H35, H95, H96, H97, H98, L30, L31, L32, L34 and L96. All the residues listed above as suitable for diversification in these libraries are known to make contacts in one or more antibody-antigen complexes. Since in both libraries, not all of the residues in the antigen binding site are varied, additional diversity is incorporated during selection by varying the remaining residues, if it is desired to do so. It shall be apparent to one skilled in the art that any subset of any of these residues (or additional residues which comprise the antigen binding site) can be used for the initial and/or subsequent diversification of the antigen binding site.
In the construction of libraries for use in the invention, diversification of chosen positions is typically achieved at the nucleic acid level, by altering the coding sequence which specifies the sequence of the polypeptide such that a number of possible amino acids (all 20 or a subset thereof) can be incorporated at that position.
Using the IUPAC nomenclature, the most versatile codon is NNK, which encodes all amino acids as well as the TAG stop codon. The NNK codon is preferably used iri order to introduce the required diversity. Other codons which achieve the same ends are also of use, including the NNN codon, which leads to the production of the additional stop codons TGA and TAA.
A feature of side-chain diversity in the antigen binding site of human antibodies is a pronounced bias which favours certain amino acid residues. If the amino acid composition of the ten most diverse positions in each of the VH, V,; and V~, regions are summed, more than 76% of the side-chain diversity comes from only seven different residues, these being, serine (24%), tyrosine (14%), asparagine (11%), glycine (9%), alanine (7%), aspartate (6%) ' and threonine (6%). This bias towards hydrophilic residues and small residues which can provide main-chain flexibility probably reflects the evolution of surfaces which are predisposed to binding a wide range of antigens or epitopes and may help to explain the required promiscuity of antibodies in the primary repertoire.
Since it is preferable to mimic this distribution of amino acids, the distribution of amino acids at the positions to be varied preferably mimics that seen in the antigen binding site of antibodies. Such bias in the substitution of amino acids that permits selection of certain polypeptides (not just, antibody polypeptides) against a range of target antigens is easily applied to any polypeptide repertoire. There are various methods for biasing the amino acid distribution at the position to be varied (including the use of tri-nucleotide mutagenesis, see W097/08320), of which the preferred method, due to ease of synthesis, is the use of conventional degenerate codons. By comparing the amino acid profile encoded by all combinations of degenerate codons (with single, double, triple and quadruple degeneracy in equal ratios at each position) with the natural amino acid use it is possible to calculate the most representative codon. The codons (AGT)(AGC)T, (AGT)(AGC)C and (AGT)(AGC)(CT) - that is, DVT, DVC and DVY, respectively using IUPAC nomenclature - are those closest to the desired amino acid profile: they encode 22% serine and 11% tyrosine, asparagine, glycine, alanine, aspartate, threonine and cysteine. Preferably, therefore, libraries are constructed using either the DVT, DVC or DVY codon at each of the diversified positions.
Increased Half-life In vivo, the PEGylated monovalent anti-CD40L antibodies as described herein confer a distinct advantage over non-PEGylated antibody polypeptides, in that the PEGylated antibody molecules will have a greatly prolonged in vivo half life.
Without being bound to one particular tlleory, it is believed that the increased half-life of the molecules described herein is conferred by the increased hydrodynamic size of the antibody polypeptide resulting from the attachment of PEG polymer(s). More specifically, it is believed that two parameters play an important role in determining the serum half-life of PEGylated antibody polypeptides. The first criterion is the nature and size of the PEG attachment, i.e., if the polymer used is simply a linear chain or a branched/forked chain, wherein the branched/forked chain gives rise to a longer half-life. The second is the location of the PEG moiety or moieties on the antibody polypeptide in the final format and how many "free" unmodified PEG
arms the molecule has. The resulting hydrodynamic size of the PEGylated antibody polypeptide, as estimated, for example, by size exclusion chromatography, reflects the serum half-life of the molecule. Accordingly, the larger the hydrodynamic size of the PEGylated molecule, the greater the serum half life.
Increased half-life is useful in vivo applications of immunoglobulins, especially antibodies and most especially antibody fragments of small size.
Such fragments (Fvs, Fabs, scFvs, dAbs) suffer from rapid clearance from the body;
thus, while they are able to reach most parts of the body rapidly, and are quick to produce and easier to handle, their in vivo applications have been limited by their only brief persistence in vivo.
In one aspect, a monovalent anti-CD40L antibody polypeptide as described herein is stabilized in vivo by fusion with a moiety, such as PEG, that increases the hydrodynamic size of the antibody polypeptide. Methods for pharmacokinetic analysis and determination of half-life will be familiar to those skilled in the art.
Details may be found in Kenneth et al: Chemical Stability of Pharmaceuticals:
A
Handbook for Pharmacists and in Peters et al, Pharmacokinetc analysis: A
Practical Approach (1996). Reference is also made to "Pharmacokinetics", M Gibaldi & D
Perron, published by Marcel Dekker, 2 d Rev. ex edition (1982), which describes pharmacokinetic parameters such as t alpha and t beta half lives and area under the curve (AUC).
Typically, the half life of a PEGylated antibody polypeptide as described herein is increased by 10%, 20%, 30%, 40%, 50% or more relative to a non-PEGylated dAb (wherein the antibody polypeptide of the PEGylated antibody polypeptide and non-PEGylated antibody polypeptide are the same). Increases in the range of 2x, 3x, 4x, 5x, 7x, l Ox, 20x, 30x, 40x, and up to 50x or more of the half life are possible. Alternatively, or in addition, increases in the range of up to 30x, 40x, 50x, 60x, 70x, 80x, 90x, I OOx, 150x of the half life are possible.
Half lives (t%z alpha and t'/2 beta) and AUC can be determined from a curve of serum concentration of ligand against time. The WinNonlin analysis package (available from Pharsight Corp., Mountain View, CA 94040, USA) can be used, for example, to model the curve. In a first phase (the alpha phase) the ligand is undergoing mainly distribution in the patient, with some elimination. A second phase (beta phase) is the terminal phase when the ligand has been distributed and the serum concentration is decreasing as the ligand is cleared from the patient. The ta half life is the half life of the first phase and the tj3 half life is the half life of the second phase.
"Half-life" as used herein, unless otherwise noted, refers to the overall half-life of an antibody single variable domain of the invention determined by non-compartment modeling (as contrasted with biphasic modeling, for example). Beta half-life is a measurement of the time it takes for the amount of dAb monomer or multimer to be cleared from the mammal to which it is administered. Thus, advantageously, the present invention provides a dAb-containing composition, e.g., a dAb-effector group composition, having a ta half-life in the range of 0.25 hours to 6 hours or more. In one embodiment, the lower end of the range is 30 minutes, 45 minutes, 1 hour, 1.3 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 10 hours, 11 hours or 12 hours. In addition or alternatively, a dAb containing composition will have a ta half-life in the range of up to and including 12 hours. In one embodiment, the upper end of the range is 11, 10, 9, 8, 7, 6, or 5 hours. An example of a suitable range is 1.3 to 6 hours, 2 to 5 hours or 3 to 4 hours.
Advantageously, the present invention provides a dAb containing composition comprising a ligand according to the invention having a t(3 half-life in the range of 1-170 hours or more. In one embodiment, the lower end of the range is 2.5 hours, hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours or 12 hours. In addition, or alternatively, a dAb containing composition, e.g. a dAb-effector group composition has a t(1 half-life in the range of up to and including 21 days. In one embodiment, the upper end of the range is 12 hours, 24 hours, 2 days, 3 days, 5 days, 10 days, 15 days, or 20 days. Advantageously a dAb containing composition according to the invention will have a t(3 half-life in the range 2-100 hours, hours, and 10-40 hours. In a further embodiment, it will be in the range 12-48 hours.
In a further embodiment still, it will be in the range 12-26 hours. The present invention provides a dAb containing composition comprising a ligand according to the invention having a half-life in the range of 1-170 hours or more. In one embodiment, the lower end of the range is 1.3 hours, 2.5 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours or 12. hours. In addition, or alternatively, a dAb containing composition, e.g. a dAb-effector group composition has a half-life in the range of up to and including 21 days. In one embodiment, the upper end of the range is 12 hours, 24 hours, 2 days, 3 days, 5 days, 10 days, 15 days, or 20 days.
In addition, or alternatively to the above criteria, the present invention provides a dAb containing composition comprising a ligand according to the invention having an AUC value (area under the curve) in the range of 1 mg.min/ml or more. In one embodiment, the lower end of the range is 5, 10, 15, 20, 30, 100, 200 or 300 mg.min/ml. In addition, or alternatively, a ligand or composition according to the invention has an AUC in the range of up to 600 mg.min/ml. In one embodiment, the upper end of the range is 500, 400, 300, 200, 150, 100, 75 or 50 mg.min/ml.
Advantageously a ligand according to the invention will have an AUC in the range selected from the group consisting of the following: 15 to 150 mg.min/ml, 15 to 100 mg.min/ml, 15 to 75 mg.min/ml, and 15 to 50 mg.min/ml.
The ligands according to the invention, including, mono-, dual- and multi-specific, in one configuration thereof, are capable of binding to one or more molecules which can increase the half-life of the ligand in vivo. Typically, such molecules are polypeptides which occur naturally in vivo and which resist degradation or removal by endogenous mechanisms which remove unwanted material from the organism. For example, the molecule which increases the half-life of the organism may be selected from the following:
Proteins from the extracellular matrix; for example collagen, laminins, integrins and fibronectin. Collagens are the major proteins of the extracellular matrix.
About 15 types of collagen molecules are currently knovvn, found in different parts of the body, eg type I collagen (accounting for 90% of body collagen) found in bone, skin, tendon, ligaments, cornea, internal organs or type II collagen found in cartilage, invertebral disc, notochord, vitreous humour of the eye.
Proteins found in blood, including:
Plasma proteins such as fibrin, a-2 macroglobulin, serum albumin, fibrinogen A, fibrinogen B, serum amyloid protein A, heptaglobin, profilin, ubiquitin, uteroglobulin and (3-2-microglobulin;
Enzymes and inhibitors such as plasrninogen, lysozyme, cystatin C, alpha-l-antitrypsin and pancreatic trypsin inhibitor. Plasminogen is the inactive precursor of the trypsin-like serine protease plasmin. It is normally found circulating through the blood stream. When plasminogen becomes activated and is converted to plasmin, it unfolds a potent enzymatic domain that dissolves the fbrinogen fibers that entgangle the blood cells in a blood clot. This is called fibrinolysis.
Immune system proteins, such as IgE, IgG, IgM.
Transport proteins such as retinol binding protein, a-1 microglobulin.
Defensins such as beta-defensin 1, Neutrophil defensins 1,2 and 3.
Proteins found at the blood brain barrier or in neural tissues, such as melanocortin receptor, myelin, ascorbate transporter.
Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins (see US5977307); brain capillary endothelial cell receptor, transferrin, transferrin receptor, insulin, insulin-like growth factor 1(IGF 1) receptor, insulin-lilce growth factor 2 (IGF 2) receptor, insulin receptor.
Proteins localised to the kidney, such as polycystin, type IV collagen, organic anion transporter K1, Heymann's antigen.
Proteins localised to the liver, for example alcohol dehydrogenase, G250.
Blood coagulation factor X
al antitrypsin HNF la Proteins localised to the lung, such as secretory component (binds IgA).
Proteins localised to the Heart, for example HSP 27. This is associated with dilated cardiomyopathy.
Proteins localised to the skin, for example keratin.
Bone specific proteins, such as bone morphogenic proteins (BIvIPs), which are a subset of the transforming growth factor ji superfamily that demonstrate osteogenic activity. Examples include BMP-2, -4, -5, -6, -7 (also referred to as osteogenic protein (OP-1) and -8 (OP-2).
Tumour specific proteins, including human trophoblast antigen, herceptin receptor, oestrogen receptor, cathepsins eg cathepsin B (found in liver and spleen).
Disease-specific proteins, such as antigens expressed only on activated T-cells:
including LAG-3 (lymphocyte activation gene), osteoprotegerin ligand (OPGL) see Nature 402, 304-309; 1999, OX40 (a member of the TNF receptor 'fainily, expressed on activated T cells and the only costimulatory T cell molecule known to be specifically up-regulated in human T cell leukaemia virus type-I (HTLV-I)-producing cells.) See J I nfnunol. 2000 Jul 1;165(1):263-70; Metalloproteases (associated with arthritis/cancers), including CG6512 Drosophila, human paraplegin, human FtsH, human AFG3L2, murine ftsH; angiogenic growth factors, including acidic fibroblast growth factor (FGF-1), basic fibroblast growth factor (FGF-2), Vascular endothelial growth factor / vascular permeability factor (VEGF/VPF), transforming growth factor-a (TGF a), tumor necrosis factor-alpha (TNF-a), angiogenin, interleukin-3 (IL-3), interleukin-8 (IL-8), platelet-derived endothelial growth factor (PD-ECGF), placental growth factor (PIGF), midkine platelet-derived growth factor-BB
(PDGF), fractalkine.
Stress proteins (heat shock proteins) HSPs are normally found intracellularly. When they are found extracellularly, it is an indicator that a cell has died and spilled out its contents. This unprogrammed cell death (necrosis) only occurs when as a result of trauma, disease or injury and therefore in vivo, extracellular HSPs trigger a response from the immune system that will fight infection and disease. A dual specific which binds to extracellular HSP can be localised to a disease site.
Proteins involved in Fc transport Brambell receptor (also known as FcRB):
This Fc receptor has two functions, both of which are potentially useful for delivery The functions are (1) The transport of IgG from mother to child across the placenta (2) the protection of IgG from degradation thereby prolonging its serum half life of IgG. It-is thought that the receptor recycles IgG from endosome.
See Holliger et al, Nat Biotechnol 1997 Jul;15(7):632-6.
Other proteins involved in Fe transport include the neonatal Fc receptor (FcRn) described in Gastinel et al., 1992, PNAS 89:638; and Roopenian et al., 2003 J.
Immunol. 170:3528.
Ligands according to the invention may designed to be specific for the above targets without requiring any increase in or increasing half life in vivo. For example, ligands according to the invention can be specific for targets selected from the foregoing wllich are tissue-specific, thereby enabling tissue-specific targeting of the dual specific ligand, or a dAb monomer that binds a tissue-specific therapeutically relevant target, irrespective of any increase in half-life, although this may result.
Moreover, where the ligand or dAb monomer targets kidney or liver, this may redirect the ligand or dAb monomer to an alternative clearance pathway in vivo (for example, the ligand may be directed away from liver clearance to kidney clearance).
Polypeptides useful for increasing half-life include, but are not limited to those shown in Annex I.
Increased Protease.Stability A further advantage of the present invention is that the PEGylated dAbs and dAb multimers described herein possess increased stability to the action of proteases.
Depending on the assay conditions, dAbs are generally intrinsically stable to the action of proteases. In the presence of pepsin, however, many dAbs are totally degraded at pH 2 because the protein is unfolded under the acid conditions, thus making the protein more accessible to the protease enzyme. The present invention provides PEGylated dAb molecules, including dAb multimers, wherein it is believed that the PEG polymer provides protection of the polypeptide backbone due the physical coverage of the backbone by the PEG polymer, thereby preventing the protease from gaining access to the polypeptide backbone and cleaving it. In a preferred embodiment a PEGylated dAb having a higher hydrodynamic size (e.g., to 500 kDa) is generated according to the invention, because the larger hydrodynamic size will confirm a greater level of protection from protease degradation than a PEGylated dAb having a lower hydrodynamic size. In one embodiment, a PEG- or other polymer-linked antibody single variable domain monomer or multimer is degraded by no more than 10% when exposed to one or more of pepsin, trypsin, elastase, chymotrypsin, or carboxypeptidase, wherein if the protease is pepsin then exposure is carried out at pH 2.0 for 30 minutes, and if the protease is one or more of trypsin, elastase, chymotrypsin, or carboxypeptidase, then exposure is carried out at pH 8.0 for 30 minutes. In a preferred embodiment, a PEG- or other polymer-linlced dAb monomer or multimer is degraded by no more than 10% when exposed to pepsin at pH 2.0 for 30 minutes, preferably no more than 5%, and preferably not degraded at all. In a further preferred embodiment, a PEG- or other polymer-linked dAb multimer (e.g., hetero- or homodimer, trirner, tetramer, octamer, etc.) of the invention is degraded by less than 5%, and is preferably not degraded at all in the presence of pepsin at pH 2.0 for 30 minutes. In a preferred embodiment, a PEG- or other polymer-linked dAb monomer or multimer is degraded by no more than 10% when exposed to trypsin, elastase, chymotrypsin, or carboxypeptidase at pH 8.0 for minutes, preferably no more than 5%, and preferably not degraded at all. In a further preferred embodiment, a PEG- or other polymer-linked dAb multimer (e.g., hetero- or homodimer, trimer, tetramer, octamer, etc.) of the invention is degraded by, less than 5%, and is preferably not degraded at all in the presence of trypsin, elastase, chymotrypsin, or carboxypeptidase at pH 8.0 for 30 minutes.
The relative ratios of protease:antibody single variable domain polypeptide may be altered according to the invention to achieve the desired level of degradation as described above. For example the ratio or protease to antibody single variable domain may be from about 1:30, to about 10:40, to about 20:50, to about 30:50, about 40:50, about 50:50, about 50:40, about 50:30, about 50:20, about 50:10, about 50:1, about 40:1, and about 30:1.
Accordingly, the present invention provides a method for decreasing the degradation of an antibody single variable domain comprising linking an antibody single variable domain monomer or multimer to a PEG polymer according to any of the embodiments described herein. According to this aspect of the invention, the antibody single variable domain is degraded by no more than 10% in the presence of pepsin at pH2.0 for 30 minutes. In particular, a PEG-linked dAb multimer is degraded by no more than 5%, and preferably not degraded at all in the presence of pepsin at pH 2.0 for 30 minutes. In an alternate embodiment, the antibody single variable domain is degraded by no more than 10% when exposed to trypsin, elastase, chymotrypsin, or carboxypeptidase at pH 8.0 for 30 minutes, preferably no more than 5%, and preferably not degraded at all.
Degradation of PEG-linked dAb monomers and multimers according to the invention may be measured using methods which are well known to those of skill in the art. For example, following incubation of a PEG-linked dAb with pepsin at pH
2.0 for 30 minutes, or with trypsin, elastase, chymotrypsin, or carboxypeptidase at pH
8.0 for 30 minutes, the dAb samples may be analyzed by gel filtration, wherein degradation of the dAb monomer or multimer is evidenced by a gel band of a smaller molecular weight than an un-degraded (i.e., control dAb not treated with pepsin, trypsin, chymotrypsin, elastase, or carboxypeptidase) dAb. Molecular weight of the dAb bands on the gel may be determined by comparing the migration of the band with the migration of a molecular weight ladder (see Figure 5). Other methods of measuring protein degradation are known in the art and may be adapted to evaluate the PEG-linked dAb monomers and multimers of the present invention.
Pharmaceutical Compositions. Dosage and Administration The antibody polypeptides of the invention can be incorporated into pharmaceutical compositions suitable for administration to a subject.
Typically, the pharmaceutical composition comprises a monovalent anti-CD40L antibody polypeptide and a pharmaceutically acceptable carrier. As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. The term "pharmaceutically acceptable carrier" excludes tissue culture medium comprising bovine or horse serum.
Examples of pharmaceutically acceptable carriers include one or more of water, saline, phosphate buffered saline, dextrose, glycerol, ethanol and the like, as well as combinations thereof. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition. Pharmaceutically acceptable substances include minor amounts of auxiliary substances such as wetting or emulsifying agents, preservatives or buffers, whicll enhance the shelf life or effectiveness of the antibody polypeptide.
The compositions as described herein may be in a variety of forms. These include, for example, liquid, semi-solid and solid dosage forms, such as liquid solutions (e.g., injectable and infusible solutions), dispersions or suspensions, tablets, pills, powders, liposomes and suppositories. The preferred form depends on the intended mode of administration and therapeutic application. Typical preferred compositions are in the form of injectable or infusible solutions, such as compositions similar to those used for passive immunization of humans with other antibodies. The preferred mode of administration is parenteral (e.g., intravenous, subcutaneous, intraperitoneal, intramuscurar).
Therapeutic compositions typically must be sterile and stable under the conditions of manufacture and storage. The composition can be formulated as a solution, microemulsion, dispersion, liposome, or other ordered structure suitable to high drug concentration. Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filter sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-f ltered solution thereof. The proper fluidity of a solution can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
The antibody polypeptides described herein can be administered by a variety of methods known in the art, although for many therapeutic applications, the preferred route/mode of administration is intravenous injection or infusion. The polypeptide can also be administered by intramuscular or subcutaneous injection.
As will be appreciated by the skilled artisan, the route and/or mode of administration will vary depending upon the desired results. In certain embodiments, the active compound may be prepared with a carrier that will protect the compound against rapid release, such as a controlled release formulation, including implants, transdermal patches, and microencapsulated delivery systems. Single immunoglobulin variable domains and other relatively small monovalent antibody polypeptides are well suited for formulation as extended release preparations due, in part, to their small size - the number of moles per dose can be significantly higher than the dosage of, for example, full sized antibodies. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Prolonged absorption of injectable compositions can be brought about by including in the composition an agent that delays absorption, for example, monostearate salts and gelatin.
Many methods for the preparation of such formulations are patented or generally known to those skilled in the art. See, e.g., Sustained and Controlled Release Drug Delivery Systems, J. R. Robinson, ed., Marcel Dekker, Inc., New York, 1978. Additional methods applicable to the controlled or extended release of polypeptide agents such as the monovalent antibody polypeptides disclo"sed herein are described, for example, in U.S. Patent Nos. 6,306,406 and 6,346,274, as well as, for example, in U.S.
Patent Application Nos. US20020182254 and US20020051808, all of which are incorporated herein by reference.
In certain einbodiments, a monovalent anti-CD40L antibody polypeptide can be orally administered, for example, with an inert diluent or an assimilable edible carrier. The compound (and other ingredients, if desired) may also be enclosed in a hard or soft shell gelatin capsule, compressed into tablets, or incorporated directly into the individual's diet. For oral therapeutic administration, the compounds may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the lilce. To administer a compound of the invention by other than parenteral administration, it may be necessary to coat the compound with, or co-administer the compound with, a material to prevent its inactivation.
Additional active compounds can also be incorporated into the compositions.
In certain embodiments, a monovalent anti-CD40L antibody polypeptide is coformulated with and/or coadministered with one or more additional therapeutic agents. For example, a monovalent anti-CD40L antibody polypeptide can be coformulated and/or coadministered with one or more additional antibodies that bind other targets (e.g., antibodies that bind other cytokines or that bind cell surface molecules), or, for example, one or more cytokines. Such combination therapies may utilize lower dosages of the administered therapeutic agents, thus avoiding possible toxicities or complications associated with the various monotherapies.
The pharmaceutical compositions of the invention can include a "therapeutically effective amount" or a "prophylactically effective amount" of a monovalent anti-CD40L antibody polypeptide. A "therapeutically effective amount"
refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result. A therapeutically effective amount of the antibody polypeptide can vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the monovalent anti-CD40L
antibody polypeptide to elicit a desired response in the individual. A therapeutically effective amount is also one in which any toxic or detrimental effects of the antibody or antibody portion are outweighed by the therapeutically beneficial effects. A
"prophylactically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result.
Typically, because a prophylactic dose is used in subjects prior to or at an earlier stage of disease, the prophylactically effective amount will be less than the therapeutically effective amount.
Dosage regimens may be adjusted to provide the optimum desired response (e.g., a therapeutic or prophylactic response). For example, a single bolus may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. It is advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
A non-limiting range for a therapeutically or prophylactically effective amount of a monovalent anti-CD40L antibody polypeptide is 0.1-20 mg/kg, more preferably 1-10 mg/kg. It is to be noted that dosage values can vary with the type and severity of the condition to be alleviated. It is to be furtller understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the administering clinician.
The efficacy of treatment with a monovalent anti-CD40L antibody polypeptide as described herein is judged by the skilled clinician on the basis of improvement in one or more symptoms or indicators of the disease state or disorder being treated. An improvement of at least 10% (increase or decrease, depending upon the indicator being measured) in one or more clinical indicators is considered "effective treatment," although greater improvements are preferred, such as 20%, 30%, 40%, 50%, 75%, 90%, or even 100%, or, depending upon the indicator being measured, more than 100% (e.g., two-fold, three-fold, ten-fold, etc., up to and including attainment of a disease-free state. Indicators can be physical measurements, e.g., enzyme, cytokine, growth factor or metabolite levels, rate of cell growth or cell death, or the presence or amount of abnormal cells. One can also measure, for example, differences in the amount of time between flare-ups of symptoms of the disease or disorder (e.g., for remitting/relapsing diseases, such as multiple sclerosis).
Alternatively, non-physical measurements, such as a reported reduction in pain or discomfort or other indicator of disease status can be relied upon to gauge the effectiveness of treatment. VWhere non-physical measurements are made, various clinically acceptable scales or indices can be used, for example, the Crohn's Disease Activity Index, or CDAI (Best et al., 1976, Gastroenterology 70: 439), which combines both physical indicators, such as hematocrit and the number of liquid or very soft stools, among others, with patient-reported factors such as the severity of abdominal pain or cramping and general well-being, to assign a disease score.
As the term is used herein, "prophylaxis" performed using a composition as described herein is "effective" if the onset or severity of one or more symptoms is delayed or reduced by at least 10%, or abolished, relative to such symptoms in a similar individual (human or animal model) not treated with the composition.
Whereas the monovalent anti-CD40L antibody polypeptides described herein must bind human CD40L, where one is to evaluate its effect in an animal model system, the polypeptide must cross-react with one or more antigens in the animal model system, preferably at high affinity. One of skill in the art can readily determine if this condition is satisfied for a given animal model system and a given monovalent anti-CD40L antibody polypeptide. If this condition is satisfied, the efficacy of the monovalent anti-CD40L antibody polypeptide can be examined by administering it to an animal model under conditions which mimic a disease state and monitoring one or more indicators of that disease state for at least a 10% improvement.
Animal Models:
Monovalent anti-CD40L antibody polypeptides as described herein are useful for the treatment of autoimmune disorders in which CD40/CD40L signaling is inappropriately active. There are several animal models in which the therapeutic efficacy of a given monovalent anti-CD40L antibody polypeptide can be assessed, as discussed below.
Systemic Lupus Erythematosis (SLE):
Anti-CD40L antibody treatment prevents the development of lupus-like nephritis in NZB/NZW and SNF1 SLE mice. Treatment of SNFl mice with anti-CD40L antibody reverses established nephritis and preserves kidney function.
See, e.g., Mohan et al., 1995, J. Iminunol. 154: 1470-1480; Early et al., 1996, J.
Immunol.
157: 3159-3164; Kalled et al., 1998, J..Immunol. 160: 2158-2165 and Chess, 2001, "Blockade of the CD40L/CD40 Pathway," in Therapeutic Immunology 2"d Edition, Austen, Burakof, Rosen and Strom, Eds., Blackwell Sciences (Pubs.), pp 441-456.
Multiple Sclerosis:
Specific blockade of CD40L at the time of immunization markedly suppresses the incidence, mortality, day of onset, and clinical scores of experimental autoimmune encephalomyelitis (EAE) in B 10P IL and (PLJ x SJL)F1 mice induced by eitller myelin basic protein or PLP myelin antigens. See, for example, Gerritse, 1996, Proc.
Natl. Acad. Sci. U.S.A. 93: 2494; Grewal et al., 1996, Science 273: 186; Laman et al., 1998, Mult. Scler. 4: 14; and Chess, 2001, supra.
Rheumatoid Arthritis:
Anti-CD40L blocks the development of joint inflammation, serum antibody titers to collagen, the infiltration of inflammatory cells into the synovial tissue, ant the erosion of cartilage and bone in collagen-induced arthritis. See, e.g., Durie et al., 1993, Science 261: 132; and Chess, 2001, supra.
Insulin-dependent Type I Diabetes Models:
The non-obese diabetic (NOD) mouse spontaneously develops T cell dependent autoimmune diabetes. Anti-CD40L monoclonal antibody treatinent of 3 to 4 week old NOD females (the age- at which insulitis typically begins) completely prevented the insulitis and diabetes. Cytokine analysis revealed a dramatic decrease in IFN-g and IL-2 release without a concomitatnt increase in IL-4 production by T
cells from anti-CD40L-treated mice. See, e.g., Balasa et al., 1997, J.
Immunol. 159:
1420; and Chess, 2001, supra.
Inhibition of Allograft and Xenograft Transplant Rejection:
Anti-CD40L prevents the development of renal rejection of fully allogeneic grafts in mice. Moreover, the survival of renal allografts transplanted into nephrectomized rehsus monkeys is typically prolonged by anti-CD40L therapy alone.
Similarly, anti CD40L therapy has prevented graft rejection of skin, islet cells and cardiac transplants as well as GVHD in rodents. See, e.g., Kirk et al., 1997, Proc.
Natl. Acad. Sci. U.S.A. 94: 8789-8794; Parker et al., 1995, Proc. Natl. Acad.
Sci.
U.S.A. 92: 9560; Larsen et al., 1996, Transplantation 61: 4; and Chess, 2001, supra.
Uses of Monovalent Anti-CD40L Antibody Polypeptides Anti-CD40L antibody polypeptides as described herein are useful for the treatment or prevention of diseases or disorders in which inappropriate activation of a CD40L/CD40-mediated pathway is involved. In particular, autoimmune diseases frequently involve inappropriate regulation or activity of CD40L/CD40 pathways.
Administration of an anti-CD40L antibody polypeptide as described herein to an individual suffering from such a disease, can reduce one or more symptoms of the disease. Non-limiting examples of diseases for which the antibody polypeptides described herein can be therapeutically useful include Systemic Lupus Erythematosus (SLE), Idiotypic Thrombocytopenic Purpura (ITP), transplant rejection, Crohn's Disease, Inflammatory Bowel Disease (IBD), colitis, asthma/allergy, atherosclerosis, Myasthenia Gravis, immune response to recombinant drug products, e.g., factor VII
in hemophilia, Multiple Sclerosis, Psoriasis, Rheumatoid Arthritis, Ankylosing Spondylitis, Coronary Heart Disease, and Diabetes, including Type 1 and/or Type 2 Diabetes.
The anti-CD40L antibody polypeptides described herein are additionally useful in the way that generally any antibody preparation is useful, e.g., for in vivo imaging or diagnostic uses, in vitro diagnostic uses, etc. For these and otller uses it may be desirable to, label the anti-CD40L antibody polypeptides, e.g., with a fluorescent, colorimetric, enzymatic or radioactive label. Methods of labeling antibody polypeptides are well known in the art.
EXAMPLES
Example 1. Biotinylation of Recombinant CD40L
Recombinant human soluble CD40L (PeproTech) was biotinylated and used during phage selections. Reagents, equipment and sources from which they are available are provided in Table 1.
Biotinylation of CD40L was performed by incubating CD40L (0.5mg/ml) with EZ-Lin1cTM Sulfo-NHS-LC-Biotin [Sulfosuccinimidyl-6-(biotinamido)hexanoate]
(Pierce) at a molar ratio of 5:1 on ice for 2 hours according to the product instructions. The biotinylation reaction mixture was then dialysed against 3 exchanges of PBS (1000x sample volume) in a Slide-A-Lyzer Dialysis Cassette at 4 C to remove the unincorporated biotinylation reagent.
The biotinylated-CD40L was tested by receptor binding assay for binding to CD40/Fc to confirm its biological activity. Quality of biotin-CD40L was also monitored by analysing on a NuPaGE 4-12% Bis-Tris gel and detected by Simply Blue Safe-Stain (Invitrogen) (Figure la), and western-blotting by probing with Streptavidin-HR.P (Figure lb). The biotinylated-CD40L was further analysed by mass spectrometry with the majority of CD40L subunits containing 1 or 2 biotin moieties (data not shown).
Table 1.
Equipment/Reagent Suggested or required supplier Recombinant human PeproTech, Cat No:
soluble CD40 310-02 ligand/TRAP
Reconstituted in 5 mM
Sodium phosphate, pH5.0 to concentration of 0.5 mg/ml EZ-LinkTM Sulfo-NHS- Pierce, Cat No: 21335 LC-Biotin Slide-A-Lyzer Pierce, Cat No: 66110 Dialysis Cassette Recombinant human R&D Systems, Cat No:
CD40/Fc chimera 1493-CD
NuPAGE 4-120/o Bis- Invitrogen life Tris gel technologies Ltd Cat. No NP0322 Streptavidin-HRP Amersham Biosciences Cat No: 1231V
InvitrogenTM Simply Invitrogen Cat Blue Safe-stain No:LC6065 Example 2. PhaLye Selections using Biotinylated Antigen The Domain Antibody (dAb) libraries are based on a single human framework for the VH (DP47 and JH4b) and for the VK (DPK9 and JK1) with side chain diversity incorporated at positions in the antigen binding site that make contact with antigen in known molecular structures and mirror residues diversified in the human antibody repertoire. The antibodies are displayed as fusion proteins covalently linked to the N - terminus of the Fd-phage protein pIII, using the phage vector pDOM4 (Fd-Tet) with encodes the Fd phage genome with dAb expression under the control of the gene-III promoter. The dAb cassette consists of (5' to 3'): eukaryotic leader sequence, dAb, myc tag, gIII. The vector contains both the M13 and colEl origins of replication and is selectable using tetracycline. The VH and V,; libraries each have a calculated size of over 1x1010 molecules. Reagents, equipment and sources from which they are available are provided in Table 2.
Approximately lxl011 phage from the each of the Domantis dAb libraries were incubated in a final volume of 1 ml PBS containing 2% MarvelTM at room temperature for I h. Biotinylated antigen was added to the blocked phage such that the phage antigen mixture had a final concentration of 2% MarvelTM in PBS. The antigen concentration used for the first round of selection was 60 nM; the antigen concentration was decreased to 6 nM for round 2, and to 0.6 nM for round 3.
The antigen/phage mix was incubated for I h at room temperature with rotation at -rpm.
For each selection, 100 l of streptavidin-coated paramagnetic beads (Dynal Biotech) were prepared by washing once in 1 ml of PBS containing 0.1% Tween-20 followed by a second wash in 1 ml of PBS. The beads were then blocked in 1 ml of PBS containing 2% MarvelTM in a 2 ml eppendorf tube at room temperature on a rotating wlleel for 1 h.
The tube containing the blocked streptavidin-coated magnetic beads was placed into a magnetic holder, enabling capture of the magnetic beads. The supernatant was removed and the beads resuspended in the antigen/phage mix.
This mixture was rotated for 10 min to allow for bead capture of phage/antigen complexes.
The beads were captured using a magnetic holder and repeatedly washed 19 times using 1 ml of PB S containing 0.1 % Tween-20, followed by a final wash of I ml PBS. The eppendorf tubes were changed following washing steps 3, 9, 15 and 19 to minimise background phage carryover.
The washed beads were then recaptured and all washing solution removed.
The phage were eluted through resuspension in 500 l of trypsin solution (50 l of 10 mg/mi trypsin stock solution added to 450 l PBS, freshly diluted) and rotated for 10 min at room temperature. The eluted phage were recovered by capturing the beads using the magnetic holder and the liquid containing the eluted phage recovered. The eluted phage were used to infect E. eoli TG1 to prepare phage for a further round of selection.
The eluted phage (250 41) were mixed with 1.75 ml of log phase E. coli TGI
(OD600 between 0.3 and 0.6) and infection allowed to occur for 30 min at 37 C
without shaking. The infected E. coli TGI culture was centrifuged at 11,600 g in a micro centrifuge for 1 min at room temperature. The pelleted bacteria were resuspended in 100 ,l of 2xTY and plated on regular 9 cm diameter plates containing TYE supplemented with 15 g/ml tetracycline. Plates were grown at 37 C
overnight.
After overnight growth, 2 ml of 2xTY containing 15% glycerol was added to the culture plates and cells loosened with a spreader, ensuring the cells were thoroughly mixed. Two millilitres of the culture were recovered by pipetting into a cryo-vial, from which 50 l was used to inoculate 50 m1 of 2xTY supplemented with 15 g/ml tetracycline. The remaining cells in the cryo-vial were stored at -80 C.
The 50 ml culture was grown at 37 C for 16 to 24 hours with shaking at 250 rpm.
Following overnight growth, the culture was centrifuged at 3,300 g for 15 min to pellet the bacteria. The phage were then precipitated from the supernatant through the addition of 10 ml of PEG/NaCI to 40 ml of clarified supernatant. The phage/PEG
solution was mixed and incubated on ice for at least 1 h. To pellet the phage, the solution was centrifuged at 3,300 g for 30 min at 4 C. The supernatant was decanted and any remaining supernatant removed by aspiration.
The resulting phage pellet was resuspended in 2 ml PBS and centrifuged at 11,600 g for 10 min in a micro centrifuge to remove any remaining bacterial debris.
The supernatant was filtered through a 0.45 zn filter (Sartorius, Minisart).
The resuspended phage solution was used for the next round of selection.
Table 2 Eguipment/Reagent Suggested or Ins>irument setiring, required supplier reagent preparation Dynabeads M-280 Dynal Biotech UK Resuspend Streptavidin (Prod. 11 Bassendale Road, thoroughly through No.: 112.05) Croft Business Park, repeated pipetting.
Bromborough, Wirral UK
Tween 20 Sigma Chemical 0.1% in PBS.
Company Ltd.
99.5% dried skim MarvelT" (premier 2% in PBS (prepare milk powder brands) from fresh and do not supermarkets. store).
Trypsin (T-8642) Type Sigma Chemical made up in 50 mM
XIII from Bovine Company Ltd. Tris-HCI pH7.4; 1 mM
Pancreas. CaC12 and stored at -Fancy Road 20 C
Dorset BH17 7NH The trypsin stock U.K solution should be stored aliquotted at -Tel +44 1202 733114 20 C to avoid autoproteolysis.
Fax +44 1202 PEG/NaCI Sigma Chemical 20% Polyethylene Company Ltd. glycol 8000 [formally known as 6000], 2.5 M NaCI pre-chilled to 40C.
Dynal MPC-S Dynal Biotech UK
magnetic particle 11 Bassendale Road, concentrator (Prod. Croft Business Park, Bromborough, Wirral No.: 120.20) CH62 3QL
UK
2xTY 16 g Tryptone, 10 g Yeast Extract and 5 g NaCI in 1 litre.
Autoclave (1210C, 15 min) and store at RT
Example 3: Cloning Enriched PhaQe Selection Outputs into the Soluble dAb Expression Vector pDOM5 Following the second and third rounds of selection, E. coli cells infected with the enriched dAb displaying fd-phage populations were obtained. An aliquot of these cells was used to prepare phage DNA and the enriched V-genes excised by digestion using the restriction endonucleases, SalI and NotI. The purified V-genes were ligated into the corresponding sites of pDOM5 (expression vector derived from pUC 119 with LacZ
promoter, eukaryotic leader, dAb cloning site, myc tag), and the ligated DNA
used to electro-transform E. coli HB2151 cells which were grown overnight on agar plates containing the antibiotic carbenicillin. The resulting colonies were induced to express dAb protein either as 200 l microcultures or 50 ml cultures. The resulting dAb was analysed for inhibitory activity using the CD40L receptor binding assay.
Following selection of phage, pDOM4 DNA was purified from the cell pellet obtained from a 50 ml overnight E. coli culture using the QIA.filter Plasmid Midi DNA purification kit from Qiagen, following the manufacturer's instructions.
The dAb genes were excised from the pDOM4 vector by mixing: 10 l of 10x SalI
buffer;
1 l of 100x BSA; 20 g of purified DNA fragment; 2.5 ul of SalI enzyme (10 U/
l);
2.5 l of NotI enzyme (10 U/ l); the digestion mix was made up to a final volume of 100 1 using sterile water. The digestion mix was incubated for 5 hours at 37 C.
The digested DNA samples were electrophoresed on a 1.5% agarose gel and the band corresponding to the dAb V-genes (-324 bp to 372 bp) was excised from the gel. The dAb gene DNA was purified from the gel slice using the QlAquick Gel Extraction kit from Qiagen, following the manufacturer's instructions.
The expression vector pDOM5 was digested with SaII and Notl as follows: 10 l of lOx SaII buffer; 1 l of 100x BSA; 20 g of plasmid pDOM5; 1.5 l of Sall enzyme (10 U/ l); 1.5 l of NotI enzyme (10 U/ l); the digestion mix was made up to a final volume of 100 l using sterile water. The digestion mix was incubated for 2 hours at 37 C. The digested vector fragment was purified using the QlAquick PCR
Purification Kit.
The digested pDOM5 and digested dAb genes were ligated by mixing: 2 1 of I Ox T4 DNA ligase buffer; 400 ng of digested pDOM5 vector; 100 ng of digested dAb genes;
I l of T4 DNA ligase (400 U/ l); the ligation mix was made up to 20 l with sterile water. The ligation mixes were incubated for 2 hours at 25 C.
'Two microlitres of the ligation mix was transferred to the bottom of a pre-chilled (on ice) 0.2 cm electroporation cuvette to which 100 l of electrocompetent E.
coli HB2151 cells were added. The DNA / cell mixture was incubated on ice for min, then electroporated at 2.5 kV (25 gF, 200 Q). One millilitre of 2xTY was imnlediately added to the cuvette and the cells gently resuspended. The resuspended cells were transferred to a 14 ml disposable culture tube and incubated for 1 hour at 37 C with shaking at 250 rpm. Dilutions of the cells from 10'0 to 10"3 were plated on regular 9 cm diameter plates containing TYE supplemented with 5% glucose and g/ml carbenicillin. The cells are incubated overnight at 37 C in an inverted position.
Reagents, equipment and sources from which they are available are provided in Table 3.
Table 3 Eqeeipment/i2eagent Suggested or required Instrument supptier setting, reagent preparation QIAfilter Plasmid Midi Qiagen Ltd Supplied as kit DNA purification kit Cat. No.: 12143 SaII restriction New England Biolabs endonuclease + lOx Sa/I buffer Cat. No.: R0138S
NotI restriction New England Biolabs endonuclease + lOx NotI buffer + 100x Cat. No.: R0189S
BSA
QIAquick Gel Qiagen Ltd Supplied as kit Extraction kit Cat. No.: 28706 Expression plasmid pDOM5 T4 DNA ligase + lOx New England Biolabs The T4 DNA
T4 DNA ligase buffer ligase buffer Cat. No.: M0202L should be stored aliquotted at -20 C.
Repeated freeze-thawing should be avoided to minimise the hydrolysis of ATP in the buffer.
Example 4. Microwell Expression of Soluble dAbs Following cloning of the selected phage dAb outputs into pDOM5, individual bacterial colonies were inoculated as microwell cultures and induced using IPTG to express dAb protein which was analysed for inhibitory activity using the CD40L
receptor binding assay. Reagents, equipment and sources from which they are available are provided in Table 4.
Individual bacterial colonies were carefully picked to ensure that contamination from neighbouring colonies was avoided. The picked colonies were used to inoculate 96 well cell culture plates containing 100 l per well of 2xTY
supplemented with 5% glucose and 50 g/ml carbenicillin. The lids were placed on the cell culture plates which were incubated overnight in a HiGro orbital shaker (GeneMachines, 935 Washington St, San Carlos, CA 94070, USA) under a humidified atmosphere at 37 C with shaking at 450 rpm (4 mm shaking orbital diameter), with gas (30% 02 + 70% N,)) pulsed for 10 seconds every 5 minutes at a flow rate of 5 SLPM (standard litres per minute). [These plates are referred to as Master Plates].
Following overnight growth, a 96 well transfer device was used to transfer between 1-5 l of the bacterial culture into a fresh 96 well culture plate containing 100 l per well of 2xTY supplemented with 0.1 % glucose and 50 g/ml carbenicillin.
The freshly inoculated plates were incubated at 37 C for 3 to 4 h(shaking at 450 rpm, gas (30% 02 + 70% N,)) pulsed for 10 seconds every 5 minutes at a flow rate of 5 SLPM) until the culture OD600 reached approximately 1Ø The cultures were then induced by the addition of 100 l per well of 2xTY containing 50 g/ml carbenicillin and 2 mM IPTG (final IPTG concentration of 1 mM) and incubated overnight at 30 C with shaking at 450 rpm, with gas (30% 02 + 70% N2) pulsed for 10 seconds every 5 minutes at a flow rate of 5 SLPM. [These plates are referred to a Induction Plates].
Glycerol stocks of the original Master Plates were made by the addition of 100 l per well of 2xTY containing 50% sterile glycerol. These plates were stored at -80 C.
Following overnight incubation of the Induction Plates, the bacterial cells were pelleted by centrifugation at 1,800 g for 10 min at 4 C. The supernatant (containing expressed dAb) was then analysed to determine if dAbs were capable of inhibiting binding of CD40L to CD40-Fc fusion in a receptor binding assay.
Table 4 Equipment/Reagent Suggested or Instrument setting, required supplier reagent preparation 96 Well Cell Culture Corning Incorporated, Cluster with round Costar.
bottom and lid, Non- Number:3799 pyrogenic, Polystyrene 2xTY 16 g Tryptone, 10 g Yeast Extract and 5 g NaCf in 1 litre.
Autoclave (1210C, 15min) and store at RT
Example 5. Expression of dAb in E. coli at 50 ml To generate greater quantities of dAb protein for analysis, 50 ml cultures were used for induction. A single colony of the desired dAb (for example DOM-24) grown on TYE plates was inoculated into 10 ml 2xTY supplemented with 5% glucose and 50 g/ml carbenicillin in a 30 ml universal tube and grown overnight at 37 C
with shaking at 250 rpm. Five hundred microlitres of the overnight culture was added into 50 ml of 2xTY supplemented with 0.1% glucose and 50 g/ml carbenicillin and grown,at 37 C with shaking at 250 rpm. The OD600 of the culture was monitored regularly in comparison with sterile 2xTY and at an OD600 of 0.9 the culture was induced by the addition of 1 M IPTG to a final concentration of 1 mM. The inoculated culture was incubated at 30 C with shaking at 250 rpm overnight.
The next day, the culture was centrifuged at 6000 g for 15 min at 4 C and the clarified supernatant mixed with 100 l of protein-A streamline or protein-L agarose (pre-washed with 5 mM MgSO4) overnight at 4 C. The supernatant/bead mixture was then centrifuged at 180 g at 4 C for 2 minutes. The supernatant was decanted and the retained beads washed with 10 ml of PBS containing 0.5M NaCl. The bead solution was transferred into a 96 well Whatman filter plate and the beads washed once with 400 l of PBS containing 0.5M NaCI, then once with 400 l of PBS, followed by centrifugation for 2 minutes at 180 g after each washing step. dAb protein was eluted using 70 l of 0.1 M glycine (pH 2.0) and the solution neutralised by the addition of 40 1 of 1 M Tris-HCI (pH 8.0). The purified dAb concentration was determinate by OD2s0.
Reagents, equipment and sources from which they are available are provided in Table 5.
Table 5 Equipment/Reagent Suggested or Instrument setting, required supplier reagent preparation TYE 15 g Bacto-Agar, 8 g NaCI, 10 g Tryptone, g Yeast Extract in 1 litre water. Autoclave (1210C, 15 min) and store at RT
2xTY 16 g Tryptone, 10 g Yeast Extract and 5 g NaCl in 1 litre.
Autoclave (7210C, min) and store at RT
1 M IPTG stock made up in MQ
water is sterile filtered through 0.22 pM filter and stored in aliquots at -Carbenicillin 50 mg/mI stock made in water, 0.2 rn filter sterilised and stored in aliquots at -200C
40% glucose solution 0.2 m filter sterilise, store at RT
5 mM MgSO4 prepare fresh from 1 M stock solution, 0.2 m filter sterilise and store at RT
0.5M NaCI/PBS Autoclave or 0.2 m filter sterilise and store at RT
Protein A agarose Sigma P3476 store 40C
Protein L agarose Sigma P3351 store 40C
Streamline rProtein A Amersham store 40C
Biosciences, cat no. 17-1281-02 (300 mi) 1 M Tris-HCI, pH 8.0 0.2 m filter sterilise or autoclave and store at RT
0.2 M Glycine, pH2.0 0.2 m filter sterilise and store at 40C
Example 6: CD40L Receptor Bindintr Assay The CD40L assay was used to measure the binding of CD40L to CD40 and the ability of binding entities (eg, monvalent antibody fragments such a dAbs) to bloclc this interaction, as described below and shown schematically in Figure 7. (The soluble proteins from R&D Systems are CD40/Fc = homodimer and CD40L =
homotrimer).
A 96 well Nunc Maxisorp assay plate was coated overnight at 4 C with 100 l per well of recombinant human CD40/Fc (R&D Systems) at 0.5 g/ml in carbonate buffer. The plate was washed 3 times with 300 1 of 0.05% Tween/PBS and 3 times with 300 l of PBS using a Tecan plate washer. The wells were blocked using 200 ,l of PBS containing 2% (w/v) BSA and incubated for a minimum of I h at room temperature. The wells were washed as above, then 50 l of purified dAb protein (or unpurified supernatant containing dAb from a micro-culture expression) was added to each well. To each well 50 l of CD40L, at 6 ng/ml in diluent (for a final concentration of 3 ng/ml), was also added and the plate incubated for 1 hr at room temperature.
The plate was washed as described previously and 100 l biotinylated anti-CD40L antibody, 0.5 g/ml in diluent, was added and incubated for 1 hr at room temperature. The plate was washed as described above, then 100 l HRP
conjugated anti-biotin antibody (1:5000 dilution in diluent) added to each well and the plate incubated for 1 hr at room temperature. The plate was washed again as described above using a Tecan plate washer and the assay developed using 100 l of SureBlue 1-Component TMB MicroWell Peroxidase solution (the plate was left at room temperature for up to 20 min). The reaction was stopped by the addition of 100 l I
M hydrochloric acid. The OD450õn, of the plate was assayed within 30 minutes of acid addition. The OD4,onm is -proportional to the amount of bound streptavidin-HRP
conjugate, therefore the greater the degree of dAb inhibition the lower the OD450,,,T, of the resulting signal. Reagents, equipment and sources from which they are available are provided in Table 6.
Controls The following controls were included:
= 0 ng/ml CD40L (diluent only) = 3 ng/ml CD40L
= 3 ng/ml CD40L with 1 g/ml anti-CD40L antibody Table 6 Equipment/Reagent Suggest or required Reagent preparation supplier (specify) F96 Maxisorp 96 well Nunc, Cat No: 439454 immunoplate 0.2M sodium Pierce, Cat No: 28382 Dissolve 1 sachet in carbonate bicarbonate 500 mi deionised water buffer pH9.4 and keep solution.at 4 C
Recombinant human R&D Systems, Cat No: Stock 50 pg/ml at-80 C
CD40/Fc chimera 1493-CD
Phosphate buffered Sigma, Cat No: P4417 lOx solution100 tablets/L
saline (PBS) water.
Wash buffer 0.05% Tween-20/PBS
Diluent 0.1% BSA, Ø05%
Tween-20 in PBS
Block 2% BSA in PBS
Recombinant human R&D Systems, Cat No: Stock 50 pg/ml at-80 C
Neutralising anti- Calbiochem, Cat No: Stock 1 mg/ml at 4 C
CD40L antibody 217595 Biotinylated anti- R&D Systems, Cat No: Stock 50 pg/ml at -80 C
CD40L antibody BAF617 Anti-biotin-HRP Stratech, Cat No: Stock 800 g/mi at -BOC, conjugate 200-032-096 diluted 1:5000 in antibody diluent. Keep for 1 week only.
SureBlue TMB 1- KPL, Cat No: 52-00-00 at 4 C .
component microwell peroxidase substrate Example 7: Results Receptor binding data for.the most potent inhibitors is summarised in Figures 2, 3, and 4, and in Table 7, below. Table 8, below, provides DNA and translated amino acid sequence of unique dAbs identified in the receptor binding assay as inhibiting CD40L binding to CD40.
Figure 2 shows a dose response receptor binding assay(RBA) readout, analysing the inhibition of CD40L binding to CD40-Fc by dAbs DOM-10, -20, -27, -30, -31, -62, -77, titrated from 1 M down to 10 pM. dAbs DOM-20, -30, and -31 are the most potent, with IC50 values of approximately 8 nM.
Figure 3 shows a dose response receptor binding assay readout, analysing the inhibition of CD40L binding to CD40-Fc by dAbs DOM-4 and DOM-5, titrated from 1 M down to 500 pM. The IC50 values for dAbs DOM-5 and DOM-4 are approximately 3 nM and 100 nM respectively.
Figure 4 shows a dose response receptor binding assay readout, analysing the inhibition of CD40L binding to CD40-Fc by dAb DOM-24, titrated from 100 nM
down to 0.5 pM. The data were curve-fitted using GraphPad Prism software.
Table 7 Clone Name dAb Type IC50 (nM) DOM-8 VK 900.
DOM-24 VH 0.417 approx.
Table 8: Summary of dAbs exhibitina a range of CD40L inhibitory IC50 values as determined usiny the CD40L / CD40-Fc receptor inhibition assay.
The DNA and translated amino acid sequence of unique dAbs identified in the receptor binding assay as inhibiting CD40L binding to CD40 are detailed below:
DOM-2 SEQ ID NO: 7 E V Q L I. E S G G G L V Q P G G S L R L S C A A S G F T F S D
Y E M =
CCTCCGGATT CACCTTTTCT
GATTATGAGA
GGAGGCCTAA GTGGAAAAGA
CTAATACTCT
= M W V R Q A p G K G L E W V S T I T S D G I S T Y Y A. D S V K G R =
ATGGTATTTC TACATACTAC GCAGACTCCG
TAATGAAGCC TACCATAAAG P_TGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I F R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
K S G
201 GTTCACCATC TTCCGCGACA ATTCCAAGAA CACGCTGTAT CTGCP.AATGA ACAGCCTGCG
TGCCGAGGAT ACCGCGGTAT ATTACTGTGC
GAAAAGTGGG
CAAGTGGTAG AAGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTA
TGGCGCCATA TAATGACACG
CTTTTCACCC
R F F D Y W G Q G T L V T V S S
301 AGGTTTTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 94) TCCAAAAAAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 95) DOM-4 SEQ ID NO: 8 Y E M =
CCTCCGGATT CACCTTTGAT
AATTATGAGA
AGGACACGTC GGAGGCCTAA GTGGAAACTA
TTAATACTCT
= T W V R Q A P G K G L E W V S S I T S D G T S T Y Y A D S V
K G R =
101 TGACGTGGGT CCGCCAGGCT CCP_GGGAAGG GTCTAGAGTG GGTCTCP_TCT ATTACGAGTG
ATGGTACTTC GACATACTAC GCAGACTCCG
TGAAGGGCCG
ACTGCACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTAGA TAATGCTCAC TACCATGAAG
CTGTATGATG CGTCTGP_GGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
R P N
201 GTTCACCATC TCCCGCGACA ATTCCAAGAP_ CACGCTGTAT CTGCAAATGA ACAGCCTGCG
TGCCGAGGAT ACCGCGGTAT ATTACTGTGC
GAAACCTAAT
CAAGTGGSAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTA
TGGCGCCATA TAATGACACG
CTTTGGATTA
301 CCGCCGTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 96) GGCGGCAAAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 97) DOM-5 SEQ ID NO: 9 Y E M =
3~ 1 GAGGTGCAGC TGTTGGAGTC TGGGGGAGGC TTGGTACAGC CTGGGGGGTC CCTGCGTCTC
TCCTGTGCAG CCTCCGGATT CACCTTTGAT
GGGTATGAGA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGAAACTA
CCCATACTCT
A W V R Q A P G K G L E W V S S I T S D G T S T Y Y A D S V
K G R =
ATGGTACGAG TACATACTAC GCAGACTCCG
TGAAGGGCCG
ACCGCACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTAGA TAATGCTCAC TACCATGCTC
ATGTATGATG CGTCTGAGGC ACTTCCCGGC
F T I S R D ld S E 14 T L Y L Q M ld S L R A E D T A V Y Y C A
K P G
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GP.AACCGGGG
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CTTTGGCCCC
L R F D Y W G Q G T L V T V S S
301 CTGCGTTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 98) GACGCAAAAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NOc 99) DOM-7 SEQ ID NO: 10 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F N L
Y E M =
CCTCCGGATT CACCTTTPAT
TTGTATGAGA
CTCCACGTCG ACAACCTCAG P_CCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCT_taA GTGGU-ATTA
AACATACTCT
T W V R Q A P G K G L E W V S S I T S D G V S T Y Y A D S V
K G R =
ATGGTGTTTC TACATACTAC GCAGACTCCG
TG.4AGGGCCG
ACTGPACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTAGA TAATGATCAC TACCACAAAG
ATGTATGP_TG CGTCTGAGGC
ACTTCCCGGC
F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
K A G
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAAAGCTGGG
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CTTTCGACCC
301 GTGATTTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 100) CACTAAAAAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 101) DOM-8 SEQ ID NO: 11 D I Q M T Q S P S S L S A S V G D R V T I T C R P S Q F I D T
S L E =
1 GACP_TCCAGA TGACCCAGTC TCCP_TCCTCC CTGTCTGCAT CTGTAGGAGA CCGTGTCACC
ATCACTTGCC GGGCAAGTCA GTTTPTTGAT
ACGTCGTTAG
CTGTAGGTCT ACTGGGTCAG AGGTAGGAGG GACAGACGTA GACATCCTCT GGCACAGTGG TAGTGAACGG
CCCGTTCAGT CAAATAACTA
TGCAGCAATC
= W Y Q Q K P G K A P K L L I Y D G S H L Q S G V P S R F S G
S G S = ' TGCAAAGTGG GGTCCCATCA CGTTTCAGTG
GCAGTGGATC
TCACCATAGT CGTCTTTGGT CCCTTTCGGG GATTCGAGGA CTAGATACTA CCCAGGGTAA ACGTTTCACC
CCAGGGTAGT GCAAAGTCAC
CGTCACCTAG
= G T D FT L T I S S L Q P E D L A T Y Y C Q Q Y W V L P L T
F G Q
201 TGGGACAGAT TTCACTCTCA CCATCAGCAG TCTGCAkCCT GAAGATTTAG CTACGTACTA
CTGTCAACAG TATTGGGTTC TTCCTCTGAC
GTTCGGCCAA
ACCCTGTCTA AAGTGAGAGT GGTAGTCGTC AGACGTTGGP CTTCTAAATC GATGCATGAT GACAGTTGTC
ATAACCCAAG AAGGAGACTG
CAAGCCGGTT G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG (SEQ ID N0: 102) CCCTGGTTCC ACCTTTAGTT TGCC (SEQ ID NO: 103) DOM-10 SEQ ID NO: 12 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F I A
Y D M =
CCTCCGGATT CACCTTTATS
GCTTATGATA CTCCACGTCG ACAACCTCAG ACCCCCTCCG AATCATGTCG GACCCCCCAG GGACGCAGAG
AGGACACGTC GGAGGCCTAA GTGGAAATAA
CGAATACTAT
S W V R Q A P G K G L E W V S W I D E W G L Q T Y Y A D S V
K G R =
GGGGTCTGCA GACATACTAC GCAGACTCCG
TGAAGGGCCG
ACTCAACCCA GGCGGTCCGA GGTCCCTTCC CAGACCTCAC CCAGAGTACC TAACTACTCA CCCCAGACGT
CTGTATGA_TG CGTCTGAGGC
ACTTCCCGGC
'== F T'I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C P_ K K T
201 GTTCACCATC TCCCGCGACA ATTCCAAGAP. CACGCTGTAT CTGCAAATGA ACAGCCTGCG
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAAAAAGACG
C.WiGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATP. GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCP_TA TAATGACACG
CTTTTTCTGC
301 CCTGAGGAGT TTGACTACTG GGGTCAGGGA ACCCTGGTCA CCGTCTCGAG C(SEQ ID NO: 104) GGACTCCTCA AACTGATGAC CCCAGTCCCT TGGGACCAGT GGCAGAGCTC G (SEQ ID NO: 105) DOM-11 SEQ ID NO: 13 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F G D
Y E M =
CCTCCGGP_TT CACCTTTGGT
GATTATGAGA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGAAACCA
CTAATACTCT
= S W V R Q A P G R G L E W V S G I D G E G S D T Y Y A D S V
IC G R =
AGGGTTCTGA TACATACTAC GCAGACTCCG
TGAAGGGCCG
ACTCAACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTCCC TAACTACCAC TCCCAAGACT
ATGTATGATG CGTCTGAGGC ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R P. E D T A V Y Y C A
K P G
201 GTTCACCATC TCCCGCGACP. ATTCCAAGAB CACGCTGTAT CTGCAAATGA ACAGCCTGCG
TGCCGAGGAT ACCGCGGTAT ATTACTGTGC
GAAACCGGGG CATiGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC
ACGGCTCCTA TGGCGCCATA TAATGACACG
CTTTGGCCCC
CTGGTCACCG TCTCGAGC (SEQ ID NO: 106) TCCTCAAAAC TGETGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 107) DOM-12 SEQ ID NO: 14 Y E M =
CCTCCGGATT CACCTTTAGG
TTGTATGAGA
GGAGGCCTAA GTGGAWLTCC
AACATACTCT
= A W V R Q A P G K G L E W V S G I D I L G S R T Y Y A D S V
K G R =
TGGGTTCGAG GACATACTAC GCAGACTCCG, TGAAGGGCCG
ACCGCACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTCCC TAACTATARA ACCCAAGCTC
CTGTATGATG CGTCTGAGGC
ACTTCCCGGC
F T I S R D N S K N T L Y L Q M N S I. R A E D T A V Y Y C A
K D L
201 GTTCACCATC TCCCGCGACA ATTCCPAGRP CACGCTGTAT CTGCAAP_TGA ACAGCCTGCG
TGCCGAGGAT ACCGCGGTAT ATTACTGTGC
GAAAGATCTG
CAAGTGGTAG AGGGCGCTGT T_AAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTP_ TGGCGCCATA TAATGACACG
CTTTCTAGAC
S W Q G F D Y W G Q G T L V T V S S
301 TCGTGGCAGG GTTTTGACTP CTGGGGTCAG GGAACCCTGG TCACCGTCTC GAGC (SEQ ID NOC
108) AGCACCGTCC CAAAACTGP_T GACCCCAGTC CCTTGGGACC AGTGGCAGAG CTCG (SEQ ID NO: 109) DOM-13 SEQ ID NO: 15 E V Q L L E S G G G L V Q P G G S L R L S C P. A 5 G F T F S Y
Y S M =
CCTCCGGHTT CACCTTTTCT
TATTATTCGA CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG
AGGACACGTC GGAGGCCTAA GTGGAAAziGA
ATAATAkGCT
= Y W V R Q A P G K G L E W V S S I S P F G W G T Y Y P_ D S V
K G R =
TTGGTTGGGG TACATACTAC GCAGACTCCG
TGAAGGGCCG
ACATAACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTAGC TAAAGCGGAA AACCAACCCC
ATGTATGATG CGTCTGAGGC
ACTTCCCGGC.35 = F T I S R D N S K D T L Y L Q M 11 S L R A E D T A V Y Y C A
K Y G
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAAATATGGG
CPAGTGGTAG AGGGCGCTGT TAAGGTTCCT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CTTTATACCC
E T S G P I S E N F D Y W G Q G T L V T V S S
GTCTCGAGC (SEQ ID NO: 110) CTCTGCTCAC CAGGCTAAAG ACTCTTAHAP CTGATGACCC CAGTCCCTTG GGACCAGTGG CAGAGCTCG
(SEQ ID NO: 111) DOM-14 SEQ ID NO: 16 Y D M =
CCTCCGGATT CACCTTTTGG
TCTTATGATA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAP GTGGAAAACC
AGAATACTAT
= T W V R Q A P G K G L E W V S S I M A S G D D T Y Y A D S V
K G R =
CGGGTGATGA TACATACTAC GCAGACTCCG
TGAAGGGCCG
ACTGCACCCP_ GGCGGTCCGA GGTCCCTTCC CRGATCTCAC CCAGAGTAGA TAATACCGAA GCCCACTACT
ATGTATGP_TG CGTCTGAGGC
ACTTCCCGGC 20 = F T I S R D N S K N T L Y L Q M N S L R P E D T A V Y Y C P
K W D
201 GTTCACCP_TC TCCCGCGACA ATTCCAAGAA CACGCTGTAT CTGCAAATGA ACAGCCTGCG
TGCCGAGGAT ACCGCGGTRT ATTACTGTGC
GAPATGGGAT ~ 5 CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACPTA GACGTTTACT
TGTCGGACGC ACGGCTCCTA TGGCGCCATA TAATGACACG
CTTTACCCTA
R D F D Y W G Q G T L V T V S S
301 CGGGATTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 112) GCCCTAAAAC TGPTGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 113) DOM-15 SEQ ID NO: 17 E V 0' L L E S G G' G L V Q P G G S L R L S C A A S G F T F E E
Y V M =
CCTCCGGP_TT CACCTTTGAG
GAGTATGTTA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGAAACTC
CTCATACAAT
= S W V R QA P G K G L E W V S T I S P I G L T T Y Y A D S V
K G R =
TTGGTCTGAC TACP_TACTAC GCAGACTCCG
' TGAAGGGCCG
ACAGCACCCE GGCGGTCCGA GGTCCCTTCC CAGACCTCAC CCAGAGTTGA TAAAGAGGAT AECCAGACTG
ATGTATGATG CGTCTGAGGC
ACTTCCCGGC
E F P
201 GTTCACCATC TCCCGCGACA ATTCCAAG.W? CACGCTGTAT CTGCAAATGA ACAGCCTGCG
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GGAATTTCCT
CAyGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CCTTAAAGGA
L I I L P D F D Y W G Q G T L V T V S S
301 TTGATTATTC TTCCTGATTT TGACTACTGG GGTCAGGGAA CCCTGGTCAC CGTCTCGAGC (SEQ ID
NO: 114) AACTAATAAG AAGGACTAAA ACTGATGACC CCAGTCCCTT GGGACCAGTG GCAGAGCTCG (SEQ ID NO:
115) DOM-16 SEQ ID NO: 18 Y A M =
CCTCCGGATT CACCTTTATG
GAGT_ATGCGA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG GACCP_TGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAP. GTGGvTaATAC
CTCP_TP_CGCT
K G R =
101 TGATTTGGGT CCGCCAGGCT CCAGGGAAGG GTCTAGAGTG GGTCTCATiTT ATTTCTCCGC
TTGGTTTGTC TACATACTAC GCAGACTCCG
TGAAGGGCCG
ACTAAACCCA GGCGGTCCGP_ GGTCCCTTCC CAGATCTCAC CCAGAGTTAA TAAAGAGGCG AACCAAACAG
ATGTATGP_TG CGTCTGAGGC
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
K Y Q
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAAnTATCAG
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CTTTATAGTC
301 GATTCGTCTG P.TAGTCAGTA TACGAATTTT GACTACTGGG GTCAGGGPAC CCTGGTCACC
GTCTCGAGC (SEQ ID NO: 116) CTAAGCAGAC TATCAGTCAT ATGCTTAAAP. CTGATGACCC CAGTCCCTTG GGACCAGTGG CAGAGCTCG
(SEQ ID NO: 117) DOM-17 SEQ ID NO: 19 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F E D
Y G M =
CCTCCGGATT CACCTTTGAG
GATTATGGGA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCP_TGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAL GTGGAAACTC
CTAATACCCT
G W A R Q A P G K G L E W V S S I G P L G L W T Y Y P_ D S A
K G R
TGGGTCTTTG GACATACTAC GCAGACTCCG
CGPAGGGCCG
~ ACCCCACCCG GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTTCA TAACCAGGAG ACCCAGAAAC
CTGTATGATG CGTCTGAGGC
GCTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
K S P
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAAATCTCCG
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CTTTAGAGGC
301 CTTGAGGGTT TGATTACGAA TTTTGACTAC TGGGGTCAGG GAACCCTGGT CACCGTCTCG AGC (SEQ
ID NO: 118) GAACTCCCAA ACTAATGCTT AAAACTGATG ACCCCAGTCC CTTGGGACCA GTGGCAGAGC TCG (SEQ ID
NO: 119) DOM-18 SEQ ID NO: 20 E V Q L L E S G G G L V Q P G G $ L R L S C A A S G F T F P E
Y D M =
CCTCCGGATT CACCTTTCCT
GAGTATGATA
AGGACACGTC GGAGGCCTAA GTGGAAAGGA
CTCATACTAT
= T W V R Q A P G K G L E W V S Y I S S D G Y S T Y Y A D S V
K G R =
ATGGTTATTC TACATACTAC GCAGACTCCG
TGAAGGGCCG
ACTGCACCCA GGCGGTCCGA GGTCCCTTCC CAGACCTCAC CCAGAGTATA TAATCAAGAC TACCAATAAG
ATGTATGP_TG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q N. N S L R E E D T A V Y Y C A
K P H
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAAACCGCAT
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACP.TA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CTTTGGCGTA
301 GGGAGTCCGC GGGAGTTTGA CTACTGGGGT CAGGGAACCC TGGTCACCGT CTCGAGC (SEQ ID NO:
120) CCCTCAGGCG CCCTCAAACT GATGACCCCA GTCCCTTGGG ACCAGTGGCA GAGCTCG (SEQ ID NO:
121) DOM-19 SEQ ID NO: 21 Y Q M =
CCTCCGGATT CCCCTTTCCG
CAGTATCAGP.
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GGGGAAAGGC
GTCATAGTCT
= P_ W V R Q A P G K G L E W V S M I T S D G L D T Y Y A D S V
K G R =
101 TGGCGTGGGT CCGCCAGGCT CCAGGGAAGG GTCTAGAGTG GGTCTCAATG P_TTACTTCTG
ATGGTCTTGA TACATATTAC GCAGACTCCG
TAATGAAGAC TACCAGAACT ATGTATAaTG CGTCTGAGGC ACTTCCCGGC = F T I S R D N S K N T
L Y L Q M N S L R A E D T A V Y Y C P.
K P E
TGCCGAGGAT ACCGCGGTAT A_TTACTGTGC
GAAACCTGAG
CAAGTGGTAG AGGGCGCTGT TPAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTA
TGGCGCCATA TAP_TGACACG
CTTTGGACTC
301 CCTCTTTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC.(SEQ ID NO: 122) GGAGAAAAAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 123) DOM-20 SEQ ID NO: 22 Y Q M =
CCTCCGGATT CACCT_TTTCG
GGTTATCAGA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGAAAAGC
CCAATAGTCT
= A W V A Q A P G F: G L E W V S G I S S E G L T T Y Y A D S V
A G R =
AGGGTCTTAC TACATACTAC GCAGACTCCG
TGAAGGGCCG
TCCCAGP.ATG ATGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N 5 L R A E D T P. V Y Y C P.
K L G
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAAATTGGGG
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CTTTAACCCC
R R F D Y W G Q G T L V T V S S
301 CGTAGGTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 124) GCATCCAAAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 125) DOM-21 SEQ ID NO: 23 E V Q L L E S G G G L V Q P G G S L R L S C P. A S G F T F A N
Y E M =
CCTCCGGATT CACCTTTGCG
AATTATGAGA
O CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGAAACGC
TTAATACTCT
= G W A R Q A P G K G L E W V S V I S E W G Y S T Y Y F: D S A
K G R =
GGGGTTATTC TACATACTAC GCAGACTCCG
CGAAGGGCCG
ACCCCACCCG GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTCAA TAAAGACTCA CCCCAATAAG
ATGTATGATG CGTCTGAGGC
GCTTCCCGGC
F T I S R D N S % N T L Y L Q M N S L R A E D T A V Y Y C A
K L V
201 GTTCACCATC TCCCGCGACA ATTCCAAGAA CACGCTGTAT CTGCATiATGA ACAGCCTGCG
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAAACTTGTG
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CTTTGAACAC
G G T Q Y E F D Y W G Q G T L V T V S S
301 GGTGGGACTC AGTATGAGTT TGACTACTGG GGTCAGGGAA CCCTGGTCAC CGTCTCGAGC (SEQ ID
NO: 126) CCACCCTGAG TCATACTCAA ACTGATGACC CCAGTCCCTT GGGACCAGTG GCAGAGCTCG (SEQ ID NO:
127) DOM-22 SEQ ID NO: 24 Y E M =
CCTCCGGATT CACCTTTCP_T
AATTATGAGA CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG
AGGACACGTC GGAGGCCTAA GTGGAAAGTA
TTAATACTCT
. 5 W V R Q P_ P G K G L E W V S S I S 5 G G 5 5 T Y Y P. D S V
K G R =
101 TGTCGTGGGT CCGCCAGGCT CCAGGGAAGG GTCTAGAGTG GGTCTCAAGT P_TTTCTTCGG
GTGGTTCTTC TACATACTAC GCAGACTCCG
TGAAGGGCCG
ACAGCACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTTCA TAAAGA_AGCC CACCAAG.SAG
ATGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R P_ E D T A V Y Y C A
K P G
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAAACCGGGG
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATP GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CTTTGGCCCC
V K F D Y W G Q G T L V T V S S
301 GTTAAGTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 128) CPATTCAAAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 129) DOM-23 SEQ ID NO: 25 Y E M =
CCTCCGGATT CACCTTTGGG
CTGTATGAGA
CTCCACGTCG ACAACCTCAG GCCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGAAACCC
GACATACTCT
= T W V R Q A P G K G L E W V S S I T G D G I S T Y Y A D S V
K G R =
ATGGTATTTC GACATACTAC GCAGACTCCG
TGAAGGGCCG
ACTGCACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTTCA TAATGCCCAC TACCATAAAG
CTGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N 5 R N T L Y I. Q M N S L R A_ E D T A V Y Y C A
K A G
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAAAGCTGGG
CAAGTGGTAG AGGGCGCTGT TAAGGTCCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CTTTCGACCC
R K F D Y W G Q G T L V T V S S
301 AGGAAGTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 130) TCCTTCAAAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 131) DOM-24 SEQ ID NO: 26 E V Q L L E S G G G L V Q P G G 5 L R L S C A P_ S G F T F S N
Y Q M =
CCTCCGGATT CACCTTTAGT
AATTATCAGA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCP.TGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGAAATCA
j 5 TTAATAGTCT
. = A W V R Q A P G K G L E W V 5 S I T S E G G S T Y Y A D S V
K G R =
AGGGTGGTTC GACATACTAC GCAGACTCCG
TGAAGGGCCG
ACCGCACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTTCA TAATGATCAC TCCCACCAAG
CTGTP_TGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S P. D A: S K N T L Y L Q M N S L R P. E D T A V Y Y C A
K P G
201 GTTCACCP_TC TCCCGCGACA P_TTCCAAGAA CACACTGTAT CTGCAAATGA ACAGCCTGCG
TGCCGAGGAC ACCGCGGTAT P_TTACTGTGC
GAAACCGGGT
CPAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGTGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA T_A TGACACG
CTTTGGCCCP
301 AAGAATTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 132) TTCTTAAAAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 133) DOM-25 SEQ ID NO: 27 Y E N. =
CCTCCGGP_TT CACCTTTGAT
PATTATGAGP.
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCPGAG AGGACACGTC
GGAGGCCTAA GTGGAAACTA
TTAATACTCT
= T W V R Q A P G K G L E W V S T I T S Q G T S T Y Y A D S V
K G R. =
101 TGACGTGGGT CCGCCAGGCT CCAGGGAAGG GTCTAGAGTG GGTCTCAACT P_TTACGTCGC
AGGGTACTAG TACATACTAC GCAGACTCCG
TGAAGGGCCG
ACTGCACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTTGA TAaTGCAGCG TCCCP_TGP_TC
ATGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
R P D
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAPACCTGAT
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CTTTGGACTA
R S F D Y W G Q G T L V T V S S
301 CGTTCTTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 134) GCAAGAAAAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID 140: 135) DOM-26 SEQ ID NO: 28 E V Q L L E S. G G G L V Q P G G S L R L S C A A S G F T F R 5 Y E M =
1 GAGGTGCAGC TGTTGGAGTC TGGGGGAGGC TTGGTP_CAGC CTGGGGGGTC CCTGCGTCTC
TCCTGTGCAG CCTCCGGATT CACCTTTCGT
AGTTATGAGA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCP_TGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAb GTGGAAAGCP_ TCAATACTCT
= T W V R Q A P G K G L E W V S S I T S D G G T T Y Y A D S V
K G R =
ATGGTGGTAC TACATAC'fAC GCAGACTCCG
TGAAGGGCCG
ACTGAACCCA GGCGGTCCGA GGTCCCTTCC CAGACCTCAC CCAGAGTAGA TAATGCAGCC TACCACCATG
ATGTP_TGATG CGTCTGAGGC
ACTTCCCGGC
= F T I 5 R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
K P D
201 GTTCACCATC TCCCGCGACP ATTCCAAGAA CACGCTGTAT CTGCAAATGA P.CAGCCTGCG
TGCCGAGGAC ACCGCGGTP_T ATTACTGTGC
GAAACCTGAT CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC
ACGGCTCCTG TGGCGCCATA TAATGACACG
CTTTGGACTA
301 AkGACGTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 136) TTCTGCAAAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 137) DOM-27 SEQ ID NO: 29 Y E M =
CCTCCGGATT CACCTTTAAT
TTGTATGAGA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCP_TGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGAAATTA
AACATACTCT
= T W V R Q A P G K G L E W V S S I T S D G V S T YY A D S V
K G R =
.35 101 TGACTTGGGT CCGCCAGGCT CCAGGGAAGG GTCTAGAGTG GGTCTCPTCT ATTACTAGTG
ATGGTGTTTC TACATACTAC GCAGACTCCG
TGAAGGGCCG
ACTGAACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTAGP. TAATGATCAC TACCACAAAG
ATGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N 5 K N T L Y L Q M N 5 L R A E D T A V Y Y C A
K P D
201 GTTCACCATC TCCCGCGACA P.TTCCAAGAA CACGCTGTAT CTGCAAaTGA ACAGCCTGCG
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAAACCGGAT
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATP. TAATGACACG
CTTTGGCCTA
S P F L Y W G Q G T L V T V S S
301 TCTCCGTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 138) AGAGGCAAAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 139) DOM-28 SEQ ID NO: 30 E V Q L L E S G G G L V Q P G G S L R L S C P_ A S G F T F G H
Y D M =
GAGGTGCAGC TGTTGGAGTC TGGGGGAGGC TTGGTACAGC CTGGGGGGTC CCTGCGTCTC TCCTGTGCAG
CCTCCGGATT CACCTTTGGG
CP_TTATGATA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGAAACCC
GTAATACTAT
A W V R Q A P G H G L E W V S T I S D N G N G T Y Y A D S V
K G R =
ATGGTAATGG GP_CP_TACTAC GCAGACTCCG
TGAAGGGCCG
ACCGAACCCA GGCGGTCCGA GGTCCCTTCCCAGATCTCAC CCAGAGTTGA TAATCACTAT TACCATTACC
CTGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R A E D T P. V Y Y C A
R P G
201 GTTCACCATC TCCCGCGACA AT_TCCAAGAA CACGCTGTAT CTGCAAATGA ACAGCCTGCG
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GPAACCGGGG
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TPATGACACG
CTTTGGCCCC
R D F D Y W G Q G T L V T V S S
301 CGTGATTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 140) GCACTAAAAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 141) DOM-29 SEQ ID NO: 31 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F G R
Y p N, =
1 GAGGTGCAGC TGTTGGAGTC TGGGGGAGGC T_TGGTP_CAGC CTGGGGGGTC CCTGCGTCTC
TCCTGTGCAG CCTCCGGATT CACCTTTGGT
CGTTATCAGA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAn GTGGAAACCA GCAATAGTCT
= A W V R Q A P G K G L E W V S S I S S D G G G T Y Y A D S V
K G R =
ATGGTGGGGG GACATACTAC GCAGACTCCG
TGAAGGGCCG
ACCGAACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTAGA TAAAGAAGAC TACCACCCCC
CTGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S R N T L Y L Q M N S L R A E D T A V Y Y C A
K P G
201 GTTCACCATC TCCCGCGACA ATTCCP_AGAA CACGCTGTAT CTGCAAATGA ACAGCCTGCG
TGCCGAGGAT ACCGCGGTAT ATTACTGTGC
GAAACCTGGG
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATP. GACGTTTACT TGTCGGACGC ACGGCTCCTA
TGGCGCCATA TAATGACACG
CTTTGGACCC
R A F D Y W G Q G T L V T V S E
301 CGGGCGTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 142) GCCCGCAAAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 143) DOM-30 SEQ ID NO: 32 JO E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F A R
Y Q M =
CCTCCGGATT CACCTTTGCG
AGGTATCAGA
AGGACACGTC GGAGGCCTAP. GTGGAAACGC
TCCATAGTCT
= A W V R Q A P G K G L E W V S T I S D D G D S T Y Y A D S V K G R =
ATGGTGATTC GACATACTAC GCAGACTCCG
ACCGAACCCA GGCGGTCCGA GGTCCCTTCC CAGACCTCAC CCAGAGTTGA TAAAGACTAC TACCACTAAG
CTGTATGATG CGTCTGAGGC
= F T I S R D N S K N T L Y L Q N. N S L R P. E D T A V Y Y C A
K L D
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAPACTGGAT
CAAGTGGTAC AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAP_TGACACG
CTTTGACCTA
K L F D Y Ca G Q G T L V T V S S
301 AAGTTGTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 149) TTCAACAAAC TGPTGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 145) DOM-31 SEQ ID NO: 33 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F E E
Y Q M =
CCTCCGGATT CACCTTTGAG
GAGTATCAGA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAP_ GTGGAAACTC
CTCP_TAGTCT
= A W V R Q A P G K G L E W V S T I S D D G S S T Y Y A D S V
K G R =
ATGGTTCTTC GACATACTAC GCAGACTCCG
TG.AAGGGCCG
ACCGCACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTTGC TAPAGCCTAC TACCAAGPAG
CTGTATGP_TG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
K P D
201 GTTCACCATC TCCCGCGACP P_TTCCAAGAA CACGCTGTAT CTGCAAATGP ACAGCCTGCG
TGCCGAGGAC ACCGCGGTP_T ATTACTGTGC
GAAACCTGAT
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CTTTGGACTA
L Y F D Y W G Q G T L V T V S S
301 CTTTATTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 146) GAAP_TAAAAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 147) DOM-32 SEQ ID NO: 34 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F E V
Y Q M =
j GAGGTGCAGC TGTTGGAGTC TGGGGGAGGC TTGGTACAGC CTGGGGGGTC CCTGCGTCTC TCCTGTGCAG
CCTCCGGATT CACCTTTGAG
GTGTATCAGA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG PACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
CACATAGTCT
= G W V R Q A P G K G L E W V S F I V P G G D L T Y Y A D S V
K G R =
GGGGTGATTT GACATACTAC GCAGACTCCG
TGAAGGGCCG
ACCCAACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTPAA TAACACGGAC CCCCACTAAA
CTGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V 1= Y C P_ E T W
201 GTTCACCATC TCCCGCGACA ATTCCAAGAA CACGCTGTAT CTGCAAATGP_ ACAGCCTGCG
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GGAAACGTGG
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACP_TA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CCTTTGCACC
P E F D Y W G Q G T L V T V S S
301 CCGGAGTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 148) GGCCTCATiAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 149) 25 DOM-33 SEQ ID NO: 35 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q T I G E
S L H =
GGGCAAGTCA GACGATTGGG
GAGAGTTTAC
.30 CTGTAGGTCT ACTGGGTCAG AGGTAGGAGG GACAGACGTA GACATCCTCT GGCACAGTGG
TAGTGAACGG CCCGTTCAGT CTGCTAACCC
CTCTCAAATG
= W Y Q Q K P G K A P R L L I Y F A S L L Q S G V P S R F S G
S G S =
35 101 ATTGGTACCP. GCAGAAACCA GGGAAAGCCC CTAGGCTCCT GATCTATTTT GCTTCCCTGT
TGCAAAGTGG GGTCCCP_TCG CGTTTCAGTG
GCAGTGGATC
TAACCATGGT CGTCTTTGGT CCCTTTCGGG GATCCGAGGA CTAGATAAAP. CGAAGGGACP. ACGTTTCACC
CCAGGGTAGC GCAAAGTCAC
CGTCACCTAG
F G Q
CTGTCAACAG CATCATATGC TTCCTTCTAC
GTTCGGCCAA
ACCCTGTCTA AAATGAGAGT GGTAGTCGTC AGACGTTGGA CTTCTPAAAC GATGCP_TGAT GACAGTTGTC
GTAGTATACG AAGGAAGETG
G T I( V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG (SEQ ID NO: 150) CCCTGGTTCC ACCTTTAGTT TGCC (SEQ ID NO: 151) DOM-34 SEQ ID NO: 36 D I Q M T Q S P S. S L S A S V G D R V T I T C R A S Q W I G D
S L S =
GGGCAAGTCA GTGGATTGGT
GATAGTTTAT
CTGTAGGTCT ACTGGGTCAG AGGTAGGAGG GACAGACGTA GACATCCTCT GGCACAGTGG TAGTGAACGG
CCCGTTCAGT CACCTAACCA
CTATCAAATA
W Y Q Q IC P G f: A. P K L L I Y F A S Y L Q S G V P T R F S G
S G S =
101 CTTGGTACCP GCAGAAACCP. GGGAAAGCCC CTARGCTCCT GATCTATTTT GCTTCCTPTT
TGCAAAGTGG GGTCCCAACA CGTTTCAGTG
GCAGTGGATC
GAACCATGGT CGTCTTTGGT CCCTTTCGGG GATTCGAGGA CTAGATAAAA CGAAGGATAP ACGTTTCP_CC
CCAGGGTTGT GCAPAGTCAC
CGTCACCTAG
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q Y F E N P V T
F G Q
201 TGGGACAGAT TTCACTCTCA CCATCAGCAG TCTGCAACCT GATiGATTTTG CTACGTACTA
CTGTCAACAG TP_TTTTGAGA ATCCTGTTAC
GTTCGGCCAA
ACCCTGTCTP_ AAGTGAGAGT GGTAGTCGTC AGACGTTGGA CTTCTAAAAC GATGCP_TGP_T
GACAGTTGTC ATAAAACTCT TAGGACAATG
CAAGCCGGTT
G T R V G I K R
.~ O 301 GGGACCAP_GG TGGGAATCAA ACGG (SEQ ID NO: 152) CCCTGGTTCC ACCCTTAGTT TGCC (SEQ ID NO: 153) DOM-35 SEQ ID NO: 37 D I Q M T Q S P S S L S A S V G D R V T I T C B. A S Q F I G D
L S =
ATCACTTGCC GGGCAAGTCA GTTTP_TTGGT
GATTCTTTAT
CTGTAGGTTT ACTGGGTCAG AGGTAGGAGG GACAGACGTA GACP.TCCTCT GGCACAGTGG TAGTGAACGG
CCCGTTCAGT CAAATAACCP.
CTAAGAAATA
= W Y Q Q K P G R A P K L L I Y F S S I L Q S G V P S R F S G
S G S =
TGCAAAGTGG GGTCCCP_TCA CGTTTCAGTG
GCAGTGGATC
~~ GAACCATGGT CGTCTTTGGT CCCTTTCGGG GATTCGAGGA CTAGATAAAA AGAAGGTAAF
ACGTTTCACC CCAGGGTAGT GCAAAGTCAC
CGTCACCTAG
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q Y M D I P I T
F G Q
GTTCGGCCPA
ACCCTGTCTA AAGTGAGAGT GGTAGTCGTC AGACGTTGGA CTTCTAAAAC GATGCATGAT GACAGTTGTC
ATATACCTAT AAGGP_TPATG
CAAGCCGGTT
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG (SEQ ID NO: 154) CCCTGGTTCC P.CCTTTAGTT TGCC (SEQ ID NO: 155) DOM-36 SEQ ID NO: 38 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q D I D H
N L E =
GGGCAAGTCA GGATATTGAT
CATAATTTAG
CTGTAGGTCT ACTGGGTCAG AGGTAGGAGG GACAGACGTA GACATCCTCT GGCACAGTGG TAGTGAACGG
CCCGTTCAGT CCTATAACTA
GTATTAAATC
= W Y Q Q K P G K A P P. L L I Y D S S M L Q S G V P S R F S G
S G S =
TGCAAAGTGG GGTCCCATCA CGTTTCAGTG
GCAGTGGATC
TCACCATAGT CGTCTTTGGT CCCTTTCGGG GATTCGAGGA CTAGATACTA TCAAGGTACA ACGTTTCACC
CCAGGGTAGT GCAAAGTCAC
CGTCACCTAG
, = G T D F T L T I S S L Q P E D F A T Y Y C Q Q Y H S I P V T F G Q
201 TGGGACAGAT TTCACTCTCA CCATCAGCAG TCTGCAP.CCT_ GAAGATTTTG CTACGTACTE
CTGTCAACAG TATCATTCTA TTCCTGTTAC
GTTCGGCCAP.
ACCCTGTCTA AAGTGAGAGT GGTAGTCGTC AGACGTTGGE CTTCTAAAAC GATGCATGAT GACAGTTGTC
ATAGTAAGFiT AAGGACAATG
CAAGCCGGTT
G T h V E I F. R
301 GGGACCAAGG TGGP_AATCAA ACGG (SEQ ID NO: 156) CCCTGGTTCC ACCTTTAGTT TGCC (SEQ ID NO: 157) DOM-37 SEQ ID NO: 39 D I Q N T Q S P S S L S A S V G D R V T I T C R A 8 Q Q I $ T
N L E =
1 GACPTCCAGA TGACCCAGTC TCCATCCTCC CTGTCTGCAT CTGTP_GGAGA CCGTGTCACC
ATCACTTGCC GGGCAAGTCA GCAGATTGAG
ACGAATTTAG
CTGTAGGTCT ACTGGGTCAG AGGTAGGAGG GACAGACGTA GACATCCTCT GGCACAGTGG TAGTGAACGG
CCCGTTCAGT CGTCTAACTC
TGCTTAAATC
= W Y Q Q K P G R A P K L L I Y D G S W L Q S G V P S R F S G
S G S =
TGCAAAGTGG GGTCCCATCA CGTTTCAGTG
GCAGTGGATC
TCACCATAGT CGTCTTTGGT CCCTTTCGGG GATTCGAGGA CTAGP_TACTA CCAAGGACCA ACGTTTCACC
CCAGGGTAGT GCAAAGTCAC
= G T D F T L T I 5 5 L Q P E D F A T Y Y C Q Q Y H S L P A T
F G Q
CTGTCAACAG TATCATAGTT TGCCTGCTAC
GTTCGGCCAA
ACCCTGTCTA APGTGAGAGT GGTAGTCGTC AGACGTTGGA CTTCTAAAAC GATGCATGAT GACAGTTGTC
ATAGTATCAA ACGGACGATG
CAAGCCGGTT
G T K V E I K R
307. GGGACCAAGG TGGAAATCAA ACGG (3EQ ID NO: 158) CCCTGGTTCC ACCTTTAGTT TGCC (SEQ ID NO: 159) DOM-38 SEQ ID NO: 40 N L E =
I GACATCCAGA TGACCCAGTC TCCATCCTCC CTGTCTGCAT CTGTAGGAGA CCGTGTCACC ATCACTTGCC
GGGCAAGTCP_ GGATATTGGT
AATAATTTAG
CTGTAGGTCT ACTGGGTCAG AGGTAGGAGG GACAGACGTA GACATCCTCT_ GGCACAGTGG TAGTGAACGG
CCCGTTCAGT CCTATAACCA
TTATTAAATC
= W Y Q Q R P G K A P R L L I Y H G S W L Q 5 G V P S R F 5 G
5 G S =
101 AGTGGTACCA GCAGAAACCA GGGAAAGCCC CTAGGCTCCT GATCTATCP_T GGGTCCTGGT
TGCAAAGTGG GGTCCCATCG CGTTTCAGTG
GCAGTGGATC
TCACCATGGT CGTCTTTGGT CCCTTTCGGG GATCCGAGGA CTAGATAGTA CCCAGGACCF. ACGTTTCACC
CCAGGGTAGC GCAAAGTCAC
CGTCACCTAG
= G T D F T L T I S 5 L Q P E D F A T Y Y C Q Q Y D F N P T T
F G Q
201 TGGGACAGAT TTCACTCTTA CCATCAGCAG TCTGCAACCT GAAGATTTTG CTACGTACTP.
CTGTCAACAG TATGATTTTA ATCCTACTAC
GTTCGGCCAA
ACCCTGTCTA AAGTGAGAAT GGTAGTCGTC AGACGTTGGA CTTCTAAAAC GP_TGCP_TGAT GACAGTTGTC
ATACTAAAAT TAGGP_TGATG
CAAGCCGGTT
G T K V E I K R
301 GGGACCAAGG TGGAAATCAP_ ACGG (SEQ ID NO: 160) 20 CCCTGGTTCC ACCTTTAGTT TGCC
(SEQ ID NO: 161) DOM-39 SEQ ID NO: 41 L L W =
GGGCAAGTCA GAPTATTGAT
GGTCTGTTAT
CTGTAGGTCT ACTGGGTCAG AGGTAGGAGG GACAGACGTA GACATCCTCT GACACAGTGG TAGTGAACGG
CCCGTTCAGT CTTATAACTA
CCAGACAATA
~
J = W Y Q Q K P G K P_ P K L L I Y A G 9 G L Q S G V P S R F S G
S G 5 =
TGCAAAGTGG GGTCCCP_TCA CGTTTCAGTG
GCAGTGGP.TC
CCACCATAGT CGTCTTTGGT CCCTTTCGGG GATTCGAGGA CTAGATACGC CCCAGGCCCA ACGTTTCACC
CCAGGGTAGT GCAAAGTCAC
CGTCACCTAG
= G T D F T L T I 5 S L Q P E D P A T Y Y C O Q K A F E P F T
F G Q
CTGTCAACAG AAGGCTTTTG AGCCTTTTAC
GTTCGGCCAA
ACCCTGTCTA AAGTGAGAGT GGTAGTCGTC AGACGTTGGP_ CTTCTAAAAC GATGCATGAT GACAGTTGTC
TTCCGAAAAC TCGGAAAATG
CAAGCCGGTT
G T R V E I K R
301 GGGACCAAGG TGGAA.TSTCAP ACGG (SEQ ID NO: 162) CCCTGGTTCC ACCTTTAGTT TGCC (SEQ ID NO: 163) DOM-40 SEQ ID NO: 42 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F K A
Y D M =
CCTCCGGATT CACCTTTAAG
GCGTATGATA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCPTGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGAAP_TTC
CGCATACTAT
= G W V R Q A P G K G L E W V S Q I G R D G S F T Y Y A D S V
K G R =
ATGGTTCTTT TACP_TACTAC GCAGACTCCG
TGTi'9GGGCCG
ACCCAACCCP GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTGTC TAACCCTCCC TACCAAGAAz ATGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
K P R
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAAAACCTCGT
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CTTTGGAGCP_ R Y A I F T F D R G Q G T L V T V S S
301 CGGTATGCTA TTTTTACTTT TGATCGGGGT CAGGGAACCC TGGTCACCGT CTCGAGC (SEQ ID NO:
164) GCCATACGPT AAAAATGAAA ACTAGCCCCP_ GTCCCTTGGG ACCAGTGGCA GAGCTCG (SEQ ID NO:
165) DOM-41 SEQ ID N0: 43 E V Q L L E S G G G L V Q P G G S L R L S C A A. S G F T F F E
Y E M =
CCTCCGGATT CACCTTTTTT
GAGTATGAGA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGP_GGCCTAA GTGGAAAAAA
CTCATACTCT
= T W V R Q A P G K G L E W V S S I A N D G S T T Y Y A D S V
K G R =
ATGGTTCGAC TACATACTAC GCAGACTCCG
TGAAGGGCCG
~~ ACTGCACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTAGA TAACGCTTAC
TACCAAGCTG ATGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T 1 S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
K P D
201 GTTCACCP_TC TCCCGCGACA ATTCCPAGAA CACGCTGTAT CTGCAAATGA ACAGCCTGCG
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAAACCTGAT
CPAGTGGTAG AGGGCGCTGT TPAGGTTCTT GTGCGACP_TA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATP_ TAATGACACG
CTTTGGACTA
R Q F D Y W G Q G T L V T V S S
301 CGGCAGTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 166) GCCGTCAPAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 167) DOM-42 SEQ ID NO: 44 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F G P
Y E M =
CCTCCGGATT CACCTTTGGT
CCGTATGAGA
AGGACACGTC GGAGGCCTAA GTGGAAACCA
GGCATACTCT
= T W V R Q A P G K G L E W V S S I V G D G L D T Y Y A D S V
K G R =
ATGGTCTGGP. TACP_TACTAC GCAGACTCCG
TGAAGGGCCG
ACTGAACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTAGC TAACAACCAC TACCAGACCT
ATGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S P. D N S K N T L Y L Q N N S L R A E D T A V Y Y C n K P D
201 GTTCACCATC TCCCGCGACA ATTCCAAGAA CACGCTGTAT CTGCAAP_TGA ACAGCCTGCG
TGCCGAGGAC ACCGCGGTAT P.TTACTGTGC
GAAACCGGAT
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAP_TGACACG
CTTTGGCCTA
R V F D Y W G Q G T L V T V S S
301 CGGGTTTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC t5EQ ID NO: 168) GCCCAAAAAC TGP_TGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 169) DOM-43 SEQ ID NO: 45 ~5 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F A S
Y E N, =
CCTCCGGATT CACCTTTGCT
TCTTATGAGA CTCCACGTCG ACP_ACCTCAG ACCCCCTCCG AP_CCPTGTCG GACCCCCCAG GGACGCAGAG
AGGACACGTC GGAGGCCTAA GTGGAAACGA
AGAATACTCT
= A W V R Q A P G K G L E W V S S I G 5 D G G P T Y Y A D S V
K G R =
101 TGGCGTGGGT CCGCCP_GGCT CCAGGGATaGG GTCTAGAGTG GGTCTCATCG ATTGGTAGTG
ATGGTGGGCC GACATACTAC GCAGACTCCG
TGAAGGGCCG
ACCGCACCCA GGCGGTCCGA GGTCCCTTCC CAGP_TCTCAC CCAGAGTAGC TAACCATCAC TACCACCCGG
CTGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R P_ E D S A V Y Y C A
IS P D
201 GTTCACCP_TC TCCCGCGACA ATTCCAAGAA CACGCTGTAT CTGCAAATGA ACAGCCTGCG
TGCCGAGGAC TCCGCGGTAT ATTACTGTGC
GAAACCTGAT
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATP_ GACGTTTACT TGTCGGACGC ACGGCTCCTG
AGGCGCCATA TAATGACACG
CTTTGGACTA
R A F D Y W G Q G T L V T V S S
301 AGGGCTTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 170) TCCCGAAAAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 171) 40 DOM-44 SEQ ID NO: 46 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F T S
Y E 14 =
CCTCCGGATT CACCTTTACG
TCTTATGAGA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCP_TGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAi GTGGAAATGC
AGAATACTCT
= G W V R Q A P G K G L E'W V S S I E P T G I T T Y Y A D S V
F. G R S.
CTGGTATTAC GACATACTAC GCAGACTCCG
TGAAGGGCCG
ACCCCACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTAGA TAACTCGGAT GACCATAATG
CTGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q N. N S L R A E D T A V Y Y C A
K P H
201 GTTCACCATC TCCCGCGACA ATTCCAAGAA CACGCTGTP_T CTGCAAATGA ACAGCCTGCG
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC GAAACCTCAT
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CTTTGGAGTA
F T E L G F D Y W G Q G T L V T V S S
301 TTTACTGAGC TTGGTTTT_GP_ CTACTGGGGT CAGGGAACCC TGGTCACCGT CTCGAGC (SEQ ID
NO: 172) AAATGACTCG AACCAAPACT GATGACCCCA GTCCCTTGGG ACCAGTGGCA GAGCTCG (SEQ ID NO:
173) DOM-45 SEQ ID NO: 47 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F G N
Y A M =
CCTCCGGATT CACCTTTGGT
AATTATGCGA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCRTGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGAAACCA
TTAATACGCT
= A W V R Q A P G K G L E W V S K I G A Q G L H T Y Y A G S V
K G R =
AGGGTCTTCA TACATACTAC GCAGGCTCCG
TGAAGGGCCG
ACCGCACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTTTC TAACCCCGCG TCCCAGAAGT
ATGTATGATG CGTCCGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
K Q T
TGCCGAGGAC ACCGCGGTAT A_TTACTGTGC
GAAACAGACG
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGAC.ATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CTTTGTCTGC
T M D Y E A F D Y W G Q G T L V T V S S
301 ACGATGGATT ATGAGAGGTT TGACTACTGG GGTCAGGGAP. CCCTGGTCAC CGTCTCGAGC (SEQ ID
NO: 174) TGCTACCTAA TACTCTCCAA ACTGATGACC CCAGTCCCTT GGGACCAGTG GCAGAGCTCG (SEQ ID NO:
175) DOM-46 SEQ ID NO: 48 E V Q L L E S G G G L V Q P G G S L R L S C P. A S G F T F E L
Y A M =
CCTCCGGATT CACCTTTGAG
TTGTATGCTA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACP_CGTC
GGAGGCCTAA GTGGAAACTC
AACATACGAT
= A W V R Q A P G K G L E W V S G I G A V G E T T Y Y A D S V
K G R =
TGGGTGAG.AC TACATACTAC GCAGACTCCG
TGAAGGGCCG
r ACCGCRCCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTCCA TAACCACGAC ACCCACTCTG
ATGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N 'S K N T L Y L Q M N S L R A E D T A V Y Y C P_ K E A
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAAAGAGGCT
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CTTTCTCCGA
N N L S D N L V F D Y W G Q G T L V T V S S
(SEQ ID NO: 176) TTATTAGAAA GACTATTAGA ACACAAACTG ATGACCCCAG TCCCTTGGGA CCAGTGGCAG AGCTCG (SEQ
ID NO: 177) DOM-47 SEQ ID NO: 49 S L S =
GGGCAAGTCA GTGGATTGGG
GATTCGTTAA CTGTAGGTCT ACTGGGTCAG AGGTAGGAGG GACAGACGTA GACATCCTCT GGCACAGTGG
TAGTGAACGG CCCGTTCAGT CACCTAACCC
CTAAGCAATT
= W Y Q Q K P G K A P K L L I Y F G S Y L Q S G V P S R F S G
S G S =
TGCAAAGTGG GGTCCCATCA CGTTTCAGTG
GCAGTGGATC
CAACCATGGT CGTCTTTGGT CCCTTTCGGG GATTCGP.GGA CTAGATAAAA CCAAGGATAA ACGTTTCACC
CCAGGGTAGT GCAAAGTCAC
CGTCACCTAG
= G T D F T L T I S S L Q P ~ D F A T Y Y C Q Q Y L H T P 5 T
F G Q
201 TGGGACAGAT TTCACTCTCP. CCP.TCAGCAG TCTGCAACCT GAAGATTTTG CTACGTACTA
CTGTCAACAG TATTTGCATP CTCCTTCGAC
GTTCGGCCAA
ACCCTGTCTA PAGTGAGAGT GGTAGTCGTC AGACGTTGGA CTTCTAAAAC GATGCATGAT GACAGTTGTC
ATAAACGTAT GAGGAAGCTG
CAAGCCGGTT
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG (SEQ ID NO: 178) CCCTGGTTCC ACCTTTAGTT TGCC (SEQ ID NO: 179) DOM-48 SEQ ID NO: 50 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q W I G D
5 L S =
GGGCAAGTCA GTGGATTGGG
GATTCGTTAA
CTGTAGGTCT ACTGGGTCAG AGGTAGGAGG GACAGACGTA GACATCCTCT GGCACAGTGG TAGTGAACGG
CCCGTTCAGT CACCTAACCC
CTAAGCAP_TT
= W Y Q Q K P G K A P K L L I Y F G S Y L Q N G V P S R F 5 G
5 G 5 =
101 GTTGGTACCA GCAGAAACCA GGGAA~GCCC CTAAGCTCCT GATCTATTTT GGTTCCTATT
TGCAAPATGG GGTCCCATC? CGTTTCAGTG
GCAGTGGATC
CAACCATGGT CGTCTTTGGT CCCTTTCGGG GATTCGAGGA CTAGATAAAA CCt1AGGATAP_ ACGTTTTACC
CCAGGGTAGT GCPAAGTCAC
CGTCACCTAG = G T D F T L T I S S L Q P E D F A T Y Y C Q Q Y N I T P T T
F G Q
201 TGGGACAGAT TTCACTCTCB CCATCAGCAG TCTGCAACCT GAAGATTTTG CTACGTACTP.
CTGTCAACAG TETATGATTA CTCCTACTAC
GTTCGGCCAA
ACCCTGTCTA AAGTGAGAGT GGTAGTCGTC AGACGTTGGA CTTCTAAAAC GATGCATGP_T GACAGTTGTC
ATATACTAAT GAGGATGATG
CAAGCCGGTT
G T K V E I R R
301 GGGACCAAGG TGGMATCAA ACGG (SEQ ID NO: 180) CCCTGGTTCC ACCTTTAGTT TGCC (SEQ ID NO: 1B1) DOM-49 SEQ ID NO: 51 D V Q M T Q S F 5 5 L S A S V G D P. V T I T C R P. S Q W I G D
S L S =
GGGCAAGTCA GTGGATTGGG
GATTCGTTAP_ CTGCAGGTCT ACTGGGTCAG AGGTAGGAGG GACAGACGTA GACATCCTCT GGCACAGTGG TAGTGAACGG
CCCGTTCAGT CACCTAACCC
CTAAGCAATT
= W Y Q Q K P G R P. P K L L I Y F G S Y L Q S G V P S R F S G
S G S =
101 GTTGGTACCA GCAGAAACCP. GGGAAAGCCC CTAAGCTCCT GATCTATTTT GGTTCCTATT
TGCAAAGTGG GGTCCCATCA CGTTTCAGTG
GCAGTGGP_TC CAACCATGGT CGTCTTTGGT CCCTTTCGGG GATTCGAGGA CTAGATAAAA CCAAGGATAA
ACGTTTCACC CCAGGGTAGT GCAAAGTCAC
CGTCACCTAG
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q Y M S A P S T
F G Q
201 TGGGACAGAT TTCACTCTCA CCATCAGCAG TCTGCAACCT GAAGATTTTG CTACGTACTP_ CTGTCAACAG TATATGAGTG CTCCTTCTAC
GTTCGGCCAA
,, O ACCCTGTCTA PAGTGAGAGT GGTAGTCGTC AGACGTTGGA CTTCT.9PAAC GATGCATGAT
GACAGTTGTC ATATACTCAC GAGGAAGP_TG
CAAGCCGGTT
G T K V E I K R
301 GGGACCAAGG TGGA.WiTCAA ACGG (SEQ ID NO: 182) CCCTGGTTCC ACCTTTAGTT TGCC ISEQ ID N0: 183) DOM-50 SEQ ID NO: 52 D I Q M T Q S P S S L S A S V G D R V T I T C R P. S Q W I G D
S L 5 =
GGGCAAGTCA GTGGATTGGG
GATTCGTTAA
CTGTAGGTCT ACTGGGTCAG AGGTAGGAGG GACAGACGTA GACATCCTCT GGCACAGTGG TAGTGAACGG
CCCGTTCAGT CACCTAACCC
CTAAGCAATT
J5 = W Y Q Q K P G K A P K L L I Y F G S Y L Q S G V P S R F S G
S G S =
TGCAAAGTGG GGTCCCATCA CGTTTCAGTG
CCAAGGATAA ACGTTTCACC CCAGGGTAGT GCAAAGTCAC
CGTCACCTAG
= G T D F T L T I S S L Q P E D S A T Y Y C Q 0 y Q Y V PS T
F G Q
CTGTCAACAG TATCAGTATG TTCCTTCTAC
GTTCGGCCAA
ACCCTGTCTb AAGTGAGAGT GGTAGTCGTC AGACGTTGGA CTTCTAAGAC GATGCATGAT GACAGTTGTC
ATAGTCP_TAC AAGGPAGATG
CAAGCCGGTT
G T K V E I K Q
301 GGGACCAAGG TGGAAATCAA ACAG (SEQ ID NO: 184) CCCTGGTTCC ACCTTTAGTT TGTC (SEQ ID NO: 185) DOM-51 SEQ ID NO: 53 D I Q M T Q S P S S L S A S V G D R V T I T C R P S Q P I V D
E L. D =
GGGCAAGTCP. GCCTPTTGTT
GATGAGTTAC
CTGTAGGTCT ACTGGGTCAG AGGTAGGAGG GACAGACGTA GACATCCTCT GGCACAGTGG TAGTGAACGG
CCCGTTCAGT CGGP_TAACAA
CTACTCAATC
= W Y Q Q K P G K P_ P K L L I Y A A S I L Q S G V P S R F S G
S G S =
TGCAAAGTGG GGTCCCATCA CGTTTCAGTG
GCAGTGGATC
TAACCATGGT CGTCTTTGGT CCCTTTCGGG GATTCGAGGA CTAGATACGP CGCAGGTAAA ACGTTTCACC
CCAGGGTAGT GCAAAGTCAC
CGTCACCTAG
= G T D F T L T I S S L Q P E D F A T Y Y C H Q W S T Y P T T
F G Q
201 TGGGACAGAT TTCACTCTCA CCATCAGCAG TCTGCAACCT GAAGP_TTTTG CTACGTACTA
CTGTCATCAG TGGTCTACTT PTCCTACGAC
GTTCGGCCAA
ACCCTGTCTP AAGTGAGAGT GGTAGTCGTC AGACGTTGGA CTTCTAAAAC GATGCATGAT GACAGTAGTC
ACCAGATGAA TPGGPTGCTG
CAAGCCGGTT
G T K V E I K R
301 GGGACCAAGG TGGAAATTAA ACGG (SEQ ID NO: 186) CCCTGGTTCC ACCTTTPATT TGCC (SEQ ID NO: 187) DOM-52 SEQ ID NO: 54 A L R =
GGGCAAGTCA GGATATTGGG
TCTGCGTTAA
CTGTAGGTCT ACTGGGTCAG AGGTAGGAGG GACAGACGTA GACPTCCACT GGCACAGTGG TAGTGAACGG
CCCGTTCAGT CCTATAACCC
= W Y Q Q K P G IC P. P K L L I Y L G S D L Q 5 G V P S R F S G
S G S =
TGCAAAGTGG GGTCCCATCA CGTTTCAGTG
GCAGTGGATC
CCACCATAGT CGTCTTTGGT CCCTTTCGGG GATTCGAGGA CTAGATAAAC CCAAGGCTAA ACGTTTCACC
CCAGGGTAGT GCAAAGTCAC
CGTCACCTPG
= G T D F T L T I S S L Q P E D F P. T Y Y C Q Q T Q Y F P T T
F G Q
201 TGGGACAGAT TTCACTCTCb CCATCAGCAG TCTGCAACCT GAAGATTTTG CTACGTACTA
CTGTCAACAG ACGCAGTATT TTCCTACGAC
GTTCGGCCAA
ACCCTGTCTA AAGTGAGAGT GGTAGTCGTC AGACGTTGGA CTTCTAAAAC GATGCATGAT GACAGTTGTC
TGCGTCATAA AAGGPTGCTG
CAAGCCGGTT
G T K V E I K R
301 GGGP_CCAAGG TGGAAATCAP ACGG (SEQ ID NO: 188) CCCTGGTTCC ACCTTTAGTT TGCC (SEQ ID NO: 189) DOM-53 SEQ ID N0: 55 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q A I Y G
G L R =
1 GACATCCP_GP_ TGACCCAGTC TCCATCCTCC CTGTCTGCAT CTGTAGGAGA CCGTGTCACC
ATCACTTGCC GGGCAAGTCA GGCGATTTAT
GGGGGGTTAC
CTGTAGGTCT ACTGGGTCAG AGGTAGGAGG GACAGACGTA GACATCCTCT GGCACAGTGG TAGTGAACGG
CCCGTTCAGT CCGCTAAATP CCCCCCAP_TG
= W Y Q Q K P G K A P R L L I Y G E S M L Q S G V P S R F S G
S G S =
TGCAAAGTGG GGTCCCATCE CGTTTCAGTG GCAGTGGATC
CCACCATGGT CGTCTTTGGT CCCTTTCGGG GATTCGAGGA CTAGATACCC CTCAGGTACA ACGTTTCACC
CCAGGGTAGT GCAAAGTCAC
CGTCPCCTAG
= G T D F T L T I S S L H P E D F A T Y Y C Q Q V Y H K P F T
F G Q
CTGTCAACAG GTTTATCATA AGCCTTTTAC
GTTCGGCCAA
ACCCTGTCTA AAGTGAGAGT GGTAGTCGTC AGACGTAGGP CTTCTAAAAC GATGCATGAT GACAGTTGTC
CAAATAGTAT TCGGAAAATG
CAAGCCGGTT
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG (SEQ ID NO: 190) CCCTGGTTCC ACCTTTAGTT TGCC (SEQ ID NO: 191) DOM-54 SEQ ID NO: 56 E V Q L L E S G G G L V Q P G G S L R L S C A I: S G F T F T A
Y R M =
CCTCCGGATT CACCTTTACG
GCGTATAGGA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGAAATGC
CGCATP_TCCT
= A W V R Q A P G K G L E W V S W I S P S G S G T Y Y A D S V
K G R =
CTGGTTCGGG GACATACTAC GCAGACTCCG
TGAAGGGCCG
ACCGAACCCA GGCGGTCCGP_ GGTCCCTTCC CAGATCTCAC CCAGAGTACC TAAAGCGGzfA GACCAAGCCC
CTGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
K T L
201 GTTCACCATC TCCCGCGACA ATTCCAAG.~A CACGCTGTAT CTGCAAATGP ACAGCCTGCG
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAAAACTTTG
CHAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TPATGACACG
CTTTTGAP.AC
T D S P S G R Y E F D Y W G Q G T L V T V S S
301 ACGGATTCGC CGTCGGGGCA TTP_TGAGTTT GACTACTGGG GTCAGGGAAC CCTGGTCACC
GTCTCGAGC (SEQ ID NO: 192) TGCCTAAGCG GCAGCCCCGT ApTACTCAAP CTGP_TGACCC CAGTCCCTTG GGACCAGTGG CAGnGCTCG
(SEQ ID NO: 193) DOM-55 SEQ ID N0; 57 Y E M =
CCTCCGGPTT CACCTTTGCG
CGGTPTGAGA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGPkACGC
GCCATACTCT
= G W V R Q A P G K G L E tV V S R I T A Q G L G T Y Y A D S V
K G R =
AGGGTCTTGG GACATACTAC GCAGACTCCG
TGAAGGGCCG
ACCCCACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTGCC TAATGACGAG TCCCAGAACC
CTGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
K Y L
TGCCGAGGAT ACCGCGGTAT ATTACTGTGC
GAAATATCTT
CAAGTGGTAG AGGGCGCTGT TGAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC P_CGGCTCCTF
TGGCGCCATA TAATGACACG
CTT_TATAGAA
T D F S S G H Q E F D Y P! G Q G T L V T V S S
GTCTCGAGC (SEQ ID NO: 194) TGACTAAAAT CATCACCCGT AGTCCTCAAA CTGATGACCC CAGTCCCTTG GGACCAGTGG CAGP.GCTCG
(SEQ ID NO: 195) DOM-56 SEQ ID NO: 58 Y T M =
CCTCCGGP_TT CACCT_TTAAT
GATTATACTA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGAAATTA
CTPATATGAT
= G W V R Q A P G K G L E W V 5 W I H G T G G Q T Y Y A D S V
P: G R =
CTGGTGGTCA GACATACTAC GCAGACTCCG
TGAAGGGCCG
ACCCAACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTACC TAAGTACCCT GACCACCAGT
CTGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R P. E D T A V Y Y C A
K A L
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAAAGCTTTG
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACBTA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CTTTCGAAAC
GTCTCGAGC (SEQ ID NO: 196) CGACTATCCT CACCCCCCCA ACAACTCAAA CTGATGACCC CAGTCCCTTG GGACCAGTGG CAGAGCTCG
(SEQ ID NO: 297) DOM-57 SEQ ID NO: 59 Y D M -CCTCCGGATT CACCTTTTCT
GAGTATGATA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGAAAAGA
CTCATACTAT
. Y W V R Q A P G K G L E W V S W I D T D G G D T Y Y A D S V
K G R =
~O 101 TGTATTGGGT CCGCCAGGCT CCAGGGAAGG GTCTAGAGTG GGTCTCATGG ATTGATACTG
ATGGTGGGGA TACATACTAC GCAGACTCCG
TGAAGGGCCG
ACATAACCCP. GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTACC TAACTATGAC TACCACCCCT
ATGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
K P G
201 GTTCACCATC TCCCGCGACA ATTCCPAGPA CP_CGCTGTAT CTGCFfA.ATGA PCAGCCTGCG
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAAACCTGGT
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACPTA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CTTTGGACCP
L K F D Y W G Q G T L V T V S S
301 CTGAAGTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 198) GACTTCAAAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 199) DOM-58 SEQ ID NO: 60 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T P E V
Y T M =
CCTCCGGATT CACCTTTGAG
GTTTATACTA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACPCGTC
GGAGGCCTAP_ GTGGAAACTC
CAAATATGAT
= P_ W V R Q A P G K G L E W V S T I D E S G R D T Y Y A D S V
K G R = e CTGGTCGTGA TACATACTAC GCAGACTCCG
TGAAGGGCCG
ACCGCACCCA GGCGGTCCGA GGTCCCTTCC CAGACCTCAC CCAGAGTTGC TAACTACTCA GACCAGCACT
P_TGTATGATG CGTCTGP_GGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
K P G
201 GTTCACCPTC TCCCGCGACP_ P_TTCCAAGAA CACGCTGTAT CTGCAAATGA ACAGCCTGCG
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAAACCTGGT
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACP_TA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CTTTGGACCA
V W F D Y W G Q G T L V T V S S
301 GTTTGGTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 200) CAAACCAAAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 201) DOM-59 SEQ ID NO: 61 E V Q L L E S G G G L V Q P G G S L R L 5 C P_ P. S G F T F L D
Y A M =
CCTCCGGATT CACCTTTCTG
GATTATGCGA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGAAPGAC
CTAATACGCT
= G W V R Q A P G K G L E W V S T I S P M G M G T Y Y A D S V
K G R =
TGGGTP_TGGG TACATACTAC GCAGACTCCG
TGAAGGGCCG
ACCCAACCCA GGCGGTCCGP GGTCCCTTCC CAGACCTCAC CCAGAGTTGA TAAAGAGGCT ACCCATACCC
ATGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
K s s 201 GTTCACCATC TCCCGCGACA ATTCCAAGAP. CACGCTGTAT CTGCAAATGA ACAGCCTGCG
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAAATCGAGT
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCP_TP TAATGACACG
CTTTAGCTCA
ACCGTCTCGk GC (SEQ ID NO: 202) CGATAAAGCP AATGAAGACT ATAAAGATTP AAACTGATGA CCCCAGTCCC TTGGGACCAG TGGCAGAGCT
CG (SEQ ID NO: 203) DOM-61 SEQ ID NO: 62 E V Q L L E S G G G L V Q P G G S L R L S C P_ P_ S G F T F A A
Y A M =
TCCTGTGCAG CCTCCGGATT CACCTTTGCT
GCTTATGCTA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGAAACGA
CGAATACGPT
= T W V R Q A P G K G L E W V S Y I S P N G T A T Y Y A D S V
K G R =
ATGGTACGGC GACATACTAC GCAGACTCCG
TGAAGGGCCG
ACTGCACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTPTA TAATCAGGCT TACCP_TGCCG
CTGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N 5 K N T L Y L Q M ld S L R A E D T A V Y Y C A
E Y V
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GGAATP_TGTG
CAAGTGGTAG AGGGCGCTGT T_kAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CCTTATACAC
G N R W N S F D Y W G Q G T L V T V S S
301 GGGATGCGTT GGAATTCTTT TGACTACTGG GGTCAGGGAA CCCTGGTCAC CGTCTCGAGC (SEQ ID
NO: 204) CCCTACGCAA CCTTAAGAAA ACTGATGACC CCAGTCCCTT GGGACCAGTG GCAGAGCTCG (SEQ ID 140:
205) DOM-62 SEQ ID NO: 63 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F S S
Y E M =
CCTCCGGATT CACCTTTTCG
AGTTATGAGA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGAAAAGC
TCAATACTCT
= A W V R Q A P G K G L E W V S S I T S L G T S T Y Y A D S V
K G R =
TTGGTACTTC TACATACTAC GCAGACTCCG
TGAAGGGCCG
ACCGAACCCP. GGCGGTCCGP. GGTCCCTTCC CAGATCTCAC CCAGAGTAGA TAATGCTCAG AACCATGAAG
ATGTPTGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R P_ E D T P_ V Y Y C A
K P G
201 GTTCACCATC TCCCGCGACP ATTCCAAGAA CACGCTGTAT CTGCAAP_TGE ACAGCCTGCG
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GPAtLCCGGGT
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCP_TA TAATGACP_CG CTTTGGCCCA
R K F D Y W G Q G T L V T V S S
301 AGGAAGTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 206) TCCTTCP0AC TGP_TGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID N0: 207) DOM-65 SEQ ID NO: 64 Y E M =
CCTCCGGATT CACCTTTAAT
GGACGCAGAG AGGACACGTC GGAGGCCTAP. GTGGAAATTA
CTCATACTCT
= T W V R Q A P G K G L E W V S T I T S E G 5 G T Y Y A D S V
K G R =
AGGGTAGTGG GACATACTAC GCAGACTCCG
TAAAGGGCCG
ACTGCACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTTGC TAATGATCAC TCCCATCACC
CTGTATGP.TG CGTCTGAGGC
ATTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
R P N
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAAACCTAAT
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACP_TA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCP_TA TAATGACACG
CTTTGGATTA
G K F D Y W G Q G T L V T V S S
301 GGTA4GTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 208) CCATTCAAAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 209) DOM-66 SEQ ID NO: 65 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F S D
Y E M =
CCTCCGGATT CACCTTTTCT
GATTATGAGA
CTCCACGTCG AGAACCTCAG ACCCCCTCCG AACCP_TGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGAAAAGA
CTA7,TACTCT
= L W V R Q A. P G K G L E W V S T I T S E G H S T Y Y A D S V
K G R =
AGGGTCATTC TACATACTAC GCAGACTCCG TGALAGGGCCG
P_CAACACCCA GGCGGTCCGA GGTCCCTTCC CAGACCTCAC CCAGAGTTGA TAATGATCAC TCCCAGTAAG
ATGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
K P G
201 GTTCACCATC TCCCGCGACP_ ATTCCAAGAP CACGCTGTAT CTGCAAATGA ACAGCCTGCG
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAAACCTGGG
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
301 ACTTCGTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 210) TGAAGCAAAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 211) DOM-67 SEQ ID NO: 66 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F S D
Y E M =
CCTCCGGATT CACCTTTAGT
GATTATGAGA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG APCCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAP GTGGAAP_TCA
CTAATACTCT
= S W V R Q A P G K G L E W V 5 T I D S D G S F T Y Y A D S V
K G R =
101 TGAGTTGGGT CCGCCAGGCT CCAGGG.AAGG GTCTAGAGTG GGTCTCAACG P_TTGATTCTG
ATGGTAGTTT TACATACTAC GCAGACTCCG
TGAAGGGCCG
ACTCAACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTTGC TAACTAAGAC TACCATCAAA
ATGTATGATG CGTCTGAGGC
ACTTCCCGGC
" F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
K P G
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAAACCGGGT
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGP_CGC ACGGCTCCTG
TGGCGCCATP. TAP_TGACACG
CTTTGGCCCA
V K F D Y W G Q G T L V T V S S
301 GTGAAGTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 212) CACTTCAAAC TGPTGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 213) DOM-68 SEQ ID NO: 67 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F K D
Y E M =
TCCTGTGCAG CCTCCGGATT CACCTTTAAG
GATTATGAGA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGAAATTC
CTAATACTCT
= T W V R Q A P G K G L E W V S S I S S T G Q 5 T Y Y A D S V
K G R =
CTGGTCAGTC TACATACTAC GCAGACTCCG
TGA.AGGGCCG
ATGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
K P G
TGCCGAGGAC ACCGCGGTAT P_TTACTGTGC
GAAACCGGGT
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CTTTGGCCCA
N Ii F D Y 47 G Q G T L V T V S S
301 AATAAGTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 214) TTATTCAAAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 215) DOM-69 SEQ ID NO: 68 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F L D
Y G M =
CCTCCGGATT CACCTTTCTT
GP_TTATGGTA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCP.TGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGAAAGAA
CTAP_TACCP_T
= A W V R Q A P G K G L E W V S A I S P L G L S T Y Y P. D 5 V
K S R =
TTGGTCTTAG TACATACTAC GCAGACTCCG
TGAAGAGCCG
ACCGAACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTCGP TAAAGCGGAG AACCAGAATC
ATGTATGATG CGTCTGAGGC
ACTTCTCGGC
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
K E V
TGCCGAGGAT ACCGCGGTAT ATTACTGTGC
GAAAGAGGTG
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATP GACGTTTACT TGTCGGACGC ACGGCTCCTA
TGGCGCCATA TAATGACACG
CTTTCTCCAC
R V G R G V H P P K F D Y W G Q G T L V T V S S
301 AGGGTGGGTA GGGGTGTTCA TCCTCCGAAG TTTGACTACT GGGGTCP_GGG AACCCTGGTC
ACCGTCTCGA GC (SEQ ID NO: 216) TCCCACCCAT CCCCACAAGT AGGAGGCTTC AAACTGATGA CCCCAGTCCC TTGGGACCAG TGGCAGAGCT
CG (SEQ ID NO: 217) DOM-70 SEQ ID NO: 69 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F E N
Y A M =
CCTCCGGATT CACCTTTGAG
AATTP_TGCTA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCP_TGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGAAACTC
= S W V R Q A P G K G L E W V S T I A P L G V P T Y Y A D S V
K G R =
TGGGTGTTCC GACATACTAC GCAGACTCCG
TGAAGGGCCG
ACAGCACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTTGC TAACGAGGCG ACCCACAAGG
CTGTP_TGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M ld S L R A E D T A V Y Y C A
K K K
TGCCGAGGAT ACCGCGGTAT ATTACTGTGC
GAAAAAGAAG
CAkGTGGTAG AGGGCGCTGT TPAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTA
TGGCGCCATA TPATGACACG
CTTTTTCTTC
V G A W L Q S R S F D Y W G Q G T L V T V S S
GTCTCGAGC (SEQ ID NO: 218) CAACCCCGCA CCGACGTCAG CGCCTCAAAA CTGATGACCC CAGTCCCTTG GGACCAGTGG CAGAGCTCG
(SEQ ID NO: 219) DOM-71 SEQ ID NO: 70 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F E G
Y P M =
CCTCCGGATT CACCTTTGAG
GGTTATCCTA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGAAACTC
CCAATAGGAT
= S W V R Q A P G K G L E W V S T I S P L G P D T Y Y A D S V
K G R =
TGGGTCCTGA TACATACTAC GCAGACTCCG
TGAAGGGCCG
ACAGCACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTTGA TAATCAGGAA ACCCAGGACT
ATGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R A E D T P_ V Y Y C A
K L L
TGCCGAGGAT ACCGCGGTAT ATTACTGTGC
GAAACTGTTG
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTA
TGGCGCCATA TAATGACACG
CTTTGACAAC
M G E Y L N S R T F D Y W G Q G T L V T V S S
GTCTCGAGC (SEQ ID NO: 220) TACCCCCTCA TAAACTTAAG ATCCTGCAAA CTGP.TGACCC CAGTCCCTTG GGACCAGTGG CAGAGCTCG
(SEQ ID NO: 221) DOM-72 SEQ ID NO: 71 E V Q I. L E S G G G l V Q P G G S L R L S C A A S G F T F E A
Y P M =
TCCTv~TGCAG CCTCCGGATT CACCTTTGAG
GCGTATCCTA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAL GTGGP.AACTC
CGCATAGGAT
= S W V R Q A P G b: G L E W V S S I S P L G L W T Y Y A D S V
K G R =
TTGGTTTGTG GACP_TACTAC GCAGACTCCG
TGAAGGGCCG
ACAGCACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTTCA TAAAGGGGAG AACCAAACAC
CTGTP.TGATG CGTCTGAGGC
ACTTCCCGGC
FT ? S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
K L S
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAAACTTAGT
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CTTTGAATCA
A G A E T H V Y R L F D Y W G Q G T L V T V S S
ACCGTCTCGP_ GC (SEQ ID NO: 222) CGACCCCGCC TCTGAGTACA AATAGCCGAA AAACTG.ATGP_ CCCCAGTCCC TTGGGACCAG TGGCAGAGCT
CG (SEQ ID NO: 223) DOM-73 SEQ ID NO: 72 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F S K
Y D M =
1 GAGGTGCP.GC TGTTGGAGTC TGGGGGAGGC TTGGTACAGC CTGGGGGGTC CCTGCGTCTC
TCCTGTGCAG CCTCCGGATT CACCTTTTCS
AAGTATGATA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAP_ GTGGAAAAGA
TTCATACTAT
= S W V R Q A P G K G L E W V S T L L E D G L T T Y Y A D S V
K G R =
ATGGTCTGAC TACATACTAC GCAGACTCCG
TGAAGGGCCG
ACAGAACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTTGA TAAGACCTCC TACCAGACTG
ATGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
K P G
~ 5 201 GTTCACCATC TCCCGCGACA ATTCCAAGAA CACGCTGTAT CTGCAAATGA ACAGCCTGCG
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAAACCGGGG
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCP.TA TAATGACACG
CTTTGGCCCC
R L F D Y h G Q G T L V T V S S
301 CGTTTGTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 224) GCAAACAAAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 225) DOM-74 SEQ ID NO: 73 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F S D
y p M =
CCTCCGGATT CACCTTTTCG
GATTATCCTA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGAAAAGC
CTAATAGGAT
= T W V R Q A P G K G L E W V S T I L S P G T E T Y Y A D S V
K G R =
CGGGTACGGP_ GACATACTAC GCAGACTCCG
TGAAGGGCCG
ACTGCACCCk GGCGGTCCGA GGTCCCTTCC CAGACCTCAC CCAGAGTTGA TAAGACAGAG GCCCATGCCT
CTGTATGP_TG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R P. E D T A V Y Y C A
K A E
201 GTTCP_CCP_TC TCCCGCGACA ATTCCAAGAA CACGCTGTAT CTGCAAATGA ACAGCCTGCG
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAAAGCTGAG
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACP_TA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CTTTCGACTC
K D F D Y W G Q G T L V T V S S
301 AAGGATTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID N0: 226) TTCCTAAAAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 227) DOM-75 SEQ ID NO: 74 AvaI
E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F L Q
Y P M =
1 GAGGTGCP_GC TGTTGGAGTC TGGGGGAGGC TTGGTACAGC CTGGGGGGTC CCTGCGTCTC
TCCTGTGCAG CCTCGGGATT CACCTTTTTG
CAGTATCCGA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGCCCTAA GTGGAP.AAAC
GTCATAGGCT
= G W V R Q A P G K G L E W V S T I S P V G L T T Y Y A D S V
K G R =
TTGGTTTGAC TACATACTAC GCAGACTCCG
TGAAGGGCCG
ACCCAACCCi GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTTGA TAAAGP_GGPC AACCAAACTG
ATGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
K L F
TGCCGAGGAT ACCGCGGTAT ATTACTGTGC
GAAATTGTTT
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACP.TA GACGTTTACT TGTCGGACGC ACGGCTCCTA
TGGCGCCATP_ T_ZIATGACACG
CTTTAACAW?
E G S R I Q R D V G F D Y W G Q G T L V T V S S
ACCGTCTCGF. GC (SEQ ID NO: 228) CTCCCCAGCT CCTAAGTCGC ACTACACCCA AAACTGP_TGA CCCCAGTCCC TTGGGACCAG TGGCAGAGCT
CG (SEQ ID NO: 229) DOM-77 SEQ ID NO: 75 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F E E
Y G M =
CCTCCGGATT CACCTTTGAG 20 G.AGTATGGTA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTPA GTGGAAACTC
CTCP_TACCAT
= A W V R Q A P G K G L E W V S T I S P L G I S T Y Y A D S V
K G R =
101 TGGCGTGGGT CCGCCAGGCT CCAGGGAAGG GTCTAGAGTG GGTCTCAACT P_TTTCTCCGC
TGGGTATTTC GACATACTAC GCAGACTCCG
TGAAGGGCCG
ACCGCACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTTGA TAAAGAGGCG ACCCATAAAG
CTGTATGATG CGTCTGP_GGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
K H A
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAAACATGCT
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CTTTGTACGA
T S Q E S L R S F D Y W G Q G T L V T V S S
(SEQ ID NO: 230) TGCAGAGTCC TCAGAAACGC CAGAAAACTG ATGACCCCAG TCCCTTGGGA CCAGTGGCAG AGCTCG (SEQ
ID D10: 231) DOM-78 SEQ ID NO: 76 Y Q M =
CCTCCGGATT CACCTTTGAG
AGGTATCAGA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAP_ GTGGAAACTC
TCCATAGTCT
= A W V R Q A P G K G L E W V S T I S S D G G G T Y Y A D S V
K G R =
ATGGTGGGGG GACATACTAC GCAGACTCCG
TGAAGGGCCG
ACCGCACCCA GGCGGTCCGA GGCCCCTTCC CAGATCTCAC CCAGAGTTGC TAATCAAGAC TACCACCCCC
CTGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
K P G
201 GTTCACCATC TCCCGCGACF. ATTCCAAGAP_ CACGCTGTAT CTGCAAATGA ACAGCCTGCG
TGCCGAGCAC ACCGCGGTAT ATTACTGTGC
GAAACCTGGT
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CTTTGGACCA
CTGGTCACCG TCTCGAGC (SEQ ID NO: 232) GTAGCCAAAC TGP.TGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 233) DOM-80 SEQ ID NO: 77 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F G R
Y Q M =
CCTCCGGATT CACCTTTGGT
CGTTATCAGA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGAAACCA
GCAATAGTCT
= A W V R Q A P G K G L E W V S S I S S D G G G T Y Y P_ D 5 V
K G R =
ATGGTGGGGG GACATACTAC GCAGACTCCG
TGAAGGGCCG
ACCGAACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTAGA TAAAGAAGAC TACCACCCCC
CTGTATGA_TG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R A E D T R V Y Y C A
K P S
201 GTTCACCP.TC TCCCGCGACA ATTCCAAGAA CACGCTGTAT CTGCAAATGA ACAGCCTGCG
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
ACGGCTCCTG TGGCGCCATA TAATGACACG
CTTTGGCAGA
R R F D Y W G Q G T L V T V S S
301 CGTCGGTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 234) GCAGCCAAAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 235) DOM-81 SEQ ID NO: 78 E V Q L L E S G G G L V Q P G G F L R L S C A A S G F T F E L
Y P 11 =
CCTCCGGATT CACCTTTGAG
TTGTATCCGA
CTCCACGTCG ACAACCTCAG P_CCCCCTCCG AACCATGTCG GACCCCCCAA GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGAAACTC
AACP_TAGGCT
= P_ W V R Q A P G K G L E W V S S I S P V G F L T Y Y A D S V
K G R =
101 TGGCGTGGGT CCGCCAGGCT CCAGGGAAGG GTCTGGAGTG GGTCTCP_TCG ATTTCTCCGG
TTGGTTTTCT GACATACTAC GCAGACTCCG
TGAAGGGCCG
AACCAAAAGA CTGTPTGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
K G H
2 n 201 GTTCACCP_TC TCCCGCGACA P_TTCCAAGAA CACGCTGTAT CTGCAAATGA ACAGCCTGCG
TGCCGAGGAT ACCGCGGTAT ATTACTGTGC
~f GAAAGGGCPT
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC PCGGCTCCTA
TGGCGCCATA TAATGACACG
CTTTCCCGTA
E G S Y T P R S A F D Y W G Q G T L V T V S S
GTCTCGAGC (SEQ ID NO: 236) CTCCCCAGCA TATGAGGCGC CAGCCGAAPA CTGATGACCC CAGTCCCTTG GGACCAGTGG CAGAGCTCG
(SEQ ID NO: 237) DOM-82 SEQ ID NO: 79 Y P M =
CCTCCGGATT CACCTTTGTG
GCGTATCCTA
AGGACACGTC GGAGGCCTAA GTGGAAACAC
CGCATAGGAT
= A W V R Q A P G K G L E W V S T I A P L G G N T Y Y A D S V
K G R =
TGGGTGGTAP_ TACATACTAC GCAGACTCCG
ACCGCACCCP GGCGGTCCGP_ GGTCCCTTCC CAGACCTCAC CCAGAGTTGA TAACGCGGAG ACCCACCATT
P_TGTATGP_TG CGTCTGAGGC
ACTTCCCGGC
= F T I S F. D 117 S K N T L Y L Q M N S L R A E D T A V Y Y C A.
K F. P
201 GTTCACCP_TC TCCCGCGACA ATTCCAAGAA CACGCTGTAT CTGCAFiATGA ACAGCCTGCG
TGCCGAGGAC ACCGCGGTAT PTTACTGTGC
GAAACGGCCG
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACPTA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCPTP TAPTGACACG
CTTTGCCGGC
GTCTCGAGC (SEQ ID NO: 238) CTCCCCGACG TCTAACTAAG AGTCTTAAP3. CTGATGACCC CAGTCCCTTG GGACCAGTGG CAGAGCTCG
(SEQ ID NO: 239 DOM-83 SEQ ID NO: 80 Y Q M =
1 GPGGTGCAGC TGTTGGAGTC TGGGGGAGGC TTGGTACAGC CTGGGGGGTC CCTGCGTCTC TCCTGTGCyG
CCTCCGGATT CACCTTTGCG
TTGTP_TCAG)l CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAP_ GTGGAP.ACGC
AACATAGTCT
= P W V R Q A P G K G L E W V S S I D 5 5 G S D T Y Y A D S V
K G R =
CTGGTAGTGA TACATACTAC GCAGACTCCG
TGAAGGGCCG
ACCGAACCCP GGCGGTCCGA GGTCCCTTCC CAGP_TCTCAC CCAGAGTAGC TAACTAkGAA GACCATCACT
PTGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M M S L R A E D T A V Y Y C A
K P E
.30 201 GTTCACCATC TCCCGCGACA ATTCCAAGAA CACGCTGTAT CTGCAAATGP ACAGCCTGCG
TGCCGAGGAC ACCGCGGTHT ATTACTGTGC
GAAACCTGAG
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CTTTGGACTC
301 CGTGATTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 240) GCACTAAAAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID N0: 241) DOM-84 SEQ ID NO: 81 E V Q L L E S G G G L V Q P G G S L R L S C A P_ S G F T F R 0 Y Q 14 =
CCTCCGGATT CACCTTTAGG
CAGTACCAGA
CTCCACGTCG ACAACCTCP.G ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGAAP_TCC
GTCATGGTCT
= A W A R Q A P G K G L E W V S T I P_ 5 D G V S T Y Y A D 5 V
K G R =
ATGGTGTTTC TACP_TACTAC GCAGACTCCG
TGAAGGGCCG
ACCGAACCCG GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTTGC TAACGCAGCC TACCACAAAG
ATGTATGATG CGTCTGAGGC
ACTTCCCGGC
. F T I S R D N 5 K N T L Y L Q M N 5 L R A E D T A V Y Y C A
K V G
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
G.WWGTTGGT
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TPATGACACG
CTTTCAACCA
R D F D Y W G Q G T L V T V S S
301 CGTGATTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC ISEQ ID 140: 242) GCACTAAAAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID N0: 243) DOM-116 SEQ ID NO: 82 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q P I G P
D L L =
GGGCAAGTCA GCCTATTGGT
CCTGATTTAC
CTGTAGGTCT ACTGGGTCAG AGGTAGGAGG GACAGACGTA GACATCCTCT GGCACAGTGG TAGTGAACGG
CCCGTTCAGT CGGP_TAACCA
GGACTAAATG
. W Y Q Q K P G K A P K L L I Y Q T S I L Q S G V P S R F S G
S G 5 =
101 TGTGGTACCA GCAGAAACCP_ GGGAAAGCCC CTPAGCTCCT GATCTATCAG ACGTCCP_TTT
TGCAAAGTGG GGTCCCATCA CGTTTCAGTG
GCAGTGGATC
ACACCATGGT CGTCTTTGGT CCCTTTCGGG GATTCGAGGA CTAGATAGTC TGCAGGTAAA ACGTTTCACC
CCAGGGTAGT GCAAAGTCAC
CGTCACCTAG
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q Y W A F P V T
F G Q
CTGTCAACAG TATTGGGCTT TTCCTGTGAC
GTTCGGCCAA
ACCCTGTCTA AAGTGAGAGT GGTAGTCGTC AGACGTTGGA CTTCTAAAAC GATGCATGAT GACAGTTGTC
ATAACCCGAA AAGGACACTG
CAAGCCGGTT
G T R V E I E R
301 GGGACCAAGG TGGAAATCAA ACGG (SEQ IL NO: 244) CCCTGGTTCC ACCTTTAGTT TGCC (3EQ ID NO: 245)--SUBSTITUTE SHEET (RULE 26) DOM-85 - SEQ ID NO.: 246 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F E Q Y D M-CCTCCGGATT
J CACCTTTGAG CAGTATGATA
= R W V R Q A P G K G L E W V S W I D E A G H E T Y Y A D
S V K G R-CGGGTCATGA GACATACTAT
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S R N T L Y L Q M N S L R A E D T A V Y Y
C A K G M
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAAGGGATG
D G F D Y W G Q G T L V T V S S
301 GATGGGTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC - SEQ ID NO .: 3 61 DOM-86 - SEQ ID NO.: 247 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q D
I G D ALF
GGGCAAGTCA
GGATATTGGG GATGCTTTAT
= W Y Q Q K P G K A P K L L I Y Y S S M L Q 5 G V P S R F
S G G G S-TGC_AAAGTGG GGTCCCATCA
CGTTTCAGTG GCGGTGGATC
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q R H S T P
A T F G Q
CTGTCAACAG CGGCATAGTA
CTCCTGCTAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO .: 362 DOM-87 - SEQ ID NO.: 248 SUBSTITUTE SHEET (RULE 26) D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q D
I D E S L M-GGGCAAGTCA
GGATATTGAT GAGTCTTTAA
= W Y Q Q K P G K A P R L L I Y G V S Y L Q S G V P S R F
S G S G 8=
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q R W K A P
F T F G Q
CTGTCAACAG CGGTGGAAGG
CTCCTTTTAC GTTCGGCCAA
G T K V E I K R - SEQ ID NO.: 363 DOM-88 - SEQ ID NO.: 249 D I Q M T Q S P S S I. S A S V G D R V T I T C R A S Q E
I V E D L Y-GGGCAAGTCA
GGAGATTGTG GAGGATTTAT
= W Y Q Q K P G K A A K L L I Y G A S W L Q S G V P S R F
S G S G S
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
.. G T D F T L T I S S L Q P E D F A T Y Y C Q Q T R R R P
Y T F G Q
CTGTCAACAG ACGCGTAGGC
GTCCTTATAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO. : 364 DOM-89 - SEQ ID NO.: 250 D I Q M T Q S P A S L S A S V G D R V T I T C R A S Q D
I D P M L R
SUBSTITUTE SHEET (RULE 26) GGGCAAGTCA
GGATATTGAT CCTATGTTAk = W Y Q Q K P G K A P K L L I Y A G S I L Q S G V P S R F
S G S G S
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
G T D F T L T I S S L Q P E D F A T Y Y C Q Q T L V T P
Y T F G Q
CTGTCAACAG ACGCTGGTGA
CTCCTTATAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO. : 365 DOM-90 - SEQ ID NO.: 251 I S D A L F-GGGCAAGTCA
GTCGATTTCG GATGCGTTAT
= W Y Q Q K P G K A P R L L I Y Y G S V L Q S G V P S P. F
S G S G S=
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q R F Q E P
V T F G Q
201, TGGGACAGAT TTCACTCTCA CCATCAGCAG TCTGCAACCT GAAGATTTTG CTACGTACTA
CTGTCAACAG CGTTTTCAGG
AGCCTGTGAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO. : 366 DOM-91 - SEQ ID NO.: 252 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q Q
I S D E L N
SUBSTITUTE SHEET (RULE 26) I GACATCCAGA TGACCCAGTC TCCATCCTCC CTGTCCGCAT CTGTAGGAGA CCGTGTCACC ATCACTTGCC
GGGCAZIGTCA
GCAGATTAGT GATGAGTTAA
= W Y Q Q K P G K A P K L L I Y A V S I L Q S G V P S R F
S G S G S=
101 ATTGGTATCA GCAGAAACCA GGGAAAGCCC CTAkGCTCCT GATCTATGCT GTGTCCATTT
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I 5 S L Q P E D F A T Y Y C Q Q W L S F P
S T F G Q
CTGTCAACAG TGGTTGAGTT
TTCCTTCGAC GTTTGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO. :' 367 DOM-92 - SEQ ID NO.: 253 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F V D Y P M=
CCTCCGGATT CACCTTTGTT GATTATCCGA
= G W V R Q A P G K G L E W V S T I S T G G F S T Y Y A D
S V K G R-GGGGTTTTTC GACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K A R
201 GTTCACCATC TCCCGCGACA ATTCCAAGAA CACGCTGTAT CTGCAAP.TGA ACAGCCTGCG
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAAGCGCGG Y Y Y L S Q I K N F D Y W G Q G T L V T V S S
GTCTCGAGC - SEQ ID
NO.: 368 DOM-93 - SEQ ID NO.: 254 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F D I Y G M
SUBSTITUTE SHEET (RULE 26) CCTCCGGATT
CACCTTTGAT ATTTPTGGGP_ = T W V R Q A P G K G L E W V S S I S P L G L V T Y Y A D
P V K G R-TTGGTCTTGT TACATACTAC
GCAGACCCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y y C A K L K
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAACTGAAG
E H G D V P F D Y W G Q G T L V T V S S
NO .
DOM-94 - SEQ ID NO.: 255 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F E L Y P M-I GAGGTGCAGC TGTTGGAGTC TGGGGGAGGC TTGGTACAGC CTGGGGGGTC CCTGCGTCTC TCCTGTGCAG
CCTCCGGATT
CACCTTTGAG CTTTATCCGA
= S W V R Q A P G K G L E W V S T I S P T G L L T Y Y A D
S V K G R=
CGGGTTTGTT GACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K F K
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAATTTAAG
R S G K T D D T N F D Y W G Q G T L V T V S S
GTCTCGAGC - SEQ ID
NO.: 370 DOM-95 - SEQ ID NO.: 256 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F R E Y D M
SUBSTITUTE SHEET (RULE 26) CCTCCGGATT
CACCTTTCGG GAGTATGATA
= L W V R Q A P G K G L E W V S T I V G D G N G T Y Y A D
S V K G R-ATGGTAATGG TACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y I Q M N S L R A E D T A V Y Y
C A K Q D
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAACAGGAT
R Q F D Y W G Q G T L V T V S S
301 CGTCAGTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC - SEQ ID NO, 371 DOM-96 - SEQ ID NO.: 257 E V Q P L E S G G G L V Q P G G S L R L S C A A S G F T
F T D Y K M-CCTCCGGATT
CACCTTTACT GATTATAAGA
= L W V R Q A P G K G L E W V S S I S P S G R W T Y Y A D
S V K G R=
GTGGTCGTTG GACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K S L
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAAAGTCTT
F E G S F D Y W G Q G T L V T V S S
301 TTTGAGGGTA GTTTTGACTA CTGGGGTCAG GGAACCCTGG TCACCGTCTC GAGC - SEQ ID NO .:
DOM-97 - SEQ ID NO.: 258 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F E E Y G M
SUBSTITUTE SHEET (RULE 26) I GAGGTGCAGC TGTTGGAGTC TGGGGGAGGC TTGGTACAGC CTGGGGGGTC CCTGCGTCTC TCCTGTGCAG
CCTCCGGATT
CACCTTTGAG GAGTATGGTA
= S W V R Q A P G K G L E W V S T I S P I G V T T Y Y A D
S V K G R-TTGGTGTTAC TACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T P. V Y Y
C A K N A
TGCCGAGGAT ACCGCGGTAT
Y D R K S N F D Y W G Q G T L V T V S S
NO .
DOM-98 - SEQ ID NO.: 259 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F D R Y V M-CCTCCGGATT
CACCTTTGAT CGGTATGTGA
= V W V R Q A P G K D L E W V S G I T P S G R R T Y Y A D
S V K G R
GTGGTAGGAG GACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K D T L Y L Q M N S L R A E D T A V Y y C A K V L
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAAGTGTTG
G R H F D P L L P S F D Y W G Q G T L V T V S S
ACCGTCTCGA GC - SEQ
ID NO.: 374 DOM-99 - SEQ ID NO.: 260 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F E D Y A M
SUBSTITUTE SHEET (RULE 26) CCTCCGG?1TT
CACCTTTGAG GATTATGCTA
= 5 W V R Q A P G K G L E W V S T I T P G G F W T Y Y A D
S V K G R-GTGGTTTTTG GACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K T S
TGCCGAGGAT ACCGCGGTAT
ATTACTGTGC GAAAACGTCT
S G E L Q L V E D F D Y W G Q G T L V T V S S
GTCTCGAGC - SEQ ID
NO.: 375 DOM-100 - SEQ ID NO.: 261 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q N
I K H S L R=
GAGCAAGTCA
GAATATTAAG CATTCGTTAC
= W Y Q Q K P G K A P R L L I Y H R S Q L Q S G V P S R F
S G S G S=
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q V R H R P
Y T F G Q
CTGTCAACAG GTTAGGCATC
GTCCTTATAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO.: 376 DOM-101 - SEQ ID NO.: 262 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q A
I G H R L R
SUBSTITUTE SHEET (RULE 26) GGGCAAGTCA
GGCTATTGGG CATCGGTTAC
W Y Q Q K P G K A P K L L I Y H R S K L Q S G V P S R F
S G S G S-TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I 5 S L Q P E D F A T Y Y C Q Q V A L F p Y T F G Q
CTGTCAACAG GTTGCTTTGT
TTCCCTATAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO .: 377 DOM-102 - SEQ ID NO.: 263 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q H
I G H H L R
GGGCAAGTCA
GCATATTGGT CATCATTTAA
= W Y Q Q K P G K A P K L L I Y H R S H L Q S G V P S R F
S G S G S=
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S S L Q P E D S A T Y Y C Q Q W D R P P
Y T F G Q
CTGTCAACAG TGGGATAGGC
CGCCTTATAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG -.S'EQ ID NO .: 378 DOM-103 - SEQ ID NO.: 264 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q A
I G H R L R=
SUBSTITUTE SHEET (RULE 26) GGGC_z1~iGTCA
GGCTATTGGG CATCGGTTAC
= W Y Q Q K P G H A P K L L I Y H R S K L Q S G V P S R P
S G S G S
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q V R A V P
Y T F G Q
CTGTCAACAG GTGCGGGCTG
TGCCTTATAC GTTTGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATTAA ACGG - SEQ ID NO .: 379 DOM-104 - SEQ ID NO.: 265 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q A
I G H R L R-I GACATCCAGA TGACCCAGTC TCCATCCTCC CTGTCTGCAT CTGTAGGAGA CCGTGTCACC ATCACTTGCC
GGGCAAGTCA
GGCTATTGGG CATCGGTTAC
= W Y Q Q K P G K A P K L L I Y H R S K L Q S G V P S R F
S G S G S=
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q V R F S P
Y T F G Q
CTGTCAACAG GTTCGTTTTT
CTCCTTATAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO.: 380 DOM-105 - SEQ ID NO.: 266 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q A
I G H R L R=
SUBSTITUTE SHEET (RULE 26) 1 GACATCCAGR_ TGACCCAGTC TCCATCCTCC CTGTCTGCAT CTGTAGGAGA CCGTGTCACC
ATCACTTGCC GGGCAZIGTCA
GGCTATTGGG CATCGGTTAC
S G S G S-TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S 5 L Q P E D F A T Y Y C Q Q S Y A R P
V T F G Q
CTGTCAACAG TCTTATGCTA
GGCCTGTGAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO. : 381 DOM-106 - SEQ ID NO.: 267 I N H R L Y-GGGCAAGTCA
AAGTATTAAT CATAGGTTAT
= W Y Q Q K P G K A P K L L I Y H R 6 R L Q S G V P S R F
S G S G S=
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC = G T D F T L T I S S L Q P E D F A T Y Y C Q Q Y K. V R
P
N T F G Q
201 TGGGACAGAT TTCACTCTCA CCATCAGCAG TCTGCAACCT G_AGGATTTTG CTACGTACTA
CTGTCAACAG TATAAGGTTA
GGCCTAATAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG SEQ ID NO.: 382 DOM-107 - SEQ ID NO.: 268 I G H R I, R
SUBSTITUTE SHEET (RULE 26) GGGC_AAGTCA
_ GGGTATTGGG_.CATCGG TTAC_.
= N] Y Q Q K P G K A P K L L I Y H R S K L Q S G V P S R F
S G S G S-TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q T Y S S P
H T F G Q
CTGTCAACAG ACTTATTCGT
CTCCTCATAC GTTCGGCCAA
G T K V E I-K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO .: 383 DOM-108 - SEQ ID NO.: 269 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q A
I G H R L R-GGGCAAGTCA
GGCTATTGGG CATCGGTTAC
= W Y Q Q K P G K A P K L L I Y H R S K L Q S G V P S R F
S G S G S=
TGCAA.i1GTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
G T D F T L T I S S L Q P E D F A T Y Y C Q Q R A V R P
F T F G Q
CTGTCAACAG AGGGCGGTGA
GGCCTTTTAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAAG TGGAAATCAA ACGG - SEQ ID NO .: 384 DOM-109 - SEQ ID NO.: 270 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q A
I G H R L R
SUBSTITUTE SHEET (RULE 26) ATCACTTGCC GGGCAAGTCA
GGCTATTGGG CATCGGTTAC
= W Y Q Q K P G K A P K L L I Y H R S K L Q 5 G V P S R F
S G S G S=
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q T Y Y R P
L T F G Q
CTGTCAACAG ACTTATTATC
GTCCTCTTAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO .: 385 DOM-110 - SEQ ID NO.: 271 I D P M L R-GGGC_AAGTCA
GGATATTGAT CCTATGTTAA
= W Y Q Q K P G K A P K L L I Y A G S I L Q S G V P S R F
S G S G S-TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
~1 G T D F T L T I 5 5 L Q P E D F A T Y Y C Q Q T S I R P
201 TGGGACAGAT TTCACTCTCA CCATCAGCAG TCTGCAACCT GAAG_ATTTTG CTACGTACTA
CTGTCAACAG ACTAGTATTA
GGCCTTATAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO. : 386 DOMB-111 - SEQ ID NO.: 272 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F E R Y P M
SUBSTITUTE SHEET (RULE 26) CCTCCGGATT
CACCTTTGAG CGTTATCCTA
= T W V R Q A P G K G L E W V S T I H G S G S A T Y Y A D
S V K G R-CTGGTAGTGC TACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K G P
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAAGGGCCG
Y T S R H N S L G H F D Y W G Q G T L V T V S S
ACCGTCTCGA GC - SEQ
ID NO.: 387 DOM-112 - SEQ ID NO.: 273 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F M D Y P M-CCTCCGGATT
CACCTTTATG GATTATCCTA
= G W V R Q A P G K G L E W V S S I G P V G M S T Y Y A D
S V K G R-TTGGTATGAG TACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y y C A K Y G
TGCCGAGGAT ACCGCGGTAT
ATTACTGTGC GAAATATGGG .
G T S G R H N T K F D Y W G Q G T L V T V S S
GTCTCGAGC - SEQ ID
NO.: 388 DOM-113 - SEQ ID NO.: 274 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F T E Y P M
SUBSTITUTE SHEET (RULE 26) CCTCCGGATT
CACCTTTACT G?1GTATCCTA
= S W V R Q A P G K G L E Td V S V I S P L G F T T Y Y A D
S V K G R=
TTGGTTTTAC GACATACTAC
GCAGACTCCG TGAAGGGCCG = F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y
Y
C A K W T
TGCCGAGGAT ACCGCGGTAT
ATTACTGTGC GAAATGGACT
G G S G I L N S S F D Y W G Q G T L V T V S S
GTCTCGAGC - SEQ ID
NO.: 389 DOM-114 - SEQ ID NO.: 275 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F R
V S N Y D L-CCTCCGGATT
TAGGGTTAGC AATTACGATT
= T W V R Q A P G K G L E W V S T I S A T N G S T Y Y A D
S V K G R
CAAACGGTAG CACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A A V T
TGCCGAGGAC ACCGCGGTAT
ATTATTGCGC GGCAGTGACG
W W L L R H N D N L G F W G Q G T L V T V S S
GTCTCGAGC - SEQ ID
NO.: 390 DOM-115 - SEQ ID NO.: 276 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F S
I S Y K N M
SUBSTITUTE SHEET (RULE 26) CCTCCGGATT
TAGCATTAGC TATAAGAATA
= A W V R Q A P G K G L E W V S A I K A A N G S T Y Y A D
S V K G R-CAAACGGTAG CACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A T G S
TGCCGAGGAC ACCGCGGTAT
ATTATTGCGC GACAGGGAGT
Q K K R T Y T F D F W G Q G T L V T V S S
SEQ ID NO.
DOM-120 - SEQ ID NO.: 277 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F R S Y T M=
CCTCCGGATT
CACCTTTAGG TCTTATACGA =
= G W V R Q A P G K G L E W V S S I N P M G Y Q T Y Y A D
S V K G R=
TGGGTTATCA GACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y y C A K H G
TGCCGAGGAT ACCGCGGTAT
ATTACTGTGC GAAACATGGG
V G K G T K P H N F D Y W G Q G T L V T V S S
GTCTCGAGC - SEQ ID
NO.: 392 DOM-121 - SEQ ID NO.: 278 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F E L Y R M
SUBSTITUTE SHEET (RULE 26) CCTCCGGATT
CACCTTTGAG CTGTATAGGA
= S W V R Q A P G K G L E W V S E I S G S G F P T Y Y A D
S V K G R=
GTGGTTTTCC TACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K S L
201 GTTCACCATC TCCCGCGACA ATTCCAAG_AA CACGCTGTAT CTGCAAATGA ACAGCCTGCG
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAAAGTCTG
H D K T Q H H Q E F D Y W G Q G T L V T V S S
GTCTCGAGC - SEQ ID
NO.: 393 DOM-123 - SEQ ID NO.: 279 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F I E Y P M=
CCTCCGGATT
CACCTTTATT GAGTATCCTA
= R W V R Q A P G K G L E W V S L I S P S G V F T Y Y A D
5 V K G R= 101 TGCGGTGGGT CCGCCAGGCT CCAGGGAAGG GTCTAGAGTG GGTCTCACTT
ATTTCTCCGT CTGGTGTGTT TACATACTAC GCAGACTCCG TGAAGGGCCG
F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y y C A K G D
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAAGGGGAT
E S S T F D Y W G Q G T L V T V S S
~ O 301 GAGTCTAGTA CTTTTGACTA CTGGGGTCAG GGAACCCTGG TCACCGTCTC GAGC - SEQ ID
NO .: 394 DOM-124 - SEQ ID NO.: 280 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F K R Y D M
SUBSTITUTE SHEET (RULE 26) CCTCCGGATT
CACCTTTAAG CGGTATGATA
. 'D W V R Q A P G K G L E W V S T I G S S G Y P T Y Y A D
S V K G R-CGGGTTATCC GACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A E R M
yI~ 201 GTTCACCATC TCCCGCGACA ATTCCAAGAA CACGCTGTAT CTGCAAATGA ACAGCCTGCG
TGCCGAGGAC ACCGCGGTAT
P G Y F P G F A R Q F D Y W G Q G T L V T V S S
301 CCTGGTTATT TTCCTGGGTT TGCTCGGCAG TTTGACTACT GGGGTCAGGG AkCCCTGGTC
ACCGTCTCGA GC - SEQ
ID NO.: 395 DOM-125 - SEQ ID NO.: 281 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F W R Y A M=
CCTCCGGATT
CACCTTTTGG CGGTATGCTA
G WVRQA P G K G L E W V S T I N D E G R E T Y Y A D
S V K G R
AGGGTCGGGA GACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K K R
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAAAAGCGG
V S S S V N A P Y E F D Y W G Q G T L V T V S S
ACCGTCTCGA GC - SEQ
ID NO.: 396 DOM-126 - SEQ ID NO.: 282 F A N Y S M
SUBSTITUTE SHEET (RULE 26) CCTCCGGATT
CACCTTTGCG AATTATAGTA
= S W V R Q P_ P G K G L E W V S S = D R L G T H T Y Y A D
S V K G R-TTGGTACGCA TACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K V L
=~ 201 GTTCACCATC TCCCGCGACA ATTCCAAGAA TACGCTGTAT CTGCAAATGA ACAGCCTGCG
TGCCGAGGAT ACCGCGGTAT
ATTACTGTGC GAAAGTGCTG
A D L I A G H A E F D Y W G Q G T L V T V S S
GTCTCGAGC - SEQ ID
NO.: 397 DOM-127 - SEQ ID NO.: 283 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F P S Y D M
CCTCCGGATT
CACCTTTCCG TCGTATGATA
= A W V R Q A P G K G L E W V S G I S R S G S M T Y Y A D
S V K G R-CTGGTTCTAT GACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K G V
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAAGGTGTT
D A H V Y Y M E P F F D Y W G Q G T L V T V S S
ACCGTCTCGA GC - SEQ
ID NO.: 398 DOM-128 - SEQ ID NO.: 284 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F E R Y Q M=
SUBSTITUTE SHEET (RULE 26) CCTCCGGATT
CACCTTTGAG AGGTATCAGA
= A W V R Q A P G K G L E W V S T I S S D G G G T Y Y A D
S V K G R-ATGGTGGGGG GACATACTAC
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K P G
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAACCGGGT
T V F D Y W G Q G T L V T V S S
301 ACTGTTTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC - SEQ ID NO .: 399 DOM-129 - SEQ ID NO.: 285 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F P K Y E M-CCTCCGGATT
CACATTTCCG AAGTATGAGA
= A W V R Q A P G K G L E W V S S I D G D G K S T Y Y A D
S V K G R-ATGGTAAGTC TACATACTAC
GCAGACTCCG TGAAGGGCCG
F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K P D
TGCCGAGGAT ACCGCGGTAT
ATTACTGTGC GAAACCGGAT
Q F F D Y W G Q G T L V T V S S
301 CAGTTTTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC - SEQ ID NO .: 400 DOM-130 - SEQ ID NO.: 286 E V Q L L E S G G G L V Q P G G S L R L S C T A S G F T
F A G Y Q M=
SUBSTITUTE SHEET (RULE 26) CCTCCGGATT
CACCTTTGCG GGTTATCAGA
= S W V R Q A P G K G L E W V S S I T N E G V S T Y Y A D
S V K G R-AGGGTGTTTC TACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K P G
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAACCGGGG
301 AAGTATTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC - SEQ ID NO.: 401 DOM-131 - SEQ ID NO.: 287 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F G E Y E M
CCTCCGGATT
CACCTTTGGG GAGTATGAGA
= V W V R Q A P G K G L E W V S S I T 5 D G L 5 T Y Y A D
S V K G R-ATGGTCTGAG TACATACTAC
GCAGACTCCG TGAAGGGCCG
C A K P G
TGCTGAGGAC ACCGCGGTAT
ATTACTGTGC GAAACCGGGT
I R F D Y W G Q G T L V T V S S
301 ATTCGTTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC - SEQ ID NO .: 402 DOM-132 - SEQ ID NO.: 288 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F A D Y D M
SUBSTITUTE SHEET (RULE 26) CCTCCGGATT
CACCTTTGCT GATTATGATA
= A W V R Q A P G K G L E W V S G I V D D G L M T Y Y A D
S V K G R-ATGGTCTTAT GACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K P D
201 GTTCACCATC TCCCGCGACA ATTCCAAGAP_ CACGCTGTAT CTGCAAATGA ACAGCCTGCG
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAACCGGAT
V A F D Y W G Q G T L V T V S N
301 GTTGCTTTTG ACTACTGGGG TCAGGGGACC CTGGTCACCG TCTCGAAC - SEQ ID NO .: 403 DOM-133 - SEQ ID NO.: 289 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F I G Y A M-CCTCCGGATT
CACCTTTATT GGTTATGCTA
= A W V R Q A P G K G L E W V S S I G P L G A T T Y Y A D
S V K G R-TGGGTGCGAC TACATACTAC
GCAGACTCCG TGAAGGGCCG
h = F T I S R D N S K N T L Y L Q M N S L P. A E D T A V Y Y
E,5 C A K L P
201 GTTCACCATC TCCCGCGACA ATTCCAAG_AA CACGCTGTAT CTGCAAATGA ACAGCCTGCG
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAATTGCCT
A G T S S H S V D F D Y W G Q G T L V T V S S
GTCTCGAGC - SEQ ID
NO. : 404 DOM-134 - SEQ ID NO.: 290 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F A D Y E M
SUBSTITUTE SHEET (RULE 26) CCTCCGGATT
CACCTTTGCG GATTATGAGA
= T W V R Q A P G K G L E W V S S I T S D G V S T Y Y A D
S V K G R-ATGGTGTTTC TACATACTAC
GCAGACTCCG TGAAGGGCCG
F T I S R D N S K N T I. Y L Q M N S L R A E D T A V Y y C A K P S
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAACCGTCG
V Q F D Y W G Q G T L V T V S S
301 GTTCAGTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC - SEQ ID NO . 405 DOM-135 - SEQ ID NO.: 291 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F R R Y V M=
CCTCCGGATT
CACCTTTCGT AGGTATGTTA
= G W V R Q A P G K G L E W V S W I E A D G R T T Y Y A D
S V K G R=
101 TGGGGTGGGT CCGCC_AGGCT CCAGGGAAGG GTCTAGAGTG GGTCTCATGG ATTGAGGCTG
ATGGTCGTAC GACATACTAC
GCAGACTCCG TG_AAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K G L
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAAGGGCTT
SEQ ID NO .
DOM-136 - SEQ ID NO.: 292 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F D G Y R M=
SUBSTITUTE SHEET (RULE 26) CCTCCGGATT
CACCTTTGAT GGTTATCGTA
G W V R Q A P G K G L E W V S S I A P D G N Y T Y Y A D
S V K G R
101 TGGGGTGGGT CCGCCAGGCT CCAGGGAAGG GTCTAGAGTG GGTCTCP_TCG ATTGCTCCGG
P_TGGTAATTA TACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K F W
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAATTTTGG
G M Q F D Y W G Q G T L V T V S S
301 GGGATGCAGT TTGACTACTG GGGTCAGGGA ACCCTGGTCA CCGTCTCGAG C - SEQ ID NO.: 407 DOM-137 - SEQ ID NO.: 293 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F A S Y P M-CCTCCGGATT
CACCTTTGCT TCGTATCCGA
G W V R Q A P G K G L E W V S S I G P I G F T T Y Y A D
S V K G R=
TTGGTTTTAC TACATACTAC
GCAGACTCCG TGAfiGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A E M K
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GGAAATGAAG
S P Y K P Q F D Y W G Q G T L V T V S S
NO .
DOM-138 - SEQ ID NO.: 294 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F L A Y W M
SUBSTITUTE SHEET (RULE 26) CCTCCGGATT
CACCTTTTTG GCTTATTGGA
= V W V R Q A P G K G L E W V S S I S P S G T H T Y Y A D
S V K G R-CGGGTACGCA TACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D 14 S K N T L Y L Q M N S L R V E D T A V Y Y
C A K Y T
1 201 GTTCACCATC TCCCGCGACA ATTCCAAGAA CACGCTGTAT CTGCAA.ATGA ACAGCCTGCG
TGTCGAGGAC ACCGCGGTAT
1~ ATTACTGTGC GAAATATACT
E P G L G S F D Y W G Q G T L V T V S S
NO .:
DOM-139 - SEQ ID NO.: 295 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F S N Y E M-CCTCCGGATT
CACCTTTTCG AATTATGAGA
= G W V R Q A P G K G L E W V S V I S E V G S L T Y Y A D
S V K G R-TGGGTTCTCT GACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y y C A K P H
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAACCTCAT
.
DOM-141 - SEQ ID NO.: 296 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q W
I G D T L T
SUBSTITUTE SHEET (RULE 26) GGGCAAGTCA
GTGGATTGGG GATACGTTAA
= A' Y Q Q K L G K A P K L L I Y G G S E L Q S G V P P R F
S G S G S=
TGCAAAGTGG GGTCCCACCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S 5 L Q P E D F A T Y Y C Q Q C I S S P
C T F G Q
CTGTCAACAG TGTATTAGTA
GTCCTTGTAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO .: 411 DOM-142 - SEQ ID NO.: 297 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q F
I G D S L S=
GGGCAAGTCA
GTTTATTGGT GATTCTTTAT
= W Y Q Q % P G K A P K L L I Y F S S I L Q S G V P S R F
S G S G S=
101 CTTGGTACCA GCAG_AAACCA GGGAAAGCCC CTAAGCTCCT GATCTATTTT TCTTCCATTT
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S 8 L Q P E D F A T Y Y C Q Q Y H T S P
T T F G R
CTGTCAACAG TATCATACTT
CGCCTACTAC GTTCGGCCGA
G T K V K. I K R
301 GGGACCAAGG TGAAAATCAA ACGG - SEQ ID NO .: 412 DOM-143 - SEQ ID NO.: 298 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q T
I E T N L E
SUBSTITUTE SHEET (RULE 26) GGGCAAGTCA
GACTATTGAG ACTAATTTAG
= W Y Q Q K P G K A P K L L I Y D S S Q L Q S G V P S R F
S G S G S=
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S S L Q P E D L A T Y Y C Q Q YHGYP
T T F G Q
CTGTCAACAG TATCATGGGT
ATCCTACGAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO .: 413 DOM-144 - SEQ ID NO.: 299 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q M
I D Q D L E-GGGCAAGTCA
GATGATTGAT CAGGATTTAG
= W Y Q Q K P G K A P K L L I Y N A S W L Q S G V P S R F
S G S G S-TGCAAAGTGG GGTCCCATCA
CGTTTCAGCG GCAGTGGATC
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q Y H G Y P
I T F G Q
CTGTCAACAG TATCATGGTT
ATCCTATTAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO. : 414 DOM-145 - SEQ ID NO.: 300 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q T
SUBSTITUTE SHEET (RULE 26) GGGCAAGTCA
GACGATTTP_T ACTTCGTTAA
= W Y Q Q K P G K A P K L L I H Y G S V L Q S G V P S R F
S G S G S-TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S S L Q P E D S A T Y Y C Q Q V H Q A P
T T F G Q
CTGTCAACAG GTTCATCAGG
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO. : 4Zr'J
DOM-146 - SEQ ID NO.: 301 D I R M T Q S P S S L S A S V G D R V T I T C R A S Q W
I G D S L A-GTGGATTGGG GATTCTTTAG
= W Y Q Q K P G K A P K L L I Y G I S E L Q S G V P S R F
S G S G S-TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
C = G T D F T L T I S S L Q P E D S A T Y Y C Q L S S 5 M P
H T F G Q
CTGTCAACTG TCTAGTAGTA
TGCCTCATAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO .: 416 DOM-147 - SEQ ID NO.: 302 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q E
I E T N L E=
SUBSTITUTE SHEET (RULE 26) 1 GACATCCAGA TGACCCAGTC TCCP_TCCTCC CTGTCTGCAT CTGTAGGAGA CCGTGTCACC
ATCACTTGCC GGGCAAGTCA
GGAGATTGAG ACGAATTTAG
= W Y Q Q K P G K A P K L L I Y D S S H L Q S G V P S R F
G S G S=
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q Y H Q N P
P T F G Q
y 201 TGGGACAGAT TTCACTCTCA CCATCAGCAG TCTGCAMCT GAAGATTTTG CTACGTACTA
CTGTC_AACAG TATCATCAGA
ATCCTCCGAC GTTCGGCCAA
G T K V E I K R
301 GGAACCAAGG TGGAAATCAA ACGG - SEQ ID NO .: 417 DOM-149 - SEQ ID NO.: 303 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q W
I G R Q L V=
GGGCAAGTCA
GTGGATTGGG AGGCAGTTAG
= W Y Q Q K P G K A P K L L I Y G A T E L Q S G V P S R F
S G S G S=
TGCAAAGTGG GGTCCCATCA
CGTTTTAGTG GCAGTGGATC
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q Q S K G P
L T F G H
CTGTCAACAG CAGTCGAAGG
GTCCTCTTAC GTTCGGCCAT
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO .: 418 DOM-150 - SEQ ID NO.: 304 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q G
I G T D L N
SUBSTITUTE SHEET (RULE 26) ' 1 GACATCCAGA TGACCCAGTC TCCATCCTCC CTGTCTGCAT CTGTAGGAGA CCGTGTCACC
ATCACTTGCC GGGCAAGTCA
GGGGATTGGT ACTGATTTAA
= W Y Q Q K P G K A P K L L I Y M G S Y L Q S G V P S R F
S G S G S=
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q I Y S F p I T F G Q
CTGTCAACAG ATTTATTCTT
TTCCTATTAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO .: 419 DOM-154 - SEQ ID NO.: 305 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q D
I E E M L H-GGGCAAGTCA
GGATATTGAG GAGATGTTAC
= W Y Q Q K P G K A P K L L I Y F G S L L Q S G V P S R F
S G S R S-TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTAGATC
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q H H T R P
Y T F G Q
CTGTCAACAG CATCATACTC
GTCCTTATAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO. : 420 DOM-155 - SEQ ID NO.: 306 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q D
I G M D L E
SUBSTITUTE SHEET (RULE 26) GGGCAAGTCA
GGATP_TTGGG ATGGATTTAG
= W Y Q Q I P G K V P K L L I Y D A S Y L Q S G V P S R F
S G S G S
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T T S S L Q P E D F A T Y Y C Q Q Y H K L P
A T F G Q
CTGTCAACAG TATCATAAGC
TTCCTGCGAC GTTTGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO .: 421 DOM-156 - SEQ ID NO.: 307 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q D
I M D N L E=
GGGCAAGTCA
GGATATTATG GATAATTTAG
= W Y Q Q K P G K A P K L L I Y A A S W L Q S G V P S R F
S G S G S=
TGCAATkGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q Y H K L P
V T F G Q
CTGTCAACAG TATCATAAGT
TGCCTGTGAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO .: 422 DOM-157 - SEQ ID NO.: 308 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q N
I G E D L E=
SUBSTITUTE SHEET (RULE 26) GAGCAAGTCA
GAATATTGGG GAGGATTTAG
= W Y Q Q K P G N A p K L L I Y S A S H L Q S G V P S R F
S G S G S=
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q Y 5 S Y P
V T F G Q
CTGTCAACAG TATTCTAGTT
ATCCTGTTAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO .: 423 DOM-158 - SEQ ID NO.: 309 I D E D L E-GGGCAAGTCA
GCCGATTGAT GAGGATTTAG
= W Y Q Q K P G N A P K L L I Y 5 A S Y L Q S G V P S R F
S G SGS =
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S R L Q P E D F A T Y Y C Q Q Y H L L P25 A T F G Q
CTGTCAACAG TATCATCTTC
TGCCTGCTAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO. : 424 DOM-159 - SEQ ID NO.: 310 I N E D L E
SUBSTITUTE SHEET (RULE 26) GGGCPAGTCA
GGATATTAAT GAGGATTTAG
= W Y Q Q K P G K A P K L L I Y N A S M L Q S G V P S R F
S G S G S-101 AGTGGTATCA GCAGAAACCA GGGAAAGCCC CTAAGCTCCT GATCTATAAT GCTTCCP.TGT
TGCAAAGCGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S S ,L Q P K D F A T Y Y C Q Q Y H T N P
T T F G Q
CTGTCAACAG TATCATACTA
ATCCTACTAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO.: 425 DOM-160 - SEQ ID NO.: 311 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q D
I E A D L E-GGGCAAGTCA
GGATATTGAG GCGGATTTAG
. W Y Q Q K P G K A P K L L I Y H S S E L Q S G V P S R F
S G S G S=
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GAAGTGGATC
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q Y H M S P
V T F G Q
CTGTCAACAG TATCATATGT
CGCCTGTGAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO.: 426 DOM-161 - SEQ ID NO.: 312 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q D
I D SDLE
SUBSTITUTE SHEET (RULE 26) 1 GACATCCAGP. TGACCCAGTC TCCATCCTCC CTGTCTGCAT CTGTAGGAGA CCGTGTCACC
ATCACTTGCC GGGCAAGTCA
GGATATTGAT AGTGATTTAG
= W Y Q Q K P G Y. A P M L L I Y S S S D L Q 5 G V P S R F
S G S G S-101 AGTGGTACCA GCAGAAACCA GGGAAAGCCC CTATGCTCCT GATCTP_TTCT TCGTCCGATT
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC =
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q Y H S L P
V T F G Q
CTGTCAACAG TATCATAGTC
TGCCTGTTAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO. : 427 DOM-162 - SEQ ID NO.: 313 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q D
I S D D L E=
GGGCAAGTCA
GGATATTTCG GATGATTTAG
= W Y Q Q K P G K A P K L L I Y N S S F L Q S G V P S R F
S G S G S=
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
G A D F T L T I S S L Q P E D F A T Y Y C Q Q Y H S L P
V T F G Q
CTGTCAACAG TATCATAGTT
TGCCTGTTAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO. : 428 DOM-163 - SEQ ID NO.: 314 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q D
I E G N L E
SUBSTITUTE SHEET (RULE 26) I GP.CATCCAGE TGACCCAGTC TCCATCCTCC CTGTCTGCAT CTGTAGGAGA CCGTGTCACC
ATCACTTGCC GGGCAAGTCA
GGP_TATTGAG GGTAATTTAG
= W Y Q Q K P G K A P K L L I Y D S S Q L Q S G V P S R F
S G S G S-J 101 AGTGGTACCA GCAGAAACCA GGGAAAGCCC CT_AAGCTCCT GATCTATGAT TCGTCCCAGT
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGGTC
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q Y H H L P
T T F G Q
CTGTCAACAG TATCATCATC
TTCCTACGAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO .: 429 DOM-164 - SEQ ID NO.: 315 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q S
I D T D L E-GGGCAAGTCA
GAGTATTGAT ACGGATTTAG
= W Y Q Q K P G K A P K L L I Y D G S W L Q S G V P S R F
S G S G S
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D_ F T L T I S S L Q P E D F A T Y Y C Q Q Y R W I P
V T F G Q
CTGTCAACAG TATCGGTGGA
TTCCTGTTAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO. : 430 DOM-165 - SEQ ID NO.: 316 I S T D L E
SUBSTITUTE SHEET (RULE 26) GGGCAAGTCA
GAGTATTAGT ACTGATTTAG
= W Y Q Q K L G K A P K L L I Y D A S L L Q S G V P S R F
S G S G S-TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I 5 5 L Q P E D F A T Y Y C Q Q Y S S L P
V T F G Q
CTGTCAACAG TATTCGAGTC
TGCCTGTTAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO. : 431 DOM-166 - SEQ ID NO.: 317 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q P
I T T S L E-GGGCAAGTCA
GCCTATTACG ACGTCTTTAG
= W Y Q Q K P G K A P K L L I Y D A S M L Q S G V P S R F
S G S G S
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q Y W V T P
V T F G Q
CTGTCAACAG TATTGGGTTA
CGCCTGTTAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGABATCAA ACGG - SEQ ID NO .: 432 DOM-167 - SEQ ID NO.: 318 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q N
I H T N L E
SUBSTITUTE SHEET (RULE 26) GGGCTIAGTCA
GAATATTCAT ACGAATTTAG
= W Y Q Q K P G K A P K L L I Y D G S M L Q S G V P S R F
S G S G S=
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S 5 L Q P E D F A T Y Y C Q Q Y S A N P
V T F G Q
CTGTCAACAG TATTCGGCTA
ATCCTGTTAC GTTCGGCCAA
G T K V G I K R
301 GGGACCAAGG TGGGAATCAA ACGG - SEQ ID NO. : 433 DOM-168 - SEQ ID NO.: 319 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q W
I H T D L E-GGGCAAGTCA
GTGGATTCAT ACGGATTTAG 20 = W Y Q Q K P G K A P K L L I Y D G S M L Q S G V P S
R F
S G S G S=
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q Y S V S P
V T F G Q
CTGTCAACAG TATAGTGTGT
CGCCTGTTAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO. : 434 DOM-169 - SEQ ID NO.: 320 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q S
I D N N L E
SUBSTITUTE SHEET (RULE 26) GGGCAAGTCA
GAGTATTGAT AATAATTTAG
= W Y Q Q K P G E P_ P K L L I Y D G S L L Q S G V P S R F
S G S G 5=
TGCAzIAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q Y H L H P
V T F G Q
CTGTCAACAG TATCATCTTC
ATCCTGTTAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO. : 435 DOM-170 - SEQ ID NO.: 321 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q D
I D T N L E
GGGCAAGTCA
GGATATTGAT ACGAATTTAG
= W Y Q Q K P G E A P K L L I Y D R S T L Q S G V P S R F
S G S G S
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q Y D S Y P
V T F G Q
CTGTCAACAG TATGATTCTT
ATCCTGTGAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO. : 436 DOM-171 - SEQ ID NO.: 322 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q S
I E S N L E=
SUBSTITUTE SHEET (RULE 26) 1 GACATCCAGA TGACCCAGTC TCCATCCTCC CTGTCTGCAT CTGTAGGAG_A CCGTGTCACC
ATCACTTGCC GGGCARGTCA
GTCTATTGAG TCTAATTTAG
= W Y Q Q K P G K A P K L L I Y N A S E L Q S G V P S R F
S G S G S-TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S S L R P E D F A T Y Y C Q Q Y D Q W P
T T F G Q
CTGTCAACAG TATGATCAGT
GGCCTACGAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO. : 437 DOM-172 - SEQ ID NO.: 323 I G N T L R-GGGCAAGTCA
GGCTATTGGT AATACTTTAC
= W Y Q Q K P G K A P K L L I Y L S S R L Q S G V P S R F
S G S G S=
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
G T D F T L T I S S L Q P E D F A T Y Y C Q Q L K K P P
Y T F G Q
CTGTCAACAG CTGAAGAAGC
CTCCTTATAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO. : 438 DOM-173 - SEQ ID NO.: 324 I K N R L A
SUBSTITUTE SHEET (RULE 26) 1 GACETCCAGA TGACCCAGTC TCCATCCTCC CTGTCTGCAT CTGTAGGAG_A CCGTGTCACC
ATCACTTGCC GGGCAAGTCA
GAAGATTAAG AATCGGTTAG
= W Y Q Q K P G K A P K L L I Y E V S H L Q S G V P S R F
S G S O S
=
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I G S L Q P E D F A T Y Y C Q Q R R Q S P
Y T F G Q
CTGTCAACAG AGGAGGCAGT
CGCCTTATAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO. : 439 DOM-174 - SEQ ID NO.: 325 I G E E L F-GGGCAAGTGA
GGATATTGGG GAGGAGTTAT
= W Y Q Q K P G K A P K L L I Y S A S T L Q S E V P S R F
S G S G S-101 TTTGGTATCA GCAGAA.'ACCA GGGAAAGCCC CTAAGCTCCT GATCTATTCG GCGTCCACGT
TGCAAAGTGA GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S S L Q H E D F A T Y Y C Q Q V Y E W P
Y T F G Q
CTGTCAACAG GTTTATGAGT
GGCCTTATAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO. : 440 DOM-175 - SEQ ID NO.: 326 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q P
I S G G L R=
GGGCAAGTCA
GCCTATTTCT GGGGGTTTAA
SUBSTITUTE SHEET (RULE 26) = W Y Q Q K P G K A P K L L I Y S T S M L Q S G V P S R F
S G S G S-TGCAA.AGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q L Y S A P
Y T F G Q
CTGTCAACAG CTTTATTCTG
CTCCTTATAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO. : 441 DOM-176 - SEQ ID NO.: 327 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F D A Y E M-CCTCCGGATT
CACCTTTGAT GCGTATGAGA
G W V R Q A P G K G L E W V S I I D W D G N S T Y Y A D
S V K G R=
ATGGTAATTC TACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K P G
TGCCGAGGAT ACCGCGGTAT
ATTACTGTGC GAAACCTGGG
D N V G I F D Y W G Q G T L V T V S S
NO.
DOM-177 - SEQ ID NO.: 328 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F S N Y Y M
CCTCCGGATT
CACCTTTAGT AATTATTATA
SUBSTITUTE SHEET (RULE 26) = V W V R Q A P G K G L E W V S A I D E W G F A T Y Y A D
S V K G R-GGGGTTTTGC GACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K H W
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAAACATTGG
E F T S D T S R F D Y W G Q G T L V T V S S
SEQ ID
NO.. 443 DOM-178 - SEQ ID NO.: 329 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F E D F D M-CCTCCGGATT
CACCTTTGAG GATTTTGATA
A W V R Q A P G K G L E W V S S I N D Q G S L T Y Y A D
S V K G R=
AGGGTTCTCT GACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K P D
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAACCGGAT
Q F F D Y W G Q G T L V T V S S
301 CAGTTTTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC - SEQ ID NO .: 444 DOM-179 - SEQ ID NO.: 330 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F S A Y D M=
CCTCCGGATT
CACCTTTAGT GCTTATGATA
SUBSTITUTE SHEET (RULE 26) = M W V R Q A P G K G L E W V S R I S P Q G Q R T Y Y A D
S V K G R=
AGGGTCAGCG GACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K I R
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAAATTCGT
G Q S R I P M R F D Y W G Q G T L V
301 GGGCAGTCGC GGATTCCTAT GAGGTTTGAC TACTGGGGTC AGGGAACCCT GGTC - SEQ ID NO .:
DOM-180 - SEQ ID NO.: 331 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F T D Y E M-CCTCCGGATT
CACCTTTACG GATTATGAGA
= G W V R Q A P G K G L E W V S T I T S L G E S T Y Y A D
5 V K G R=
TGGGTGAGAG TACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K P G
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAACCTGGT
R I F D Y W G Q G T L V T V S S
301 CGTATTTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC - SEQ ID NO .: 446 DOM-181 - SEQ ID NO.: 332 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F A F Y P M=
CCTCCGGATT
CACCTTTGCT TTTTATCCTA
SUBSTITUTE SHEET (RULE 26) = M W V R Q A P G K G L E W V S W I D A T G T R T Y Y A D
V K G R=
CGGGTACGAG GACATACTAC
GCAGACTCCG TGAAGGGCCG
5 = F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A E G N
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GGAAGGTAAT
GTCTCGAGC - SEQ ID
NO.: 447 DOM-182 - SEQ ID NO.: 333 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F D E Y P M-CCTCCGGATT
CACCTTTGAT GAGTATCCGA
Y W V R Q A P G K G L E W V S S I G P S G P N T Y Y A D
S V K G R=
CTGGTCCGAA TACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K S P
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAATCTCCG
Y F D V I P S Y F D Y W G Q G T L V T V S S
SEQ ID
NO.: 448 DOM-183 - SEQ ID NO.: 334 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F A D Y G M-CCTCCGGATT
CACCTTTGCG GATTACGGTA
SUBSTITUTE SHEET (RULE 26) = G W V R Q A P G K G L E W V S S I Q S S G L R T Y Y A D
S V K G R=
CGGGTTTGCG GACATACTAC
GCAGACTCCG TGAAGGGCCG
F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K R A
TGCCGAGGAT ACCGCGGTAT
ATTACTGTGC GAAACGGGCT
N S R R G F D Y W G Q G T L V T V S S
.
DOM-184 - SEQ ID NO.: 335 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F S D Y E M
CCTCCGGATT
CACCTTTTCT GATTATGAGA
M W V R Q A P G K G L E W V S S I T S H G G S T Y Y A D
S V K G R-ATGGTGGGTC TACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K P D
TGCCGAGGAT ACCGCGGTAT
ATTACTGTGC GAAACCTGAT
K D F D Y W G Q G T L V T V S S
301 AAGGATTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC - SEQ ID NO.: 450 DOM-185 - SEQ ID NO.: 336 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F A H Y P M
TCCTGTGCAG CCTCCGGATT
CACCTTTGCG CATTATCCGA
SUBSTITUTE SHEET (RULE 26) = S W V R Q A P G K G L E W V S S i G R L G N R T Y Y A D
S V K G R=
TGGGTAATCG TACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I 5 R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K R A
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAACGTGCT
T P V P I K G L F D Y W G Q G T L V T V S S
SEQ ID
NO.. 451 DOM-186 - SEQ ID NO.: 337 E V Q L L E S G G G L V Q P G G S L R L S C A A S G L T
F G R Y E M-CCTCCGGACT
CACCTTTGGG AGGTATGAGA
A W V R Q A P G K G L E W V S S I D S D G W V T Y Y A D
S V K G R
ATGGTTGGGT GACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A Q P D
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GCAACCGGAT
S L F D Y W G Q G T L V T V S S
301 TCGTTGTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC - SEQ ID NO .: 452 DOM-187 - SEQ ID NO.: 338 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F S 5 Y S M=
TCCTGTGCAG CCTCCGGATT
CACCTTTTCT AGTTATTCTA
SUBSTITUTE SHEET (RULE 26) = V W V R Q A P G K G L E W V S G I N R G G T R T Y Y A D
S V K G R =
GTGGTACTCG TACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K G W
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAAGGTTGG
R R G F D Y W G Q G T L V T V S S
301 AGGAGGGGGT TTGACTACTG GGGTCAGGGA ACCCTGGTCA CCGTCTCGAG C - SEQ ID NO .:
DOM-188 - SEQ ID NO.: 339 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F T R Y R M.
CCTCCGGATT
CACCTTTACG CGTTATAGGA
= S W V R Q A P G K G L E W V S G I S R D G Y R T Y Y A D
S V K G R=
ATGGTTATCG GACATACTAC
GCAGACTCCG TG_AAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K G M
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAAGGTATG
301 ACTGCGTCGT TTGACTACTG GGGTCAGGGA ACCCTGGTCA CCGTCTCGAG C - SEQ ID NO .:
DOM-189 - SEQ ID NO.: 340 F Q M Y P M-CCTCCGGATT
CACCTTTCAG ATGTATCCGA
SUBSTITUTE SHEET (RULE 26) = G W V R Q A P G K G L E W V S M I E P A G D L T Y Y A D
S V K G R-CTGGTGATCT TACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K Y Q
201 GTTCACCATC TCCCGCGACA ATTCCAAG_AA CACGCTGTAT CTGCAAATGA ACAGCCTGCG
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAATATCAG
E Q P W F D Y W G Q G T L V T V S S
301 GAGCAGCCTT GGTTTGACTA CTGGGGTCAG GGAACCCTGG TCACCGTCTC GAGC - SEQ ID NO .:
DOM-190 - SEQ ID NO.: 341 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F S M Y D M-CCTCCGGATT CACCTTTAGT ATGTATGATA
= H W V R Q A P G K G L E W V S T I L S D G T D T Y Y A D
S V K G R-ATGGTACGGA TACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K Y G
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAATATGGG
A M F D Y W G Q G T L V T V S S
301 GCTATGTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC - SEQ ID NO.: 456 30 DOM-191 - SEQ ID NO.: '342 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F K L Y P M
CCTCCGGATT
CACCTTTAAG TTGTATCCGA
SUBSTITUTE SHEET (RULE 26) T W V R Q A P G K G L E W V S S I D A G G H E T Y Y A D
S V K G R=
GGGGTCATGP_ GACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K D W
TGCCGAGGAT ACCGCGGTAT
ATTACTGTGC GAAAGATTGG
W D Y L F D Y W G Q G T L V T V S S
301 TGGGATTATC TGTTTGACTA CTGGGGTCAG GGAACCCTGG TCACCGTCTC GAGC - SEQ ID NO.:
DOM-192 - SEQ ID NO.: 343 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F S R Y P M-CCTCCGGATT
CACCTTTTCG CGGTATCCGA
= S W V R Q A P G K G L E W V S S I N R S G M R T Y Y A D
S V K G R=
CGGGTATGCG GACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A E G H
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GGAAGGGCAT
Q A P F D Y W G Q G T L V T V S S
301 CAGGCGCCGT TTGACTACTG GGGTCAGGGA ACCCTGGTCA CCGTCTCGAG C - SEQ ID NO .:
DOM-193 - SEQ ID NO.: 344 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F T G Y A M
CCTCCGGATT
CACCTTTACG GGGTATGCTA
SUBSTITUTE SHEET (RULE 26) = S W V R Q A P G K G L E W V B T I N A N G I R T Y Y A D
S V K G R
ATGGTATTCG GACATACTAC
GCCGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N G L R A E D T A V Y Y
C A K G G
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAAGGGGGG
V W R W G T G H K F D Y W G Q G T L V T V S S
GTCTCGAGC - SEQ ID
NO.: 459 DOM-194 - SEQ ID NO.: 345 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F K Q Y D M-CCTCCGGATT
CACCTTTAAG CAGTATGATA
R W V R Q A P G K G L E W V S T I S Q N GT K T Y Y A D
S V K G R-ATGGTACTAA GACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K S R
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAATCGAGG
T G R Y F D Y W G Q G T L V T V S S
301 ACTGGTAGGT ATTTTGACTA CTGGGGTCAG GGAACCCTGG TCACCGTCTC GAGC - SEQ ID NO .:
DOM-195 - SEQ ID NO.: 346 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F G T Y D M
CCTCCGGATT
CACCTTTGGG ACTTATGATA
SUBSTITUTE SHEET (RULE 26) = G W V R Q A P G K G L E W V S R I N W Q G D R T Y Y A D
S V K G R=
AGGGTGATCG TACATACTAC
GCAGACTCCG TGAAGGGCCG
F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y y C A K A G
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAAGCGGGG
F G H Y V D G L G F D Y W G Q G T L V T V S S
GTCTCGAGC - SEQ ID
NO.. 461 DOM-196 - SEQ ID NO.: 347 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F S G Y E M-CCTCCGGATT
CACCTTTAGT GGGTATGAGA
A W V R Q A P G K G L E W V S S I T D M G D S T Y. Y A D
S V K G R=
TGGGTGATTC TACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K P G
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAACCTGGG
T A F D Y W G P G T L V T V S S
301 ACTGCGTTTG ACTACTGGGG TCCGGGAACC CTGGTCACCG TCTCGAGC - SEQ ID NO .: 462 DOM-197 - SEQ ID NO.: 348 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F A K Y K M
TCCTGTGCAG CCTCCGGATT
CACCTTTGCG AAGTATAAGA
SUBSTITUTE SHEET (RULE 26) = W W V R Q A P G K G L E W V S 5 I T P K G H S T Y Y A D
S V K G R=
AGGGTCATTC TACATACTAC
GCAGACTCCG TGAAGGGCCG
C A K R P
TGCCGAGGAT ACCGCGGTAT
ATTACTGTGC GAAAAGGCCG
M T P F D Y W G Q G T L V T V S S
301 ATGACTCCGT TTGACTACTG GGGTCAGGGA ACCCTGGTCA CCGTCTCGAG C - SEQ ID NO .:
DOM-198 - SEQ ID NO.: 349 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F E R Y N M-CCTCCGGATT
CACCTTTGAG CGGTATAATA
= S W V R Q A P G K G L E W V S S I R P R G G K T Y Y A D
S V K G R
GGGGTGGGAP_ GACATACTAC GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K W R
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAATGGCGG
R E G Y T G S K F D Y W G Q G T L V T V S S
SEQ ID
NO.: 464 DOM-199 - SEQ ID NO.: 350 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F E R Y G M
CCTCCGGATT
CACCTTTGAG AGGTATGGTA
SUBSTITUTE SHEET (RULE 26) T W V R Q A P G K G L E W V S S I W P R G Q K T Y Y A D
S V K G R=
GGGGTCAGAA GACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K G N
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAAGGGAAT
S R Y V P D Y W G Q G T L V T V S S
301 AGTCGGTATG TTTTTGACTA CTGGGGTCAG GGAACCCTGG TCACCGTCTC GAGC - SEQ ID NO .:
DOM-200 - SEQ ID NO.: 351 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F T N Y S M=
CCTCCGGATT
CACCTTTACT AATTATAGTA
= G W V R Q A P G K G L E W V S T I R P N G T K T Y Y A D
S V K G R=
ATGGTACTAA GACATACTAC
GCAGACTCCG TGAAGGGCCG F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y y C A K R S
201 GTTCACCATC TCCCGCGACA ATTCCAAG_AA CACGCTGTAT CTGCAAATGA ACAGCCTGCG
TGCCGAGGAT ACCGCGGTAT
ATTACTGTGC GAAACGGTCG
S A H L Q R F D Y W G Q G T L V T V S S
NO.
DOM-201 - SEQ ID NO.: 352 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F G N Y S M
CCTCCGGATT
CACCTTTGGT AATTATTCGA
SUBSTITUTE SHEET (RULE 26) = G W V R Q A P G I< G L E W V S S I G R H G G R T Y Y A D
S V K G R-ATGGTGGGCG TACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K 19 T L Y L Q M N S L R A E D T A V Y y C A K K G
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAAAAGGGG
S T Y P R F D Y W G Q G T L V T V S S
NO.
DOM-202 - SEQ ID NO.:. 353 E V Q L L E S G G G L V Q P G G S L R L S C T A S G P T
F S H Y E MI
CCTCCGGATT
CACCTTTTCG CATTATGAGA G W V R Q A P G K G L E W V S S I E P F G G G T Y Y A D
S V K G R
TTGGTGGTGG GACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K V Y
TGCCGAGGAT ACCGCGGTAT
ATTACTGTGC GAAAGTGTAT
P Q G S F D Y W G Q G T L V T V S S
301 CCTCAGGGTT CTTTTGACTA CTGGGGTCAG GGAACCCTGG TCACCGTCTC GAGC - SEQ ID NO.:
DOM-203 - SEQ ID NO.: 354 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F S N Y T M-CCTCCGGATT
CACCTTTAGT AATTATACTA
SUBSTITUTE SHEET (RULE 26) S V K G G R W V R Q A P G K G L E W V S S I R P D G K I T Y Y p D
ATGGTAAGAT TACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A E V Y
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GGAAGTTTAT
S S C A M C T P L L F D Y W G Q G T L V T V S S
ACCGTCTCGA GC - SEQ
ID NO.: 469 DOM-204 - SEQ ID NO.: 355 F K R Y S M-CCTCCGGATT
CACCTTTAAG CGGTATTCGA
S V K G A R W V R Q A P G K G L E W V S D I' G P R G F S T Y Y A D
GGGGTTTTTC GACATACTAC
GCAGACTCCG TGAAGGGCCG
F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K V G
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAAGTGGGT
R G Q R D T S Q P F D Y W G Q G T L V T V S S
GTCTCGAGC - SEQ ID
NO.: 470 DOM-205 - SEQ ID NO.: 356 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F A S Y Q M-CCTCCGGATT
CACCTTTGCT TCTTATCAGA
SUBSTITUTE SHEET (RULE 26) = A W V R Q A P G K G L E W V S G I T S G G L S T Y Y A D
S V K G R-GTGGTCTTAG TACGTACTAC
GCAGACTCCG TGAAGGGCCG
F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K P G
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAACCGGGG
R G F D Y W G Q G T L V T V S S
301 AGGGGTTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC - SEQ ID NO .: 471 DOM-206 - SEQ ID NO.: 357 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F A S Y E M.
CCTCCGGATT
CACCTTTGCT TCTTATGAGA
= T W V R Q A P G K G L E W V S G I S S D G L S T Y Y A D
S V K G R=
ATGGTCTGTC TACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K P G
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAACCGGGG
V L F D Y W G Q G T L V T V S S
301 GTGTTGTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC - SEQ ID NO .: 472 DOM-207 - SEQ ID NO.: 358 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F D K Y L M=
CCTCTGGATT
CACCTTTGAT AAGTATTTGA
SUBSTITUTE SHEET (RULE 26) = S W V R Q A P G K G L E W V S G I E P L G D V T Y Y A D
S V K G R-TGGGTGATGT TACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y y C A K E A
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAAGAGGCT
S G D F D Y W G Q G T L V T V S S
301 TCGGGGGATT TTGACTACTG GGGTCAGGGA ACCCTGGTCA CCGTCTCGAG C- SEQ ID NO .: 473 DOM-208 - SEQ ID NO.: 359 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
J F T E Y E M-I GAGGTGCAGC TGTTGGAGTC TGGGGGAGGC TTGGTACAGC CTGGGGGGTC CCTGCGTCTC TCCTGTGCAG
CCTCCGGGTT
CACCTTTACT GAGTATGAGA
= S W V R Q A P G K G L E W V S S I D N V G S S T Y Y A D
S V K G R=
TGGGTAGTAG TACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N 5 K N T L Y L Q M N S L R A E D T A V Y Y
C A K P G
TGCCGAGGAT ACCGCGGTAT
ATTACTGTGC GAAACCTGGG
K L F D Y W G Q G T L V T V S S
301 AAGCTTTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC - SEQ ID NO.: 474 DOM-209 - SEQ ID NO.: 360 E V Q L L E S G G G T, V Q P G G S L R L S C A A S G F T
F A D Y E M=
CCTCCGGATT
CACCTTTGCT GATTATGAGA
SUBSTITUTE SHEET (RULE 26) W W V R Q A P G K G L E W V S A I S R Q G F A T Y Y A D
S V K G R-AGGGTTTTGC TACATACTAC
GCAGACTCCG TGAAAGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K D L
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAAGATCTG
E R D D F D Y W G Q G T L V T V S S
301 GAGCGGGATG ATTTTGACTA CTGGGGTCAG GGAACCCTGG TCACCGTCTC GAGC ~ SEQ ID NO .:
Among the DOM clones described, a number of observations have been made regarding homology among clones, and properties of amino acids predicted at particular positions in the anti-CD40L dAbs. These are shown in Tables 9 and 10 below:
Table 9. Predictions for anti-VPI CD40L clones: (using standard sin6le letter amino acid code Predicted Predicted Predicted Properties of Amino acid amino acid Kabat dummy amino amino acids frequently number numbering acid at this frequently fount at the relative to position fount at the designated dummy designated position in sequence position in anti-CD40L
anti-CD40L dAbs dAbs 30 30 S acidic; small D, E, A, G
33 33 A mix Q,E,P,G
35 35 S mix A,M,G,T
50 50 A nucleophilic; S, T, G, W
or G, W
52 52 S hydrophilic; or T, S, G, D, N
G,D,N
53 53 G mix P, R, S, D
54 54 S acidic; or L, I, D, E, L, I, Q
Q
99* 95 S hydrophobic; P, G, V, L
or P, G
100 96 y mix G, D, R, L
* If amino acid at position 99 (dummy) is P then G or D is frequently found at position 100.
Table 10. Predictions for anti-VK CD40L clones:
Predicted Predicted Predicted Properties of Amino acid amino acid Kabat dummy amino amino acids frequently number numbering acid at this frequently fount at the relative to position fount at the designated dummy designated position in sequence position in anti-CD40L
anti-CD40L dAbs dAbs 28M 28 S mix A, D, W, P
30 30 S acidic; or G G, D, E
32 32 Y mix R, S, D, N
34 34 N acidic or basic R. E
50 50 A mix H, D, G, S
51 51 A mix S, G, R
53 53 S hydrophobic; I, L, M, K, E, or K, E W
91 91 S mix Y, R, V
92 92 Y basic; or S, W H, S, W, R
96 96 N mix Y, V, A, T
*If amino acid at position 28 (dummy) is D then E is frequently found at position 34.
**If amino acid at position 34 (dummy) is E then Y is frequently found at position 91 and H or D
at position 92.
Example 8: PEGylation of DOM8-24 Site specific maleimide-PEGylation of DOMB-24 requires a solvent accessible cysteine to be provided on the surface of the protein, in this example, at the C-terminus. The cysteine residue, once reduced to give the free thiol, can then be used to specifically couple the protein to PEG via a wide range of chemistries such as maleimide or another thiol to give a disulphide. A
wide range of chemical modified PEGs of different sizes and branched formats are available 0 from Nektar (formally known as Shearwater Corp). This allows the basic dAb-cys monomer to be formatted in a variety of ways for example as a PEGylated monomer, dimer, trimer, tetramer etc. The size of the PEGs is given in kDa but can also be referred to as K
(i.e. "40K PEG" = 40 l:Da PEG).
PCR construction of DOMB-24eys 5 The site of attachment for the PEG may be placed elsewhere on the surface of the dAb as .
long as the targeted amino acid is solvent accessible and the resultant PEGylated protein still maintains antigen binding. Thus it is also possible to engineer the cys into any one of frameworks 1-4 of the dAb for PEGylation and still maintain some antigen binding. The following oligonucleotides were used to specifically PCR DOM8-24 with a SaZI
and BannHI sites .0 for cloning and also to introduce a C-terminal cysteine residue.
SalI
Ala Ser Thr Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val GTA
CGC AGC TGC CTC CAC GTC GAC AAC CTC AGA CCC CCT CCG AAC
CAT
Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe TTC
AAG
Thr Phe Ser Asn Tyr Gln Met Ala Trp Val Arg Gln Ala Pro Gly GGG
TGG AAA TCA TTA ATA GTC TAC CGC ACC CAG GCG GTC CGA GGT
CCC
,0 Lys Gly Leu Glu Trp Val Ser Ser Ile Thr Ser Glu Gly Gly Ser TCG
TTC CCA GAT CTC ACC CAG AGT TCA TAA TGA TCA CTC CCA CCA
,5 AGC
Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg TGT ATG ATG CGT CTG AGG CAC TTC CCG GCC AAG TGG TAG AGG
GCG
Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu 5 Arg CGT
CTG TTA AGG TTC TTG TGT GAC ATA GAC GTT TAC TTG TCG GAC
GCA
Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Pro Gly Lys Asn AAT
TTA
Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Cys ***
TAA
AAA CTG ATG ACC CCA GTC CCT TGG GAC CAG TGG CAG AGC ACG
ATT
BamHI
.0 *** Gly Ser (SEQ ID NI: 85) 361 TAA GGA TCC (SEQ ID NO: 83) ATT CCT AGG (SEQ ID NO: 84) The DNA sequence of the PCR primers used to amplify the engineered dAb are shown .5 below.
Forward primer 5'- AGTGCGTCGACGGAGGTGCAGCTGTTGGAGTCT-3' (SEQ ID NO: 86) Reverse primer 5'- AAAGGATCCTTATTAGCACGAGACGGTGACCAGGGTTCCCTG-3' (SEQ ID NO: 87) ;0 The PCR reaction (50 L volume) was set up as follows: 200 M dNTP's, 0.4 M
of each primer, 5 L of lOx PfuTurbo buffer (Stratagene), 100 ng of template plasmid (DOM8-24), 1 L of PfuTurbo enzyme (Stratagene) and the volume adjusted to 50 L using sterile water. The following PCR conditions were used: initial denaturing step 94 C for 2 mins, then 25 cycles of 94 C for 30 secs, 64 C for 30 sec and 72 C for 30 sec. A final extension step was also included ;5 of 72 C for 5 mins. The PCR product was purified and digested with SaZI
and Ba777HI and ligated into the vector (pDOM5) which had also been cut with the same restriction enzymes.
Correct clones were verified by DNA sequencing.
Expression and purification of DOM8-24 DOM8-24 vector was transformed into HB2151 electro-competent cells. Cells carrying 0 the dAb plasmid were selected for using 100 g/mL carbenicillin. Cultures were set up in 2L
baffled flasks containing 500 mL of teiTific broth (Sigma-Aldrich) and 100 g/mL carbenicillin.
The cultures were grown at 30 C at 200rpm to an O.D.600 of 1-1.5 and then induced with 1mM
IPTG (isopropyl-beta-D-thiogalactopyranoside, from Melford Laboratories). The expression of the dAb was allowed to continue for 12-16 hrs at 30 C. It was found that most of the dAb was present in the culture media. Therefore, the cells were separated from the media by centrifugation (8,000xg for 30 mins), and the supernatant used to purify the dAb. Per litre of supernatant, 10 mL of Streamline Protein A (Amersham Biosciences) was added and the dAb allowed to batch bind with stirring for 3 hours at room temperature, or overniglit at 4 C. The resin was then allowed to settle under gravity for an hour before the supernatant removed. The agarose was then packed into a XK 16 column (Amersham Pharmacia) and was washed with 10 column volumes of 2xPBS. The bound dAb was eluted with 100 mM glycine pH 3.0 and protein containing fractions were then neutralized by the addition of 1/5 volume of 1 M Tris pH 8Ø
PEGylation of DOM8-24cys using MAL activated PEG
Mono iei- PEGylation The cysteine residue which had been engineered onto the surface of the VH dAb was specifically modified with a single linear or branched PEG-MAL to give monomeric modified protein. mPEG-MAL formats which may be used to PEGylate a monomeric VH or Vk dAb. The PEGs may be of MW from 500 to 60,000 (eg, from 2,000 to 40,000) in size.
c mPtx-a-~-N 14 mPECa-1*1 I ~ [0~ 1,a 0 r- r oll C _~Itf / \11 8 1i mPEG-1VIAI, mPEG2-MAL
2.5 ml of 500 M DOM8-24cys was reduced with 5 mM dithiothreitol and left at room ?0 temperature for 20 minutes. The sample was then buffer exchanged using a PD-10 column (Amersham Pharmacia). The column had been pre-equilibrated with 5 mM EDTA, 20 mM
sodium phosphate pH 6.5, 10% glycerol, and the sample applied and eluted following the manufactures guidelines. The eluted sample (3.5 ml of -360 M dAb) was placed on ice until required. A four fold molar excess of 30K PEG-MAL or 40K PEG2-MAL (Nektar) was weighed out and added directly to the reduced dAb solution and gently mixed until the polymer had dissolved. The reaction was left to proceed at room temperature for 3 hours.
Purification of 30K and 40K PEGvlated DOM8-24cys monomer The PEGylated dAb was purified using cation exchange chromatography as the isoelectric point (pI) of the protein is -8. 40 .L of 40% glacial acetic acid was added per mL of the 30K or 40K PEG DOMB-24cys reaction to reduce the pH to -4. The sample was then applied to a 1mL Resource S cation exchange column (Amersham Pharmacia), which had been pre-0 equilibrated with 50 mM sodium acetate pH 4Ø The PEGylated material was separated from the unmodified dAb by running a linear sodium chloride gradient from 0 to 500 mM
over 20 column volumes. Fractions containing PEGylated dAb only were identified using SDS-PAGE and then pooled and the pH increased to 8 by the addition of 1/5 volume of 1M Tris pH
8.0 In vitro functional binding assay: CD40 liaand receptor assay (CD40L RBA) .5 The CD40L assay was used to measure the binding of CD40L to CD40 and the ability of binding entities (including monovalent antibody fragments such a dAbs) to block this interaction, as shown Figure 7.
A 96 well Nunc Maxisorp assay plate was coated overnight at 4 C with 100 l per well of recombinant human CD40/Fc (R&D Systems) at 0.5 g/ml in carbonate buffer. The plate was '.0 washed 3 times with 300 l of 0.05% Tween/PBS and 3 times with 300 l of PBS using a Tecan plate washer. The wells were blocked using 200 l of PBS containing 2% (w/v) BSA and incubated for a minimum of 1 h at room temperature. The wells were washed as above, then 50 l of purified dAb protein was added to each well. To each well 50 l of CD40L, at 6 ng/ml in diluent (for a final concentration of 3 ng/ml), was also added and the plate incubated for 1 hr at room temperature. The plate was washed as described previously and 100 l biotinylated anti-CD40L antibody, 0.5 g/ml in diluent, was added and incubated for 1 hr at room temperature.
The plate was washed as described above, then 100 l HRP conjugated anti-biotin antibody (1:5000 dilution in diluent) added to each well and the plate incubated for 1 hr at room temperature. The plate was washed again as described above using a Tecan plate washer and the assay developed using 100 l of SureBlue 1-Component TMB MicroWell Peroxidase solution (the plate was left at room temperature for up to 20 min). The reaction was stopped by the addition of 100 l 1 M hydrochloric acid. The OD45on,,, of the plate was assayed within 30 minutes of acid addition. The OD45o,,,,, is proportional to the amount of bound streptavidin-HRP conjugate, therefore the greater the degree of dAb inhibition the lower the OD45or,m of the resulting signal. The following controls were included; 0 ng/ml CD40L (diluent only), 3 ng/ml CD40L and 3 ng/ml CD40L with 1 g/ml anti-CD40L antibody.
The results of the CD40L RBA are shown in Fig. 9. It can be seen that PEGylated 0 DOM8-24cys has a similar affinity for CD40L as the unmodified protein. The size of the polymer attached (either 30 or 40K) does not seem to significantly affect the IC 50 of 1 nM.
Example 9: Generation and Expression of a Dual Specific dAb Dimer (DOM7h-26-DOM-24) A dual specific dAb dimer was constructed essentially as described in and as described below.
.5 A PCR fragment introducing 5' Notl and 3' EcoRl restriction sites into the DNA sequence was generated using the primers VH-5'-Not1 (5'-GTATGTCTGGCGGCCGCAGAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTG-3'; SEQ
ID NO: 90) and VH-NO-Xhol (5'-TAGAATTCTTATTAGCTGGAGACGGTGACCAGGGT-3'; SEQ ID NO: 91). The PCR product was electrophoresed on a 1% agarose gel and the !0 appropriate band was excised and gel cleaned using the Qiagen Gel Extraction Kit. The purified DNA was digested with Notl and EcoRI for 1 hour at 37 C and then the digested DNA fragment purified using the Qiagen PCR Cleanup Kit. The digested PCR product was ligated using T4 DNA ligase into the vector pCH3, derived from pPICz-alpha (Invitrogen Ltd, Paisley, UK), which had been previously been digested with NotI and EcoRI, tllereby enabling the ligation of !5 the DOM-24 DNA sequence 3' relative to the anti-human serum albumin dAb DNA
sequence (DOM7h-26). One micro-litre of the ligation mix was used to electroporate 50 l of E. coli TOPlOF' (0.2 mm diameter cuvettes; 25 FD; 200n; 2.500 kV) using a Biorad Genepulser II
with pulse controller module. The electroporated cells were immediately resuspended in 1 ml low salt LB medium (10 g/l tryptone; 5 g/1 yeast extract; 5 g/1 NaCl; pH to 7.5 with 4 M NaOH;
then autoclaved at 121 C for 15 min) and 100 l of the cell suspension plated onto low salt LB
agar plates (10 gIl tryptone; 5 g/1 yeast extract; 5 g/1 NaCI; pH to 7.5 with 4 M NaOH; 15 g/l agar; then autoclaved at 121 C for 15 min) supplemented with 25 g/ml zeocin (Invitrogen Ltd, Paisley, UK) and grown at 37 C overnight.
Several individual clones from the overnight growth plate were analysed by DNA
sequencing using the alpha-factor sequencing primer (5'-TACTATTGCCAGCATTGCTGC-3';
SEQ ID NO: 92) and the reverse 3' AOX1 primer (5'-GCAAATGGCATTCTGACATCC-3';
SEQ ID NO: 93). A plasmid prep derived from a single clone containing the desired DNA
sequence was made by inoculating 100 ml of low salt LB medium supplemented with 25 g/ml 0 zeocin and grown overnight at 37 C with shaking at 250 rpm, followed by purification of the plasmid DNA using a Qiagen Plasmid Midi Prep Kit (Qiagen).
The concentration and purity of the DNA was determined by measuring the absorbance at 280 nm and 260 nm. Between 10 and 50 g of DNA was digested with Pmel, SacI or BstXI
restriction enzymes and the DNA digestion confirmed by analysis on a 0.8%
agarose gel. The 5 digested DNA was purified using the Qiagen Qiaex II Kit (Qiagen) and the DNA
eluted into l purified water per 20 l of Qiaex II resin.
Competent yeast cells were made by streaking the wild type Pichia pastoris strain X33 onto a YPD agar plate (for 1 litre of media: 20 g peptone from meat type 1; 10 g yeast extract;
g agar dissolved in 900 ml water and sterilise by autoclaving at 121 C for 15 minutes;
,0 followed by the aseptic addition of 100m1 of 20% destrose and the desired amount of zeocin once the media had cooled below 50 C) and grown at 30 C for 36-48 h until colonies appeared.
A single colony was inoculated into 5 ml of YPD medium (as for YPD agar, without the addition of 20 g agar) and grown overnight in a 50 ml baffled flask at 30 C with shaking at 250 rpm.
Five hundred millilitres of YPD medium in a 21 baffled flask was inoculated with 0.1-0.5 ml of ,5 the overnight culture and grown at 30 C with shaking at 250 rpm overnight to an OD600 of approximately 1.3-1.5. The culture was cooled on ice then the Pichia harvested by centrifugation at 1500 g for 5 min at 4 C. The supernatant was discarded and the pellet resuspended in 500 ml ice cold ultrapure water. The Pichia were recovered again by centrifugation at 1500 g for 5 min at 4 C. The pellet was resuspended aild centrifuged for a further three times, the first time in 250 ml ice cold ultrapure water, then twice in 20 ml ice cold 1M sorbitol. The competent Pichia were kept on ice for up to 6 hours prior to use.
To transform the Pichia by electroporation, between 10 to 20 g of linearised vector in l of water was mixed with 80 l of competent Pichia in a precooled microfuge tube and 5 incubate on ice for 5 min. The Pichia mixture was then transferred to a precooled 0.2 cm gap electroporation cuvette, and electroporated: 25 F, resistance set to infinity, 0.54 kV in a Biorad Genepulser II with pulse controller module. Immediately 1 ml ice cold I M
sorbitol was added to the electroporation cuvette and the electroporated Pichia transferred into a 15 ml polypropylene tube. This culture was incubated at 30 C without shalcing for 2 hours to allow the 10 cells to recover. The cells were then plated onto YPDS agar plates (YPD
agar supplemented with 1 M sorbitol) and zeocin added to final concentrations of 100 g/ml, 500 .g/ml, 1000 g/ml, and 2000 g/ml. The plates were incubated at 30 C in the dark for 2-10 days until colonies appeared. Several clones were picked from each plate and restrealced onto YPD plates supplemented with the same amount of zeocin as they were originally selected against. For [5 small to medium scale shaking flask expression the Mut status of each X33 clone was not determined.
Individual restreaked colonies were used to inoculate 50 ml of BMGY medium (for 1 litre of medium: 20 g peptone from meat type 1; 10 g yeast extract were dissolved in 700 ml with water and sterilise by autoclaving at 121 C for 15 minutes; followed by the aseptic addition of ?0 100 ml 1 M KPO4 pH 6.0; 100 ml 10% glycerol; and 100 ml lOxYNB (Yeast Nitrogen Base);
2 ml of 500x biotin) in a 250 ml flask and grown at 30 C with shaking at 250 rpm until an OD600 of 2 to 6 was attained. The Pichia was recovered by centrifugation at 1500 g for 5 min at room temperature. The resulting pellet was resuspended in 20 ml BMMH medium (as for BMGY medium except the 100 ml 10% glycerol was replaced with 100 ml of 5%
methanol), and ?5 returned to a fresh 250 ml baffled flask and incubated at 30 C with shaking at 250 rpm for up to 5 days post induction. At 24 h intervals, 0.5 ml samples were recovered and assessed by analysis of the supernatant by SDS-PAGE.
Dimer dAb was purified from the culture supernatant using Streamline protein-A
matrix (Amersham Biosciences). Following binding of the dimer dAb, the matrix was transferred to an empty 20 ml chromatography column containing a frit and the supernatant allowed to flow through the column, retaining the matrix. The matrix was washed with 10 times the matrix volume of high salt buffer (10 mM Phosphate buffer, 2.7 mM KCI, 487 mM NaCI, pH 7.4). The bound protein was eluted with 0.1 M glycine pH 3 supplemented with 0.15 M NaCI
and 0.8 ml fractions were collected which were immediately neutralised with the addition of 0.2 ml of 1 M
Tris-HCI pH 8Ø
Simultaneous Antigen Binding of the Dual Specific dAb Dimer To demonstrate that the dual specific dimeric dAb was functional and could bind both antigens simultaneously, an antigen binding ELISA was performed. Fifty microlitres per well of human serium albumin at 100 g/m1 in PBS was coated on to a Maxisorb ELISA
plate (Nunc) overnight at 4 C. The plate was washed 3 times with 250 l/well of PBS
supplemented with 0.1% (v/v) Tween 20 (Sigma). The plate was then blocked for 1 h at room temperature with 200 l per well of PBSM (PBS supplemented with 2% (w/v) low fat milk powder).
The plate was washed as before, then 50 l per well of doubling dilutions of the dimer dAb in PBSM were added and incubated for 1 hour at room temperature. The plate was washed as before then 50 1 per well of a 5 nM solution of biotinylated CD40L in PBSM added and incubated for 1 hour at room temperature. The plate was washed as before then 50 l per well of streptavidin-HRP
(Amersham Biosciences) diluted 1 in 4000 in PBSM was added and incubated for 1 hour at room temperature. The plate was washed 4 times with 250 l/well of PBS supplemented with 0.1%
10 (v/v) Tween 20, followed by two washes with 250 l/well of PBS. The ELISA
was developed by adding 50 l per well of SureBlue 1-Component TMB MicroWell Peroxidase solution (KPL, Gaithersberg, MD) and incubated at room temperature for several minutes until the desired colour intensity was obtained. The reaction was stopped by the addition of 100 1 of 1 M
hydrochloric acid and read at 450 nm (Figure 10).
?5 Generation and Expression of a Dual Specific Fab (DOM7h-2:CK DOM-24:CH) The produce a dual specific Fab the method used was essentially the same method as described for the dual specific dAb dimer (DOM7h-26-DOM-24) except that the DNA for the DOM7h-2 and DOM-24 dAbs were cloned into separate pPICz-alpha based vectors containing the human CK or human CH1 domain respectively. Each of the two vectors were designed to enable the expression of a single polypeptide consisting of the CH1 or CK
domain fused in frame to the 3' end of the appropriate dAb. To obtain expression of the complete Fab fragment, competent Pichia pastoris strain X33 were cotransformed with two linearised vectors.
Purification was as described for the dimer Fab.
Simultaneous AntiQen BindinLy of the Dual Specific Fab The simultaneous antigen binding of the dual specific Fab was carried out using the same assay as described for the dual specific dAb dimmer above. The results are shown in Figure 11.
Inhibition of CD40 mediated CD54 upregulation disruption of CD40 / CD40L
interaction in L3055 cells.
Monomeric dAb molecules were assayed for their ability to disrupt the binding of cellularly associated CD40L to CD40. This was determined by measuring the level inhibition of CD40 mediated CD54 upregulation on group 1 Burkitt lymphoma cell line L3055 by FACS.
CD40 displayed on the L3055 cells was stimulated by CD40L expressed on the surface of fibroblasts (typically mouse L-cells) transfected with the CD40L gene as previously described by 5 Garrone et al., 1995 (Garrone P., Neidhardt E.V., Garcia E., Galibert L., van Kooten C., Banchereau J. (1995) J Exp Med 182, 1265-1273.) Samples containing the dAbs were preincubated with the L-cells cells for 1 hour prior to the addition of the L3055 cells. Both cell lines were co-cultured for 22 hours following which the L-cells were stained for FACS analysis, as described by Baker et al., 1998 (Baker, M.P., ',0 Eliopoulos, A.G., Young, L.S., Armitage, R.J., Gregory, C.D., Gordon, J.
(1998) Blood, 92 (8), 2830-2843) and by Challa et al., 2002 (Challa, A., Eliopoulos, A.G., Holder, M.J., Burguete, A.S., Pound, J.D., Chamba, A., Grafton, G., Armitage, R.J., Gregory, C.D., Martinez-Valdez, H., Young, L. and Gordon, J. (2002) Blood, 99 (9), 3411-3418.
The FACS analysis of DOM-24 (monomeric form) at a concentration of 12 m showed :5 inhibition.
FACS analysis of the Vlc DOM-1 16 at a concentration of 9 M showed inhibition compared with a control blank dAb and the stimulated cell trace (Figure 13).
Effect of anti-CD40L therap)7 on primary immune response to KLH immunisation.
To show the effect of anti-CD40L therapy on the primary immune response to KLH
immunization a similar study to that described by Gobburu, J.V.S. et al., 1998 can be carried out (Gobburu, J.V.S., Tenhoor, C., Rogge, M.C., Frazier, D.E., Thomas, D., Benjamin, C., Hess, D.M., & Jusko, W.J. (1998) JPET, 286, 925-930.
A study example could be as follows: Cynomolgus monkeys are injected with an anti-CD40L antibody or dAb format at a dosing of 10mg/kg at time Oh, 168h and 336h.
At 24h the animals receive a single intradermal injection of 100 g highly purified keyhole limpet hemocyanin (KLH). The serum is tested for a KLH response prior to the start and following [0 completion of the study. The animals are allowed to recover for a suitable time to ensure that the dAb molecule has cleared the circulation, then injected with KLH (without dAb) to determine if the animal can raise an immune response against KLH. Alternative antigens can be used for the study if an earlier response to KLH is detected prior to the start of the study.
The immune response to KLH will be measured by a suitable ELISA, RIA or antibody 5 titer assay. It is anticipated that the results would show that that the PEglyated monomeric DOM-24 would suppress the animals immune response to KLH. This would be shown in the reduction of the antibody titer compared to a positive control. The results could be normalized such that the positive control was deemed to be 100 and the reduction in immune response after the administration of the dAbs would be in the range of 10 to 90% ie 90 to 10 units.
?0 Sequence of the DOM7h-26-DOM-24 LEKREV QLLES GGGL VQPGGSLRLSCTASGFTFDEYNMS WVRQAPGKGLEWV STILPH
GDRTYYAD SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKQDPLYRFDYWGQG
TLVTV S SAAAEVQLLESGGGLV QPGGSLRLSCAAS GFTFSNYQMAWVRQAPGKGLEW
V S SITSEGGSTYYAD S VKGRFTISRDNSKNTLYLQIv1NSLRAEDTA VYYCAKPGKNFDY
?5 WGQGTLVTVSS (SEQ ID NO: 88) Sequence of the DOM7h-26 DIQMTQ SPS SLSASV GDRVTITCRASQKIATYL-NTWYQQKPGKAPKLLIYRS S SLQSAVP S
RFSGSGSGTVFTLTISSLQPEDFATYYCQQTYAVPPTFGQGTRVEIKR (SEQ ID NO: 89) All patents, patent applications, and published references cited herein are hereby incorporated by reference in their entirety. While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.
Annex 1; polypeptides which enhance half-life in vivo.
Alpha-I Glycoprotein (Orosomucoid) (AAG) Alpha-1 Antichyromotrypsin (ACT) Alpha-I Antitrypsin (AAT) Alpha-1 Microglobulin (Protein HC) (AIM) Alpha-2 Macroglobulin (A2M) Antithrombin III (AT III) Apolipoprotein A-1 (Apo A-1) Apoliprotein B (Apo B) Beta-2-microglobulin (B2M) Ceruloplasmin (Cp) Complement Component (C3) Complement Component (C4) 5 C 1 Esterase Inhibitor (Cl INH) C-Reactive Protein (CRP) Cystatin C (Cys C) Ferritin (FER) Fibrinogen (FIB) ) Fibronectin (FN) Haptoglobin (Hp) Hemopea:in (HPX) Immunoglobulin A (IgA) Immunoglobulin D (IgD) Immunoglobulin E (1gE) Immunoglobulin G (IgG) Immunoglobulin M (IgM) Immunoglobulin Light Chains (kapa/lambda) Lipoprotein(a) [Lp(a)]
Mannose-bindign protein (MBP) l0 Myoglobin (Myo) Neonatal Fc (FcRn) Plasminogen (PSM) Prealbumin (Transthyretin) (PAL) Retinol-binding protein (RBP) Rheomatoid Factor (RF) Serum Amyloid A (SAA) Soluble Tranferrin Receptor (sTfR) Transferrin (Tf) Annex 2 Pairing Therapeutic relevant references.
TNF = TGF-b and TNF when injected into the ankle joint of collagen ALPHA/TGF- induced arthritis model significantly enhanced joint inflammation. In non-collagen challenged mice there was no effect.
TNF = TNF and IL-1 synergize in the pathology of uveitis.
= TNF and IL-1 synergize in the pathology of malaria (hypoglycaemia, NO).
= TNF and IL-1 synergize in the induction of polymorphonuclear (PMN) cells migration in inflammation.
= IL-1 and TNF synergize to induce PMN infiltration into the peritoneum.
= IL-1 and TNF synergize to induce the secretion of IL-1 by endothelial cells. Important in inflammation.
= IL-1 or TNF alone induced some cellular infiltration into knee synovium. IL-1 induced PMNs, TNF - monocytes. Together they induced a more severe infiltration due to increased PMNs.
= Circulating myocardial depressant substance (present in sepsis) is low levels of IL-1 and TNFacting synergistically.
TNF = Most relating to synergisitic activation of killer T-cells.
TNF = Synergy of interleukin 3 and tumor necrosis factor alpha in ALPHA/IL-3 stimulating clonal growtli of acute myelogenous leukemia blasts is the result of induction of secondary hematopoietic cytokines by tumor necrosis factor alpha.
= Cancer Res. 1992 Apr 15;52(8):2197-201.
TNF ,= IL-4 and TNF synergize to induce VCAM expression on ALPHA/IL-4 endothelial cells. Implied to have a role in asthma. Same for synovium - implicated in RA.
= TNF and IL-4 synergize to induce IL-6 expression in keratinocytes.
= Sustained elevated levels of VCAM-1 in cultured fibroblast-like synoviocytes can be achieved by TNF-alpha in combination with either IL-4 or IL-13 through increased mRNA stability. Am JPatliol. 1999 Apr;154(4):1149-58 TNF = Relationship between the tumor necrosis factor system and the ALPHA/IL-5 serum interleukin-4, interleukin-5, interleukin-8, eosinophil cationic protein, and immunoglobulin E levels in the bronchial hyperreactivity of adults and their children. Allergy Asthma Proc. 2003 Mar-Apr;24(2):111-8.
TNF = TNF and IL-6 are potent growth factors for OH-2, a novel ALPHA/IL-6 human myeloma cell line. Eur JHaefraatol. 1994 Ju1;53(1):31-7.
TNF = TNF and IL-8 synergized with PMNs to activate platelets.
ALPHA/IL-8 Implicated in Acute Respiratory Distress Syndrome.
= See IL-5/TNF (asthma). Synergism between interleukin-8 and tumor necrosis factor-alpha for neutrophil-mediated platelet activation. Eur Cytokine Netw. 1994 Sep-Oct;5(5):455-60.
(adult respiratory distress syndrome (ARDS)) TNF
TNF = IL-10 induces and synergizes with TNF in the induction of ALPHA/IL-10 HIV expression in chronically infected T-cells.
TNF = Cytokines synergistically induce osteoclast differentiation:
ALPHA/IL-11 support by immortalized or normal calvarial cells. A777 J
Physiol Cell Physiol. 2002 Sep;283(3):C679-87. (Bone loss) TNF
TNF = Sustained elevated levels of VCAM-1 in cultured fibroblast-ALPHA/IL-13 like synoviocytes can be achieved by TNF-alpha in combination with either IL-4 or IL-13 through increased mRNA stability. Am J Pathol. 1999 Apr;154(4):1149-58.
= Interleulcin-13 and tumour necrosis factor-alpha synergistically induce eotaxin production in human nasal fibroblasts. Clin Exp Allergy. 2000 Mar;30(3):348-55.
= Interleulcin-13 and tumour necrosis factor-alpha synergistically induce eotaxin production in human nasal fibroblasts. Cli Exp Alle7gv. 2000 Mar;30(3):348-55 (allergic inflammation) = Implications of serum TNF-beta and IL-13 in the treatment response of childhood nephrotic syndrome. Cytokine. 2003 Feb 7;21(3):155-9.
TNF = Effects of inhaled tumour necrosis factor alpha in subjects with ALPHA/IL-14 mild asthma. Thorax. 2002 Sep;57(9):774-8.
TNF = Effects of inhaled tumour necrosis factor alpha in subjects with ALPHA/IL-15 mild asthma. Thorax. 2002 Sep;57(9):774-8.
TNF = Tumor necrosis factor-alpha-induced synthesis of interleukin-ALPHA/IL-16 16 in airway epithelial cells: priming for serotonin stimulation.
An7 J Respir Cell Mol Biol. 2003 Mar;28(3):354-62. (airway inflainmation) = Correlation of circulating interleukin 16 with proinflammatory cytokines in patients with rheumatoid arthritis. Rheunatology (Oxford). 2001 Apr;40(4):474-5. No abstract available.
= Interleukin 16 is up-regulated in Crohn's disease and participates in TNBS colitis in mice. Gastroenterology. 2000 Oct;119(4):972-82.
TNF = Inhibition of interleukin-17 prevents the development of ALPHA/IL-17 arthritis in vaccinated mice challenged with Borrelia burgdorferi. Infect bnmun. 2003 Jun;71(6):3437-42.
= Interleukin 17 synergises with tumour necrosis factor alpha to induce cartilage destruction in vitro. Ann Rheum Dis. 2002 Oct;61(10):870-6.
= A role of GM-CSF in the accumulation of neutrophils in the airways caused by IL-17 and TNF-alpha. Eur Respir J. 2003 Mar;21(3):387-93. (Airway inflammation) = Abstract Interleukin-1, tumor necrosis factor alpha, and interleukin-17 synergistically up-regulate nitric oxide and prostaglandin E2 production in explants of human osteoarthritic knee menisci. Arthritis Rheum. 2001 Sep;44(9):2078-83.
TNF = Association of interleukin-18 expression with enhanced levels of both interleukin-Ibeta and tumor necrosis factor alpha in ALPHA/IL-18 I:nee synovial tissue of patients with rheumatoid arthritis.
A71h7-itis Rheum. 2003 Feb;48(2):33 9-47.
= Abstract Elevated levels of interleul:in-18 and tumor necrosis factor-alpha in serum of patients with type 2 diabetes mellitus:
relationship with diabetic nephropathy. Metabolisnz. 2003 May;52(5):605-8.
TNF = Abstract IL-19 induces production of IL-6 and TNF-alpha and ALPHA/IL-19 results in cell apoptosis through TNF-alpha. J Immunol. 2002 Oct 15;169(8):4288-97.
TNF = Abstract Cytolcines: IL-20 - a new effector in skin ALPHA/IL-20 inflammation. CurrBiol. 2001 Jul 10;11(13):R531-4 TNF = Inflammation and coagulation: implications for the septic ALPHA/Comp patient. Clin Infect Dis. 2003 May 15;36(10):1259-65. Epub lement 2003 May 08. Review.
TNF = MHC induction in the brain.
ALPHA/IFN-y = Synergize in anti-viral response/IFN-(3 induction.
= Neutrophil activation/ respiratory burst.
= Endothelial cell activation = Toxicities noted when patients treated with TNF/IFN-y as anti-viral therapy = Fractalkine expression by human astrocytes.
= Many papers on inflammatory responses - i.e. LPS, also macrophage activation.
= Anti-TNF and anti-IFN-7 synergize to protect mice from lethal endotoxemia.
TGF-(3/IL-1 = Prostaglndin synthesis by osteoblasts = IL-6 production by intestinal epithelial cells (inflammation model) = Stimulates IL-11 and IL-6 in lung fibroblasts (inflammation model) = IL-6 and IL-8 production in the retina TGF-(3/IL-6 = Chondrocarcoma proliferation IL-1/IL-2 = B-cell activation = LAK cell activation = T-cell activation = IL-1 synergy with IL-2 in the generation of lymphokine activated killer cells is mediated by TNF-alpha and beta (lymphotoxin). Cytokine. 1992 Nov;4(6) :479-87.
IL-1/IL-4 = B-cell activation = IL-4 induces IL-1 expression in endothelial cell activation.
IL-1/IL-6 = B cell activation = T cell activation (can replace accessory cells) = IL-1 induces IL-6 expression = C3 and serum amyloid expression (acute phase response) = HIV expression = Cartilage collagen breakdown.
IL-1/IL-7 = IL-7 is requisite for IL-1-induced thymocyte proliferation.
Involvement of IL-7 in the synergistic effects of granulocyte-macrophage colony-stimulating factor or tumor necrosis factor with IL-1. Jbnmu ol. 1992 Jan 1;148(1):99-105.
IL-1/IL-ll = Cytokines synergistically induce osteoclast differentiation:
support by immortalized or normal calvarial cells. A i J
Pliysiol Cell Pliysiol. 2002 Sep;283('D):C679-87. (Bone loss) IL-1/IL-16 = Correlation of circulating interleukin 16 with proinflammatory cytokines in patients with rheumatoid arthritis. Rheumatology (Oxford). 2001 Apr;40(4):474-5. No abstract available.
IL-1/IL-17 = Inhibition of interleukin-17 prevents the development of arthritis in vaccinated mice challenged with Borrelia burgdorferi. If7fect Imr~~ur~. 2003 Jun;71(6):3437-42.
= Contribution of interleukin 17 to human cartilage degradation and synovial inflammation in osteoarthritis. Osteoarthritis Cartilage. 2002 Oct;10(10):799-807.
= Abstract Interleukin-1, tumor necrosis factor alpha, and interleukin-17 synergistically up-regulate nitric oxide and prostaglandin E2 production in explants of human osteoarthritic knee menisci. Arthritis Rheum. 2001 Sep;44(9):2078-83.
IL-1/IL-18 = Association of interleukin-18 expression with enhanced levels of both interleukin-lbeta and tumor necrosis factor alpha in lcnee synovial tissue of patients with rheumatoid arthritis.
A7=tlzritis Rheum. 2003 Feb;48(2):339-47.
IL-1 /IFN-g IL-2/IL-3 = T-cell proliferation = B cell proliferation IL-2/IL-4 = B-cell proliferation = T-cell proliferation =(selectively inducing activation of CD8 and NK
lymphocytes)IL-2R beta agonist P 1-30 acts in synergy with IL-2, IL-4, IL-9, and IL-15: biological and molecular effects. J
1777mu7lol. 2000 Oct 15;165(8): 4312-8.
IL-2/IL-5 = B-cell proliferation/ Ig secretion = IL-5 induces IL-2 receptors on B-cells IL-2/IL-6 = Development of cytotoxic T-cells IL-2/IL-9 = See IL-2/IL-4 (NK-cells) IL-2/IL-10 = B-cell activation IL-2/IL-12 = IL-12 synergizes with IL-2 to induce lymphokine-activated c3,totoxicity and perforin and granzyme gene expression in fresh human NK cells. Cell Inninunol. 1995 Oct 1;165(1):33-43. (T-cell activation) IL-2/IL-15 = See IL-2/IL-4 (NK cells) =(T cell activation and proliferation) IL- 15 and IL-2: a matter of life and death for T cells in vivo. Nat Med. 2001 Jan;7(1):114-8.
IL-2/IL-16 = Synergistic activation of CD4+ T cells by IL-16 and IL-2. J
Inanzunol. 1998 Mar 1;160(5):2115-20.
IL-2/IL-17 = Evidence for the early involvement of interleukin 17 in human and experimental renal allograft rejection. J Pat.hol. 2002 Jul;197(3):322-32.
IL-2/IL-18 = Interleukin 18 (IL-18) in synergy with IL-2 induces lethal lung injury in mice: a potential role for cytokines, chemokines, and natural killer cells in the pathogenesis of interstitial pneumonia. Blood. 2002 Feb 15;99(4):1289-98.
IL-2/TGF-(3 = Control of CD4 effector fate: transforming growth factor beta 1 and interleukin 2 synergize to prevent apoptosis and promote effector expansion. JExp Med. 1995 Sep 1;182(3):699-709.
IL-2/IFN-y = Ig secretion by B-cells = IL-2 induces IFN-y expression by T-cells IL-2/IFN-a/(3 = None IL-3/IL-4 = Synergize in mast cell growth = Synergistic effects of IL-4 and either GM-CSF or IL-3 on the induction of CD23 expression by human monocytes:
regulatory effects of IFN-alpha and IFN-gamma. Cytokine.
1994 Jul;6(4):407-13.
IL-3/IFN-y = IL-4 and IFN-gamma synergistically increase total polymeric IgA receptor levels in human intestinal epithelial cells. Role of protein tyrosine kinases. J Imnaunol. 1996 Jun 15;156(12):4807-14.
IL-3/GM-CSF = Differential regulation of human eosinophil IL-3, IL-5, and GM-CSF receptor alpha-chain expression by cytokines: IL-3, IL-5, and GM-CSF down-regulate IL-5 receptor alpha expression with loss of IL-5 responsiveness, but up-regulate IL-3 receptor alpha expression. J Irnnunol. 2003 Jun 1;170(11):5359-66. (allergic inflammation) IL-4/IL-2 = IL-4 synergistically enhances both IL-2- and IL-12-induced IFN-{gamma} expression in murine NK cells. Blood. 2003 Mar 13 [Epub ahead of print]
IL-4/IL-5 = Enhanced mast cell histamine etc. secretion in response to IgE
= A Th2-like cytokine response is involved in bullous pemphigoid. the role of IL-4 and IL-5 in the pathogenesis of the disease. Iizt J brnnunopathol PharMacol. 1999 May-Aug;12(2):55-61.
IL-4/IL-11 = Synergistic interactions between interleulcin-11 and interleukin-4 in support of proliferation of primitive hematopoietic progenitors of mice. Blood. 1991 Sep 15;78(6):1448-5 1.
IL-4/IL-12 = Synergistic effects of IL-4 and IL-18 on IL-12-dependent IFN-gamma production by dendritic cells. J 17n777u7iol. 2000 Jan 1;164(1):64-71. (increase Thl/Th2 differentiation) = IL-4 synergistically enhances both IL-2- and IL-12-induced IFN-{gamma} expression in murine NK cells. Blood. 2003 Mar 13 [Epub ahead of print]
IL-4/IL-13 = Abstract Interleukin-4 and interleukin-13 signaling connections maps. Scie ce. 2003 Jun 6;300(5625):1527-8.
(allergy, asthma) = Inhibition of the IL-4/IL-13 receptor system prevents allergic sensitization without affecting established allergy in a mouse model for allergic asthma. J Allergy Clin Imrnunol. 2003 Jun;111(6):1361-1369.
IL-4/IL-16 =(asthrna) Interleukin (IL)-4/IL-9 and exogenous IL-16 induce IL-16 production by BEAS-2B cells, a bronchial epithelial cell line. Celllmmunol. 2001 Feb 1;207(2):75-80 IL-4/IL-17 = Interleukin (IL)-4 and IL-17 synergistically stimulate IL-6 secretion in human colonic myofibroblasts. bzt J Mol Med.
2002 Nov;10(5):631-4. (Gut inflammation) IL-4/IL-24 = IL-24 is expressed by rat and human macrophages.
Immunobiology. 2002 Jul;205(3):321-34.
IL-4/IL-25 = Abstract New IL-17 family members promote Thl or Th2 responses in the lung: in vivo function of the novel cytokine IL-25. J Inznzunol. 2002 Jul 1;169(1):443-53. (allergic inflammation) = Abstract Mast cells produce interleukin-25 upon Fcepsilon RI-mediated activation. Blood. 2003 May 1;101(9):3594-6. Epub 2003 Jan 02. (allergic inflammation) IL-4/IFN-y = Abstract Interleukin 4 induces interleukin 6 production by endothelial cells: synergy with interferon-gamma. Eur J
Ir munol. 1991 Jan;21(1):97-101.
IL-4/SCF = Regulation of human intestinal mast cells by stem cell factor and IL-4. Inzmunol Rev. 2001 Feb;179:57-60. Review.
IL-5/IL-3 = Differential regulation of human eosinophil IL-3, IL-5, and GM-CSF receptor alpha-chain expression by cytokines: IL-3, IL-5, and GM-CSF down-regulate IL-5 receptor alpha expression with loss of IL-5 responsiveness, but up-regulate IL-3 receptor alpha expression. J Irnfnunol. 2003 Jun 1;170(11):5359-66. (Allergic inflammation see abstract) IL-5/IL-13 = Inhibition of allergic airways inflammation and airway hyperresponsiveness in mice by dexamethasone: role of eosinophils, IL-5, eotaxin, and IL-13. JAllergy Clif1 I717771unol.
2003 May;111(5):1049-61.
IL-5/IL-17 = Interleukin-17 orchestrates the granulocyte influx into airways after allergen inhalation in a mouse model of allergic asthma.
Am JRespir Cell Mol Biol. 2003 Jan;28(1):42-50.
IL-5/IL-25 = Abstract New IL-17 family members promote Thl or Th2 responses in the lung: in vivo function of the novel cytokine IL-25. J Irl?7nu ol. 2002 Jul 1;169(1):443-53. (allergic inflammation) = Abstract Mast cells produce interleukin-25 upon Fcepsilon RI-mediated activation. Blood. 2003 May 1;101(9):3594-6. Epub 2003 Jan 02. (allergic inflammation) IL-5/IFN-y IL-5/GM-CSF = Differential regulation of human eosinophil IL-3, IL-5, and GM-CSF receptor alpha-chain expression by cytokines: IL-3, IL-5, and GM-CSF down-regulate IL-5 receptor alpha expression with loss of IL-5 responsiveness, but up-regulate IL-3 receptor alpha expression. J bnzmunol. 2003 Jun 1;170(11):5359-66. (Allergic inflammation) IL-6/IL-16 = Interleukin-16 stimulates the expression and production of pro-inflammatory cytokines by human monocytes. Immunology.
2000 May;100(1):63-9.
IL-6/IL-17 = Stimulation of airway mucin gene expression by interleukin (IL)-17 through IL-6 paracrine/autocrine loop. J Biol Chem.
2003 May 9;278(19):17036-43. Epub 2003 Mar 06. (airway inflammation, asthma) IL-6/IL-19 = Abstract IL-19 induces production of IL-6 and TNF-alpha and results in cell apoptosis through TNF-alpha. J Inamunol. 2002 Oct 15;169(8):4288-97.
IL-6/IFN-g IL-7/IL-2 = Interleukin 7 worsens graft-versus-host disease. Blood. 2002 Oct 1;100(7):2642-9.
IL-7/IL-12 = Synergistic effects of IL-7 and IL-12 on human T cell activation. Jlnnnunol. 1995 May 15;154(10):5093-102.
IL-7/IL-15 = Interleukin-7 and interleukin-15 regulate the expression of the bcl-2 and c-myb enes in cutaneous T-cell lymphoma cells.
Blood. 2001 Nov 1;98(9):2778-83. (growth factor) IL-8/IL-11 = Abnormal production of interleukin (IL)-11 and IL-8 in polycythaemia vera. Cytokine. 2002 Nov 21;20(4):178-83.
IL-8/IL-17 = The Role of IL-17 in Joint Destruction. D7-ug NeWs Perspect.
2002 Jan;15(l):17-23. (arthritis) = Abstract Interleukin-17 stimulates the expression of interleukin-8, growth-related oncogene-alpha, and granulocyte-colony-stimulating factor by human airway epithelial cells. Am J Respir Cell Mol Biol. 2002 Jun;26(6):748-53. (airway inflammation) IL-8/GSF = Interleukin-8: an autocrine/paracrine growth factor for human hematopoietic progenitors acting in synergy with colony stimulating factor-1 to promote monocyte-macrophage growth and differentiation. Exp Hematol. 1999 Jan;27(1):28-36.
IL-8/VGEF = Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. J Neurooncol. 2003 May;62(3):297-303.
IL-9/IL-4 = Anti-interleukin-9 antibody treatment inhibits airway inflammation and hyperreactivity in mouse asthma model. A777 JRespiT Crit Care Med. 2002 Aug 1;166(3):409-16.
IL-9/IL-5 = Pulmonary overexpression of IL-9 induces Th2 cytokine expression, leading to immune pathology. J Clin Invest. 2002 Jan;109(1):29-39.
= Th2 cytokines and asthma. Interleukin-9 as a therapeutic target for asthma. Respir Res. 2001;2(2):80-4. Epub 2001 Feb 15.
Review.
= Abstract Interleukin-9 enhances interleukin-5 receptor expression, differentiation, and survival of human eosinophils.
Blood. 2000 Sep 15;96(6):2163-71 (asthma) IL-9/IL-13 = Anti-interleukin-9 antibody treatment inhibits airway inflainmation and hyperreactivity in mouse asthma model. A771 JRespir Crit Care Med. 2002 Aug 1;166(3):409-16.
= Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma. Nat Med.
2002 Aug;8(8):885-9.
IL-9/IL-16 = See IL-4/IL-16 IL-10/IL-2 = The interplay of interleukin-10 (IL-10) and interleukin-2 (IL-2) in humoral immune responses: IL-l0 synergizes with IL-2 to enhance responses of human B lymphocytes in a mechanism which is different from upregulation of CD25 expression. Cell linmunol. 1994 Sep;157(2):478-88.
IL-10/TGF-(3 = IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur Jlmmunol. 2003 May;33(5):1205-14.
IL-10/IFN-y IL-11/IL-6 = Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone. 2003 Jan;32(1):1-7. (bone resorption in inflammation) IL-11/IL-17 = Polarized in vivo expression of IL-11 and IL-17 between acute and chronic skin lesions. J Allergy Clin Imnaunol. 2003 Apr;111(4):875-81. (allergic dermatitis) = IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B
ligand/osteoprotegerin balance. J Imniunol. 2003 Mar 1;170(5):2655-62.
IL-11/TGF-(3 = Polarized in vivo expression of IL-11 and IL- 17 between acute and chronic skin lesions. J Allergy Clin Iinmunol. 2003 Apr;111(4):875-81. (allergic dermatitis) IL-12/IL-13 = Relationship of Interleukin-12 and Interleukin-13 imbalance with class-specific rheumatoid factors and anticardiolipin antibodies in systemic lupus erythematosus. Clin Rh.eu7natol.
2003 May;22(2):107-11.
IL-12/IL-17 = Upregulation of interleukin-12 and -17 in active inflammatory bowel disease. Scand JGastroenterol. 2003 Feb;38(2):180-5.
IL-12/IL-18 = Synergistic proliferation and activation of natural killer cells by interleukin 12 and interleukin 18. Cytokine. 1999 Nov;11(11):822-30.
= Inflammatory Liver Steatosis Caused by IL-12 and IL-18. J
bzte7feron Cytokine Res. 2003 Mar;23(3):155-62.
IL-12/IL-23 = nterleukin-23 rather than interleukin- 12 is the critical cytokine for autoimmune inflammation of the brain. Nature. 2003 Feb 13;421(6924):744-8.
= Abstract A unique role for IL-23 in promoting cellular immunity. JLeukoc Biol. 2003 Jan;73(1):49-56. Review.
IL-12/IL-27 = Abstract IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells.
1777772unity. 2002 Jun;16(6):779-90.
IL-12/IFN-y = IL-12 induces IFN-y expression by B and T-cells as part of immune stimulation.
IL-13/IL-5 = See IL-5/IL-13 IL-13/IL-25 = Abstract New IL-17 family members promote Th1 or Th2 responses in the lung: in vivo function of the novel cytokine IL-25. J.Iinmunol. 2002 Jul 1;169(1):443-53. (allergic inflammation) = Abstract Mast cells produce interleukin-25 upon Fcepsilon RI-mediated activation. Blood. 2003 May 1;101(9):3594-6. Epub 2003 Jan 02. (allergic inflammation) IL-15/IL-13 = Differential expression of interleukins (IL)-13 and IL-15 in ectopic and eutopic endometrium of women with endometriosis and normal fertile women. Am J Reprod Irnnaunol. 2003 Feb;49(2):75-83.
IL-15/IL-16 = IL-15 and IL-16 overexpression in cutaneous T-cell lymphomas: stage-dependent increase in mycosis fungoides progression. Ea.p Dermatol. 2000 Aug;9(4):248-5 1.
IL-15/IL-17 = Abstract IL-17, produced by lymphocytes and neutrophils, is necessary for lipopolysaccharide-induced airway neutrophilia:
IL-15 as a possible trigger. J b77777unol. 2003 Feb 15;170(4):2106-12. (airway inflammation) IL-15/IL-21 = IL-21 in Synergy with IL-15 or IL-18 Enhances IFN-gamma Production in Human NK and T Cells. J hnmunol. 2003 Jun 1;170(11):5464-9.
IL-17/IL-23 = Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleulcin-17. J Biol Clzem. 2003 Jan 17;278(3):1910-4. Epub 2002 Nov 0'j IL-17/TGF-(3 = Polarized in vivo expression of IL-I l and IL- 17 between acute and chronic skin lesions. J Allergy Clin Inzmunol. 2003 Apr;111(4):875-81. (allergic dermatitis) IL-18/IL-12 = Synergistic proliferation and activation of natural killer cells by interleukin 12 and interleukin 18. Cytokine. 1999 Nov;11(11):822-30.
= Abstract Inhibition of in vitro immunoglobulin production by IL-12 in murine chronic graft-vs.-host disease: synergism with IL-18. EurJln7777unol. 1998 Jun;28(6):2017-24.
IL-18/IL-21 = IL-21 in Synergy with IL-15 or IL-18 Enhances IFN-gamma Production in Human NK and T Cells. J Irnmunol. 2003 Jun 1;170(11):5464-9.
IL-18/TGF-(3 = Interleukin 18 and transforming growth factor betal in the serum of patients with Graves' ophthalmopathy treated with corticosteroids. Int Innmunopharnzacol. 2003 Apr;3(4):549-52.
IL-18/IFN-y Anti-TNF = Synergistic therapeutic effect in DBA/1 arthritic mice.
ALPHA/anti-Annex 3: Oneology combinations Target Disease Pair with CD89* Use as cytotoxic cell all recruiter CD 19 B cell lymphomas HLA-DR
HLA-DR B cell lymphomas CD89 CD38 Multiple myeloma CD138 HLA-DR
CD138 Multiple myeloma CD38 HLA-DR
CD138 Lung cancer CD56 CEA
CD33 Acute myelod lymphoma CD34 HLA-DR
CD56 Lung cancer CD138 CEA
CEA Pan carcinoma MET receptor"
VEGF Pan carcinoma MET receptor VEGF Pan carcinoma MET receptor receptor IL-13 Asthma/pulmonary IL-4 inflammation Eotaxin(s) MDC
TARC
TNFa EGFR
TGF(3 IL-4 Asthma IL-13 Eotaxin(s) MDC
TARC
TNFa EGFR
MCP-l TGF(3 Eotaxin Astlima IL-5 Eotaxin-2 Eotaxin-3 EGFR cancer HER2/neu HER2 cancer HER3 TNFRI RA/Crohn's disease IL-1R
TNFa RAICrohn's disease IL-la/(3 IL-IR RA/Crohn's disease IL-6R
IL-18R RA/Crolin's disease IL-6R
DEMANDE OU BREVET VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND
PLUS D'UN TOME.
NOTE : Pour les tomes additionels, veuillez contacter le Bureau canadien des brevets JUMBO APPLICATIONS/PATENTS
THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE
VOLUME
NOTE: For additional volumes, please contact the Canadian Patent Office NOM DU FICHIER / FILE NAME:
NOTE POUR LE TOME / VOLUME NOTE:
Following identification of phage expressing a single immunoglobulin variable domain that binds a desired target, if a phagemid vector such as pHENI has been used, the variable domain fusion proteins are easily produced in soluble form by infecting non-suppressor strains of bacteria, e.g., HB2151 that permit the secretion of soluble gene III fusion protein. If a GAS I secretion signal peptide is encoded by the vector, the fusion polypeptide can be secreted by eukaryotic (e.g., yeast or mammalian) or prokaryotic (e.g., E. coli) cells. Alternatively, the V domain sequence can be sub-cloned into an appropriate expression vector to produce soluble protein according to methods Icnown in the art.
Purification and Concentration of Sinale Immunoglobulin Variable Domains:
Single immunoglobulin variable domain polypeptides or other monovalent antibody polypeptides secreted into the periplasmic space or into the medium of bacteria are harvested and purified according to known methods (Harrison et al., 1996, supra). Skerra & Pluckthun (1988, Science 240: 1038) and Breitling et al.
(1991, Gene 104: 147) describe the harvest of antibody polypeptides from the periplasm,, and Better et al. (1988, Science 240: 1041) describes harvest from the culture supernatant. For some antibody polypeptides, purification can also be achieved by binding to generic ligands, such as protein A or Protein L.
Alternatively, the variable domains can be expressed with a peptide tag, e.g., the Myc, HA or His tags, which facilitates purification by affinity chromatography.
If necessary, monovalent anti-CD40L antibody polypeptides are concentrated by any of several methods well known in the art, including, for example, ultrafiltration, diafiltration and tangential flow filtration. The process of ultrafiltration uses semi-permeable membranes and pressure to separate molecular species on the basis of size and shape. The pressure is provided by gas pressure or by centrifugation. Commercial' ultrafiltration products are widely available, e.g., from Millipore (Bedford, MA; examples include the CentriconTM and MicroconTM
concentrators) and Vivascience (Haiulover, Germany; examples include the VivaspinTM concentrators). By selection of a molecular weight cutoff smaller than the target polypeptide (usually 1/3 to 1/6 the molecular weight of the target polypeptide, although differences of as little as 10 kD can be used successfully), the polypeptide is retained when solvent and smaller solutes pass through the membrane.
Thus, a molecular weight cutoff of about 5 kD is useful for concentration of anti-CD40L single immunoglobulin variable domain polypeptides described herein.
1 Diafiltration, which uses ultrafiltration membranes with a "washing"
process, is used where it is desired to remove or exchange the salt or buffer in a polypeptide preparation. The polypeptide is concentrated by the passage of solvent and small solutes through the membrane, and remaining salts or buffer are removed by dilution of the retained polypeptide with a new buffer or salt solution or water, as desired, accompanied by continued ultrafiltration. In continuous diafiltration, new buffer is added at the same rate that filtrate passes through the membrane. A
diafiltration volume is the volume of polypeptide solution prior to the start of diafiltration - using continuous diafiltration, greater than 99.5% of a fully permeable solute can be removed by washing through six diafiltration volumes with the new buffer.
Alternatively, the process can be performed in a discontinuous manner, wherein the sample is.repeatedly diluted and then filtered back to its original volume to remove or exchange salt or buffer and ultimately concentrate the polypeptide. Equipment for diafiltration and detailed methodologies for its use are available, for example, from Pall Life Sciences (Ann Arbor, MI) and Sartorius AG/Vivascience (Hannover, Germany).
Tangential flow filtration (TFF), also known as "cross-flow filtration," also uses ultrafiltration membrane. Fluid containing the target polypeptide is pumped tangentially along the surface of the membrane. The pressure causes a portion of the fluid to pass through the membrane while the target polypeptide is retained above the filter. In contrast to standard ultrafiltration, however, the retained molecules do not accumulate on the surface of the membrane, but are carried along by the tangential flow. The solution that does not pass through the filter (containing the target polypeptide) can be repeatedly circulated across the membrane to achieve the desired degree of concentration. Equipment for TFF and detailed methodologies for its use 3 0 are available, for example, from Millipore (e.g., the ProFlux M12TM
Benchtop TFF
system and the PelliconTM systems), Pall Life Sciences (e.g., the MiniinTM
Tangential Flow Filtration system).
Protein concentration is measured in a number of ways that are well known in the art. These include, for example, amino acid analysis, absorbance at 280 nm, the "Bradford" and "Lowry" methods, and SDS-PAGE. The most accurate method is total hydrolysis followed by amino acid analysis by HPLC, concentration is then determined then comparison with the lcnown sequence of the single immunoglobulin variable domain polypeptide. While this method is the most accurate, it is expensive and time-consuming. Protein determination by measurement of W absorbance at 280 nm faster and much less expensive, yet relatively accurate and is preferred as a compromise over amino acid analysis. Absorbance at 280 nm was used to determine protein concentrations reported in the Examples described herein.
"Bradford" and "Lowry" protein assays (Bradford, 1976, Anal. Biochem. 72:
248-254; Lowry et al.,1951, J. Biol. Chem. 193: 265-275) compare sample protein concentration to a standard curve most often based on bovine serum albumin (BSA).
These methods are less accurate, tending to undersetimate the concentration of single immunoglobulin variable domains. Their accuracy could be improved, however, by using a VH or V,; single domain polypeptide as a standard.
An additional protein assay method is the bicinchoninic acid assay described in U.S. Patent No. 4,839,295 (incorporated herein by reference) and marketed by Pierce= Biotechnology (Rockford, IL) as the "BCA Protein Assay" (e.g., Pierce Catalog No. 23227).
The SDS-PAGE method uses gel electrophoresis and Coomassie Blue staining .in comparison to known concentration standards, e.g., known amounts of a single immunoglobulin variable domain polypeptide. Quantitation can be done by eye or by densitometry.
Single human immunoglobulin variable domain antigen-binding polypeptides described herein retain solubility at high concentration (e.g., at least 4.8 mg (-400 M) in aqueous solution (e.g., PBS), and preferably at least 5 mg/ml (-417 M), mg/ml (-833 gM), 20 mg/ml (- 1.7 mM), 25 mg/ml (-2.1 mM), 30 mg/ml (-2.5 mM), 35 mg/ml (-2.9 mM), 40 mg/ml (-3.3 mM), 45 mg/ml (-3.75 mM), 50 mg/ml (-4.2 mM), 55 mg/m1 (-4.6 mM), 60 mg/ml (-5.0 mM), 65 mg/ml (-5.4 mM), 70 mg/ml (-5.8 mM), 75 mg/ml (-6.3 mM), 100 mg/ml (-8.33 mM), 150 mg/mI (-12.5 mM), 200 mg/ml (-16.7 mM), 240 mg/ml (-20 mM) or higher). One structural feature that promotes high solubility is the relatively small size of the single immunoglobulin variable domain polypeptides. A full length conventional four chain antibody, e.g., IgG is about 150 kD in size. In contrast, single immunoglobulin variable domains, which all have a general structure comprising 4 framework (FW) regions and 3 CDRs, have a size of approximately 12 kD, or less than 1/10 the size of a conventional antibody. Similarly, single immunoglobulin variable domains are approximately % the size of an scFv molecule (-26 kD), and approximately 1/5 the size of a Fab molecule (-60 kD). It is preferred that the size of a single immunoglobulin variable domain-containing structure disclosed herein is 100 kD
or less, including structures of, for example, about 90 kD or less, 80 kD or less, 70 kD or less, 60 kD or less, 50 kD or less, 40 kD or less, 30 kD or less, 20 kD or less, down to and including about 12 kD, or a single immunoglobulin variable domain in isolation.
The solubility of a polypeptide is primarily determined by the interactions of the amino acid side chains with the surrounding solvent. Hydrophobic side chains tend to be localized internally as a polypeptide folds, away from the solvent-interacting surfaces of the polypeptide. Conversely, hydrophilic residues tend to be localized at the solvent-interacting surfaces of a polypeptide. Generally, polypeptides having a primary sequence ,that permits the molecule to fold to expose more hydrophilic residues to the aqueous environment are more soluble than one that folds to expose fewer hydrophilic residues to the surface. Thus, the arrangement and number of hydrophobic and hydrophilic residues is an important determinant of solubility. Other parameters that determine polypeptide solubility include solvent pH, temperature, and ionic strength. In a common practice, the solubility of polypeptides can be maintained or enhanced by the addition of glycerol (e.g., -10% v/v) to the solution.
As discussed above, specific amino acid residues have been identified in conserved residues of human VH domains that vary in the VH domains of camelid species, which are generally more soluble than human VH domains. These include, for example, Gly 44 (Glu in camelids), Leu 45 (Arg in camelids) and Trp 47 (Gly in camelids). Amino acid residue 103 of VH is also implicated in solubility, with mutation from Trp to Arg tending to confer increased VH solubility.
ln preferred aspects of the invention, single immunoglobulin variable domain polypeptides are based on the DP47 germline VH gene segment or the DPK9 germline VK gene segment. Thus, these germline gene segments are capable, particularly when diversified at selected structural locations described herein, of producing specific binding single immunoglobulin variable domain polypeptides that are highly soluble.
In particular, the four framework regions, which are preferably not diversified, can contribute to the high solubility of the resulting proteins.
It is expected that a single human immunoglobulin variable domain that is highly homologous to one having a known high solubility will also tend to be highly soluble. Thus, as one means of prediction or recognition that a given single immunoglobulin variable domain would have the high solubility recited herein, one can compare the sequence of a single immunoglobulin variable domain polypeptide to one or more single immunoglobulin variable domain polypeptides having known solubility. Thus, when a single immunoglobulin variable domain polypeptide is identified that 'has high binding affinity but unlcnown solubility, comparison of its amino acid sequence with that of one or more (preferably more) human single immunoglobulin variable domain polypeptides known to have high solubility (e.g., a dAb sequence disclosed herein) can permit prediction of its solubility. While it is not an absolute predictor, where there is a high degree of similarity to a known highly soluble sequence, e.g., 90-95% or greater similarity, and particularly where there is a hig11 degree of similarity with respect to hydrophilic amino acid residues, or residues likely to be exposed,at the solvent interface, it is more likely that a newly identified binding polypeptide will have solubility similar to that of the known highly soluble sequence.
Molecular modeling software can also be used to predict the solubility of a polypeptide sequence relative to that of a polypeptide of known solubility.
For example, the substitution or addition of a hydrophobic residue at the solvent-exposed surface, relative to a molecule of lcnown solubility that has a less hydrophobic or even hydrophilic residue exposed in that position is expected to decrease the relative solubility of the polypeptide. Similarly, the substitution or addition of a more hydrophilic residue at such a location is expected to increase the relative solubility.
That is, a change in the net number of hydrophilic or hydrophobic residues located at the surface of the molecule (or the overall hydrophobic or hydrophilic nature of the surface-exposed residues) relative to a single immunoglobulin variable domain polypeptide structure with known solubility can predict the relative solubility of a single immunoglobulin variable domain polypeptide.
Alternatively, or in conjunction with such prediction, one can determine limits of a single immunoglobulin variable domain polypeptide's solubility by simply concentrating the polypeptide.
Affinity Determination:
Isolated single immunoglobulin variable domain- and antibody polypeptide-containing polypeptides as described herein preferably have affinities (dissociation constant, Kd, = Koff/Koõ) of at least 500 nM or less, and preferably at least 400 nM-50 pM, 300 nM-50 pM, 200 nM - 50 pM, and more preferably at least 100 nM - 50 pM, 75nM-50pM,50nM-50pM,25nM-50pM, 10 nM - 50 pM, 5 nM - 50 pM, 1 nM - 50 pM, 950 pM - 50 pM, 900 pM - 50 pM, 850 pM - 50 pM, 800 pM - 50 pM, 750pM-50pM, 700 pM - 50 pM, 650 pM - 50 pM, 600pM-50pM, 550pM-50 pM, 500 pM - 50 pM, 450 pM - 50 pM, 400 pM - 50 pM., 350 pM - 50 pM, 300 pM
-50pM,250pM-50pM,200pM-50pM, l50pM-50pM, 100pM-50pM,90 pM - 50 pM, 80 pM - 50 pM, 70 pM - 50 pM, 60 pM - 50 pM, or even as Iow as 50 pM.
The antigen-binding affinity of an antibody. polypeptide, e.g., a single immunoglobulin variable domain polypeptide or other monovalent antibody polypeptide, can be conveniently measured by SPR using the BlAcore system (Pharmacia Biosensor, Piscataway, N.J.). In this method, antigen is coupled to the BlAcore chip at known concentrations, and variable domain polypeptides are introduced. Specific binding between the variable domain polypeptide and the immobilized antigen results in increased protein concentration on the chip matrix and a change in the SPR signal. Changes in SPR signal are recorded as resonance units (RU) and displayed with respect to time along the Y axis of a sensorgram.
Baseline signal is taken with solvent alone (e.g., PBS) passing over the chip. The net difference between baseline signal and signal after completion of antibody polypeptide injection represents the binding value of a given sample. To determine the off rate (Koff), on rate (Koõ) and dissociation rate (Kd) constants, BlAcore kinetic evaluation software (e.g., version 2.1) is used.
Thus, SPR can be used to monitor antagonism of CD40L binding to CD40 by a monovalent anti-CD40L antibody preparation by measuring the displacement or inhibition of binding of CD40L to CD40 caused the monovalent antibody preparation.
SPR can also be used to monitor the dimerization, or preferably, the lack of dimerization, occurring via Fc region in antibody preparations as described herein.
High affinity is dependent upon the complementarity between a surface of the antigen and the CDRs of the antibody or antibody fragment. Complementarity is determined by the type and strength of the molecular interactions possible between portions of the target and the CDR, for example, the potential ionic interactions, van der Waals attractions, hydrogen bonding or other interactions that can occur.
tends to contribute more to antigen binding interactions than CDRs 1 and 2, probably due to its generally larger size, which provides more opportunity for favorable surface interactions. (See, e.g., Padlan et al., 1994, Mol. Immunol. 31: 169-217;
Chothia &
Lesk, 1987, J. Mol. Biol. 196: 904-917; and Chotllia et al., 1985, J. Mol.
Biol. 186:
651-663.) High affinity indicates antibody polypeptide/antigen pairings that have a high degree of complementarity, which is directly related to the structures of the variable domain and the target.
In one aspect, a monovalent anti-CD40L antibody polypeptide, e.g., a single immunoglobulin variable domain polypeptide, is linked to another antibody polypeptide to form a heterodimer in which each individual antibody polypeptide is capable of binding a different cognate antigen. Fusing antibody polypeptides, such as single immunoglobulin variable domains, as heterodimers, wherein each monomer binds a different target antigen, can produce a dual-specific ligand capable, for example, of bridging the respective target antigens. Such dual specific ligands may be used to target cytokines and other molecules which cooperate synergistically in therapeutic situations in the body of an organism. Thus, there is provided a method for synergising the activity of two or more cytokines, comprising administering a dual specific antibody heterodimer capable of binding to the two or more cytokines.
Non-limiting examples of second targets for anti-CD40L dual specific antibody polypeptides include the following: TNF-a; IL-l; IL-2; IL-4; IL-6; IL-8; IL-12; IL-18; IFN-y; CD2; CD4; CD8; CTLA4; LFAl; LFA3, VLA4, CD80, B7-1, CD28, CD86, B7-2, and CTLA-4. In particular, second targets useful according to the invention include CD80, B7-1, CD28, CD86, B7-2, and CTLA-4. These targets are thought to be involved in a co-stimulatory pathway critical for T-cell activation (termed, co-stimulatory signal pathway antigens). This pathway includes activation of the molecule CD28 on the surface of T cells. This molecule can receive a costimulatory signal delivered by a ligand on B cells or other APCs. Ligands for CD28 include members of the B7 family of B lymphocyte activation antigens, such as B7-1 and/or B7-2 (Freedman, A. S. et al. (1987) J. Immunol. 137, 3260-3267;
Freeman, G. J. et al. (1989) J. Immunol. 143, 2714-2722; Freeman, G. J. et al.
(1991) J. Exp. Med. 174, 625-631; Freeman, G. J. et al. (1993) Science 262, 909-911;
Azuma, M. et al. (1993) Nature 366, 76-79; Freeman, G. J. et al. (1993) J.
Exp. Med.
178, 2185-2192). B7-1 and B7-2 are also ligands for anotller molecule, CTLA4, present on the surface of activated T cells. Accordingly, the present invention contemplates that members of the CD28 signalling pathway may be useful second targets for the dual-specific format anti-CD40L antibody polypeptides.
Homolo og us sequences;
The invention encompasses anti-CD40L antibody polypeptides, e.g., CD40L-binding single immunoglobulin variable domain clones, and clones with substantial sequence similarity or homology to them that also bind target antigen with high affinity. As used herein, "substantial" sequence similarity or homology is at least 85% similarity or homology.
Calculations of "homology" or "sequence identity" between two sequences (the terms are equivalent and used interchangeably herein) are performed as follows.
The sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, the length of a reference sequence aligned for comparison purposes is at least 30%, preferably at least 40%, more preferably at least 50%, even more preferably at least 60%, and even more preferably at least 70%, 80%, 90%, 100% of the length of the reference sequence. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid or nucleic acid "homology" is equivalent to amino acid or nucleic acid "identity").
The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.
As used herein, sequence "similarity" is a measure of the degree to which amino acid sequences share similar ainino acid residues at corresponding positions in an alignment of the sequences. Amino acids are similar to each other where their side chains are similar. Specifically, "similarity" encompasses amino acids that are conservative substitutes for each other. A "conservative" substitution is any substitution that has a positive score in the blosum62 substitution matrix (Hentikoff and Hentikoff, 1992, Proc. Natl. Acad. Sci. USA 89: 10915-10919). By the statement "sequence A is n% similar to sequence B" is meant that n% of the positions of an optimal global alignment between sequences A and B consists of identical amino acids or conservative substitutions. Optimal global alignments can be performed using the following parameters in the Needleman-Wunsch alignment algorithm:
For polypeptides:
Substitution matrix: biosum62.
Gap scoring function: -A -B*LG, where A=11 (the gap penalty), B=1 (the gap length penalty) and LG is the length of the gap.
For nucleotide sequences:
Substitution matrix: 10 for matches, 0 for mismatches.
Gap scoring function: -A -B*LG where A=50 (the gap penalty), B=3 (the gap length penalty) and LG is the length of the gap.
Typical conservative substitutions are among Met, Val, Leu and lle; among Ser and Thr; among the residues Asp, Glu and Asn; among the residues Gln, Lys and Arg; or aromatic residues Phe and Tyr. In calculating the degree (most often as a percentage) of similarity between two polypeptide sequences, one considers the number of positions at which identity or similarity is observed between corresponding amino acid residues in the two polypeptide sequences in relation to the entire lengths of the two molecules being compared.
Alternatively, the BLAST (Basic Local Alignment Search Tool) algoritlun is employed for sequence alignment, with parameters set to default values. The BLAST
algorithm "BLAST 2 Sequences" is available at the world wide web site ("www") of the National Center for Biotechnology Information (".nebi"), of the National Library of Medicine (".nlm") of the National Institutes of Health ("nih") of the U.S.
government (".gov"), in the "/blast/" directory, sub-directories "bl2seq/b12.htm1."
This algorithm aligns two sequences for comparison and is described by Tatusova &
Madden, 1999, FEMS Microbiol Lett. 174:247-250.
An additional measure of homology or similarity is the ability to hybridize under highly stringent hybridization conditions. Thus, a first sequence encoding a single immunoglobulin variable domain polypeptide is substantially similar to a second coding sequence if the first sequence hybridizes to the second sequence (or its complement) under highly stringent hybridization conditions (such as those described by Sambrook et al., Molecular Cloning, Laboratory Manuel, Cold Spring, Harbor Laboratory press, New York). "Highly stringent hybridization conditions" refer to hybridization in 6X SSC at about 45 C, followed by one or more washes in 0.2X
SSC, 0.1% SDS at 65 C. "Very highly stringent hybridization conditions" refer to hybridization in 0.5M sodium phosphate, 7% SDS at 65 C, followed by one or more washes at 0.2X SSC, 1% SDS at 65 C.
Assays for CD40L Activities:
It is preferred that a monovalent anti-CD40L antibody polypeptides as described herein bind to CD40L yet do not substantially agonize CD40 signaling.
Activation of the CD40L/CD40 pathway manifests a number of different outcomes that can be measured in order to assess the effect of a given monovalent anti-antibody polypeptide on the activity of the pathway. However, for the assessment of the antagonist or agonist function of monovalent anti-CD40L antibody polypeptides described herein, at least one of the following CD40L assays can be used:
1) Activation of Jun-N-Terminal Kinase (JNK):
Stimulation of T-lymphocytes via CD40L induces strong activation of JNIL.
The ability of a monovalent anti-CD40L antibody polypeptide to activate this signaling pathway is measured as follows. Human leukemic Jurlcat cells are stimulated with a positive control agonistic anti-CD40L antibody (2 g/ml monoclonal anti-human or anti-mouse gp39/CD40L antibody (Pharmingen, San Diego, CA, USA) or isotype matched hamster or mouse immunoglobulins (Dianova, Hanlburg, Germany)), monovalent anti-CD40L antibody polypeptide, or a negative control irrelevant antibody as described by Brenner et al., 1997, FEBS Lett.
417: 301-306, which is incorporated herein by reference. The cells are lysed and the extract assayed for phosphorylated JNK via colorimetric assay (e.g., TiterzymeTM
colorimetric (EIA) phospho-JNK1/2 immunoassay lcit, by Assay Designs Inc., Catalog # 900-106). An increase in phospho-JNK (e.g., by 5% or more) for anti-CD40L-stimulated cells over non-stimulated cells indicates agonism of CD40L
activity by the antibody polypeptide.
2. Induction of Cytokine Secretion:
Co-stimulation of T cells with anti-CD3 Ab and CD40L has been shown to upregulate the production of IL-10, IFN-y and TNF-a by those cells. The ability of a monovalent anti-CD40L antibody polypeptide to activate this signaling pathway is measured as follows. Human leukemic Jurkat T cells (or freshly isolated CD4+ T
cells) are plated into 96 well plates containing immobilized anti-CD3 antibody. The cells are then cultured for 72 hours in the presence of a positive control agonistic anti-CD40L antibody, CD40L, monovalent anti-CD40L antibody polypeptide, or a negative control irrelevant antibody, as described by Blair et al., 2000, J.
Exp. Med.
191: 651-660. IFN-y (or IL-10 of TNF-a) is then quantitated in the supernatant by sandwich ELISA using an IFN-g standard to generate a standard curve from which all other unknowns can be calculated. An increase in IFN-g (e.g., by 5% or more) for anti-CD40L-stimulated cells over non-stimulated cells indicates agonism by the antibody polypeptide.
3. Platelet Aggregation Assay:
Divalent anti-CD40L antibodies tend to cause platelet aggregation, which is likely associated with the thromboembolic events observed in clinical trials of divalent anti-CD40L antibodies in the prior art. Monovalent anti-CD40L
antibody polypeptides as described herein preferably do not substantially mediate or agonize CD40L-mediated platelet aggregation. With regard tothis aspect, the "standard platelet aggregation assay" is as follows:
Platelets are prepared at 2.5x105/ml and left stirring in a 500-Ca lumi-aggregometer (or its equivalent, e.g., a Platelet Aggregation Profiler (BioData, Horsham, PA)). Platelets are partially activated by the addition of a dilution series of 0.1-10 M ADP (the 10 M ADP induces aggregation, and is used as a positive control - lower concentrations activate platelets but do not induce aggregation).
CD40L mediated platelet aggregation is stimulated by addition of either anti-monoclonal antibodies (i.e., divalent monoclonal antibodies, available from, e.g., Pharmingen, San Diego, CA, USA) or soluble CD40/Fc fusion protein (available from R&D Systems). The reaction is allowed to proceed for between 3 and 5 minutes. Stimulation of platelet aggregation above the mininimal aggregation/activation achieved with ADP alone is plotted against stimulating anti-CD40L or CD40/Fc concentration. The percentage of platelet aggregation is measured by the change in light transmittance following addition of antibody polypeptide being tested or positive control peptide. A value greater than that observed for negative control lacking antibody and amounting to 25% or more of the positive control value (divalent anti-CD40L or CD40/Fc fusion) is considered to be indicative of induction of platelet aggregation.
Other methods to assess platelet aggregation and/or activation, including events which precede aggregation, or which are downstream from platelet aggregation, include assays which deterinine various indicators of platelet activation, and are known in the art. For example, platelet activation (and, thus, activity) can be determined by assaying for CD62P expression in platelets (e.g., using anti-CD26P antibodies and flow cytometry), assaying for monocyte-platelet-conjugate formation, assaying for platelet closure time under high shear conditions (e.g., using a PFA-100, Dade Behring, Newark, DE), and assaying for platelet dense granule release. Methods for performing such assays are known in the art and can be found, for example, in Langer et al., 2005 Thromb. Haemost. 93: 1137-46.
PEGylation of monovalent anti-CD40L antibody polypeptides The present invention provides PEGylated monovalent anti-CD40L antibody polypeptides which have increased half-life and preferably also resistance to degradation witliout a loss in activity (e.g., binding affinity) relative to non-PEGylated antibody polypeptides.
Monovalent anti-CD40L antibody polypeptides according to this aspect can be coupled, using methods known in the art to polymer molecules (preferably PEG) useful for achieving the increased half-life and degradation resistance properties encompassed by the present invention. Polymer moieties which can be utilized in the invention can be synthetic or naturally occurring and include, but are not limited to straight or branched chain polyalkylene, polyallcenylene or polyoxyalkylene polymers, or a branched or unbranched polysaccharide such as a homo- or heteropolysaccharide. Preferred examples of synthetic polymers which may be used in the invention include straight or branched chain poly(ethylene glycol) (PEG), poly(propylene glycol), or poly(vinyl alcohol) and derivatives or substituted forms thereof. Particularly preferred substituted polymers useful in the invention include substituted PEG, including methoxy(polyethylene glycol). Naturally occurring polymer moieties which may be used according to the invention in addition to or in place of PEG include lactose, amylose, dextran, or glycogen, as well as derivatives thereof which would be recognized by one of skill in the art. Derivatized forms of polymer molecules of the invention include, for example, derivatives which have additional moieties or reactive groups present therein to permit interaction with amino acid residues of the dAb polypeptides described herein. Such derivatives include N-hydroxylsuccinimide (NHS) active esters, succinimidyl propionate polymers, and sulfhydryl-selective reactive agents such as maleimide, vinyl sulfone, and thiol.
Particularly preferred derivatized polymers include, but are not limited to PEG
polymers having the formulae: PEG-O-CH~CH2CH2-C02-NHS; PEG-O-CHZ-NHS;
PEG-O-CH2CH2-C0,-NHS; PEG-S-CH,CH2-CO-NHS; PEG-O2CNH-CH(R)-COZ-NHS; PEG-NHCO-CH,,CH?-CO-NHS; and PEG-O-CH.,-C02-NHS; where R is (CH2)4)NHC02(mPEG). PEG polymers useful in the invention may be linear molecules, or may be branched wherein multiple PEG moieties are present in a single polymer. Some particularly preferred PEG derivatives which are useful in the invention include, but are not limited to the following:
O
rnPfC-o-Cr- NI H
O ICtiAA
CH
,-hslH--CHCi t,-NH
mPEta-N ~ 1t+~~""~y"'CC~11[/ \j O
mPEG-MAL mPEG2-MAL
CH2CONH(CHZCHzO)Z CH2CH2N
C l '~H OH (H
~ ~
//
mPEG-CONHCH O Ho-pm/ 0i'v(gp ,yPEO-om I f.-04 CHaCONH(CH 2CH20)2-CHzCHZN I
mPEG-(MAL)2 multi-arin PEG
It ~~-3-t~- C~t~H
O 0 [C~2?4 0 mf-EG--O-CHzC}~~=,..=C-Q-N
11 ~~'~-~ ~t.
mPEG-SPA mPEG2-NHS
mPEG2-(MAL)2 II CH2CONH(CH2CH2O)2-CH2CH2N I
mPEG-O- C-Ni oi mPEG-O-Ii NH
0 CH2CONH(CH2CH2O)2- CH2CH2N
; and The reactive group (e.g., MAL, NHS, SPA, VS, or Thiol) may be attached directly to the PEG polymer or may be attached to PEG via a linker molecule.
The size of polymers useful in the invention can be in the range of between 500 Da to 60 kDa, for example, between 1000 Da and 60 kDa, 10 kDa and 60 kDa, kDa and 60 kDa, 30 kDa and 60 kDa, 40 kDa and 60 kDa, and up to between 50 kDa and 60 kDa. The polymers used in the invention, particularly PEG, can be straight chain polymers or can possess a branched conformation. Depending on the combination of molecular weight and conformation, the polymer molecules useful in the invention, when attached to a monovalent anti-CD40L antibody polypeptide, will yield a molecule having an average hydrodynamic size of between 24 and 500 kDa.
The hydrodynamic size of a polymer molecule used herein refers to the apparent size of a molecule (e.g., a protein molecule) based on the diffusion of the molecule through an aqueous solution. The diffusion, or motion of a protein through solution can be processed to derive an apparent size of the protein, where the size is given by the Stokes radius or hydrodynamic radius of the protein particle. The "hydrodynamic size" of a protein depends on both mass and shape (conformation), such that two proteins having the same molecular mass may have differing hydrodynamic sizes based on the overall conformation of the protein. The hydrodynamic size of a PEG-linked monovalent anti-CD40L antibody polypeptide, e.g., an anti-CD40L single immunoglobulin variable domain as described herein, can be in the range of 24 kDa to 500 kDa; 30 to 500 kDa; 40 to 500 kDa; 50 to 500 kDa; 100 to 500 kDa; 150 to 500 kDa; 200 to 500 kDa; 250 to 500 kDa; 300 to 500 kDa; 350 to 500 l:Da; 400 to 500 lcba and 450 to 500 kDa. Preferably the hydrodynamic size of a PEGylated antibody polypeptide as described herein is 30 to 40 kDa; 70 to 80 l:Da or 200 to 300 lcDa. The size of a polymer molecule attached to a monovalent anti-CD40L
antibody polypeptide may thus be varied depending upon the desired application. For example, where the PEGylated antibody polypeptide is intended to leave the circulation and enter into peripheral tissues, it is desirable to keep the size of the attached polymer low to facilitate extravazation from the blood stream. Alternatively, where it is desired to have the PEGylated antibody polypeptide remain in the circulation for a longer period of time, a higher molecular weight polymer can be used (e.g., a 30 to 60 kDa polymer).
The polymer (PEG) molecules useful in the invention can be attached to antibody polypeptides using methods that are well known in the art. The first step in the attachment of PEG or other polymer moieties to an antibody polypeptide is the substitution of the hydroxyl end-groups of the PEG polymer by electrophile-containing functional groups. Particularly, PEG polymers are attached to either cysteine or lysine residues present in the antibody polypeptide. The cysteine and lysine residues can be naturally occurring, or can be engineered into the antibody polypeptide molecule. For example, cysteine residues can be recombinantly engineered at the C-terminus of antibody polypeptides, or residues at specific solvent accessible locations in the antibody polypeptide can be substituted with cysteine or lysine. In a preferred embodiment, a PEG moiety is attached to a cysteine residue which is present in the hinge region at the C-terminus of an antibody polypeptide.
In a further preferred embodiment a PEG moiety or other polymer is attached to a cysteine or lysine residue which is either naturally occurring at or engineered into the N-terminus of antibody single variable domain polypeptide of the invention. In a still further embodimeilt, a PEG moiety or other polymer is attached to an antibody single variable domain according to the invention at a cysteine or lysiiie residue (either naturally occurring or engineered) which is at least 2 residues away from (e.g., internal to) the C- and/or N-terminus of the antibody single variable domain polypeptide.
In one embodiment, the PEG polymer(s) is attached to one or more cysteine or lysine residues present in a framework region (FWs) and one or more heterologous CDRs of a single immunoglobulin variable domain. CDRs and framework regions (e.g., CDR1-CDR3 and FWI-FW4) are those regions of an immunoglobulin variable domain as defined in the Kabat database of Sequences of Proteins of Immunological Interest (Kabat et al., 1991, supra). In a preferred embodiment, a PEG polymer is linked to a cystine or lysine residue in the VH framework segment DP47, or the Vk, framework segment DPK9. Cysteine and/or lysine residues of DP47 which may be linked to PEG according to the invention include the cysteine at positions 22, or 96 and the lysine at positions 43, 65, 76, or 98 of SEQ ID NO: 1(Figure 5).
Cysteine and/or lysine residues of DPK9 which may be linked to PEG according to the invention include the cysteine residues at positions 23, or 88 and the lysine residues at positions 39, 42, 45, 103, or 107 of SEQ ID NO: 3 (Figure 6). In addition, specific cysteine or lysine residues may be linked to PEG in the VH canonical framework region DP38, or DP45.
In addition, specific solvent accessible sites in the antibody molecule which are not naturally occurring cysteine or lysine residues may be mutated to a cysteine or lysine for attachment of a PEG polymer. Solvent accessible residues in any given antibody, e.g., a dAb, can be determined using metllods known in the art such as analysis of the crystal structure of the antibody polypeptide. For example, using the solved crystal structure of the VH dAb HEL4 (SEQ ID NO: 3; a dAb that binds hen egg lysozyme), the residues Gln-13, Pro-14, Gly-15, Pro-41, Gly-42, Lys-43, Asp-62, Lys-65, Arg-87, Ala-88, Glu-89, Gln-112, Leu-115, Thr-117, Ser-119, and Ser-have been identified as being solvent accessible, and according to the present invention would be attractive candidates for mutation to cysteine or lysine residues for the attachment of a PEG polymer. In addition, using the solved crystal structure of the Vk dummy dAb (SEQ ID NO: 4), the residues Val-15, Pro-40, Gly-41, Ser-56, Gly-57, Ser-60, Pro-80, Glu-81, Gin-100, Lys-107, and Arg-108 have been identified as being solvent accessible, and according to the present invention would be attractive candidates for mutation to cysteine or lysine residues for the attachment of a PEG
polymer. In one embodiment of the invention, a PEG polymer is linked to multiple solvent accessible cysteine or lysine residues, or to solvent accessible residues which have been mutated to a cysteine or lysine residue. Alternatively, only one solvent accessible residue is linked to PEG, either where the particular antibody polypeptide only possesses one solvent accessible cysteine or lysine (or residue modified to a cysteine or lysine) or where a particular solvent accessible residue is selected from among several such residues for PEGylation.
Primary amino acid sequence of HEL4 (SEQ ID NO: 5).
PGKGLEWVSS
TAVYYCASAL
Primary amino acid sequence of Vk- dummy (SEQ ID NO: 6).
GKAPKLLIYA
SYSTPNTFGQ
Several PEG attachment schemes which are useful in the invention are provided by the company Nektar (SanCarlos, CA). For example, where attachment of PEG or other polymer to a lysine residue is desired, active esters of PEG
polymers which have been derivatized with N-hydroxylsuccinimide, such as succinimidyl propionate may be used. Where attachment to a cysteine residue is intended, PEG
polymers which have been derivatized with sulfhydryl-selective reagents such as maleimide, vinyl sulfone, or thiols may be used. Other examples of specific embodiments of PEG derivatives which may be used according to the invention to generate PEGylated antibodies can be found in the Nektar Catalog (available on the world wide web at nektar.com). In addition, several derivitized forms of PEG
may be used according to the invention to facilitate attachment of the PEG polymer to an antibody polypeptide. PEG derivatives useful in the invention include, but are not limited to PEG-succinimidyl succinate, urethane liill;ed PEG, PEG
phenylcarbonate, PEG succinimidyl carbonate, PEG-carboxymethyl azide, dimethylmaleic anhydride PEG, PEG dithiocarbonate derivatives, PEG-tresylates (2,2,2-trifluoroethanesolfonates), mPEG imidoesters, and other as described in Zalipsky and Lee, (1992) ("Use of functionalized poly(ethylene glycol)s for modification of peptides" in Poly(Ethylene Glycol) Chemistry: Biotechnical and Biomedical Applications, J. Milton Harris, Ed., Plenum Press, NY).
In one embodiment, the invention provides an anti-CD40L antibody single variable domain composition comprising an antibody single variable domain and PEG
polymer wherein the ratio of PEG polymer to antibody single variable domain is a molar ratio of at least 0.25:1. In a further einbodiment, the molar ratio of PEG
polymer to antibody single variable domain is 0.33:1 or greater. In a still further embodiment the molar ratio of PEG polymer to antibody single variable domain is 0.5:1 or greater.
Dual-specific Ligands The invention also provides dual-specific ligands comprising immunoglobulin single variable domains which each have different specificities; that is, the first and the second epitopes bound by the dual-specific ligand are preferably different. As used herein a "dual-specific ligand" refers to a ligand comprising a first immunoglobulin single variable domain and a second immunoglobulin single variable domain as herein defined, wherein the variable regions are capable of binding to two different antigens or two epitopes on the same antigen which are not normally bound by a monospecific immunoglobulin. For example, the two epitopes may be on the same hapten, but are not the same epitope or sufficiently adjacent to be bound by a monospecific ligand. The dual specific ligands according to the invention are composed of variable domains which have different specificities, and do not contain mutually complementary variable domain pairs which have the same specificity.
Dual-specific ligands may be, or be part of, polypeptides, proteins or nucleic acids, which may be naturally occurring or synthetic. In this respect, the ligand of the invention may bind an epiotpe or antigen and act as an antagonist or agonist (eg, EPO
receptor agonist). The epitope binding domains of the ligand in one embodiment have the same epitope specificity, and may for example simultaneously bind their epitope when multiple copies of the epitope are present on the same antigen. In another embodiment, these epitopes are provided on different antigens such that the ligand can bind the epitopes and bridge the antigens. One skilled in the art will appreciate that the choice of epitopes and antigens is large and varied. They may be for instance human or animal proteins, cytokines, cytokine receptors, enzymes co-factors for enzymes or DNA binding proteins. Suitable cytokines and growth factors include but are not limited to: ApoE, Apo-SAA, BDNF, Cardiotrophin-1, EGF, EGF
receptor, ENA-78, Eotaxin, Eotaxin-2, Exodus-2, EpoR, FGF-acidic, FGF-basic, fibroblast growth factor-10, FLT3 ligand, Fractalkine (CX3C), GDNF, G-CSF, GM-CSF, GF-j31, insulin, IFN-y, IGF-I, IGF-II, IL-la, IL-1(3, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8(72 a.a.), IL-8 (77 a.a.), IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, IL-16, IL-17, IL-1$
(IGIF), Inhibin a, Inhibin (3, IP-10, keratinocyte growth factor-2 (KGF-2), KGF, Leptin, LIF, Lymphotactin, Mullerian inhibitory substance, monocyte colony inhibitory factor, monocyte attractant protein, M-CSF, MDC (67 a.a.), NIDC (69 a.a.), MCP-1 (MCAF), MCP-2, MCP-3, MCP-4, MDC (67 a.a.), MDC (69 a.a.), MIG, MIP-la, MIP-1f3, MIP-3a, MIP-3(3, MIP-4, myeloid progenitor inhibitor factor-I
(MPIF-1), NAP-2, Neurturin, Nerve growth factor, (3-NGF, NT-3, NT-4, Oncostatin M, PDGF-AA, PDGF-AB, PDGF-BB, PF-4, RANTES, SDFla, SDFl(3, SCF, SCGF, stem cell factor (SCF), TARC, TGF-a, TGF-(3, TGF-(32, TGF-(33, tumour necrosis factor (TNF), TNF-a, TNF-(3, TNF receptor I, TNF receptor II, TNIL-1, TPO, VEGF, VEGF receptor 1, VEGF receptor 2, VEGF receptor 3, GCP-2, GRO/MGSA, GRO-(3, GRO-y, HCC1, 1-309, HER 1, HER 2, HER 3, HER 4, TACE recognition site, TNF
BP-I and TNF BP-II, as well as any target disclosed in Annex 2 or Annex 3 hereto, whether in combination as set forth in the Annexes, in a different combination or individually. Cytokine receptors include receptors for the foregoing cytokines, e.g.
IL-1 RI; IL-6R; IL-10R; IL-18R, as well as receptors for cytokines set forth in Annex 2 or Annex 3 and also receptors disclosed in Annex 2 and 3. It will be appreciated that this list is by no means exhaustive. Where the multispecific ligand binds to two epitopes (on the same or different antigens), the antigen(s) may be selected from this list.
In one embodiment of the second configuration of the invention, the variable domains are derived from an antibody directed against the first and/or second antigen or epitope. In a preferred embodiment the variable domains are derived from a repertoire of single variable antibody domains. In one example, the repertoire is a repertoire that is not created in an animal or a synthetic repertoire. In another example, the single variable domains are not isolated (at least in part) by animal immunisation. Thus, the single domains can be isolated from a naive library.
In another aspect, the invention provides a multi-specific ligand comprising a first epitope binding domain having a first epitope binding specificity and a non-complementary second epitope binding domain having a second epitope binding specificity. The first and second binding specificities may be the same or different.
In a furtlier aspect, the present invention provides a closed conformation multi-specific ligand comprising a first epitope binding domain having a first epitope binding specificity and a non-complementary second epitope binding domain having a second epitope binding specificity wllerein the first and second binding specificities are capable of competing for epitope binding such that the closed conformation multi-specific ligand caimot bind both epitopes simultaneously.
In a still further aspect, the invention provides open conformation ligands comprising non-complementary binding domains, wherein the domains are specific for a different epitope on the same target. Such ligands bind to targets with increased avidity. Similarly, the invention provides multivalent ligands comprising non-complementary binding domains specific for the same epitope and directed to targets which comprise multiple copies of said epitope.
In a similar aspect, ligands according to the invention can be configured to bind individual epitopes with low affinity, such that binding to individual epitopes is not therapeutically significant; but the increased avidity resulting from binding to two epitopes provides a therapeutic benefit. In a particular example, epitopes may be targeted which are present individually on normal cell types, but present together only on abnormal or diseased cells, such as tumour cells. In such a situation, only the abnormal or diseased cells are effectively targeted by the bispecific ligands according to the invention.
Ligand specific for multiple copies of the same epitope, or adjacent epitopes, on the same target (known as chelating dAbs) may also be trimeric or polymeric (tertrameric or more) ligands coinprising three, four or more non-complementary binding domains. For example, ligands may be constructed comprising three or four VH domains or VL domains.
Moreover, ligands are provided which bind to multisubunit targets, wherein each binding domain is specific for a subunit of said target. The ligand may be dimeric, trimeric or polymeric.
The invention also includes a dual specific ligand comprising a first immunoglobulin single variable domain having a binding specificity to a first antigen and a second single variable domain having a binding activity to a second antigen, wherein the first antigen is CD40L and the second single variable domain is an Antigen Presenting Cell surface antigen or a T cell surface antigen. The Antigen Presenting Cell (APC) surface antigen can be selected from one of the group consisting of dendritic cell surface antigens, activated macrophage surface antigens, activated B cell surface antigens, co-stimulatory signal pathway surface antigens, and MHC, such as MHC II alpha or beta.
The (APC) surface antigen may be selected from the group consisting of CD28, Inducible costimulatory molecule (ICOS), CD27, CD30, OX40, CD45, CD69, CD3, CD70, Inducible costimulatory molecule ligand (ICOSL), OX40L, CD80, CD86, HVEM (Herpes Virus Entry Mediator), and LIGHT, but is preferably one of CD28, Inducible costimulatory molecule (ICOS), CD27, CD'O, OX40, CD45, CD69, or CD3.
The surface antigen is preferably a B7 gene surface antigen such as B7-2 or B7-1.
Dendritic cell surface antigens are known in the art and can include but are not limited to ICAM-1, ICAM-2, LFA-1, LFA-3, DEC205, MHC class I, MHC class II, B7-1, and B7-2. Activated macrophage surface antigens include, but are not limited to, TNF receptor, CD40, MHC class I and II, and B7 molecules. Activated B-cell surface antigens are lcnown in the art (e.g., including but not limited to CD20 and CD86)and further described above (see, for example, Janeway et al., 1999, Immunobiolow, Garland Publishing NY, NY).
Preferably, the multi-specific ligands according to the above aspects of the invention are obtainable by the method comprising the steps of:
a) selecting a first epitope binding domain by its ability to bind to a first epitope, b) selecting a second epitope binding domain by its ability to bind to a second epitope, c) combining the epitope binding domains; and d) selecting the closed conformation multispecific ligand. by its ability to bind to said first second epitope and said second epitope..
Advantageously the first epitope binding domain and the second epitope binding domains are non-complementary immunoglobulin variable domains, as herein defined. That is either ~7H vH or VL-VL variable domains.
Chelating dAbs in particular may be prepared according to a preferred aspect of the invention, namely the use of anchor dAbs, in which a library of dimeric, trimeric or multimeric dAbs is constructed using a vector which comprises a constant dAb upstream or downstream of a linker sequence, with a repertoire of second, third and further dAbs being inserted on the other side of the linker. In alternative methodologies, the use of linlcers may be avoided, for example by the use of non-covalent bonding or natural affinity between binding domains such as VH and V.
The invention accordingly provides a method for preparing a multimeric ligand comprising the steps of:
(a) providing a vector comprising a nucleic acid sequence encoding a single binding domain specific for a first epitope on a target;
(b) providing a vector encoding a repertoire comprising second binding domains specific for a second epitope on said target, which epitope can be the same or different to the first epitope, said second epitope being adjacent to said first epitope;
and (c) expressing said first and second binding domains; and (d) isolating those combinations of first and second binding domains which combine together to produce a target-binding dimer.
The first and second epitopes are adjacent such that a multimeric ligand is capable of binding to both epitopes simultaneously. This provides the ligand with the advantages of increased avidity if binding. Where the epitopes are the same, the increased avidity is obtained by the presence of multiple copies of the epitope on the target, allowing at least two copies to be simultaneously bound in order to obtain the increased avidity effect.
In an alternative embodiment of the above aspect of the second configuration of the invention, at least one epitope binding domain comprises a non-immunoglobulin 'protein scaffold' or 'protein skeleton' as herein defined.
Suitable non-immunoglobulin protein scaffolds include but are not limited to any of those selected from the group consisting of: SpA, fibronectin, GroEL and other chaperones, lipocallin, CCTLA4 and affibodies, as set forth above.
According to the above aspect of the second configuration of the invention, advantageously, the epitope binding domains are attached to a'protein skeleton'.
Advantageously, a protein skeleton according to the invention is an immunoglobulin skeleton.
According to the present invention, the term 'immunoglobulin skeleton' refers to a protein which comprises at least one immunoglobulin fold and which acts as a nucleus for one or more epitope binding domains, as defined herein.
Preferred immunoglobulin skeletons as herein defined includes any one or more of those selected from the following: an immunoglobulin molecule comprising at least (i) the CL (kappa or lambda subclass) domain of an antibody; or (ii) the CH1 domain of an antibody heavy chain; an immunoglobulin molecule comprising the CHI and CH2 domains of an antibody heavy chain; an immunoglobulin molecule comprising the CH1, CH2 and CH3 domains of an antibody heavy chain; or any of the subset (ii) in conjunction with the CL (kappa or lambda subclass) domain of an antibody. A hinge region domain may also be included. Such combinations of domains may, for example, mimic natural antibodies, such as IgG or IgM, or fragments thereof, such as Fv, scFv, Fab or F(ab')2 molecules. Those skilled in the art will be aware that this list is not intended to be exhaustive.
Linking of the skeleton to the epitope binding domains, as herein defined may be achieved at the polypeptide level, that is after expression of the nucleic acid encoding the skeleton and/or the epitope binding domains. Altematively, the linlcing step may be performed at the nucleic acid level. Methods of linking a protein skeleton according to the present invention, to the one or more epitope binding domains include the use of protein chemistry and/or molecular biology techniques which will be familiar to those skilled in the art and are described herein.
Advantageously, the dual- or multispecific ligand may comprise a first domain capable of binding a target molecule, and a second domain capable of binding a molecule or group which extends the half-life of the ligand. For example, the molecule or group may be a bulky agent, such as HSA or a cell matrix protein.
As used herein, the phrase "molecule or group which extends the half-life of a ligand"
refers to a molecule or chemical group which, when bound by a dual-specific ligand as described herein increases the .in vivo half-life of such dual specific ligand when administered to an animal, relative to a ligand that does not bind that molecule or group. Examples of molecules or groups that extend the half-life of a ligand are described hereinbelow. Iti a preferred embodiment, the closed conformation multispecific ligand may be capable of binding the target molecule only on displacement of the half-life enhancing molecule or group. Thus, for example, a closed conformation multispecific Iigand is maintained in circulation in the bloodstream of a subject by a bulky molecule such as HSA. When a target molecule is encountered, competition between the binding domains of the closed conformation multispecifc ligand results in displacement of the HSA and binding of the target.
Molecules which increase half-life are discussed in further detail above.
Ligands according to any aspect of the present invention, as well as dAb monomers useful in constructing such ligands, may advantageously dissociate from their cognate target(s) with a Kd of 300nM to 5pM (ie, 3 x 10-7 to 5 x 10-12 M), preferably 50nM to20pM, or 5nM to 200pM or InM to I00pM, 1 x 10'7 M or less, I
x 10-8 M or less, 1 x 10"9 M or less, I x 10"10 M or less, 1 x 10"31 M or less;
and/or a Koff rate constant of 5 x 10'1 to 1 x 10-7 S-', preferably 1 x 10'2 to 1 x 10-6 S"1, or 5 x 10"' to 1 x 10"5 S-I, or 5 x 10-1 S-1 or less, or I x 10"2 S"1 or less, or 1 x 10-3 S-1 or less, or 1 x 10-4 S-1 or less, or I x 10'5 S-1 or less, or 1 x I0"6 S-1 or less as determined by surface plasmon resonance. The Kd rate constand is defined as Koff/Kor,.
Furthermore, the invention provides a dAb monomer(or dual specific ligand comprising such a dAb) that binds to serum albumin (SA) with a Kd of 1nM to 500gM (ie, x 10"9 to 5 x 10-4), preferably lOOnM to lO M. Preferably, for a dual specific ligand comprising a first anti-SA dAb and a second dAb to another target, the affinity (eg Kd and/or Koff as measured by surface plasmon resonance, eg using BiaCore) of the second dAb for its target is from 1 to 100000 times (preferably 100 to 100000, more preferably 1000 to 100000, or 10000 to 100000 times) the affinity of the first dAb for SA. For example, the first dAb binds SA with an affinity of approximately 10 M, while the second dAb binds its target with an affinity of 100pM. Preferably, the serum albumin is human serum albumin (HSA).
In one embodiment, the first dAb (or a dAb monomer) binds SA (eg, HSA) with a Kd of approximately 50, preferably 70, and more preferably 100, 150 or nM.
The invention moreover provides dimers, trimers and polymers of the aforementioned dAb monomers, in accordance with the foregoing aspect of the present invention.
Ligands according to the invention, including dAb monomers, dimers and trimers, can be linked to an antibody Fc region, comprising one or both of CH2 and CH3 domains, and optionally a hinge region. For example, vectors encoding ligands linked as a single nucleotide sequence to an Fc region may be used to prepare such polypeptides. Alternatively, ligands according to the invention may be free of an Fc domain.
In a further aspect, the present invention provides one or more nucleic acid molecules encoding at least a dual- or multispecific ligand as herein defined.
In one embodiment, the ligand is a closed conformation ligand. In another embodiment, it is an open conformation ligand. The multispecific ligand may be encoded on a single nucleic acid molecule; alternatively, each epitope binding domain may be encoded by a separate nucleic acid molecule. Where the ligand is encoded by a single nucleic acid molecule, the domains may be expressed as a fusion polypeptide, or may be separately expressed and subsequently linked together, for example using chemical linking agents. Ligands expressed from separate nucleic acids will be linked together by appropriate means.
The nucleic acid may further encode a signal sequence for export of the polypeptides from a host cell upon expression and may be fused with a surface component of a filamentous bacteriophage particle (or other component of a selection display system) upon expression. Leader sequences, which may be used in bacterial expression and/or phage or phagemid display, include pelB, stII, ompA, phoA, bla and pelA.
In a further aspect of the second configuration of the invention the present invention provides a vector comprising nucleic acid according to the present invention.
In a yet further aspect, the present invention provides a host cell transfected with a vector according to the present invention.
Expression from such a vector may be configured to produce, for example on the surface of a bacteriophage particle, epitope binding domains for selection. This allows selection of displayed domains and thus selection of 'multispecific ligands' using the method of the present invention.
Combining single variable domains Domains useful in the invention, once selected using methods exemplified above, may be combined by a variety of methods known in the art, including covalent and non-covalent methods.
Preferred methods include the use of polypeptide linkers, as described, for example, in connection with scFv molecules (Bird et al., (1988) Science 242:423-426). Discussion of suitable linkers is provided in Bird et al. Science 242, 423-426;
Hudson et al, Journal Immunol Methods 231 (1999) 177-189; Hudson et al, Proc Nat Acad Sci USA 85, 5879-5883. Linkers are preferably flexible, allowing the two single domains to interact. One linker example is a(Gly4 Ser)õ linker, where n=1 to 8, eg, 2, 3, 4, 5 or 7. The linkers used in diabodies, which are less flexible, may also be employed (Holliger et al., (1993) PNAS (USA) 90:6444-6448).
In one embodiment, the linker employed is not an immunoglobulin hinge region.
Variable domains may be combined using methods other than linkers. For example, the use of disulphide bridges, provided through naturally-occurring or engineered cysteine residues, may be exploited to stabilise VH-VH,VL-VL or VIi-VL
dimers (Reiter et al., (1994) Protein Eng. 7:697-704) or by remodelling the interface between the variable domains to improve the "fit" and thus the stability of interaction (Ridgeway et al., (1996) Protein Eng. 7:617-621; Zhu et al., (1997) Protein Science 6:781-788).
Other techniques for joining or stabilizing variable domains of immunoglobulins, and in particular antibody VH domains, may be employed as appropriate.
In accordance with the present invention, dual specific ligands can be in "closed" conformations in solution. A "closed" configuration is that in which the two domains (for example VH and VL) are present in associated form, such as that of an associated VH-VL pair which forins an antibody binding site. For example, scFv may be in a closed conformation, depending on the arrangement of the linker used to link the VH and VL domains. If this is sufficiently flexible to allow the domains to associate, or rigidly holds them in the associated position, it is likely that the domains will adopt a closed conformation.
Similarly, VH domain pairs and VL domain pairs may exist in a closed conformation. Generally, this will be a function of close association of the domains, such as by a rigid linlcer, in the ligand molecule. Ligands in a closed conformation will be unable to bind both the molecule which increases the half-life of the ligand and a second target molecule. Thus, the ligand will typically only bind the second target molecule on dissociation from the molecule which increases the half-life of the ligand.
Moreover, the construction of VH/VH, VLIVL or VH/VL dimers without linkers provides for competition between the domains.
Ligands according to the invention may moreover be in an open conformation.
In such a conformation, the ligands will be able to simultaneously bind both the molecule which increases the half-life of the ligand and the second target molecule.
Typically, variable domains in an open configuration are (in the case of VH-VL
pairs) held far enough apart for the domains not to interact and form an antibody binding site and not to compete for binding to their respective epitopes. In the case of VH/VH
or VL/VL dimers, the domains are not forced together by rigid linkers.
Naturally, such domain pairings will not compete for antigen binding or form an antibody binding site.
Fab fragments and whole antibodies will exist primarily in the closed conformation, although it will be appreciated that open and closed dual specific ligands are likely to exist in a variety of equilibria under different circumstances.
Binding of the ligand to a target is likely to shift the balance of the equilibrium towards the open configuration. Thus, certain ligands according to the invention can exist in two conformations in solution, one of which (the open form) can bind two antigens or epitopes independently, whilst the alternative conformation (the closed form) can only bind one antigen or epitope; antigens or epitopes thus compete for binding to the ligand in this conformation.
Although the open form of the dual specific ligand may thus exist in equilibrium with the closed form in solution, it is envisaged that the equilibrium will favor the closed form; moreover, the open form can be sequestered by target binding into a closed conformation. Preferably, therefore, certain dual specific ligands of the invention are present in an equilibrium between two (open and closed) conformations.
Dual specific ligands according to the invention may be modified in order to favor an open or closed conformation. For example, stabilisation of VH-VL
interactions with disulphide bonds stabilises -the closed conformation.
Moreover, linkers used to join the domains, including VH domain and VL domain pairs, may be constructed such that the open from is favoured; for example, the linkers may sterically hinder the association of the domains, such as by incorporation of large amino acid residues in opportune locations, or the designing of a suitable rigid structure which will keep the domains physically spaced apart.
Characterisation of the dual-specific IiQand.
The binding of the dual-specific ligand to its specific antigens or epitopes (e.g., CD40L and/or an epitope bound by DOM8-24) can be tested by methods which will be familiar to those skilled in the art and include ELISA. In a preferred embodiment of the invention binding is tested using monoclonal phage ELISA.
Phage ELISA may be performed according to any suitable procedure: an exemplary protocol is set forth below.
Populations of phage produced at each round of selection can be screened for binding by ELISA to the selected antigen or epitope, to identify "polyclonal"
phage antibodies. Phage from single infected bacterial colonies from these populations can then be screened by ELISA to identify "monoclonal" phage antibodies. It is also desirable to screen soluble antibody fragments for binding to antigen or epitope, and this can also be undertaken by ELISA using reagents, for example, against a C-or N-terminal tag (see for example Winter et al. (1994) Ann. Rev. Immunology 12, and references cited therein.
The diversity of the selected phage monoclonal antibodies may also be assessed by gel electrophoresis of PCR products (Marks et al. 1991, supra;
Nissim et al. 1994 supra), probing (Tomlinson et al., 1992) J. Mol. Biol. 227, 776) or by sequencing of the vector DNA.
Structure of 'Dual-specific ligands'.
As described above, an antibody is herein defined as an antibody (for exaznple IgG, IgM, IgA, IgA, IgE) or fragment (Fab, Fv, disulphide linked Fv, scFv, diabody) which comprises at least one heavy and a light chain variable domain, at least two heavy chain variable domains or at least two light chain variable domains. It may be at least partly derived from any species naturally producing an antibody, or createdby recombinant DNA technology; whether isolated from serum, B-cells, hybridomas, transfectomas, yeast or bacteria).
in a preferred embodiment of the invention the dual-specific ligand comprises at least one single heavy chain variable domain of an antibody and one single light chain variable domain of an antibody, or two single heavy or light chain variable domains. For example, the ligand may comprise a VH/VL pair, a pair of VH
domains or a pair of VL domains.
The first and the second variable domains of such a ligand may be on the same polypeptide chain. Alternatively they may be on separate polypeptide chains.
In the case that they are on the same polypeptide chain they may be linked by a linker, which is preferentially a peptide sequence, as described above.
The first and second variable domains may be covalently or non-covalently associated. In the case that they are covalently associated, the covalent bonds may be disulphide bonds.
In the case that the variable domains are selected from V-gene repertoires selected for instance using phage display technology as herein described, then these variable domains comprise a universal framework region, such that is they may be recognised by a specific generic ligand as herein defined. The use of universal frameworks, generic ligands and the like is described in W099/20749.
Where V-gene repertoires are used variation in polypeptide sequence is preferably located within the structural loops of the variable domains. The polypeptide sequences of either variable domain may be altered by DNA
shuffling or by mutation in order to enhance the interaction of each variable domain with its complementary pair. DNA shuffling is known in the art and taught, for example, by Stemmer, 1994, Nature 370: 389-391 and U.S. Patent No. 6,297,053, both of which are incorporated herein by reference. Other methods of mutagenesis are well known to those of skill in the art.
In one embodiment of the invention the 'dual-specific ligand' is a single chain Fv fragment. In an alternative embodiment of the invention, the 'dual-specific ligand' consists of a Fab format.
In a further aspect, the present invention provides nucleic acid encoding at least a'dual-specific ligatld' as herein defined.
One skilled in the art will appreciate that, depending on the aspect of the invention, both antigens or epitopes may bind simultaneously to the same antibody molecule. Alternatively, they may compete for binding to the same antibody molecule. For example, where both epitopes are bound simultaneously, both variable domains of a dual specific ligand are able to independently bind their target epitopes.
Where the domains compete, the one variable domain is capable of binding its target, but not at the same time as the other variable domain binds its cognate target; or the first variable domain is capable of binding its target, but not at the same time as the second variable domain binds its cognate target.
The variable regions may be derived from antibodies directed against target antigens or epitopes. Alternatively they may be derived from a repertoire of single antibody domains such as those expressed on the surface of filamentous bacteriophage. Selection may be performed as described below.
In general, the nucleic acid molecules and vector constructs required for the performance of the present invention may be constructed and manipulated as set forth in standard laboratory manuals, such as Sambrook et al. (1989) Molecular Cloning: A
Laboratwy Manual, Cold Spring Harbor, USA.
The manipulation of nucleic acids useful in the present invention is typically carried out in recombinant vectors.
Thus in a further aspect, the present invention provides a vector comprising nucleic acid encoding at least a'dual-specific ligand' as herein defined.
As used herein, vector refers to a discrete element that is used to introduce heterologous DNA into cells for the expression and/or replication thereof.
Methods by which to select or construct and, subsequently, use such vectors are well known to one of ordinary skill in the art. Numerous vectors are publicly available, including bacterial plasmids, bacteriophage, artificial clu-omosomes and episomal vectors. Such vectors may be used for simple cloning aiid mutagenesis; alternatively gene expression vector is employed. A vector of use according to the invention may be selected to accommodate a polypeptide coding sequence of a desired size, typically from 0.25 kilobase (kb) to 40 kb or more in length A suitable host cell is transformed with the vector after in vitro cloning manipulations. Each vector contains various functional components, which generally include a cloning (or "polylinker") site, an origin of replication and at least one selectable marker gene. If given vector is an expression vector, it additionally possesses one or more of the following:
enhancer element, promoter, transcription termination and signal sequences, each positioned in the vicinity of the cloning site, such that they are operatively linked to the gene encoding a ligand according to the invention.
Both cloning and expression vectors generally contain nucleic acid sequences that enable the vector to replicate in one or more selected host cells.
Typically in cloning vectors, this sequence is one that enables the vector to replicate independently of the host chromosomal DNA and includes origins of replication or autonomously replicating sequences. Such sequences are well known for a variety of bacteria, yeast and viruses. The origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, the 2 micron plasmid origin is suitable for yeast, and various viral origins (e.g. SV 40, adenovirus) are useful for cloning vectors in mammalian cells. Generally, the origin of replication is not needed for mammalian expression vectors unless these are used in mammalian cells able to replicate high levels of DNA, such as COS cells.
Advantage.ously, a cloning or expression vector may contain a selection gene also referred to as selectable marker. This gene encodes a protein necessary for the survival or growth of transformed host cells grown in a selective culture medium.
Host cells not transformed with the vector containing the selection gene will therefore not survive in the culture medium. Typical selection genes encode proteins that confer resistance to antibiotics and other toxins, e.g. ampicillin, neomycin, methotrexate or tetracycline, complement auxotrophic deficiencies, or supply critical nutrients not available in the growth media.
Since the replication of vectors encoding a ligand according to the present invention is most conveniently performed in E. coli, an E. coli-selectable marker, for example, the j3-lactamase gene that confers resistance to the antibiotic ampicillin, is of use. These can be obtained from E. coli plasmids, such as pBR' )22 or a pUC
plasmid such as pUC 18 or pUC 19.
Expression vectors usually contain a promoter that is recognised by the host organism and is operably linked to the coding sequence of interest. Such a promoter may be inducible or constitutive. The term "operably linked" refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner. A coiltrol sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences.
Promoters suitable for use with prokaryotic hosts include, for example, the (3-lactamase and lactose promoter systems, alkaline phosphatase, the tryptophan (trp) promoter system and hybrid promoters such as the tac promoter. Promoters for use in bacterial systems will also generally contain a Shine-Delgamo sequence operably linked to the coding sequence.
The preferred vectors are expression vectors that enables the expression of a nucleotide sequence corresponding to a polypeptide library member. Thus, selection with the first andlor second antigen or epitope can be performed by separate propagation and expression of a single clone expressing the polypeptide library member or by use of any selection display system. As described above, the preferred selection display system is bacteriophage display. Thus, phage or phagemid vectors may be used, eg pITI or pIT2. Leader sequences useful in the invention include pelB, stll, ompA, phoA, bla and pelA. One example are phagemid vectors which have an E. coli. origin of replication (for double stranded replication) and also a phage origin of replication (for production of single-stranded DNA). The manipulation and expression of such vectors is well known in the art (Hoogenboom and Winter (1992) supra; Nissim et al. (1994) supra). Briefly, the vector contains a(3-lactarnase gene to confer selectivity on the phagemid and a lac promoter upstream of a expression cassette that consists (N to C terminal) of a pe1B leader sequence (which directs the expressed polypeptide to the periplasmic space), a multiple cloning site (for cloning the nucleotide version of the library member), optionally, one or more peptide tag (for detection), optionally, one or more TAG stop codon and the phage protein pIIl.
Thus, using various suppressor and non-suppressor strains of E. coli and with the addition of glucose, iso-propyl thio-(3-D-galactoside (IPTG) or a helper phage, such as VCS M13, the vector is able to replicate as a plasmid with no expression, produce large quantities of the polypeptide library member only or produce phage, some of which contain at least one copy of the polypeptide-plII fusion on their surface.
Construction of vectors encoding ligands according to the invention employs conventional ligation techniques. Isolated vectors or DNA fragments are cleaved, tailored, and religated in the form desired to generate the required vector.
If desired, analysis to confirm that the correct sequences are present in the constructed vector can be performed in a known fashion. Suitable methods for constructing expression vectors, preparing in >>itro transcripts, introducing DNA into host cells, and performing analyses for assessing expression and function are known to those skilled in the art. The presence of a gene sequence in a sample is detected, or its amplification and/or expression quantified by conventional methods, such as Southern or Northern analysis, Western blotting, dot blotting of DNA, RNA or protein, in situ hybridisation, immunocytochemistry or sequence analysis of nucleic acid or protein molecules. Those skilled in the art will readily envisage how these methods may be modified, if desired.
Structure of ligands According to one aspect of the invention, two or more non-complementary epitope binding domains are linked so that they are in a closed conformation as herein defined. Advantageously, they may be further attached to a skeleton which may, as a alternative, or on addition to a linker described herein, facilitate the formation and/or maintenance of the closed conformation of the epitope binding sites with respect to one another. Alternatively, the monomeric anti-CD40L antibody single variable domain polypeptides of the invention may be constructed using scaffold or skeleton frameworks as discussed herein.
(1) Skeletons Skeletons may be based on immunoglobulin molecules or may be non-immunoglobulin in origin as set forth above. Preferred immunoglobulin skeletons as herein defined includes any one or more of those selected from the following:
an immunoglobulin molecule comprising at least (i) the CL (kappa or lambda subclass) domain of an antibody; or (ii) the CH1 domain of an antibody heavy chain; an immunoglobulin molecule comprising the CH1 and CH2 domains of an antibody heavy chain; an immunoglobulin molecule comprising the CHI, CH2 and CH3 domains of an antibody heavy chain; or any of the subset (ii) in conjunction with the CL (kappa or lambda subclass) domain of an antibody. A hinge region domain may also be included.. Such combinations of domains may, for example, mimic natural antibodies, such as IgG or lgM, or fragments thereof, such as Fv, scFv, Fab or F(ab')2 molecules. Those skilled in the art will be aware that this list is not intended to be exhaustive.
(II) Protein scaffolds Each epitope binding domain comprises a protein scaffold and one or more CDRs which are involved in the specific interaction of the domain with one or more epitopes. Advantageously, an epitope binding domain according to the present invention comprises three CDRs. Suitable protein scaffolds, in addition to those based on immunoglobulin domains, may also. be based on protein scaffolds or skeletons other than iminunoglobulin domains. For exainple natural bacterial receptors such as SpA have been used as scaffolds for the grafting of CDRs to generate ligands which bind specifically to one or more epitopes. Details of this procedure are described in US 5,831,012. Other suitable scaffolds include those based on fibronectin and affibodies (Affibody, Bromma, Sweeden). Details of suitable procedures are described in WO 98/58965. Other suitable. scaffolds include lipocallin and CTLA4, as described in van den Beuken etal., J. Mol. Biol. (2001) 310, 591-601, and scaffolds such as those described in W00069907 (Medical Research Coi.uncil), which are based for example on the ring structure of bacterial GroEL or other chaperone polypeptides. Other non-immunoglobulin based scaffolds which may be used according to the invention include those based on the LDL receptor class A, EGF domain monomers and mutimers, and scaffolds available from Biorexis (King of Prussia, PA) or Avidia (Mountaiii View, CA). Other non-immunoglobulin scaffolds which may be used are described, for example, in W005/040229, W004/044011, and Scaffolds for use in Constructing Ligands i. Selection of the main-chain conformation The members of the immunoglobulin superfamily all share a similar fold for their polypeptide chain. For example, although antibodies are highly diverse in terms of their primary sequence, comparison of sequences and crystallographic structures has revealed that, contrary to expectation, five of the six antigen binding loops of antibodies (H1, H2, LI, L2, L3) adopt a limited number of main-chain conformations, or canonical structures (Chothia and Lesk (1987) J. Mol. Biol., 196: 901;
Chothia et al. (1989) Nature, 342: 877). Analysis of loop lengths and key residues has therefore enabled prediction of the main-chain conformations of H1, H2, L1, L2 and L3 found in the majority of human antibodies (Chothia et al. (1992) J. Mol. Biol., 227:
799;
Tomlinson et al. (1995) EMBO J., 14: 4628; Williams et al. (1996) J. Mol.
Biol., 264:
220). Although the H3 region is much more diverse in terms of sequence, length and structure (due to the use of D segments), it also for'ms a limited number of main-chain conformations for short loop lengths which depend on the length and the presence of particular residues, or types of residue, at key positions in the loop and the antibody framework (Martin et al. (1996) J. Mol. Biol., 263: 800; Shirai et al. (1996) FEBS
Letters, 399: 1).
The ligands of the present invention are advantageously selected and/or assembled from libraries of domains, suc11 as libraries 'of VH domains and/or libraries of VL domains. Moreover, the ligands of the invention may themselves be provided in the form of libraries. In one aspect of the present invention, libraries of ligands and/or domains are designed in which certain loop lengths and key residues have been chosen to ensure that the main-chain conformation of the members is l:nown.
Advantageously, these are real conformations of immunoglobulin superfamily molecules found in nature, to minimise the chances that they are non-functional, as discussed above. Germline V gene segments serve as one suitable basic framework for constructing antibody or T-cell receptor libraries; other sequences are also of use.
Variations may occur at a low frequency, such that a small number of functional members may possess an altered main-chain conformation, which does not affect its function.
Canonical structure theory is also of use to assess the number of different main-chain conformations encoded by ligands, to predict the main-chain conformation based on ligand sequences and to chose residues for diversification which do not affect the canonical structure.-It is known that, in the human V,; domain, the Ll loop can adopt one of four canonical structures, the L2 loop has a single canonical structure and that 90% of human V,; domains adopt one of four or five canonical structures for the L3 loop (Tomlinson et al. (1995) supra); thus, in the V,;
domain alone, different canonical structures can combine to create a range of different main-chain conformations. Given that the Va, domain encodes a different range of canonical structures for the L1, L2 and L3 loops and that V,; and V?, domains can pair with any VH domain which can encode. several canonical structures for the HI
and H2 loops, the number of canonical structure combinations observed for these five loops is very large. This implies that the generation of diversity in the main-chain conformation may be essential for the production of a wide range of binding specificities. However, by constructing an antibody library based on a single known main-chain conformation it has been found, contrary to expectation, that diversity in the main-chain conformation is not required to generate sufficient diversity to target substantially all antigens. Even more surprisingly, the single main-chain conformation need not be a consensus structure - a single naturally occurring conformation can be used as the basis for an entire library. Tllus, in a preferred aspect, the ligands of the invention possess a single lmown main-chain conformation.
The single main-chain confonnation that is chosen is preferably commonplace among molecules of the immunoglobulin superfamily type in 'question. A
conformation is commonplace when a significant number of naturally occurring molecules are observed to adopt it. Accordingly, in a preferred aspect of the invention, the natural occurrence of the different main-chain conformations for each binding loop of an immunoglobulin domain are considered separately and then a naturally occurring variable domain is chosen which possesses the desired combination of main-chain conformations for the different loops. If none is available, the nearest.equivalent may be chosen. It is preferable that the desired combination of main-chain conformations for the different loops is created by selecting germline gene segments which encode the desired main-chain conformations. It is more preferable, that the selected germline gene segments are frequently expressed in nature, and most preferable that they are the most frequently expressed of all natural germline gene segments.
In designing ligands or libraries thereof the incidence of the different main-chain conformations for each of the antigen binding loops may be considered separately. For H1, H2, L1, L2 and L3, a given conformation that is adopted by between 20% and 100% of the antigen binding loops of naturally occurring molecules is chosen. Typically, its observed incidence is above 35% (i.e. between 35%
and 100%) and, ideally, above 50% or even above 65%. Since the vast majority of H3 loops do not have canonical structures, it is preferable to select a main-chain conformation which is commonplace among those loops which do display canonical structures. For each of the loops, the conformation which is observed most often in the natural repertoire is therefore selected. In human antibodies, the most popular canonical structures (CS) for each loop are as follows: H1 - CS 1 (79% of the expressed repertoire), H2 - CS 3 (46%), L1 - CS 2 of V,; (39%), L2 - CS 1 (100%), L3 - CS 1 of V,; (36%) (calculation assumes a 1c:~ ratio of 70:30, Hood et al.
(1967) Cold Spring Harbo7- Sy77p. Quant. Biol., 48: 133). For H3 loops that have canonical structures, a CDR3 length (Kabat et al. (1991) Sequences of proteins of innmunological interest, U.S. Department of Health and Human Services) of seven residues with a salt-bridge from residue 94 to residue 101 appears to be the most common. There are at least 16 human antibody sequences in the EMBL data library with the required H3 length and key residues to form this conformation and at least two crystallographic structures in the protein data bank which can be used as a basis for antibody modelling (2cgr and ltet). The most frequently expressed germline gene segments that this combination of canonical structures are the VH segment 3-23 (DP-47), the JH segment JH4b, the V,; segment 02/012 (DPK9) and the J,; segment Jl.
VH segments DP45 and DP38 are also suitable. These segments can therefore be used in combination as a basis to construct a library with the desired single main-chain conformation.
Alternatively, instead of choosing the single main-chain conformation based on the natural occurrence of the different main-chain conformations for each of the binding loops in isolation, the natural occurrence of combinations of main-chain conformations is used as the basis for choosing the single main-chain conformation.
In the case of antibodies, for example, -the natural occurrence of canonical structure combinations for any two, three, four, five or for all six of the antigen binding loops can be determined. Here, it is preferable that the chosen conformation, is commonplace in naturally occurring antibodies and most preferable that it observed most frequently in the natural repertoire. Thus, in human antibodies, for example, when natural combinations of the five antigen binding loops, H1, H2, Ll, L2 and L3, are considered, -the most frequent combination of canonical structures is determined and then combined with the most popular conformation for the H3 loop, as a basis for choosing the single main-chain conformation.
ii. Diversification of the canonical sequence Having selected several known main-chain conformations or, preferably a single known main-chain conformation, ligands according to the invention or libraries for use in the invention can be constructed by varying the binding site of the molecule in order to generate a repertoire with structural and/or functional diversity.
This means that variants are generated such that they possess sufficient diversity in their structure and/or in their function so that they are capable of providing a range of activities.
The desired diversity is typically generated by varying the selected molecule at one or more positions. The positions to be changed can be chosen at random or are preferably selected. The variation can then be achieved either by randomisation, during which the resident amino acid is replaced by any amino acid or analogue thereof, natural or synthetic, producing a very large number of variants or by replacing the resident amino acid with one or more of a defined subset of amino acids, producing a more limited number of variants.
Various methods have been reported for introducing such diversity. Error-prone PCR (Hawkins et al. (1992) J. Mol. Biol., 226: 889), chemical mutagenesis (Deng et al. (1994) J. Biol. Chem., 269: 9533) or bacterial mutator strains (Low et al.
(1996) J. Mol. Biol., 260: 359) can be used to introduce random mutations into the genes that encode the molecule. Methods for mutating selected positions are also well known in the art and include the use of mismatched oligonucleotides or degenerate oligonucleotides, with or without the use of PCR. For example, several synthetic antibody libraries have been created by targeting mutations to the antigen binding loops. The H3 region of a human tetanus toxoid-binding Fab has been randomised to create a range of new binding specificities (Barbas et al. (1992) Proc. Natl.
Acad. Sci.
USA, 89: 4457). Random or semi-random H3 and L3 regions have been appended to germline V gene segments to produce large libraries with unmutated framework regions (Hoogenboom & Winter (1992) J. Mol. Biol., 227: 381; Barbas et al.
(1992) Proc. Natl. Acad. Sci. USA, 89: 4457; Nissim et al. (1994) EMBO J., 13: 692;
Griffiths et al. (1994) EMBO J., 13: 3245; De Kruif et al. (1995) J. Mol.
Biol., 248:
97). Such diversification has been extended to include some or all of the other antigen binding loops (Crameri et al. (1996) Nature Med., 2: 100; Riechmann et al.
(1995) Bio/Technology, 13: 475; Morphosys, W097/08320, supra).
Since loop randomisation has the potential to create approximately more tlian 101' structures for 113 alone and a similarly large number of variants for the other five loops, it is not feasible using current transformation technology or even by using cell free systems to produce a library representing all possible combinations. For example, in one of the largest libraries constructed to date, 6 x 1010 different antibodies, which is only a fraction of the potential diversity for a library of this design, were generated (Griffiths et al. (1994) supra).
In a preferred embodiment, only those residues which are directly involved in creating or modifying the desired function of the molecule are diversified.
For many molecules, the function will be to bind a target and therefore diversity should be concentrated in the target binding site, while avoiding changing residues which are crucial to the overall packing of the molecule or to maintaining the chosen main-chain conformation.
Diversification of the canonical sequence as it applies to antibodv domains In the case of the ligands of the invention, the binding site for the target is most often the antigen binding site. Thus, in a highly preferred aspect, the invention provides libraries of or for the assembly of antibody ligands in which only those residues in the antigen binding site are varied. These residues are extremely diverse in the human antibody repertoire and are known to make contacts in high-resolution antibody/antigen complexes. For example, in L2 it is known that positions 50 and 53 are diverse in naturally occurring antibodies and are observed to make contact with the antigen. In contrast, the conventional approach would have been to diversify all the residues in the corresponding Complementarity Determining Region (CDRl) as defined by Kabat et al. (1991, supra), some seven residues compared to the two diversified in the library for use according to the invention. This represents a significant improvement in terms of the functional diversity required to create a range of antigen binding specificities.
In nature, antibody diversity is the result of two processes: somatic recombination of germline V, D and J gene segments to create a naive primary repertoire (so called germline and junctional diversity) and somatic hypennutation of the resulting rearranged V genes. Analysis of human antibody sequences has shown that diversity in the primary repertoire is focused at the centre of the antigen binding site whereas somatic hypermutation spreads diversity to regions at the periphery of the antigen binding site that are highly conserved in the primary repertoire (see Tomlinson et al. (1996) J. Mol. Biol., 256: 813). This complementarity has probably evolved as an efficient strategy for searching sequence space and, although apparently unique to antibodies, it can easily be applied to other polypeptide repertoires. The residues which are varied are a subset of those that form the binding site for the target. Different (including overlapping) subsets of residues in the target binding site are diversified at different stages during selection, if desired.
In the case of an antibody repertoire, an initial 'naive' repertoire is created where some, but not all, of the residues in the antigen binding site are diversified. As used herein in this context, the term "naive" refers to antibody molecules that have no pre-determined target. These molecules resemble those which are encoded by the immunoglobulin genes of an individual who has not undergone immune diversification, as is the case with fetal and newborn individuals, whose immune systems have not yet been challenged by a wide variety of antigenic stimuli.
This repertoire is then selected against a range of antigens or epitopes. If required, further diversity can then be introduced outside the region diversified in the initial repertoire.
This matured repertoire can be selected for modified function, specificity or affinity.
The invention provides two different naive repertoires of binding domains for the construction of ligands, or a naive library of ligands, in which some or all of the residues in the antigen binding site are varied. The "primary" library mimics the natural primary repertoire, with diversity restricted to residues at the centre of the antigen binding site that are diverse in the germline V gene segments (germline diversity) or diversified during the recombination process (junctional diversity).
Those residues which are diversified include, but are not limited to, H50, H52, H52a, H53, H55, H56, H58, H95, H96, H97, H98, L50, L53, L91, L92, L93, L94 and L96.
In the "somatic" library, diversity is restricted to residues that are diversified during the recombination process (junctional diversity) or are highly somatically mutated).
Those residues which are diversified include, but are not limited to: H31, 1133, H35, H95, H96, H97, H98, L30, L31, L32, L34 and L96. All the residues listed above as suitable for diversification in these libraries are known to make contacts in one or more antibody-antigen complexes. Since in both libraries, not all of the residues in the antigen binding site are varied, additional diversity is incorporated during selection by varying the remaining residues, if it is desired to do so. It shall be apparent to one skilled in the art that any subset of any of these residues (or additional residues which comprise the antigen binding site) can be used for the initial and/or subsequent diversification of the antigen binding site.
In the construction of libraries for use in the invention, diversification of chosen positions is typically achieved at the nucleic acid level, by altering the coding sequence which specifies the sequence of the polypeptide such that a number of possible amino acids (all 20 or a subset thereof) can be incorporated at that position.
Using the IUPAC nomenclature, the most versatile codon is NNK, which encodes all amino acids as well as the TAG stop codon. The NNK codon is preferably used iri order to introduce the required diversity. Other codons which achieve the same ends are also of use, including the NNN codon, which leads to the production of the additional stop codons TGA and TAA.
A feature of side-chain diversity in the antigen binding site of human antibodies is a pronounced bias which favours certain amino acid residues. If the amino acid composition of the ten most diverse positions in each of the VH, V,; and V~, regions are summed, more than 76% of the side-chain diversity comes from only seven different residues, these being, serine (24%), tyrosine (14%), asparagine (11%), glycine (9%), alanine (7%), aspartate (6%) ' and threonine (6%). This bias towards hydrophilic residues and small residues which can provide main-chain flexibility probably reflects the evolution of surfaces which are predisposed to binding a wide range of antigens or epitopes and may help to explain the required promiscuity of antibodies in the primary repertoire.
Since it is preferable to mimic this distribution of amino acids, the distribution of amino acids at the positions to be varied preferably mimics that seen in the antigen binding site of antibodies. Such bias in the substitution of amino acids that permits selection of certain polypeptides (not just, antibody polypeptides) against a range of target antigens is easily applied to any polypeptide repertoire. There are various methods for biasing the amino acid distribution at the position to be varied (including the use of tri-nucleotide mutagenesis, see W097/08320), of which the preferred method, due to ease of synthesis, is the use of conventional degenerate codons. By comparing the amino acid profile encoded by all combinations of degenerate codons (with single, double, triple and quadruple degeneracy in equal ratios at each position) with the natural amino acid use it is possible to calculate the most representative codon. The codons (AGT)(AGC)T, (AGT)(AGC)C and (AGT)(AGC)(CT) - that is, DVT, DVC and DVY, respectively using IUPAC nomenclature - are those closest to the desired amino acid profile: they encode 22% serine and 11% tyrosine, asparagine, glycine, alanine, aspartate, threonine and cysteine. Preferably, therefore, libraries are constructed using either the DVT, DVC or DVY codon at each of the diversified positions.
Increased Half-life In vivo, the PEGylated monovalent anti-CD40L antibodies as described herein confer a distinct advantage over non-PEGylated antibody polypeptides, in that the PEGylated antibody molecules will have a greatly prolonged in vivo half life.
Without being bound to one particular tlleory, it is believed that the increased half-life of the molecules described herein is conferred by the increased hydrodynamic size of the antibody polypeptide resulting from the attachment of PEG polymer(s). More specifically, it is believed that two parameters play an important role in determining the serum half-life of PEGylated antibody polypeptides. The first criterion is the nature and size of the PEG attachment, i.e., if the polymer used is simply a linear chain or a branched/forked chain, wherein the branched/forked chain gives rise to a longer half-life. The second is the location of the PEG moiety or moieties on the antibody polypeptide in the final format and how many "free" unmodified PEG
arms the molecule has. The resulting hydrodynamic size of the PEGylated antibody polypeptide, as estimated, for example, by size exclusion chromatography, reflects the serum half-life of the molecule. Accordingly, the larger the hydrodynamic size of the PEGylated molecule, the greater the serum half life.
Increased half-life is useful in vivo applications of immunoglobulins, especially antibodies and most especially antibody fragments of small size.
Such fragments (Fvs, Fabs, scFvs, dAbs) suffer from rapid clearance from the body;
thus, while they are able to reach most parts of the body rapidly, and are quick to produce and easier to handle, their in vivo applications have been limited by their only brief persistence in vivo.
In one aspect, a monovalent anti-CD40L antibody polypeptide as described herein is stabilized in vivo by fusion with a moiety, such as PEG, that increases the hydrodynamic size of the antibody polypeptide. Methods for pharmacokinetic analysis and determination of half-life will be familiar to those skilled in the art.
Details may be found in Kenneth et al: Chemical Stability of Pharmaceuticals:
A
Handbook for Pharmacists and in Peters et al, Pharmacokinetc analysis: A
Practical Approach (1996). Reference is also made to "Pharmacokinetics", M Gibaldi & D
Perron, published by Marcel Dekker, 2 d Rev. ex edition (1982), which describes pharmacokinetic parameters such as t alpha and t beta half lives and area under the curve (AUC).
Typically, the half life of a PEGylated antibody polypeptide as described herein is increased by 10%, 20%, 30%, 40%, 50% or more relative to a non-PEGylated dAb (wherein the antibody polypeptide of the PEGylated antibody polypeptide and non-PEGylated antibody polypeptide are the same). Increases in the range of 2x, 3x, 4x, 5x, 7x, l Ox, 20x, 30x, 40x, and up to 50x or more of the half life are possible. Alternatively, or in addition, increases in the range of up to 30x, 40x, 50x, 60x, 70x, 80x, 90x, I OOx, 150x of the half life are possible.
Half lives (t%z alpha and t'/2 beta) and AUC can be determined from a curve of serum concentration of ligand against time. The WinNonlin analysis package (available from Pharsight Corp., Mountain View, CA 94040, USA) can be used, for example, to model the curve. In a first phase (the alpha phase) the ligand is undergoing mainly distribution in the patient, with some elimination. A second phase (beta phase) is the terminal phase when the ligand has been distributed and the serum concentration is decreasing as the ligand is cleared from the patient. The ta half life is the half life of the first phase and the tj3 half life is the half life of the second phase.
"Half-life" as used herein, unless otherwise noted, refers to the overall half-life of an antibody single variable domain of the invention determined by non-compartment modeling (as contrasted with biphasic modeling, for example). Beta half-life is a measurement of the time it takes for the amount of dAb monomer or multimer to be cleared from the mammal to which it is administered. Thus, advantageously, the present invention provides a dAb-containing composition, e.g., a dAb-effector group composition, having a ta half-life in the range of 0.25 hours to 6 hours or more. In one embodiment, the lower end of the range is 30 minutes, 45 minutes, 1 hour, 1.3 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 10 hours, 11 hours or 12 hours. In addition or alternatively, a dAb containing composition will have a ta half-life in the range of up to and including 12 hours. In one embodiment, the upper end of the range is 11, 10, 9, 8, 7, 6, or 5 hours. An example of a suitable range is 1.3 to 6 hours, 2 to 5 hours or 3 to 4 hours.
Advantageously, the present invention provides a dAb containing composition comprising a ligand according to the invention having a t(3 half-life in the range of 1-170 hours or more. In one embodiment, the lower end of the range is 2.5 hours, hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours or 12 hours. In addition, or alternatively, a dAb containing composition, e.g. a dAb-effector group composition has a t(1 half-life in the range of up to and including 21 days. In one embodiment, the upper end of the range is 12 hours, 24 hours, 2 days, 3 days, 5 days, 10 days, 15 days, or 20 days. Advantageously a dAb containing composition according to the invention will have a t(3 half-life in the range 2-100 hours, hours, and 10-40 hours. In a further embodiment, it will be in the range 12-48 hours.
In a further embodiment still, it will be in the range 12-26 hours. The present invention provides a dAb containing composition comprising a ligand according to the invention having a half-life in the range of 1-170 hours or more. In one embodiment, the lower end of the range is 1.3 hours, 2.5 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours or 12. hours. In addition, or alternatively, a dAb containing composition, e.g. a dAb-effector group composition has a half-life in the range of up to and including 21 days. In one embodiment, the upper end of the range is 12 hours, 24 hours, 2 days, 3 days, 5 days, 10 days, 15 days, or 20 days.
In addition, or alternatively to the above criteria, the present invention provides a dAb containing composition comprising a ligand according to the invention having an AUC value (area under the curve) in the range of 1 mg.min/ml or more. In one embodiment, the lower end of the range is 5, 10, 15, 20, 30, 100, 200 or 300 mg.min/ml. In addition, or alternatively, a ligand or composition according to the invention has an AUC in the range of up to 600 mg.min/ml. In one embodiment, the upper end of the range is 500, 400, 300, 200, 150, 100, 75 or 50 mg.min/ml.
Advantageously a ligand according to the invention will have an AUC in the range selected from the group consisting of the following: 15 to 150 mg.min/ml, 15 to 100 mg.min/ml, 15 to 75 mg.min/ml, and 15 to 50 mg.min/ml.
The ligands according to the invention, including, mono-, dual- and multi-specific, in one configuration thereof, are capable of binding to one or more molecules which can increase the half-life of the ligand in vivo. Typically, such molecules are polypeptides which occur naturally in vivo and which resist degradation or removal by endogenous mechanisms which remove unwanted material from the organism. For example, the molecule which increases the half-life of the organism may be selected from the following:
Proteins from the extracellular matrix; for example collagen, laminins, integrins and fibronectin. Collagens are the major proteins of the extracellular matrix.
About 15 types of collagen molecules are currently knovvn, found in different parts of the body, eg type I collagen (accounting for 90% of body collagen) found in bone, skin, tendon, ligaments, cornea, internal organs or type II collagen found in cartilage, invertebral disc, notochord, vitreous humour of the eye.
Proteins found in blood, including:
Plasma proteins such as fibrin, a-2 macroglobulin, serum albumin, fibrinogen A, fibrinogen B, serum amyloid protein A, heptaglobin, profilin, ubiquitin, uteroglobulin and (3-2-microglobulin;
Enzymes and inhibitors such as plasrninogen, lysozyme, cystatin C, alpha-l-antitrypsin and pancreatic trypsin inhibitor. Plasminogen is the inactive precursor of the trypsin-like serine protease plasmin. It is normally found circulating through the blood stream. When plasminogen becomes activated and is converted to plasmin, it unfolds a potent enzymatic domain that dissolves the fbrinogen fibers that entgangle the blood cells in a blood clot. This is called fibrinolysis.
Immune system proteins, such as IgE, IgG, IgM.
Transport proteins such as retinol binding protein, a-1 microglobulin.
Defensins such as beta-defensin 1, Neutrophil defensins 1,2 and 3.
Proteins found at the blood brain barrier or in neural tissues, such as melanocortin receptor, myelin, ascorbate transporter.
Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins (see US5977307); brain capillary endothelial cell receptor, transferrin, transferrin receptor, insulin, insulin-like growth factor 1(IGF 1) receptor, insulin-lilce growth factor 2 (IGF 2) receptor, insulin receptor.
Proteins localised to the kidney, such as polycystin, type IV collagen, organic anion transporter K1, Heymann's antigen.
Proteins localised to the liver, for example alcohol dehydrogenase, G250.
Blood coagulation factor X
al antitrypsin HNF la Proteins localised to the lung, such as secretory component (binds IgA).
Proteins localised to the Heart, for example HSP 27. This is associated with dilated cardiomyopathy.
Proteins localised to the skin, for example keratin.
Bone specific proteins, such as bone morphogenic proteins (BIvIPs), which are a subset of the transforming growth factor ji superfamily that demonstrate osteogenic activity. Examples include BMP-2, -4, -5, -6, -7 (also referred to as osteogenic protein (OP-1) and -8 (OP-2).
Tumour specific proteins, including human trophoblast antigen, herceptin receptor, oestrogen receptor, cathepsins eg cathepsin B (found in liver and spleen).
Disease-specific proteins, such as antigens expressed only on activated T-cells:
including LAG-3 (lymphocyte activation gene), osteoprotegerin ligand (OPGL) see Nature 402, 304-309; 1999, OX40 (a member of the TNF receptor 'fainily, expressed on activated T cells and the only costimulatory T cell molecule known to be specifically up-regulated in human T cell leukaemia virus type-I (HTLV-I)-producing cells.) See J I nfnunol. 2000 Jul 1;165(1):263-70; Metalloproteases (associated with arthritis/cancers), including CG6512 Drosophila, human paraplegin, human FtsH, human AFG3L2, murine ftsH; angiogenic growth factors, including acidic fibroblast growth factor (FGF-1), basic fibroblast growth factor (FGF-2), Vascular endothelial growth factor / vascular permeability factor (VEGF/VPF), transforming growth factor-a (TGF a), tumor necrosis factor-alpha (TNF-a), angiogenin, interleukin-3 (IL-3), interleukin-8 (IL-8), platelet-derived endothelial growth factor (PD-ECGF), placental growth factor (PIGF), midkine platelet-derived growth factor-BB
(PDGF), fractalkine.
Stress proteins (heat shock proteins) HSPs are normally found intracellularly. When they are found extracellularly, it is an indicator that a cell has died and spilled out its contents. This unprogrammed cell death (necrosis) only occurs when as a result of trauma, disease or injury and therefore in vivo, extracellular HSPs trigger a response from the immune system that will fight infection and disease. A dual specific which binds to extracellular HSP can be localised to a disease site.
Proteins involved in Fc transport Brambell receptor (also known as FcRB):
This Fc receptor has two functions, both of which are potentially useful for delivery The functions are (1) The transport of IgG from mother to child across the placenta (2) the protection of IgG from degradation thereby prolonging its serum half life of IgG. It-is thought that the receptor recycles IgG from endosome.
See Holliger et al, Nat Biotechnol 1997 Jul;15(7):632-6.
Other proteins involved in Fe transport include the neonatal Fc receptor (FcRn) described in Gastinel et al., 1992, PNAS 89:638; and Roopenian et al., 2003 J.
Immunol. 170:3528.
Ligands according to the invention may designed to be specific for the above targets without requiring any increase in or increasing half life in vivo. For example, ligands according to the invention can be specific for targets selected from the foregoing wllich are tissue-specific, thereby enabling tissue-specific targeting of the dual specific ligand, or a dAb monomer that binds a tissue-specific therapeutically relevant target, irrespective of any increase in half-life, although this may result.
Moreover, where the ligand or dAb monomer targets kidney or liver, this may redirect the ligand or dAb monomer to an alternative clearance pathway in vivo (for example, the ligand may be directed away from liver clearance to kidney clearance).
Polypeptides useful for increasing half-life include, but are not limited to those shown in Annex I.
Increased Protease.Stability A further advantage of the present invention is that the PEGylated dAbs and dAb multimers described herein possess increased stability to the action of proteases.
Depending on the assay conditions, dAbs are generally intrinsically stable to the action of proteases. In the presence of pepsin, however, many dAbs are totally degraded at pH 2 because the protein is unfolded under the acid conditions, thus making the protein more accessible to the protease enzyme. The present invention provides PEGylated dAb molecules, including dAb multimers, wherein it is believed that the PEG polymer provides protection of the polypeptide backbone due the physical coverage of the backbone by the PEG polymer, thereby preventing the protease from gaining access to the polypeptide backbone and cleaving it. In a preferred embodiment a PEGylated dAb having a higher hydrodynamic size (e.g., to 500 kDa) is generated according to the invention, because the larger hydrodynamic size will confirm a greater level of protection from protease degradation than a PEGylated dAb having a lower hydrodynamic size. In one embodiment, a PEG- or other polymer-linked antibody single variable domain monomer or multimer is degraded by no more than 10% when exposed to one or more of pepsin, trypsin, elastase, chymotrypsin, or carboxypeptidase, wherein if the protease is pepsin then exposure is carried out at pH 2.0 for 30 minutes, and if the protease is one or more of trypsin, elastase, chymotrypsin, or carboxypeptidase, then exposure is carried out at pH 8.0 for 30 minutes. In a preferred embodiment, a PEG- or other polymer-linlced dAb monomer or multimer is degraded by no more than 10% when exposed to pepsin at pH 2.0 for 30 minutes, preferably no more than 5%, and preferably not degraded at all. In a further preferred embodiment, a PEG- or other polymer-linked dAb multimer (e.g., hetero- or homodimer, trirner, tetramer, octamer, etc.) of the invention is degraded by less than 5%, and is preferably not degraded at all in the presence of pepsin at pH 2.0 for 30 minutes. In a preferred embodiment, a PEG- or other polymer-linked dAb monomer or multimer is degraded by no more than 10% when exposed to trypsin, elastase, chymotrypsin, or carboxypeptidase at pH 8.0 for minutes, preferably no more than 5%, and preferably not degraded at all. In a further preferred embodiment, a PEG- or other polymer-linked dAb multimer (e.g., hetero- or homodimer, trimer, tetramer, octamer, etc.) of the invention is degraded by, less than 5%, and is preferably not degraded at all in the presence of trypsin, elastase, chymotrypsin, or carboxypeptidase at pH 8.0 for 30 minutes.
The relative ratios of protease:antibody single variable domain polypeptide may be altered according to the invention to achieve the desired level of degradation as described above. For example the ratio or protease to antibody single variable domain may be from about 1:30, to about 10:40, to about 20:50, to about 30:50, about 40:50, about 50:50, about 50:40, about 50:30, about 50:20, about 50:10, about 50:1, about 40:1, and about 30:1.
Accordingly, the present invention provides a method for decreasing the degradation of an antibody single variable domain comprising linking an antibody single variable domain monomer or multimer to a PEG polymer according to any of the embodiments described herein. According to this aspect of the invention, the antibody single variable domain is degraded by no more than 10% in the presence of pepsin at pH2.0 for 30 minutes. In particular, a PEG-linked dAb multimer is degraded by no more than 5%, and preferably not degraded at all in the presence of pepsin at pH 2.0 for 30 minutes. In an alternate embodiment, the antibody single variable domain is degraded by no more than 10% when exposed to trypsin, elastase, chymotrypsin, or carboxypeptidase at pH 8.0 for 30 minutes, preferably no more than 5%, and preferably not degraded at all.
Degradation of PEG-linked dAb monomers and multimers according to the invention may be measured using methods which are well known to those of skill in the art. For example, following incubation of a PEG-linked dAb with pepsin at pH
2.0 for 30 minutes, or with trypsin, elastase, chymotrypsin, or carboxypeptidase at pH
8.0 for 30 minutes, the dAb samples may be analyzed by gel filtration, wherein degradation of the dAb monomer or multimer is evidenced by a gel band of a smaller molecular weight than an un-degraded (i.e., control dAb not treated with pepsin, trypsin, chymotrypsin, elastase, or carboxypeptidase) dAb. Molecular weight of the dAb bands on the gel may be determined by comparing the migration of the band with the migration of a molecular weight ladder (see Figure 5). Other methods of measuring protein degradation are known in the art and may be adapted to evaluate the PEG-linked dAb monomers and multimers of the present invention.
Pharmaceutical Compositions. Dosage and Administration The antibody polypeptides of the invention can be incorporated into pharmaceutical compositions suitable for administration to a subject.
Typically, the pharmaceutical composition comprises a monovalent anti-CD40L antibody polypeptide and a pharmaceutically acceptable carrier. As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. The term "pharmaceutically acceptable carrier" excludes tissue culture medium comprising bovine or horse serum.
Examples of pharmaceutically acceptable carriers include one or more of water, saline, phosphate buffered saline, dextrose, glycerol, ethanol and the like, as well as combinations thereof. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition. Pharmaceutically acceptable substances include minor amounts of auxiliary substances such as wetting or emulsifying agents, preservatives or buffers, whicll enhance the shelf life or effectiveness of the antibody polypeptide.
The compositions as described herein may be in a variety of forms. These include, for example, liquid, semi-solid and solid dosage forms, such as liquid solutions (e.g., injectable and infusible solutions), dispersions or suspensions, tablets, pills, powders, liposomes and suppositories. The preferred form depends on the intended mode of administration and therapeutic application. Typical preferred compositions are in the form of injectable or infusible solutions, such as compositions similar to those used for passive immunization of humans with other antibodies. The preferred mode of administration is parenteral (e.g., intravenous, subcutaneous, intraperitoneal, intramuscurar).
Therapeutic compositions typically must be sterile and stable under the conditions of manufacture and storage. The composition can be formulated as a solution, microemulsion, dispersion, liposome, or other ordered structure suitable to high drug concentration. Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filter sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-f ltered solution thereof. The proper fluidity of a solution can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
The antibody polypeptides described herein can be administered by a variety of methods known in the art, although for many therapeutic applications, the preferred route/mode of administration is intravenous injection or infusion. The polypeptide can also be administered by intramuscular or subcutaneous injection.
As will be appreciated by the skilled artisan, the route and/or mode of administration will vary depending upon the desired results. In certain embodiments, the active compound may be prepared with a carrier that will protect the compound against rapid release, such as a controlled release formulation, including implants, transdermal patches, and microencapsulated delivery systems. Single immunoglobulin variable domains and other relatively small monovalent antibody polypeptides are well suited for formulation as extended release preparations due, in part, to their small size - the number of moles per dose can be significantly higher than the dosage of, for example, full sized antibodies. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Prolonged absorption of injectable compositions can be brought about by including in the composition an agent that delays absorption, for example, monostearate salts and gelatin.
Many methods for the preparation of such formulations are patented or generally known to those skilled in the art. See, e.g., Sustained and Controlled Release Drug Delivery Systems, J. R. Robinson, ed., Marcel Dekker, Inc., New York, 1978. Additional methods applicable to the controlled or extended release of polypeptide agents such as the monovalent antibody polypeptides disclo"sed herein are described, for example, in U.S. Patent Nos. 6,306,406 and 6,346,274, as well as, for example, in U.S.
Patent Application Nos. US20020182254 and US20020051808, all of which are incorporated herein by reference.
In certain einbodiments, a monovalent anti-CD40L antibody polypeptide can be orally administered, for example, with an inert diluent or an assimilable edible carrier. The compound (and other ingredients, if desired) may also be enclosed in a hard or soft shell gelatin capsule, compressed into tablets, or incorporated directly into the individual's diet. For oral therapeutic administration, the compounds may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the lilce. To administer a compound of the invention by other than parenteral administration, it may be necessary to coat the compound with, or co-administer the compound with, a material to prevent its inactivation.
Additional active compounds can also be incorporated into the compositions.
In certain embodiments, a monovalent anti-CD40L antibody polypeptide is coformulated with and/or coadministered with one or more additional therapeutic agents. For example, a monovalent anti-CD40L antibody polypeptide can be coformulated and/or coadministered with one or more additional antibodies that bind other targets (e.g., antibodies that bind other cytokines or that bind cell surface molecules), or, for example, one or more cytokines. Such combination therapies may utilize lower dosages of the administered therapeutic agents, thus avoiding possible toxicities or complications associated with the various monotherapies.
The pharmaceutical compositions of the invention can include a "therapeutically effective amount" or a "prophylactically effective amount" of a monovalent anti-CD40L antibody polypeptide. A "therapeutically effective amount"
refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result. A therapeutically effective amount of the antibody polypeptide can vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the monovalent anti-CD40L
antibody polypeptide to elicit a desired response in the individual. A therapeutically effective amount is also one in which any toxic or detrimental effects of the antibody or antibody portion are outweighed by the therapeutically beneficial effects. A
"prophylactically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result.
Typically, because a prophylactic dose is used in subjects prior to or at an earlier stage of disease, the prophylactically effective amount will be less than the therapeutically effective amount.
Dosage regimens may be adjusted to provide the optimum desired response (e.g., a therapeutic or prophylactic response). For example, a single bolus may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. It is advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
A non-limiting range for a therapeutically or prophylactically effective amount of a monovalent anti-CD40L antibody polypeptide is 0.1-20 mg/kg, more preferably 1-10 mg/kg. It is to be noted that dosage values can vary with the type and severity of the condition to be alleviated. It is to be furtller understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the administering clinician.
The efficacy of treatment with a monovalent anti-CD40L antibody polypeptide as described herein is judged by the skilled clinician on the basis of improvement in one or more symptoms or indicators of the disease state or disorder being treated. An improvement of at least 10% (increase or decrease, depending upon the indicator being measured) in one or more clinical indicators is considered "effective treatment," although greater improvements are preferred, such as 20%, 30%, 40%, 50%, 75%, 90%, or even 100%, or, depending upon the indicator being measured, more than 100% (e.g., two-fold, three-fold, ten-fold, etc., up to and including attainment of a disease-free state. Indicators can be physical measurements, e.g., enzyme, cytokine, growth factor or metabolite levels, rate of cell growth or cell death, or the presence or amount of abnormal cells. One can also measure, for example, differences in the amount of time between flare-ups of symptoms of the disease or disorder (e.g., for remitting/relapsing diseases, such as multiple sclerosis).
Alternatively, non-physical measurements, such as a reported reduction in pain or discomfort or other indicator of disease status can be relied upon to gauge the effectiveness of treatment. VWhere non-physical measurements are made, various clinically acceptable scales or indices can be used, for example, the Crohn's Disease Activity Index, or CDAI (Best et al., 1976, Gastroenterology 70: 439), which combines both physical indicators, such as hematocrit and the number of liquid or very soft stools, among others, with patient-reported factors such as the severity of abdominal pain or cramping and general well-being, to assign a disease score.
As the term is used herein, "prophylaxis" performed using a composition as described herein is "effective" if the onset or severity of one or more symptoms is delayed or reduced by at least 10%, or abolished, relative to such symptoms in a similar individual (human or animal model) not treated with the composition.
Whereas the monovalent anti-CD40L antibody polypeptides described herein must bind human CD40L, where one is to evaluate its effect in an animal model system, the polypeptide must cross-react with one or more antigens in the animal model system, preferably at high affinity. One of skill in the art can readily determine if this condition is satisfied for a given animal model system and a given monovalent anti-CD40L antibody polypeptide. If this condition is satisfied, the efficacy of the monovalent anti-CD40L antibody polypeptide can be examined by administering it to an animal model under conditions which mimic a disease state and monitoring one or more indicators of that disease state for at least a 10% improvement.
Animal Models:
Monovalent anti-CD40L antibody polypeptides as described herein are useful for the treatment of autoimmune disorders in which CD40/CD40L signaling is inappropriately active. There are several animal models in which the therapeutic efficacy of a given monovalent anti-CD40L antibody polypeptide can be assessed, as discussed below.
Systemic Lupus Erythematosis (SLE):
Anti-CD40L antibody treatment prevents the development of lupus-like nephritis in NZB/NZW and SNF1 SLE mice. Treatment of SNFl mice with anti-CD40L antibody reverses established nephritis and preserves kidney function.
See, e.g., Mohan et al., 1995, J. Iminunol. 154: 1470-1480; Early et al., 1996, J.
Immunol.
157: 3159-3164; Kalled et al., 1998, J..Immunol. 160: 2158-2165 and Chess, 2001, "Blockade of the CD40L/CD40 Pathway," in Therapeutic Immunology 2"d Edition, Austen, Burakof, Rosen and Strom, Eds., Blackwell Sciences (Pubs.), pp 441-456.
Multiple Sclerosis:
Specific blockade of CD40L at the time of immunization markedly suppresses the incidence, mortality, day of onset, and clinical scores of experimental autoimmune encephalomyelitis (EAE) in B 10P IL and (PLJ x SJL)F1 mice induced by eitller myelin basic protein or PLP myelin antigens. See, for example, Gerritse, 1996, Proc.
Natl. Acad. Sci. U.S.A. 93: 2494; Grewal et al., 1996, Science 273: 186; Laman et al., 1998, Mult. Scler. 4: 14; and Chess, 2001, supra.
Rheumatoid Arthritis:
Anti-CD40L blocks the development of joint inflammation, serum antibody titers to collagen, the infiltration of inflammatory cells into the synovial tissue, ant the erosion of cartilage and bone in collagen-induced arthritis. See, e.g., Durie et al., 1993, Science 261: 132; and Chess, 2001, supra.
Insulin-dependent Type I Diabetes Models:
The non-obese diabetic (NOD) mouse spontaneously develops T cell dependent autoimmune diabetes. Anti-CD40L monoclonal antibody treatinent of 3 to 4 week old NOD females (the age- at which insulitis typically begins) completely prevented the insulitis and diabetes. Cytokine analysis revealed a dramatic decrease in IFN-g and IL-2 release without a concomitatnt increase in IL-4 production by T
cells from anti-CD40L-treated mice. See, e.g., Balasa et al., 1997, J.
Immunol. 159:
1420; and Chess, 2001, supra.
Inhibition of Allograft and Xenograft Transplant Rejection:
Anti-CD40L prevents the development of renal rejection of fully allogeneic grafts in mice. Moreover, the survival of renal allografts transplanted into nephrectomized rehsus monkeys is typically prolonged by anti-CD40L therapy alone.
Similarly, anti CD40L therapy has prevented graft rejection of skin, islet cells and cardiac transplants as well as GVHD in rodents. See, e.g., Kirk et al., 1997, Proc.
Natl. Acad. Sci. U.S.A. 94: 8789-8794; Parker et al., 1995, Proc. Natl. Acad.
Sci.
U.S.A. 92: 9560; Larsen et al., 1996, Transplantation 61: 4; and Chess, 2001, supra.
Uses of Monovalent Anti-CD40L Antibody Polypeptides Anti-CD40L antibody polypeptides as described herein are useful for the treatment or prevention of diseases or disorders in which inappropriate activation of a CD40L/CD40-mediated pathway is involved. In particular, autoimmune diseases frequently involve inappropriate regulation or activity of CD40L/CD40 pathways.
Administration of an anti-CD40L antibody polypeptide as described herein to an individual suffering from such a disease, can reduce one or more symptoms of the disease. Non-limiting examples of diseases for which the antibody polypeptides described herein can be therapeutically useful include Systemic Lupus Erythematosus (SLE), Idiotypic Thrombocytopenic Purpura (ITP), transplant rejection, Crohn's Disease, Inflammatory Bowel Disease (IBD), colitis, asthma/allergy, atherosclerosis, Myasthenia Gravis, immune response to recombinant drug products, e.g., factor VII
in hemophilia, Multiple Sclerosis, Psoriasis, Rheumatoid Arthritis, Ankylosing Spondylitis, Coronary Heart Disease, and Diabetes, including Type 1 and/or Type 2 Diabetes.
The anti-CD40L antibody polypeptides described herein are additionally useful in the way that generally any antibody preparation is useful, e.g., for in vivo imaging or diagnostic uses, in vitro diagnostic uses, etc. For these and otller uses it may be desirable to, label the anti-CD40L antibody polypeptides, e.g., with a fluorescent, colorimetric, enzymatic or radioactive label. Methods of labeling antibody polypeptides are well known in the art.
EXAMPLES
Example 1. Biotinylation of Recombinant CD40L
Recombinant human soluble CD40L (PeproTech) was biotinylated and used during phage selections. Reagents, equipment and sources from which they are available are provided in Table 1.
Biotinylation of CD40L was performed by incubating CD40L (0.5mg/ml) with EZ-Lin1cTM Sulfo-NHS-LC-Biotin [Sulfosuccinimidyl-6-(biotinamido)hexanoate]
(Pierce) at a molar ratio of 5:1 on ice for 2 hours according to the product instructions. The biotinylation reaction mixture was then dialysed against 3 exchanges of PBS (1000x sample volume) in a Slide-A-Lyzer Dialysis Cassette at 4 C to remove the unincorporated biotinylation reagent.
The biotinylated-CD40L was tested by receptor binding assay for binding to CD40/Fc to confirm its biological activity. Quality of biotin-CD40L was also monitored by analysing on a NuPaGE 4-12% Bis-Tris gel and detected by Simply Blue Safe-Stain (Invitrogen) (Figure la), and western-blotting by probing with Streptavidin-HR.P (Figure lb). The biotinylated-CD40L was further analysed by mass spectrometry with the majority of CD40L subunits containing 1 or 2 biotin moieties (data not shown).
Table 1.
Equipment/Reagent Suggested or required supplier Recombinant human PeproTech, Cat No:
soluble CD40 310-02 ligand/TRAP
Reconstituted in 5 mM
Sodium phosphate, pH5.0 to concentration of 0.5 mg/ml EZ-LinkTM Sulfo-NHS- Pierce, Cat No: 21335 LC-Biotin Slide-A-Lyzer Pierce, Cat No: 66110 Dialysis Cassette Recombinant human R&D Systems, Cat No:
CD40/Fc chimera 1493-CD
NuPAGE 4-120/o Bis- Invitrogen life Tris gel technologies Ltd Cat. No NP0322 Streptavidin-HRP Amersham Biosciences Cat No: 1231V
InvitrogenTM Simply Invitrogen Cat Blue Safe-stain No:LC6065 Example 2. PhaLye Selections using Biotinylated Antigen The Domain Antibody (dAb) libraries are based on a single human framework for the VH (DP47 and JH4b) and for the VK (DPK9 and JK1) with side chain diversity incorporated at positions in the antigen binding site that make contact with antigen in known molecular structures and mirror residues diversified in the human antibody repertoire. The antibodies are displayed as fusion proteins covalently linked to the N - terminus of the Fd-phage protein pIII, using the phage vector pDOM4 (Fd-Tet) with encodes the Fd phage genome with dAb expression under the control of the gene-III promoter. The dAb cassette consists of (5' to 3'): eukaryotic leader sequence, dAb, myc tag, gIII. The vector contains both the M13 and colEl origins of replication and is selectable using tetracycline. The VH and V,; libraries each have a calculated size of over 1x1010 molecules. Reagents, equipment and sources from which they are available are provided in Table 2.
Approximately lxl011 phage from the each of the Domantis dAb libraries were incubated in a final volume of 1 ml PBS containing 2% MarvelTM at room temperature for I h. Biotinylated antigen was added to the blocked phage such that the phage antigen mixture had a final concentration of 2% MarvelTM in PBS. The antigen concentration used for the first round of selection was 60 nM; the antigen concentration was decreased to 6 nM for round 2, and to 0.6 nM for round 3.
The antigen/phage mix was incubated for I h at room temperature with rotation at -rpm.
For each selection, 100 l of streptavidin-coated paramagnetic beads (Dynal Biotech) were prepared by washing once in 1 ml of PBS containing 0.1% Tween-20 followed by a second wash in 1 ml of PBS. The beads were then blocked in 1 ml of PBS containing 2% MarvelTM in a 2 ml eppendorf tube at room temperature on a rotating wlleel for 1 h.
The tube containing the blocked streptavidin-coated magnetic beads was placed into a magnetic holder, enabling capture of the magnetic beads. The supernatant was removed and the beads resuspended in the antigen/phage mix.
This mixture was rotated for 10 min to allow for bead capture of phage/antigen complexes.
The beads were captured using a magnetic holder and repeatedly washed 19 times using 1 ml of PB S containing 0.1 % Tween-20, followed by a final wash of I ml PBS. The eppendorf tubes were changed following washing steps 3, 9, 15 and 19 to minimise background phage carryover.
The washed beads were then recaptured and all washing solution removed.
The phage were eluted through resuspension in 500 l of trypsin solution (50 l of 10 mg/mi trypsin stock solution added to 450 l PBS, freshly diluted) and rotated for 10 min at room temperature. The eluted phage were recovered by capturing the beads using the magnetic holder and the liquid containing the eluted phage recovered. The eluted phage were used to infect E. eoli TG1 to prepare phage for a further round of selection.
The eluted phage (250 41) were mixed with 1.75 ml of log phase E. coli TGI
(OD600 between 0.3 and 0.6) and infection allowed to occur for 30 min at 37 C
without shaking. The infected E. coli TGI culture was centrifuged at 11,600 g in a micro centrifuge for 1 min at room temperature. The pelleted bacteria were resuspended in 100 ,l of 2xTY and plated on regular 9 cm diameter plates containing TYE supplemented with 15 g/ml tetracycline. Plates were grown at 37 C
overnight.
After overnight growth, 2 ml of 2xTY containing 15% glycerol was added to the culture plates and cells loosened with a spreader, ensuring the cells were thoroughly mixed. Two millilitres of the culture were recovered by pipetting into a cryo-vial, from which 50 l was used to inoculate 50 m1 of 2xTY supplemented with 15 g/ml tetracycline. The remaining cells in the cryo-vial were stored at -80 C.
The 50 ml culture was grown at 37 C for 16 to 24 hours with shaking at 250 rpm.
Following overnight growth, the culture was centrifuged at 3,300 g for 15 min to pellet the bacteria. The phage were then precipitated from the supernatant through the addition of 10 ml of PEG/NaCI to 40 ml of clarified supernatant. The phage/PEG
solution was mixed and incubated on ice for at least 1 h. To pellet the phage, the solution was centrifuged at 3,300 g for 30 min at 4 C. The supernatant was decanted and any remaining supernatant removed by aspiration.
The resulting phage pellet was resuspended in 2 ml PBS and centrifuged at 11,600 g for 10 min in a micro centrifuge to remove any remaining bacterial debris.
The supernatant was filtered through a 0.45 zn filter (Sartorius, Minisart).
The resuspended phage solution was used for the next round of selection.
Table 2 Eguipment/Reagent Suggested or Ins>irument setiring, required supplier reagent preparation Dynabeads M-280 Dynal Biotech UK Resuspend Streptavidin (Prod. 11 Bassendale Road, thoroughly through No.: 112.05) Croft Business Park, repeated pipetting.
Bromborough, Wirral UK
Tween 20 Sigma Chemical 0.1% in PBS.
Company Ltd.
99.5% dried skim MarvelT" (premier 2% in PBS (prepare milk powder brands) from fresh and do not supermarkets. store).
Trypsin (T-8642) Type Sigma Chemical made up in 50 mM
XIII from Bovine Company Ltd. Tris-HCI pH7.4; 1 mM
Pancreas. CaC12 and stored at -Fancy Road 20 C
Dorset BH17 7NH The trypsin stock U.K solution should be stored aliquotted at -Tel +44 1202 733114 20 C to avoid autoproteolysis.
Fax +44 1202 PEG/NaCI Sigma Chemical 20% Polyethylene Company Ltd. glycol 8000 [formally known as 6000], 2.5 M NaCI pre-chilled to 40C.
Dynal MPC-S Dynal Biotech UK
magnetic particle 11 Bassendale Road, concentrator (Prod. Croft Business Park, Bromborough, Wirral No.: 120.20) CH62 3QL
UK
2xTY 16 g Tryptone, 10 g Yeast Extract and 5 g NaCI in 1 litre.
Autoclave (1210C, 15 min) and store at RT
Example 3: Cloning Enriched PhaQe Selection Outputs into the Soluble dAb Expression Vector pDOM5 Following the second and third rounds of selection, E. coli cells infected with the enriched dAb displaying fd-phage populations were obtained. An aliquot of these cells was used to prepare phage DNA and the enriched V-genes excised by digestion using the restriction endonucleases, SalI and NotI. The purified V-genes were ligated into the corresponding sites of pDOM5 (expression vector derived from pUC 119 with LacZ
promoter, eukaryotic leader, dAb cloning site, myc tag), and the ligated DNA
used to electro-transform E. coli HB2151 cells which were grown overnight on agar plates containing the antibiotic carbenicillin. The resulting colonies were induced to express dAb protein either as 200 l microcultures or 50 ml cultures. The resulting dAb was analysed for inhibitory activity using the CD40L receptor binding assay.
Following selection of phage, pDOM4 DNA was purified from the cell pellet obtained from a 50 ml overnight E. coli culture using the QIA.filter Plasmid Midi DNA purification kit from Qiagen, following the manufacturer's instructions.
The dAb genes were excised from the pDOM4 vector by mixing: 10 l of 10x SalI
buffer;
1 l of 100x BSA; 20 g of purified DNA fragment; 2.5 ul of SalI enzyme (10 U/
l);
2.5 l of NotI enzyme (10 U/ l); the digestion mix was made up to a final volume of 100 1 using sterile water. The digestion mix was incubated for 5 hours at 37 C.
The digested DNA samples were electrophoresed on a 1.5% agarose gel and the band corresponding to the dAb V-genes (-324 bp to 372 bp) was excised from the gel. The dAb gene DNA was purified from the gel slice using the QlAquick Gel Extraction kit from Qiagen, following the manufacturer's instructions.
The expression vector pDOM5 was digested with SaII and Notl as follows: 10 l of lOx SaII buffer; 1 l of 100x BSA; 20 g of plasmid pDOM5; 1.5 l of Sall enzyme (10 U/ l); 1.5 l of NotI enzyme (10 U/ l); the digestion mix was made up to a final volume of 100 l using sterile water. The digestion mix was incubated for 2 hours at 37 C. The digested vector fragment was purified using the QlAquick PCR
Purification Kit.
The digested pDOM5 and digested dAb genes were ligated by mixing: 2 1 of I Ox T4 DNA ligase buffer; 400 ng of digested pDOM5 vector; 100 ng of digested dAb genes;
I l of T4 DNA ligase (400 U/ l); the ligation mix was made up to 20 l with sterile water. The ligation mixes were incubated for 2 hours at 25 C.
'Two microlitres of the ligation mix was transferred to the bottom of a pre-chilled (on ice) 0.2 cm electroporation cuvette to which 100 l of electrocompetent E.
coli HB2151 cells were added. The DNA / cell mixture was incubated on ice for min, then electroporated at 2.5 kV (25 gF, 200 Q). One millilitre of 2xTY was imnlediately added to the cuvette and the cells gently resuspended. The resuspended cells were transferred to a 14 ml disposable culture tube and incubated for 1 hour at 37 C with shaking at 250 rpm. Dilutions of the cells from 10'0 to 10"3 were plated on regular 9 cm diameter plates containing TYE supplemented with 5% glucose and g/ml carbenicillin. The cells are incubated overnight at 37 C in an inverted position.
Reagents, equipment and sources from which they are available are provided in Table 3.
Table 3 Eqeeipment/i2eagent Suggested or required Instrument supptier setting, reagent preparation QIAfilter Plasmid Midi Qiagen Ltd Supplied as kit DNA purification kit Cat. No.: 12143 SaII restriction New England Biolabs endonuclease + lOx Sa/I buffer Cat. No.: R0138S
NotI restriction New England Biolabs endonuclease + lOx NotI buffer + 100x Cat. No.: R0189S
BSA
QIAquick Gel Qiagen Ltd Supplied as kit Extraction kit Cat. No.: 28706 Expression plasmid pDOM5 T4 DNA ligase + lOx New England Biolabs The T4 DNA
T4 DNA ligase buffer ligase buffer Cat. No.: M0202L should be stored aliquotted at -20 C.
Repeated freeze-thawing should be avoided to minimise the hydrolysis of ATP in the buffer.
Example 4. Microwell Expression of Soluble dAbs Following cloning of the selected phage dAb outputs into pDOM5, individual bacterial colonies were inoculated as microwell cultures and induced using IPTG to express dAb protein which was analysed for inhibitory activity using the CD40L
receptor binding assay. Reagents, equipment and sources from which they are available are provided in Table 4.
Individual bacterial colonies were carefully picked to ensure that contamination from neighbouring colonies was avoided. The picked colonies were used to inoculate 96 well cell culture plates containing 100 l per well of 2xTY
supplemented with 5% glucose and 50 g/ml carbenicillin. The lids were placed on the cell culture plates which were incubated overnight in a HiGro orbital shaker (GeneMachines, 935 Washington St, San Carlos, CA 94070, USA) under a humidified atmosphere at 37 C with shaking at 450 rpm (4 mm shaking orbital diameter), with gas (30% 02 + 70% N,)) pulsed for 10 seconds every 5 minutes at a flow rate of 5 SLPM (standard litres per minute). [These plates are referred to as Master Plates].
Following overnight growth, a 96 well transfer device was used to transfer between 1-5 l of the bacterial culture into a fresh 96 well culture plate containing 100 l per well of 2xTY supplemented with 0.1 % glucose and 50 g/ml carbenicillin.
The freshly inoculated plates were incubated at 37 C for 3 to 4 h(shaking at 450 rpm, gas (30% 02 + 70% N,)) pulsed for 10 seconds every 5 minutes at a flow rate of 5 SLPM) until the culture OD600 reached approximately 1Ø The cultures were then induced by the addition of 100 l per well of 2xTY containing 50 g/ml carbenicillin and 2 mM IPTG (final IPTG concentration of 1 mM) and incubated overnight at 30 C with shaking at 450 rpm, with gas (30% 02 + 70% N2) pulsed for 10 seconds every 5 minutes at a flow rate of 5 SLPM. [These plates are referred to a Induction Plates].
Glycerol stocks of the original Master Plates were made by the addition of 100 l per well of 2xTY containing 50% sterile glycerol. These plates were stored at -80 C.
Following overnight incubation of the Induction Plates, the bacterial cells were pelleted by centrifugation at 1,800 g for 10 min at 4 C. The supernatant (containing expressed dAb) was then analysed to determine if dAbs were capable of inhibiting binding of CD40L to CD40-Fc fusion in a receptor binding assay.
Table 4 Equipment/Reagent Suggested or Instrument setting, required supplier reagent preparation 96 Well Cell Culture Corning Incorporated, Cluster with round Costar.
bottom and lid, Non- Number:3799 pyrogenic, Polystyrene 2xTY 16 g Tryptone, 10 g Yeast Extract and 5 g NaCf in 1 litre.
Autoclave (1210C, 15min) and store at RT
Example 5. Expression of dAb in E. coli at 50 ml To generate greater quantities of dAb protein for analysis, 50 ml cultures were used for induction. A single colony of the desired dAb (for example DOM-24) grown on TYE plates was inoculated into 10 ml 2xTY supplemented with 5% glucose and 50 g/ml carbenicillin in a 30 ml universal tube and grown overnight at 37 C
with shaking at 250 rpm. Five hundred microlitres of the overnight culture was added into 50 ml of 2xTY supplemented with 0.1% glucose and 50 g/ml carbenicillin and grown,at 37 C with shaking at 250 rpm. The OD600 of the culture was monitored regularly in comparison with sterile 2xTY and at an OD600 of 0.9 the culture was induced by the addition of 1 M IPTG to a final concentration of 1 mM. The inoculated culture was incubated at 30 C with shaking at 250 rpm overnight.
The next day, the culture was centrifuged at 6000 g for 15 min at 4 C and the clarified supernatant mixed with 100 l of protein-A streamline or protein-L agarose (pre-washed with 5 mM MgSO4) overnight at 4 C. The supernatant/bead mixture was then centrifuged at 180 g at 4 C for 2 minutes. The supernatant was decanted and the retained beads washed with 10 ml of PBS containing 0.5M NaCl. The bead solution was transferred into a 96 well Whatman filter plate and the beads washed once with 400 l of PBS containing 0.5M NaCI, then once with 400 l of PBS, followed by centrifugation for 2 minutes at 180 g after each washing step. dAb protein was eluted using 70 l of 0.1 M glycine (pH 2.0) and the solution neutralised by the addition of 40 1 of 1 M Tris-HCI (pH 8.0). The purified dAb concentration was determinate by OD2s0.
Reagents, equipment and sources from which they are available are provided in Table 5.
Table 5 Equipment/Reagent Suggested or Instrument setting, required supplier reagent preparation TYE 15 g Bacto-Agar, 8 g NaCI, 10 g Tryptone, g Yeast Extract in 1 litre water. Autoclave (1210C, 15 min) and store at RT
2xTY 16 g Tryptone, 10 g Yeast Extract and 5 g NaCl in 1 litre.
Autoclave (7210C, min) and store at RT
1 M IPTG stock made up in MQ
water is sterile filtered through 0.22 pM filter and stored in aliquots at -Carbenicillin 50 mg/mI stock made in water, 0.2 rn filter sterilised and stored in aliquots at -200C
40% glucose solution 0.2 m filter sterilise, store at RT
5 mM MgSO4 prepare fresh from 1 M stock solution, 0.2 m filter sterilise and store at RT
0.5M NaCI/PBS Autoclave or 0.2 m filter sterilise and store at RT
Protein A agarose Sigma P3476 store 40C
Protein L agarose Sigma P3351 store 40C
Streamline rProtein A Amersham store 40C
Biosciences, cat no. 17-1281-02 (300 mi) 1 M Tris-HCI, pH 8.0 0.2 m filter sterilise or autoclave and store at RT
0.2 M Glycine, pH2.0 0.2 m filter sterilise and store at 40C
Example 6: CD40L Receptor Bindintr Assay The CD40L assay was used to measure the binding of CD40L to CD40 and the ability of binding entities (eg, monvalent antibody fragments such a dAbs) to bloclc this interaction, as described below and shown schematically in Figure 7. (The soluble proteins from R&D Systems are CD40/Fc = homodimer and CD40L =
homotrimer).
A 96 well Nunc Maxisorp assay plate was coated overnight at 4 C with 100 l per well of recombinant human CD40/Fc (R&D Systems) at 0.5 g/ml in carbonate buffer. The plate was washed 3 times with 300 1 of 0.05% Tween/PBS and 3 times with 300 l of PBS using a Tecan plate washer. The wells were blocked using 200 ,l of PBS containing 2% (w/v) BSA and incubated for a minimum of I h at room temperature. The wells were washed as above, then 50 l of purified dAb protein (or unpurified supernatant containing dAb from a micro-culture expression) was added to each well. To each well 50 l of CD40L, at 6 ng/ml in diluent (for a final concentration of 3 ng/ml), was also added and the plate incubated for 1 hr at room temperature.
The plate was washed as described previously and 100 l biotinylated anti-CD40L antibody, 0.5 g/ml in diluent, was added and incubated for 1 hr at room temperature. The plate was washed as described above, then 100 l HRP
conjugated anti-biotin antibody (1:5000 dilution in diluent) added to each well and the plate incubated for 1 hr at room temperature. The plate was washed again as described above using a Tecan plate washer and the assay developed using 100 l of SureBlue 1-Component TMB MicroWell Peroxidase solution (the plate was left at room temperature for up to 20 min). The reaction was stopped by the addition of 100 l I
M hydrochloric acid. The OD450õn, of the plate was assayed within 30 minutes of acid addition. The OD4,onm is -proportional to the amount of bound streptavidin-HRP
conjugate, therefore the greater the degree of dAb inhibition the lower the OD450,,,T, of the resulting signal. Reagents, equipment and sources from which they are available are provided in Table 6.
Controls The following controls were included:
= 0 ng/ml CD40L (diluent only) = 3 ng/ml CD40L
= 3 ng/ml CD40L with 1 g/ml anti-CD40L antibody Table 6 Equipment/Reagent Suggest or required Reagent preparation supplier (specify) F96 Maxisorp 96 well Nunc, Cat No: 439454 immunoplate 0.2M sodium Pierce, Cat No: 28382 Dissolve 1 sachet in carbonate bicarbonate 500 mi deionised water buffer pH9.4 and keep solution.at 4 C
Recombinant human R&D Systems, Cat No: Stock 50 pg/ml at-80 C
CD40/Fc chimera 1493-CD
Phosphate buffered Sigma, Cat No: P4417 lOx solution100 tablets/L
saline (PBS) water.
Wash buffer 0.05% Tween-20/PBS
Diluent 0.1% BSA, Ø05%
Tween-20 in PBS
Block 2% BSA in PBS
Recombinant human R&D Systems, Cat No: Stock 50 pg/ml at-80 C
Neutralising anti- Calbiochem, Cat No: Stock 1 mg/ml at 4 C
CD40L antibody 217595 Biotinylated anti- R&D Systems, Cat No: Stock 50 pg/ml at -80 C
CD40L antibody BAF617 Anti-biotin-HRP Stratech, Cat No: Stock 800 g/mi at -BOC, conjugate 200-032-096 diluted 1:5000 in antibody diluent. Keep for 1 week only.
SureBlue TMB 1- KPL, Cat No: 52-00-00 at 4 C .
component microwell peroxidase substrate Example 7: Results Receptor binding data for.the most potent inhibitors is summarised in Figures 2, 3, and 4, and in Table 7, below. Table 8, below, provides DNA and translated amino acid sequence of unique dAbs identified in the receptor binding assay as inhibiting CD40L binding to CD40.
Figure 2 shows a dose response receptor binding assay(RBA) readout, analysing the inhibition of CD40L binding to CD40-Fc by dAbs DOM-10, -20, -27, -30, -31, -62, -77, titrated from 1 M down to 10 pM. dAbs DOM-20, -30, and -31 are the most potent, with IC50 values of approximately 8 nM.
Figure 3 shows a dose response receptor binding assay readout, analysing the inhibition of CD40L binding to CD40-Fc by dAbs DOM-4 and DOM-5, titrated from 1 M down to 500 pM. The IC50 values for dAbs DOM-5 and DOM-4 are approximately 3 nM and 100 nM respectively.
Figure 4 shows a dose response receptor binding assay readout, analysing the inhibition of CD40L binding to CD40-Fc by dAb DOM-24, titrated from 100 nM
down to 0.5 pM. The data were curve-fitted using GraphPad Prism software.
Table 7 Clone Name dAb Type IC50 (nM) DOM-8 VK 900.
DOM-24 VH 0.417 approx.
Table 8: Summary of dAbs exhibitina a range of CD40L inhibitory IC50 values as determined usiny the CD40L / CD40-Fc receptor inhibition assay.
The DNA and translated amino acid sequence of unique dAbs identified in the receptor binding assay as inhibiting CD40L binding to CD40 are detailed below:
DOM-2 SEQ ID NO: 7 E V Q L I. E S G G G L V Q P G G S L R L S C A A S G F T F S D
Y E M =
CCTCCGGATT CACCTTTTCT
GATTATGAGA
GGAGGCCTAA GTGGAAAAGA
CTAATACTCT
= M W V R Q A p G K G L E W V S T I T S D G I S T Y Y A. D S V K G R =
ATGGTATTTC TACATACTAC GCAGACTCCG
TAATGAAGCC TACCATAAAG P_TGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I F R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
K S G
201 GTTCACCATC TTCCGCGACA ATTCCAAGAA CACGCTGTAT CTGCP.AATGA ACAGCCTGCG
TGCCGAGGAT ACCGCGGTAT ATTACTGTGC
GAAAAGTGGG
CAAGTGGTAG AAGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTA
TGGCGCCATA TAATGACACG
CTTTTCACCC
R F F D Y W G Q G T L V T V S S
301 AGGTTTTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 94) TCCAAAAAAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 95) DOM-4 SEQ ID NO: 8 Y E M =
CCTCCGGATT CACCTTTGAT
AATTATGAGA
AGGACACGTC GGAGGCCTAA GTGGAAACTA
TTAATACTCT
= T W V R Q A P G K G L E W V S S I T S D G T S T Y Y A D S V
K G R =
101 TGACGTGGGT CCGCCAGGCT CCP_GGGAAGG GTCTAGAGTG GGTCTCP_TCT ATTACGAGTG
ATGGTACTTC GACATACTAC GCAGACTCCG
TGAAGGGCCG
ACTGCACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTAGA TAATGCTCAC TACCATGAAG
CTGTATGATG CGTCTGP_GGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
R P N
201 GTTCACCATC TCCCGCGACA ATTCCAAGAP_ CACGCTGTAT CTGCAAATGA ACAGCCTGCG
TGCCGAGGAT ACCGCGGTAT ATTACTGTGC
GAAACCTAAT
CAAGTGGSAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTA
TGGCGCCATA TAATGACACG
CTTTGGATTA
301 CCGCCGTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 96) GGCGGCAAAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 97) DOM-5 SEQ ID NO: 9 Y E M =
3~ 1 GAGGTGCAGC TGTTGGAGTC TGGGGGAGGC TTGGTACAGC CTGGGGGGTC CCTGCGTCTC
TCCTGTGCAG CCTCCGGATT CACCTTTGAT
GGGTATGAGA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGAAACTA
CCCATACTCT
A W V R Q A P G K G L E W V S S I T S D G T S T Y Y A D S V
K G R =
ATGGTACGAG TACATACTAC GCAGACTCCG
TGAAGGGCCG
ACCGCACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTAGA TAATGCTCAC TACCATGCTC
ATGTATGATG CGTCTGAGGC ACTTCCCGGC
F T I S R D ld S E 14 T L Y L Q M ld S L R A E D T A V Y Y C A
K P G
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GP.AACCGGGG
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CTTTGGCCCC
L R F D Y W G Q G T L V T V S S
301 CTGCGTTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 98) GACGCAAAAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NOc 99) DOM-7 SEQ ID NO: 10 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F N L
Y E M =
CCTCCGGATT CACCTTTPAT
TTGTATGAGA
CTCCACGTCG ACAACCTCAG P_CCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCT_taA GTGGU-ATTA
AACATACTCT
T W V R Q A P G K G L E W V S S I T S D G V S T Y Y A D S V
K G R =
ATGGTGTTTC TACATACTAC GCAGACTCCG
TG.4AGGGCCG
ACTGPACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTAGA TAATGATCAC TACCACAAAG
ATGTATGP_TG CGTCTGAGGC
ACTTCCCGGC
F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
K A G
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAAAGCTGGG
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CTTTCGACCC
301 GTGATTTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 100) CACTAAAAAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 101) DOM-8 SEQ ID NO: 11 D I Q M T Q S P S S L S A S V G D R V T I T C R P S Q F I D T
S L E =
1 GACP_TCCAGA TGACCCAGTC TCCP_TCCTCC CTGTCTGCAT CTGTAGGAGA CCGTGTCACC
ATCACTTGCC GGGCAAGTCA GTTTPTTGAT
ACGTCGTTAG
CTGTAGGTCT ACTGGGTCAG AGGTAGGAGG GACAGACGTA GACATCCTCT GGCACAGTGG TAGTGAACGG
CCCGTTCAGT CAAATAACTA
TGCAGCAATC
= W Y Q Q K P G K A P K L L I Y D G S H L Q S G V P S R F S G
S G S = ' TGCAAAGTGG GGTCCCATCA CGTTTCAGTG
GCAGTGGATC
TCACCATAGT CGTCTTTGGT CCCTTTCGGG GATTCGAGGA CTAGATACTA CCCAGGGTAA ACGTTTCACC
CCAGGGTAGT GCAAAGTCAC
CGTCACCTAG
= G T D FT L T I S S L Q P E D L A T Y Y C Q Q Y W V L P L T
F G Q
201 TGGGACAGAT TTCACTCTCA CCATCAGCAG TCTGCAkCCT GAAGATTTAG CTACGTACTA
CTGTCAACAG TATTGGGTTC TTCCTCTGAC
GTTCGGCCAA
ACCCTGTCTA AAGTGAGAGT GGTAGTCGTC AGACGTTGGP CTTCTAAATC GATGCATGAT GACAGTTGTC
ATAACCCAAG AAGGAGACTG
CAAGCCGGTT G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG (SEQ ID N0: 102) CCCTGGTTCC ACCTTTAGTT TGCC (SEQ ID NO: 103) DOM-10 SEQ ID NO: 12 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F I A
Y D M =
CCTCCGGATT CACCTTTATS
GCTTATGATA CTCCACGTCG ACAACCTCAG ACCCCCTCCG AATCATGTCG GACCCCCCAG GGACGCAGAG
AGGACACGTC GGAGGCCTAA GTGGAAATAA
CGAATACTAT
S W V R Q A P G K G L E W V S W I D E W G L Q T Y Y A D S V
K G R =
GGGGTCTGCA GACATACTAC GCAGACTCCG
TGAAGGGCCG
ACTCAACCCA GGCGGTCCGA GGTCCCTTCC CAGACCTCAC CCAGAGTACC TAACTACTCA CCCCAGACGT
CTGTATGA_TG CGTCTGAGGC
ACTTCCCGGC
'== F T'I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C P_ K K T
201 GTTCACCATC TCCCGCGACA ATTCCAAGAP. CACGCTGTAT CTGCAAATGA ACAGCCTGCG
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAAAAAGACG
C.WiGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATP. GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCP_TA TAATGACACG
CTTTTTCTGC
301 CCTGAGGAGT TTGACTACTG GGGTCAGGGA ACCCTGGTCA CCGTCTCGAG C(SEQ ID NO: 104) GGACTCCTCA AACTGATGAC CCCAGTCCCT TGGGACCAGT GGCAGAGCTC G (SEQ ID NO: 105) DOM-11 SEQ ID NO: 13 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F G D
Y E M =
CCTCCGGP_TT CACCTTTGGT
GATTATGAGA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGAAACCA
CTAATACTCT
= S W V R Q A P G R G L E W V S G I D G E G S D T Y Y A D S V
IC G R =
AGGGTTCTGA TACATACTAC GCAGACTCCG
TGAAGGGCCG
ACTCAACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTCCC TAACTACCAC TCCCAAGACT
ATGTATGATG CGTCTGAGGC ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R P. E D T A V Y Y C A
K P G
201 GTTCACCATC TCCCGCGACP. ATTCCAAGAB CACGCTGTAT CTGCAAATGA ACAGCCTGCG
TGCCGAGGAT ACCGCGGTAT ATTACTGTGC
GAAACCGGGG CATiGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC
ACGGCTCCTA TGGCGCCATA TAATGACACG
CTTTGGCCCC
CTGGTCACCG TCTCGAGC (SEQ ID NO: 106) TCCTCAAAAC TGETGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 107) DOM-12 SEQ ID NO: 14 Y E M =
CCTCCGGATT CACCTTTAGG
TTGTATGAGA
GGAGGCCTAA GTGGAWLTCC
AACATACTCT
= A W V R Q A P G K G L E W V S G I D I L G S R T Y Y A D S V
K G R =
TGGGTTCGAG GACATACTAC GCAGACTCCG, TGAAGGGCCG
ACCGCACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTCCC TAACTATARA ACCCAAGCTC
CTGTATGATG CGTCTGAGGC
ACTTCCCGGC
F T I S R D N S K N T L Y L Q M N S I. R A E D T A V Y Y C A
K D L
201 GTTCACCATC TCCCGCGACA ATTCCPAGRP CACGCTGTAT CTGCAAP_TGA ACAGCCTGCG
TGCCGAGGAT ACCGCGGTAT ATTACTGTGC
GAAAGATCTG
CAAGTGGTAG AGGGCGCTGT T_AAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTP_ TGGCGCCATA TAATGACACG
CTTTCTAGAC
S W Q G F D Y W G Q G T L V T V S S
301 TCGTGGCAGG GTTTTGACTP CTGGGGTCAG GGAACCCTGG TCACCGTCTC GAGC (SEQ ID NOC
108) AGCACCGTCC CAAAACTGP_T GACCCCAGTC CCTTGGGACC AGTGGCAGAG CTCG (SEQ ID NO: 109) DOM-13 SEQ ID NO: 15 E V Q L L E S G G G L V Q P G G S L R L S C P. A 5 G F T F S Y
Y S M =
CCTCCGGHTT CACCTTTTCT
TATTATTCGA CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG
AGGACACGTC GGAGGCCTAA GTGGAAAziGA
ATAATAkGCT
= Y W V R Q A P G K G L E W V S S I S P F G W G T Y Y P_ D S V
K G R =
TTGGTTGGGG TACATACTAC GCAGACTCCG
TGAAGGGCCG
ACATAACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTAGC TAAAGCGGAA AACCAACCCC
ATGTATGATG CGTCTGAGGC
ACTTCCCGGC.35 = F T I S R D N S K D T L Y L Q M 11 S L R A E D T A V Y Y C A
K Y G
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAAATATGGG
CPAGTGGTAG AGGGCGCTGT TAAGGTTCCT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CTTTATACCC
E T S G P I S E N F D Y W G Q G T L V T V S S
GTCTCGAGC (SEQ ID NO: 110) CTCTGCTCAC CAGGCTAAAG ACTCTTAHAP CTGATGACCC CAGTCCCTTG GGACCAGTGG CAGAGCTCG
(SEQ ID NO: 111) DOM-14 SEQ ID NO: 16 Y D M =
CCTCCGGATT CACCTTTTGG
TCTTATGATA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAP GTGGAAAACC
AGAATACTAT
= T W V R Q A P G K G L E W V S S I M A S G D D T Y Y A D S V
K G R =
CGGGTGATGA TACATACTAC GCAGACTCCG
TGAAGGGCCG
ACTGCACCCP_ GGCGGTCCGA GGTCCCTTCC CRGATCTCAC CCAGAGTAGA TAATACCGAA GCCCACTACT
ATGTATGP_TG CGTCTGAGGC
ACTTCCCGGC 20 = F T I S R D N S K N T L Y L Q M N S L R P E D T A V Y Y C P
K W D
201 GTTCACCP_TC TCCCGCGACA ATTCCAAGAA CACGCTGTAT CTGCAAATGA ACAGCCTGCG
TGCCGAGGAT ACCGCGGTRT ATTACTGTGC
GAPATGGGAT ~ 5 CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACPTA GACGTTTACT
TGTCGGACGC ACGGCTCCTA TGGCGCCATA TAATGACACG
CTTTACCCTA
R D F D Y W G Q G T L V T V S S
301 CGGGATTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 112) GCCCTAAAAC TGPTGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 113) DOM-15 SEQ ID NO: 17 E V 0' L L E S G G' G L V Q P G G S L R L S C A A S G F T F E E
Y V M =
CCTCCGGP_TT CACCTTTGAG
GAGTATGTTA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGAAACTC
CTCATACAAT
= S W V R QA P G K G L E W V S T I S P I G L T T Y Y A D S V
K G R =
TTGGTCTGAC TACP_TACTAC GCAGACTCCG
' TGAAGGGCCG
ACAGCACCCE GGCGGTCCGA GGTCCCTTCC CAGACCTCAC CCAGAGTTGA TAAAGAGGAT AECCAGACTG
ATGTATGATG CGTCTGAGGC
ACTTCCCGGC
E F P
201 GTTCACCATC TCCCGCGACA ATTCCAAG.W? CACGCTGTAT CTGCAAATGA ACAGCCTGCG
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GGAATTTCCT
CAyGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CCTTAAAGGA
L I I L P D F D Y W G Q G T L V T V S S
301 TTGATTATTC TTCCTGATTT TGACTACTGG GGTCAGGGAA CCCTGGTCAC CGTCTCGAGC (SEQ ID
NO: 114) AACTAATAAG AAGGACTAAA ACTGATGACC CCAGTCCCTT GGGACCAGTG GCAGAGCTCG (SEQ ID NO:
115) DOM-16 SEQ ID NO: 18 Y A M =
CCTCCGGATT CACCTTTATG
GAGT_ATGCGA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG GACCP_TGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAP. GTGGvTaATAC
CTCP_TP_CGCT
K G R =
101 TGATTTGGGT CCGCCAGGCT CCAGGGAAGG GTCTAGAGTG GGTCTCATiTT ATTTCTCCGC
TTGGTTTGTC TACATACTAC GCAGACTCCG
TGAAGGGCCG
ACTAAACCCA GGCGGTCCGP_ GGTCCCTTCC CAGATCTCAC CCAGAGTTAA TAAAGAGGCG AACCAAACAG
ATGTATGP_TG CGTCTGAGGC
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
K Y Q
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAAnTATCAG
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CTTTATAGTC
301 GATTCGTCTG P.TAGTCAGTA TACGAATTTT GACTACTGGG GTCAGGGPAC CCTGGTCACC
GTCTCGAGC (SEQ ID NO: 116) CTAAGCAGAC TATCAGTCAT ATGCTTAAAP. CTGATGACCC CAGTCCCTTG GGACCAGTGG CAGAGCTCG
(SEQ ID NO: 117) DOM-17 SEQ ID NO: 19 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F E D
Y G M =
CCTCCGGATT CACCTTTGAG
GATTATGGGA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCP_TGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAL GTGGAAACTC
CTAATACCCT
G W A R Q A P G K G L E W V S S I G P L G L W T Y Y P_ D S A
K G R
TGGGTCTTTG GACATACTAC GCAGACTCCG
CGPAGGGCCG
~ ACCCCACCCG GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTTCA TAACCAGGAG ACCCAGAAAC
CTGTATGATG CGTCTGAGGC
GCTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
K S P
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAAATCTCCG
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CTTTAGAGGC
301 CTTGAGGGTT TGATTACGAA TTTTGACTAC TGGGGTCAGG GAACCCTGGT CACCGTCTCG AGC (SEQ
ID NO: 118) GAACTCCCAA ACTAATGCTT AAAACTGATG ACCCCAGTCC CTTGGGACCA GTGGCAGAGC TCG (SEQ ID
NO: 119) DOM-18 SEQ ID NO: 20 E V Q L L E S G G G L V Q P G G $ L R L S C A A S G F T F P E
Y D M =
CCTCCGGATT CACCTTTCCT
GAGTATGATA
AGGACACGTC GGAGGCCTAA GTGGAAAGGA
CTCATACTAT
= T W V R Q A P G K G L E W V S Y I S S D G Y S T Y Y A D S V
K G R =
ATGGTTATTC TACATACTAC GCAGACTCCG
TGAAGGGCCG
ACTGCACCCA GGCGGTCCGA GGTCCCTTCC CAGACCTCAC CCAGAGTATA TAATCAAGAC TACCAATAAG
ATGTATGP_TG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q N. N S L R E E D T A V Y Y C A
K P H
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAAACCGCAT
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACP.TA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CTTTGGCGTA
301 GGGAGTCCGC GGGAGTTTGA CTACTGGGGT CAGGGAACCC TGGTCACCGT CTCGAGC (SEQ ID NO:
120) CCCTCAGGCG CCCTCAAACT GATGACCCCA GTCCCTTGGG ACCAGTGGCA GAGCTCG (SEQ ID NO:
121) DOM-19 SEQ ID NO: 21 Y Q M =
CCTCCGGATT CCCCTTTCCG
CAGTATCAGP.
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GGGGAAAGGC
GTCATAGTCT
= P_ W V R Q A P G K G L E W V S M I T S D G L D T Y Y A D S V
K G R =
101 TGGCGTGGGT CCGCCAGGCT CCAGGGAAGG GTCTAGAGTG GGTCTCAATG P_TTACTTCTG
ATGGTCTTGA TACATATTAC GCAGACTCCG
TAATGAAGAC TACCAGAACT ATGTATAaTG CGTCTGAGGC ACTTCCCGGC = F T I S R D N S K N T
L Y L Q M N S L R A E D T A V Y Y C P.
K P E
TGCCGAGGAT ACCGCGGTAT A_TTACTGTGC
GAAACCTGAG
CAAGTGGTAG AGGGCGCTGT TPAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTA
TGGCGCCATA TAP_TGACACG
CTTTGGACTC
301 CCTCTTTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC.(SEQ ID NO: 122) GGAGAAAAAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 123) DOM-20 SEQ ID NO: 22 Y Q M =
CCTCCGGATT CACCT_TTTCG
GGTTATCAGA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGAAAAGC
CCAATAGTCT
= A W V A Q A P G F: G L E W V S G I S S E G L T T Y Y A D S V
A G R =
AGGGTCTTAC TACATACTAC GCAGACTCCG
TGAAGGGCCG
TCCCAGP.ATG ATGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N 5 L R A E D T P. V Y Y C P.
K L G
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAAATTGGGG
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CTTTAACCCC
R R F D Y W G Q G T L V T V S S
301 CGTAGGTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 124) GCATCCAAAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 125) DOM-21 SEQ ID NO: 23 E V Q L L E S G G G L V Q P G G S L R L S C P. A S G F T F A N
Y E M =
CCTCCGGATT CACCTTTGCG
AATTATGAGA
O CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGAAACGC
TTAATACTCT
= G W A R Q A P G K G L E W V S V I S E W G Y S T Y Y F: D S A
K G R =
GGGGTTATTC TACATACTAC GCAGACTCCG
CGAAGGGCCG
ACCCCACCCG GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTCAA TAAAGACTCA CCCCAATAAG
ATGTATGATG CGTCTGAGGC
GCTTCCCGGC
F T I S R D N S % N T L Y L Q M N S L R A E D T A V Y Y C A
K L V
201 GTTCACCATC TCCCGCGACA ATTCCAAGAA CACGCTGTAT CTGCATiATGA ACAGCCTGCG
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAAACTTGTG
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CTTTGAACAC
G G T Q Y E F D Y W G Q G T L V T V S S
301 GGTGGGACTC AGTATGAGTT TGACTACTGG GGTCAGGGAA CCCTGGTCAC CGTCTCGAGC (SEQ ID
NO: 126) CCACCCTGAG TCATACTCAA ACTGATGACC CCAGTCCCTT GGGACCAGTG GCAGAGCTCG (SEQ ID NO:
127) DOM-22 SEQ ID NO: 24 Y E M =
CCTCCGGATT CACCTTTCP_T
AATTATGAGA CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG
AGGACACGTC GGAGGCCTAA GTGGAAAGTA
TTAATACTCT
. 5 W V R Q P_ P G K G L E W V S S I S 5 G G 5 5 T Y Y P. D S V
K G R =
101 TGTCGTGGGT CCGCCAGGCT CCAGGGAAGG GTCTAGAGTG GGTCTCAAGT P_TTTCTTCGG
GTGGTTCTTC TACATACTAC GCAGACTCCG
TGAAGGGCCG
ACAGCACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTTCA TAAAGA_AGCC CACCAAG.SAG
ATGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R P_ E D T A V Y Y C A
K P G
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAAACCGGGG
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATP GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CTTTGGCCCC
V K F D Y W G Q G T L V T V S S
301 GTTAAGTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 128) CPATTCAAAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 129) DOM-23 SEQ ID NO: 25 Y E M =
CCTCCGGATT CACCTTTGGG
CTGTATGAGA
CTCCACGTCG ACAACCTCAG GCCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGAAACCC
GACATACTCT
= T W V R Q A P G K G L E W V S S I T G D G I S T Y Y A D S V
K G R =
ATGGTATTTC GACATACTAC GCAGACTCCG
TGAAGGGCCG
ACTGCACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTTCA TAATGCCCAC TACCATAAAG
CTGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N 5 R N T L Y I. Q M N S L R A_ E D T A V Y Y C A
K A G
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAAAGCTGGG
CAAGTGGTAG AGGGCGCTGT TAAGGTCCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CTTTCGACCC
R K F D Y W G Q G T L V T V S S
301 AGGAAGTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 130) TCCTTCAAAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 131) DOM-24 SEQ ID NO: 26 E V Q L L E S G G G L V Q P G G 5 L R L S C A P_ S G F T F S N
Y Q M =
CCTCCGGATT CACCTTTAGT
AATTATCAGA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCP.TGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGAAATCA
j 5 TTAATAGTCT
. = A W V R Q A P G K G L E W V 5 S I T S E G G S T Y Y A D S V
K G R =
AGGGTGGTTC GACATACTAC GCAGACTCCG
TGAAGGGCCG
ACCGCACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTTCA TAATGATCAC TCCCACCAAG
CTGTP_TGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S P. D A: S K N T L Y L Q M N S L R P. E D T A V Y Y C A
K P G
201 GTTCACCP_TC TCCCGCGACA P_TTCCAAGAA CACACTGTAT CTGCAAATGA ACAGCCTGCG
TGCCGAGGAC ACCGCGGTAT P_TTACTGTGC
GAAACCGGGT
CPAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGTGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA T_A TGACACG
CTTTGGCCCP
301 AAGAATTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 132) TTCTTAAAAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 133) DOM-25 SEQ ID NO: 27 Y E N. =
CCTCCGGP_TT CACCTTTGAT
PATTATGAGP.
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCPGAG AGGACACGTC
GGAGGCCTAA GTGGAAACTA
TTAATACTCT
= T W V R Q A P G K G L E W V S T I T S Q G T S T Y Y A D S V
K G R. =
101 TGACGTGGGT CCGCCAGGCT CCAGGGAAGG GTCTAGAGTG GGTCTCAACT P_TTACGTCGC
AGGGTACTAG TACATACTAC GCAGACTCCG
TGAAGGGCCG
ACTGCACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTTGA TAaTGCAGCG TCCCP_TGP_TC
ATGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
R P D
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAPACCTGAT
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CTTTGGACTA
R S F D Y W G Q G T L V T V S S
301 CGTTCTTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 134) GCAAGAAAAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID 140: 135) DOM-26 SEQ ID NO: 28 E V Q L L E S. G G G L V Q P G G S L R L S C A A S G F T F R 5 Y E M =
1 GAGGTGCAGC TGTTGGAGTC TGGGGGAGGC TTGGTP_CAGC CTGGGGGGTC CCTGCGTCTC
TCCTGTGCAG CCTCCGGATT CACCTTTCGT
AGTTATGAGA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCP_TGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAb GTGGAAAGCP_ TCAATACTCT
= T W V R Q A P G K G L E W V S S I T S D G G T T Y Y A D S V
K G R =
ATGGTGGTAC TACATAC'fAC GCAGACTCCG
TGAAGGGCCG
ACTGAACCCA GGCGGTCCGA GGTCCCTTCC CAGACCTCAC CCAGAGTAGA TAATGCAGCC TACCACCATG
ATGTP_TGATG CGTCTGAGGC
ACTTCCCGGC
= F T I 5 R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
K P D
201 GTTCACCATC TCCCGCGACP ATTCCAAGAA CACGCTGTAT CTGCAAATGA P.CAGCCTGCG
TGCCGAGGAC ACCGCGGTP_T ATTACTGTGC
GAAACCTGAT CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC
ACGGCTCCTG TGGCGCCATA TAATGACACG
CTTTGGACTA
301 AkGACGTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 136) TTCTGCAAAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 137) DOM-27 SEQ ID NO: 29 Y E M =
CCTCCGGATT CACCTTTAAT
TTGTATGAGA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCP_TGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGAAATTA
AACATACTCT
= T W V R Q A P G K G L E W V S S I T S D G V S T YY A D S V
K G R =
.35 101 TGACTTGGGT CCGCCAGGCT CCAGGGAAGG GTCTAGAGTG GGTCTCPTCT ATTACTAGTG
ATGGTGTTTC TACATACTAC GCAGACTCCG
TGAAGGGCCG
ACTGAACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTAGP. TAATGATCAC TACCACAAAG
ATGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N 5 K N T L Y L Q M N 5 L R A E D T A V Y Y C A
K P D
201 GTTCACCATC TCCCGCGACA P.TTCCAAGAA CACGCTGTAT CTGCAAaTGA ACAGCCTGCG
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAAACCGGAT
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATP. TAATGACACG
CTTTGGCCTA
S P F L Y W G Q G T L V T V S S
301 TCTCCGTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 138) AGAGGCAAAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 139) DOM-28 SEQ ID NO: 30 E V Q L L E S G G G L V Q P G G S L R L S C P_ A S G F T F G H
Y D M =
GAGGTGCAGC TGTTGGAGTC TGGGGGAGGC TTGGTACAGC CTGGGGGGTC CCTGCGTCTC TCCTGTGCAG
CCTCCGGATT CACCTTTGGG
CP_TTATGATA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGAAACCC
GTAATACTAT
A W V R Q A P G H G L E W V S T I S D N G N G T Y Y A D S V
K G R =
ATGGTAATGG GP_CP_TACTAC GCAGACTCCG
TGAAGGGCCG
ACCGAACCCA GGCGGTCCGA GGTCCCTTCCCAGATCTCAC CCAGAGTTGA TAATCACTAT TACCATTACC
CTGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R A E D T P. V Y Y C A
R P G
201 GTTCACCATC TCCCGCGACA AT_TCCAAGAA CACGCTGTAT CTGCAAATGA ACAGCCTGCG
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GPAACCGGGG
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TPATGACACG
CTTTGGCCCC
R D F D Y W G Q G T L V T V S S
301 CGTGATTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 140) GCACTAAAAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 141) DOM-29 SEQ ID NO: 31 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F G R
Y p N, =
1 GAGGTGCAGC TGTTGGAGTC TGGGGGAGGC T_TGGTP_CAGC CTGGGGGGTC CCTGCGTCTC
TCCTGTGCAG CCTCCGGATT CACCTTTGGT
CGTTATCAGA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAn GTGGAAACCA GCAATAGTCT
= A W V R Q A P G K G L E W V S S I S S D G G G T Y Y A D S V
K G R =
ATGGTGGGGG GACATACTAC GCAGACTCCG
TGAAGGGCCG
ACCGAACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTAGA TAAAGAAGAC TACCACCCCC
CTGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S R N T L Y L Q M N S L R A E D T A V Y Y C A
K P G
201 GTTCACCATC TCCCGCGACA ATTCCP_AGAA CACGCTGTAT CTGCAAATGA ACAGCCTGCG
TGCCGAGGAT ACCGCGGTAT ATTACTGTGC
GAAACCTGGG
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATP. GACGTTTACT TGTCGGACGC ACGGCTCCTA
TGGCGCCATA TAATGACACG
CTTTGGACCC
R A F D Y W G Q G T L V T V S E
301 CGGGCGTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 142) GCCCGCAAAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 143) DOM-30 SEQ ID NO: 32 JO E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F A R
Y Q M =
CCTCCGGATT CACCTTTGCG
AGGTATCAGA
AGGACACGTC GGAGGCCTAP. GTGGAAACGC
TCCATAGTCT
= A W V R Q A P G K G L E W V S T I S D D G D S T Y Y A D S V K G R =
ATGGTGATTC GACATACTAC GCAGACTCCG
ACCGAACCCA GGCGGTCCGA GGTCCCTTCC CAGACCTCAC CCAGAGTTGA TAAAGACTAC TACCACTAAG
CTGTATGATG CGTCTGAGGC
= F T I S R D N S K N T L Y L Q N. N S L R P. E D T A V Y Y C A
K L D
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAPACTGGAT
CAAGTGGTAC AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAP_TGACACG
CTTTGACCTA
K L F D Y Ca G Q G T L V T V S S
301 AAGTTGTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 149) TTCAACAAAC TGPTGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 145) DOM-31 SEQ ID NO: 33 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F E E
Y Q M =
CCTCCGGATT CACCTTTGAG
GAGTATCAGA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAP_ GTGGAAACTC
CTCP_TAGTCT
= A W V R Q A P G K G L E W V S T I S D D G S S T Y Y A D S V
K G R =
ATGGTTCTTC GACATACTAC GCAGACTCCG
TG.AAGGGCCG
ACCGCACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTTGC TAPAGCCTAC TACCAAGPAG
CTGTATGP_TG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
K P D
201 GTTCACCATC TCCCGCGACP P_TTCCAAGAA CACGCTGTAT CTGCAAATGP ACAGCCTGCG
TGCCGAGGAC ACCGCGGTP_T ATTACTGTGC
GAAACCTGAT
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CTTTGGACTA
L Y F D Y W G Q G T L V T V S S
301 CTTTATTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 146) GAAP_TAAAAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 147) DOM-32 SEQ ID NO: 34 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F E V
Y Q M =
j GAGGTGCAGC TGTTGGAGTC TGGGGGAGGC TTGGTACAGC CTGGGGGGTC CCTGCGTCTC TCCTGTGCAG
CCTCCGGATT CACCTTTGAG
GTGTATCAGA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG PACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
CACATAGTCT
= G W V R Q A P G K G L E W V S F I V P G G D L T Y Y A D S V
K G R =
GGGGTGATTT GACATACTAC GCAGACTCCG
TGAAGGGCCG
ACCCAACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTPAA TAACACGGAC CCCCACTAAA
CTGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V 1= Y C P_ E T W
201 GTTCACCATC TCCCGCGACA ATTCCAAGAA CACGCTGTAT CTGCAAATGP_ ACAGCCTGCG
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GGAAACGTGG
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACP_TA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CCTTTGCACC
P E F D Y W G Q G T L V T V S S
301 CCGGAGTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 148) GGCCTCATiAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 149) 25 DOM-33 SEQ ID NO: 35 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q T I G E
S L H =
GGGCAAGTCA GACGATTGGG
GAGAGTTTAC
.30 CTGTAGGTCT ACTGGGTCAG AGGTAGGAGG GACAGACGTA GACATCCTCT GGCACAGTGG
TAGTGAACGG CCCGTTCAGT CTGCTAACCC
CTCTCAAATG
= W Y Q Q K P G K A P R L L I Y F A S L L Q S G V P S R F S G
S G S =
35 101 ATTGGTACCP. GCAGAAACCA GGGAAAGCCC CTAGGCTCCT GATCTATTTT GCTTCCCTGT
TGCAAAGTGG GGTCCCP_TCG CGTTTCAGTG
GCAGTGGATC
TAACCATGGT CGTCTTTGGT CCCTTTCGGG GATCCGAGGA CTAGATAAAP. CGAAGGGACP. ACGTTTCACC
CCAGGGTAGC GCAAAGTCAC
CGTCACCTAG
F G Q
CTGTCAACAG CATCATATGC TTCCTTCTAC
GTTCGGCCAA
ACCCTGTCTA AAATGAGAGT GGTAGTCGTC AGACGTTGGA CTTCTPAAAC GATGCP_TGAT GACAGTTGTC
GTAGTATACG AAGGAAGETG
G T I( V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG (SEQ ID NO: 150) CCCTGGTTCC ACCTTTAGTT TGCC (SEQ ID NO: 151) DOM-34 SEQ ID NO: 36 D I Q M T Q S P S. S L S A S V G D R V T I T C R A S Q W I G D
S L S =
GGGCAAGTCA GTGGATTGGT
GATAGTTTAT
CTGTAGGTCT ACTGGGTCAG AGGTAGGAGG GACAGACGTA GACATCCTCT GGCACAGTGG TAGTGAACGG
CCCGTTCAGT CACCTAACCA
CTATCAAATA
W Y Q Q IC P G f: A. P K L L I Y F A S Y L Q S G V P T R F S G
S G S =
101 CTTGGTACCP GCAGAAACCP. GGGAAAGCCC CTARGCTCCT GATCTATTTT GCTTCCTPTT
TGCAAAGTGG GGTCCCAACA CGTTTCAGTG
GCAGTGGATC
GAACCATGGT CGTCTTTGGT CCCTTTCGGG GATTCGAGGA CTAGATAAAA CGAAGGATAP ACGTTTCP_CC
CCAGGGTTGT GCAPAGTCAC
CGTCACCTAG
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q Y F E N P V T
F G Q
201 TGGGACAGAT TTCACTCTCA CCATCAGCAG TCTGCAACCT GATiGATTTTG CTACGTACTA
CTGTCAACAG TP_TTTTGAGA ATCCTGTTAC
GTTCGGCCAA
ACCCTGTCTP_ AAGTGAGAGT GGTAGTCGTC AGACGTTGGA CTTCTAAAAC GATGCP_TGP_T
GACAGTTGTC ATAAAACTCT TAGGACAATG
CAAGCCGGTT
G T R V G I K R
.~ O 301 GGGACCAP_GG TGGGAATCAA ACGG (SEQ ID NO: 152) CCCTGGTTCC ACCCTTAGTT TGCC (SEQ ID NO: 153) DOM-35 SEQ ID NO: 37 D I Q M T Q S P S S L S A S V G D R V T I T C B. A S Q F I G D
L S =
ATCACTTGCC GGGCAAGTCA GTTTP_TTGGT
GATTCTTTAT
CTGTAGGTTT ACTGGGTCAG AGGTAGGAGG GACAGACGTA GACP.TCCTCT GGCACAGTGG TAGTGAACGG
CCCGTTCAGT CAAATAACCP.
CTAAGAAATA
= W Y Q Q K P G R A P K L L I Y F S S I L Q S G V P S R F S G
S G S =
TGCAAAGTGG GGTCCCP_TCA CGTTTCAGTG
GCAGTGGATC
~~ GAACCATGGT CGTCTTTGGT CCCTTTCGGG GATTCGAGGA CTAGATAAAA AGAAGGTAAF
ACGTTTCACC CCAGGGTAGT GCAAAGTCAC
CGTCACCTAG
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q Y M D I P I T
F G Q
GTTCGGCCPA
ACCCTGTCTA AAGTGAGAGT GGTAGTCGTC AGACGTTGGA CTTCTAAAAC GATGCATGAT GACAGTTGTC
ATATACCTAT AAGGP_TPATG
CAAGCCGGTT
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG (SEQ ID NO: 154) CCCTGGTTCC P.CCTTTAGTT TGCC (SEQ ID NO: 155) DOM-36 SEQ ID NO: 38 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q D I D H
N L E =
GGGCAAGTCA GGATATTGAT
CATAATTTAG
CTGTAGGTCT ACTGGGTCAG AGGTAGGAGG GACAGACGTA GACATCCTCT GGCACAGTGG TAGTGAACGG
CCCGTTCAGT CCTATAACTA
GTATTAAATC
= W Y Q Q K P G K A P P. L L I Y D S S M L Q S G V P S R F S G
S G S =
TGCAAAGTGG GGTCCCATCA CGTTTCAGTG
GCAGTGGATC
TCACCATAGT CGTCTTTGGT CCCTTTCGGG GATTCGAGGA CTAGATACTA TCAAGGTACA ACGTTTCACC
CCAGGGTAGT GCAAAGTCAC
CGTCACCTAG
, = G T D F T L T I S S L Q P E D F A T Y Y C Q Q Y H S I P V T F G Q
201 TGGGACAGAT TTCACTCTCA CCATCAGCAG TCTGCAP.CCT_ GAAGATTTTG CTACGTACTE
CTGTCAACAG TATCATTCTA TTCCTGTTAC
GTTCGGCCAP.
ACCCTGTCTA AAGTGAGAGT GGTAGTCGTC AGACGTTGGE CTTCTAAAAC GATGCATGAT GACAGTTGTC
ATAGTAAGFiT AAGGACAATG
CAAGCCGGTT
G T h V E I F. R
301 GGGACCAAGG TGGP_AATCAA ACGG (SEQ ID NO: 156) CCCTGGTTCC ACCTTTAGTT TGCC (SEQ ID NO: 157) DOM-37 SEQ ID NO: 39 D I Q N T Q S P S S L S A S V G D R V T I T C R A 8 Q Q I $ T
N L E =
1 GACPTCCAGA TGACCCAGTC TCCATCCTCC CTGTCTGCAT CTGTP_GGAGA CCGTGTCACC
ATCACTTGCC GGGCAAGTCA GCAGATTGAG
ACGAATTTAG
CTGTAGGTCT ACTGGGTCAG AGGTAGGAGG GACAGACGTA GACATCCTCT GGCACAGTGG TAGTGAACGG
CCCGTTCAGT CGTCTAACTC
TGCTTAAATC
= W Y Q Q K P G R A P K L L I Y D G S W L Q S G V P S R F S G
S G S =
TGCAAAGTGG GGTCCCATCA CGTTTCAGTG
GCAGTGGATC
TCACCATAGT CGTCTTTGGT CCCTTTCGGG GATTCGAGGA CTAGP_TACTA CCAAGGACCA ACGTTTCACC
CCAGGGTAGT GCAAAGTCAC
= G T D F T L T I 5 5 L Q P E D F A T Y Y C Q Q Y H S L P A T
F G Q
CTGTCAACAG TATCATAGTT TGCCTGCTAC
GTTCGGCCAA
ACCCTGTCTA APGTGAGAGT GGTAGTCGTC AGACGTTGGA CTTCTAAAAC GATGCATGAT GACAGTTGTC
ATAGTATCAA ACGGACGATG
CAAGCCGGTT
G T K V E I K R
307. GGGACCAAGG TGGAAATCAA ACGG (3EQ ID NO: 158) CCCTGGTTCC ACCTTTAGTT TGCC (SEQ ID NO: 159) DOM-38 SEQ ID NO: 40 N L E =
I GACATCCAGA TGACCCAGTC TCCATCCTCC CTGTCTGCAT CTGTAGGAGA CCGTGTCACC ATCACTTGCC
GGGCAAGTCP_ GGATATTGGT
AATAATTTAG
CTGTAGGTCT ACTGGGTCAG AGGTAGGAGG GACAGACGTA GACATCCTCT_ GGCACAGTGG TAGTGAACGG
CCCGTTCAGT CCTATAACCA
TTATTAAATC
= W Y Q Q R P G K A P R L L I Y H G S W L Q 5 G V P S R F 5 G
5 G S =
101 AGTGGTACCA GCAGAAACCA GGGAAAGCCC CTAGGCTCCT GATCTATCP_T GGGTCCTGGT
TGCAAAGTGG GGTCCCATCG CGTTTCAGTG
GCAGTGGATC
TCACCATGGT CGTCTTTGGT CCCTTTCGGG GATCCGAGGA CTAGATAGTA CCCAGGACCF. ACGTTTCACC
CCAGGGTAGC GCAAAGTCAC
CGTCACCTAG
= G T D F T L T I S 5 L Q P E D F A T Y Y C Q Q Y D F N P T T
F G Q
201 TGGGACAGAT TTCACTCTTA CCATCAGCAG TCTGCAACCT GAAGATTTTG CTACGTACTP.
CTGTCAACAG TATGATTTTA ATCCTACTAC
GTTCGGCCAA
ACCCTGTCTA AAGTGAGAAT GGTAGTCGTC AGACGTTGGA CTTCTAAAAC GP_TGCP_TGAT GACAGTTGTC
ATACTAAAAT TAGGP_TGATG
CAAGCCGGTT
G T K V E I K R
301 GGGACCAAGG TGGAAATCAP_ ACGG (SEQ ID NO: 160) 20 CCCTGGTTCC ACCTTTAGTT TGCC
(SEQ ID NO: 161) DOM-39 SEQ ID NO: 41 L L W =
GGGCAAGTCA GAPTATTGAT
GGTCTGTTAT
CTGTAGGTCT ACTGGGTCAG AGGTAGGAGG GACAGACGTA GACATCCTCT GACACAGTGG TAGTGAACGG
CCCGTTCAGT CTTATAACTA
CCAGACAATA
~
J = W Y Q Q K P G K P_ P K L L I Y A G 9 G L Q S G V P S R F S G
S G 5 =
TGCAAAGTGG GGTCCCP_TCA CGTTTCAGTG
GCAGTGGP.TC
CCACCATAGT CGTCTTTGGT CCCTTTCGGG GATTCGAGGA CTAGATACGC CCCAGGCCCA ACGTTTCACC
CCAGGGTAGT GCAAAGTCAC
CGTCACCTAG
= G T D F T L T I 5 S L Q P E D P A T Y Y C O Q K A F E P F T
F G Q
CTGTCAACAG AAGGCTTTTG AGCCTTTTAC
GTTCGGCCAA
ACCCTGTCTA AAGTGAGAGT GGTAGTCGTC AGACGTTGGP_ CTTCTAAAAC GATGCATGAT GACAGTTGTC
TTCCGAAAAC TCGGAAAATG
CAAGCCGGTT
G T R V E I K R
301 GGGACCAAGG TGGAA.TSTCAP ACGG (SEQ ID NO: 162) CCCTGGTTCC ACCTTTAGTT TGCC (SEQ ID NO: 163) DOM-40 SEQ ID NO: 42 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F K A
Y D M =
CCTCCGGATT CACCTTTAAG
GCGTATGATA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCPTGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGAAP_TTC
CGCATACTAT
= G W V R Q A P G K G L E W V S Q I G R D G S F T Y Y A D S V
K G R =
ATGGTTCTTT TACP_TACTAC GCAGACTCCG
TGTi'9GGGCCG
ACCCAACCCP GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTGTC TAACCCTCCC TACCAAGAAz ATGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
K P R
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAAAACCTCGT
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CTTTGGAGCP_ R Y A I F T F D R G Q G T L V T V S S
301 CGGTATGCTA TTTTTACTTT TGATCGGGGT CAGGGAACCC TGGTCACCGT CTCGAGC (SEQ ID NO:
164) GCCATACGPT AAAAATGAAA ACTAGCCCCP_ GTCCCTTGGG ACCAGTGGCA GAGCTCG (SEQ ID NO:
165) DOM-41 SEQ ID N0: 43 E V Q L L E S G G G L V Q P G G S L R L S C A A. S G F T F F E
Y E M =
CCTCCGGATT CACCTTTTTT
GAGTATGAGA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGP_GGCCTAA GTGGAAAAAA
CTCATACTCT
= T W V R Q A P G K G L E W V S S I A N D G S T T Y Y A D S V
K G R =
ATGGTTCGAC TACATACTAC GCAGACTCCG
TGAAGGGCCG
~~ ACTGCACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTAGA TAACGCTTAC
TACCAAGCTG ATGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T 1 S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
K P D
201 GTTCACCP_TC TCCCGCGACA ATTCCPAGAA CACGCTGTAT CTGCAAATGA ACAGCCTGCG
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAAACCTGAT
CPAGTGGTAG AGGGCGCTGT TPAGGTTCTT GTGCGACP_TA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATP_ TAATGACACG
CTTTGGACTA
R Q F D Y W G Q G T L V T V S S
301 CGGCAGTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 166) GCCGTCAPAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 167) DOM-42 SEQ ID NO: 44 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F G P
Y E M =
CCTCCGGATT CACCTTTGGT
CCGTATGAGA
AGGACACGTC GGAGGCCTAA GTGGAAACCA
GGCATACTCT
= T W V R Q A P G K G L E W V S S I V G D G L D T Y Y A D S V
K G R =
ATGGTCTGGP. TACP_TACTAC GCAGACTCCG
TGAAGGGCCG
ACTGAACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTAGC TAACAACCAC TACCAGACCT
ATGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S P. D N S K N T L Y L Q N N S L R A E D T A V Y Y C n K P D
201 GTTCACCATC TCCCGCGACA ATTCCAAGAA CACGCTGTAT CTGCAAP_TGA ACAGCCTGCG
TGCCGAGGAC ACCGCGGTAT P.TTACTGTGC
GAAACCGGAT
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAP_TGACACG
CTTTGGCCTA
R V F D Y W G Q G T L V T V S S
301 CGGGTTTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC t5EQ ID NO: 168) GCCCAAAAAC TGP_TGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 169) DOM-43 SEQ ID NO: 45 ~5 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F A S
Y E N, =
CCTCCGGATT CACCTTTGCT
TCTTATGAGA CTCCACGTCG ACP_ACCTCAG ACCCCCTCCG AP_CCPTGTCG GACCCCCCAG GGACGCAGAG
AGGACACGTC GGAGGCCTAA GTGGAAACGA
AGAATACTCT
= A W V R Q A P G K G L E W V S S I G 5 D G G P T Y Y A D S V
K G R =
101 TGGCGTGGGT CCGCCP_GGCT CCAGGGATaGG GTCTAGAGTG GGTCTCATCG ATTGGTAGTG
ATGGTGGGCC GACATACTAC GCAGACTCCG
TGAAGGGCCG
ACCGCACCCA GGCGGTCCGA GGTCCCTTCC CAGP_TCTCAC CCAGAGTAGC TAACCATCAC TACCACCCGG
CTGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R P_ E D S A V Y Y C A
IS P D
201 GTTCACCP_TC TCCCGCGACA ATTCCAAGAA CACGCTGTAT CTGCAAATGA ACAGCCTGCG
TGCCGAGGAC TCCGCGGTAT ATTACTGTGC
GAAACCTGAT
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATP_ GACGTTTACT TGTCGGACGC ACGGCTCCTG
AGGCGCCATA TAATGACACG
CTTTGGACTA
R A F D Y W G Q G T L V T V S S
301 AGGGCTTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 170) TCCCGAAAAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 171) 40 DOM-44 SEQ ID NO: 46 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F T S
Y E 14 =
CCTCCGGATT CACCTTTACG
TCTTATGAGA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCP_TGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAi GTGGAAATGC
AGAATACTCT
= G W V R Q A P G K G L E'W V S S I E P T G I T T Y Y A D S V
F. G R S.
CTGGTATTAC GACATACTAC GCAGACTCCG
TGAAGGGCCG
ACCCCACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTAGA TAACTCGGAT GACCATAATG
CTGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q N. N S L R A E D T A V Y Y C A
K P H
201 GTTCACCATC TCCCGCGACA ATTCCAAGAA CACGCTGTP_T CTGCAAATGA ACAGCCTGCG
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC GAAACCTCAT
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CTTTGGAGTA
F T E L G F D Y W G Q G T L V T V S S
301 TTTACTGAGC TTGGTTTT_GP_ CTACTGGGGT CAGGGAACCC TGGTCACCGT CTCGAGC (SEQ ID
NO: 172) AAATGACTCG AACCAAPACT GATGACCCCA GTCCCTTGGG ACCAGTGGCA GAGCTCG (SEQ ID NO:
173) DOM-45 SEQ ID NO: 47 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F G N
Y A M =
CCTCCGGATT CACCTTTGGT
AATTATGCGA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCRTGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGAAACCA
TTAATACGCT
= A W V R Q A P G K G L E W V S K I G A Q G L H T Y Y A G S V
K G R =
AGGGTCTTCA TACATACTAC GCAGGCTCCG
TGAAGGGCCG
ACCGCACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTTTC TAACCCCGCG TCCCAGAAGT
ATGTATGATG CGTCCGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
K Q T
TGCCGAGGAC ACCGCGGTAT A_TTACTGTGC
GAAACAGACG
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGAC.ATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CTTTGTCTGC
T M D Y E A F D Y W G Q G T L V T V S S
301 ACGATGGATT ATGAGAGGTT TGACTACTGG GGTCAGGGAP. CCCTGGTCAC CGTCTCGAGC (SEQ ID
NO: 174) TGCTACCTAA TACTCTCCAA ACTGATGACC CCAGTCCCTT GGGACCAGTG GCAGAGCTCG (SEQ ID NO:
175) DOM-46 SEQ ID NO: 48 E V Q L L E S G G G L V Q P G G S L R L S C P. A S G F T F E L
Y A M =
CCTCCGGATT CACCTTTGAG
TTGTATGCTA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACP_CGTC
GGAGGCCTAA GTGGAAACTC
AACATACGAT
= A W V R Q A P G K G L E W V S G I G A V G E T T Y Y A D S V
K G R =
TGGGTGAG.AC TACATACTAC GCAGACTCCG
TGAAGGGCCG
r ACCGCRCCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTCCA TAACCACGAC ACCCACTCTG
ATGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N 'S K N T L Y L Q M N S L R A E D T A V Y Y C P_ K E A
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAAAGAGGCT
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CTTTCTCCGA
N N L S D N L V F D Y W G Q G T L V T V S S
(SEQ ID NO: 176) TTATTAGAAA GACTATTAGA ACACAAACTG ATGACCCCAG TCCCTTGGGA CCAGTGGCAG AGCTCG (SEQ
ID NO: 177) DOM-47 SEQ ID NO: 49 S L S =
GGGCAAGTCA GTGGATTGGG
GATTCGTTAA CTGTAGGTCT ACTGGGTCAG AGGTAGGAGG GACAGACGTA GACATCCTCT GGCACAGTGG
TAGTGAACGG CCCGTTCAGT CACCTAACCC
CTAAGCAATT
= W Y Q Q K P G K A P K L L I Y F G S Y L Q S G V P S R F S G
S G S =
TGCAAAGTGG GGTCCCATCA CGTTTCAGTG
GCAGTGGATC
CAACCATGGT CGTCTTTGGT CCCTTTCGGG GATTCGP.GGA CTAGATAAAA CCAAGGATAA ACGTTTCACC
CCAGGGTAGT GCAAAGTCAC
CGTCACCTAG
= G T D F T L T I S S L Q P ~ D F A T Y Y C Q Q Y L H T P 5 T
F G Q
201 TGGGACAGAT TTCACTCTCP. CCP.TCAGCAG TCTGCAACCT GAAGATTTTG CTACGTACTA
CTGTCAACAG TATTTGCATP CTCCTTCGAC
GTTCGGCCAA
ACCCTGTCTA PAGTGAGAGT GGTAGTCGTC AGACGTTGGA CTTCTAAAAC GATGCATGAT GACAGTTGTC
ATAAACGTAT GAGGAAGCTG
CAAGCCGGTT
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG (SEQ ID NO: 178) CCCTGGTTCC ACCTTTAGTT TGCC (SEQ ID NO: 179) DOM-48 SEQ ID NO: 50 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q W I G D
5 L S =
GGGCAAGTCA GTGGATTGGG
GATTCGTTAA
CTGTAGGTCT ACTGGGTCAG AGGTAGGAGG GACAGACGTA GACATCCTCT GGCACAGTGG TAGTGAACGG
CCCGTTCAGT CACCTAACCC
CTAAGCAP_TT
= W Y Q Q K P G K A P K L L I Y F G S Y L Q N G V P S R F 5 G
5 G 5 =
101 GTTGGTACCA GCAGAAACCA GGGAA~GCCC CTAAGCTCCT GATCTATTTT GGTTCCTATT
TGCAAPATGG GGTCCCATC? CGTTTCAGTG
GCAGTGGATC
CAACCATGGT CGTCTTTGGT CCCTTTCGGG GATTCGAGGA CTAGATAAAA CCt1AGGATAP_ ACGTTTTACC
CCAGGGTAGT GCPAAGTCAC
CGTCACCTAG = G T D F T L T I S S L Q P E D F A T Y Y C Q Q Y N I T P T T
F G Q
201 TGGGACAGAT TTCACTCTCB CCATCAGCAG TCTGCAACCT GAAGATTTTG CTACGTACTP.
CTGTCAACAG TETATGATTA CTCCTACTAC
GTTCGGCCAA
ACCCTGTCTA AAGTGAGAGT GGTAGTCGTC AGACGTTGGA CTTCTAAAAC GATGCATGP_T GACAGTTGTC
ATATACTAAT GAGGATGATG
CAAGCCGGTT
G T K V E I R R
301 GGGACCAAGG TGGMATCAA ACGG (SEQ ID NO: 180) CCCTGGTTCC ACCTTTAGTT TGCC (SEQ ID NO: 1B1) DOM-49 SEQ ID NO: 51 D V Q M T Q S F 5 5 L S A S V G D P. V T I T C R P. S Q W I G D
S L S =
GGGCAAGTCA GTGGATTGGG
GATTCGTTAP_ CTGCAGGTCT ACTGGGTCAG AGGTAGGAGG GACAGACGTA GACATCCTCT GGCACAGTGG TAGTGAACGG
CCCGTTCAGT CACCTAACCC
CTAAGCAATT
= W Y Q Q K P G R P. P K L L I Y F G S Y L Q S G V P S R F S G
S G S =
101 GTTGGTACCA GCAGAAACCP. GGGAAAGCCC CTAAGCTCCT GATCTATTTT GGTTCCTATT
TGCAAAGTGG GGTCCCATCA CGTTTCAGTG
GCAGTGGP_TC CAACCATGGT CGTCTTTGGT CCCTTTCGGG GATTCGAGGA CTAGATAAAA CCAAGGATAA
ACGTTTCACC CCAGGGTAGT GCAAAGTCAC
CGTCACCTAG
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q Y M S A P S T
F G Q
201 TGGGACAGAT TTCACTCTCA CCATCAGCAG TCTGCAACCT GAAGATTTTG CTACGTACTP_ CTGTCAACAG TATATGAGTG CTCCTTCTAC
GTTCGGCCAA
,, O ACCCTGTCTA PAGTGAGAGT GGTAGTCGTC AGACGTTGGA CTTCT.9PAAC GATGCATGAT
GACAGTTGTC ATATACTCAC GAGGAAGP_TG
CAAGCCGGTT
G T K V E I K R
301 GGGACCAAGG TGGA.WiTCAA ACGG (SEQ ID NO: 182) CCCTGGTTCC ACCTTTAGTT TGCC ISEQ ID N0: 183) DOM-50 SEQ ID NO: 52 D I Q M T Q S P S S L S A S V G D R V T I T C R P. S Q W I G D
S L 5 =
GGGCAAGTCA GTGGATTGGG
GATTCGTTAA
CTGTAGGTCT ACTGGGTCAG AGGTAGGAGG GACAGACGTA GACATCCTCT GGCACAGTGG TAGTGAACGG
CCCGTTCAGT CACCTAACCC
CTAAGCAATT
J5 = W Y Q Q K P G K A P K L L I Y F G S Y L Q S G V P S R F S G
S G S =
TGCAAAGTGG GGTCCCATCA CGTTTCAGTG
CCAAGGATAA ACGTTTCACC CCAGGGTAGT GCAAAGTCAC
CGTCACCTAG
= G T D F T L T I S S L Q P E D S A T Y Y C Q 0 y Q Y V PS T
F G Q
CTGTCAACAG TATCAGTATG TTCCTTCTAC
GTTCGGCCAA
ACCCTGTCTb AAGTGAGAGT GGTAGTCGTC AGACGTTGGA CTTCTAAGAC GATGCATGAT GACAGTTGTC
ATAGTCP_TAC AAGGPAGATG
CAAGCCGGTT
G T K V E I K Q
301 GGGACCAAGG TGGAAATCAA ACAG (SEQ ID NO: 184) CCCTGGTTCC ACCTTTAGTT TGTC (SEQ ID NO: 185) DOM-51 SEQ ID NO: 53 D I Q M T Q S P S S L S A S V G D R V T I T C R P S Q P I V D
E L. D =
GGGCAAGTCP. GCCTPTTGTT
GATGAGTTAC
CTGTAGGTCT ACTGGGTCAG AGGTAGGAGG GACAGACGTA GACATCCTCT GGCACAGTGG TAGTGAACGG
CCCGTTCAGT CGGP_TAACAA
CTACTCAATC
= W Y Q Q K P G K P_ P K L L I Y A A S I L Q S G V P S R F S G
S G S =
TGCAAAGTGG GGTCCCATCA CGTTTCAGTG
GCAGTGGATC
TAACCATGGT CGTCTTTGGT CCCTTTCGGG GATTCGAGGA CTAGATACGP CGCAGGTAAA ACGTTTCACC
CCAGGGTAGT GCAAAGTCAC
CGTCACCTAG
= G T D F T L T I S S L Q P E D F A T Y Y C H Q W S T Y P T T
F G Q
201 TGGGACAGAT TTCACTCTCA CCATCAGCAG TCTGCAACCT GAAGP_TTTTG CTACGTACTA
CTGTCATCAG TGGTCTACTT PTCCTACGAC
GTTCGGCCAA
ACCCTGTCTP AAGTGAGAGT GGTAGTCGTC AGACGTTGGA CTTCTAAAAC GATGCATGAT GACAGTAGTC
ACCAGATGAA TPGGPTGCTG
CAAGCCGGTT
G T K V E I K R
301 GGGACCAAGG TGGAAATTAA ACGG (SEQ ID NO: 186) CCCTGGTTCC ACCTTTPATT TGCC (SEQ ID NO: 187) DOM-52 SEQ ID NO: 54 A L R =
GGGCAAGTCA GGATATTGGG
TCTGCGTTAA
CTGTAGGTCT ACTGGGTCAG AGGTAGGAGG GACAGACGTA GACPTCCACT GGCACAGTGG TAGTGAACGG
CCCGTTCAGT CCTATAACCC
= W Y Q Q K P G IC P. P K L L I Y L G S D L Q 5 G V P S R F S G
S G S =
TGCAAAGTGG GGTCCCATCA CGTTTCAGTG
GCAGTGGATC
CCACCATAGT CGTCTTTGGT CCCTTTCGGG GATTCGAGGA CTAGATAAAC CCAAGGCTAA ACGTTTCACC
CCAGGGTAGT GCAAAGTCAC
CGTCACCTPG
= G T D F T L T I S S L Q P E D F P. T Y Y C Q Q T Q Y F P T T
F G Q
201 TGGGACAGAT TTCACTCTCb CCATCAGCAG TCTGCAACCT GAAGATTTTG CTACGTACTA
CTGTCAACAG ACGCAGTATT TTCCTACGAC
GTTCGGCCAA
ACCCTGTCTA AAGTGAGAGT GGTAGTCGTC AGACGTTGGA CTTCTAAAAC GATGCATGAT GACAGTTGTC
TGCGTCATAA AAGGPTGCTG
CAAGCCGGTT
G T K V E I K R
301 GGGP_CCAAGG TGGAAATCAP ACGG (SEQ ID NO: 188) CCCTGGTTCC ACCTTTAGTT TGCC (SEQ ID NO: 189) DOM-53 SEQ ID N0: 55 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q A I Y G
G L R =
1 GACATCCP_GP_ TGACCCAGTC TCCATCCTCC CTGTCTGCAT CTGTAGGAGA CCGTGTCACC
ATCACTTGCC GGGCAAGTCA GGCGATTTAT
GGGGGGTTAC
CTGTAGGTCT ACTGGGTCAG AGGTAGGAGG GACAGACGTA GACATCCTCT GGCACAGTGG TAGTGAACGG
CCCGTTCAGT CCGCTAAATP CCCCCCAP_TG
= W Y Q Q K P G K A P R L L I Y G E S M L Q S G V P S R F S G
S G S =
TGCAAAGTGG GGTCCCATCE CGTTTCAGTG GCAGTGGATC
CCACCATGGT CGTCTTTGGT CCCTTTCGGG GATTCGAGGA CTAGATACCC CTCAGGTACA ACGTTTCACC
CCAGGGTAGT GCAAAGTCAC
CGTCPCCTAG
= G T D F T L T I S S L H P E D F A T Y Y C Q Q V Y H K P F T
F G Q
CTGTCAACAG GTTTATCATA AGCCTTTTAC
GTTCGGCCAA
ACCCTGTCTA AAGTGAGAGT GGTAGTCGTC AGACGTAGGP CTTCTAAAAC GATGCATGAT GACAGTTGTC
CAAATAGTAT TCGGAAAATG
CAAGCCGGTT
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG (SEQ ID NO: 190) CCCTGGTTCC ACCTTTAGTT TGCC (SEQ ID NO: 191) DOM-54 SEQ ID NO: 56 E V Q L L E S G G G L V Q P G G S L R L S C A I: S G F T F T A
Y R M =
CCTCCGGATT CACCTTTACG
GCGTATAGGA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGAAATGC
CGCATP_TCCT
= A W V R Q A P G K G L E W V S W I S P S G S G T Y Y A D S V
K G R =
CTGGTTCGGG GACATACTAC GCAGACTCCG
TGAAGGGCCG
ACCGAACCCA GGCGGTCCGP_ GGTCCCTTCC CAGATCTCAC CCAGAGTACC TAAAGCGGzfA GACCAAGCCC
CTGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
K T L
201 GTTCACCATC TCCCGCGACA ATTCCAAG.~A CACGCTGTAT CTGCAAATGP ACAGCCTGCG
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAAAACTTTG
CHAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TPATGACACG
CTTTTGAP.AC
T D S P S G R Y E F D Y W G Q G T L V T V S S
301 ACGGATTCGC CGTCGGGGCA TTP_TGAGTTT GACTACTGGG GTCAGGGAAC CCTGGTCACC
GTCTCGAGC (SEQ ID NO: 192) TGCCTAAGCG GCAGCCCCGT ApTACTCAAP CTGP_TGACCC CAGTCCCTTG GGACCAGTGG CAGnGCTCG
(SEQ ID NO: 193) DOM-55 SEQ ID N0; 57 Y E M =
CCTCCGGPTT CACCTTTGCG
CGGTPTGAGA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGPkACGC
GCCATACTCT
= G W V R Q A P G K G L E tV V S R I T A Q G L G T Y Y A D S V
K G R =
AGGGTCTTGG GACATACTAC GCAGACTCCG
TGAAGGGCCG
ACCCCACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTGCC TAATGACGAG TCCCAGAACC
CTGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
K Y L
TGCCGAGGAT ACCGCGGTAT ATTACTGTGC
GAAATATCTT
CAAGTGGTAG AGGGCGCTGT TGAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC P_CGGCTCCTF
TGGCGCCATA TAATGACACG
CTT_TATAGAA
T D F S S G H Q E F D Y P! G Q G T L V T V S S
GTCTCGAGC (SEQ ID NO: 194) TGACTAAAAT CATCACCCGT AGTCCTCAAA CTGATGACCC CAGTCCCTTG GGACCAGTGG CAGP.GCTCG
(SEQ ID NO: 195) DOM-56 SEQ ID NO: 58 Y T M =
CCTCCGGP_TT CACCT_TTAAT
GATTATACTA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGAAATTA
CTPATATGAT
= G W V R Q A P G K G L E W V 5 W I H G T G G Q T Y Y A D S V
P: G R =
CTGGTGGTCA GACATACTAC GCAGACTCCG
TGAAGGGCCG
ACCCAACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTACC TAAGTACCCT GACCACCAGT
CTGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R P. E D T A V Y Y C A
K A L
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAAAGCTTTG
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACBTA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CTTTCGAAAC
GTCTCGAGC (SEQ ID NO: 196) CGACTATCCT CACCCCCCCA ACAACTCAAA CTGATGACCC CAGTCCCTTG GGACCAGTGG CAGAGCTCG
(SEQ ID NO: 297) DOM-57 SEQ ID NO: 59 Y D M -CCTCCGGATT CACCTTTTCT
GAGTATGATA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGAAAAGA
CTCATACTAT
. Y W V R Q A P G K G L E W V S W I D T D G G D T Y Y A D S V
K G R =
~O 101 TGTATTGGGT CCGCCAGGCT CCAGGGAAGG GTCTAGAGTG GGTCTCATGG ATTGATACTG
ATGGTGGGGA TACATACTAC GCAGACTCCG
TGAAGGGCCG
ACATAACCCP. GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTACC TAACTATGAC TACCACCCCT
ATGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
K P G
201 GTTCACCATC TCCCGCGACA ATTCCPAGPA CP_CGCTGTAT CTGCFfA.ATGA PCAGCCTGCG
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAAACCTGGT
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACPTA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CTTTGGACCP
L K F D Y W G Q G T L V T V S S
301 CTGAAGTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 198) GACTTCAAAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 199) DOM-58 SEQ ID NO: 60 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T P E V
Y T M =
CCTCCGGATT CACCTTTGAG
GTTTATACTA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACPCGTC
GGAGGCCTAP_ GTGGAAACTC
CAAATATGAT
= P_ W V R Q A P G K G L E W V S T I D E S G R D T Y Y A D S V
K G R = e CTGGTCGTGA TACATACTAC GCAGACTCCG
TGAAGGGCCG
ACCGCACCCA GGCGGTCCGA GGTCCCTTCC CAGACCTCAC CCAGAGTTGC TAACTACTCA GACCAGCACT
P_TGTATGATG CGTCTGP_GGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
K P G
201 GTTCACCPTC TCCCGCGACP_ P_TTCCAAGAA CACGCTGTAT CTGCAAATGA ACAGCCTGCG
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAAACCTGGT
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACP_TA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CTTTGGACCA
V W F D Y W G Q G T L V T V S S
301 GTTTGGTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 200) CAAACCAAAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 201) DOM-59 SEQ ID NO: 61 E V Q L L E S G G G L V Q P G G S L R L 5 C P_ P. S G F T F L D
Y A M =
CCTCCGGATT CACCTTTCTG
GATTATGCGA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGAAPGAC
CTAATACGCT
= G W V R Q A P G K G L E W V S T I S P M G M G T Y Y A D S V
K G R =
TGGGTP_TGGG TACATACTAC GCAGACTCCG
TGAAGGGCCG
ACCCAACCCA GGCGGTCCGP GGTCCCTTCC CAGACCTCAC CCAGAGTTGA TAAAGAGGCT ACCCATACCC
ATGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
K s s 201 GTTCACCATC TCCCGCGACA ATTCCAAGAP. CACGCTGTAT CTGCAAATGA ACAGCCTGCG
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAAATCGAGT
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCP_TP TAATGACACG
CTTTAGCTCA
ACCGTCTCGk GC (SEQ ID NO: 202) CGATAAAGCP AATGAAGACT ATAAAGATTP AAACTGATGA CCCCAGTCCC TTGGGACCAG TGGCAGAGCT
CG (SEQ ID NO: 203) DOM-61 SEQ ID NO: 62 E V Q L L E S G G G L V Q P G G S L R L S C P_ P_ S G F T F A A
Y A M =
TCCTGTGCAG CCTCCGGATT CACCTTTGCT
GCTTATGCTA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGAAACGA
CGAATACGPT
= T W V R Q A P G K G L E W V S Y I S P N G T A T Y Y A D S V
K G R =
ATGGTACGGC GACATACTAC GCAGACTCCG
TGAAGGGCCG
ACTGCACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTPTA TAATCAGGCT TACCP_TGCCG
CTGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N 5 K N T L Y L Q M ld S L R A E D T A V Y Y C A
E Y V
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GGAATP_TGTG
CAAGTGGTAG AGGGCGCTGT T_kAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CCTTATACAC
G N R W N S F D Y W G Q G T L V T V S S
301 GGGATGCGTT GGAATTCTTT TGACTACTGG GGTCAGGGAA CCCTGGTCAC CGTCTCGAGC (SEQ ID
NO: 204) CCCTACGCAA CCTTAAGAAA ACTGATGACC CCAGTCCCTT GGGACCAGTG GCAGAGCTCG (SEQ ID 140:
205) DOM-62 SEQ ID NO: 63 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F S S
Y E M =
CCTCCGGATT CACCTTTTCG
AGTTATGAGA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGAAAAGC
TCAATACTCT
= A W V R Q A P G K G L E W V S S I T S L G T S T Y Y A D S V
K G R =
TTGGTACTTC TACATACTAC GCAGACTCCG
TGAAGGGCCG
ACCGAACCCP. GGCGGTCCGP. GGTCCCTTCC CAGATCTCAC CCAGAGTAGA TAATGCTCAG AACCATGAAG
ATGTPTGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R P_ E D T P_ V Y Y C A
K P G
201 GTTCACCATC TCCCGCGACP ATTCCAAGAA CACGCTGTAT CTGCAAP_TGE ACAGCCTGCG
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GPAtLCCGGGT
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCP_TA TAATGACP_CG CTTTGGCCCA
R K F D Y W G Q G T L V T V S S
301 AGGAAGTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 206) TCCTTCP0AC TGP_TGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID N0: 207) DOM-65 SEQ ID NO: 64 Y E M =
CCTCCGGATT CACCTTTAAT
GGACGCAGAG AGGACACGTC GGAGGCCTAP. GTGGAAATTA
CTCATACTCT
= T W V R Q A P G K G L E W V S T I T S E G 5 G T Y Y A D S V
K G R =
AGGGTAGTGG GACATACTAC GCAGACTCCG
TAAAGGGCCG
ACTGCACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTTGC TAATGATCAC TCCCATCACC
CTGTATGP.TG CGTCTGAGGC
ATTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
R P N
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAAACCTAAT
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACP_TA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCP_TA TAATGACACG
CTTTGGATTA
G K F D Y W G Q G T L V T V S S
301 GGTA4GTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 208) CCATTCAAAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 209) DOM-66 SEQ ID NO: 65 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F S D
Y E M =
CCTCCGGATT CACCTTTTCT
GATTATGAGA
CTCCACGTCG AGAACCTCAG ACCCCCTCCG AACCP_TGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGAAAAGA
CTA7,TACTCT
= L W V R Q A. P G K G L E W V S T I T S E G H S T Y Y A D S V
K G R =
AGGGTCATTC TACATACTAC GCAGACTCCG TGALAGGGCCG
P_CAACACCCA GGCGGTCCGA GGTCCCTTCC CAGACCTCAC CCAGAGTTGA TAATGATCAC TCCCAGTAAG
ATGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
K P G
201 GTTCACCATC TCCCGCGACP_ ATTCCAAGAP CACGCTGTAT CTGCAAATGA ACAGCCTGCG
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAAACCTGGG
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
301 ACTTCGTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 210) TGAAGCAAAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 211) DOM-67 SEQ ID NO: 66 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F S D
Y E M =
CCTCCGGATT CACCTTTAGT
GATTATGAGA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG APCCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAP GTGGAAP_TCA
CTAATACTCT
= S W V R Q A P G K G L E W V 5 T I D S D G S F T Y Y A D S V
K G R =
101 TGAGTTGGGT CCGCCAGGCT CCAGGG.AAGG GTCTAGAGTG GGTCTCAACG P_TTGATTCTG
ATGGTAGTTT TACATACTAC GCAGACTCCG
TGAAGGGCCG
ACTCAACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTTGC TAACTAAGAC TACCATCAAA
ATGTATGATG CGTCTGAGGC
ACTTCCCGGC
" F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
K P G
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAAACCGGGT
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGP_CGC ACGGCTCCTG
TGGCGCCATP. TAP_TGACACG
CTTTGGCCCA
V K F D Y W G Q G T L V T V S S
301 GTGAAGTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 212) CACTTCAAAC TGPTGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 213) DOM-68 SEQ ID NO: 67 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F K D
Y E M =
TCCTGTGCAG CCTCCGGATT CACCTTTAAG
GATTATGAGA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGAAATTC
CTAATACTCT
= T W V R Q A P G K G L E W V S S I S S T G Q 5 T Y Y A D S V
K G R =
CTGGTCAGTC TACATACTAC GCAGACTCCG
TGA.AGGGCCG
ATGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
K P G
TGCCGAGGAC ACCGCGGTAT P_TTACTGTGC
GAAACCGGGT
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CTTTGGCCCA
N Ii F D Y 47 G Q G T L V T V S S
301 AATAAGTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 214) TTATTCAAAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 215) DOM-69 SEQ ID NO: 68 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F L D
Y G M =
CCTCCGGATT CACCTTTCTT
GP_TTATGGTA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCP.TGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGAAAGAA
CTAP_TACCP_T
= A W V R Q A P G K G L E W V S A I S P L G L S T Y Y P. D 5 V
K S R =
TTGGTCTTAG TACATACTAC GCAGACTCCG
TGAAGAGCCG
ACCGAACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTCGP TAAAGCGGAG AACCAGAATC
ATGTATGATG CGTCTGAGGC
ACTTCTCGGC
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
K E V
TGCCGAGGAT ACCGCGGTAT ATTACTGTGC
GAAAGAGGTG
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATP GACGTTTACT TGTCGGACGC ACGGCTCCTA
TGGCGCCATA TAATGACACG
CTTTCTCCAC
R V G R G V H P P K F D Y W G Q G T L V T V S S
301 AGGGTGGGTA GGGGTGTTCA TCCTCCGAAG TTTGACTACT GGGGTCP_GGG AACCCTGGTC
ACCGTCTCGA GC (SEQ ID NO: 216) TCCCACCCAT CCCCACAAGT AGGAGGCTTC AAACTGATGA CCCCAGTCCC TTGGGACCAG TGGCAGAGCT
CG (SEQ ID NO: 217) DOM-70 SEQ ID NO: 69 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F E N
Y A M =
CCTCCGGATT CACCTTTGAG
AATTP_TGCTA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCP_TGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGAAACTC
= S W V R Q A P G K G L E W V S T I A P L G V P T Y Y A D S V
K G R =
TGGGTGTTCC GACATACTAC GCAGACTCCG
TGAAGGGCCG
ACAGCACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTTGC TAACGAGGCG ACCCACAAGG
CTGTP_TGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M ld S L R A E D T A V Y Y C A
K K K
TGCCGAGGAT ACCGCGGTAT ATTACTGTGC
GAAAAAGAAG
CAkGTGGTAG AGGGCGCTGT TPAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTA
TGGCGCCATA TPATGACACG
CTTTTTCTTC
V G A W L Q S R S F D Y W G Q G T L V T V S S
GTCTCGAGC (SEQ ID NO: 218) CAACCCCGCA CCGACGTCAG CGCCTCAAAA CTGATGACCC CAGTCCCTTG GGACCAGTGG CAGAGCTCG
(SEQ ID NO: 219) DOM-71 SEQ ID NO: 70 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F E G
Y P M =
CCTCCGGATT CACCTTTGAG
GGTTATCCTA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGAAACTC
CCAATAGGAT
= S W V R Q A P G K G L E W V S T I S P L G P D T Y Y A D S V
K G R =
TGGGTCCTGA TACATACTAC GCAGACTCCG
TGAAGGGCCG
ACAGCACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTTGA TAATCAGGAA ACCCAGGACT
ATGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R A E D T P_ V Y Y C A
K L L
TGCCGAGGAT ACCGCGGTAT ATTACTGTGC
GAAACTGTTG
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTA
TGGCGCCATA TAATGACACG
CTTTGACAAC
M G E Y L N S R T F D Y W G Q G T L V T V S S
GTCTCGAGC (SEQ ID NO: 220) TACCCCCTCA TAAACTTAAG ATCCTGCAAA CTGP.TGACCC CAGTCCCTTG GGACCAGTGG CAGAGCTCG
(SEQ ID NO: 221) DOM-72 SEQ ID NO: 71 E V Q I. L E S G G G l V Q P G G S L R L S C A A S G F T F E A
Y P M =
TCCTv~TGCAG CCTCCGGATT CACCTTTGAG
GCGTATCCTA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAL GTGGP.AACTC
CGCATAGGAT
= S W V R Q A P G b: G L E W V S S I S P L G L W T Y Y A D S V
K G R =
TTGGTTTGTG GACP_TACTAC GCAGACTCCG
TGAAGGGCCG
ACAGCACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTTCA TAAAGGGGAG AACCAAACAC
CTGTP.TGATG CGTCTGAGGC
ACTTCCCGGC
FT ? S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
K L S
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAAACTTAGT
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CTTTGAATCA
A G A E T H V Y R L F D Y W G Q G T L V T V S S
ACCGTCTCGP_ GC (SEQ ID NO: 222) CGACCCCGCC TCTGAGTACA AATAGCCGAA AAACTG.ATGP_ CCCCAGTCCC TTGGGACCAG TGGCAGAGCT
CG (SEQ ID NO: 223) DOM-73 SEQ ID NO: 72 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F S K
Y D M =
1 GAGGTGCP.GC TGTTGGAGTC TGGGGGAGGC TTGGTACAGC CTGGGGGGTC CCTGCGTCTC
TCCTGTGCAG CCTCCGGATT CACCTTTTCS
AAGTATGATA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAP_ GTGGAAAAGA
TTCATACTAT
= S W V R Q A P G K G L E W V S T L L E D G L T T Y Y A D S V
K G R =
ATGGTCTGAC TACATACTAC GCAGACTCCG
TGAAGGGCCG
ACAGAACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTTGA TAAGACCTCC TACCAGACTG
ATGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
K P G
~ 5 201 GTTCACCATC TCCCGCGACA ATTCCAAGAA CACGCTGTAT CTGCAAATGA ACAGCCTGCG
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAAACCGGGG
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCP.TA TAATGACACG
CTTTGGCCCC
R L F D Y h G Q G T L V T V S S
301 CGTTTGTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 224) GCAAACAAAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 225) DOM-74 SEQ ID NO: 73 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F S D
y p M =
CCTCCGGATT CACCTTTTCG
GATTATCCTA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGAAAAGC
CTAATAGGAT
= T W V R Q A P G K G L E W V S T I L S P G T E T Y Y A D S V
K G R =
CGGGTACGGP_ GACATACTAC GCAGACTCCG
TGAAGGGCCG
ACTGCACCCk GGCGGTCCGA GGTCCCTTCC CAGACCTCAC CCAGAGTTGA TAAGACAGAG GCCCATGCCT
CTGTATGP_TG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R P. E D T A V Y Y C A
K A E
201 GTTCP_CCP_TC TCCCGCGACA ATTCCAAGAA CACGCTGTAT CTGCAAATGA ACAGCCTGCG
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAAAGCTGAG
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACP_TA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CTTTCGACTC
K D F D Y W G Q G T L V T V S S
301 AAGGATTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID N0: 226) TTCCTAAAAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 227) DOM-75 SEQ ID NO: 74 AvaI
E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F L Q
Y P M =
1 GAGGTGCP_GC TGTTGGAGTC TGGGGGAGGC TTGGTACAGC CTGGGGGGTC CCTGCGTCTC
TCCTGTGCAG CCTCGGGATT CACCTTTTTG
CAGTATCCGA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGCCCTAA GTGGAP.AAAC
GTCATAGGCT
= G W V R Q A P G K G L E W V S T I S P V G L T T Y Y A D S V
K G R =
TTGGTTTGAC TACATACTAC GCAGACTCCG
TGAAGGGCCG
ACCCAACCCi GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTTGA TAAAGP_GGPC AACCAAACTG
ATGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
K L F
TGCCGAGGAT ACCGCGGTAT ATTACTGTGC
GAAATTGTTT
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACP.TA GACGTTTACT TGTCGGACGC ACGGCTCCTA
TGGCGCCATP_ T_ZIATGACACG
CTTTAACAW?
E G S R I Q R D V G F D Y W G Q G T L V T V S S
ACCGTCTCGF. GC (SEQ ID NO: 228) CTCCCCAGCT CCTAAGTCGC ACTACACCCA AAACTGP_TGA CCCCAGTCCC TTGGGACCAG TGGCAGAGCT
CG (SEQ ID NO: 229) DOM-77 SEQ ID NO: 75 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F E E
Y G M =
CCTCCGGATT CACCTTTGAG 20 G.AGTATGGTA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTPA GTGGAAACTC
CTCP_TACCAT
= A W V R Q A P G K G L E W V S T I S P L G I S T Y Y A D S V
K G R =
101 TGGCGTGGGT CCGCCAGGCT CCAGGGAAGG GTCTAGAGTG GGTCTCAACT P_TTTCTCCGC
TGGGTATTTC GACATACTAC GCAGACTCCG
TGAAGGGCCG
ACCGCACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTTGA TAAAGAGGCG ACCCATAAAG
CTGTATGATG CGTCTGP_GGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
K H A
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
GAAACATGCT
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CTTTGTACGA
T S Q E S L R S F D Y W G Q G T L V T V S S
(SEQ ID NO: 230) TGCAGAGTCC TCAGAAACGC CAGAAAACTG ATGACCCCAG TCCCTTGGGA CCAGTGGCAG AGCTCG (SEQ
ID D10: 231) DOM-78 SEQ ID NO: 76 Y Q M =
CCTCCGGATT CACCTTTGAG
AGGTATCAGA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAP_ GTGGAAACTC
TCCATAGTCT
= A W V R Q A P G K G L E W V S T I S S D G G G T Y Y A D S V
K G R =
ATGGTGGGGG GACATACTAC GCAGACTCCG
TGAAGGGCCG
ACCGCACCCA GGCGGTCCGA GGCCCCTTCC CAGATCTCAC CCAGAGTTGC TAATCAAGAC TACCACCCCC
CTGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
K P G
201 GTTCACCATC TCCCGCGACF. ATTCCAAGAP_ CACGCTGTAT CTGCAAATGA ACAGCCTGCG
TGCCGAGCAC ACCGCGGTAT ATTACTGTGC
GAAACCTGGT
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CTTTGGACCA
CTGGTCACCG TCTCGAGC (SEQ ID NO: 232) GTAGCCAAAC TGP.TGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 233) DOM-80 SEQ ID NO: 77 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F G R
Y Q M =
CCTCCGGATT CACCTTTGGT
CGTTATCAGA
CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGAAACCA
GCAATAGTCT
= A W V R Q A P G K G L E W V S S I S S D G G G T Y Y P_ D 5 V
K G R =
ATGGTGGGGG GACATACTAC GCAGACTCCG
TGAAGGGCCG
ACCGAACCCA GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTAGA TAAAGAAGAC TACCACCCCC
CTGTATGA_TG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R A E D T R V Y Y C A
K P S
201 GTTCACCP.TC TCCCGCGACA ATTCCAAGAA CACGCTGTAT CTGCAAATGA ACAGCCTGCG
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
ACGGCTCCTG TGGCGCCATA TAATGACACG
CTTTGGCAGA
R R F D Y W G Q G T L V T V S S
301 CGTCGGTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 234) GCAGCCAAAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID NO: 235) DOM-81 SEQ ID NO: 78 E V Q L L E S G G G L V Q P G G F L R L S C A A S G F T F E L
Y P 11 =
CCTCCGGATT CACCTTTGAG
TTGTATCCGA
CTCCACGTCG ACAACCTCAG P_CCCCCTCCG AACCATGTCG GACCCCCCAA GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGAAACTC
AACP_TAGGCT
= P_ W V R Q A P G K G L E W V S S I S P V G F L T Y Y A D S V
K G R =
101 TGGCGTGGGT CCGCCAGGCT CCAGGGAAGG GTCTGGAGTG GGTCTCP_TCG ATTTCTCCGG
TTGGTTTTCT GACATACTAC GCAGACTCCG
TGAAGGGCCG
AACCAAAAGA CTGTPTGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A
K G H
2 n 201 GTTCACCP_TC TCCCGCGACA P_TTCCAAGAA CACGCTGTAT CTGCAAATGA ACAGCCTGCG
TGCCGAGGAT ACCGCGGTAT ATTACTGTGC
~f GAAAGGGCPT
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC PCGGCTCCTA
TGGCGCCATA TAATGACACG
CTTTCCCGTA
E G S Y T P R S A F D Y W G Q G T L V T V S S
GTCTCGAGC (SEQ ID NO: 236) CTCCCCAGCA TATGAGGCGC CAGCCGAAPA CTGATGACCC CAGTCCCTTG GGACCAGTGG CAGAGCTCG
(SEQ ID NO: 237) DOM-82 SEQ ID NO: 79 Y P M =
CCTCCGGATT CACCTTTGTG
GCGTATCCTA
AGGACACGTC GGAGGCCTAA GTGGAAACAC
CGCATAGGAT
= A W V R Q A P G K G L E W V S T I A P L G G N T Y Y A D S V
K G R =
TGGGTGGTAP_ TACATACTAC GCAGACTCCG
ACCGCACCCP GGCGGTCCGP_ GGTCCCTTCC CAGACCTCAC CCAGAGTTGA TAACGCGGAG ACCCACCATT
P_TGTATGP_TG CGTCTGAGGC
ACTTCCCGGC
= F T I S F. D 117 S K N T L Y L Q M N S L R A E D T A V Y Y C A.
K F. P
201 GTTCACCP_TC TCCCGCGACA ATTCCAAGAA CACGCTGTAT CTGCAFiATGA ACAGCCTGCG
TGCCGAGGAC ACCGCGGTAT PTTACTGTGC
GAAACGGCCG
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACPTA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCPTP TAPTGACACG
CTTTGCCGGC
GTCTCGAGC (SEQ ID NO: 238) CTCCCCGACG TCTAACTAAG AGTCTTAAP3. CTGATGACCC CAGTCCCTTG GGACCAGTGG CAGAGCTCG
(SEQ ID NO: 239 DOM-83 SEQ ID NO: 80 Y Q M =
1 GPGGTGCAGC TGTTGGAGTC TGGGGGAGGC TTGGTACAGC CTGGGGGGTC CCTGCGTCTC TCCTGTGCyG
CCTCCGGATT CACCTTTGCG
TTGTP_TCAG)l CTCCACGTCG ACAACCTCAG ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAP_ GTGGAP.ACGC
AACATAGTCT
= P W V R Q A P G K G L E W V S S I D 5 5 G S D T Y Y A D S V
K G R =
CTGGTAGTGA TACATACTAC GCAGACTCCG
TGAAGGGCCG
ACCGAACCCP GGCGGTCCGA GGTCCCTTCC CAGP_TCTCAC CCAGAGTAGC TAACTAkGAA GACCATCACT
PTGTATGATG CGTCTGAGGC
ACTTCCCGGC
= F T I S R D N S K N T L Y L Q M M S L R A E D T A V Y Y C A
K P E
.30 201 GTTCACCATC TCCCGCGACA ATTCCAAGAA CACGCTGTAT CTGCAAATGP ACAGCCTGCG
TGCCGAGGAC ACCGCGGTHT ATTACTGTGC
GAAACCTGAG
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TAATGACACG
CTTTGGACTC
301 CGTGATTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC (SEQ ID NO: 240) GCACTAAAAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID N0: 241) DOM-84 SEQ ID NO: 81 E V Q L L E S G G G L V Q P G G S L R L S C A P_ S G F T F R 0 Y Q 14 =
CCTCCGGATT CACCTTTAGG
CAGTACCAGA
CTCCACGTCG ACAACCTCP.G ACCCCCTCCG AACCATGTCG GACCCCCCAG GGACGCAGAG AGGACACGTC
GGAGGCCTAA GTGGAAP_TCC
GTCATGGTCT
= A W A R Q A P G K G L E W V S T I P_ 5 D G V S T Y Y A D 5 V
K G R =
ATGGTGTTTC TACP_TACTAC GCAGACTCCG
TGAAGGGCCG
ACCGAACCCG GGCGGTCCGA GGTCCCTTCC CAGATCTCAC CCAGAGTTGC TAACGCAGCC TACCACAAAG
ATGTATGATG CGTCTGAGGC
ACTTCCCGGC
. F T I S R D N 5 K N T L Y L Q M N 5 L R A E D T A V Y Y C A
K V G
TGCCGAGGAC ACCGCGGTAT ATTACTGTGC
G.WWGTTGGT
CAAGTGGTAG AGGGCGCTGT TAAGGTTCTT GTGCGACATA GACGTTTACT TGTCGGACGC ACGGCTCCTG
TGGCGCCATA TPATGACACG
CTTTCAACCA
R D F D Y W G Q G T L V T V S S
301 CGTGATTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC ISEQ ID 140: 242) GCACTAAAAC TGATGACCCC AGTCCCTTGG GACCAGTGGC AGAGCTCG (SEQ ID N0: 243) DOM-116 SEQ ID NO: 82 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q P I G P
D L L =
GGGCAAGTCA GCCTATTGGT
CCTGATTTAC
CTGTAGGTCT ACTGGGTCAG AGGTAGGAGG GACAGACGTA GACATCCTCT GGCACAGTGG TAGTGAACGG
CCCGTTCAGT CGGP_TAACCA
GGACTAAATG
. W Y Q Q K P G K A P K L L I Y Q T S I L Q S G V P S R F S G
S G 5 =
101 TGTGGTACCA GCAGAAACCP_ GGGAAAGCCC CTPAGCTCCT GATCTATCAG ACGTCCP_TTT
TGCAAAGTGG GGTCCCATCA CGTTTCAGTG
GCAGTGGATC
ACACCATGGT CGTCTTTGGT CCCTTTCGGG GATTCGAGGA CTAGATAGTC TGCAGGTAAA ACGTTTCACC
CCAGGGTAGT GCAAAGTCAC
CGTCACCTAG
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q Y W A F P V T
F G Q
CTGTCAACAG TATTGGGCTT TTCCTGTGAC
GTTCGGCCAA
ACCCTGTCTA AAGTGAGAGT GGTAGTCGTC AGACGTTGGA CTTCTAAAAC GATGCATGAT GACAGTTGTC
ATAACCCGAA AAGGACACTG
CAAGCCGGTT
G T R V E I E R
301 GGGACCAAGG TGGAAATCAA ACGG (SEQ IL NO: 244) CCCTGGTTCC ACCTTTAGTT TGCC (3EQ ID NO: 245)--SUBSTITUTE SHEET (RULE 26) DOM-85 - SEQ ID NO.: 246 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F E Q Y D M-CCTCCGGATT
J CACCTTTGAG CAGTATGATA
= R W V R Q A P G K G L E W V S W I D E A G H E T Y Y A D
S V K G R-CGGGTCATGA GACATACTAT
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S R N T L Y L Q M N S L R A E D T A V Y Y
C A K G M
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAAGGGATG
D G F D Y W G Q G T L V T V S S
301 GATGGGTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC - SEQ ID NO .: 3 61 DOM-86 - SEQ ID NO.: 247 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q D
I G D ALF
GGGCAAGTCA
GGATATTGGG GATGCTTTAT
= W Y Q Q K P G K A P K L L I Y Y S S M L Q 5 G V P S R F
S G G G S-TGC_AAAGTGG GGTCCCATCA
CGTTTCAGTG GCGGTGGATC
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q R H S T P
A T F G Q
CTGTCAACAG CGGCATAGTA
CTCCTGCTAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO .: 362 DOM-87 - SEQ ID NO.: 248 SUBSTITUTE SHEET (RULE 26) D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q D
I D E S L M-GGGCAAGTCA
GGATATTGAT GAGTCTTTAA
= W Y Q Q K P G K A P R L L I Y G V S Y L Q S G V P S R F
S G S G 8=
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q R W K A P
F T F G Q
CTGTCAACAG CGGTGGAAGG
CTCCTTTTAC GTTCGGCCAA
G T K V E I K R - SEQ ID NO.: 363 DOM-88 - SEQ ID NO.: 249 D I Q M T Q S P S S I. S A S V G D R V T I T C R A S Q E
I V E D L Y-GGGCAAGTCA
GGAGATTGTG GAGGATTTAT
= W Y Q Q K P G K A A K L L I Y G A S W L Q S G V P S R F
S G S G S
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
.. G T D F T L T I S S L Q P E D F A T Y Y C Q Q T R R R P
Y T F G Q
CTGTCAACAG ACGCGTAGGC
GTCCTTATAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO. : 364 DOM-89 - SEQ ID NO.: 250 D I Q M T Q S P A S L S A S V G D R V T I T C R A S Q D
I D P M L R
SUBSTITUTE SHEET (RULE 26) GGGCAAGTCA
GGATATTGAT CCTATGTTAk = W Y Q Q K P G K A P K L L I Y A G S I L Q S G V P S R F
S G S G S
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
G T D F T L T I S S L Q P E D F A T Y Y C Q Q T L V T P
Y T F G Q
CTGTCAACAG ACGCTGGTGA
CTCCTTATAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO. : 365 DOM-90 - SEQ ID NO.: 251 I S D A L F-GGGCAAGTCA
GTCGATTTCG GATGCGTTAT
= W Y Q Q K P G K A P R L L I Y Y G S V L Q S G V P S P. F
S G S G S=
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q R F Q E P
V T F G Q
201, TGGGACAGAT TTCACTCTCA CCATCAGCAG TCTGCAACCT GAAGATTTTG CTACGTACTA
CTGTCAACAG CGTTTTCAGG
AGCCTGTGAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO. : 366 DOM-91 - SEQ ID NO.: 252 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q Q
I S D E L N
SUBSTITUTE SHEET (RULE 26) I GACATCCAGA TGACCCAGTC TCCATCCTCC CTGTCCGCAT CTGTAGGAGA CCGTGTCACC ATCACTTGCC
GGGCAZIGTCA
GCAGATTAGT GATGAGTTAA
= W Y Q Q K P G K A P K L L I Y A V S I L Q S G V P S R F
S G S G S=
101 ATTGGTATCA GCAGAAACCA GGGAAAGCCC CTAkGCTCCT GATCTATGCT GTGTCCATTT
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I 5 S L Q P E D F A T Y Y C Q Q W L S F P
S T F G Q
CTGTCAACAG TGGTTGAGTT
TTCCTTCGAC GTTTGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO. :' 367 DOM-92 - SEQ ID NO.: 253 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F V D Y P M=
CCTCCGGATT CACCTTTGTT GATTATCCGA
= G W V R Q A P G K G L E W V S T I S T G G F S T Y Y A D
S V K G R-GGGGTTTTTC GACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K A R
201 GTTCACCATC TCCCGCGACA ATTCCAAGAA CACGCTGTAT CTGCAAP.TGA ACAGCCTGCG
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAAGCGCGG Y Y Y L S Q I K N F D Y W G Q G T L V T V S S
GTCTCGAGC - SEQ ID
NO.: 368 DOM-93 - SEQ ID NO.: 254 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F D I Y G M
SUBSTITUTE SHEET (RULE 26) CCTCCGGATT
CACCTTTGAT ATTTPTGGGP_ = T W V R Q A P G K G L E W V S S I S P L G L V T Y Y A D
P V K G R-TTGGTCTTGT TACATACTAC
GCAGACCCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y y C A K L K
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAACTGAAG
E H G D V P F D Y W G Q G T L V T V S S
NO .
DOM-94 - SEQ ID NO.: 255 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F E L Y P M-I GAGGTGCAGC TGTTGGAGTC TGGGGGAGGC TTGGTACAGC CTGGGGGGTC CCTGCGTCTC TCCTGTGCAG
CCTCCGGATT
CACCTTTGAG CTTTATCCGA
= S W V R Q A P G K G L E W V S T I S P T G L L T Y Y A D
S V K G R=
CGGGTTTGTT GACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K F K
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAATTTAAG
R S G K T D D T N F D Y W G Q G T L V T V S S
GTCTCGAGC - SEQ ID
NO.: 370 DOM-95 - SEQ ID NO.: 256 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F R E Y D M
SUBSTITUTE SHEET (RULE 26) CCTCCGGATT
CACCTTTCGG GAGTATGATA
= L W V R Q A P G K G L E W V S T I V G D G N G T Y Y A D
S V K G R-ATGGTAATGG TACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y I Q M N S L R A E D T A V Y Y
C A K Q D
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAACAGGAT
R Q F D Y W G Q G T L V T V S S
301 CGTCAGTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC - SEQ ID NO, 371 DOM-96 - SEQ ID NO.: 257 E V Q P L E S G G G L V Q P G G S L R L S C A A S G F T
F T D Y K M-CCTCCGGATT
CACCTTTACT GATTATAAGA
= L W V R Q A P G K G L E W V S S I S P S G R W T Y Y A D
S V K G R=
GTGGTCGTTG GACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K S L
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAAAGTCTT
F E G S F D Y W G Q G T L V T V S S
301 TTTGAGGGTA GTTTTGACTA CTGGGGTCAG GGAACCCTGG TCACCGTCTC GAGC - SEQ ID NO .:
DOM-97 - SEQ ID NO.: 258 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F E E Y G M
SUBSTITUTE SHEET (RULE 26) I GAGGTGCAGC TGTTGGAGTC TGGGGGAGGC TTGGTACAGC CTGGGGGGTC CCTGCGTCTC TCCTGTGCAG
CCTCCGGATT
CACCTTTGAG GAGTATGGTA
= S W V R Q A P G K G L E W V S T I S P I G V T T Y Y A D
S V K G R-TTGGTGTTAC TACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T P. V Y Y
C A K N A
TGCCGAGGAT ACCGCGGTAT
Y D R K S N F D Y W G Q G T L V T V S S
NO .
DOM-98 - SEQ ID NO.: 259 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F D R Y V M-CCTCCGGATT
CACCTTTGAT CGGTATGTGA
= V W V R Q A P G K D L E W V S G I T P S G R R T Y Y A D
S V K G R
GTGGTAGGAG GACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K D T L Y L Q M N S L R A E D T A V Y y C A K V L
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAAGTGTTG
G R H F D P L L P S F D Y W G Q G T L V T V S S
ACCGTCTCGA GC - SEQ
ID NO.: 374 DOM-99 - SEQ ID NO.: 260 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F E D Y A M
SUBSTITUTE SHEET (RULE 26) CCTCCGG?1TT
CACCTTTGAG GATTATGCTA
= 5 W V R Q A P G K G L E W V S T I T P G G F W T Y Y A D
S V K G R-GTGGTTTTTG GACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K T S
TGCCGAGGAT ACCGCGGTAT
ATTACTGTGC GAAAACGTCT
S G E L Q L V E D F D Y W G Q G T L V T V S S
GTCTCGAGC - SEQ ID
NO.: 375 DOM-100 - SEQ ID NO.: 261 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q N
I K H S L R=
GAGCAAGTCA
GAATATTAAG CATTCGTTAC
= W Y Q Q K P G K A P R L L I Y H R S Q L Q S G V P S R F
S G S G S=
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q V R H R P
Y T F G Q
CTGTCAACAG GTTAGGCATC
GTCCTTATAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO.: 376 DOM-101 - SEQ ID NO.: 262 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q A
I G H R L R
SUBSTITUTE SHEET (RULE 26) GGGCAAGTCA
GGCTATTGGG CATCGGTTAC
W Y Q Q K P G K A P K L L I Y H R S K L Q S G V P S R F
S G S G S-TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I 5 S L Q P E D F A T Y Y C Q Q V A L F p Y T F G Q
CTGTCAACAG GTTGCTTTGT
TTCCCTATAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO .: 377 DOM-102 - SEQ ID NO.: 263 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q H
I G H H L R
GGGCAAGTCA
GCATATTGGT CATCATTTAA
= W Y Q Q K P G K A P K L L I Y H R S H L Q S G V P S R F
S G S G S=
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S S L Q P E D S A T Y Y C Q Q W D R P P
Y T F G Q
CTGTCAACAG TGGGATAGGC
CGCCTTATAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG -.S'EQ ID NO .: 378 DOM-103 - SEQ ID NO.: 264 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q A
I G H R L R=
SUBSTITUTE SHEET (RULE 26) GGGC_z1~iGTCA
GGCTATTGGG CATCGGTTAC
= W Y Q Q K P G H A P K L L I Y H R S K L Q S G V P S R P
S G S G S
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q V R A V P
Y T F G Q
CTGTCAACAG GTGCGGGCTG
TGCCTTATAC GTTTGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATTAA ACGG - SEQ ID NO .: 379 DOM-104 - SEQ ID NO.: 265 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q A
I G H R L R-I GACATCCAGA TGACCCAGTC TCCATCCTCC CTGTCTGCAT CTGTAGGAGA CCGTGTCACC ATCACTTGCC
GGGCAAGTCA
GGCTATTGGG CATCGGTTAC
= W Y Q Q K P G K A P K L L I Y H R S K L Q S G V P S R F
S G S G S=
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q V R F S P
Y T F G Q
CTGTCAACAG GTTCGTTTTT
CTCCTTATAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO.: 380 DOM-105 - SEQ ID NO.: 266 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q A
I G H R L R=
SUBSTITUTE SHEET (RULE 26) 1 GACATCCAGR_ TGACCCAGTC TCCATCCTCC CTGTCTGCAT CTGTAGGAGA CCGTGTCACC
ATCACTTGCC GGGCAZIGTCA
GGCTATTGGG CATCGGTTAC
S G S G S-TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S 5 L Q P E D F A T Y Y C Q Q S Y A R P
V T F G Q
CTGTCAACAG TCTTATGCTA
GGCCTGTGAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO. : 381 DOM-106 - SEQ ID NO.: 267 I N H R L Y-GGGCAAGTCA
AAGTATTAAT CATAGGTTAT
= W Y Q Q K P G K A P K L L I Y H R 6 R L Q S G V P S R F
S G S G S=
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC = G T D F T L T I S S L Q P E D F A T Y Y C Q Q Y K. V R
P
N T F G Q
201 TGGGACAGAT TTCACTCTCA CCATCAGCAG TCTGCAACCT G_AGGATTTTG CTACGTACTA
CTGTCAACAG TATAAGGTTA
GGCCTAATAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG SEQ ID NO.: 382 DOM-107 - SEQ ID NO.: 268 I G H R I, R
SUBSTITUTE SHEET (RULE 26) GGGC_AAGTCA
_ GGGTATTGGG_.CATCGG TTAC_.
= N] Y Q Q K P G K A P K L L I Y H R S K L Q S G V P S R F
S G S G S-TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q T Y S S P
H T F G Q
CTGTCAACAG ACTTATTCGT
CTCCTCATAC GTTCGGCCAA
G T K V E I-K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO .: 383 DOM-108 - SEQ ID NO.: 269 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q A
I G H R L R-GGGCAAGTCA
GGCTATTGGG CATCGGTTAC
= W Y Q Q K P G K A P K L L I Y H R S K L Q S G V P S R F
S G S G S=
TGCAA.i1GTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
G T D F T L T I S S L Q P E D F A T Y Y C Q Q R A V R P
F T F G Q
CTGTCAACAG AGGGCGGTGA
GGCCTTTTAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAAG TGGAAATCAA ACGG - SEQ ID NO .: 384 DOM-109 - SEQ ID NO.: 270 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q A
I G H R L R
SUBSTITUTE SHEET (RULE 26) ATCACTTGCC GGGCAAGTCA
GGCTATTGGG CATCGGTTAC
= W Y Q Q K P G K A P K L L I Y H R S K L Q 5 G V P S R F
S G S G S=
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q T Y Y R P
L T F G Q
CTGTCAACAG ACTTATTATC
GTCCTCTTAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO .: 385 DOM-110 - SEQ ID NO.: 271 I D P M L R-GGGC_AAGTCA
GGATATTGAT CCTATGTTAA
= W Y Q Q K P G K A P K L L I Y A G S I L Q S G V P S R F
S G S G S-TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
~1 G T D F T L T I 5 5 L Q P E D F A T Y Y C Q Q T S I R P
201 TGGGACAGAT TTCACTCTCA CCATCAGCAG TCTGCAACCT GAAG_ATTTTG CTACGTACTA
CTGTCAACAG ACTAGTATTA
GGCCTTATAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO. : 386 DOMB-111 - SEQ ID NO.: 272 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F E R Y P M
SUBSTITUTE SHEET (RULE 26) CCTCCGGATT
CACCTTTGAG CGTTATCCTA
= T W V R Q A P G K G L E W V S T I H G S G S A T Y Y A D
S V K G R-CTGGTAGTGC TACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K G P
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAAGGGCCG
Y T S R H N S L G H F D Y W G Q G T L V T V S S
ACCGTCTCGA GC - SEQ
ID NO.: 387 DOM-112 - SEQ ID NO.: 273 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F M D Y P M-CCTCCGGATT
CACCTTTATG GATTATCCTA
= G W V R Q A P G K G L E W V S S I G P V G M S T Y Y A D
S V K G R-TTGGTATGAG TACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y y C A K Y G
TGCCGAGGAT ACCGCGGTAT
ATTACTGTGC GAAATATGGG .
G T S G R H N T K F D Y W G Q G T L V T V S S
GTCTCGAGC - SEQ ID
NO.: 388 DOM-113 - SEQ ID NO.: 274 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F T E Y P M
SUBSTITUTE SHEET (RULE 26) CCTCCGGATT
CACCTTTACT G?1GTATCCTA
= S W V R Q A P G K G L E Td V S V I S P L G F T T Y Y A D
S V K G R=
TTGGTTTTAC GACATACTAC
GCAGACTCCG TGAAGGGCCG = F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y
Y
C A K W T
TGCCGAGGAT ACCGCGGTAT
ATTACTGTGC GAAATGGACT
G G S G I L N S S F D Y W G Q G T L V T V S S
GTCTCGAGC - SEQ ID
NO.: 389 DOM-114 - SEQ ID NO.: 275 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F R
V S N Y D L-CCTCCGGATT
TAGGGTTAGC AATTACGATT
= T W V R Q A P G K G L E W V S T I S A T N G S T Y Y A D
S V K G R
CAAACGGTAG CACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A A V T
TGCCGAGGAC ACCGCGGTAT
ATTATTGCGC GGCAGTGACG
W W L L R H N D N L G F W G Q G T L V T V S S
GTCTCGAGC - SEQ ID
NO.: 390 DOM-115 - SEQ ID NO.: 276 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F S
I S Y K N M
SUBSTITUTE SHEET (RULE 26) CCTCCGGATT
TAGCATTAGC TATAAGAATA
= A W V R Q A P G K G L E W V S A I K A A N G S T Y Y A D
S V K G R-CAAACGGTAG CACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A T G S
TGCCGAGGAC ACCGCGGTAT
ATTATTGCGC GACAGGGAGT
Q K K R T Y T F D F W G Q G T L V T V S S
SEQ ID NO.
DOM-120 - SEQ ID NO.: 277 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F R S Y T M=
CCTCCGGATT
CACCTTTAGG TCTTATACGA =
= G W V R Q A P G K G L E W V S S I N P M G Y Q T Y Y A D
S V K G R=
TGGGTTATCA GACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y y C A K H G
TGCCGAGGAT ACCGCGGTAT
ATTACTGTGC GAAACATGGG
V G K G T K P H N F D Y W G Q G T L V T V S S
GTCTCGAGC - SEQ ID
NO.: 392 DOM-121 - SEQ ID NO.: 278 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F E L Y R M
SUBSTITUTE SHEET (RULE 26) CCTCCGGATT
CACCTTTGAG CTGTATAGGA
= S W V R Q A P G K G L E W V S E I S G S G F P T Y Y A D
S V K G R=
GTGGTTTTCC TACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K S L
201 GTTCACCATC TCCCGCGACA ATTCCAAG_AA CACGCTGTAT CTGCAAATGA ACAGCCTGCG
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAAAGTCTG
H D K T Q H H Q E F D Y W G Q G T L V T V S S
GTCTCGAGC - SEQ ID
NO.: 393 DOM-123 - SEQ ID NO.: 279 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F I E Y P M=
CCTCCGGATT
CACCTTTATT GAGTATCCTA
= R W V R Q A P G K G L E W V S L I S P S G V F T Y Y A D
5 V K G R= 101 TGCGGTGGGT CCGCCAGGCT CCAGGGAAGG GTCTAGAGTG GGTCTCACTT
ATTTCTCCGT CTGGTGTGTT TACATACTAC GCAGACTCCG TGAAGGGCCG
F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y y C A K G D
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAAGGGGAT
E S S T F D Y W G Q G T L V T V S S
~ O 301 GAGTCTAGTA CTTTTGACTA CTGGGGTCAG GGAACCCTGG TCACCGTCTC GAGC - SEQ ID
NO .: 394 DOM-124 - SEQ ID NO.: 280 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F K R Y D M
SUBSTITUTE SHEET (RULE 26) CCTCCGGATT
CACCTTTAAG CGGTATGATA
. 'D W V R Q A P G K G L E W V S T I G S S G Y P T Y Y A D
S V K G R-CGGGTTATCC GACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A E R M
yI~ 201 GTTCACCATC TCCCGCGACA ATTCCAAGAA CACGCTGTAT CTGCAAATGA ACAGCCTGCG
TGCCGAGGAC ACCGCGGTAT
P G Y F P G F A R Q F D Y W G Q G T L V T V S S
301 CCTGGTTATT TTCCTGGGTT TGCTCGGCAG TTTGACTACT GGGGTCAGGG AkCCCTGGTC
ACCGTCTCGA GC - SEQ
ID NO.: 395 DOM-125 - SEQ ID NO.: 281 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F W R Y A M=
CCTCCGGATT
CACCTTTTGG CGGTATGCTA
G WVRQA P G K G L E W V S T I N D E G R E T Y Y A D
S V K G R
AGGGTCGGGA GACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K K R
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAAAAGCGG
V S S S V N A P Y E F D Y W G Q G T L V T V S S
ACCGTCTCGA GC - SEQ
ID NO.: 396 DOM-126 - SEQ ID NO.: 282 F A N Y S M
SUBSTITUTE SHEET (RULE 26) CCTCCGGATT
CACCTTTGCG AATTATAGTA
= S W V R Q P_ P G K G L E W V S S = D R L G T H T Y Y A D
S V K G R-TTGGTACGCA TACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K V L
=~ 201 GTTCACCATC TCCCGCGACA ATTCCAAGAA TACGCTGTAT CTGCAAATGA ACAGCCTGCG
TGCCGAGGAT ACCGCGGTAT
ATTACTGTGC GAAAGTGCTG
A D L I A G H A E F D Y W G Q G T L V T V S S
GTCTCGAGC - SEQ ID
NO.: 397 DOM-127 - SEQ ID NO.: 283 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F P S Y D M
CCTCCGGATT
CACCTTTCCG TCGTATGATA
= A W V R Q A P G K G L E W V S G I S R S G S M T Y Y A D
S V K G R-CTGGTTCTAT GACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K G V
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAAGGTGTT
D A H V Y Y M E P F F D Y W G Q G T L V T V S S
ACCGTCTCGA GC - SEQ
ID NO.: 398 DOM-128 - SEQ ID NO.: 284 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F E R Y Q M=
SUBSTITUTE SHEET (RULE 26) CCTCCGGATT
CACCTTTGAG AGGTATCAGA
= A W V R Q A P G K G L E W V S T I S S D G G G T Y Y A D
S V K G R-ATGGTGGGGG GACATACTAC
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K P G
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAACCGGGT
T V F D Y W G Q G T L V T V S S
301 ACTGTTTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC - SEQ ID NO .: 399 DOM-129 - SEQ ID NO.: 285 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F P K Y E M-CCTCCGGATT
CACATTTCCG AAGTATGAGA
= A W V R Q A P G K G L E W V S S I D G D G K S T Y Y A D
S V K G R-ATGGTAAGTC TACATACTAC
GCAGACTCCG TGAAGGGCCG
F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K P D
TGCCGAGGAT ACCGCGGTAT
ATTACTGTGC GAAACCGGAT
Q F F D Y W G Q G T L V T V S S
301 CAGTTTTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC - SEQ ID NO .: 400 DOM-130 - SEQ ID NO.: 286 E V Q L L E S G G G L V Q P G G S L R L S C T A S G F T
F A G Y Q M=
SUBSTITUTE SHEET (RULE 26) CCTCCGGATT
CACCTTTGCG GGTTATCAGA
= S W V R Q A P G K G L E W V S S I T N E G V S T Y Y A D
S V K G R-AGGGTGTTTC TACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K P G
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAACCGGGG
301 AAGTATTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC - SEQ ID NO.: 401 DOM-131 - SEQ ID NO.: 287 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F G E Y E M
CCTCCGGATT
CACCTTTGGG GAGTATGAGA
= V W V R Q A P G K G L E W V S S I T 5 D G L 5 T Y Y A D
S V K G R-ATGGTCTGAG TACATACTAC
GCAGACTCCG TGAAGGGCCG
C A K P G
TGCTGAGGAC ACCGCGGTAT
ATTACTGTGC GAAACCGGGT
I R F D Y W G Q G T L V T V S S
301 ATTCGTTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC - SEQ ID NO .: 402 DOM-132 - SEQ ID NO.: 288 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F A D Y D M
SUBSTITUTE SHEET (RULE 26) CCTCCGGATT
CACCTTTGCT GATTATGATA
= A W V R Q A P G K G L E W V S G I V D D G L M T Y Y A D
S V K G R-ATGGTCTTAT GACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K P D
201 GTTCACCATC TCCCGCGACA ATTCCAAGAP_ CACGCTGTAT CTGCAAATGA ACAGCCTGCG
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAACCGGAT
V A F D Y W G Q G T L V T V S N
301 GTTGCTTTTG ACTACTGGGG TCAGGGGACC CTGGTCACCG TCTCGAAC - SEQ ID NO .: 403 DOM-133 - SEQ ID NO.: 289 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F I G Y A M-CCTCCGGATT
CACCTTTATT GGTTATGCTA
= A W V R Q A P G K G L E W V S S I G P L G A T T Y Y A D
S V K G R-TGGGTGCGAC TACATACTAC
GCAGACTCCG TGAAGGGCCG
h = F T I S R D N S K N T L Y L Q M N S L P. A E D T A V Y Y
E,5 C A K L P
201 GTTCACCATC TCCCGCGACA ATTCCAAG_AA CACGCTGTAT CTGCAAATGA ACAGCCTGCG
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAATTGCCT
A G T S S H S V D F D Y W G Q G T L V T V S S
GTCTCGAGC - SEQ ID
NO. : 404 DOM-134 - SEQ ID NO.: 290 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F A D Y E M
SUBSTITUTE SHEET (RULE 26) CCTCCGGATT
CACCTTTGCG GATTATGAGA
= T W V R Q A P G K G L E W V S S I T S D G V S T Y Y A D
S V K G R-ATGGTGTTTC TACATACTAC
GCAGACTCCG TGAAGGGCCG
F T I S R D N S K N T I. Y L Q M N S L R A E D T A V Y y C A K P S
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAACCGTCG
V Q F D Y W G Q G T L V T V S S
301 GTTCAGTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC - SEQ ID NO . 405 DOM-135 - SEQ ID NO.: 291 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F R R Y V M=
CCTCCGGATT
CACCTTTCGT AGGTATGTTA
= G W V R Q A P G K G L E W V S W I E A D G R T T Y Y A D
S V K G R=
101 TGGGGTGGGT CCGCC_AGGCT CCAGGGAAGG GTCTAGAGTG GGTCTCATGG ATTGAGGCTG
ATGGTCGTAC GACATACTAC
GCAGACTCCG TG_AAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K G L
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAAGGGCTT
SEQ ID NO .
DOM-136 - SEQ ID NO.: 292 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F D G Y R M=
SUBSTITUTE SHEET (RULE 26) CCTCCGGATT
CACCTTTGAT GGTTATCGTA
G W V R Q A P G K G L E W V S S I A P D G N Y T Y Y A D
S V K G R
101 TGGGGTGGGT CCGCCAGGCT CCAGGGAAGG GTCTAGAGTG GGTCTCP_TCG ATTGCTCCGG
P_TGGTAATTA TACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K F W
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAATTTTGG
G M Q F D Y W G Q G T L V T V S S
301 GGGATGCAGT TTGACTACTG GGGTCAGGGA ACCCTGGTCA CCGTCTCGAG C - SEQ ID NO.: 407 DOM-137 - SEQ ID NO.: 293 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F A S Y P M-CCTCCGGATT
CACCTTTGCT TCGTATCCGA
G W V R Q A P G K G L E W V S S I G P I G F T T Y Y A D
S V K G R=
TTGGTTTTAC TACATACTAC
GCAGACTCCG TGAfiGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A E M K
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GGAAATGAAG
S P Y K P Q F D Y W G Q G T L V T V S S
NO .
DOM-138 - SEQ ID NO.: 294 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F L A Y W M
SUBSTITUTE SHEET (RULE 26) CCTCCGGATT
CACCTTTTTG GCTTATTGGA
= V W V R Q A P G K G L E W V S S I S P S G T H T Y Y A D
S V K G R-CGGGTACGCA TACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D 14 S K N T L Y L Q M N S L R V E D T A V Y Y
C A K Y T
1 201 GTTCACCATC TCCCGCGACA ATTCCAAGAA CACGCTGTAT CTGCAA.ATGA ACAGCCTGCG
TGTCGAGGAC ACCGCGGTAT
1~ ATTACTGTGC GAAATATACT
E P G L G S F D Y W G Q G T L V T V S S
NO .:
DOM-139 - SEQ ID NO.: 295 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F S N Y E M-CCTCCGGATT
CACCTTTTCG AATTATGAGA
= G W V R Q A P G K G L E W V S V I S E V G S L T Y Y A D
S V K G R-TGGGTTCTCT GACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y y C A K P H
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAACCTCAT
.
DOM-141 - SEQ ID NO.: 296 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q W
I G D T L T
SUBSTITUTE SHEET (RULE 26) GGGCAAGTCA
GTGGATTGGG GATACGTTAA
= A' Y Q Q K L G K A P K L L I Y G G S E L Q S G V P P R F
S G S G S=
TGCAAAGTGG GGTCCCACCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S 5 L Q P E D F A T Y Y C Q Q C I S S P
C T F G Q
CTGTCAACAG TGTATTAGTA
GTCCTTGTAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO .: 411 DOM-142 - SEQ ID NO.: 297 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q F
I G D S L S=
GGGCAAGTCA
GTTTATTGGT GATTCTTTAT
= W Y Q Q % P G K A P K L L I Y F S S I L Q S G V P S R F
S G S G S=
101 CTTGGTACCA GCAG_AAACCA GGGAAAGCCC CTAAGCTCCT GATCTATTTT TCTTCCATTT
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S 8 L Q P E D F A T Y Y C Q Q Y H T S P
T T F G R
CTGTCAACAG TATCATACTT
CGCCTACTAC GTTCGGCCGA
G T K V K. I K R
301 GGGACCAAGG TGAAAATCAA ACGG - SEQ ID NO .: 412 DOM-143 - SEQ ID NO.: 298 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q T
I E T N L E
SUBSTITUTE SHEET (RULE 26) GGGCAAGTCA
GACTATTGAG ACTAATTTAG
= W Y Q Q K P G K A P K L L I Y D S S Q L Q S G V P S R F
S G S G S=
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S S L Q P E D L A T Y Y C Q Q YHGYP
T T F G Q
CTGTCAACAG TATCATGGGT
ATCCTACGAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO .: 413 DOM-144 - SEQ ID NO.: 299 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q M
I D Q D L E-GGGCAAGTCA
GATGATTGAT CAGGATTTAG
= W Y Q Q K P G K A P K L L I Y N A S W L Q S G V P S R F
S G S G S-TGCAAAGTGG GGTCCCATCA
CGTTTCAGCG GCAGTGGATC
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q Y H G Y P
I T F G Q
CTGTCAACAG TATCATGGTT
ATCCTATTAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO. : 414 DOM-145 - SEQ ID NO.: 300 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q T
SUBSTITUTE SHEET (RULE 26) GGGCAAGTCA
GACGATTTP_T ACTTCGTTAA
= W Y Q Q K P G K A P K L L I H Y G S V L Q S G V P S R F
S G S G S-TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S S L Q P E D S A T Y Y C Q Q V H Q A P
T T F G Q
CTGTCAACAG GTTCATCAGG
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO. : 4Zr'J
DOM-146 - SEQ ID NO.: 301 D I R M T Q S P S S L S A S V G D R V T I T C R A S Q W
I G D S L A-GTGGATTGGG GATTCTTTAG
= W Y Q Q K P G K A P K L L I Y G I S E L Q S G V P S R F
S G S G S-TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
C = G T D F T L T I S S L Q P E D S A T Y Y C Q L S S 5 M P
H T F G Q
CTGTCAACTG TCTAGTAGTA
TGCCTCATAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO .: 416 DOM-147 - SEQ ID NO.: 302 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q E
I E T N L E=
SUBSTITUTE SHEET (RULE 26) 1 GACATCCAGA TGACCCAGTC TCCP_TCCTCC CTGTCTGCAT CTGTAGGAGA CCGTGTCACC
ATCACTTGCC GGGCAAGTCA
GGAGATTGAG ACGAATTTAG
= W Y Q Q K P G K A P K L L I Y D S S H L Q S G V P S R F
G S G S=
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q Y H Q N P
P T F G Q
y 201 TGGGACAGAT TTCACTCTCA CCATCAGCAG TCTGCAMCT GAAGATTTTG CTACGTACTA
CTGTC_AACAG TATCATCAGA
ATCCTCCGAC GTTCGGCCAA
G T K V E I K R
301 GGAACCAAGG TGGAAATCAA ACGG - SEQ ID NO .: 417 DOM-149 - SEQ ID NO.: 303 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q W
I G R Q L V=
GGGCAAGTCA
GTGGATTGGG AGGCAGTTAG
= W Y Q Q K P G K A P K L L I Y G A T E L Q S G V P S R F
S G S G S=
TGCAAAGTGG GGTCCCATCA
CGTTTTAGTG GCAGTGGATC
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q Q S K G P
L T F G H
CTGTCAACAG CAGTCGAAGG
GTCCTCTTAC GTTCGGCCAT
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO .: 418 DOM-150 - SEQ ID NO.: 304 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q G
I G T D L N
SUBSTITUTE SHEET (RULE 26) ' 1 GACATCCAGA TGACCCAGTC TCCATCCTCC CTGTCTGCAT CTGTAGGAGA CCGTGTCACC
ATCACTTGCC GGGCAAGTCA
GGGGATTGGT ACTGATTTAA
= W Y Q Q K P G K A P K L L I Y M G S Y L Q S G V P S R F
S G S G S=
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q I Y S F p I T F G Q
CTGTCAACAG ATTTATTCTT
TTCCTATTAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO .: 419 DOM-154 - SEQ ID NO.: 305 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q D
I E E M L H-GGGCAAGTCA
GGATATTGAG GAGATGTTAC
= W Y Q Q K P G K A P K L L I Y F G S L L Q S G V P S R F
S G S R S-TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTAGATC
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q H H T R P
Y T F G Q
CTGTCAACAG CATCATACTC
GTCCTTATAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO. : 420 DOM-155 - SEQ ID NO.: 306 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q D
I G M D L E
SUBSTITUTE SHEET (RULE 26) GGGCAAGTCA
GGATP_TTGGG ATGGATTTAG
= W Y Q Q I P G K V P K L L I Y D A S Y L Q S G V P S R F
S G S G S
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T T S S L Q P E D F A T Y Y C Q Q Y H K L P
A T F G Q
CTGTCAACAG TATCATAAGC
TTCCTGCGAC GTTTGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO .: 421 DOM-156 - SEQ ID NO.: 307 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q D
I M D N L E=
GGGCAAGTCA
GGATATTATG GATAATTTAG
= W Y Q Q K P G K A P K L L I Y A A S W L Q S G V P S R F
S G S G S=
TGCAATkGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q Y H K L P
V T F G Q
CTGTCAACAG TATCATAAGT
TGCCTGTGAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO .: 422 DOM-157 - SEQ ID NO.: 308 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q N
I G E D L E=
SUBSTITUTE SHEET (RULE 26) GAGCAAGTCA
GAATATTGGG GAGGATTTAG
= W Y Q Q K P G N A p K L L I Y S A S H L Q S G V P S R F
S G S G S=
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q Y 5 S Y P
V T F G Q
CTGTCAACAG TATTCTAGTT
ATCCTGTTAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO .: 423 DOM-158 - SEQ ID NO.: 309 I D E D L E-GGGCAAGTCA
GCCGATTGAT GAGGATTTAG
= W Y Q Q K P G N A P K L L I Y 5 A S Y L Q S G V P S R F
S G SGS =
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S R L Q P E D F A T Y Y C Q Q Y H L L P25 A T F G Q
CTGTCAACAG TATCATCTTC
TGCCTGCTAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO. : 424 DOM-159 - SEQ ID NO.: 310 I N E D L E
SUBSTITUTE SHEET (RULE 26) GGGCPAGTCA
GGATATTAAT GAGGATTTAG
= W Y Q Q K P G K A P K L L I Y N A S M L Q S G V P S R F
S G S G S-101 AGTGGTATCA GCAGAAACCA GGGAAAGCCC CTAAGCTCCT GATCTATAAT GCTTCCP.TGT
TGCAAAGCGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S S ,L Q P K D F A T Y Y C Q Q Y H T N P
T T F G Q
CTGTCAACAG TATCATACTA
ATCCTACTAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO.: 425 DOM-160 - SEQ ID NO.: 311 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q D
I E A D L E-GGGCAAGTCA
GGATATTGAG GCGGATTTAG
. W Y Q Q K P G K A P K L L I Y H S S E L Q S G V P S R F
S G S G S=
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GAAGTGGATC
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q Y H M S P
V T F G Q
CTGTCAACAG TATCATATGT
CGCCTGTGAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO.: 426 DOM-161 - SEQ ID NO.: 312 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q D
I D SDLE
SUBSTITUTE SHEET (RULE 26) 1 GACATCCAGP. TGACCCAGTC TCCATCCTCC CTGTCTGCAT CTGTAGGAGA CCGTGTCACC
ATCACTTGCC GGGCAAGTCA
GGATATTGAT AGTGATTTAG
= W Y Q Q K P G Y. A P M L L I Y S S S D L Q 5 G V P S R F
S G S G S-101 AGTGGTACCA GCAGAAACCA GGGAAAGCCC CTATGCTCCT GATCTP_TTCT TCGTCCGATT
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC =
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q Y H S L P
V T F G Q
CTGTCAACAG TATCATAGTC
TGCCTGTTAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO. : 427 DOM-162 - SEQ ID NO.: 313 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q D
I S D D L E=
GGGCAAGTCA
GGATATTTCG GATGATTTAG
= W Y Q Q K P G K A P K L L I Y N S S F L Q S G V P S R F
S G S G S=
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
G A D F T L T I S S L Q P E D F A T Y Y C Q Q Y H S L P
V T F G Q
CTGTCAACAG TATCATAGTT
TGCCTGTTAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO. : 428 DOM-163 - SEQ ID NO.: 314 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q D
I E G N L E
SUBSTITUTE SHEET (RULE 26) I GP.CATCCAGE TGACCCAGTC TCCATCCTCC CTGTCTGCAT CTGTAGGAGA CCGTGTCACC
ATCACTTGCC GGGCAAGTCA
GGP_TATTGAG GGTAATTTAG
= W Y Q Q K P G K A P K L L I Y D S S Q L Q S G V P S R F
S G S G S-J 101 AGTGGTACCA GCAGAAACCA GGGAAAGCCC CT_AAGCTCCT GATCTATGAT TCGTCCCAGT
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGGTC
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q Y H H L P
T T F G Q
CTGTCAACAG TATCATCATC
TTCCTACGAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO .: 429 DOM-164 - SEQ ID NO.: 315 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q S
I D T D L E-GGGCAAGTCA
GAGTATTGAT ACGGATTTAG
= W Y Q Q K P G K A P K L L I Y D G S W L Q S G V P S R F
S G S G S
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D_ F T L T I S S L Q P E D F A T Y Y C Q Q Y R W I P
V T F G Q
CTGTCAACAG TATCGGTGGA
TTCCTGTTAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO. : 430 DOM-165 - SEQ ID NO.: 316 I S T D L E
SUBSTITUTE SHEET (RULE 26) GGGCAAGTCA
GAGTATTAGT ACTGATTTAG
= W Y Q Q K L G K A P K L L I Y D A S L L Q S G V P S R F
S G S G S-TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I 5 5 L Q P E D F A T Y Y C Q Q Y S S L P
V T F G Q
CTGTCAACAG TATTCGAGTC
TGCCTGTTAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO. : 431 DOM-166 - SEQ ID NO.: 317 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q P
I T T S L E-GGGCAAGTCA
GCCTATTACG ACGTCTTTAG
= W Y Q Q K P G K A P K L L I Y D A S M L Q S G V P S R F
S G S G S
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q Y W V T P
V T F G Q
CTGTCAACAG TATTGGGTTA
CGCCTGTTAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGABATCAA ACGG - SEQ ID NO .: 432 DOM-167 - SEQ ID NO.: 318 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q N
I H T N L E
SUBSTITUTE SHEET (RULE 26) GGGCTIAGTCA
GAATATTCAT ACGAATTTAG
= W Y Q Q K P G K A P K L L I Y D G S M L Q S G V P S R F
S G S G S=
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S 5 L Q P E D F A T Y Y C Q Q Y S A N P
V T F G Q
CTGTCAACAG TATTCGGCTA
ATCCTGTTAC GTTCGGCCAA
G T K V G I K R
301 GGGACCAAGG TGGGAATCAA ACGG - SEQ ID NO. : 433 DOM-168 - SEQ ID NO.: 319 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q W
I H T D L E-GGGCAAGTCA
GTGGATTCAT ACGGATTTAG 20 = W Y Q Q K P G K A P K L L I Y D G S M L Q S G V P S
R F
S G S G S=
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q Y S V S P
V T F G Q
CTGTCAACAG TATAGTGTGT
CGCCTGTTAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO. : 434 DOM-169 - SEQ ID NO.: 320 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q S
I D N N L E
SUBSTITUTE SHEET (RULE 26) GGGCAAGTCA
GAGTATTGAT AATAATTTAG
= W Y Q Q K P G E P_ P K L L I Y D G S L L Q S G V P S R F
S G S G 5=
TGCAzIAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q Y H L H P
V T F G Q
CTGTCAACAG TATCATCTTC
ATCCTGTTAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO. : 435 DOM-170 - SEQ ID NO.: 321 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q D
I D T N L E
GGGCAAGTCA
GGATATTGAT ACGAATTTAG
= W Y Q Q K P G E A P K L L I Y D R S T L Q S G V P S R F
S G S G S
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q Y D S Y P
V T F G Q
CTGTCAACAG TATGATTCTT
ATCCTGTGAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO. : 436 DOM-171 - SEQ ID NO.: 322 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q S
I E S N L E=
SUBSTITUTE SHEET (RULE 26) 1 GACATCCAGA TGACCCAGTC TCCATCCTCC CTGTCTGCAT CTGTAGGAG_A CCGTGTCACC
ATCACTTGCC GGGCARGTCA
GTCTATTGAG TCTAATTTAG
= W Y Q Q K P G K A P K L L I Y N A S E L Q S G V P S R F
S G S G S-TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S S L R P E D F A T Y Y C Q Q Y D Q W P
T T F G Q
CTGTCAACAG TATGATCAGT
GGCCTACGAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO. : 437 DOM-172 - SEQ ID NO.: 323 I G N T L R-GGGCAAGTCA
GGCTATTGGT AATACTTTAC
= W Y Q Q K P G K A P K L L I Y L S S R L Q S G V P S R F
S G S G S=
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
G T D F T L T I S S L Q P E D F A T Y Y C Q Q L K K P P
Y T F G Q
CTGTCAACAG CTGAAGAAGC
CTCCTTATAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO. : 438 DOM-173 - SEQ ID NO.: 324 I K N R L A
SUBSTITUTE SHEET (RULE 26) 1 GACETCCAGA TGACCCAGTC TCCATCCTCC CTGTCTGCAT CTGTAGGAG_A CCGTGTCACC
ATCACTTGCC GGGCAAGTCA
GAAGATTAAG AATCGGTTAG
= W Y Q Q K P G K A P K L L I Y E V S H L Q S G V P S R F
S G S O S
=
TGCAAAGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I G S L Q P E D F A T Y Y C Q Q R R Q S P
Y T F G Q
CTGTCAACAG AGGAGGCAGT
CGCCTTATAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO. : 439 DOM-174 - SEQ ID NO.: 325 I G E E L F-GGGCAAGTGA
GGATATTGGG GAGGAGTTAT
= W Y Q Q K P G K A P K L L I Y S A S T L Q S E V P S R F
S G S G S-101 TTTGGTATCA GCAGAA.'ACCA GGGAAAGCCC CTAAGCTCCT GATCTATTCG GCGTCCACGT
TGCAAAGTGA GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S S L Q H E D F A T Y Y C Q Q V Y E W P
Y T F G Q
CTGTCAACAG GTTTATGAGT
GGCCTTATAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO. : 440 DOM-175 - SEQ ID NO.: 326 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q P
I S G G L R=
GGGCAAGTCA
GCCTATTTCT GGGGGTTTAA
SUBSTITUTE SHEET (RULE 26) = W Y Q Q K P G K A P K L L I Y S T S M L Q S G V P S R F
S G S G S-TGCAA.AGTGG GGTCCCATCA
CGTTTCAGTG GCAGTGGATC
= G T D F T L T I S S L Q P E D F A T Y Y C Q Q L Y S A P
Y T F G Q
CTGTCAACAG CTTTATTCTG
CTCCTTATAC GTTCGGCCAA
G T K V E I K R
301 GGGACCAAGG TGGAAATCAA ACGG - SEQ ID NO. : 441 DOM-176 - SEQ ID NO.: 327 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F D A Y E M-CCTCCGGATT
CACCTTTGAT GCGTATGAGA
G W V R Q A P G K G L E W V S I I D W D G N S T Y Y A D
S V K G R=
ATGGTAATTC TACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K P G
TGCCGAGGAT ACCGCGGTAT
ATTACTGTGC GAAACCTGGG
D N V G I F D Y W G Q G T L V T V S S
NO.
DOM-177 - SEQ ID NO.: 328 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F S N Y Y M
CCTCCGGATT
CACCTTTAGT AATTATTATA
SUBSTITUTE SHEET (RULE 26) = V W V R Q A P G K G L E W V S A I D E W G F A T Y Y A D
S V K G R-GGGGTTTTGC GACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K H W
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAAACATTGG
E F T S D T S R F D Y W G Q G T L V T V S S
SEQ ID
NO.. 443 DOM-178 - SEQ ID NO.: 329 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F E D F D M-CCTCCGGATT
CACCTTTGAG GATTTTGATA
A W V R Q A P G K G L E W V S S I N D Q G S L T Y Y A D
S V K G R=
AGGGTTCTCT GACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K P D
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAACCGGAT
Q F F D Y W G Q G T L V T V S S
301 CAGTTTTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC - SEQ ID NO .: 444 DOM-179 - SEQ ID NO.: 330 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F S A Y D M=
CCTCCGGATT
CACCTTTAGT GCTTATGATA
SUBSTITUTE SHEET (RULE 26) = M W V R Q A P G K G L E W V S R I S P Q G Q R T Y Y A D
S V K G R=
AGGGTCAGCG GACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K I R
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAAATTCGT
G Q S R I P M R F D Y W G Q G T L V
301 GGGCAGTCGC GGATTCCTAT GAGGTTTGAC TACTGGGGTC AGGGAACCCT GGTC - SEQ ID NO .:
DOM-180 - SEQ ID NO.: 331 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F T D Y E M-CCTCCGGATT
CACCTTTACG GATTATGAGA
= G W V R Q A P G K G L E W V S T I T S L G E S T Y Y A D
5 V K G R=
TGGGTGAGAG TACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K P G
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAACCTGGT
R I F D Y W G Q G T L V T V S S
301 CGTATTTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC - SEQ ID NO .: 446 DOM-181 - SEQ ID NO.: 332 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F A F Y P M=
CCTCCGGATT
CACCTTTGCT TTTTATCCTA
SUBSTITUTE SHEET (RULE 26) = M W V R Q A P G K G L E W V S W I D A T G T R T Y Y A D
V K G R=
CGGGTACGAG GACATACTAC
GCAGACTCCG TGAAGGGCCG
5 = F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A E G N
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GGAAGGTAAT
GTCTCGAGC - SEQ ID
NO.: 447 DOM-182 - SEQ ID NO.: 333 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F D E Y P M-CCTCCGGATT
CACCTTTGAT GAGTATCCGA
Y W V R Q A P G K G L E W V S S I G P S G P N T Y Y A D
S V K G R=
CTGGTCCGAA TACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K S P
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAATCTCCG
Y F D V I P S Y F D Y W G Q G T L V T V S S
SEQ ID
NO.: 448 DOM-183 - SEQ ID NO.: 334 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F A D Y G M-CCTCCGGATT
CACCTTTGCG GATTACGGTA
SUBSTITUTE SHEET (RULE 26) = G W V R Q A P G K G L E W V S S I Q S S G L R T Y Y A D
S V K G R=
CGGGTTTGCG GACATACTAC
GCAGACTCCG TGAAGGGCCG
F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K R A
TGCCGAGGAT ACCGCGGTAT
ATTACTGTGC GAAACGGGCT
N S R R G F D Y W G Q G T L V T V S S
.
DOM-184 - SEQ ID NO.: 335 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F S D Y E M
CCTCCGGATT
CACCTTTTCT GATTATGAGA
M W V R Q A P G K G L E W V S S I T S H G G S T Y Y A D
S V K G R-ATGGTGGGTC TACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K P D
TGCCGAGGAT ACCGCGGTAT
ATTACTGTGC GAAACCTGAT
K D F D Y W G Q G T L V T V S S
301 AAGGATTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC - SEQ ID NO.: 450 DOM-185 - SEQ ID NO.: 336 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F A H Y P M
TCCTGTGCAG CCTCCGGATT
CACCTTTGCG CATTATCCGA
SUBSTITUTE SHEET (RULE 26) = S W V R Q A P G K G L E W V S S i G R L G N R T Y Y A D
S V K G R=
TGGGTAATCG TACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I 5 R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K R A
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAACGTGCT
T P V P I K G L F D Y W G Q G T L V T V S S
SEQ ID
NO.. 451 DOM-186 - SEQ ID NO.: 337 E V Q L L E S G G G L V Q P G G S L R L S C A A S G L T
F G R Y E M-CCTCCGGACT
CACCTTTGGG AGGTATGAGA
A W V R Q A P G K G L E W V S S I D S D G W V T Y Y A D
S V K G R
ATGGTTGGGT GACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A Q P D
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GCAACCGGAT
S L F D Y W G Q G T L V T V S S
301 TCGTTGTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC - SEQ ID NO .: 452 DOM-187 - SEQ ID NO.: 338 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F S 5 Y S M=
TCCTGTGCAG CCTCCGGATT
CACCTTTTCT AGTTATTCTA
SUBSTITUTE SHEET (RULE 26) = V W V R Q A P G K G L E W V S G I N R G G T R T Y Y A D
S V K G R =
GTGGTACTCG TACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K G W
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAAGGTTGG
R R G F D Y W G Q G T L V T V S S
301 AGGAGGGGGT TTGACTACTG GGGTCAGGGA ACCCTGGTCA CCGTCTCGAG C - SEQ ID NO .:
DOM-188 - SEQ ID NO.: 339 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F T R Y R M.
CCTCCGGATT
CACCTTTACG CGTTATAGGA
= S W V R Q A P G K G L E W V S G I S R D G Y R T Y Y A D
S V K G R=
ATGGTTATCG GACATACTAC
GCAGACTCCG TG_AAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K G M
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAAGGTATG
301 ACTGCGTCGT TTGACTACTG GGGTCAGGGA ACCCTGGTCA CCGTCTCGAG C - SEQ ID NO .:
DOM-189 - SEQ ID NO.: 340 F Q M Y P M-CCTCCGGATT
CACCTTTCAG ATGTATCCGA
SUBSTITUTE SHEET (RULE 26) = G W V R Q A P G K G L E W V S M I E P A G D L T Y Y A D
S V K G R-CTGGTGATCT TACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K Y Q
201 GTTCACCATC TCCCGCGACA ATTCCAAG_AA CACGCTGTAT CTGCAAATGA ACAGCCTGCG
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAATATCAG
E Q P W F D Y W G Q G T L V T V S S
301 GAGCAGCCTT GGTTTGACTA CTGGGGTCAG GGAACCCTGG TCACCGTCTC GAGC - SEQ ID NO .:
DOM-190 - SEQ ID NO.: 341 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F S M Y D M-CCTCCGGATT CACCTTTAGT ATGTATGATA
= H W V R Q A P G K G L E W V S T I L S D G T D T Y Y A D
S V K G R-ATGGTACGGA TACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K Y G
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAATATGGG
A M F D Y W G Q G T L V T V S S
301 GCTATGTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC - SEQ ID NO.: 456 30 DOM-191 - SEQ ID NO.: '342 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F K L Y P M
CCTCCGGATT
CACCTTTAAG TTGTATCCGA
SUBSTITUTE SHEET (RULE 26) T W V R Q A P G K G L E W V S S I D A G G H E T Y Y A D
S V K G R=
GGGGTCATGP_ GACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K D W
TGCCGAGGAT ACCGCGGTAT
ATTACTGTGC GAAAGATTGG
W D Y L F D Y W G Q G T L V T V S S
301 TGGGATTATC TGTTTGACTA CTGGGGTCAG GGAACCCTGG TCACCGTCTC GAGC - SEQ ID NO.:
DOM-192 - SEQ ID NO.: 343 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F S R Y P M-CCTCCGGATT
CACCTTTTCG CGGTATCCGA
= S W V R Q A P G K G L E W V S S I N R S G M R T Y Y A D
S V K G R=
CGGGTATGCG GACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A E G H
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GGAAGGGCAT
Q A P F D Y W G Q G T L V T V S S
301 CAGGCGCCGT TTGACTACTG GGGTCAGGGA ACCCTGGTCA CCGTCTCGAG C - SEQ ID NO .:
DOM-193 - SEQ ID NO.: 344 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F T G Y A M
CCTCCGGATT
CACCTTTACG GGGTATGCTA
SUBSTITUTE SHEET (RULE 26) = S W V R Q A P G K G L E W V B T I N A N G I R T Y Y A D
S V K G R
ATGGTATTCG GACATACTAC
GCCGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N G L R A E D T A V Y Y
C A K G G
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAAGGGGGG
V W R W G T G H K F D Y W G Q G T L V T V S S
GTCTCGAGC - SEQ ID
NO.: 459 DOM-194 - SEQ ID NO.: 345 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F K Q Y D M-CCTCCGGATT
CACCTTTAAG CAGTATGATA
R W V R Q A P G K G L E W V S T I S Q N GT K T Y Y A D
S V K G R-ATGGTACTAA GACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K S R
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAATCGAGG
T G R Y F D Y W G Q G T L V T V S S
301 ACTGGTAGGT ATTTTGACTA CTGGGGTCAG GGAACCCTGG TCACCGTCTC GAGC - SEQ ID NO .:
DOM-195 - SEQ ID NO.: 346 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F G T Y D M
CCTCCGGATT
CACCTTTGGG ACTTATGATA
SUBSTITUTE SHEET (RULE 26) = G W V R Q A P G K G L E W V S R I N W Q G D R T Y Y A D
S V K G R=
AGGGTGATCG TACATACTAC
GCAGACTCCG TGAAGGGCCG
F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y y C A K A G
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAAGCGGGG
F G H Y V D G L G F D Y W G Q G T L V T V S S
GTCTCGAGC - SEQ ID
NO.. 461 DOM-196 - SEQ ID NO.: 347 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F S G Y E M-CCTCCGGATT
CACCTTTAGT GGGTATGAGA
A W V R Q A P G K G L E W V S S I T D M G D S T Y. Y A D
S V K G R=
TGGGTGATTC TACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K P G
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAACCTGGG
T A F D Y W G P G T L V T V S S
301 ACTGCGTTTG ACTACTGGGG TCCGGGAACC CTGGTCACCG TCTCGAGC - SEQ ID NO .: 462 DOM-197 - SEQ ID NO.: 348 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F A K Y K M
TCCTGTGCAG CCTCCGGATT
CACCTTTGCG AAGTATAAGA
SUBSTITUTE SHEET (RULE 26) = W W V R Q A P G K G L E W V S 5 I T P K G H S T Y Y A D
S V K G R=
AGGGTCATTC TACATACTAC
GCAGACTCCG TGAAGGGCCG
C A K R P
TGCCGAGGAT ACCGCGGTAT
ATTACTGTGC GAAAAGGCCG
M T P F D Y W G Q G T L V T V S S
301 ATGACTCCGT TTGACTACTG GGGTCAGGGA ACCCTGGTCA CCGTCTCGAG C - SEQ ID NO .:
DOM-198 - SEQ ID NO.: 349 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F E R Y N M-CCTCCGGATT
CACCTTTGAG CGGTATAATA
= S W V R Q A P G K G L E W V S S I R P R G G K T Y Y A D
S V K G R
GGGGTGGGAP_ GACATACTAC GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K W R
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAATGGCGG
R E G Y T G S K F D Y W G Q G T L V T V S S
SEQ ID
NO.: 464 DOM-199 - SEQ ID NO.: 350 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F E R Y G M
CCTCCGGATT
CACCTTTGAG AGGTATGGTA
SUBSTITUTE SHEET (RULE 26) T W V R Q A P G K G L E W V S S I W P R G Q K T Y Y A D
S V K G R=
GGGGTCAGAA GACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K G N
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAAGGGAAT
S R Y V P D Y W G Q G T L V T V S S
301 AGTCGGTATG TTTTTGACTA CTGGGGTCAG GGAACCCTGG TCACCGTCTC GAGC - SEQ ID NO .:
DOM-200 - SEQ ID NO.: 351 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F T N Y S M=
CCTCCGGATT
CACCTTTACT AATTATAGTA
= G W V R Q A P G K G L E W V S T I R P N G T K T Y Y A D
S V K G R=
ATGGTACTAA GACATACTAC
GCAGACTCCG TGAAGGGCCG F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y y C A K R S
201 GTTCACCATC TCCCGCGACA ATTCCAAG_AA CACGCTGTAT CTGCAAATGA ACAGCCTGCG
TGCCGAGGAT ACCGCGGTAT
ATTACTGTGC GAAACGGTCG
S A H L Q R F D Y W G Q G T L V T V S S
NO.
DOM-201 - SEQ ID NO.: 352 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F G N Y S M
CCTCCGGATT
CACCTTTGGT AATTATTCGA
SUBSTITUTE SHEET (RULE 26) = G W V R Q A P G I< G L E W V S S I G R H G G R T Y Y A D
S V K G R-ATGGTGGGCG TACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K 19 T L Y L Q M N S L R A E D T A V Y y C A K K G
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAAAAGGGG
S T Y P R F D Y W G Q G T L V T V S S
NO.
DOM-202 - SEQ ID NO.:. 353 E V Q L L E S G G G L V Q P G G S L R L S C T A S G P T
F S H Y E MI
CCTCCGGATT
CACCTTTTCG CATTATGAGA G W V R Q A P G K G L E W V S S I E P F G G G T Y Y A D
S V K G R
TTGGTGGTGG GACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K V Y
TGCCGAGGAT ACCGCGGTAT
ATTACTGTGC GAAAGTGTAT
P Q G S F D Y W G Q G T L V T V S S
301 CCTCAGGGTT CTTTTGACTA CTGGGGTCAG GGAACCCTGG TCACCGTCTC GAGC - SEQ ID NO.:
DOM-203 - SEQ ID NO.: 354 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F S N Y T M-CCTCCGGATT
CACCTTTAGT AATTATACTA
SUBSTITUTE SHEET (RULE 26) S V K G G R W V R Q A P G K G L E W V S S I R P D G K I T Y Y p D
ATGGTAAGAT TACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A E V Y
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GGAAGTTTAT
S S C A M C T P L L F D Y W G Q G T L V T V S S
ACCGTCTCGA GC - SEQ
ID NO.: 469 DOM-204 - SEQ ID NO.: 355 F K R Y S M-CCTCCGGATT
CACCTTTAAG CGGTATTCGA
S V K G A R W V R Q A P G K G L E W V S D I' G P R G F S T Y Y A D
GGGGTTTTTC GACATACTAC
GCAGACTCCG TGAAGGGCCG
F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K V G
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAAGTGGGT
R G Q R D T S Q P F D Y W G Q G T L V T V S S
GTCTCGAGC - SEQ ID
NO.: 470 DOM-205 - SEQ ID NO.: 356 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F A S Y Q M-CCTCCGGATT
CACCTTTGCT TCTTATCAGA
SUBSTITUTE SHEET (RULE 26) = A W V R Q A P G K G L E W V S G I T S G G L S T Y Y A D
S V K G R-GTGGTCTTAG TACGTACTAC
GCAGACTCCG TGAAGGGCCG
F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K P G
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAACCGGGG
R G F D Y W G Q G T L V T V S S
301 AGGGGTTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC - SEQ ID NO .: 471 DOM-206 - SEQ ID NO.: 357 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F A S Y E M.
CCTCCGGATT
CACCTTTGCT TCTTATGAGA
= T W V R Q A P G K G L E W V S G I S S D G L S T Y Y A D
S V K G R=
ATGGTCTGTC TACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K P G
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAACCGGGG
V L F D Y W G Q G T L V T V S S
301 GTGTTGTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC - SEQ ID NO .: 472 DOM-207 - SEQ ID NO.: 358 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
F D K Y L M=
CCTCTGGATT
CACCTTTGAT AAGTATTTGA
SUBSTITUTE SHEET (RULE 26) = S W V R Q A P G K G L E W V S G I E P L G D V T Y Y A D
S V K G R-TGGGTGATGT TACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y y C A K E A
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAAGAGGCT
S G D F D Y W G Q G T L V T V S S
301 TCGGGGGATT TTGACTACTG GGGTCAGGGA ACCCTGGTCA CCGTCTCGAG C- SEQ ID NO .: 473 DOM-208 - SEQ ID NO.: 359 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T
J F T E Y E M-I GAGGTGCAGC TGTTGGAGTC TGGGGGAGGC TTGGTACAGC CTGGGGGGTC CCTGCGTCTC TCCTGTGCAG
CCTCCGGGTT
CACCTTTACT GAGTATGAGA
= S W V R Q A P G K G L E W V S S I D N V G S S T Y Y A D
S V K G R=
TGGGTAGTAG TACATACTAC
GCAGACTCCG TGAAGGGCCG
= F T I S R D N 5 K N T L Y L Q M N S L R A E D T A V Y Y
C A K P G
TGCCGAGGAT ACCGCGGTAT
ATTACTGTGC GAAACCTGGG
K L F D Y W G Q G T L V T V S S
301 AAGCTTTTTG ACTACTGGGG TCAGGGAACC CTGGTCACCG TCTCGAGC - SEQ ID NO.: 474 DOM-209 - SEQ ID NO.: 360 E V Q L L E S G G G T, V Q P G G S L R L S C A A S G F T
F A D Y E M=
CCTCCGGATT
CACCTTTGCT GATTATGAGA
SUBSTITUTE SHEET (RULE 26) W W V R Q A P G K G L E W V S A I S R Q G F A T Y Y A D
S V K G R-AGGGTTTTGC TACATACTAC
GCAGACTCCG TGAAAGGCCG
= F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y
C A K D L
TGCCGAGGAC ACCGCGGTAT
ATTACTGTGC GAAAGATCTG
E R D D F D Y W G Q G T L V T V S S
301 GAGCGGGATG ATTTTGACTA CTGGGGTCAG GGAACCCTGG TCACCGTCTC GAGC ~ SEQ ID NO .:
Among the DOM clones described, a number of observations have been made regarding homology among clones, and properties of amino acids predicted at particular positions in the anti-CD40L dAbs. These are shown in Tables 9 and 10 below:
Table 9. Predictions for anti-VPI CD40L clones: (using standard sin6le letter amino acid code Predicted Predicted Predicted Properties of Amino acid amino acid Kabat dummy amino amino acids frequently number numbering acid at this frequently fount at the relative to position fount at the designated dummy designated position in sequence position in anti-CD40L
anti-CD40L dAbs dAbs 30 30 S acidic; small D, E, A, G
33 33 A mix Q,E,P,G
35 35 S mix A,M,G,T
50 50 A nucleophilic; S, T, G, W
or G, W
52 52 S hydrophilic; or T, S, G, D, N
G,D,N
53 53 G mix P, R, S, D
54 54 S acidic; or L, I, D, E, L, I, Q
Q
99* 95 S hydrophobic; P, G, V, L
or P, G
100 96 y mix G, D, R, L
* If amino acid at position 99 (dummy) is P then G or D is frequently found at position 100.
Table 10. Predictions for anti-VK CD40L clones:
Predicted Predicted Predicted Properties of Amino acid amino acid Kabat dummy amino amino acids frequently number numbering acid at this frequently fount at the relative to position fount at the designated dummy designated position in sequence position in anti-CD40L
anti-CD40L dAbs dAbs 28M 28 S mix A, D, W, P
30 30 S acidic; or G G, D, E
32 32 Y mix R, S, D, N
34 34 N acidic or basic R. E
50 50 A mix H, D, G, S
51 51 A mix S, G, R
53 53 S hydrophobic; I, L, M, K, E, or K, E W
91 91 S mix Y, R, V
92 92 Y basic; or S, W H, S, W, R
96 96 N mix Y, V, A, T
*If amino acid at position 28 (dummy) is D then E is frequently found at position 34.
**If amino acid at position 34 (dummy) is E then Y is frequently found at position 91 and H or D
at position 92.
Example 8: PEGylation of DOM8-24 Site specific maleimide-PEGylation of DOMB-24 requires a solvent accessible cysteine to be provided on the surface of the protein, in this example, at the C-terminus. The cysteine residue, once reduced to give the free thiol, can then be used to specifically couple the protein to PEG via a wide range of chemistries such as maleimide or another thiol to give a disulphide. A
wide range of chemical modified PEGs of different sizes and branched formats are available 0 from Nektar (formally known as Shearwater Corp). This allows the basic dAb-cys monomer to be formatted in a variety of ways for example as a PEGylated monomer, dimer, trimer, tetramer etc. The size of the PEGs is given in kDa but can also be referred to as K
(i.e. "40K PEG" = 40 l:Da PEG).
PCR construction of DOMB-24eys 5 The site of attachment for the PEG may be placed elsewhere on the surface of the dAb as .
long as the targeted amino acid is solvent accessible and the resultant PEGylated protein still maintains antigen binding. Thus it is also possible to engineer the cys into any one of frameworks 1-4 of the dAb for PEGylation and still maintain some antigen binding. The following oligonucleotides were used to specifically PCR DOM8-24 with a SaZI
and BannHI sites .0 for cloning and also to introduce a C-terminal cysteine residue.
SalI
Ala Ser Thr Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val GTA
CGC AGC TGC CTC CAC GTC GAC AAC CTC AGA CCC CCT CCG AAC
CAT
Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe TTC
AAG
Thr Phe Ser Asn Tyr Gln Met Ala Trp Val Arg Gln Ala Pro Gly GGG
TGG AAA TCA TTA ATA GTC TAC CGC ACC CAG GCG GTC CGA GGT
CCC
,0 Lys Gly Leu Glu Trp Val Ser Ser Ile Thr Ser Glu Gly Gly Ser TCG
TTC CCA GAT CTC ACC CAG AGT TCA TAA TGA TCA CTC CCA CCA
,5 AGC
Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg TGT ATG ATG CGT CTG AGG CAC TTC CCG GCC AAG TGG TAG AGG
GCG
Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu 5 Arg CGT
CTG TTA AGG TTC TTG TGT GAC ATA GAC GTT TAC TTG TCG GAC
GCA
Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Pro Gly Lys Asn AAT
TTA
Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Cys ***
TAA
AAA CTG ATG ACC CCA GTC CCT TGG GAC CAG TGG CAG AGC ACG
ATT
BamHI
.0 *** Gly Ser (SEQ ID NI: 85) 361 TAA GGA TCC (SEQ ID NO: 83) ATT CCT AGG (SEQ ID NO: 84) The DNA sequence of the PCR primers used to amplify the engineered dAb are shown .5 below.
Forward primer 5'- AGTGCGTCGACGGAGGTGCAGCTGTTGGAGTCT-3' (SEQ ID NO: 86) Reverse primer 5'- AAAGGATCCTTATTAGCACGAGACGGTGACCAGGGTTCCCTG-3' (SEQ ID NO: 87) ;0 The PCR reaction (50 L volume) was set up as follows: 200 M dNTP's, 0.4 M
of each primer, 5 L of lOx PfuTurbo buffer (Stratagene), 100 ng of template plasmid (DOM8-24), 1 L of PfuTurbo enzyme (Stratagene) and the volume adjusted to 50 L using sterile water. The following PCR conditions were used: initial denaturing step 94 C for 2 mins, then 25 cycles of 94 C for 30 secs, 64 C for 30 sec and 72 C for 30 sec. A final extension step was also included ;5 of 72 C for 5 mins. The PCR product was purified and digested with SaZI
and Ba777HI and ligated into the vector (pDOM5) which had also been cut with the same restriction enzymes.
Correct clones were verified by DNA sequencing.
Expression and purification of DOM8-24 DOM8-24 vector was transformed into HB2151 electro-competent cells. Cells carrying 0 the dAb plasmid were selected for using 100 g/mL carbenicillin. Cultures were set up in 2L
baffled flasks containing 500 mL of teiTific broth (Sigma-Aldrich) and 100 g/mL carbenicillin.
The cultures were grown at 30 C at 200rpm to an O.D.600 of 1-1.5 and then induced with 1mM
IPTG (isopropyl-beta-D-thiogalactopyranoside, from Melford Laboratories). The expression of the dAb was allowed to continue for 12-16 hrs at 30 C. It was found that most of the dAb was present in the culture media. Therefore, the cells were separated from the media by centrifugation (8,000xg for 30 mins), and the supernatant used to purify the dAb. Per litre of supernatant, 10 mL of Streamline Protein A (Amersham Biosciences) was added and the dAb allowed to batch bind with stirring for 3 hours at room temperature, or overniglit at 4 C. The resin was then allowed to settle under gravity for an hour before the supernatant removed. The agarose was then packed into a XK 16 column (Amersham Pharmacia) and was washed with 10 column volumes of 2xPBS. The bound dAb was eluted with 100 mM glycine pH 3.0 and protein containing fractions were then neutralized by the addition of 1/5 volume of 1 M Tris pH 8Ø
PEGylation of DOM8-24cys using MAL activated PEG
Mono iei- PEGylation The cysteine residue which had been engineered onto the surface of the VH dAb was specifically modified with a single linear or branched PEG-MAL to give monomeric modified protein. mPEG-MAL formats which may be used to PEGylate a monomeric VH or Vk dAb. The PEGs may be of MW from 500 to 60,000 (eg, from 2,000 to 40,000) in size.
c mPtx-a-~-N 14 mPECa-1*1 I ~ [0~ 1,a 0 r- r oll C _~Itf / \11 8 1i mPEG-1VIAI, mPEG2-MAL
2.5 ml of 500 M DOM8-24cys was reduced with 5 mM dithiothreitol and left at room ?0 temperature for 20 minutes. The sample was then buffer exchanged using a PD-10 column (Amersham Pharmacia). The column had been pre-equilibrated with 5 mM EDTA, 20 mM
sodium phosphate pH 6.5, 10% glycerol, and the sample applied and eluted following the manufactures guidelines. The eluted sample (3.5 ml of -360 M dAb) was placed on ice until required. A four fold molar excess of 30K PEG-MAL or 40K PEG2-MAL (Nektar) was weighed out and added directly to the reduced dAb solution and gently mixed until the polymer had dissolved. The reaction was left to proceed at room temperature for 3 hours.
Purification of 30K and 40K PEGvlated DOM8-24cys monomer The PEGylated dAb was purified using cation exchange chromatography as the isoelectric point (pI) of the protein is -8. 40 .L of 40% glacial acetic acid was added per mL of the 30K or 40K PEG DOMB-24cys reaction to reduce the pH to -4. The sample was then applied to a 1mL Resource S cation exchange column (Amersham Pharmacia), which had been pre-0 equilibrated with 50 mM sodium acetate pH 4Ø The PEGylated material was separated from the unmodified dAb by running a linear sodium chloride gradient from 0 to 500 mM
over 20 column volumes. Fractions containing PEGylated dAb only were identified using SDS-PAGE and then pooled and the pH increased to 8 by the addition of 1/5 volume of 1M Tris pH
8.0 In vitro functional binding assay: CD40 liaand receptor assay (CD40L RBA) .5 The CD40L assay was used to measure the binding of CD40L to CD40 and the ability of binding entities (including monovalent antibody fragments such a dAbs) to block this interaction, as shown Figure 7.
A 96 well Nunc Maxisorp assay plate was coated overnight at 4 C with 100 l per well of recombinant human CD40/Fc (R&D Systems) at 0.5 g/ml in carbonate buffer. The plate was '.0 washed 3 times with 300 l of 0.05% Tween/PBS and 3 times with 300 l of PBS using a Tecan plate washer. The wells were blocked using 200 l of PBS containing 2% (w/v) BSA and incubated for a minimum of 1 h at room temperature. The wells were washed as above, then 50 l of purified dAb protein was added to each well. To each well 50 l of CD40L, at 6 ng/ml in diluent (for a final concentration of 3 ng/ml), was also added and the plate incubated for 1 hr at room temperature. The plate was washed as described previously and 100 l biotinylated anti-CD40L antibody, 0.5 g/ml in diluent, was added and incubated for 1 hr at room temperature.
The plate was washed as described above, then 100 l HRP conjugated anti-biotin antibody (1:5000 dilution in diluent) added to each well and the plate incubated for 1 hr at room temperature. The plate was washed again as described above using a Tecan plate washer and the assay developed using 100 l of SureBlue 1-Component TMB MicroWell Peroxidase solution (the plate was left at room temperature for up to 20 min). The reaction was stopped by the addition of 100 l 1 M hydrochloric acid. The OD45on,,, of the plate was assayed within 30 minutes of acid addition. The OD45o,,,,, is proportional to the amount of bound streptavidin-HRP conjugate, therefore the greater the degree of dAb inhibition the lower the OD45or,m of the resulting signal. The following controls were included; 0 ng/ml CD40L (diluent only), 3 ng/ml CD40L and 3 ng/ml CD40L with 1 g/ml anti-CD40L antibody.
The results of the CD40L RBA are shown in Fig. 9. It can be seen that PEGylated 0 DOM8-24cys has a similar affinity for CD40L as the unmodified protein. The size of the polymer attached (either 30 or 40K) does not seem to significantly affect the IC 50 of 1 nM.
Example 9: Generation and Expression of a Dual Specific dAb Dimer (DOM7h-26-DOM-24) A dual specific dAb dimer was constructed essentially as described in and as described below.
.5 A PCR fragment introducing 5' Notl and 3' EcoRl restriction sites into the DNA sequence was generated using the primers VH-5'-Not1 (5'-GTATGTCTGGCGGCCGCAGAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTG-3'; SEQ
ID NO: 90) and VH-NO-Xhol (5'-TAGAATTCTTATTAGCTGGAGACGGTGACCAGGGT-3'; SEQ ID NO: 91). The PCR product was electrophoresed on a 1% agarose gel and the !0 appropriate band was excised and gel cleaned using the Qiagen Gel Extraction Kit. The purified DNA was digested with Notl and EcoRI for 1 hour at 37 C and then the digested DNA fragment purified using the Qiagen PCR Cleanup Kit. The digested PCR product was ligated using T4 DNA ligase into the vector pCH3, derived from pPICz-alpha (Invitrogen Ltd, Paisley, UK), which had been previously been digested with NotI and EcoRI, tllereby enabling the ligation of !5 the DOM-24 DNA sequence 3' relative to the anti-human serum albumin dAb DNA
sequence (DOM7h-26). One micro-litre of the ligation mix was used to electroporate 50 l of E. coli TOPlOF' (0.2 mm diameter cuvettes; 25 FD; 200n; 2.500 kV) using a Biorad Genepulser II
with pulse controller module. The electroporated cells were immediately resuspended in 1 ml low salt LB medium (10 g/l tryptone; 5 g/1 yeast extract; 5 g/1 NaCl; pH to 7.5 with 4 M NaOH;
then autoclaved at 121 C for 15 min) and 100 l of the cell suspension plated onto low salt LB
agar plates (10 gIl tryptone; 5 g/1 yeast extract; 5 g/1 NaCI; pH to 7.5 with 4 M NaOH; 15 g/l agar; then autoclaved at 121 C for 15 min) supplemented with 25 g/ml zeocin (Invitrogen Ltd, Paisley, UK) and grown at 37 C overnight.
Several individual clones from the overnight growth plate were analysed by DNA
sequencing using the alpha-factor sequencing primer (5'-TACTATTGCCAGCATTGCTGC-3';
SEQ ID NO: 92) and the reverse 3' AOX1 primer (5'-GCAAATGGCATTCTGACATCC-3';
SEQ ID NO: 93). A plasmid prep derived from a single clone containing the desired DNA
sequence was made by inoculating 100 ml of low salt LB medium supplemented with 25 g/ml 0 zeocin and grown overnight at 37 C with shaking at 250 rpm, followed by purification of the plasmid DNA using a Qiagen Plasmid Midi Prep Kit (Qiagen).
The concentration and purity of the DNA was determined by measuring the absorbance at 280 nm and 260 nm. Between 10 and 50 g of DNA was digested with Pmel, SacI or BstXI
restriction enzymes and the DNA digestion confirmed by analysis on a 0.8%
agarose gel. The 5 digested DNA was purified using the Qiagen Qiaex II Kit (Qiagen) and the DNA
eluted into l purified water per 20 l of Qiaex II resin.
Competent yeast cells were made by streaking the wild type Pichia pastoris strain X33 onto a YPD agar plate (for 1 litre of media: 20 g peptone from meat type 1; 10 g yeast extract;
g agar dissolved in 900 ml water and sterilise by autoclaving at 121 C for 15 minutes;
,0 followed by the aseptic addition of 100m1 of 20% destrose and the desired amount of zeocin once the media had cooled below 50 C) and grown at 30 C for 36-48 h until colonies appeared.
A single colony was inoculated into 5 ml of YPD medium (as for YPD agar, without the addition of 20 g agar) and grown overnight in a 50 ml baffled flask at 30 C with shaking at 250 rpm.
Five hundred millilitres of YPD medium in a 21 baffled flask was inoculated with 0.1-0.5 ml of ,5 the overnight culture and grown at 30 C with shaking at 250 rpm overnight to an OD600 of approximately 1.3-1.5. The culture was cooled on ice then the Pichia harvested by centrifugation at 1500 g for 5 min at 4 C. The supernatant was discarded and the pellet resuspended in 500 ml ice cold ultrapure water. The Pichia were recovered again by centrifugation at 1500 g for 5 min at 4 C. The pellet was resuspended aild centrifuged for a further three times, the first time in 250 ml ice cold ultrapure water, then twice in 20 ml ice cold 1M sorbitol. The competent Pichia were kept on ice for up to 6 hours prior to use.
To transform the Pichia by electroporation, between 10 to 20 g of linearised vector in l of water was mixed with 80 l of competent Pichia in a precooled microfuge tube and 5 incubate on ice for 5 min. The Pichia mixture was then transferred to a precooled 0.2 cm gap electroporation cuvette, and electroporated: 25 F, resistance set to infinity, 0.54 kV in a Biorad Genepulser II with pulse controller module. Immediately 1 ml ice cold I M
sorbitol was added to the electroporation cuvette and the electroporated Pichia transferred into a 15 ml polypropylene tube. This culture was incubated at 30 C without shalcing for 2 hours to allow the 10 cells to recover. The cells were then plated onto YPDS agar plates (YPD
agar supplemented with 1 M sorbitol) and zeocin added to final concentrations of 100 g/ml, 500 .g/ml, 1000 g/ml, and 2000 g/ml. The plates were incubated at 30 C in the dark for 2-10 days until colonies appeared. Several clones were picked from each plate and restrealced onto YPD plates supplemented with the same amount of zeocin as they were originally selected against. For [5 small to medium scale shaking flask expression the Mut status of each X33 clone was not determined.
Individual restreaked colonies were used to inoculate 50 ml of BMGY medium (for 1 litre of medium: 20 g peptone from meat type 1; 10 g yeast extract were dissolved in 700 ml with water and sterilise by autoclaving at 121 C for 15 minutes; followed by the aseptic addition of ?0 100 ml 1 M KPO4 pH 6.0; 100 ml 10% glycerol; and 100 ml lOxYNB (Yeast Nitrogen Base);
2 ml of 500x biotin) in a 250 ml flask and grown at 30 C with shaking at 250 rpm until an OD600 of 2 to 6 was attained. The Pichia was recovered by centrifugation at 1500 g for 5 min at room temperature. The resulting pellet was resuspended in 20 ml BMMH medium (as for BMGY medium except the 100 ml 10% glycerol was replaced with 100 ml of 5%
methanol), and ?5 returned to a fresh 250 ml baffled flask and incubated at 30 C with shaking at 250 rpm for up to 5 days post induction. At 24 h intervals, 0.5 ml samples were recovered and assessed by analysis of the supernatant by SDS-PAGE.
Dimer dAb was purified from the culture supernatant using Streamline protein-A
matrix (Amersham Biosciences). Following binding of the dimer dAb, the matrix was transferred to an empty 20 ml chromatography column containing a frit and the supernatant allowed to flow through the column, retaining the matrix. The matrix was washed with 10 times the matrix volume of high salt buffer (10 mM Phosphate buffer, 2.7 mM KCI, 487 mM NaCI, pH 7.4). The bound protein was eluted with 0.1 M glycine pH 3 supplemented with 0.15 M NaCI
and 0.8 ml fractions were collected which were immediately neutralised with the addition of 0.2 ml of 1 M
Tris-HCI pH 8Ø
Simultaneous Antigen Binding of the Dual Specific dAb Dimer To demonstrate that the dual specific dimeric dAb was functional and could bind both antigens simultaneously, an antigen binding ELISA was performed. Fifty microlitres per well of human serium albumin at 100 g/m1 in PBS was coated on to a Maxisorb ELISA
plate (Nunc) overnight at 4 C. The plate was washed 3 times with 250 l/well of PBS
supplemented with 0.1% (v/v) Tween 20 (Sigma). The plate was then blocked for 1 h at room temperature with 200 l per well of PBSM (PBS supplemented with 2% (w/v) low fat milk powder).
The plate was washed as before, then 50 l per well of doubling dilutions of the dimer dAb in PBSM were added and incubated for 1 hour at room temperature. The plate was washed as before then 50 1 per well of a 5 nM solution of biotinylated CD40L in PBSM added and incubated for 1 hour at room temperature. The plate was washed as before then 50 l per well of streptavidin-HRP
(Amersham Biosciences) diluted 1 in 4000 in PBSM was added and incubated for 1 hour at room temperature. The plate was washed 4 times with 250 l/well of PBS supplemented with 0.1%
10 (v/v) Tween 20, followed by two washes with 250 l/well of PBS. The ELISA
was developed by adding 50 l per well of SureBlue 1-Component TMB MicroWell Peroxidase solution (KPL, Gaithersberg, MD) and incubated at room temperature for several minutes until the desired colour intensity was obtained. The reaction was stopped by the addition of 100 1 of 1 M
hydrochloric acid and read at 450 nm (Figure 10).
?5 Generation and Expression of a Dual Specific Fab (DOM7h-2:CK DOM-24:CH) The produce a dual specific Fab the method used was essentially the same method as described for the dual specific dAb dimer (DOM7h-26-DOM-24) except that the DNA for the DOM7h-2 and DOM-24 dAbs were cloned into separate pPICz-alpha based vectors containing the human CK or human CH1 domain respectively. Each of the two vectors were designed to enable the expression of a single polypeptide consisting of the CH1 or CK
domain fused in frame to the 3' end of the appropriate dAb. To obtain expression of the complete Fab fragment, competent Pichia pastoris strain X33 were cotransformed with two linearised vectors.
Purification was as described for the dimer Fab.
Simultaneous AntiQen BindinLy of the Dual Specific Fab The simultaneous antigen binding of the dual specific Fab was carried out using the same assay as described for the dual specific dAb dimmer above. The results are shown in Figure 11.
Inhibition of CD40 mediated CD54 upregulation disruption of CD40 / CD40L
interaction in L3055 cells.
Monomeric dAb molecules were assayed for their ability to disrupt the binding of cellularly associated CD40L to CD40. This was determined by measuring the level inhibition of CD40 mediated CD54 upregulation on group 1 Burkitt lymphoma cell line L3055 by FACS.
CD40 displayed on the L3055 cells was stimulated by CD40L expressed on the surface of fibroblasts (typically mouse L-cells) transfected with the CD40L gene as previously described by 5 Garrone et al., 1995 (Garrone P., Neidhardt E.V., Garcia E., Galibert L., van Kooten C., Banchereau J. (1995) J Exp Med 182, 1265-1273.) Samples containing the dAbs were preincubated with the L-cells cells for 1 hour prior to the addition of the L3055 cells. Both cell lines were co-cultured for 22 hours following which the L-cells were stained for FACS analysis, as described by Baker et al., 1998 (Baker, M.P., ',0 Eliopoulos, A.G., Young, L.S., Armitage, R.J., Gregory, C.D., Gordon, J.
(1998) Blood, 92 (8), 2830-2843) and by Challa et al., 2002 (Challa, A., Eliopoulos, A.G., Holder, M.J., Burguete, A.S., Pound, J.D., Chamba, A., Grafton, G., Armitage, R.J., Gregory, C.D., Martinez-Valdez, H., Young, L. and Gordon, J. (2002) Blood, 99 (9), 3411-3418.
The FACS analysis of DOM-24 (monomeric form) at a concentration of 12 m showed :5 inhibition.
FACS analysis of the Vlc DOM-1 16 at a concentration of 9 M showed inhibition compared with a control blank dAb and the stimulated cell trace (Figure 13).
Effect of anti-CD40L therap)7 on primary immune response to KLH immunisation.
To show the effect of anti-CD40L therapy on the primary immune response to KLH
immunization a similar study to that described by Gobburu, J.V.S. et al., 1998 can be carried out (Gobburu, J.V.S., Tenhoor, C., Rogge, M.C., Frazier, D.E., Thomas, D., Benjamin, C., Hess, D.M., & Jusko, W.J. (1998) JPET, 286, 925-930.
A study example could be as follows: Cynomolgus monkeys are injected with an anti-CD40L antibody or dAb format at a dosing of 10mg/kg at time Oh, 168h and 336h.
At 24h the animals receive a single intradermal injection of 100 g highly purified keyhole limpet hemocyanin (KLH). The serum is tested for a KLH response prior to the start and following [0 completion of the study. The animals are allowed to recover for a suitable time to ensure that the dAb molecule has cleared the circulation, then injected with KLH (without dAb) to determine if the animal can raise an immune response against KLH. Alternative antigens can be used for the study if an earlier response to KLH is detected prior to the start of the study.
The immune response to KLH will be measured by a suitable ELISA, RIA or antibody 5 titer assay. It is anticipated that the results would show that that the PEglyated monomeric DOM-24 would suppress the animals immune response to KLH. This would be shown in the reduction of the antibody titer compared to a positive control. The results could be normalized such that the positive control was deemed to be 100 and the reduction in immune response after the administration of the dAbs would be in the range of 10 to 90% ie 90 to 10 units.
?0 Sequence of the DOM7h-26-DOM-24 LEKREV QLLES GGGL VQPGGSLRLSCTASGFTFDEYNMS WVRQAPGKGLEWV STILPH
GDRTYYAD SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKQDPLYRFDYWGQG
TLVTV S SAAAEVQLLESGGGLV QPGGSLRLSCAAS GFTFSNYQMAWVRQAPGKGLEW
V S SITSEGGSTYYAD S VKGRFTISRDNSKNTLYLQIv1NSLRAEDTA VYYCAKPGKNFDY
?5 WGQGTLVTVSS (SEQ ID NO: 88) Sequence of the DOM7h-26 DIQMTQ SPS SLSASV GDRVTITCRASQKIATYL-NTWYQQKPGKAPKLLIYRS S SLQSAVP S
RFSGSGSGTVFTLTISSLQPEDFATYYCQQTYAVPPTFGQGTRVEIKR (SEQ ID NO: 89) All patents, patent applications, and published references cited herein are hereby incorporated by reference in their entirety. While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.
Annex 1; polypeptides which enhance half-life in vivo.
Alpha-I Glycoprotein (Orosomucoid) (AAG) Alpha-1 Antichyromotrypsin (ACT) Alpha-I Antitrypsin (AAT) Alpha-1 Microglobulin (Protein HC) (AIM) Alpha-2 Macroglobulin (A2M) Antithrombin III (AT III) Apolipoprotein A-1 (Apo A-1) Apoliprotein B (Apo B) Beta-2-microglobulin (B2M) Ceruloplasmin (Cp) Complement Component (C3) Complement Component (C4) 5 C 1 Esterase Inhibitor (Cl INH) C-Reactive Protein (CRP) Cystatin C (Cys C) Ferritin (FER) Fibrinogen (FIB) ) Fibronectin (FN) Haptoglobin (Hp) Hemopea:in (HPX) Immunoglobulin A (IgA) Immunoglobulin D (IgD) Immunoglobulin E (1gE) Immunoglobulin G (IgG) Immunoglobulin M (IgM) Immunoglobulin Light Chains (kapa/lambda) Lipoprotein(a) [Lp(a)]
Mannose-bindign protein (MBP) l0 Myoglobin (Myo) Neonatal Fc (FcRn) Plasminogen (PSM) Prealbumin (Transthyretin) (PAL) Retinol-binding protein (RBP) Rheomatoid Factor (RF) Serum Amyloid A (SAA) Soluble Tranferrin Receptor (sTfR) Transferrin (Tf) Annex 2 Pairing Therapeutic relevant references.
TNF = TGF-b and TNF when injected into the ankle joint of collagen ALPHA/TGF- induced arthritis model significantly enhanced joint inflammation. In non-collagen challenged mice there was no effect.
TNF = TNF and IL-1 synergize in the pathology of uveitis.
= TNF and IL-1 synergize in the pathology of malaria (hypoglycaemia, NO).
= TNF and IL-1 synergize in the induction of polymorphonuclear (PMN) cells migration in inflammation.
= IL-1 and TNF synergize to induce PMN infiltration into the peritoneum.
= IL-1 and TNF synergize to induce the secretion of IL-1 by endothelial cells. Important in inflammation.
= IL-1 or TNF alone induced some cellular infiltration into knee synovium. IL-1 induced PMNs, TNF - monocytes. Together they induced a more severe infiltration due to increased PMNs.
= Circulating myocardial depressant substance (present in sepsis) is low levels of IL-1 and TNFacting synergistically.
TNF = Most relating to synergisitic activation of killer T-cells.
TNF = Synergy of interleukin 3 and tumor necrosis factor alpha in ALPHA/IL-3 stimulating clonal growtli of acute myelogenous leukemia blasts is the result of induction of secondary hematopoietic cytokines by tumor necrosis factor alpha.
= Cancer Res. 1992 Apr 15;52(8):2197-201.
TNF ,= IL-4 and TNF synergize to induce VCAM expression on ALPHA/IL-4 endothelial cells. Implied to have a role in asthma. Same for synovium - implicated in RA.
= TNF and IL-4 synergize to induce IL-6 expression in keratinocytes.
= Sustained elevated levels of VCAM-1 in cultured fibroblast-like synoviocytes can be achieved by TNF-alpha in combination with either IL-4 or IL-13 through increased mRNA stability. Am JPatliol. 1999 Apr;154(4):1149-58 TNF = Relationship between the tumor necrosis factor system and the ALPHA/IL-5 serum interleukin-4, interleukin-5, interleukin-8, eosinophil cationic protein, and immunoglobulin E levels in the bronchial hyperreactivity of adults and their children. Allergy Asthma Proc. 2003 Mar-Apr;24(2):111-8.
TNF = TNF and IL-6 are potent growth factors for OH-2, a novel ALPHA/IL-6 human myeloma cell line. Eur JHaefraatol. 1994 Ju1;53(1):31-7.
TNF = TNF and IL-8 synergized with PMNs to activate platelets.
ALPHA/IL-8 Implicated in Acute Respiratory Distress Syndrome.
= See IL-5/TNF (asthma). Synergism between interleukin-8 and tumor necrosis factor-alpha for neutrophil-mediated platelet activation. Eur Cytokine Netw. 1994 Sep-Oct;5(5):455-60.
(adult respiratory distress syndrome (ARDS)) TNF
TNF = IL-10 induces and synergizes with TNF in the induction of ALPHA/IL-10 HIV expression in chronically infected T-cells.
TNF = Cytokines synergistically induce osteoclast differentiation:
ALPHA/IL-11 support by immortalized or normal calvarial cells. A777 J
Physiol Cell Physiol. 2002 Sep;283(3):C679-87. (Bone loss) TNF
TNF = Sustained elevated levels of VCAM-1 in cultured fibroblast-ALPHA/IL-13 like synoviocytes can be achieved by TNF-alpha in combination with either IL-4 or IL-13 through increased mRNA stability. Am J Pathol. 1999 Apr;154(4):1149-58.
= Interleulcin-13 and tumour necrosis factor-alpha synergistically induce eotaxin production in human nasal fibroblasts. Clin Exp Allergy. 2000 Mar;30(3):348-55.
= Interleulcin-13 and tumour necrosis factor-alpha synergistically induce eotaxin production in human nasal fibroblasts. Cli Exp Alle7gv. 2000 Mar;30(3):348-55 (allergic inflammation) = Implications of serum TNF-beta and IL-13 in the treatment response of childhood nephrotic syndrome. Cytokine. 2003 Feb 7;21(3):155-9.
TNF = Effects of inhaled tumour necrosis factor alpha in subjects with ALPHA/IL-14 mild asthma. Thorax. 2002 Sep;57(9):774-8.
TNF = Effects of inhaled tumour necrosis factor alpha in subjects with ALPHA/IL-15 mild asthma. Thorax. 2002 Sep;57(9):774-8.
TNF = Tumor necrosis factor-alpha-induced synthesis of interleukin-ALPHA/IL-16 16 in airway epithelial cells: priming for serotonin stimulation.
An7 J Respir Cell Mol Biol. 2003 Mar;28(3):354-62. (airway inflainmation) = Correlation of circulating interleukin 16 with proinflammatory cytokines in patients with rheumatoid arthritis. Rheunatology (Oxford). 2001 Apr;40(4):474-5. No abstract available.
= Interleukin 16 is up-regulated in Crohn's disease and participates in TNBS colitis in mice. Gastroenterology. 2000 Oct;119(4):972-82.
TNF = Inhibition of interleukin-17 prevents the development of ALPHA/IL-17 arthritis in vaccinated mice challenged with Borrelia burgdorferi. Infect bnmun. 2003 Jun;71(6):3437-42.
= Interleukin 17 synergises with tumour necrosis factor alpha to induce cartilage destruction in vitro. Ann Rheum Dis. 2002 Oct;61(10):870-6.
= A role of GM-CSF in the accumulation of neutrophils in the airways caused by IL-17 and TNF-alpha. Eur Respir J. 2003 Mar;21(3):387-93. (Airway inflammation) = Abstract Interleukin-1, tumor necrosis factor alpha, and interleukin-17 synergistically up-regulate nitric oxide and prostaglandin E2 production in explants of human osteoarthritic knee menisci. Arthritis Rheum. 2001 Sep;44(9):2078-83.
TNF = Association of interleukin-18 expression with enhanced levels of both interleukin-Ibeta and tumor necrosis factor alpha in ALPHA/IL-18 I:nee synovial tissue of patients with rheumatoid arthritis.
A71h7-itis Rheum. 2003 Feb;48(2):33 9-47.
= Abstract Elevated levels of interleul:in-18 and tumor necrosis factor-alpha in serum of patients with type 2 diabetes mellitus:
relationship with diabetic nephropathy. Metabolisnz. 2003 May;52(5):605-8.
TNF = Abstract IL-19 induces production of IL-6 and TNF-alpha and ALPHA/IL-19 results in cell apoptosis through TNF-alpha. J Immunol. 2002 Oct 15;169(8):4288-97.
TNF = Abstract Cytolcines: IL-20 - a new effector in skin ALPHA/IL-20 inflammation. CurrBiol. 2001 Jul 10;11(13):R531-4 TNF = Inflammation and coagulation: implications for the septic ALPHA/Comp patient. Clin Infect Dis. 2003 May 15;36(10):1259-65. Epub lement 2003 May 08. Review.
TNF = MHC induction in the brain.
ALPHA/IFN-y = Synergize in anti-viral response/IFN-(3 induction.
= Neutrophil activation/ respiratory burst.
= Endothelial cell activation = Toxicities noted when patients treated with TNF/IFN-y as anti-viral therapy = Fractalkine expression by human astrocytes.
= Many papers on inflammatory responses - i.e. LPS, also macrophage activation.
= Anti-TNF and anti-IFN-7 synergize to protect mice from lethal endotoxemia.
TGF-(3/IL-1 = Prostaglndin synthesis by osteoblasts = IL-6 production by intestinal epithelial cells (inflammation model) = Stimulates IL-11 and IL-6 in lung fibroblasts (inflammation model) = IL-6 and IL-8 production in the retina TGF-(3/IL-6 = Chondrocarcoma proliferation IL-1/IL-2 = B-cell activation = LAK cell activation = T-cell activation = IL-1 synergy with IL-2 in the generation of lymphokine activated killer cells is mediated by TNF-alpha and beta (lymphotoxin). Cytokine. 1992 Nov;4(6) :479-87.
IL-1/IL-4 = B-cell activation = IL-4 induces IL-1 expression in endothelial cell activation.
IL-1/IL-6 = B cell activation = T cell activation (can replace accessory cells) = IL-1 induces IL-6 expression = C3 and serum amyloid expression (acute phase response) = HIV expression = Cartilage collagen breakdown.
IL-1/IL-7 = IL-7 is requisite for IL-1-induced thymocyte proliferation.
Involvement of IL-7 in the synergistic effects of granulocyte-macrophage colony-stimulating factor or tumor necrosis factor with IL-1. Jbnmu ol. 1992 Jan 1;148(1):99-105.
IL-1/IL-ll = Cytokines synergistically induce osteoclast differentiation:
support by immortalized or normal calvarial cells. A i J
Pliysiol Cell Pliysiol. 2002 Sep;283('D):C679-87. (Bone loss) IL-1/IL-16 = Correlation of circulating interleukin 16 with proinflammatory cytokines in patients with rheumatoid arthritis. Rheumatology (Oxford). 2001 Apr;40(4):474-5. No abstract available.
IL-1/IL-17 = Inhibition of interleukin-17 prevents the development of arthritis in vaccinated mice challenged with Borrelia burgdorferi. If7fect Imr~~ur~. 2003 Jun;71(6):3437-42.
= Contribution of interleukin 17 to human cartilage degradation and synovial inflammation in osteoarthritis. Osteoarthritis Cartilage. 2002 Oct;10(10):799-807.
= Abstract Interleukin-1, tumor necrosis factor alpha, and interleukin-17 synergistically up-regulate nitric oxide and prostaglandin E2 production in explants of human osteoarthritic knee menisci. Arthritis Rheum. 2001 Sep;44(9):2078-83.
IL-1/IL-18 = Association of interleukin-18 expression with enhanced levels of both interleukin-lbeta and tumor necrosis factor alpha in lcnee synovial tissue of patients with rheumatoid arthritis.
A7=tlzritis Rheum. 2003 Feb;48(2):339-47.
IL-1 /IFN-g IL-2/IL-3 = T-cell proliferation = B cell proliferation IL-2/IL-4 = B-cell proliferation = T-cell proliferation =(selectively inducing activation of CD8 and NK
lymphocytes)IL-2R beta agonist P 1-30 acts in synergy with IL-2, IL-4, IL-9, and IL-15: biological and molecular effects. J
1777mu7lol. 2000 Oct 15;165(8): 4312-8.
IL-2/IL-5 = B-cell proliferation/ Ig secretion = IL-5 induces IL-2 receptors on B-cells IL-2/IL-6 = Development of cytotoxic T-cells IL-2/IL-9 = See IL-2/IL-4 (NK-cells) IL-2/IL-10 = B-cell activation IL-2/IL-12 = IL-12 synergizes with IL-2 to induce lymphokine-activated c3,totoxicity and perforin and granzyme gene expression in fresh human NK cells. Cell Inninunol. 1995 Oct 1;165(1):33-43. (T-cell activation) IL-2/IL-15 = See IL-2/IL-4 (NK cells) =(T cell activation and proliferation) IL- 15 and IL-2: a matter of life and death for T cells in vivo. Nat Med. 2001 Jan;7(1):114-8.
IL-2/IL-16 = Synergistic activation of CD4+ T cells by IL-16 and IL-2. J
Inanzunol. 1998 Mar 1;160(5):2115-20.
IL-2/IL-17 = Evidence for the early involvement of interleukin 17 in human and experimental renal allograft rejection. J Pat.hol. 2002 Jul;197(3):322-32.
IL-2/IL-18 = Interleukin 18 (IL-18) in synergy with IL-2 induces lethal lung injury in mice: a potential role for cytokines, chemokines, and natural killer cells in the pathogenesis of interstitial pneumonia. Blood. 2002 Feb 15;99(4):1289-98.
IL-2/TGF-(3 = Control of CD4 effector fate: transforming growth factor beta 1 and interleukin 2 synergize to prevent apoptosis and promote effector expansion. JExp Med. 1995 Sep 1;182(3):699-709.
IL-2/IFN-y = Ig secretion by B-cells = IL-2 induces IFN-y expression by T-cells IL-2/IFN-a/(3 = None IL-3/IL-4 = Synergize in mast cell growth = Synergistic effects of IL-4 and either GM-CSF or IL-3 on the induction of CD23 expression by human monocytes:
regulatory effects of IFN-alpha and IFN-gamma. Cytokine.
1994 Jul;6(4):407-13.
IL-3/IFN-y = IL-4 and IFN-gamma synergistically increase total polymeric IgA receptor levels in human intestinal epithelial cells. Role of protein tyrosine kinases. J Imnaunol. 1996 Jun 15;156(12):4807-14.
IL-3/GM-CSF = Differential regulation of human eosinophil IL-3, IL-5, and GM-CSF receptor alpha-chain expression by cytokines: IL-3, IL-5, and GM-CSF down-regulate IL-5 receptor alpha expression with loss of IL-5 responsiveness, but up-regulate IL-3 receptor alpha expression. J Irnnunol. 2003 Jun 1;170(11):5359-66. (allergic inflammation) IL-4/IL-2 = IL-4 synergistically enhances both IL-2- and IL-12-induced IFN-{gamma} expression in murine NK cells. Blood. 2003 Mar 13 [Epub ahead of print]
IL-4/IL-5 = Enhanced mast cell histamine etc. secretion in response to IgE
= A Th2-like cytokine response is involved in bullous pemphigoid. the role of IL-4 and IL-5 in the pathogenesis of the disease. Iizt J brnnunopathol PharMacol. 1999 May-Aug;12(2):55-61.
IL-4/IL-11 = Synergistic interactions between interleulcin-11 and interleukin-4 in support of proliferation of primitive hematopoietic progenitors of mice. Blood. 1991 Sep 15;78(6):1448-5 1.
IL-4/IL-12 = Synergistic effects of IL-4 and IL-18 on IL-12-dependent IFN-gamma production by dendritic cells. J 17n777u7iol. 2000 Jan 1;164(1):64-71. (increase Thl/Th2 differentiation) = IL-4 synergistically enhances both IL-2- and IL-12-induced IFN-{gamma} expression in murine NK cells. Blood. 2003 Mar 13 [Epub ahead of print]
IL-4/IL-13 = Abstract Interleukin-4 and interleukin-13 signaling connections maps. Scie ce. 2003 Jun 6;300(5625):1527-8.
(allergy, asthma) = Inhibition of the IL-4/IL-13 receptor system prevents allergic sensitization without affecting established allergy in a mouse model for allergic asthma. J Allergy Clin Imrnunol. 2003 Jun;111(6):1361-1369.
IL-4/IL-16 =(asthrna) Interleukin (IL)-4/IL-9 and exogenous IL-16 induce IL-16 production by BEAS-2B cells, a bronchial epithelial cell line. Celllmmunol. 2001 Feb 1;207(2):75-80 IL-4/IL-17 = Interleukin (IL)-4 and IL-17 synergistically stimulate IL-6 secretion in human colonic myofibroblasts. bzt J Mol Med.
2002 Nov;10(5):631-4. (Gut inflammation) IL-4/IL-24 = IL-24 is expressed by rat and human macrophages.
Immunobiology. 2002 Jul;205(3):321-34.
IL-4/IL-25 = Abstract New IL-17 family members promote Thl or Th2 responses in the lung: in vivo function of the novel cytokine IL-25. J Inznzunol. 2002 Jul 1;169(1):443-53. (allergic inflammation) = Abstract Mast cells produce interleukin-25 upon Fcepsilon RI-mediated activation. Blood. 2003 May 1;101(9):3594-6. Epub 2003 Jan 02. (allergic inflammation) IL-4/IFN-y = Abstract Interleukin 4 induces interleukin 6 production by endothelial cells: synergy with interferon-gamma. Eur J
Ir munol. 1991 Jan;21(1):97-101.
IL-4/SCF = Regulation of human intestinal mast cells by stem cell factor and IL-4. Inzmunol Rev. 2001 Feb;179:57-60. Review.
IL-5/IL-3 = Differential regulation of human eosinophil IL-3, IL-5, and GM-CSF receptor alpha-chain expression by cytokines: IL-3, IL-5, and GM-CSF down-regulate IL-5 receptor alpha expression with loss of IL-5 responsiveness, but up-regulate IL-3 receptor alpha expression. J Irnfnunol. 2003 Jun 1;170(11):5359-66. (Allergic inflammation see abstract) IL-5/IL-13 = Inhibition of allergic airways inflammation and airway hyperresponsiveness in mice by dexamethasone: role of eosinophils, IL-5, eotaxin, and IL-13. JAllergy Clif1 I717771unol.
2003 May;111(5):1049-61.
IL-5/IL-17 = Interleukin-17 orchestrates the granulocyte influx into airways after allergen inhalation in a mouse model of allergic asthma.
Am JRespir Cell Mol Biol. 2003 Jan;28(1):42-50.
IL-5/IL-25 = Abstract New IL-17 family members promote Thl or Th2 responses in the lung: in vivo function of the novel cytokine IL-25. J Irl?7nu ol. 2002 Jul 1;169(1):443-53. (allergic inflammation) = Abstract Mast cells produce interleukin-25 upon Fcepsilon RI-mediated activation. Blood. 2003 May 1;101(9):3594-6. Epub 2003 Jan 02. (allergic inflammation) IL-5/IFN-y IL-5/GM-CSF = Differential regulation of human eosinophil IL-3, IL-5, and GM-CSF receptor alpha-chain expression by cytokines: IL-3, IL-5, and GM-CSF down-regulate IL-5 receptor alpha expression with loss of IL-5 responsiveness, but up-regulate IL-3 receptor alpha expression. J bnzmunol. 2003 Jun 1;170(11):5359-66. (Allergic inflammation) IL-6/IL-16 = Interleukin-16 stimulates the expression and production of pro-inflammatory cytokines by human monocytes. Immunology.
2000 May;100(1):63-9.
IL-6/IL-17 = Stimulation of airway mucin gene expression by interleukin (IL)-17 through IL-6 paracrine/autocrine loop. J Biol Chem.
2003 May 9;278(19):17036-43. Epub 2003 Mar 06. (airway inflammation, asthma) IL-6/IL-19 = Abstract IL-19 induces production of IL-6 and TNF-alpha and results in cell apoptosis through TNF-alpha. J Inamunol. 2002 Oct 15;169(8):4288-97.
IL-6/IFN-g IL-7/IL-2 = Interleukin 7 worsens graft-versus-host disease. Blood. 2002 Oct 1;100(7):2642-9.
IL-7/IL-12 = Synergistic effects of IL-7 and IL-12 on human T cell activation. Jlnnnunol. 1995 May 15;154(10):5093-102.
IL-7/IL-15 = Interleukin-7 and interleukin-15 regulate the expression of the bcl-2 and c-myb enes in cutaneous T-cell lymphoma cells.
Blood. 2001 Nov 1;98(9):2778-83. (growth factor) IL-8/IL-11 = Abnormal production of interleukin (IL)-11 and IL-8 in polycythaemia vera. Cytokine. 2002 Nov 21;20(4):178-83.
IL-8/IL-17 = The Role of IL-17 in Joint Destruction. D7-ug NeWs Perspect.
2002 Jan;15(l):17-23. (arthritis) = Abstract Interleukin-17 stimulates the expression of interleukin-8, growth-related oncogene-alpha, and granulocyte-colony-stimulating factor by human airway epithelial cells. Am J Respir Cell Mol Biol. 2002 Jun;26(6):748-53. (airway inflammation) IL-8/GSF = Interleukin-8: an autocrine/paracrine growth factor for human hematopoietic progenitors acting in synergy with colony stimulating factor-1 to promote monocyte-macrophage growth and differentiation. Exp Hematol. 1999 Jan;27(1):28-36.
IL-8/VGEF = Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. J Neurooncol. 2003 May;62(3):297-303.
IL-9/IL-4 = Anti-interleukin-9 antibody treatment inhibits airway inflammation and hyperreactivity in mouse asthma model. A777 JRespiT Crit Care Med. 2002 Aug 1;166(3):409-16.
IL-9/IL-5 = Pulmonary overexpression of IL-9 induces Th2 cytokine expression, leading to immune pathology. J Clin Invest. 2002 Jan;109(1):29-39.
= Th2 cytokines and asthma. Interleukin-9 as a therapeutic target for asthma. Respir Res. 2001;2(2):80-4. Epub 2001 Feb 15.
Review.
= Abstract Interleukin-9 enhances interleukin-5 receptor expression, differentiation, and survival of human eosinophils.
Blood. 2000 Sep 15;96(6):2163-71 (asthma) IL-9/IL-13 = Anti-interleukin-9 antibody treatment inhibits airway inflainmation and hyperreactivity in mouse asthma model. A771 JRespir Crit Care Med. 2002 Aug 1;166(3):409-16.
= Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma. Nat Med.
2002 Aug;8(8):885-9.
IL-9/IL-16 = See IL-4/IL-16 IL-10/IL-2 = The interplay of interleukin-10 (IL-10) and interleukin-2 (IL-2) in humoral immune responses: IL-l0 synergizes with IL-2 to enhance responses of human B lymphocytes in a mechanism which is different from upregulation of CD25 expression. Cell linmunol. 1994 Sep;157(2):478-88.
IL-10/TGF-(3 = IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur Jlmmunol. 2003 May;33(5):1205-14.
IL-10/IFN-y IL-11/IL-6 = Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone. 2003 Jan;32(1):1-7. (bone resorption in inflammation) IL-11/IL-17 = Polarized in vivo expression of IL-11 and IL-17 between acute and chronic skin lesions. J Allergy Clin Imnaunol. 2003 Apr;111(4):875-81. (allergic dermatitis) = IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B
ligand/osteoprotegerin balance. J Imniunol. 2003 Mar 1;170(5):2655-62.
IL-11/TGF-(3 = Polarized in vivo expression of IL-11 and IL- 17 between acute and chronic skin lesions. J Allergy Clin Iinmunol. 2003 Apr;111(4):875-81. (allergic dermatitis) IL-12/IL-13 = Relationship of Interleukin-12 and Interleukin-13 imbalance with class-specific rheumatoid factors and anticardiolipin antibodies in systemic lupus erythematosus. Clin Rh.eu7natol.
2003 May;22(2):107-11.
IL-12/IL-17 = Upregulation of interleukin-12 and -17 in active inflammatory bowel disease. Scand JGastroenterol. 2003 Feb;38(2):180-5.
IL-12/IL-18 = Synergistic proliferation and activation of natural killer cells by interleukin 12 and interleukin 18. Cytokine. 1999 Nov;11(11):822-30.
= Inflammatory Liver Steatosis Caused by IL-12 and IL-18. J
bzte7feron Cytokine Res. 2003 Mar;23(3):155-62.
IL-12/IL-23 = nterleukin-23 rather than interleukin- 12 is the critical cytokine for autoimmune inflammation of the brain. Nature. 2003 Feb 13;421(6924):744-8.
= Abstract A unique role for IL-23 in promoting cellular immunity. JLeukoc Biol. 2003 Jan;73(1):49-56. Review.
IL-12/IL-27 = Abstract IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells.
1777772unity. 2002 Jun;16(6):779-90.
IL-12/IFN-y = IL-12 induces IFN-y expression by B and T-cells as part of immune stimulation.
IL-13/IL-5 = See IL-5/IL-13 IL-13/IL-25 = Abstract New IL-17 family members promote Th1 or Th2 responses in the lung: in vivo function of the novel cytokine IL-25. J.Iinmunol. 2002 Jul 1;169(1):443-53. (allergic inflammation) = Abstract Mast cells produce interleukin-25 upon Fcepsilon RI-mediated activation. Blood. 2003 May 1;101(9):3594-6. Epub 2003 Jan 02. (allergic inflammation) IL-15/IL-13 = Differential expression of interleukins (IL)-13 and IL-15 in ectopic and eutopic endometrium of women with endometriosis and normal fertile women. Am J Reprod Irnnaunol. 2003 Feb;49(2):75-83.
IL-15/IL-16 = IL-15 and IL-16 overexpression in cutaneous T-cell lymphomas: stage-dependent increase in mycosis fungoides progression. Ea.p Dermatol. 2000 Aug;9(4):248-5 1.
IL-15/IL-17 = Abstract IL-17, produced by lymphocytes and neutrophils, is necessary for lipopolysaccharide-induced airway neutrophilia:
IL-15 as a possible trigger. J b77777unol. 2003 Feb 15;170(4):2106-12. (airway inflammation) IL-15/IL-21 = IL-21 in Synergy with IL-15 or IL-18 Enhances IFN-gamma Production in Human NK and T Cells. J hnmunol. 2003 Jun 1;170(11):5464-9.
IL-17/IL-23 = Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleulcin-17. J Biol Clzem. 2003 Jan 17;278(3):1910-4. Epub 2002 Nov 0'j IL-17/TGF-(3 = Polarized in vivo expression of IL-I l and IL- 17 between acute and chronic skin lesions. J Allergy Clin Inzmunol. 2003 Apr;111(4):875-81. (allergic dermatitis) IL-18/IL-12 = Synergistic proliferation and activation of natural killer cells by interleukin 12 and interleukin 18. Cytokine. 1999 Nov;11(11):822-30.
= Abstract Inhibition of in vitro immunoglobulin production by IL-12 in murine chronic graft-vs.-host disease: synergism with IL-18. EurJln7777unol. 1998 Jun;28(6):2017-24.
IL-18/IL-21 = IL-21 in Synergy with IL-15 or IL-18 Enhances IFN-gamma Production in Human NK and T Cells. J Irnmunol. 2003 Jun 1;170(11):5464-9.
IL-18/TGF-(3 = Interleukin 18 and transforming growth factor betal in the serum of patients with Graves' ophthalmopathy treated with corticosteroids. Int Innmunopharnzacol. 2003 Apr;3(4):549-52.
IL-18/IFN-y Anti-TNF = Synergistic therapeutic effect in DBA/1 arthritic mice.
ALPHA/anti-Annex 3: Oneology combinations Target Disease Pair with CD89* Use as cytotoxic cell all recruiter CD 19 B cell lymphomas HLA-DR
HLA-DR B cell lymphomas CD89 CD38 Multiple myeloma CD138 HLA-DR
CD138 Multiple myeloma CD38 HLA-DR
CD138 Lung cancer CD56 CEA
CD33 Acute myelod lymphoma CD34 HLA-DR
CD56 Lung cancer CD138 CEA
CEA Pan carcinoma MET receptor"
VEGF Pan carcinoma MET receptor VEGF Pan carcinoma MET receptor receptor IL-13 Asthma/pulmonary IL-4 inflammation Eotaxin(s) MDC
TARC
TNFa EGFR
TGF(3 IL-4 Asthma IL-13 Eotaxin(s) MDC
TARC
TNFa EGFR
MCP-l TGF(3 Eotaxin Astlima IL-5 Eotaxin-2 Eotaxin-3 EGFR cancer HER2/neu HER2 cancer HER3 TNFRI RA/Crohn's disease IL-1R
TNFa RAICrohn's disease IL-la/(3 IL-IR RA/Crohn's disease IL-6R
IL-18R RA/Crolin's disease IL-6R
DEMANDE OU BREVET VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND
PLUS D'UN TOME.
NOTE : Pour les tomes additionels, veuillez contacter le Bureau canadien des brevets JUMBO APPLICATIONS/PATENTS
THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE
VOLUME
NOTE: For additional volumes, please contact the Canadian Patent Office NOM DU FICHIER / FILE NAME:
NOTE POUR LE TOME / VOLUME NOTE:
Claims (106)
1. A method of antagonizing an activity of CD40 or CD40L in an individual, the method comprising administering an antibody polypeptide that is monovalent for binding to CD40L
(gp39) to said individual wherein said polypeptide antagonizes an activity of CD40 or CD40L or both.
(gp39) to said individual wherein said polypeptide antagonizes an activity of CD40 or CD40L or both.
2. A method of antagonizing the binding of CD40 to CD40L in an individual, the method comprising administering an antibody polypeptide that is monovalent for binding to CD40L
(gp39) to said individual, wherein said polypeptide antagonizes the binding of CD40 to CD40L
in said individual.
(gp39) to said individual, wherein said polypeptide antagonizes the binding of CD40 to CD40L
in said individual.
3. A method of treating or preventing a symptom of autoimmune disease in an individual, the method comprising administering a monovalent anti-CD40L antibody polypeptide to said individual in an amount effective to treat or prevent a symptom of autoimmune disease.
4. A method of treating or preventing an autoimmune disease in an individual, the method comprising administering a monovalent anti-CD40L antibody polypeptide to said individual in an amount effective to treat or prevent a symptom of autoimmune disease.
5. The method of claim 3, wherein said autoimmune disease is a disease selected from the group consisting of systemic lupus erythematosis, multiple sclerosis, rheumatoid arthritis, Diabetes, allograft rejection, xenograft transplant rejection, and graft vs. host disease.
6. The method of claim 3, wherein said antibody polypeptide inhibits the binding of CD40L to CD40.
7. The method of claim 3, wherein said antibody polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs 7-82, SEQ ID NOs 246-360, and DOM8-24.
8. The method of claim 3, wherein said antibody polypeptide has an amino acid sequence at least 85% identical to a sequence selected from the group consisting of SEQ ID
NOs 7-82 and 246-360, which antibody polypeptide specifically and monovalently binds CD40L.
NOs 7-82 and 246-360, which antibody polypeptide specifically and monovalently binds CD40L.
9. The method of claim 6, wherein said antibody polypeptide inhibits binding of CD40L to CD40 with an IC50 in the range of 20 M to 1.5 µM, inclusive.
10. The method of claim 3, wherein said antibody polypeptide is PEG-linked.
11. The method of claim 10, wherein said PEG-linked antibody polypeptide has a hydrodynamic size of at least 24 kD.
12. The method of claim 10 wherein said PEG is linked to said antibody at a cysteine or lysine residue.
13. The method of claim 10 wherein the total PEG size is from 20 to 60 kD, inclusive.
14. The method of claim 10 wherein said PEG-linked antibody polypeptide has a hydrodynamic size of at least 200 kD.
15. The method of claim 10 wherein said PEG-linked antibody polypeptide has an increased in vivo half-life relative to the same polypeptide composition lacking linked polyethylene glycol.
16. The method of claim 15 wherein the t.alpha.-half life of the polypeptide composition is increased by l0% or more.
17. The method of claim 15 wherein the t.alpha.-half life of the polypeptide composition is in the range of 0.25 minutes to 12 hours.
18. The method of claim 15 wherein the t.alpha.-half life of the polypeptide composition is increased by 10% or more.
19. The method of claim 15 wherein the t.alpha.-half life is in the range of 12 to 48 hours.
20. The method of claim 1 or 2 wherein said antibody polypeptide is a camelid or nurse shark V HH domain.
21. An antibody polypeptide that is monovalent for binding to CD40L (gp39), wherein binding of said antibody polypeptide to CD40L does not substantially agonize CD40 and/or CD40L
activity.
activity.
22. The antibody of claim 21 wherein said antibody polypeptide inhibits the binding of CD40 to CD40L, and does not substantially agonize signaling by CD40.
23. The antibody polypeptide of claim 21 wherein binding of said antibody polypeptide to CD40L does not substantially induce JNK phosphorylation in Jurkat T-cells.
24. The antibody polypeptide of claim 21 wherein binding of said antibody polypeptide to CD40L does not substantially induce IFN-.gamma. secretion by Jurkat T-cells co-stimulated with anti-CD3 antibody.
25. The antibody polypeptide of claim 21 wherein the presence of said antibody polypeptide in a standard platelet aggregation assay does not result in aggregation of more than 25% over the aggregation observed in a negative control assay.
26. The antibody polypeptide of claim 21 in which said antibody polypeptide is selected from the group consisting of an antibody single variable domain polypeptide, dAb, FAb, an scFv, an Fv, or a disulfide-bonded Fv.
27. An antibody polypeptide that is monovalent for binding to CD40L (gp39), wherein the presence of said antibody polypeptide in a standard platelet aggregation assay does not result in aggregation of more than 25% over the aggregation observed in a negative control assay.
28. A PEG-linked antibody polypeptide of claim 21.
29. The PEG-linked antibody polypeptide of claim 28 which has a hydrodynamic size of at least 24 kD.
30. The PEG-linked antibody polypeptide of claim 28 wherein said PEG is linked to said antibody at a cysteine or lysine residue.
31. The PEG-linked antibody polypeptide of claim 28 wherein the total PEG size is from 20 to 60 kD, inclusive.
32. The PEG-linked antibody polypeptide of claim 28 which has a hydrodynamic size of at least 200 kD.
33. The PEG-linked antibody polypeptide of claim 28 which has an increased in vivo half-life relative to the same polypeptide composition lacking linked polyethylene glycol.
34. The PEG-linked antibody polypeptide of claim 33 wherein the t.alpha.-half life of the polypeptide composition is increased by 10% or more.
35. The PEG-linked antibody polypeptide of claim 33 wherein the t.alpha.-half life of the polypeptide composition is in the range of 0.25 minutes to 12 hours.
36. The PEG-linked antibody polypeptide of claim 33 wherein the t.alpha.-half life of the polypeptide composition is increased by 10% or more.
37. The PEG-linked antibody polypeptide of claim 33 wherein the t.alpha.-half life is in the range of 12 to 48 hours.
38. The antibody of claim 21 which comprises an amino acid sequence selected from the group consisting of SEQ ID NOs 7-82 and 246-360.
39. The antibody polypeptide of claim 21 which is free of an Fc domain.
40. The antibody polypeptide of claim 39 wherein the presence of said antibody polypeptide in a standard platelet aggregation assay does not result in aggregation of more than 25% over the aggregation observed in a negative control assay.
41. The antibody of claim 21 which inhibits binding of CD40L to CD40 with an IC50 in the range of 20 pM to 1.5 µM, inclusive.
42. A composition comprising the antibody polypeptide of claim 21 and a second antibody polypeptide which binds a ligand other than CD40L, wherein said antibody polypeptide which binds a ligand other than CD40L binds a ligand selected from the group consisting of HSA, TNF.alpha., IL-1, IL-2, IL-4, IL-6, IL-8, IL-12, IL-18, IFN-.gamma., CD2, CD4, CD8, LFA1, LFA3, VLA4, CD80, B7-1, CD28, CD86, B7-2, CTLA-4 CD28, Inducible costimulatory molecule (ICOS), CD27, CD30, OX40, CD45, CD69, CD3, CD70, Inducible costimulatory molecule ligand (ICOSL), OX40L, HVEM (Herpes Virus Entry Mediator), LIGHT.
43. An antibody polypeptide which has an amino acid sequence at least 85%
identical to a sequence selected from the group consisting of SEQ ID NOs 7-82, SEQ ID NOs 246-360, and DOM8-24, which antibody polypeptide specifically and monovalently binds CD40L.
identical to a sequence selected from the group consisting of SEQ ID NOs 7-82, SEQ ID NOs 246-360, and DOM8-24, which antibody polypeptide specifically and monovalently binds CD40L.
44. An antigen-binding polypeptide, said polypeptide comprising a immunoglobulin single variable domain which specifically and monovalently binds CD40L, wherein said polypeptide substantially inhibits the binding of CD40L to CD40.
45. The antigen-binding polypeptide of claim 44 which inhibits the binding of CD40 to CD40L
with an IC50 in the range of 20 pM to 1.5 µM, inclusive.
with an IC50 in the range of 20 pM to 1.5 µM, inclusive.
46. The antigen-binding polypeptide of claim 44 wherein binding of said polypeptide to CD40L
does not substantially agonize CD40 and/or CD40L activity.
does not substantially agonize CD40 and/or CD40L activity.
47. The antigen-binding polypeptide of claim 44 wherein binding of said polypeptide to CD40L
does not substantially induce JNK phosphorylation in Jurkat T-cells.
45. The antigen-binding polypeptide of claim 44 wherein binding of said polypeptide to CD40L
does not substantially induce IFN-.gamma. secretion by Jurkat T-cells co-stimulated with anti-CD3 antibody.
46. The antigen-binding polypeptide of claim 44 wherein the presence of said antibody polypeptide in a standard platelet aggregation assay does not result in aggregation of more than 25% over the aggregation observed in a negative control assay.
47. The antigen-binding polypeptide of claim 44 in which said antigen-binding polypeptide is selected from the group consisting of an antibody single variable domain polypeptide, dAb, FAb, an scFv, an Fv, or a disulfide-bonded Fv.
does not substantially induce JNK phosphorylation in Jurkat T-cells.
45. The antigen-binding polypeptide of claim 44 wherein binding of said polypeptide to CD40L
does not substantially induce IFN-.gamma. secretion by Jurkat T-cells co-stimulated with anti-CD3 antibody.
46. The antigen-binding polypeptide of claim 44 wherein the presence of said antibody polypeptide in a standard platelet aggregation assay does not result in aggregation of more than 25% over the aggregation observed in a negative control assay.
47. The antigen-binding polypeptide of claim 44 in which said antigen-binding polypeptide is selected from the group consisting of an antibody single variable domain polypeptide, dAb, FAb, an scFv, an Fv, or a disulfide-bonded Fv.
48. A polypeptide according to claim 21 or 44, wherein the anti-CD40L variable domain or dAb comprises one or more framework regions comprising an amino acid sequence that is the same as the amino acid sequence of a corresponding framework region encoded by a human germline antibody gene segment, or the amino acid sequence of one or more of said framework regions collectively comprises up to 5 amino acid differences relative to the amino acid sequence of said corresponding framework region encoded by a human germline antibody gene segment.
49. A polypeptide according to claim 21 or 44, wherein the amino acid sequences of FW1, FW2, FW3 and FW4 of the anti-CD40L variable domain or dAb are the same as the amino acid sequences of corresponding framework regions encoded by a human germline antibody gene segment, or the amino acid sequences of FW1, FW2, FW3 and FW4 collectively contain up to amino acid differences relative to the amino acid sequences of corresponding framework regions encoded by said human germline antibody gene segment.
50. The polypeptide according to claim 49, wherein the amino acid sequences of said FW1, FW2 and FW3 of the anti-CD40L variable domain or dAb are the same as the amino acid sequences of corresponding framework regions encoded by human germline antibody gene segments.
51. The polypeptide according to claim 49, wherein said human germline antibody gene segment is selected from the group consisting of DP47, DP45, DP48 and DPK9.
52. A PEG-linked antigen-binding polypeptide comprising a single immunoglobulin variable domain which specifically and monovalently binds CD40L.
53. The PEG-linked polypeptide of claim 52 which has a hydrodynamic size of at least 24 kD.
54. The PEG-linked polypeptide of claim 52 wherein said PEG is linked to said antibody at a cysteine or lysine residue.
55. The PEG-linked polypeptide of claim 52 wherein the total PEG size is from 20 to 60 kD, inclusive.
56. The PEG-linked polypeptide of claim 52 which has a hydrodynamic size of at least 200 kD.
57. The PEG-linked polypeptide of claim 52 which has an increased in vivo half-life relative to the same polypeptide composition lacking linked polyethylene glycol.
58. The PEG-linked polypeptide of claim 52 wherein the t.alpha.-half life of the polypeptide composition is increased by 10% or more.
59. The PEG-linked polypeptide of claim 52 wherein the t.alpha.-half life of the polypeptide composition is in the range of 0.25 minutes to 12 hours.
60. The PEG-linked polypeptide of claim 52 wherein the t.alpha.-half life of the polypeptide composition is increased by 10% or more.
61. The PEG-linked polypeptide of claim 60 wherein the t.alpha.-half life is in the range of 12 to 48 hours.
62. An immunoglobulin variable domain polypeptide, said polypeptide comprising a single immunoglobulin variable domain which specifically and monovalently binds CD40L, and which comprises an amino acid sequence selected from the group consisting of SEQ ID
NOs 7-82, SEQ
ID NOs 246-360, and DOM8-24.
NOs 7-82, SEQ
ID NOs 246-360, and DOM8-24.
63. An immunoglobulin variable domain polypeptide which has an amino acid sequence at least 85% identical to a sequence selected from the group consisting of SEQ ID NOs 7-82, SEQ ID
NOs 246-360, and DOM8-24, which polypeptide specifically and monovalently binds CD40L.
NOs 246-360, and DOM8-24, which polypeptide specifically and monovalently binds CD40L.
64. The immunoglobulin variable domain polypeptide of claim 63 which comprises a single immunoglobulin variable domain which specifically and monovalently binds CD40L.
65. The immunoglobulin variable domain polypeptide of claim 63 which antagonizes the binding of CD40L.
66. The immunoglobulin variable domain polypeptide of claim 63 which inhibits the binding of CD40 to CD40L and which has an IC50 in the range of 20 pM to 1.5 µM, inclusive.
67. The immunoglobulin variable domain polypeptide of claim 63 wherein said antigen-binding polypeptide inhibits the interaction of CD40 with CD40L, but does not substantially agonize signaling by CD40.
68. A composition comprising the immunoglobulin variable domain polypeptide of claim 63 and a second immunoglobulin variable domain polypeptide which binds a ligand other than CD40L.
69. The composition of claim 68 wherein said antibody polypeptide which binds a ligand other than CD40L binds a ligand selected from the group consisting of HSA, TNF.alpha., IL-1, IL-2, IL-4, IL-6, IL-8, IL-12, IL-18, IFN-.gamma., CD2, CD4, CD8, LFA1, LFA3, VLA4, CD80, B7-1, CD28, CD86, B7-2, CTLA-4 CD28, Inducible costimulatory molecule (ICOS), CD27, CD30, OX40, CD45, CD69, CD3, CD70, Inducible costimulatory molecule ligand (ICOSL), OX40L, HVEM
(Herpes Virus Entry Mediator), LIGHT.
(Herpes Virus Entry Mediator), LIGHT.
70. An extended release pharmaceutical formulation comprising a monovalent anti-CD40L
antibody polypeptide.
antibody polypeptide.
71. The extended release pharmaceutical formulation of claim 70, wherein said antibody polypeptide is selected from the group consisting of a dAb, Fab, scFv, Fv, or a disulfide bonded Fv.
72. The formulation of claim 70 wherein said monovalent anti-CD40L antibody polypeptide comprises a single immunoglobulin variable domain that binds CD40L.
73. An antibody single variable domain polypeptide that binds to CD40L, said polypeptide comprising the sequence of DOM8-24.
74. An antibody single variable domain polypeptide that binds to CD40L, wherein the polypeptide has an amino acid sequence that is identical to the amino acid sequence of DOM8-24, or differs from the amino acid sequence of DOM8-24 at no more than 25 amino acid positions and has a sequence that is at least 80% homologous to the sequence of DOM8-24.
75. An antibody single variable domain polypeptide that binds to CD40L, wherein the polypeptide has an amino acid sequence that is identical to the amino acid sequence of DOM8-24, or differs from the amino acid sequence of DOM8-24 at no more than 25 amino acid positions and has a CDR1 sequence that is at least 50% homologous to the CDR1 sequence of DOM8-24.
76. An antibody single variable domain polypeptide that binds to CD40L, wherein the polypeptide has an amino acid sequence that is identical to the amino acid sequence of DOM8-24, or differs from the amino acid sequence of DOM8-24 at no more than 25 amino acid positions and has a CDR2 sequence that is at least 50% homologous to the CDR2 sequence of DOM8-24.
77. An antibody single variable domain polypeptide that binds CD40L, wherein the polypeptide has an amino acid sequence that is identical to the amino acid sequence of DOM8-24, or differs from the amino acid sequence of DOM8-24 at no more than 25 amino acid positions and has a CDR3 sequence that is at least 50% homologous to the CDR3 sequence of DOM8-24.
78. An antibody single variable domain polypeptide that binds CD40L, wherein the dAb has an amino acid sequence that is identical to the amino acid sequence of DOM8-24, or differs from the amino acid sequence of DOM8-24 at no more than 25 amino acid positions and has a CDR1 sequence that is at least 50% homologous to the CDR1 sequence of DOM8-24 and has a CDR2 sequence that is at least 50% homologous to the CDR2 sequence of DOM8-24.
79. An antibody single variable domain polypeptide that binds CD40L, wherein the dAb has an amino acid sequence that is identical to the amino acid sequence of DOM8-24, or differs from the amino acid sequence of DOM8-24 at no more than 25 amino acid positions and has a CDR2 sequence that is at least 50% homologous to the CDR2 sequence of DOM8-24 and has a CDR3 sequence that is at least 50% homologous to the CDR3 sequence of DOM8-24.
80. An antibody single variable domain polypeptide that binds CD40L, wherein the dAb has an amino acid sequence that is identical to the amino acid sequence of DOM8-24, or differs from the amino acid sequence of DOMS-24 at no more than 25 amino acid positions and has a CDR1 sequence that is at least 50% homologous to the CDR1 sequence of DOM8-24 and has a CDR3 sequence that is at least 50% homologous to the CDR3 sequence of DOM8-24.
81. An antibody single variable domain polypeptide that binds CD40L, wherein the dAb has an amino acid sequence that is identical to the amino acid sequence of DOM8-24, or differs from the amino acid sequence of DOM8-24 at no more than 25 amino acid positions and has a CDR1 sequence that is at least 50% homologous to the CDR1 sequence of DOM8-24 and has a CDR2 sequence that is at least 50% homologous to the CDR2 sequence of DOM8-24 and has a CDR3 sequence that is at least 50% homologous to the CDR3 sequence of DOM8-24.
82. A CD40L antagonist having a CDR1 sequence that is at least 50% homologous to the CDR1 sequence of DOM8-24.
83. A CD40L antagonist having a CDR2 sequence that is at least 50% homologous to the CDR2 sequence of DOM8-24.
84. A CD40L antagonist having a CDR3 sequence that is at least 50% homologous to the CDR3 sequence of DOM8-24.
85. A CD40L antagonist having a CDR1 sequence that is at least 50% homologous to the CDR1 sequence of DOM8-24 and a CDR2 sequence that is at least 50% homologous to the sequence of DOM8-24.
86. A CD40L antagonist having a CDR2 sequence that is at least 50% homologous to the CDR2 sequence of DOM8-24 and a CDR3 sequence that is at least 50% homologous to the sequence of DOM8-24.
87. A CD40L antagonist having a CDR1 sequence that is at least 50% homologous to the CDR1 sequence of DOM8-24 and a CDR3 sequence that is at least 50% homologous to the sequence of DOM8-24.
88. A CD40L antagonist having a CDR1 sequence that is at least 50% homologous to the CDR1 sequence of DOM8-24 and a CDR2 sequence that is at least 50% homologous to the sequence of DOM8-24 and a CDR3 sequence that is at least 50% homologous to the sequence of DOM8-24.
89. The CD40L antagonist of claim 88, wherein said antagonist is an antibody single variable domain polypeptide selected from the group consisting of an antibody single variable domain polypeptide, dAb, FAb, an scFv, an Fv, or a disulfide-bonded Fv.
90. An antibody polypeptide that inhibits the binding of DOM8-24 to CD40L.
91. An antibody polypeptide that binds to the same epitope of CD40L bound by DOM8-24.
92. A method of treating or preventing a symptom of autoimmune disease in an individual, the method comprising administering the antibody polypeptide of claim 90 or 91 to said individual in an amount effective to treat or prevent a symptom of autoimmune disease.
93. An antibody polypeptide that binds to the same epitope of CD40L bound by an antibody single variable domain polypeptide comprising a sequence selected from the group consisting of SEQ ID Nos: 7-82 and 246-360.
94. An antibody single variable domain polypeptide comprising the sequence of CDR1, CDR2, and/or CDR3 of DOM8-24.
95. An antibody single variable domain polypeptide comprising the sequence of CDR1, CDR2, and/or CDR3 of an antibody single variable domain polypeptide comprising a sequence selected from the group consisting of SEQ ID Nos. 7-82 and 246-360.
96. The antibody single variable domain polypeptide of claim 94, wherein said polypeptide comprises the sequence of two or more of CDR1, CDR2, or CDR3 of DOM8-24.
97. The antibody single variable domain polypeptide of claim 95, wherein said polypeptide comprises the sequence of two or more of CDR1, CDR2, or CDR3 of an antibody single variable domain polypeptide comprising a sequence selected from the group consisting of SEQ ID Nos.
7-82 and 246-360.
7-82 and 246-360.
98. A dual specific ligand comprising a first immunoglobulin single variable domain having a binding specificity to a first antigen and a second single variable domain having a binding activity to a second antigen, wherein the first antigen is CD40L and the second single variable domain is an Antigen Presenting Cell surface antigen or a T cell surface antigen.
99. A ligand according to claim 98 wherein the Antigen Presenting Cell surface antigen is selected from one of the group consisting of, activated macrophage surface antigens, activated B
cell surface antigens, co-stimulatory signal pathway surface antigens, and MHC.
cell surface antigens, co-stimulatory signal pathway surface antigens, and MHC.
100. A ligand according to claim 99 wherein the MHC is class II.
101. A ligand according to claim 100 wherein the MHC class II is alpha.
102. A ligand according to claim 100 wherein the MHC class II is beta.
103. A ligand according to claim 99 wherein the Antigen Presenting Cell surface antigen is selected from the group consisting of CD28, Inducible costimulatory molecule (ICOS), CD27, CD30, OX40, CD45, CD69, CD3, CD70, Inducible costimulatory molecule ligand (ICOSL), OX40L, CD80, CD86, HVEM (Herpes Virus Entry Mediator), and LIGHT.
104. A ligand according to claim 99 wherein the Antigen Presenting Cell surface antigen is selected from the group consisting of CD28, Inducible costimulatory molecule (ICOS), CD27, CD30, OX40, CD45, CD69, and CD3.
105. A ligand according to claim 99 wherein the surface antigen is a B7 gene surface antigen.
106. A ligand according to claim 105 wherein the B7 gene surface antigen is B7-2, or B7-1.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61081904P | 2004-09-17 | 2004-09-17 | |
US60/610,819 | 2004-09-17 | ||
US11/102,512 | 2005-04-08 | ||
US11/102,512 US7563443B2 (en) | 2004-09-17 | 2005-04-08 | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
PCT/GB2005/003562 WO2006030220A1 (en) | 2004-09-17 | 2005-09-16 | Compositions monovalent for cd40l binding and methods of use |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2581017A1 true CA2581017A1 (en) | 2006-03-23 |
CA2581017C CA2581017C (en) | 2016-10-11 |
Family
ID=36074265
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2581017A Active CA2581017C (en) | 2004-09-17 | 2005-09-16 | Compositions monovalent for cd40l binding and methods of use |
Country Status (16)
Country | Link |
---|---|
US (5) | US7563443B2 (en) |
EP (2) | EP1797126B1 (en) |
JP (1) | JP5808880B2 (en) |
KR (2) | KR101360140B1 (en) |
AU (1) | AU2005283932B8 (en) |
BR (1) | BRPI0515404A (en) |
CA (1) | CA2581017C (en) |
ES (1) | ES2442455T3 (en) |
GE (1) | GEP20125471B (en) |
HK (1) | HK1101182A1 (en) |
IL (1) | IL181724A (en) |
MX (1) | MX2007003187A (en) |
NO (1) | NO20071312L (en) |
NZ (1) | NZ553847A (en) |
RU (1) | RU2364420C2 (en) |
WO (1) | WO2006030220A1 (en) |
Families Citing this family (349)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1678634A (en) * | 2002-06-28 | 2005-10-05 | 多曼蒂斯有限公司 | Immunoglobulin single variable antigen combination area and its opposite constituent |
US9453251B2 (en) | 2002-10-08 | 2016-09-27 | Pfenex Inc. | Expression of mammalian proteins in Pseudomonas fluorescens |
PT1639011E (en) * | 2003-06-30 | 2009-01-20 | Domantis Ltd | Pegylated single domain antibodies (dab) |
US8603824B2 (en) | 2004-07-26 | 2013-12-10 | Pfenex, Inc. | Process for improved protein expression by strain engineering |
CA2575838A1 (en) | 2004-07-26 | 2006-03-30 | Biogen Idec Ma Inc. | Anti-cd154 antibodies |
US7563443B2 (en) * | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
GB0521621D0 (en) * | 2005-10-24 | 2005-11-30 | Domantis Ltd | Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases |
WO2006059106A2 (en) * | 2004-12-02 | 2006-06-08 | Domantis Limited | Bispecific domain antibodies targeting serum albumin and glp-1 or pyy |
MX2007011356A (en) * | 2005-03-18 | 2008-03-10 | Domantis Ltd | Antibodies against candida antigens. |
EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
AU2006231622B2 (en) | 2005-04-06 | 2012-07-05 | Bristol-Myers Squibb Company | Methods for treating immune disorders associated with graft transplantation with soluble CTLA4 mutant molecules |
CN103254309B (en) | 2005-05-18 | 2017-09-26 | 埃博灵克斯股份有限公司 | For the improved nanometer body of tumor necrosis factor αTM |
EP2532679B1 (en) * | 2005-10-21 | 2017-04-12 | Novartis AG | Human antibodies against il13 and therapeutic uses |
UA96139C2 (en) * | 2005-11-08 | 2011-10-10 | Дженентек, Інк. | Anti-neuropilin-1 (nrp1) antibody |
WO2007114319A1 (en) | 2006-03-31 | 2007-10-11 | Chugai Seiyaku Kabushiki Kaisha | Method for control of blood kinetics of antibody |
CN105177091A (en) | 2006-03-31 | 2015-12-23 | 中外制药株式会社 | Antibody modification method for purifying bispecific antibody |
AU2007248628B2 (en) | 2006-05-03 | 2013-02-07 | The Regents Of The University Of Colorado, A Body Corporate | CD40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity |
EP1854810A1 (en) * | 2006-05-09 | 2007-11-14 | PanGenetics B.V. | Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody |
JP2009536527A (en) * | 2006-05-09 | 2009-10-15 | ジェネンテック・インコーポレーテッド | Binding polypeptide with optimized scaffold |
PL2044111T3 (en) | 2006-06-21 | 2015-02-27 | Musc Found For Res Dev | Targeting complement factor h for treatment of diseases |
AU2007336243B2 (en) | 2006-12-19 | 2012-07-26 | Ablynx N.V. | Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders |
US9512236B2 (en) | 2006-12-19 | 2016-12-06 | Ablynx N.V. | Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders |
EP2557090A3 (en) | 2006-12-19 | 2013-05-29 | Ablynx N.V. | Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders |
JP5721951B2 (en) | 2007-03-22 | 2015-05-20 | バイオジェン アイデック マサチューセッツ インコーポレイテッド | Binding proteins that specifically bind to CD154, including antibodies, antibody derivatives, and antibody fragments, and uses thereof |
US9580719B2 (en) | 2007-04-27 | 2017-02-28 | Pfenex, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
WO2008134461A2 (en) | 2007-04-27 | 2008-11-06 | Dow Global Technologies, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
US10214588B2 (en) | 2007-07-03 | 2019-02-26 | Ablynx N.V. | Providing improved immunoglobulin sequences by mutating CDR and/or FR positions |
EP2202245B1 (en) | 2007-09-26 | 2016-08-24 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in cdr |
EP3789400A1 (en) | 2007-09-26 | 2021-03-10 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant region |
CA2706200A1 (en) | 2007-11-27 | 2009-06-04 | Ablynx N.V. | Immunoglobulin constructs comprising multiple single variable domains and an fc portion |
ES2834741T3 (en) | 2007-12-05 | 2021-06-18 | Chugai Pharmaceutical Co Ltd | Anti-NR10 antibody and its use |
JP2011525476A (en) | 2008-03-05 | 2011-09-22 | アブリンクス エン.ヴェー. | Novel antigen-binding dimer complex, its production method and use |
GB0809069D0 (en) | 2008-05-19 | 2008-06-25 | Univ Leuven Kath | Gene signatures |
EP2947097A1 (en) | 2008-04-07 | 2015-11-25 | Ablynx N.V. | Amino acid sequences directed against the Notch pathways and uses thereof |
WO2009127691A1 (en) | 2008-04-17 | 2009-10-22 | Ablynx N.V. | Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same |
KR20110020825A (en) | 2008-05-16 | 2011-03-03 | 아블린쓰 엔.브이. | Amino acid sequences directed against cxcr4 and other gpcrs and compounds comprising the same |
SG191625A1 (en) * | 2008-06-03 | 2013-07-31 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
DK2285408T3 (en) | 2008-06-05 | 2019-02-04 | Ablynx Nv | AMINO ACID SEQUENCES AGAINST COATING PROTEINS IN A VIRUS AND POLYPEPTIDES INCLUDING THESE FOR TREATMENT OF VIRUSAL DISEASES |
CA2730316A1 (en) * | 2008-07-11 | 2010-01-14 | Phylogica Limited | Peptide inhibitors of cd40l signaling and uses therefor |
US20110097339A1 (en) * | 2008-07-18 | 2011-04-28 | Domantis Limited | Compositions monovalent for CD28 binding and methods of use |
EP2315778A2 (en) * | 2008-07-18 | 2011-05-04 | Domantis Limited | Compositions monovalent for cd28 binding and methods of use |
US20100136584A1 (en) * | 2008-09-22 | 2010-06-03 | Icb International, Inc. | Methods for using antibodies and analogs thereof |
TWI440469B (en) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
WO2010043650A2 (en) | 2008-10-14 | 2010-04-22 | Ablynx Nv | Amino acid sequences directed against cellular receptors for viruses and bacteria |
DK2367849T3 (en) * | 2008-12-05 | 2018-01-22 | Als Therapy Development Inst | METHOD OF TREATING NEURODEGENERATIVE DISEASES |
US9044459B2 (en) | 2008-12-05 | 2015-06-02 | Als Therapy Development Institute | Method for the treatment of neurodegenerative diseases |
CN102307902B (en) | 2008-12-10 | 2016-02-24 | 埃博灵克斯股份有限公司 | Be used for the treatment of and the aminoacid sequence for angiogenin/Tie system of relevant disease and illness occur to blood vessel and comprises its polypeptide |
AU2009333489A1 (en) * | 2008-12-30 | 2010-07-08 | Centocor Ortho Biotech Inc. | Serum markers predicting clinical response to anti-TNF antibodies in patients with ankylosing spondylitis |
EP2210902A1 (en) * | 2009-01-14 | 2010-07-28 | TcL Pharma | Recombinant monovalent antibodies |
WO2010100135A1 (en) | 2009-03-05 | 2010-09-10 | Ablynx N.V. | Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof |
EP2409991B1 (en) | 2009-03-19 | 2017-05-03 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
JP5787446B2 (en) | 2009-03-19 | 2015-09-30 | 中外製薬株式会社 | Antibody constant region variants |
US8748581B2 (en) | 2009-04-10 | 2014-06-10 | Ablynx N.V. | Anti-IL-6R polypeptides and pharmaceutical compositions thereof |
WO2010125187A2 (en) | 2009-04-30 | 2010-11-04 | Ablynx Nv | Method for the production of domain antibodies |
AR076875A1 (en) | 2009-05-15 | 2011-07-13 | Chugai Pharmaceutical Co Ltd | ANTIBODY AGAINST TYPEOSIN KINASE RECEIVER (ANTI-AXL) |
PL2896404T3 (en) * | 2009-06-04 | 2017-12-29 | Novartis Ag | Methods for identification of sites for IgG conjugation |
WO2010139808A2 (en) | 2009-06-05 | 2010-12-09 | Ablynx Nv | IMPROVED AMINO ACID SEQUENCES DIRECTED AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS (hRSV) AND POLYPEPTIDES COMPRISING THE SAME FOR THE PREVENTION AND/OR TREATMENT OF RESPIRATORY TRACT INFECTIONS |
ME01699B (en) | 2009-07-02 | 2014-09-20 | Musc Found For Res Dev | Methods of stimulating liver regeneration |
US9150640B2 (en) | 2009-07-10 | 2015-10-06 | Ablynx N.V. | Method for the production of variable domains |
CA2768462A1 (en) * | 2009-07-16 | 2011-01-20 | Glaxo Group Ltd. | Improved anti-serum albumin binding single variable domains |
CN102574922A (en) * | 2009-07-29 | 2012-07-11 | 葛兰素集团有限公司 | Anti - TGF - BETA receptor type II single domain antibodies |
LT2805731T (en) | 2009-09-03 | 2019-02-11 | Ablynx N.V. | Stable formulations of polypeptides and uses thereof |
WO2011037158A1 (en) | 2009-09-24 | 2011-03-31 | 中外製薬株式会社 | Modified antibody constant regions |
US9109216B2 (en) | 2009-09-24 | 2015-08-18 | Ucb Pharma, S.A. | Bacterial host strain |
NZ600393A (en) | 2009-11-05 | 2014-08-29 | Alexion Cambridge Corp | Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis |
US20120269814A1 (en) * | 2009-11-10 | 2012-10-25 | Amgen Inc. | Anti-c mpl antibodies |
EP2507262A1 (en) | 2009-11-30 | 2012-10-10 | Ablynx N.V. | Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections |
EP3309176A1 (en) | 2009-12-14 | 2018-04-18 | Ablynx N.V. | Immunoglobulin single variable domain antibodies against ox40l, constructs and therapeutic use |
WO2011083141A2 (en) | 2010-01-08 | 2011-07-14 | Ablynx Nv | Method for generation of immunoglobulin sequences by using lipoprotein particles |
GB201000591D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial hoist strain |
GB201000587D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial hoist strain |
GB201000590D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial host strain |
CN102781959A (en) | 2010-02-05 | 2012-11-14 | 埃博灵克斯股份有限公司 | Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same |
US9120855B2 (en) | 2010-02-10 | 2015-09-01 | Novartis Ag | Biologic compounds directed against death receptor 5 |
CN102753148B (en) | 2010-02-11 | 2018-01-26 | 埃博灵克斯股份有限公司 | For preparing the method and composition of aerosol |
JP5889181B2 (en) | 2010-03-04 | 2016-03-22 | 中外製薬株式会社 | Antibody constant region variants |
WO2011117423A1 (en) | 2010-03-26 | 2011-09-29 | Ablynx N.V. | Immunoglobulin single variable domains directed against cxcr7 |
ES2537814T3 (en) | 2010-04-09 | 2015-06-12 | Amgen Inc. | Proteins, nucleic acids, and BTNL9 antibodies and uses thereof |
NZ603560A (en) | 2010-05-14 | 2014-09-26 | Univ Colorado Regents | Improved complement receptor 2 (cr2) targeting groups |
KR20130080790A (en) | 2010-05-20 | 2013-07-15 | 아블린쓰 엔.브이. | Biological materials related to her3 |
BR112012033119A2 (en) | 2010-06-22 | 2016-10-25 | Univ Colorado Regents | antibodies to complement component c3d fragment 3. |
WO2011161263A1 (en) | 2010-06-25 | 2011-12-29 | Ablynx Nv | Pharmaceutical compositions for cutaneous administration |
SG186983A1 (en) | 2010-07-09 | 2013-02-28 | Genentech Inc | Anti-neuropilin antibodies and methods of use |
GB201012599D0 (en) | 2010-07-27 | 2010-09-08 | Ucb Pharma Sa | Process for purifying proteins |
EP2621953B1 (en) | 2010-09-30 | 2017-04-05 | Ablynx N.V. | Biological materials related to c-met |
KR101853405B1 (en) * | 2010-10-20 | 2018-05-02 | 주식회사 티움바이오 | Fusion protein having Factor IX activity |
NO2632946T3 (en) | 2010-10-29 | 2018-05-05 | ||
EP2635607B1 (en) | 2010-11-05 | 2019-09-04 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
JP5933573B2 (en) | 2010-11-08 | 2016-06-15 | ノバルティス アーゲー | CXCR2 binding polypeptide |
TWI452135B (en) | 2010-11-17 | 2014-09-11 | 中外製藥股份有限公司 | A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation |
WO2012072731A2 (en) * | 2010-12-01 | 2012-06-07 | Glaxo Group Limited | Improved anti-serum albumin binding single variable domains |
MX352889B (en) | 2011-02-25 | 2017-12-13 | Chugai Pharmaceutical Co Ltd | Fcîriib-specific fc antibody. |
US20150158948A9 (en) | 2011-03-28 | 2015-06-11 | Francis Descamps | Bispecific anti-cxcr7 immunoglobulin single variable domains |
AU2012234282B2 (en) | 2011-03-28 | 2015-07-16 | Ablynx Nv | Method for producing solid formulations comprising immunoglobulin single variable domains |
TWI598363B (en) * | 2011-04-21 | 2017-09-11 | 必治妥美雅史谷比公司 | Antibody polypeptides that antagonize cd40 |
UA117218C2 (en) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same |
EP2707382B1 (en) | 2011-05-09 | 2019-07-17 | Ablynx NV | Method for the production of immunoglobulin single variable domains |
EP2714736A1 (en) | 2011-05-27 | 2014-04-09 | Ablynx N.V. | Inhibition of bone resorption with rankl binding peptides |
AU2012273928A1 (en) | 2011-06-23 | 2014-02-06 | Ablynx Nv | Immunoglobulin single variable domains directed against IgE |
LT2731973T (en) | 2011-07-13 | 2018-02-26 | Ucb Biopharma Sprl | Bacterial host strain expressing recombinant dsbc |
CN103842380A (en) | 2011-07-27 | 2014-06-04 | 葛兰素集团有限公司 | Anti-VEGF single variable domains fused to Fc domains |
BR112014003679B1 (en) | 2011-08-17 | 2022-08-30 | Glaxo Group Limited | SINGLE IMMUNOGLOBULIN VARIABLE DOMAIN, PHARMACEUTICAL COMPOSITION, FORMULATION, ISOLATED OR RECOMBINANT NUCLEIC ACID, VECTOR, TRANSGENIC MICROORGANISM, AND, USE OF A PHARMACEUTICAL COMPOSITION |
DK2747782T3 (en) | 2011-09-23 | 2018-04-23 | Ablynx Nv | Long-term inhibition of interleukin-6-mediated signal transmission |
TW201326209A (en) | 2011-09-30 | 2013-07-01 | Chugai Pharmaceutical Co Ltd | Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance |
CN103889451B (en) | 2011-09-30 | 2016-06-29 | 埃博灵克斯股份有限公司 | The biological substance relevant to C-Met |
EP3939996A1 (en) | 2011-09-30 | 2022-01-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
EP2766395B1 (en) * | 2011-10-13 | 2019-11-20 | Bristol-Myers Squibb Company | Antibody polypeptides that antagonize cd40l |
MX358862B (en) | 2011-11-04 | 2018-09-06 | Zymeworks Inc | Stable heterodimeric antibody design with mutations in the fc domain. |
SG11201402490XA (en) | 2011-11-23 | 2014-06-27 | Amgen Inc | Methods of treatment using an antibody against interferon gamma |
US20130336973A1 (en) | 2012-05-10 | 2013-12-19 | Zymeworks Inc. | Heteromultimer Constructs of Immunoglobulin Heavy Chains with Mutations in the Fc Domain |
AU2013260172B2 (en) * | 2012-05-11 | 2017-11-23 | Medimmune Limited | CTLA-4 variants |
GB201208367D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Biological product |
US9499634B2 (en) | 2012-06-25 | 2016-11-22 | Zymeworks Inc. | Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells |
EP2875046B1 (en) | 2012-07-19 | 2020-02-26 | Amgen Inc. | Human btnl3 proteins, nucleic acids, and antibodies and uses thereof |
US10413620B2 (en) | 2012-08-17 | 2019-09-17 | The Regents Of The University Of Colorado, A Body Corporate | Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging |
WO2014028865A1 (en) | 2012-08-17 | 2014-02-20 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for detecting complement activation |
ES2633960T3 (en) * | 2012-10-15 | 2017-09-26 | Bristol-Myers Squibb Company | Processes of mammalian cell culture for protein production |
US9914785B2 (en) | 2012-11-28 | 2018-03-13 | Zymeworks Inc. | Engineered immunoglobulin heavy chain-light chain pairs and uses thereof |
CN105358699A (en) | 2013-04-29 | 2016-02-24 | 阿格罗塞文公司 | Agrochemical compositions comprising antibodies binding to sphingolipids |
WO2016071438A2 (en) | 2014-11-05 | 2016-05-12 | Agrosavfe Nv | Transgenic plant comprising a polynucleotide encoding a variable domain of heavy-chain antibody |
DK3050896T3 (en) | 2013-09-27 | 2021-07-19 | Chugai Pharmaceutical Co Ltd | Process for the preparation of a polypeptide heteromultimer |
EP2883883A1 (en) | 2013-12-16 | 2015-06-17 | Cardio3 Biosciences S.A. | Therapeutic targets and agents useful in treating ischemia reperfusion injury |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
US10435475B2 (en) | 2014-03-07 | 2019-10-08 | Bristol-Myers Squibb Company | Method of using antibody polypeptides that antagonize CD40 to treat IBD |
NL2013007B1 (en) | 2014-06-16 | 2016-07-05 | Ablynx Nv | Methods of treating TTP with immunoglobulin single variable domains and uses thereof. |
NL2013661B1 (en) | 2014-10-21 | 2016-10-05 | Ablynx Nv | KV1.3 Binding immunoglobulins. |
MA40764A (en) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | THERAPEUTIC AGENT INDUCING CYTOTOXICITY |
US10561805B2 (en) | 2014-10-10 | 2020-02-18 | Ablynx N.V. | Methods of treating RSV infections |
RU2700650C2 (en) | 2014-10-10 | 2019-09-18 | Аблинкс Н.В. | Inhaler device for use in aerosol therapy of respiratory diseases |
CN107249318A (en) | 2014-12-10 | 2017-10-13 | 明尼苏达大学董事会 | For cell, tissue and the organ of the genetic modification for treating disease |
US9765135B2 (en) | 2014-12-19 | 2017-09-19 | Chugai Seiyaku Kabushiki Kaisha | Anti-C5 antibodies |
WO2016097313A1 (en) | 2014-12-19 | 2016-06-23 | Ablynx N.V. | Cysteine linked nanobody dimers |
KR101860280B1 (en) | 2014-12-19 | 2018-05-21 | 추가이 세이야쿠 가부시키가이샤 | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
GB201501613D0 (en) | 2015-01-30 | 2015-03-18 | Ucb Biopharma Sprl | Treatment of autoimmune disorders with CD154 antibodies |
MA41459A (en) * | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | ANTI-CD40L ANTIBODIES AND METHODS FOR TREATING CD40L ILLNESSES OR DISORDERS |
CN107531780B (en) | 2015-02-03 | 2021-11-02 | 国家健康与医学研究院 | Conformational single domain antibodies to Rho GTPase and uses thereof |
KR20170110129A (en) | 2015-02-05 | 2017-10-10 | 추가이 세이야쿠 가부시키가이샤 | Antibodies comprising ionic concentration dependent antigen binding domains, Fc region variants, antibodies that bind to IL-8, and their use |
WO2016135041A1 (en) | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
RU2730590C2 (en) | 2015-02-27 | 2020-08-24 | Чугаи Сейяку Кабусики Кайся | Composition for treating diseases associated with il-6 |
US9139653B1 (en) | 2015-04-30 | 2015-09-22 | Kymab Limited | Anti-human OX40L antibodies and methods of treatment |
US9512229B2 (en) | 2015-03-03 | 2016-12-06 | Kymab Limited | Synergistic combinations of OX40L antibodies for the treatment of GVHD |
US9434785B1 (en) | 2015-04-30 | 2016-09-06 | Kymab Limited | Anti-human OX40L antibodies and methods of treating graft versus host disease with the same |
US11142587B2 (en) | 2015-04-01 | 2021-10-12 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide hetero-oligomer |
JP6867955B2 (en) | 2015-05-07 | 2021-05-12 | アジェナス インコーポレイテッド | Anti-OX40 antibody and how to use it |
EP4345112A2 (en) | 2015-05-13 | 2024-04-03 | Ablynx N.V. | T cell recruiting polypeptides based on cd3 reactivity |
RS59376B1 (en) | 2015-05-13 | 2019-11-29 | Ablynx Nv | T cell recruiting polypeptides based on tcr alpha/beta reactivity |
MA45573A (en) | 2015-08-05 | 2019-05-15 | Janssen Biotech Inc | ANTI-CD154 ANTIBODIES AND CORRESPONDING METHODS OF USE |
CN105384825B (en) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | A kind of bispecific chimeric antigen receptor and its application based on single domain antibody |
US20170059561A1 (en) * | 2015-08-28 | 2017-03-02 | The Florida International University Board Of Trustees | Thermally Stable Electrochemical Sensor With Long Shelf-Life |
EP3350212A1 (en) | 2015-09-18 | 2018-07-25 | INSERM - Institut National de la Santé et de la Recherche Médicale | T cell receptors (tcr) and uses thereof for the diagnosis and treatment of diabetes |
EP3356551B1 (en) | 2015-09-29 | 2020-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for determining the metabolic status of b-lymphomas |
EP3362088B1 (en) | 2015-10-12 | 2020-11-25 | Institut National de la Sante et de la Recherche Medicale (INSERM) | An agent capable of depleting cd8 t cells for the treatment of myocardial infarction or acute myocardial infarction |
US20180327499A1 (en) | 2015-11-13 | 2018-11-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti- nkg2d single domain antibodies and uses thereof |
MA43302A (en) | 2015-11-27 | 2021-03-17 | Ablynx Nv | LIGAND CD40L INHIBITED POLYPEPTIDES |
MX2018006477A (en) | 2015-12-02 | 2018-09-03 | Agenus Inc | Antibodies and methods of use thereof. |
EP3394098A4 (en) | 2015-12-25 | 2019-11-13 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
WO2017115773A1 (en) | 2015-12-28 | 2017-07-06 | 中外製薬株式会社 | Method for promoting efficiency of purification of fc region-containing polypeptide |
ES2837155T3 (en) | 2016-01-04 | 2021-06-29 | Inst Nat Sante Rech Med | Use of PD-1 and Tim-3 as a measure of CD8 + cells to predict and treat renal cell carcinoma |
WO2017129558A1 (en) | 2016-01-25 | 2017-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting or treating myelopoiesis-driven cardiometabolic diseases and sepsis |
WO2017129763A1 (en) | 2016-01-28 | 2017-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer |
JP6902040B2 (en) | 2016-01-28 | 2021-07-14 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | How to Increase the Efficacy of Immune Checkpoint Inhibitors |
EP3407911B1 (en) | 2016-01-28 | 2022-05-18 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods and pharmaceutical composition for the treatment of cancer |
SG10202007025PA (en) | 2016-03-14 | 2020-08-28 | Chugai Pharmaceutical Co Ltd | Cell injury inducing therapeutic drug for use in cancer therapy |
WO2017174681A1 (en) | 2016-04-06 | 2017-10-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of age-related cardiometabolic diseases |
EP3445779A1 (en) | 2016-04-22 | 2019-02-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of inflammatory skin diseases associated with desmoglein-1 deficiency |
JP2019523213A (en) | 2016-05-02 | 2019-08-22 | アブリンクス エン.ヴェー. | Treatment of RSV infection |
JP7166512B2 (en) | 2016-05-03 | 2022-11-08 | インスティチュート ナショナル デ ラ サンテ エ デ ラ ルシェルシュ メディカル (インセルム) | CD31shed as a molecular beacon for imaging inflammation |
WO2017191300A1 (en) | 2016-05-06 | 2017-11-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Pharmaceutical compositions for the treatment of chemoresistant acute myeloid leukemia (aml) |
US20190151346A1 (en) | 2016-05-10 | 2019-05-23 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Combinations therapies for the treatment of cancer |
WO2017202962A1 (en) | 2016-05-24 | 2017-11-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd) |
WO2017202890A1 (en) | 2016-05-27 | 2017-11-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for predicting and treating myeloma |
WO2018007442A1 (en) | 2016-07-06 | 2018-01-11 | Ablynx N.V. | Treatment of il-6r related diseases |
WO2018014260A1 (en) | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
WO2018025982A1 (en) | 2016-08-05 | 2018-02-08 | 中外製薬株式会社 | Composition for prophylaxis or treatment of il-8 related diseases |
WO2018029182A1 (en) | 2016-08-08 | 2018-02-15 | Ablynx N.V. | Il-6r single variable domain antibodies for treatment of il-6r related diseases |
WO2018035046A1 (en) | 2016-08-15 | 2018-02-22 | President And Fellows Of Harvard College | Treating infections using idsd from proteus mirabilis |
WO2018041989A1 (en) | 2016-09-02 | 2018-03-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing and treating refractory celiac disease type 2 |
CN110248674B (en) * | 2016-09-07 | 2021-10-26 | 萨辛生命科学有限公司 | Synthetic antibodies against VEGF and uses thereof |
JP2019533139A (en) | 2016-09-08 | 2019-11-14 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Methods for diagnosing and treating nephrotic syndrome |
WO2018050833A1 (en) | 2016-09-15 | 2018-03-22 | Ablynx Nv | Immunoglobulin single variable domains directed against macrophage migration inhibitory factor |
WO2018068201A1 (en) | 2016-10-11 | 2018-04-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against ctla-4 |
US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
AU2017359467A1 (en) | 2016-11-09 | 2019-05-02 | Agenus Inc. | Anti-OX40 antibodies, anti-GITR antibodies, and methods of use thereof |
WO2018087391A1 (en) | 2016-11-14 | 2018-05-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for modulating stem cells proliferation or differentiation |
CA3043515A1 (en) | 2016-11-16 | 2018-05-24 | Ablynx Nv | T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta |
EP3541830A1 (en) | 2016-11-17 | 2019-09-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for increasing endogenous protein level |
WO2018099968A1 (en) | 2016-11-29 | 2018-06-07 | Ablynx N.V. | Treatment of infection by respiratory syncytial virus (rsv) |
EP3548894B1 (en) | 2016-12-02 | 2021-10-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for diagnosing renal cell carcinoma |
WO2018134389A1 (en) | 2017-01-23 | 2018-07-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating infections |
EP3579872A1 (en) | 2017-02-10 | 2019-12-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway |
CN110573604A (en) | 2017-02-28 | 2019-12-13 | 非营利性组织佛兰芒综合大学生物技术研究所 | Means and methods for oral protein delivery |
US11440951B2 (en) | 2017-03-13 | 2022-09-13 | The Government Of The United States, As Represented By The Secretary Of The Army | Therapeutic antibodies to Marburg virus |
EP3600427A1 (en) | 2017-03-24 | 2020-02-05 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods and compositions for treating melanoma |
WO2018178029A1 (en) | 2017-03-27 | 2018-10-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating degenerative muscular and/or neurological conditions or diseases |
WO2018178030A1 (en) | 2017-03-27 | 2018-10-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating degenerative muscular and/or neurological conditions or diseases |
WO2018178078A1 (en) | 2017-03-28 | 2018-10-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New tau species |
EP3600308A1 (en) | 2017-03-30 | 2020-02-05 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods for the treatment of mitochondrial genetic diseases |
EP3620531A4 (en) | 2017-05-02 | 2021-03-17 | National Center of Neurology and Psychiatry | Method for predicting and evaluating therapeutic effect in diseases related to il-6 and neutrophils |
KR20200005635A (en) | 2017-05-11 | 2020-01-15 | 브이아이비 브이지더블유 | Glycosylation of Variable Immunoglobulin Domains |
KR20200013683A (en) | 2017-05-17 | 2020-02-07 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | FLT3 inhibitors for improving pain treatment by opioids |
SG10202111207TA (en) | 2017-05-24 | 2021-11-29 | Als Therapy Development Inst | Therapeutic anti-cd40 ligand antibodies |
BR112019025392A2 (en) | 2017-06-02 | 2020-07-07 | Ablynx N.V. | aggrecan-binding immunoglobulins |
BR112019024333A2 (en) | 2017-06-02 | 2020-07-28 | Merck Patent Gmbh | adamts binding immunoglobulins |
BR112019025097A2 (en) | 2017-06-02 | 2020-07-28 | Merck Patent Gmbh | mmp13-binding immunoglobulins |
JP7249961B2 (en) | 2017-06-02 | 2023-03-31 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Polypeptides that bind ADAMTS5, MMP13 and aggrecan |
JP7265487B2 (en) | 2017-06-08 | 2023-04-26 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Chimeric receptors for use in whole-cell sensors for detecting analytes of interest |
EP3634582A1 (en) | 2017-06-08 | 2020-04-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating hyperpigmentation disorders |
WO2018234843A1 (en) | 2017-06-22 | 2018-12-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of fibrosis with agents capable of inhibiting the activation of mucosal-associated invariant t (mait) cells |
WO2019000223A1 (en) | 2017-06-27 | 2019-01-03 | Nanjing Legend Biotech Co., Ltd. | Chimeric antibody immune effctor cell engagers and methods of use thereof |
WO2019002548A1 (en) | 2017-06-29 | 2019-01-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Treating migraine by agonising trek1, trek2 or heteromers including them |
CA3070253A1 (en) | 2017-07-19 | 2019-01-24 | Vib Vzw | Serum albumin binding agents |
WO2019016310A1 (en) | 2017-07-20 | 2019-01-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating cancers |
WO2019020480A1 (en) | 2017-07-24 | 2019-01-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies and peptides to treat hcmv related diseases |
US11926664B2 (en) | 2017-07-25 | 2024-03-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for modulating monocytopoiesis |
EP3676296A1 (en) | 2017-08-30 | 2020-07-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-mesothelin radiolabelled single domain antibodies suitable for the imaging and treatment of cancers |
EP3457139A1 (en) | 2017-09-19 | 2019-03-20 | Promise Advanced Proteomics | Antibody-like peptides for quantifying therapeutic antibodies |
SG11202002366VA (en) | 2017-09-19 | 2020-04-29 | Mab Discovery Gmbh | Agonistic cd40 antibodies |
EP3684471A1 (en) | 2017-09-20 | 2020-07-29 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods and pharmaceutical compositions for modulating autophagy |
US11873347B2 (en) | 2017-10-31 | 2024-01-16 | Vib Vzw | Antigen-binding chimeric proteins and methods and uses thereof |
EP3710486A1 (en) | 2017-11-15 | 2020-09-23 | Novo Nordisk A/S | Factor x binders enhancing fx activation |
WO2019101995A1 (en) | 2017-11-27 | 2019-05-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for cardiac regeneration |
EP3732202A4 (en) | 2017-12-28 | 2022-06-15 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against tigit |
WO2019134946A1 (en) | 2018-01-04 | 2019-07-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating melanoma resistant |
SG11202004233UA (en) | 2018-01-15 | 2020-06-29 | Nanjing Legend Biotech Co Ltd | Single-domain antibodies and variants thereof against pd-1 |
WO2019145413A1 (en) | 2018-01-25 | 2019-08-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antagonists of il-33 for use in methods for preventing ischemia reperfusion injury in an organ |
AU2019217584A1 (en) | 2018-02-06 | 2020-09-17 | Ablynx Nv | Methods of treating initial episode of TTP with immunoglobulin single variable domains |
US20210061917A1 (en) | 2018-02-16 | 2021-03-04 | Inserm (Institut National De La Santé Et De La Recherche Medicale) | Methods and compositions for treating vitiligo |
CA3092421A1 (en) | 2018-03-01 | 2019-09-06 | Vrije Universiteit Brussel | Human pd-l1-binding immunoglobulins |
AU2019237215B2 (en) | 2018-03-23 | 2023-11-02 | Université Libre de Bruxelles | Wnt signaling agonist molecules |
WO2019193375A1 (en) | 2018-04-04 | 2019-10-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of fzd7 inhibitors for the treatment of retinal neovascularization |
WO2019207030A1 (en) | 2018-04-26 | 2019-10-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer |
JP7444858B2 (en) | 2018-09-05 | 2024-03-06 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Methods and compositions for treating asthma and allergic diseases |
US20220047567A1 (en) | 2018-09-10 | 2022-02-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of neurofibromatosis |
EP3850008A1 (en) | 2018-09-10 | 2021-07-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of an inhibitor of ntsr1 activation or expression for preventing weight loss, muscle loss, and protein blood level decrease in subjects in need thereof |
WO2020058201A1 (en) | 2018-09-17 | 2020-03-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of inhibitors of phosphatase activity of soluble epoxide for the treatment of cardiometabolic diseases |
CN113396160A (en) | 2018-09-19 | 2021-09-14 | 国家医疗保健研究所 | Methods and pharmaceutical compositions for treating cancer resistant to immune checkpoint therapy |
WO2020064702A1 (en) | 2018-09-25 | 2020-04-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of antagonists of th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma |
WO2020070062A1 (en) | 2018-10-01 | 2020-04-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of tim-3 inhibitors for the treatment of exacerbations in patients suffering from severe asthma |
US20210340278A1 (en) | 2018-10-04 | 2021-11-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of mucosal inflammatory diseases |
US20210355216A1 (en) | 2018-10-05 | 2021-11-18 | INSERM (Institut National de la Santé et de la Recherche Médicale | Methods and systems for controlling the agonistic properties of antibody variable domains by light |
EP3636657A1 (en) | 2018-10-08 | 2020-04-15 | Ablynx N.V. | Chromatography-free antibody purification method |
JP2022512648A (en) | 2018-10-09 | 2022-02-07 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Use of αV-integrin (CD51) inhibitors for the treatment of myocardial fibrosis |
WO2020079162A1 (en) | 2018-10-18 | 2020-04-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for inducing full ablation of hematopoiesis |
WO2020104479A1 (en) | 2018-11-20 | 2020-05-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies |
WO2020115261A1 (en) | 2018-12-07 | 2020-06-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating melanoma |
WO2020120592A1 (en) | 2018-12-12 | 2020-06-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for predicting and treating melanoma |
US20220017611A1 (en) | 2018-12-13 | 2022-01-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New anti tau svqivykpv epitope single domain antibody |
WO2020127885A1 (en) | 2018-12-21 | 2020-06-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions for treating cancers and resistant cancers |
US20220073626A1 (en) | 2019-01-03 | 2022-03-10 | Institut National De La Santé Et De La Recheche Médicale (Inserm) | Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancer |
WO2020161083A1 (en) | 2019-02-04 | 2020-08-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for modulating blood-brain barrier |
WO2020169707A1 (en) | 2019-02-21 | 2020-08-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Foxo1 inhibitor for use in the treatment of latent virus infection |
WO2020178313A1 (en) | 2019-03-05 | 2020-09-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New biomarkers and biotargets in renal cell carcinoma |
EP3935084A1 (en) | 2019-03-08 | 2022-01-12 | LinXis B.V. | Internalizing binding molecules targeting receptors involved in cell proliferation or cell differentiation |
CN113631573A (en) | 2019-03-25 | 2021-11-09 | 国家医疗保健研究所 | Methods of treating tauopathies by targeting new species of Tau |
US20220249511A1 (en) | 2019-03-29 | 2022-08-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of keloid, hypertrophic scars and/or hyperpigmentation disorders |
JP2022527972A (en) | 2019-04-02 | 2022-06-07 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | How to predict and prevent cancer in patients with premalignant lesions |
US20220175815A1 (en) | 2019-04-03 | 2022-06-09 | Orega Biotech | Combination therapies based on pd1 and il-17b inhibitors |
US20220220565A1 (en) | 2019-04-30 | 2022-07-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating melanoma |
KR20230031981A (en) | 2019-05-14 | 2023-03-07 | 프로벤션 바이오, 인코포레이티드 | Methods and compositions for preventing type 1 diabetes |
US20220228116A1 (en) | 2019-05-28 | 2022-07-21 | Vib Vzw | Cd8+ t-cells lacking plexins and their application in cancer treatment |
EP3976650A1 (en) | 2019-05-28 | 2022-04-06 | Vib Vzw | Cancer treatment by targeting plexins in the immune compartment |
CN114206938A (en) | 2019-06-20 | 2022-03-18 | 国家医疗保健研究所 | Anti-protease NEXIN-1 conformational single domain antibodies and uses thereof |
US20220275105A1 (en) | 2019-08-02 | 2022-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Neutralizing granzyme b for providing cardioprotection in a subject who experienced a myocardial infarction |
WO2021048292A1 (en) | 2019-09-11 | 2021-03-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating melanoma |
WO2021063968A1 (en) | 2019-09-30 | 2021-04-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method and composition for diagnosing chronic obstructive pulmonary disease |
EP4037714A1 (en) | 2019-10-03 | 2022-08-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for modulating macrophages polarization |
US20220363776A1 (en) | 2019-10-04 | 2022-11-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer |
WO2021078359A1 (en) | 2019-10-21 | 2021-04-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of inhibitors of cubilin for the treatment of chronic kidney diseases |
EP4058469A1 (en) | 2019-11-12 | 2022-09-21 | Institut National de la Santé et de la Recherche Médicale (INSERM) | New serological marker for the latent form of toxoplasmosis |
GB201918279D0 (en) | 2019-12-12 | 2020-01-29 | Vib Vzw | Glycosylated single chain immunoglobulin domains |
US20230076415A1 (en) | 2020-01-17 | 2023-03-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating melanoma |
EP4110810A1 (en) | 2020-02-28 | 2023-01-04 | Orega Biotech | Combination therapies based on ctla4 and il-17b inhibitors |
CA3178461A1 (en) | 2020-03-31 | 2021-10-07 | Biotalys NV | Anti-fungal polypeptides |
WO2021198511A1 (en) | 2020-04-03 | 2021-10-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treatment of sars-cov-2 infection |
WO2021213435A1 (en) | 2020-04-22 | 2021-10-28 | 迈威(上海)生物科技股份有限公司 | Single variable domain antibody targeting human programmed death ligand 1 (pd-l1) and derivative thereof |
WO2021224401A1 (en) | 2020-05-07 | 2021-11-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for determining a reference range of β-galactose exposure platelet |
KR20230008751A (en) | 2020-05-12 | 2023-01-16 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | Novel methods of treating cutaneous T-cell lymphoma and TFH derived lymphoma |
WO2021229104A1 (en) | 2020-05-15 | 2021-11-18 | Université de Liège | Anti-cd38 single-domain antibodies in disease monitoring and treatment |
JP2023526477A (en) | 2020-05-20 | 2023-06-21 | アンスティテュ・クリー | Synthetic single domain library |
CA3182333A1 (en) | 2020-05-20 | 2021-11-25 | Institut Curie | Single domain antibodies and their use in cancer therapies |
JP2023527578A (en) | 2020-06-05 | 2023-06-29 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Methods and pharmaceutical compositions for treating eye diseases |
JP2023532726A (en) | 2020-06-29 | 2023-07-31 | インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) | ANTI-PROTEIN S SINGLE DOMAIN ANTIBODY AND POLYPEPTIDE CONTAINING THE SAME |
WO2022008597A1 (en) | 2020-07-08 | 2022-01-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of infectious diseases |
WO2022023379A1 (en) | 2020-07-28 | 2022-02-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for preventing and treating a cancer |
US20230323299A1 (en) | 2020-08-03 | 2023-10-12 | Inserm (Institut National De La Santé Et De La Recherch Médicale) | Population of treg cells functionally committed to exert a regulatory activity and their use for adoptive therapy |
EP4214235A1 (en) | 2020-09-16 | 2023-07-26 | LinXis B.V. | Internalizing binding molecules |
WO2022063957A1 (en) | 2020-09-24 | 2022-03-31 | Vib Vzw | Biomarker for anti-tumor therapy |
EP4216943A1 (en) | 2020-09-24 | 2023-08-02 | Vib Vzw | Combination of p2y6 inhibitors and immune checkpoint inhibitors |
WO2022064049A1 (en) | 2020-09-28 | 2022-03-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for diagnosing brucella infection |
WO2022079270A1 (en) | 2020-10-16 | 2022-04-21 | Université D'aix-Marseille | Anti-gpc4 single domain antibodies |
WO2022084300A1 (en) | 2020-10-20 | 2022-04-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosis and monitoring form of coronavirus infection |
WO2022084531A1 (en) | 2020-10-23 | 2022-04-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating glioma |
US20240002519A1 (en) | 2020-11-05 | 2024-01-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of il-6 inhibitors for the treatment of acute chest syndrome in patients suffering from sickle cell disease |
WO2022101481A1 (en) | 2020-11-16 | 2022-05-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for predicting and treating uveal melanoma |
CA3201219A1 (en) | 2020-12-04 | 2022-06-09 | Mir Ali | Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof |
TW202222840A (en) | 2020-12-11 | 2022-06-16 | 大陸商上海華奧泰生物藥業股份有限公司 | Cd73 antigen binding protein and the application thereof |
US20240059764A1 (en) | 2021-01-11 | 2024-02-22 | Starmab Biologics (Suzhou) Co., Ltd. | ANTIGEN-BINDING PROTEIN TARGETING STAPHYLOCOCCUS AUREUS a-HEMOLYSIS AND APPLICATION THEREOF |
JP2024502758A (en) | 2021-01-13 | 2024-01-23 | 上海華奥泰生物藥業股▲フン▼有限公司 | CD73 binding protein and its use |
JP2024505428A (en) | 2021-01-14 | 2024-02-06 | アンスティテュ キュリー | HER2 single domain antibody variants and their CARs |
EP4282413A1 (en) | 2021-01-21 | 2023-11-29 | Natural Medicine Institute Of Zhejiang Yangshengtang Co., Ltd. | Composition and method for treating tumors |
JP2024505600A (en) | 2021-02-03 | 2024-02-06 | モーツァルト セラピューティクス, インコーポレイテッド | Binders and how to use them |
WO2022175392A1 (en) | 2021-02-17 | 2022-08-25 | Vib Vzw | Inhibition of slc4a4 in the treatment of cancer |
AU2022222994A1 (en) | 2021-02-19 | 2023-09-28 | Seoul National University R&Db Foundation | Single domain antibody against cd47 and use thereof |
JP2024513643A (en) | 2021-02-19 | 2024-03-27 | シャペロン インク. | Single domain antibody against PD-L1 and its uses |
WO2022177394A1 (en) | 2021-02-19 | 2022-08-25 | (주)샤페론 | Bispecific single domain antibody to pd-l1 and cd47 and use thereof |
CN117321076A (en) | 2021-02-19 | 2023-12-29 | 美国卫生及公众服务部代表 | Single domain antibodies neutralizing SARS-CoV-2 |
EP4308118A1 (en) | 2021-03-17 | 2024-01-24 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods and compositions for treating melanoma |
JP2024513746A (en) | 2021-03-22 | 2024-03-27 | 星濟生物(蘇州)有限公司 | Antigen-binding protein targeting pneumolysin and its applications |
EP4313317A1 (en) | 2021-03-23 | 2024-02-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of t cell-lymphomas |
JP2024514246A (en) | 2021-04-02 | 2024-03-29 | オリセル セラピューティクス カンパニー リミテッド | CLDN18.2 antigen binding protein and uses thereof |
EP4320153A1 (en) | 2021-04-09 | 2024-02-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of anaplastic large cell lymphoma |
EP4326871A1 (en) | 2021-04-19 | 2024-02-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of splice switching oligonucleotides for exon skipping-mediated knockdown of pim2 |
EP4326903A1 (en) | 2021-04-23 | 2024-02-28 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for treating cell senescence accumulation related disease |
WO2022242892A1 (en) | 2021-05-17 | 2022-11-24 | Université de Liège | Anti-cd38 single-domain antibodies in disease monitoring and treatment |
US20230174651A1 (en) | 2021-06-23 | 2023-06-08 | Janssen Biotech, Inc. | Materials and methods for hinge regions in functional exogenous receptors |
WO2023281120A1 (en) | 2021-07-09 | 2023-01-12 | Luxembourg Institute Of Health (Lih) | Dimeric protein complexes and uses thereof |
WO2023285362A1 (en) | 2021-07-12 | 2023-01-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of il-36 inhibitors for the treatment of netherton syndrome |
WO2023006975A2 (en) | 2021-07-30 | 2023-02-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Chimeric proteins and methods of immunotherapy |
WO2023057601A1 (en) | 2021-10-06 | 2023-04-13 | Biotalys NV | Anti-fungal polypeptides |
WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
WO2023078900A1 (en) | 2021-11-03 | 2023-05-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating triple negative breast cancer (tnbc) |
WO2023110937A1 (en) | 2021-12-14 | 2023-06-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling |
WO2023118165A1 (en) | 2021-12-21 | 2023-06-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating melanoma |
EP4209508A1 (en) | 2022-01-11 | 2023-07-12 | Centre national de la recherche scientifique | Nanobodies for the deneddylating enzyme nedp1 |
WO2023144235A1 (en) | 2022-01-27 | 2023-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for monitoring and treating warburg effect in patients with pi3k-related disorders |
WO2023144303A1 (en) | 2022-01-31 | 2023-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Cd38 as a biomarker and biotarget in t-cell lymphomas |
EP4231017A1 (en) | 2022-02-17 | 2023-08-23 | Promise Proteomics | Detection and quantification of anti-drug antibodies and anti-self antibodies |
EP4257609A1 (en) | 2022-04-08 | 2023-10-11 | iOmx Therapeutics AG | Combination therapies based on pd-1 inhibitors and sik3 inhibitors |
WO2023198648A1 (en) | 2022-04-11 | 2023-10-19 | Institut National de la Santé et de la Recherche Médicale | Methods for the diagnosis and treatment of t-cell malignancies |
WO2023198851A1 (en) | 2022-04-14 | 2023-10-19 | Institut National de la Santé et de la Recherche Médicale | Methods for controlling the tumor cell killing by light |
WO2023198874A1 (en) | 2022-04-15 | 2023-10-19 | Institut National de la Santé et de la Recherche Médicale | Methods for the diagnosis and treatment of t cell-lymphomas |
WO2023217904A1 (en) | 2022-05-10 | 2023-11-16 | Institut National de la Santé et de la Recherche Médicale | Syncitin-1 fusion proteins and uses thereof for cargo delivery into target cells |
US20240002331A1 (en) | 2022-06-08 | 2024-01-04 | Tidal Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof |
WO2023237661A1 (en) | 2022-06-09 | 2023-12-14 | Institut National de la Santé et de la Recherche Médicale | Use of endothelin receptor type b agonists for the treatment of aortic valve stenosis |
EP4299124A1 (en) | 2022-06-30 | 2024-01-03 | Universite De Montpellier | Anti-mglur2 nanobodies for use as biomolecule transporter |
WO2024003310A1 (en) | 2022-06-30 | 2024-01-04 | Institut National de la Santé et de la Recherche Médicale | Methods for the diagnosis and treatment of acute lymphoblastic leukemia |
WO2024008755A1 (en) | 2022-07-04 | 2024-01-11 | Vib Vzw | Blood-cerebrospinal fluid barrier crossing antibodies |
WO2024008274A1 (en) | 2022-07-04 | 2024-01-11 | Universiteit Antwerpen | T regulatory cell modification |
WO2024008799A1 (en) | 2022-07-06 | 2024-01-11 | Institut National de la Santé et de la Recherche Médicale | Methods for the treatment of proliferative glomerulonephritis |
WO2024013234A1 (en) | 2022-07-13 | 2024-01-18 | Institut National de la Santé et de la Recherche Médicale | Methods for diagnosis, prognosis, stratification and treating of myocarditis |
WO2024018003A1 (en) | 2022-07-21 | 2024-01-25 | Institut National de la Santé et de la Recherche Médicale | Extracellular vesicles functionalized with an erv syncitin and uses thereof for cargo delivery |
WO2024018426A1 (en) | 2022-07-22 | 2024-01-25 | Janssen Biotech, Inc. | Enhanced transfer of genetic instructions to effector immune cells |
WO2024018046A1 (en) | 2022-07-22 | 2024-01-25 | Institut National de la Santé et de la Recherche Médicale | Garp as a biomarker and biotarget in t-cell malignancies |
WO2024023283A1 (en) | 2022-07-29 | 2024-02-01 | Institut National de la Santé et de la Recherche Médicale | Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas |
WO2024028433A1 (en) | 2022-08-04 | 2024-02-08 | Institut National de la Santé et de la Recherche Médicale | Methods for the treatment of lymphoproliferative disorders |
WO2024033399A1 (en) | 2022-08-10 | 2024-02-15 | Institut National de la Santé et de la Recherche Médicale | Sigmar1 ligand for the treatment of pancreatic cancer |
WO2024033400A1 (en) | 2022-08-10 | 2024-02-15 | Institut National de la Santé et de la Recherche Médicale | Sk2 inhibitor for the treatment of pancreatic cancer |
WO2024038112A1 (en) | 2022-08-17 | 2024-02-22 | Institut National de la Santé et de la Recherche Médicale | Improved anti-albumin nanobodies and their uses |
WO2024047110A1 (en) | 2022-08-31 | 2024-03-07 | Institut National de la Santé et de la Recherche Médicale | Method to generate more efficient car-t cells |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE307996B (en) | 1965-11-30 | 1969-01-27 | Asea Ab | |
US4839295A (en) | 1984-06-08 | 1989-06-13 | Pierce Chemical Company | Measurement of protein using bicinchoninic acid |
JP2919890B2 (en) | 1988-11-11 | 1999-07-19 | メディカル リサーチ カウンスル | Single domain ligand, receptor consisting of the ligand, method for producing the same, and use of the ligand and the receptor |
CA2016842A1 (en) | 1989-05-16 | 1990-11-16 | Richard A. Lerner | Method for tapping the immunological repertoire |
SE509359C2 (en) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Use of stabilized protein or peptide conjugates for the preparation of a drug |
US5977307A (en) * | 1989-09-07 | 1999-11-02 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
ATE185601T1 (en) | 1990-07-10 | 1999-10-15 | Cambridge Antibody Tech | METHOD FOR PRODUCING SPECIFIC BONDING PAIRS |
CA2046830C (en) | 1990-07-19 | 1999-12-14 | Patrick P. Deluca | Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer |
US5843440A (en) * | 1990-10-03 | 1998-12-01 | Redcell Canada, Inc. | Cellular and serum protein anchors for modulating pharmacokinetics |
ATE150507T1 (en) | 1991-09-03 | 1997-04-15 | Catsclaw Limited | DEVICE FOR INHIBITING THE ADVANCE OF VEHICLES |
US5474771A (en) * | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
ATE463573T1 (en) * | 1991-12-02 | 2010-04-15 | Medimmune Ltd | PRODUCTION OF AUTOANTIBODIES ON PHAGE SURFACES BASED ON ANTIBODIES SEGMENT LIBRARIES |
US6005079A (en) * | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
ES2322324T3 (en) * | 1992-08-21 | 2009-06-19 | Vrije Universiteit Brussel | IMMUMOGLOBULINS DESPROVISTAS OF LIGHT CHAINS. |
EP0721469B1 (en) * | 1993-09-02 | 2000-01-05 | Trustees of Dartmouth College | Anti-gp39 antibodies and uses therefor |
EP0742721B1 (en) | 1993-09-02 | 1999-05-06 | Trustees of Dartmouth College | Methods of prolonged suppression of humoral immunity |
US5869049A (en) * | 1993-09-02 | 1999-02-09 | Trustees Of Dartmouth College | Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists |
US5922545A (en) * | 1993-10-29 | 1999-07-13 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
SE9400088D0 (en) * | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
US5605793A (en) * | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
US5683693A (en) * | 1994-04-25 | 1997-11-04 | Trustees Of Dartmouth College | Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40 |
GB9416721D0 (en) | 1994-08-18 | 1994-10-12 | Short Brothers Plc | A bias yarn assembly forming device |
US5876950A (en) * | 1995-01-26 | 1999-03-02 | Bristol-Myers Squibb Company | Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy |
JP4979843B2 (en) | 1995-03-10 | 2012-07-18 | ロッシュ ディアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング | Polypeptide-containing dosage form in microparticle form |
US5833987A (en) | 1995-06-07 | 1998-11-10 | Trustees Of Dartmouth College | Treatment of T cell mediated autoimmune disorders |
GB2302024B (en) | 1995-06-09 | 1998-10-07 | Malix Polymer Engineering Limi | Obstetric vacuum extractor |
DK0859841T3 (en) | 1995-08-18 | 2002-09-09 | Morphosys Ag | Protein / (poly) peptide libraries |
US6440418B1 (en) * | 1995-11-07 | 2002-08-27 | Idec Pharmaceuticals Corporation | Methods of treating autoimmune diseases with gp39-specific antibodies |
US6340459B1 (en) * | 1995-12-01 | 2002-01-22 | The Trustees Of Columbia University In The City Of New York | Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients |
US20040248201A1 (en) * | 1996-06-27 | 2004-12-09 | Serge Muyldermans | Recognition molecules interacting specifically with the active site or cleft of a target molecule |
JP2000515507A (en) * | 1996-07-08 | 2000-11-21 | ザ トラスティズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク | Therapeutic application of T-BAM (CD40L) technology for treating diseases involving smooth muscle cells |
WO1998058965A2 (en) | 1997-06-20 | 1998-12-30 | Innogenetics N.V. | B7-binding molecules for treating immune diseases |
JP2002507967A (en) | 1997-06-20 | 2002-03-12 | パンゲネチックス・ベー・ファウ | Anti-CD40L immunotoxin for disease treatment |
WO1999000143A1 (en) | 1997-06-27 | 1999-01-07 | Biogen, Inc. | Cd154 blockade therapy for autoimmune diseases |
GB9722131D0 (en) * | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
DE69841562D1 (en) | 1997-10-27 | 2010-04-29 | Bac Ip Bv | MULTIVALENT ANTIGENBINDING PROTEINS |
JP2002512182A (en) | 1998-04-20 | 2002-04-23 | ジェンザイム・コーポレーション | Drug delivery of proteins from polymer blends |
IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
CA2372198A1 (en) | 1999-05-14 | 2000-11-23 | Medical Research Council | Protein scaffold and its use to multimerise monomeric polypeptides |
FI991456A (en) | 1999-06-24 | 2000-12-25 | Nokia Networks Oy | EMI gasket |
US6482411B1 (en) * | 1999-08-27 | 2002-11-19 | Board Of Regents, The University Of Texas System | Methods of reducing bone loss with CD40 ligand |
GB0006398D0 (en) | 2000-03-16 | 2000-05-03 | Novartis Ag | Organic compounds |
AU2001264946A1 (en) | 2000-05-24 | 2001-12-03 | Imclone Systems Incorporated | Bispecific immunoglobulin-like antigen binding proteins and method of production |
JP2003535592A (en) | 2000-06-06 | 2003-12-02 | アイデック ファーマスーティカルズ コーポレイション | Non-agonist antibodies to human gp39, compositions containing the same, and therapeutic uses thereof |
US20020039773A1 (en) | 2000-07-13 | 2002-04-04 | Rosana Kapeller-Libermann | 47885, a novel human ubiquitin-activating enzyme and uses therefor |
AU8867501A (en) | 2000-09-01 | 2002-03-13 | Biogen Inc | Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design |
ATE513854T1 (en) | 2000-12-13 | 2011-07-15 | Bac Ip B V | PROTEIN GRID OF VARIABLE DOMAIN OF THE CAMEL IMMUNOGLOBULIN HEAVY CHAIN |
US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
US20050089932A1 (en) * | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
WO2004058821A2 (en) | 2002-12-27 | 2004-07-15 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
AU2002319402B2 (en) | 2001-06-28 | 2008-09-11 | Domantis Limited | Dual-specific ligand and its use |
ES2337986T3 (en) * | 2001-08-10 | 2010-05-03 | Aberdeen University | FISHING ANTIGENS UNION DOMAINS. |
CA2462531A1 (en) | 2001-10-05 | 2003-04-17 | Cangene Corporation | Phagemid display system |
JP2005289809A (en) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | Mutant heavy-chain antibody |
AR039067A1 (en) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | ANTIBODIES FOR CD40 |
CN1678634A (en) * | 2002-06-28 | 2005-10-05 | 多曼蒂斯有限公司 | Immunoglobulin single variable antigen combination area and its opposite constituent |
US8129330B2 (en) * | 2002-09-30 | 2012-03-06 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
EP2336179A1 (en) | 2002-11-08 | 2011-06-22 | Ablynx N.V. | Stabilized single domain antibodies |
GB0230201D0 (en) | 2002-12-27 | 2003-02-05 | Domantis Ltd | Retargeting |
PT1639011E (en) | 2003-06-30 | 2009-01-20 | Domantis Ltd | Pegylated single domain antibodies (dab) |
US20050164301A1 (en) | 2003-10-24 | 2005-07-28 | Avidia Research Institute | LDL receptor class A and EGF domain monomers and multimers |
US7563443B2 (en) * | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
-
2005
- 2005-04-08 US US11/102,512 patent/US7563443B2/en active Active
- 2005-09-16 CA CA2581017A patent/CA2581017C/en active Active
- 2005-09-16 RU RU2007114266/15A patent/RU2364420C2/en active
- 2005-09-16 AU AU2005283932A patent/AU2005283932B8/en active Active
- 2005-09-16 KR KR1020077008642A patent/KR101360140B1/en active IP Right Grant
- 2005-09-16 WO PCT/GB2005/003562 patent/WO2006030220A1/en active Application Filing
- 2005-09-16 BR BRPI0515404-9A patent/BRPI0515404A/en not_active Application Discontinuation
- 2005-09-16 NZ NZ553847A patent/NZ553847A/en unknown
- 2005-09-16 GE GEAP20059989A patent/GEP20125471B/en unknown
- 2005-09-16 US US11/663,247 patent/US8524236B2/en active Active
- 2005-09-16 JP JP2007531827A patent/JP5808880B2/en active Active
- 2005-09-16 MX MX2007003187A patent/MX2007003187A/en active IP Right Grant
- 2005-09-16 EP EP05784064.7A patent/EP1797126B1/en not_active Revoked
- 2005-09-16 ES ES05784064.7T patent/ES2442455T3/en active Active
- 2005-09-16 KR KR1020137005252A patent/KR20130039341A/en not_active Application Discontinuation
- 2005-09-16 EP EP10075557A patent/EP2371862A3/en not_active Withdrawn
-
2007
- 2007-03-05 IL IL181724A patent/IL181724A/en active IP Right Grant
- 2007-03-12 NO NO20071312A patent/NO20071312L/en not_active Application Discontinuation
- 2007-07-26 HK HK07108149.6A patent/HK1101182A1/en unknown
-
2009
- 2009-05-01 US US12/387,423 patent/US7927596B2/en active Active
- 2009-05-01 US US12/387,421 patent/US7829096B2/en active Active
-
2010
- 2010-11-08 US US12/941,870 patent/US20110172400A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8524236B2 (en) | Methods of antagonizing the binding of CD40 to CD40L with CD40L-specific monovalent polypeptides in autoimmune individuals | |
US20210047414A1 (en) | Compositions monovalent for cd28 binding and methods of use | |
US20130230540A1 (en) | Compositions monovalent for cd28 binding and methods of use | |
AU2017202454A1 (en) | Compositions monovalent for cd28 binding and methods of use | |
WO2014120916A1 (en) | Pegylated domain antibodies monovalent for cd28 binding and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |